METHOD AND REAGENT FOR THE MODULATION AND DIAGNOSIS OF CD20 AND NOGO GENE EXPRESSION

Abstract: The present invention relates to nucleic acid molecules, including antisense and enzymatic nucleic acid molecules, such as hammerhead ribozymes, DNAzymes, and antisense, which modulate the expression of the CD20 and/or NOGO genes. Diagnostic systems and methods for detecting the presence of nucleic acids are further disclosed.

Description: DESCRIPTION METHOD AND REAGENT FOR THE MODULATION AND DIAGNOSIS OF CD20 AND NOGO GENE EXPRESSION Background Of The Invention This invention claims priority from Blatt, USSN (60/181,797), filed February 11, 2000, entitled "METHOD AND REAGENT FOR THE INHIBITION OF NOGO GENE", from Blatt, USSN (60/185,516), filed February 28, 2000, and also from Usman, USSN (60/187,128), filed March 6, 2000. These patent applications are hereby incorporated by reference herein in their entirety including the drawings. The present invention concerns compounds, compositions, and methods for the study, diagnosis, and treatment of conditions and diseases that respond to the modulation of genes, including CD20 and NOGO genes. Specifically, the instant invention provides for compositions and methods for the treatment of diseases associated with the level of CD20 and NOGO. Diagnostic systems and methods for detecting the presence of nucleic acids are further disclosed. The following is a brief description of the current understanding of CD20 and NOGO, their corresponding biological function, and therapeutic relevance. The discussion is not meant to be complete and is provided only for understanding the invention that follows. The summary is not an admission that any of the work described below is prior art to the claimed invention. The vertebrate immune system has evolved to include a number of organs and cell types which specifically recognize foreign antigens (e.g., antibody generators) from invading pathogens. The immune response, which is mediated by lymphocytes, seeks out and destroys the invading foreign bodies through specific recognition of antibodies and subsequent destruction of foreign bodies. Lymphocytes, which represent about 30% of the total number of white blood cells in the adult human circulatory system, are produced in the primary lymphoid organs, the thymus, spleen, and bone marrow. The two major sub-types of lymphocytes are B-cells and T- cells. T-cells, which develop in the thymus, are responsible for cell-mediated immunity. B-cells, which develop in the adult bone marrow (or fetal liver), produce antibodies and are responsible for humoral immunity. T-cells are activated by the binding of major histocompatability complex (MHC) glycoproteins on the surface of an antigenic cell to T-cell receptors. Activated T-cells release regulatory molecules, such as interleukins, that can stimulate B-cell differentiation. Activated B-cells develop into antibody secreting cells which are filled with an extensive rough endoplasmic reticulum for the production of immunoglobulins against an antigen. B-cell diversity is central to the effective functioning to the immune system. An activated B-cell can produce large quantities of antibody in response to a given antigen. Normally, this antibody production is modulated in response to the neutralization of the antigen. However, when the production of B-cells is dysregulated, such proliferation can result in B-cell lymphoma. CD20 is a 35 kDa cell surface phosphoprotein expressed exclusively in mature B lymphocytes (Rosenthal et al, 1983, J. Immunol, 131, 232-237; Stashenko et al, 1980, J. Immunol, 125, 1678-1685). This B-cell lineage specific antigen is found on all tumor cells within most B-cell lymphomas. The increased expression of CD20 appears to be associated with tumor cell proliferation, although the magnitude of expression varies among different types of lymphoid tumors. CD20 is a transmembrane protein with four transmembrane domains with both C- and N-terminals located in the cytoplasm. The primary structure of CD20 has been determined by molecular cloning (Einfeld et al, 1986, EMBO J., 7, 711-717; Tedder et al, 1988, PNAS USA, 85, 208-212) and resembles those of ion channel and ion transporter proteins. When expressed in fibroblasts, CD20 functions as a calcium-permeable cation channel which is activated by the insulin-like growth factor-I (IGF-I) receptor (Kanzaki et al, 1997, J Biol Chem., 272, 4964-69). Modulation of cell growth is observed in fibroblasts expressing CD20. In CD20 expressing Balb/c 3T3 fibroblasts, CD20 expression accelerates cell cycle progression through the G^ phase and enables cells to enter S phase in cell culture medium containing low extracellular calcium (Kanzaki et al, 1995, J. Biol Chem., 270, 13099-04). In B-lymphocytes, CD20 appears to function directly in the regulation of transmembrane Ca 2+ conductance (Bubien et al, 1993, J Cell. Biol, 121, 1121-1132). In lymphocytes, CD20 has been shown to be associated with src family tyrosine kinases, and is phosphorylated by protein kinases such as calmodulin-dependant protein kinase. Monoclonal antibody (n AB) binding to CD20 alters cell cycle progression and differentiation in B-lymphocytes, thus indicating that CD20 plays an essential role in B-cell function (for a review of CD20 function, see Tedder and Engel, 1994, Immunol Today, 15(9), 450-4). As such, CD20 has the potential for providing a molecular target for the treatment of diseases such as B-cell lymphomas. The use of monoclonal antibodies targeting CD20 has been extensively described (for a review, see Weiner, 1999, Semin. Oncol, 26, 43-51; Gopal and Press, 1999, J. Lab. Clin. Med., 134, 445-450; White et al, 1999, Pharm. Sci. Technol. Today, 2, 95-101). Rituxan™ is an chimeric anti-CD20 monoclonal antibody which has been used widely both as a single agent and together with chemotherapy in patients with newly diagnosed and relapsed lymphomas (Davis et al, 1999, J Clin. Oncol, 17, 1851-1857; Solal-Celigny et al, 1999, Blood, 94, abstract 2802; Foran et al, 2000, J. Clin. Oncol, 18, 317-324). In addition, the use of radiolabeled antibody conjugates has been described. Bexxar™ is an 1-131 conjugated antibody which is believed to work through a dual mechanism of action resulting from the immune system activity of the niAB and the therapeutic effects of the iodine (1-131) radioisotope. The use of Bexxar in patients with transformed low-grade lymphoma is described by Zelenetz et al, 1999, Blood, 94, abstract 2806. Zevalin™ is an anti-CD20 murine IgGl kappa monoclonal antibody, conjugated to tiuxetan, which can be conjugated with either In-Ill for imaging/dosimetry or yttrium-90 for therapeutic use. A controlled study of Zevalin compared to Rituxan for patients with B-cell lymphoma is reported by Witzig et al, 1999, Blood, 94, abstract 2805. Although the use of monoclonal antibodies and conjugates has provided therapeutic value in the treatment of lymphomas, their efficacy and safety are by no means ideal. The use of monoclonal antibodies can be limiting due to factors including but not limited to toxicity, immunogenicity, and tumor resistance. In addition, radioisotope conjugated mABs can potentially damage non-pathogenic tissues, resulting in malignancy outside the scope of the original pathology. The route of administration of many of these compounds is intravenous infusion. Infusion related side effects can be problematic. Winkler et al, 1999, Blood, 94(7), 2217-2224, describe Cytokine-release syndrome and poor overall efficacy in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab). As such, there exists a need for safe and effective therapeutics in order to replace or compliment existing lymphoma treatment strategies. The ceased growth of neurons following development has severe implications for lesions of the central nervous system (CNS) caused by neurodegenerative disorders and traumatic accidents. Although CNS neurons have the capacity to rearrange their axonal and dendritic foci in the developed brain, the regeneration of severed CNS axons spanning distance does not exist. Axonal growth following CNS injury is limited by the local tissue environment rather than intrinsic factors, as indicated by transplantation experiments (Richardson et al, 1980, Nature, 284, 264-265). Non-neuronal glial cells of the CNS, including oligodendrocytes and astrocytes, have been shown to inhibit the axonal growth of dorsal root ganglion neurons in culture (Schwab and Thoenen,1985, J. Neurosci., 5, 2415-2423). Cultured dorsal root ganglion cells can extend their axons across glial cells from the peripheral nervous system, (ie; Schwann cells), but are inhibited by oligodendrocytes and yelin of the CNS (Schwab and Caroni, 1988, J. Neurosci., 8, 2381-2393). The non-conductive properties of CNS tissue in adult vertebrates is thought to result from the existence of inhibitory factors rather than the lack of growth factors. The identification of proteins with neurite outgrowth inhibitory or repulsive properties include NI-35, NI-250 (Caroni and Schwab, 1988, Neuron, 1, 85-96), myelin-associated glycoprotein (Genebank Accession No M29273), tenascin-R (Genebank Accession No X98085), and NG-2 (Genebank Accession No X61945). Monoclonal antibodies (mAb IN-1) raised against NI-35/250 have been shown to partially neutralize the growth inhibitory effect of CNS myelin and oligodendrocytes. IN-1 treatment in vivo has resulted in long distance fiber regeneration in lesioned adult mammalian CNS tissue (Weibel et al, 1994, Brain Res., 642, 259-266). Additionally, IN-1 treatment in vivo has resulted in the recovery of specific reflex and locomotor functions after spinal cord injury in adult rats (Bregman et al, 1995, Nature, 378, 498-501). Recently, the cloning of NOGO-A (Genebank Accession No AJ242961), the rat complementary DNA encoding NI-220/250 has been reported (Chen et al, 2000, Nature, 403, 434-439). The NOGO gene encodes at least three major protein products (NOGO-A, B, and C) resulting from both alternative promoter usage and alternative splicing. Recombinant NOGO-A inhibits neurite outgrowth from dorsal root ganglia and the spreading of 3T3 firboblasts. Monoclonal antibody IN-1 recognizes NOGO-A and neutralizes NOGO-A inhibition of neuronal growth in vitro. Evidence supports the proposal that NOGO-A is the previously described rat NI-250 since NOGO-A contains all six peptide sequences obtained from purified bNI-220, the bovine equivalent of rat NI-250 (Chen et al supra). Prinjha et al, 2000, Nature, 403, 383-384, report the cloning of the human NOGO gene which encodes three different NOGO isoforms that are potent inhibitors of neurite outgrowth. Using oligonucleotide primers to amplify and clone overlapping regions of the open reading frame of NOGO cDNA, Phrinjha et al, supra identified three forms of cDNA clone corresponding to the three protein isoforms. The longest ORF of 1,192 amino acids corresponds to NOGO-A (Accession No. AJ251383). An intermediate-length splice variant that lacks residues 186-1,004 corresponds to NOGO-B (Accession No. AJ251384). The shortest splice variant, NOGO-C (Accession No. AJ251385), appears to be the previously described rat vp20 (Accession No. AF051335) and foocen-s (Accession No. AF132048), and also lacks residues 186-1,004. According to Prinjha et al, supra, the NOGO amino-terminal region shows no significant homology to any known protein, while the carboxy-terminal tail shares homology with neuroendicrine-specific proteins and other members of the reticulon gene family. In addition, the carboxy-terminal tail contains a consensus sequence that may serve as an endoplasmic-reticulum retention region. Based on the NOGO protein sequence, Prinjha et al, supra, postulate NOGO to be a membrane associated protein comprising a putative large extracellular domain of 1,024 residues with seven predicted N-linked glycosylation sites, two or three transmembrane domains, and a short carboxy-terminal region of 43 residues. Grandpre et al, 2000, Nature, also report the identification of NOGO as a potent inhibitor of axon regeneration. The 4.1 kilobase NOGO human cDNA clone identified by Grandpre et al, supra, KIAA0886, is homologous to a cDNA derived from a previous effort to sequence random high molecular-weight brain derived cDNAs (Nagase et al, 1998, DNA Res., 31, 355-364). This cDNA clone encodes a protein that matches all six of the peptide sequences derived from bovine NOGO. Grandpre et al, supra demonstrate that NOGO expression is predominantly associated with the CNS and not the peripheral nervous system (PNS). Cellular localization of NOGO protein appears to be predominantly reticluar in origin, however, NOGO is found on the surface of some oligodentrocytes. An active domain of NOGO has been identified, defined as residues 31-55 of a hydrophilic 66-residue lumenal/extracellular domain. A synthetic fragment corresponding to this sequence exhibits growth-cone collapsing and outgrowth inhibiting activities (Grandpre et al, supra). Hauswirth and Flannery, International PCT Publication No. WO 98/48027, describe materials and methods for the specific expression of proteins in retinal photoreceptor cells consisting of an adeno-associated viral vector contacting a rod or cone-opsin promoter. In addition, ribozymes which degrade mutant mRNA are described for use in the treatment of retinitis pigmentosa. Fechteler et al, International PCT Publication No. WO 00/03004 describe ribozymes targeting presenilin-2 RNA for the use in treating neurodegenerative diseases such as Alzheimer's disease. Eldadah et al, 2000, J Neurosci., 20, 179-186, describe the protection of cerebellar granule cells from apoptosis induced by serum-potassium deprivation from ribozyme mediated inhibition of caspase-3. Seidman et al, 1999, Antisense Nucleic Acid Drug Dev., 9, 333-340, describe in general terms, the use of antisense and ribozyme constructs for treatment of neurodegenerative diseases. Denman et al, 1994, Nucleic Acids Research, 22, 2375-82, describe the ribozyme mediated degradation of beta-amyloid peptide precursor mRNA in COS-7 cells. Summary Of The Invention The invention features novel nucleic acid-based techniques [e.g., enzymatic nucleic acid molecules (ribozymes), antisense nucleic acids, 2-5A antisense chimeras, triplex DNA, antisense nucleic acids containing RNA cleaving chemical groups] and methods for their use to modulate the expression of genes, for example those encoding certain myelin proteins that inhibit or are involved in the inhibition of neurite growth, including axonal regeneration in the CNS. In addition, The invention also features novel nucleic acid-based techniques [e.g., enzymatic nucleic acid molecules (ribozymes), antisense nucleic acids, 2-5A antisense chimeras, triplex DNA, antisense nucleic acids containing RNA cleaving chemical groups] and methods for their use to modulate the expression of CD20. Specifically, the instant invention features nucleic-acid based techniques to inhibit the expression of NOGO-A (Accession No. AJ251383), B (Accession No. AJ251384), and/or C (Accession No. AJ251385), NI-35, 220, and/or 250, myelin-associated glycoprotein (Genebank Accession No M29273), tenascin-R (Genebank Accession No X98085), NG-2 (Genebank Accession No X61945) and CD20 gene (an exemplary CD20 sequence is found at GenBank Accession No. X07203). In a preferred embodiment, the invention features the use of one or more of the nucleic acid-based techniques independently or in combination to inhibit the expression of the gene(s) encoding NOGO-A, B, and/or C, NI-35, 220, and/or 250, myelin-associated glycoprotein, tenascin-R, NG-2, and/or CD20. Specifically, the invention features the use of nucleic acid- based techniques to specifically inhibit the expression of NOGO gene (GenBank Accession No. AB020693) and CD20 gene (GenBank Accession No. X07203). The description below of the various aspects and embodiments is provided with reference to the exemplary gene CD20 and NOGO. However, the various aspects and embodiments are also directed to other genes, including those which express CD20-like proteins involved in B- cell proliferation and NOGO-like proteins involved in neurite outgrowth inhibition. Those additional genes can be analyzed for target sites using the methods described for CD20 and/or NOGO. Thus, the inhibition and the effects of such inhibition of the other genes can be performed as described herein. In another preferred embodiment, the invention features the use of an enzymatic nucleic acid molecule, preferably in the hammerhead, NCH (Inozyme), G-cleaver, amberzyme, zinzyme and/or DNAzyme motif, to inhibit the expression of CD20 and/or NOGO genes. By "inhibit" it is meant that the activity of CD20 and/or NOGO or level of RNAs or equivalent RNAs encoding one or more protein subunits of CD20 and/or NOGO is reduced below that observed in the absence of the nucleic acid molecules of the invention. In one embodiment, inhibition with enzymatic nucleic acid molecule preferably is below that level observed in the presence of an enzymatically inactive or attenuated molecule that is able to bind to the same site on the target RNA, but is unable to cleave that RNA. In another embodiment, inhibition with antisense oligonucleotides is preferably below that level observed in the presence of, for example, an oligonucleotide with scrambled sequence or with mismatches. In another embodiment, inhibition of CD20 and/or NOGO genes with the nucleic acid molecule of the instant invention is greater than in the presence of the nucleic acid molecule than in its absence. By "enzymatic nucleic acid" is meant a nucleic acid molecule capable of catalyzing (altering the velocity and/or rate of) a variety of reactions including the ability to repeatedly cleave other separate nucleic acid molecules (endonuclease activity) or ligate other separate nucleic acid molecules (ligation activity) in a nucleotide base sequence-specific manner. Such a molecule with endonuclease and/or ligation activity may have complementarity in a substrate binding region to a specified gene target, and also has an enzymatic activity that specifically cleaves and/or ligates RNA or DNA in that target. That is, the nucleic acid molecule with endonuclease and/or ligation activity is able to intramolecularly or intermolecularly cleave and/or ligate RNA or DNA and thereby inactivate or activate a target RNA or DNA molecule. This complementarity functions to allow sufficient hybridization of the enzymatic RNA molecule to the target RNA or DNA to allow the cleavage/ligation to occur. One hundred percent complementarity is preferred, but complementarity as low as 50-75% may also be useful in this invention (see for example Werner and Uhlenbeck, 1995, Nucleic Acids Research, 23, 2092-2096; Hammann et al, 1999, Antisense and Nucleic Acid Drug Dev., 9, 25-31). The nucleic acids can be modified at the base, sugar, and/or phosphate groups. The term enzymatic nucleic acid is used interchangeably with phrases such as ribozymes, catalytic RNA, enzymatic RNA, catalytic DNA, aptazyme or aptamer-binding ribozyme, regulatable ribozyme, catalytic oligonucleotides, nucleozyme, DNAzyme, RNA enzyme, endoribonuclease, endonuclease, minizyme, leadzyme, oligozyme or DNA enzyme. All of these terminologies describe nucleic acid molecules with enzymatic activity. The specific enzymatic nucleic acid molecules described in the instant application are not limiting in the invention and those skilled in the art will recognize that all that is important in an enzymatic nucleic acid molecule of this invention is that it has a specific substrate binding site which is complementary to one or more of the target nucleic acid regions, and that it have nucleotide sequences within or surrounding that substrate binding site which impart a nucleic acid cleaving and/or ligation activity to the molecule (Cech et al, U.S. Patent No. 4,987,071; Cech et al, 1988, 260 JAMA 3030). By "nucleic acid molecule" as used herein is meant a molecule having nucleotides. The nucleic acid can be single, double, or multiple stranded and may comprise modified or unmodified nucleotides or non-nucleotides or various mixtures and combinations thereof. By "enzymatic portion" or "catalytic domain" is meant that portion/region of the enzymatic nucleic acid molecule essential for cleavage of a nucleic acid substrate (for example, see Figures 1-5). By "substrate binding arm" or "substrate binding domain" is meant that portion region of a enzymatic nucleic acid which is able to interact, for example via complementarity (i.e., able to base-pair with), with a portion of its substrate. Preferably, such complementarity is 100%, but can be less if desired. For example, as few as 10 bases out of 14 can be base-paired (see for example Werner and Uhlenbeck, 1995, Nucleic Acids Research, 23, 2092-2096; Hammann et al, 1999, Antisense and Nucleic Acid Drug Dev., 9, 25-31). Examples of such arms are shown generally in Figures 1-5. That is, these arms contain sequences within a enzymatic nucleic acid which are intended to bring enzymatic nucleic acid and target RNA together through complementary base-pairing interactions. The enzymatic nucleic acid of the invention can have binding arms that are contiguous or non-contiguous and can be of varying lengths. The length of the binding aπn(s) are preferably greater than or equal to four nucleotides and of sufficient length to stably interact with the target RNA; preferably 12-100 nucleotides; more preferably 14-24 nucleotides long (see for example Werner and Uhlenbeck, supra; Hamman et al, supra; Hampel et al, EP0360257; Berzal-Herrance et al, 1993, EMBOJ., 12, 2567-73). If two binding arms are chosen, the design is such that the length of the binding arms are symmetrical (i.e., each of the binding arms is of the same length; e.g., five and five nucleotides, or six and six nucleotides, or seven and seven nucleotides long) or asymmetrical (i.e., the binding arms are of different length; e.g., six and three nucleotides; three and six nucleotides long; four and five nucleotides long; four and six nucleotides long; four and seven nucleotides long; and the like). By "Inozyme" or "NCH" motif is meant, an enzymatic nucleic acid molecule comprising a motif as is generally described as NCH Rz in Figure 2. Inozymes possess endonuclease activity to cleave RNA substrates having a cleavage triplet NCH/, where N is a nucleotide, C is cytidine and H is adenosine, uridine or cytidine, and / represents the cleavage site. H is used interchangeably with X. Inozymes can also possess endonuclease activity to cleave RNA substrates having a cleavage triplet NCN/, where N is a nucleotide, C is cytidine, and / represents the cleavage site. "I" in Figure 2 represents an Inosine nucleotide, preferably a ribo-Inosine or xylo-Inosine nucleoside. By "G-cleaver" motif is meant, an enzymatic nucleic acid molecule comprising a motif as is generally described as G-cleaver Rz in Figure 2. G-cleavers possess endonuclease activity to cleave RNA substrates having a cleavage triplet NYN/, where N is a nucleotide, Y is uridine or cytidine and / represents the cleavage site. G-cleavers can be chemically modified as is generally shown in Figure 2. By "amberzyme" motif is meant, an enzymatic nucleic acid molecule comprising a motif as is generally described in Figure 3. Amberzymes possess endonuclease activity to cleave RNA substrates having a cleavage triplet NG/N, where N is a nucleotide, G is guanosine, and / represents the cleavage site. Amberzymes can be chemically modified to increase nuclease stability through substitutions as are generally shown in Figure 3. In addition, differing nucleoside and/or non-nucleoside linkers can be used to substitute the 5'-gaaa-3' loops shown in the figure. Amberzymes represent a non-limiting example of an enzymatic nucleic acid molecule that does not require a ribonucleotide (2' -OH) group within its own nucleic acid sequence for activity. By "zinzyme" motif is meant, an enzymatic nucleic acid molecule comprising a motif as is generally described in Figure 4. Zinzymes possess endonuclease activity to cleave RNA substrates having a cleavage triplet including but not limited to YG/Y, where Y is uridine or cytidine, and G is guanosine and / represents the cleavage site. Zinzymes can be chemically modified to increase nuclease stability through substitutions as are generally shown in Figure 4, including substituting 2'-O-methyl guanosine nucleotides for guanosine nucleotides. In addition, differing nucleotide and/or non-nucleotide linkers can be used to substitute the 5'-gaaa-2' loop shown in the figure. Zinzymes represent a non- limiting example of an enzymatic nucleic acid molecule that does not require a ribonucleotide (2' -OH) group within its own nucleic acid sequence for activity. By 'DNAzyme' is meant, an enzymatic nucleic acid molecule that does not require the presence of a 2' -OH group for its activity. In particular embodiments the enzymatic nucleic acid molecule can have an attached linker(s) or other attached or associated groups, moieties, or chains containing one or more nucleotides with 2' -OH groups. DNAzymes can be synthesized chemically or expressed endogenously in vivo, by means of a single stranded DNA vector or equivalent thereof. An example of a DNAzyme is shown in Figure 5 and is generally reviewed in Usman et al., International PCT Publication No. WO 95/11304; Chartrand et al, 1995, NAR 23, 4092; Breaker et al, 1995, Chem. Bio. 2, 655; Santoro et al, 1997, PNAS 94, 4262; Breaker, 1999, Nature Biotechnology, 17, 422-423; and Santoro et. al, 2000, J. Am. Chem. Soc, 122, 2433-39. Additional DNAzyme motifs can be selected for using techniques similar to those described in these references, and hence, are within the scope of the present invention. By "sufficient length" is meant an oligonucleotide of greater than or equal to 3 nucleotides that is of a length great enough to provide the intended function under the expected condition. For example, for binding arms of enzymatic nucleic acid "sufficient length" means that the binding arm sequence is long enough to provide stable binding to a target site under the expected binding conditions. Preferably, the binding arms are not so long as to prevent useful turnover of the nucleic acid molecule. By "stably interact" is meant interaction of the oligonucleotides with target nucleic acid (e.g., by forming hydrogen bonds with complementary nucleotides in the target under physiological conditions) that is sufficient to the intended purpose (e.g., cleavage of target RNA by an enzyme). By "equivalent" RNA to CD20 and/or NOGO is meant to include those naturally occurring RNA molecules having homology (partial or complete) to CD20 and/or NOGO proteins or encoding for proteins with similar function as CD20 and/or NOGO in various organisms, including but not limited to parasites, human, rodent, primate, rabbit, and pig. The equivalent RNA sequence also includes in addition to the coding region, regions such as 5 '-untranslated region, 3 '-untranslated region, introns, intron-exon junction and the like. By "degree of homology" is meant the nucleotide sequence of two or more nucleic acid molecules is partially or completely identical. By "antisense nucleic acid", it is meant a non-enzymatic nucleic acid molecule that binds to target RNA by means of RNA-RNA or RNA-DNA or RNA-PNA (protein nucleic acid; Egholm et al, 1993 Nature 365, 566) interactions and alters the activity of the target RNA (for a review, see Stein and Cheng, 1993 Science 261, 1004 and Woolf et al, US patent No. 5,849,902). Typically, antisense molecules are complementary to a target sequence along a single contiguous sequence of the antisense molecule. However, in certain embodiments, an antisense molecule can bind to substrate such that the substrate molecule forms a loop, and/or an antisense molecule can bind such that the antisense molecule forms a loop. Thus, the antisense molecule can complementary to two (or even more) non-contiguous substrate sequences or two (or even more) non-contiguous sequence portions of an antisense molecule can complementary to a target sequence or both. For a review of current antisense strategies, see Schmajuk et al, 1999, J. Biol. Chem., 274, 21783-21789, Delihas et al, 1997, Nature, 15, 751-753, Stein et al, 1997, Antisense N A. Drug Dev., 1, 151, Crooke, 2000, Methods Enzymol, 313, 3-45; Crooke, 1998, Biotech. Genet. Eng. Rev., 15, 121-157, Crooke, 1997, Ad. Pharmacol, 40, 1-49. In addition, antisense DNA can be used to target RNA by means of DNA-RNA interactions, thereby activating RNase H, which digests the target RNA in the duplex. The antisense oligonucleotides can comprise one or more RNAse H activating region, which is capable of activating RNAse H cleavage of a target RNA. Antisense DNA can be synthesized chemically or expressed via the use of a single stranded DNA expression vector or equivalent thereof. By "RNase H activating region" is meant a region (generally greater than or equal to 4-25 nucleotides in length, preferably from 5-11 nucleotides in length) of a nucleic acid molecule capable of binding to a target RNA to form a non-covalent complex that is recognized by cellular RNase H enzyme (see for example Arrow et al, US 5,849,902; Arrow et al, US 5,989,912). The RNase H enzyme binds to the nucleic acid molecule-target RNA complex and cleaves the target RNA sequence. The RNase H activating region comprises, for example, phosphodiester, phosphorothioate (preferably at least four of the nucleotides are phosphorothiote substitutions; more specifically, 4-11 of the nucleotides are phosphorothiote substitutions); phosphorodithioate, 5'-thiophosphate, or methylphosphonate backbone chemistry or a combination thereof. In addition to one or more backbone chemistries described above, the RNase H activating region can also comprise a variety of sugar chemistries. For example, the RNase H activating region can comprise deoxyribose, arabino, fluoroarabino or a combination thereof, nucleotide sugar chemistry. Those skilled in the art will recognize that the foregoing are non-limiting examples and that any combination of phosphate, sugar and base chemistry of a nucleic acid that supports the activity of RNase H enzyme is within the scope of the definition of the RNase H activating region and the instant invention. By "2-5A antisense chimera" is meant an antisense oligonucleotide containing a 5'- phosphorylated 2'-5 '-linked adenylate residue. These chimeras bind to target RNA in a sequence-specific manner and activate a cellular 2-5A-dependent ribonuclease which, in turn, cleaves the target RNA (Torrence et al, 1993 Proc. Natl Acad. Sci. USA 90, 1300; Silverman et al, 2000, Methods Enzymol, 313, 522-533; Player and Torrence, 1998, Pharmacol. Ther., 78, 55-113). By "triplex forming oligonucleotides" is meant an oligonucleotide that can bind to a double-stranded DNA in a sequence-specific manner to form a triple-strand helix. Formation of such triple helix structure has been shown to inhibit transcription of the targeted gene (Duval- Valentin et al, 1992 Proc. Natl Acad. Sci. USA 89, 504; Fox, 2000, Curr. Med. Chem., 7, 17-37; Praseuth et. al, 2000, Biochim. Biophys. Acta, 1489, 181-206). By "gene" it is meant a nucleic acid that encodes an RNA, for example, nucleic acid sequences including but not limited to structural genes encoding a polypeptide. "Complementarity" refers to the ability of a nucleic acid to form hydrogen bond(s) with another RNA sequence by either traditional Watson-Crick or other non-traditional types. In reference to the nucleic molecules of the present invention, the binding free energy for a nucleic acid molecule with its target or complementary sequence is sufficient to allow the relevant function of the nucleic acid to proceed, e.g., enzymatic nucleic acid cleavage, antisense or triple helix inhibition. Determination of binding free energies for nucleic acid molecules is well known in the art (see, e.g., Turner et al., 1987, CSH Symp. Quant. Biol. LII pp.123-133; Frier et al, 1986, Proc. Nat. Acad. Sci. USA 83:9373-9377; Turner et al, 1987, J. Am. Chem. Soc. 109:3783-3785). A percent complementarity indicates the percentage of contiguous residues in a nucleic acid molecule which can form hydrogen bonds (e.g., Watson-Crick base pairing) with a second nucleic acid sequence (e.g., 5, 6, 7, 8, 9, 10 out of 10 being 50%, 60%, 70%, 80%, 90%, and 100% complementary). "Perfectly complementary" means that all the contiguous residues of a nucleic acid sequence will hydrogen bond with the same number of contiguous residues in a second nucleic acid sequence. By "RNA" is meant a molecule comprising at least one ribonucleotide residue. By "ribonucleotide" or "2' -OH" is meant a nucleotide with a hydroxyl group at the 2' position of a β-D-ribo-furanose moiety. By "decoy RNA" is meant a RNA molecule that mimics the natural binding domain for a ligand. The decoy RNA therefore competes with natural binding target for the binding of a specific ligand. For example, it has been shown that over-expression of HIV trans-activation response (TAR) RNA can act as a "decoy" and efficiently binds HIV tat protein, thereby preventing it from binding to TAR sequences encoded in the HIN RΝA (Sullenger et al., 1990, Cell, 63, 601-608). This is but a specific example and those in the art will recognize that other embodiments can be readily generated using techniques generally known in the art. Several in vitro selection (evolution) strategies (Orgel, 1979, Proc. R. Soc. London, B 205, 435) have been used to evolve new nucleic acid catalysts capable of catalyzing cleavage and ligation of phosphodiester linkages (Joyce, 1989, Gene, 82, 83-87; Beaudry et al, 1992, Science 257, 635-641; Joyce, 1992, Scientific American 267, 90-97; Breaker et al, 1994, TIBTECH 12, 268; Bartel et α/., 1993, Science 261:1411-1418; Szostak, 1993, TIBS 17, 89-93; Kumar et al, 1995, FASEB , 9, 1183; Breaker, 1996, Curr. Op. Biotech., 7, 442; Santoro et al, 1997, Proc. Natl Acad. Sci., 94, 4262; Tang et al, 1997, RNA 3, 914; Nakamaye & Eckstein, 1994, supra; Long & Uhlenbeck, 1994, supra; Ishizaka et al., 1995, supra; Vaish et al, 1997, Biochemistry 36, 6495; all of these are incorporated by reference herein). Several varieties of naturally occurring enzymatic RNAs are known presently. Each can catalyze the hydrolysis of RNA phosphodiester bonds in trans (and thus can cleave other RNA molecules) under physiological conditions. Table I summarizes some of the characteristics of these ribozymes. In general, enzymatic nucleic acids act by first binding to a target RNA. Such binding occurs through the target binding portion of a enzymatic nucleic acid which is held in close proximity to an enzymatic portion of the molecule that acts to cleave the target RNA. Thus, the enzymatic nucleic acid first recognizes and then binds a target RNA through complementary base-pairing, and once bound to the correct site, acts enzymatically to cut the target RNA. Strategic cleavage of such a target RNA will destroy its ability to direct synthesis of an encoded protein. After an enzymatic nucleic acid has bound and cleaved its RNA target, it is released from that RNA to search for another target and can repeatedly bind and cleave new targets. Thus, a single ribozyme molecule is able to cleave many molecules of target RNA. In addition, the ribozyme is a highly specific inhibitor of gene expression, with the specificity of inhibition depending not only on the base-pairing mechanism of binding to the target RNA, but also on the mechanism of target RNA cleavage. Single mismatches, or base-substitutions, near the site of cleavage can completely eliminate catalytic activity of a ribozyme. The enzymatic nucleic acid molecules that cleave the specified sites in CD20-specific RNAs represent a novel therapeutic approach to treat a variety of pathologic indications, including but not limited to lymphoma, leukemia, and inflammatory arthropathy. Specifically, the enzymatic nucleic acid molecules of the instant invention can be used to treat lymphoma, leukemia, and arthropathy, including but not limited to B-cell lymphoma, low-grade or follicular non-Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lypmphocytic leukemia, HIV associated NHL, mantle-cell lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma, immune thrombocytopenia, and inflammatory arthropathy. The enzymatic nucleic acid molecule that cleave the specified sites in NOGO-specific RNAs represent a novel therapeutic approach to treat a variety of pathologic indications, including but not limited to CNS injury and cerebrovascular accident (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS), chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS), Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt- akob disease, muscular dystrophy, and/or other neurodegenerative disease states which respond to the modulation of NOGO expression In one of the preferred embodiments of the inventions described herein, the enzymatic nucleic acid molecule is formed in a hammerhead or hairpin motif, but can also be formed in the motif of a hepatitis delta virus, group I intron, group II intron or RNase P RNA (in association with an RNA guide sequence), Neurospora NS RΝA, DNAzymes, NCH cleaving motifs, or G- cleavers. Examples of such hammerhead motifs are described by Dreyfus, supra, Rossi et al, 1992, AIDS Research and Human Retroviruses 8, 183. Examples of hairpin motifs are described by Hampel et al, EP0360257, Hampel and Tritz, 1989 Biochemistry 28, 4929, Feldstein et al, 1989, Gene 82, 53, Haseloff and Gerlach, 1989, Gene, 82, 43, Hampel et al, 1990 Nucleic Acids Res. 18, 299; and Chowrira & McSwiggen, US. Patent No. 5,631,359. The hepatitis delta virus motif is described by Perrotta and Been, 1992 Biochemistry 31, 16. The RNase P motif is described by Guerrier-Takada et al, 1983 Cell 35, 849; Forster and Altman, 1990, Science 249, 783; and Li and Altman, 1996, Nucleic Acids Res. 24, 835. The Neurospora VS RNA ribozyme motif is described by Collins (Saville and Collins, 1990 Cell 61, 685-696; Saville and Collins, 1991 Proc. Natl Acad. Sci. USA 88, 8826-8830; Collins and Olive, 1993 Biochemistry 32, 2795- 2799; and Guo and Collins, 1995, EMBO. J. 14, 363). Group II introns are described by Griffin et al, 1995, Chem. Biol. 2, 761; Michels and Pyle, 1995, Biochemistry 34, 2965; and Pyle et al, International PCT Publication No. WO 96/22689. The Group I intron is described by Cech et al, U.S. Patent 4,987,071. DNAzymes are described by Usman et al, International PCT Publication No. WO 95/11304; Chartrand et al, 1995, NAR 23, 4092; Breaker et al, 1995, Chem. Bio. 2, 655; and Santoro et al, 1997, PNAS 94, 4262. NCH cleaving motifs are described in Ludwig & Sproat, International PCT Publication No. WO 98/58058; and G-cleavers are described in Kore et al, 1998, Nucleic Acids Research 26, 4116-4120 and Eckstein et al, International PCT Publication No. WO 99/16871. Additional motifs include the Aptazyme (Breaker et al, WO 98/43993), Amberzyme (Class I motif; Figure 3; Beigelman et al, International PCT publication No. WO 99/55857) and Zinzyme (Figure 4) (Beigelman et al, International PCT publication No. WO 99/55857), all these references are incorporated by reference herein in their totalities, including drawings and can also be used in the present invention. These specific motifs are not limiting in the invention and those skilled in the art will recognize that all that is important in an enzymatic nucleic acid molecule of this invention is that it has a specific substrate binding site which is complementary to one or more of the target gene RNA regions, and that it have nucleotide sequences within or surrounding that substrate binding site which impart an RNA cleaving activity to the molecule (Cech et al, U.S. Patent No. 4,987,071). In preferred embodiments of the present invention, a nucleic acid molecule of the instant invention can be between 13 and 100 nucleotides in length. Exemplary enzymatic nucleic acid molecules of the invention are shown in Tables III-XIV. For example, enzymatic nucleic acid molecules of the invention are preferably between 15 and 50 nucleotides in length, more preferably between 25 and 40 nucleotides in length, e.g., 34, 36, or 38 nucleotides in length (for example see Jarvis et al, 1996, J. Biol. Chem., 271, 29107-29112). Exemplary DNAzymes of the invention are preferably between 15 and 40 nucleotides in length, more preferably between 25 and 35 nucleotides in length, e.g., 29, 30, 31, or 32 nucleotides in length (see for example Santoro et al, 1998, Biochemistry, 37, 13330-13342; Chartrand et al, 1995, Nucleic Acids Research, 23, 4092-4096). Exemplary antisense molecules of the invention are preferably between 15 and 75 nucleotides in length, more preferably between 20 and 35 nucleotides in length, e.g., 25, 26, 27, or 28 nucleotides in length (see for example Woolf et al, 1992, PNAS., 89, 7305-7309; Milner et al, 1997, Nature Biotechnology, 15, 537-541). Exemplary triplex forming oligonucleotide molecules of the invention are preferably between 10 and 40 nucleotides in length, more preferably between 12 and 25 nucleotides in length, e.g., 18, 19, 20, or 21 nucleotides in length (see for example Maher et al, 1990, Biochemistry, 29, 8820-8826; Strobel and Dervan, 1990, Science, 249, 73-75). Those skilled in the art will recognize that all that is required is for the nucleic acid molecule are of length and conformation sufficient and suitable for the nucleic acid molecule to catalyze a reaction contemplated herein. The length of the nucleic acid molecules of the instant invention are not limiting within the general limits stated. Preferably, a nucleic acid molecule that down regulates the replication of CD20 and/or NOGO comprises between 12 and 100 bases complementary to a RNA molecule of CD20 and/or NOGO. Even more preferably, a nucleic acid molecule that down regulates the replication of CD20 and/or NOGO comprises between 14 and 24 bases complementary to a RNA molecule of CD20 and/or NOGO. In a preferred embodiment, the invention provides a method for producing a class of nucleic acid-based gene inhibiting agents which exhibit a high degree of specificity for the RNA of a desired target. For example, the enzymatic nucleic acid molecule is preferably targeted to a highly conserved sequence region of target RNAs encoding NOGO-A, B, C, and/or CD20 proteins (specifically NOGO and/or CD20 gene) such that specific treatment of a disease or condition can be provided with either one or several nucleic acid molecules of the invention. Such nucleic acid molecules can be delivered exogenously to specific tissues or cellular targets as required. Alternatively, the nucleic acid molecules (e.g., ribozymes and antisense) can be expressed from DNA and/or RNA vectors that are delivered to specific cells. In a preferred embodiment, the invention features the use of nucleic acid-based inhibitors of the invention to specifically target genes that share homology with the CD20 and/or NOGO gene. As used in herein "cell" is used in its usual biological sense, and does not refer to an entire multicellular organism, e.g., specifically does not refer to a human. The cell may be present in an organism which may be a human but is preferably a non-human multicellular organism, e.g., birds, plants and mammals such as cows, sheep, apes, monkeys, swine, dogs, and cats. The cell may be prokaryotic (e.g., bacterial cell) or eukaryotic (e.g., mammalian or plant cell). By "CD20 proteins" is meant, a protein or a mutant protein derivative thereof, comprising a cell surface phosphoprotein which is expressed, for example, in mature B lymphocytes. By "NOGO proteins" is meant, a protein or a mutant protein derivative thereof, comprising neuronal inhibitor activity, preferably CNS neuronal growth inhibitor activity. By "highly conserved sequence region" is meant, a nucleotide sequence of one or more regions in a target gene does not vary significantly from one generation to the other or from one biological system to the other. The nucleic acid-based inhibitors of CD20 expression are useful for the prevention and/or treatment of diseases and conditions such as lymphoma, leukemia, and arthropathy, including but not limited to B-cell lymphoma, low-grade or follicular non-Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lypmphocytic leukemia, HIV associated NHL, mantle-cell lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma, immune thrombocytopenia, inflammatory arthropathy, and any other diseases or conditions that are related to or will respond to the levels of CD20 in a cell or tissue, alone or in combination with other therapies. The nucleic acid-based inhibitors of NOGO expression are useful for the prevention and/or treatment of diseases and conditions such CNS injury and cerebrovascular accident (CNA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS), chemotherapy-induced neuropathy, muscular dystrophy and any other diseases or conditions that are related to or will respond to the levels of ΝOGO in a cell or tissue, alone or in combination with other therapies. In addition, ΝOGO inhibition may be used as a therapeutic target for abrogating CΝS neuronal growth inhibition; a situation that may selectively regenerate damaged or lesioned CΝS tissue to restore specific reflex and/or locomotor functions. By "related" is meant that the reduction of CD20 and/or ΝOGO expression (specifically CD20 and/or ΝOGO gene) RΝA levels and thus reduction in the level of the respective protein will relieve, to some extent, the symptoms of the disease or condition. The nucleic acid-based inhibitors of the invention are added directly, or can be complexed with cationic lipids, packaged within liposomes, or otherwise delivered to target cells or tissues. The nucleic acid or nucleic acid complexes can be locally administered to relevant tissues ex vivo, or in vivo through injection, infusion pump or stent, with or without their incorporation in biopolymers. In preferred embodiments, the enzymatic nucleic acid inhibitors comprise sequences, which are complementary to the substrate sequences in Tables III to XIV. Examples of such enzymatic nucleic acid molecules also are shown in Tables III to XIV. Examples of such enzymatic nucleic acid molecules consist essentially of sequences defined in these Tables. h yet another embodiment, the invention features antisense nucleic acid molecules and 2- 5A chimera including sequences complementary to the substrate sequences shown in Tables III to XIV. Such nucleic acid molecules can include sequences as shown for the binding arms of the enzymatic nucleic acid molecules in Tables III to XIV. Similarly, triplex molecules can be provided targeted to the corresponding DNA target regions, and containing the DNA equivalent of a target sequence or a sequence complementary to the specified target (substrate) sequence. Typically, antisense molecules are complementary to a target sequence along a single contiguous sequence of the antisense molecule. However, in certain embodiments, an antisense molecule may bind to substrate such that the substrate molecule forms a loop, and/or an antisense molecule can bind such that the antisense molecule forms a loop. Thus, the antisense molecule can be complementary to two (or even more) non-contiguous substrate sequences or two (or even more) non-contiguous sequence portions of an antisense molecule may be complementary to a target sequence or both. By "consists essentially of is meant that the active nucleic acid molecule of the invention, for example an enzymatic nucleic acid molecule, contains an enzymatic center or core equivalent to those in the examples, and binding arms able to bind RNA such that cleavage at the target site occurs. Other sequences can be present which do not interfere with such cleavage. Thus, a core region can, for example, include one or more loop, stem-loop structure, or linker which does not prevent enzymatic activity. The underlined regions in the sequences in Tables III, IV, IX and X can be such a loop, stem-loop, nucleotide linker, and/or non-nucleotide linker and can be represented generally as sequence "X". For example, a core sequence for a hammerhead enzymatic nucleic acid can comprise a conserved sequence, such as 5'-CUGAUGAG-3' and 5'- CGAA-3' connected by a sequence "X", where X is 5'-GCCGUUAGGC-3' (SEQ ID NO 9265), or any other stem II region known in the art, or a nucleotide and/or non-nucleotide linker. Similarly, for other nucleic acid molecules of the instant invention, such as Inozyme, G-cleaver, amberzyme, zinzyme, DNAzyme, antisense, 2-5A antisense, triplex forming nucleic acid, and decoy nucleic acids, other sequences or non-nucleotide linkers may be present that do not interfere with the function of the nucleic acid molecule. Sequence X may be a linker of > 2 nucleotides in length, preferably 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 26, 30, where the nucleotides may preferably be internally base-paired to form a stem of preferably > 2 base pairs. Alternatively or in addition, X may be a non-nucleotide linker. In yet another embodiment, the nucleotide linker X can be a nucleic acid aptamer, such as an ATP aptamer, HIN Rev aptamer (RRE), HIN Tat aptamer (TAR) and others (for a review see Gold et al, 1995, Annu. Rev. Biochem., 64, 763; and Szostak & Ellington, 1993, in The RNA World, ed. Gesteland and Atkins, pp. 511, CSH Laboratory Press). A "nucleic acid aptamer" as used herein is meant to indicate a nucleic acid sequence capable of interacting with a ligand. The ligand can be any natural or a synthetic molecule, including but not limited to a resin, metabolites, nucleosides, nucleotides, drugs, toxins, transition state analogs, peptides, lipids, proteins, amino acids, nucleic acid molecules, hormones, carbohydrates, receptors, cells, viruses, bacteria and others. In yet another embodiment, the non-nucleotide linker X is as defined herein. The term "non-nucleotide" as used herein include either abasic nucleotide, polyether, polyamine, polyamide, peptide, carbohydrate, lipid, or polyhydrocarbon compounds. Specific examples include those described by Seela and Kaiser, Nucleic Acids Res. 1990, 75:6353 and Nucleic Acids Res. 1987, i5:3113; Cload and Schepartz, J. Am. Chem. Soc. 1991, 113:6324; Richardson and Schepartz, J. Am. Chem. Soc. 1991, 113:5109; Ma et al., Nucleic Acids Res. 1993, 2 :2585 and Biochemistry 1993, 32:1751; Durand et al., Nucleic Acids Res. 1990, 7S:6353; McCurdy et al., Nucleosides & Nucleotides 1991, 10:287; Jschke et al., Tetrahedron Lett. 1993, 54:301; Ono et al, Biochemistiy 1991, 30:9914; Arnold et al, International Publication No. WO 89/02439; Usman et al, International Publication No. WO 95/06731; Dudycz et al, International Publication No. WO 95/11910 and Ferentz and Verdine, J Am. Chem. Soc. 1991, 7 5:4000, all hereby incorporated by reference herein. A "non-nucleotide" further means any group or compound which can be incorporated into a nucleic acid chain in the place of one or more nucleotide units, including either sugar and/or phosphate substitutions, and allows the remaining bases to exhibit their enzymatic activity. The group or compound can be abasic in that it does not contain a commonly recognized nucleotide base, such as adenosine, guanine, cytosine, uracil or thymine. Thus, in a preferred embodiment, the invention features an enzymatic nucleic acid molecule having one or more non-nucleotide moieties, and having enzymatic activity to cleave an RNA or DNA molecule. In another aspect of the invention, enzymatic nucleic acids or antisense molecules that interact with target RNA molecules and inhibit CD20 and/or NOGO (specifically CD20 and/or NOGO gene) activity are expressed from transcription units inserted into DNA or RNA vectors. The recombinant vectors are preferably DNA plasmids or viral vectors. Enzymatic nucleic acid or antisense expressing viral vectors can be constructed based on, but not limited to, adeno- associated virus, retrovirus, adenovirus, or alphavirus. Preferably, the recombinant vectors capable of expressing the enzymatic nucleic acids or antisense are delivered as described herein, and persist in target cells. Alternatively, viral vectors can be used that provide for transient expression of enzymatic nucleic acids or antisense. Such vectors can be repeatedly administered as necessary. Once expressed, the enzymatic nucleic acids or antisense bind to the target RNA and inhibit its function or expression. Delivery of enzymatic nucleic acid or antisense expressing vectors can be systemic, such as by intravenous or intramuscular administration, by administration to target cells ex-planted from the patient followed by reintroduction into the patient, or by any other means that would allow for introduction into the desired target cell. Antisense DNA can be expressed via the use of a single stranded DNA intracellular expression vector. By "vectors" is meant any nucleic acid- and/or viral-based technique used to deliver a desired nucleic acid. By "patient" is meant an organism, which is a donor or recipient of explanted cells or the cells themselves. "Patient" also refers to an organism to which the nucleic acid molecules of the invention can be administered. Preferably, a patient is a mammal or mammalian cells. More preferably, a patient is a human or human cells. By "enhanced enzymatic activity" is meant to include activity measured in cells and/or in vivo where the activity is a reflection of both the catalytic activity and the stability of the nucleic acid molecules of the invention. In this invention, the product of these properties can be increased in vivo compared to an all RNA enzymatic nucleic acid or all DNA enzyme. In some cases, the activity or stability of the nucleic acid molecule can be decreased (i.e., less than tenfold), but the overall activity of the nucleic acid molecule is enhanced, in vivo. The nucleic acid molecules of the instant invention, individually, or in combination or in conjunction with other drugs, can be used to treat diseases or conditions discussed above. For example, to treat a disease or condition associated with the levels of CD20 and/or NOGO, the patient may be treated, or other appropriate cells may be treated, as is evident to those skilled in the art, individually or in combination with one or more drugs under conditions suitable for the treatment. In a further embodiment, the described molecules, such as antisense or enzymatic nucleic acids, can be used in combination with other known treatments to treat conditions or diseases discussed above. For example, the described molecules can be used in combination with one or more known therapeutic agents to treat CNS injury and cerebrovascular accident (CNA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS), chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS), Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt- Jakob disease, muscular dystrophy, lymphoma, leukemia, and arthropathy, including but not limited to B-cell lymphoma, low-grade or follicular non-Hodgkin's lymphoma (ΝHL), bulky low-grade or follicular ΝHL, lypmphocytic leukemia, HIV associated ΝHL, mantle-cell lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma, and immune thrombocytopenia, inflammatory arthropathy, and/or other disease states or conditions which respond to the modulation of CD20 and/or NOGO expression. In another preferred embodiment, the invention features nucleic acid-based inhibitors (e.g., enzymatic nucleic acid molecules (ribozymes), antisense nucleic acids, 2-5A antisense chimeras, triplex DNA, antisense nucleic acids containing RNA cleaving chemical groups) and methods for their use to down regulate or inhibit the expression of genes (e.g., CD20) capable of progression and/or maintenance of lymphoma, leukemia, and arthropathy, including but not limited to B-cell lymphoma, low-grade or follicular non-Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lypmphocytic leukemia, HIV associated NHL, mantle-cell lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma, and immune thrombocytopenia, inflammatory arthropathy, and/or other disease states or conditions which respond to the modulation of CD20 expression. In another preferred embodiment, the invention features nucleic acid-based inhibitors (e.g., enzymatic nucleic acid molecules (eg; ribozymes), antisense nucleic acids, 2-5A antisense chimeras, triplex DNA, antisense nucleic acids containing RNA cleaving chemical groups) and methods for their use to down regulate or inhibit the expression of genes (e.g., NOGO) capable of progression and/or maintenance of CNS injury and cerebrovascular accident (CNA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS), chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS), Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt- Jakob disease, muscular dystrophy, and/or other neurodegenerative disease states which respond to the modulation of ΝOGO expression. In another aspect, the invention provides mammalian cells containing one or more nucleic acid molecules and/or expression vectors of this invention. The one or more nucleic acid molecules may independently be targeted to the same or different sites. By "comprising" is meant including, but not limited to, whatever follows the word "comprising". Thus, use of the term "comprising" indicates that the listed elements are required or mandatory, but that other elements are optional and may or may not be present. By "consisting of is meant including, and limited to, whatever follows the phrase "consisting of. Thus, the phrase "consisting of indicates that the listed elements are required or mandatory, and that no other elements may be present. Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims. Description Of The Preferred Embodiments First the drawings will be described briefly. Drawings Figure 1 shows the secondary structure model for seven different classes of enzymatic nucleic acid molecules. Arrow indicates the site of cleavage. indicate the target sequence. Lines interspersed with dots are meant to indicate tertiary interactions. - is meant to indicate base-paired interaction. Group I Intron: P1-P9.0 represent various stem-loop structures (Cech et al, 1994, Nature Struc. Bio., 1, 273). RNase P (M1RNA): EGS represents external guide sequence (Forster et al, 1990, Science, 249, 783; Pace et al, 1990, J. Biol. Chem., 265, 3587). Group II Intron: 5'SS means 5' splice site; 3'SS means 3'-splice site; IBS means intron binding site; EBS means exon binding site (Pyle et al, 1994, Biochemistry, 33, 2716). VS RNA: I-VI are meant to indicate six stem-loop structures; shaded regions are meant to indicate tertiary interaction (Collins, International PCT Publication No. WO 96/19577). HDV Ribozyme: : I-IV are meant to indicate four stem-loop structures (Been et al, US Patent No. 5,625,047). Hammerhead Ribozyme: : I-III are meant to indicate three stem-loop structures; stems I-III can be of any length and may be symmetrical or asymmetrical (Usman et al, 1996, Curr. Op. Struct. Bio., 1, 527). Hairpin Ribozyme: Helix 1, 4 and 5 can be of any length; Helix 2 is between 3 and 8 base-pairs long; Y is a pyrimidine; Helix 2 (H2) is provided with a least 4 base pairs (i.e., n is 1, 2, 3 or 4) and helix 5 can be optionally provided of length 2 or more bases (preferably 3 - 20 bases, i.e., m is from 1 - 20 or more). Helix 2 and helix 5 may be covalently linked by one or more bases (i.e., r is > 1 base). Helix 1, 4 or 5 may also be extended by 2 or more base pairs (e.g., 4 - 20 base pairs) to stabilize the ribozyme structure, and preferably is a protein binding site. In each instance, each N and N' independently is any normal or modified base and each dash represents a potential base-pairing interaction. These nucleotides may be modified at the sugar, base or phosphate. Complete base-pairing is not required in the helices, but is preferred. Helix 1 and 4 can be of any size (i.e., o and p is each independently from 0 to any number, e.g., 20) as long as some base-pairing is maintained. Essential bases are shown as specific bases in the structure, but those in the art will recognize that one or more may be modified chemically (abasic, base, sugar and/or phosphate modifications) or replaced with another base without significant effect. Helix 4 can be formed from two separate molecules, i.e., without a connecting loop. The connecting loop when present may be a ribonucleotide with or without modifications to its base, sugar or phosphate, "q" > is 2 bases. The connecting loop can also be replaced with a non-nucleotide linker molecule. H refers to bases A, U, or C. Y refers to pyrimidine bases. " " refers to a covalent bond. (Burke et al, 1996, Nucleic Acids & Mol Biol, 10, 129; Chowrira et al, US Patent No. 5,631,359). Figure 2 shows examples of chemically stabilized ribozyme motifs. HH Rz, represents hammerhead ribozyme motif (Usman et al, 1996, Curr. Op. Struct. Bio., 1, 527); NCH Rz represents the NCH ribozyme motif (Ludwig & Sproat, International PCT Publication No. WO 98/58058); G-Cleaver, represents G-cleaver ribozyme motif (Kore et al, 1998, Nucleic Acids Research 26, 4116-4120). N or n, represent independently a nucleotide which may be same or different and have complementarity to each other; rl, represents ribo-Inosine nucleotide; arrow indicates the site of cleavage within the target. Position 4 of the HH Rz and the NCH Rz is shown as having 2'-C-allyl modification, but those skilled in the art will recognize that this position can be modified with other modifications well known in the art, so long as such modifications do not significantly inhibit the activity of the ribozyme. Figure 3 shows an example of the Amberzyme enzymatic nucleic acid motif that is chemically stabilized (see, for example, Beigelman et al, International PCT publication No. WO 99/55857, incorporated by reference herein; also referred to as Class I Motif). The Amberzyme motif is a class of enzymatic nucleic molecules that do not require the presence of a ribonucleotide (2' -OH) group for its activity. Figure 4 shows an example of the Zinzyme A enzymatic nucleic acid motif that is chemically stabilized (Beigelman et al, International PCT publication No. WO 99/55857, incorporated by reference herein; also referred to as Class A or Class II Motif). The Zinzyme motif is a class of enzymatic nucleic molecules that do not require the presence of a ribonucleotide (2' -OH) group for its activity. Figure 5 shows an example of a DNAzyme motif described by Santoro et al, 1997, PNAS, 94, 4262. Figure 6 shows a non-limiting example of the detection of a target sequence using a hammerhead-based cis-blocking sequence strategy. In this case, the effector molecule, in the absence of target, is inactivated by intramolecular folding. Addition of target sequence allows hybridization of the effector molecule/target complex to the reporter sequence. Concomitant cleavage of the reporter molecule by the activated target/effector molecule complex provides a fluorescent signal due to the separation of flurophore and quench molecules. This same concept can be applied to other enzymatic nucleic acid motifs of the instant invention, including but not limited to Inozymes, G-cleavers, DNAzymes, Zinzymes, Amberzymes, and Hairpins. In addition, the configuration of the blocking sequence can hybridize with a variety of sequence positions both in cis and in trans (e.g., intermolecular binding and/or intramolecular binding) and in a variety of different locations on the effector molecule. Additional non-limiting configurations are summarized in Figures 8-14. Figure 7 shows a schematic diagram indicating the two primary configurations of a cis- acting Diagnostic effector molecule. The molecule may be either bound to a target sequence (A) or unbound and therefore bound to itself (B). Figure 8 displays a number of potential secondary structures for the diagnostic effector molecules in non-limiting examples. Figure 9 displays a number of potential secondary structures for the diagnostic effector molecules in non-limiting examples. Figure 10 displays a number of potential secondary structures for the diagnostic effector molecules in non-limiting examples. Figure 11 displays a number of potential secondary structures for the diagnostic effector molecules in non-limiting examples. Figure 12 displays a number of potential secondary structures for the diagnostic effector molecules in non-limiting examples. Figure 13 displays a number of potential secondary structures for the diagnostic effector molecules in non-limiting examples. Figure 14 displays a number of potential secondary structures for the diagnostic effector molecules in non-limiting examples. Figure 15 displays the inherent amplification capacity of the diagnostic system of the instant invention. Figure 16 shows the structure of a diagnostic system of the instant invention. Figure 17 is a bar graph that shows the results of testing enzymatic nucleic acid/inhibitor combinations in a cleavage assay. The substrate molecules were 5'-end labeled with 32P- phosphate and incubated for 12 or 60 minutes in either: (1) buffer alone (50 mM Tris, pH 7.5, 10 mM MgC12), or in the presence of (2) 10 nM enzymatic nucleic acid, (3) 10 nM enzymatic nucleic acid plus 20 nM inhibitor, (4) 10 nM enzymatic nucleic acid plus 200 nM inhibitor, or (5) 10 nM enzymatic nucleic acid plus 20 nM inhibitor and 500 nM target. At the end of the incubation the reactions were loaded onto a PAGE gel to separate cleaved product from uncleaved substrate. The gel was imaged on a Molecular Dynamics phosphorimager and quantitated to determine the percent of substrate cleaved under each set of conditions. Control reactions were carried out to ensure that addition of inhibitor or target sequence, without enzymatic nucleic acid, did not result in substrate cleavage; only 0.2-0.4% of substrate was cleaved under these conditions. Mechanism of action of Nucleic Acid Molecules of the Invention Antisense: Antisense molecules can be modified or unmodified RNA, DNA, or mixed polymer oligonucleotides which primarily function by specifically binding to matching sequences resulting in inhibition of peptide synthesis (Wu-Pong, Nov 1994, BioPharm, 20-33). The antisense oligonucleotide binds to target RNA by Watson Crick base-pairing and blocks gene expression by preventing ribosomal translation of the bound sequences either by steric blocking or by activating RNase H enzyme. Antisense molecules can also alter protein synthesis by interfering with RNA processing or transport from the nucleus into the cytoplasm (Mukhopadhyay & Roth, 1996, Crit. Rev. in Oncogenesis 7, 151-190). In addition, binding of single stranded DNA to RNA can result in nuclease degradation of the heteroduplex (Wu-Pong, supra; Crooke, supra). To date, the only backbone modified DNA chemistry which will act as substrates for RNase H are phosphorothioates, phosphorodithioates, and borontrifluoridates. Recently it has been reported that 2'-arabino and 2'-fluoro arabino- containing oligos can also activate RNase H activity. A number of antisense molecules have been described that utilize novel configurations of chemically modified nucleotides, secondary structure, and/or RNase H substrate domains (Woolf et al, International PCT Publication No. WO 98/13526; Thompson et al, International PCT Publication No. WO 99/54459; Hartmann et al, USSN 60/101,174 which was filed on September 21, 1998) all of these are incorporated by reference herein in their entirety. In addition, antisense deoxyoligoribonucleotides can be used to target RNA by means of DNA-RNA interactions, thereby activating RNase H, which digests the target RNA in the duplex. Antisense DNA can be expressed via the use of a single stranded DNA intracellular expression vector or equivalents and variations thereof. Triplex Forming Oligonucleotides (TFO : Single stranded DNA can be designed to bind to genomic DNA in a sequence specific manner. TFOs are comprised of pyrimidine-rich oligonucleotides which bind DNA helices through Hoogsteen Base-pairing (Wu-Pong, supra). The resulting triple helix composed of the DNA sense, DNA antisense, and TFO disrupts RNA synthesis by RNA polymerase. The TFO mechanism may result in gene expression or cell death since binding may be irreversible (Muldiopadhyay & Roth, supra). 2-5A Antisense Chimera: The 2-5A system is an interferon mediated mechanism for RNA degradation found in higher vertebrates (Mitra et al, 1996, Proc Nat Acad Sci USA 93, 6780- 6785). Two types of enzymes, 2-5A synthetase and RNase L, are required for RNA cleavage. The 2-5 A synthetases require double stranded RNA to form 2'-5' oligoadenylates (2-5 A). 2-5A then acts as an allosteric effector for utilizing RNase L which has the ability to cleave single stranded RNA. The ability to form 2-5 A structures with double stranded RNA makes this system particularly useful for inhibition of viral replication. (2'-5') oligoadenylate structures can be covalently linked to antisense molecules to form chimeric oligonucleotides capable of RNA cleavage (Torrence, supra). These molecules putatively bind and activate a 2-5A dependent RNase, the oligonucleotide/enzyme complex then binds to a target RNA molecule which can then be cleaved by the RNase enzyme. Enzymatic Nucleic Acid: Seven basic varieties of naturally occurring enzymatic RNAs are presently known. In addition, several in vitro selection (evolution) strategies (Orgel, 1979, Proc. R. Soc. London, B 205, 435) have been used to evolve new nucleic acid catalysts capable of catalyzing cleavage and ligation of phosphodiester linkages (Joyce, 1989, Gene, 82, 83-87; Beaudry et al, 1992, Science 257, 635-641; Joyce, 1992, Scientific American 267, 90-97; Breaker et al, 1994, TIBTECH 12, 268; Bartel et α/., 1993, Science 261:1411-1418; Szostak, 1993, TIBS 17, 89-93; Kumar et al, 1995, FASEB , 9, 1183; Breaker, 1996, Curr. Op. Biotech., 7, 442; Santoro et al, 1997, Proc. Natl Acad. Sci., 94, 4262; Tang et al, 1997, RNA 3, 914; Nakamaye & Eckstein, 1994, supra; Long & Uhlenbeck, 1994, supra; Ishizaka et al, 1995, supra; Naish et al, 1997, Biochemistry 36, 6495; all of these are incorporated by reference herein). Each can catalyze a series of reactions including the hydrolysis of phosphodiester bonds in trans (and thus can cleave other RΝA molecules) under physiological conditions. Nucleic acid molecules of this invention can block to some extent CD20, NOGO-A, B, and/or C protein expression and can be used to treat disease or diagnose disease associated with the levels of CD20, NOGO-A, B, and/or C. The enzymatic nature of a enzymatic nucleic acid has significant advantages, such as the concentration of enzymatic nucleic acid necessary to affect a therapeutic treatment is low. This advantage reflects the ability of the enzymatic nucleic acid to act enzymatically. Thus, a single enzymatic nucleic acid molecule is able to cleave many molecules of target RNA. In addition, the enzymatic nucleic acid is a highly specific inhibitor, with the specificity of inhibition depending not only on the base-pairing mechanism of binding to the target RNA, but also on the mechanism of target RNA cleavage. Single mismatches, or base-substitutions, near the site of cleavage can be chosen to completely eliminate catalytic activity of an enzymatic nucleic acid. Nucleic acid molecules having an endonuclease enzymatic activity are able to repeatedly cleave other separate RNA molecules in a nucleotide base sequence-specific manner. Such enzymatic nucleic acid molecules can be targeted to virtually any RNA transcript, and achieve efficient cleavage in vitro (Zaug et al, 324, Nature 429 1986 ; Uhlenbeck, 1987 Nature 328, 596; Kim et al, 84 Proc. Natl. Acad. Sci. USA 8788, 1987; Dreyfus, 1988, Einstein Quart. J. Bio. Med., 6, 92; Haseloff and Gerlach, 334 Nature 585, 1988; Cech, 260 JAMA 3030, 1988; Jefferies et al, 17 Nucleic Acids Research 1371, 1989; and Santoro et al, 1997 supra). Because of their sequence specificity, trans-cleaving enzymatic nucleic acids show promise as therapeutic agents for human disease (Usman & McSwiggen, 1995 Ann. Rep. Med. Chem. 30, 285-294; Christoffersen and Marr, 1995 J. Med. Chem. 38, 2023-2037). Enzymatic nucleic acids can be designed to cleave specific RNA targets within the background of cellular RNA. Such a cleavage event renders the RNA non-functional and abrogates protein expression from, that RNA. In this manner, synthesis of a protein associated with a disease state can be selectively inhibited (Warashina et al, 1999, Chemistry and Biology, 6, 237-250). The nucleic acid molecules of the instant invention are also referred to as GeneBloc™ reagents, which are essentially nucleic acid molecules (e.g.; ribozymes, antisense) capable of down-regulating gene expression. GeneBlocs are modified oligonucleotides including ribozymes and modified antisense oligonucleotides that bind to and target specific mRNA molecules. Because GeneBlocs can be designed to target any specific mRNA, their potential applications are quite broad. Traditional antisense approaches have often relied heavily on the use of phosphorothioate modifications to enhance stability in biological samples, leading to a myriad of specificity problems stemming from non-specific protein binding and general cytotoxicity (Stein, 1995, Nature Medicine, 1, 1119). In contrast, GeneBlocs contain a number of modifications that confer nuclease resistance while making minimal use of phosphorothioate linkages, which reduces toxicity, increases binding affinity and minimizes non-specific effects compared with traditional antisense oligonucleotides. Similar reagents have recently been utilized successfully in various cell culture systems (Nassar, et al, 1999, Science, 286, 735) and in vivo (Jarvis et al., manuscript in preparation). In addition, novel cationic lipids can be utilized to enhance cellular uptake in the presence of serum. Since ribozymes and antisense oligonucleotides regulate gene expression at the RΝA level, the ability to maintain a steady-state dose of GeneBloc over several days was important for target protein and phenotypic analysis. The advances in resistance to nuclease degradation and prolonged activity in vitro have supported the use of GeneBlocs in target validation applications. Target sites Targets for useful enzymatic nucleic acids and antisense nucleic acids can be determined as disclosed in Draper et al, WO 93/23569; Sullivan et al, WO 93/23057; Thompson et al, WO 94/02595; Draper et al, WO 95/04818; McSwiggen et al, US Patent No. 5,525,468. All of these publications are hereby incorporated by reference herein in their totality. Other examples include the following PCT applications, which concern inactivation of expression of disease- related genes: WO 95/23225, WO 95/13380, WO 94/02595, all of which are incorporated by reference herein. Rather than repeat the guidance provided in those documents here, specific examples of such methods are provided herein, not limiting to those in the art. Enzymatic nucleic acids and antisense to such targets are designed as described in those applications and synthesized to be tested in vitro and in vivo, as also described. The sequences of human CD20 and NOGO RNAs were screened for optimal enzymatic nucleic acid and antisense target sites using a computer-folding algorithm. Antisense, hammerhead, DNAzyme, NCH, amberzyme, zinzyme, or G-Cleaver enzymatic nucleic acid binding/cleavage sites were identified. These sites are shown in Tables III to XIV (all sequences are 5' to 3' in the tables; underlined regions can be any sequence "X" or linker X, the actual sequence is not relevant here). The nucleotide base position is noted in the Tables as that site to be cleaved by the designated type of enzymatic nucleic acid molecule. While human sequences can be screened and enzymatic nucleic acid molecule and/or antisense thereafter designed, as discussed in Stinchcomb et al, WO 95/23225, mouse targeted enzymatic nucleic acids may be useful to test efficacy of action of the enzymatic nucleic acid molecule and/or antisense prior to testing in humans. Antisense, hammerhead, DNAzyme, NCH, amberzyme, zinzyme or G-Cleaver enzymatic nucleic acid binding/cleavage sites were identified. The nucleic acid molecules are individually analyzed by computer folding (Jaeger et al, 1989 Proc. Natl. Acad. Sci. USA, 86, 7706) to assess whether the sequences fold into the appropriate secondary structure. Those nucleic acid molecules with unfavorable intramolecular interactions such as between the binding arms and the catalytic core are eliminated from consideration. Varying binding arm lengths can be chosen to optimize activity. Antisense, hammerhead, DNAzyme, NCH, amberzyme, zinzyme or G-Cleaver enzymatic nucleic acid binding/cleavage sites were identified and were designed to anneal to various sites in the RNA target. The binding arms are complementary to the target site sequences described above. The nucleic acid molecules were chemically synthesized. The method of synthesis used follows the procedure for normal DNA/RNA synthesis as described below and in Usman et al, 1987 J. Am. Chem. Soc, 109, 7845; Scaringe et al, 1990 Nucleic Acids Res., 18, 5433; Wincott et al, 1995 Nucleic Acids Res. 23, 2677-2684; and Caruthers et al, 1992, Methods in Enzymology 211,3-19. Synthesis of Nucleic acid Molecules Synthesis of nucleic acids greater than 100 nucleotides in length is difficult using automated methods, and the therapeutic cost of such molecules is prohibitive. In this invention, small nucleic acid motifs ("small refers to nucleic acid motifs no more than 100 nucleotides in length, preferably no more than 80 nucleotides in length, and most preferably no more than 50 nucleotides in length; e.g., antisense oligonucleotides, hammerhead or the NCH enzymatic nucleic acids) are preferably used for exogenous delivery. The simple structure of these molecules increases the ability of the nucleic acid to invade targeted regions of RNA structure. Exemplary molecules of the instant invention are chemically synthesized, and others can similarly be synthesized. Oligonucleotides (e.g.; antisense GeneBlocs) are synthesized using protocols known in the art as described in Caruthers et al, 1992, Methods in Enzymology 211, 3-19, Thompson et al, International PCT Publication No. WO 99/54459, Wincott et al, 1995, Nucleic Acids Res. 23, 2677-2684, Wincott et al, 1997, Methods Mol. Bio., 74, 59, Brennan et al, 1998, Biotechnol Bioeng., 61, 33-45, and Brennan, US patent No. 6,001,311. All of these references are incorporated herein by reference. The synthesis of oligonucleotides makes use of common nucleic acid protecting and coupling groups, such as dimethoxytrityl at the 5 '-end, and phosphoramidites at the 3 '-end. In a non-limiting example, small scale syntheses are conducted on a 394 Applied Biosystems, Inc. synthesizer using a 0.2 μmol scale protocol with a 2.5 min coupling step for 2'-O-methylated nucleotides and a 45 sec coupling step for 2'-deoxy nucleotides. Table II outlines the amounts and the contact times of the reagents used in the synthesis cycle. Alternatively, syntheses at the 0.2 μmol scale can be performed on a 96-well plate synthesizer, such as the instrument produced by Protogene (Palo Alto, CA) with minimal modification to the cycle. A 33-fold excess (60 μL of 0.11 M = 6.6 μmol) of 2'-O-methyl phosphoramidite and a 105-fold excess of S-ethyl tetrazole (60 μL of 0.25 M = 15 μmol) can be used in each coupling cycle of 2'-O-methyl residues relative to polymer-bound 5'-hydroxyl. A 22-fold excess (40 μL of 0.11 M = 4.4 μmol) of deoxy phosphoramidite and a 70-fold excess of S-ethyl tetrazole (40 μL of 0.25 M = 10 μmol) can be used in each coupling cycle of deoxy residues relative to polymer-bound 5'-hydroxyl. Average coupling yields on the 394 Applied Biosystems, Inc. synthesizer, determined by colorimetric quantitation of the trityl fractions, are typically 97.5-99%. Other oligonucleotide synthesis reagents for the 394 Applied Biosystems, Inc. synthesizer include; detritylation solution is 3% TCA in methylene chloride (ABI); capping is performed with 16% N-methyl imidazole in THF (ABI) and 10% acetic anhydride/10% 2,6- lutidine in THF (ABI); and oxidation solution is 16.9 mM 12, 49 mM pyridine, 9% water in THF (PERSEPTIVE™). Burdick & Jackson Synthesis Grade acetonitrile is used directly from the reagent bottle. S-Ethyltetrazole solution (0.25 M in acetonitrile) is made up from the solid obtained from American International Chemical, Inc. Alternately, for the introduction of phosphorothioate linkages, Beaucage reagent (3H-l,2-Benzodithiol-3-one 1,1-dioxide, 0.05 M in acetonitrile) is used. Deprotection of the antisense oligonucleotides is performed as follows. The polymer- bound trityl-on oligoribonucleotide is transferred to a 4 mL glass screw top vial and suspended in a solution of 40% aq. methylamine (1 mL) at 65 °C for 10 min. After cooling to -20 °C, the supernatant is removed from the polymer support. The support is washed three times with 1.0 mL of EtOH:MeCΝ:H2O/3:l:l, vortexed and the supernatant is then added to the first supernatant. The combined supernatants, containing the oligoribonucleotide, are dried to a white powder. The method of synthesis used for normal RNA, including certain enzymatic nucleic acid molecules follows, the procedure as described in Usman et al, 1987, J. Am. Chem. Soc, 109, 7845; Scaringe et al, 1990, Nucleic Acids Res., 18, 5433; Wincott et al, 1995, Nucleic Acids Res. 23, 2677-2684 and Wincott et al, 1997, Methods Mol. Bio., 74, 59, and makes use of common nucleic acid protecting and coupling groups, such as dimethoxytrityl at the 5'-end, and phosphoramidites at the 3 '-end. In a non-limiting example, small scale syntheses are conducted on a 394 Applied Biosystems, Inc. synthesizer using a 0.2 μmol scale protocol with a 7.5 min coupling step for alkylsilyl protected nucleotides and a 2.5 min coupling step for 2'-O- methylated nucleotides. Table II outlines the amounts and the contact times of the reagents used in the synthesis cycle. Alternatively, syntheses at the 0.2 μmol scale can be done on a 96-well plate synthesizer, such as the instrument produced by Protogene (Palo Alto, CA) with minimal modification to the cycle. A 33-fold excess (60 μL of 0.11 M = 6.6 μmol) of 2'-O-methyl phosphoramidite and a 75-fold excess of S-ethyl tetrazole (60 μL of 0.25 M = 15 μmol) can be used in each coupling cycle of 2'-O-methyl residues relative to polymer-bound 5'-hydroxyl. A 66-fold excess (120 μL of 0.11 M = 13.2 μmol) of alkylsilyl (ribo) protected phosphoramidite and a 150-fold excess of S-ethyl tetrazole (120 μL of 0.25 M = 30 μmol) can be used in each coupling cycle of ribo residues relative to polymer-bound 5'-hydroxyl. Average coupling yields on the 394 Applied Biosystems, Inc. synthesizer, determined by colorimetric quantitation of the trityl fractions, are typically 97.5-99%). Other oligonucleotide synthesis reagents for the 394 Applied Biosystems, Inc. synthesizer include the following: detritylation solution is 3% TCA in methylene chloride (ABI); capping is performed with 16% N-methyl imidazole in THF (ABI) and 10%) acetic anhydride/10%) 2,6-lutidine in THF (ABI); and oxidation solution is 16.9 mM 12, 49 mM pyridine, 9% water in THF (PERSEPTINE™). Burdick & Jackson Synthesis Grade acetonitrile is used directly from the reagent bottle. S-Ethyltetrazole solution (0.25 M in acetonitrile) is made up from the solid obtained from American International Chemical, Inc. Alternately, for the introduction of phosphorothioate linkages, Beaucage reagent (3H-1,2- Benzoditl iol-3-one 1,1 -dioxide 0.05 M in acetonitrile) is used. Deprotection of the RΝA is performed using either a two-pot or one-pot protocol. For the two-pot protocol, the polymer-bound trityl-on oligoribonucleotide is transferred to a 4 mL glass screw top vial and suspended in a solution of 40% aq. methylamine (1 mL) at 65 °C for 10 min. After cooling to —20 °C, the supernatant is removed from the polymer support. The support is washed three times with 1.0 mL of EtOH:MeCΝ:H2O/3:l:l, vortexed and the supernatant is then added to the first supernatant. The combined supernatants, containing the oligoribonucleotide, are dried to a white powder. The base deprotected oligoribonucleotide is resuspended in anhydrous TEA/HF/NMP solution (300 μL of a solution of 1.5 mL N-methylpyrrolidinone, 750 μL TEA and 1 mL TEA « 3HF to provide a 1.4 M HF concentration) and heated to 65 °C. After 1.5 h, the oligomer is quenched with 1.5 M NH4HCO3. Alternatively, for the one-pot protocol, the polymer-bound trityl-on oligoribonucleotide is transferred to a 4 mL glass screw top vial and suspended in a solution of 33% ethanolic methylamine/DMSO: 1/1 (0.8 mL) at 65 °C for 15 min. The vial is brought to r.t. TEA-3HF (0.1 mL) is added and the vial is heated at 65 °C for 15 min. The sample is cooled at -20 °C and then quenched with 1.5 M NH4HCO3. For purification of the trityl-on oligomers, the quenched NH4HCO3 solution is loaded onto a C-18 containing cartridge that had been prewashed with acetonitrile followed by 50 mM TEAA. After washing the loaded cartridge with water, the RNA is detritylated with 0.5% TFA for 13 min. The cartridge is then washed again with water, salt exchanged with 1 M NaCl and washed with water again. The oligonucleotide is then eluted with 30% acetonitrile. Inactive hammerhead ribozymes or binding attenuated control (BAG) oligonucleotides) are synthesized by substituting a U for G5 and a U for A14 (numbering from Hertel, K. J., et al, 1992, Nucleic Acids Res_., 20, 3252). Similarly, one or more nucleotide substitutions can be introduced in other enzymatic nucleic acid molecules to inactivate the molecule and such molecules can serve as a negative control. The average stepwise coupling yields are typically >98% (Wincott et al, 1995 Nucleic Acids Res. 23, 2677-2684). Those of ordinary skill in the art will recognize that the scale of synthesis can be adapted to be larger or smaller than the examples described above including but not limited to 96-well format, all that is important is the ratio of chemicals used in the reaction. Alternatively, the nucleic acid molecules of the present invention can be synthesized separately and joined together post-synthetically, for example, by ligation (Moore et al, 1992, Science 256, 9923; Draper et al, International PCT publication No. WO 93/23569; Shabarova et al, 1991, Nucleic Acids Research 19, 4247; Bellon et al, 1997, Nucleosides & Nucleotides, 16, 951; Bellon et al, 1997, Bioconjugate Chem. 8, 204). The nucleic acid molecules of the present invention are modified extensively to enhance stability by modification with nuclease resistant groups, for example, 2'-amino, 2'-C-allyl, 2'- flouro, 2'-O-methyl, 2'-H (for a review see Usman and Cedergren, 1992, TIBS 17, 34; Usman et al, 1994, Nucleic Acids Symp. Ser. 31, 163). Enzymatic nucleic acids are purified by gel electrophoresis using general methods or are purified by high pressure liquid chromatography (HPLC; see Wincott et al, supra, the totality of which is hereby incorporated herein by reference) and are re-suspended in water. The sequences of the enzymatic nucleic acids and antisense constructs that are chemically synthesized, useful in this study, are shown in Tables III to XV. Those in the art will recognize that these sequences are representative only of many more such sequences where the enzymatic portion of the enzymatic nucleic acid (all but the binding arms) is altered to affect activity. The enzymatic nucleic acid and antisense construct sequences listed in Tables III to XV can be formed of ribonucleotides or other nucleotides or non-nucleotides. Such enzymatic nucleic acids with enzymatic activity are equivalent to the enzymatic nucleic acids described specifically in the Tables. Optimizing Activity of the nucleic acid molecule of the invention. Chemically synthesizing nucleic acid molecules with modifications (base, sugar and/or phosphate) that prevent their degradation by serum ribonucleases may increase their potency (see e.g., Eckstein et al, International Publication No. WO 92/07065; Perrault et al, 1990 Nature 344, 565; Pieken et al, 1991, Science 253, 314; Usman and Cedergren, 1992, Trends in Biochem. Sci. 17, 334; Usman et al, International Publication No. WO 93/15187; Rossi et al, International Publication No. WO 91/03162; Sproat, US Patent No. 5,334,711; and Burgin et al, supra; all of these describe various chemical modifications that can be made to the base, phosphate and/or sugar moieties of the nucleic acid molecules described herein. All these references are incorporated by reference herein. Modifications which enhance their efficacy in cells, and removal of bases from nucleic acid molecules to shorten oligonucleotide synthesis times and reduce chemical requirements are desired. There are several examples in the art describing sugar, base and phosphate modifications that can be introduced into nucleic acid molecules with significant enhancement in their nuclease stability and efficacy. For example, oligonucleotides are modified to enhance stability and/or enhance biological activity by modification with nuclease resistant groups, for example, 2'- amino, 2'-C-allyl, 2'-flouro, 2'-O-methyl, 2'-H, nucleotide base modifications (for a review see Usman and Cedergren, 1992, TIBS. 17, 34; Usman et al, 1994, Nucleic Acids Symp. Ser. 31, 163; Burgin et al, 1996, Biochemistry , 35, 14090). Sugar modifications of nucleic acid molecules have been extensively described in the art (see Eckstein et al, International Publication PCT No. WΟ 92/07065; Perrault et al. Nature, 1990, 344, 565-568; Pieken et al. Science, 1991, 253, 314-317; Usman and Cedergren, Trends in Biochem. Sci. , 1992, 17, 334- 339; Usman et al International Publication PCT No. WO 93/15187; Sproat, US Patent No. 5,334,711, Beigelman et al, 1995, J. Biol. Chem., 270, 25702; Beigelman et al, International PCT publication No. WO 97/26270; Beigelman et al, US Patent No. 5,716,824; Usman et al, US patent No. 5,627,053; Woolf et al, International PCT Publication No. WO 98/13526; Thompson et al, USSN 60/082,404 which was filed on April 20, 1998; Karpeisky et al, 1998, Tetrahedron Lett., 39, 1131; Earnshaw and Gait, 1998, Biopolymers (Nucleic Acid Sciences), 48, 39-55; Verma and Eckstein, 1998, Annu. Rev. Biochem., 67, 99-134; and Burlina et al, 1997, Bioorg. Med. Chem., 5, 1999-2010; all of these references are hereby incorporated by reference herein in their totalities). Such publications describe general methods and strategies to determine the location of incorporation of sugar, base and/or phosphate modifications and the like into enzymatic nucleic acids without inhibiting catalysis. In view of such teachings, similar modifications can be used as described herein to modify the nucleic acid molecules of the instant invention. While chemical modification of oligonucleotide internucleotide linkages with phosphorothioate, phosphorothioate, and/or 5'-methylphosphonate linkages improves stability, too many of these modifications may cause some toxicity. Therefore when designing nucleic acid molecules, the amount of these internucleotide linkages should be minimized. The reduction in the concentration of these linkages should lower toxicity resulting in increased efficacy and higher specificity of these molecules. Nucleic acid molecules having chemical modifications which maintain or enhance activity are provided. Such nucleic acid molecules are also generally more resistant to nucleases than unmodified nucleic acid molecules. Thus, in a cell and/or in vivo the activity may not be significantly lowered. Therapeutic nucleic acid molecules delivered exogenously must optimally be stable within cells until translation of the target RNA has been inhibited long enough to reduce the levels of the undesirable protein. This period of time varies between hours to days depending upon the disease state. Clearly, nucleic acid molecules must be resistant to nucleases in order to function as effective intracellular therapeutic agents. Improvements in the chemical synthesis of RNA and DNA (Wincott et al, 1995 Nucleic Acids Res. 23, 2677; Caruthers et al, 1992, Methods in Enzymology 211,3-19 (incorporated by reference herein) have expanded the ability to modify nucleic acid molecules by introducing nucleotide modifications to enhance their nuclease stability as described above. Use of these the nucleic acid-based molecules of the invention can lead to better treatment of the disease progression by affording the possibility of combination therapies (e.g., multiple antisense or enzymatic nucleic acid molecules targeted to different genes, nucleic acid molecules coupled with known small molecule inhibitors, or intermittent treatment with combinations of molecules (including different motifs) and/or other chemical or biological molecules). The treatment of patients with nucleic acid molecules can also include combinations of different types of nucleic acid molecules. Therapeutic nucleic acid molecules (e.g., enzymatic nucleic acid molecules and antisense nucleic acid molecules) delivered exogenously should optimally be stable within cells until translation of the target RNA has been inhibited long enough to reduce the levels of the undesirable protein. This period of time varies between hours to days depending upon the disease state. In particular, these nucleic acid molecules should be resistant to nucleases in order to function as effective intracellular therapeutic agents. Improvements in the chemical synthesis of nucleic acid molecules described in the instant invention and in the art have expanded the ability to modify nucleic acid molecules by introducing nucleotide modifications to enhance their nuclease stability as described above. In yet another preferred embodiment, nucleic acid catalysts having chemical modifications which maintain or enhance enzymatic activity are provided. Such nucleic acid catalysts are also generally more resistant to nucleases than unmodified nucleic acid. Thus, in a cell and/or in vivo the activity may not be significantly lowered. As exemplified herein, such enzymatic nucleic acids are useful in a cell and/or in vivo even if activity over all is reduced 10 fold (Burgin et al, 1996, Biochemistry, 35, 14090). Such enzymatic nucleic acids herein are said to "maintain" the enzymatic activity of an all RNA enzymatic nucleic acid. In another aspect, the nucleic acid molecules comprise a 5' and/or a 3'- cap structure. By "cap structure" is meant chemical modifications, which have been incorporated at either terminus of the oligonucleotide (see, for example, Wincott et al, WO 97/26270, incorporated by reference herein). These terminal modifications protect the nucleic acid molecule from exonuclease degradation, and may help in delivery and/or localization within a cell. The cap may be present at the 5 '-terminus (5 '-cap) or at the 3 '-terminus (3 '-cap) or may be present on both termini. In non-limiting examples, the 5 '-cap is selected from the group consisting of inverted abasic residue (moiety), 4',5'-methylene nucleotide; l-(beta-D-erythrofuranosyl) nucleotide, 4'-thio nucleotide, carbocyclic nucleotide; 1,5-anhydrohexitol nucleotide; L- nucleotides; alpha-nucleotides; modified base nucleotide; phosphorodithioate linkage; threo- pentofuranosyl nucleotide; acyclic 3',4'-seco nucleotide; acyclic 3,4-dihydroxybutyl nucleotide; acyclic 3,5-dihydroxypentyl nucleotide, 3 '-3 '-inverted nucleotide moiety; 3 '-3 '-inverted abasic moiety; 3 '-2 -inverted nucleotide moiety; 3 '-2 '-inverted abasic moiety; 1,4-butanediol phosphate; 3'-phosphoramidate; hexylphosphate; aminohexyl phosphate; 3'-phosphate; 3'-phosphorothioate; phosphorodithioate; or bridging or non-bridging methylphosphonate moiety (for more details, see Wincott et al, International PCT publication No. WO 97/26270, incorporated by reference herein). In yet another preferred embodiment, the 3 '-cap is selected from a group consisting of 4',5'-methylene nucleotide; l-(beta-D-erythrofuranosyl) nucleotide; 4'-thio nucleotide, carbocyclic nucleotide; 5'-amino-alkyl phosphate; l,3-diamino-2-propyl phosphate, 3- aminopropyl phosphate; 6-aminohexyl phosphate; 1,2-aminododecyl phosphate; hydroxypropyl phosphate; 1,5-anhydrohexitol nucleotide; L-nucleotide; alpha-nucleotide; modified base nucleotide; phosphorodithioate; t&reo-pentofuranosyl nucleotide; acyclic 3',4'-seco nucleotide; 3,4-dihydroxybutyl nucleotide; 3,5-dihydroxypentyl nucleotide, 5'-5'-inverted nucleotide moiety; 5'-5'-inverted abasic moiety; 5'-phosphoramidate; 5 '-phosphorothioate; 1,4-butanediol phosphate; 5'-amino; bridging and/or non-bridging 5'-phosphoramidate, phosphorothioate and/or phosphorodithioate, bridging or non bridging methylphosphonate and 5'-mercapto moieties (for more details, see Beaucage and Iyer, 1993, Tetrahedron 49, 1925; incorporated by reference herein). By the term "non-nucleotide" is meant any group or compound which can be incorporated into a nucleic acid chain in the place of one or more nucleotide units, including either sugar and/or phosphate substitutions, and allows the remaining bases to exhibit their enzymatic activity. The group or compound is abasic in that it does not contain a commonly recognized nucleotide base, such as adenosine, guanine, cytosine, uracil or thymine. An "alkyl" group refers to a saturated aliphatic hydrocarbon, including straight-chain, branched-chain, and cyclic alkyl groups. Preferably, the alkyl group has 1 to 12 carbons. More preferably it is a lower alkyl of from 1 to 7 carbons, more preferably 1 to 4 carbons. The alkyl group can be substituted or unsubstituted. When substituted the substituted group(s) is preferably, hydroxyl, cyano, alkoxy, =O, =S, NO2 or N(CH3)2, amino, or SH. The term also includes alkenyl groups which are unsaturated hydrocarbon groups containing at least one carbon-carbon double bond, including straight-chain, branched-chain, and cyclic groups. Preferably, the alkenyl group has 1 to 12 carbons. More preferably it is a lower alkenyl of from 1 to 7 carbons, more preferably 1 to 4 carbons. The alkenyl group can be substituted or unsubstituted. When substituted the substituted group(s) is preferably, hydroxyl, cyano, alkoxy, =O, =S, NO2, halogen, N(CH3)2, amino, or SH. The term "alkyl" also includes alkynyl groups which have an unsaturated hydrocarbon group containing at least one carbon-carbon triple bond, including straight-chain, branched-chain, and cyclic groups. Preferably, the alkynyl group has 1 to 12 carbons. More preferably it is a lower alkynyl of from 1 to 7 carbons, more preferably 1 to 4 carbons. The alkynyl group can be substituted or unsubstituted. When substituted the substituted group(s) is preferably, hydroxyl, cyano, alkoxy, =O, =S, NO2 or N(CH3)2, amino or SH. Such alkyl groups can also include aryl, alkylaryl, carbocyclic aryl, heterocyclic aryl, amide and ester groups. An "aryl" group refers to an aromatic group which has at least one ring having a conjugated π electron system and includes carbocyclic aryl, heterocyclic aryl and biaryl groups, all of which can be optionally substituted. The preferred substituent(s) of aryl groups are halogen, trihalomethyl, hydroxyl, SH, OH, cyano, alkoxy, alkyl, alkenyl, alkynyl, and amino groups. An "alkylaryl" group refers to an alkyl group (as described above) covalently joined to an aryl group (as described above). Carbocyclic aryl groups are groups wherein the ring atoms on the aromatic ring are all carbon atoms. The carbon atoms are optionally substituted. Heterocyclic aryl groups are groups having from 1 to 3 heteroatoms as ring atoms in the aromatic ring and the remainder of the ring atoms are carbon atoms. Suitable heteroatoms include oxygen, sulfur, and nitrogen, and include furanyl, thienyl, pyridyl, pyrrolyl, N-lower alkyl pyrrolo, pyrimidyl, pyrazinyl, imidazolyl and the like, all optionally substituted. An "amide" refers to an -C(O)-NH-R, where R is either alkyl, aryl, alkylaryl or hydrogen. An "ester" refers to an -C(O)- OR', where R is either alkyl, aryl, alkylaryl or hydrogen. By "nucleotide" is meant a heterocyclic nitrogenous base in N-glycosidic linkage with a phosphorylated sugar. Nucleotides are recognized in the art to include natural bases (standard), and modified bases well known in the art. Such bases are generally located at the 1' position of a nucleotide sugar moiety. Nucleotides generally comprise a base, sugar and a phosphate group. The nucleotides can be unmodified or modified at the sugar, phosphate and/or base moiety, (also referred to interchangeably as nucleotide analogs, modified nucleotides, non- natural nucleotides, non-standard nucleotides and other; see for example, Usman and McSwiggen, supra; Eckstein et al., International PCT Publication No. WO 92/07065; Usman et al., International PCT Publication No. WO 93/15187; Uhhnan & Peyman, supra all are hereby incorporated by reference herein). There are several examples of modified nucleic acid bases known in the art as summarized by Limbach et al., 1994, Nucleic Acids Res. 22, 2183. Some of the non-limiting examples of chemically modified and other natural nucleic acid bases that can be introduced into nucleic acids include, inosine, purine, pyridin-4-one, pyridin-2-one, phenyl, pseudouracil, 2, 4, 6-trimethoxy benzene, 3 -methyl uracil, dihydrouridine, naphthyl, aminophenyl, 5-alkylcytidines (e.g., 5-methylcytidine), 5-alkyluridines (e.g., ribothymidine), 5-halouridine (e.g., 5-bromouridine) or 6-azapyrimidines or 6-alkylpyrimidines (e.g. 6- methyluridine), propyne, quesosine, 2-thiouridine, 4-thiouridine, wybutosine, wybutoxosine, 4- acetylcytidine, 5-(carboxyhydroxymethyl)uridine, 5 '-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluridine, beta-D-galactosylqueosine, 1-methyladenosine, 1- methylinosine, 2,2-dimethylguanosine, 3-methylcytidine, 2-methyladenosine, 2- methylguanosine, N6-methyladenosine, 7-methylguanosine, 5-methoxyaminomethyl-2- thiouridine, 5-methylaminomethyluridine, 5-methylcarbonylmethyluridine, 5-methyloxyuridine, 5-methyl-2-thiouridine, 2-methylthio-N6-isopentenyladenosine, -D-mannosylqueosine, uridine- 5-oxyacetic acid, 2-thiocytidine, threonine derivatives and others (Burgin et al., 1996, Biochemistry, 35, 14090; Uhhnan & Peyman, supra). By "modified bases" in this aspect is meant nucleotide bases other than adenine, guanine, cytosine and uracil at 1' position or their equivalents; such bases can be used at any position, for example, within the catalytic core of an enzymatic nucleic acid molecule and/or in the substrate-binding regions of the nucleic acid molecule. By "nucleoside" is meant a heterocyclic nitrogenous base in N-glycosidic linkage with a sugar. Nucleosides are recognized in the art to include natural bases (standard), and modified bases well known in the art. Such bases are generally located at the 1' position of a nucleoside sugar moiety. Nucleosides generally comprise a base and sugar group. The nucleosides can be unmodified or modified at the sugar, and/or base moiety, (also referred to interchangeably as nucleoside analogs, modified nucleosides, non-natural nucleosides, non-standard nucleosides and other; see for example, Usman and McSwiggen, supra; Eckstein et al., International PCT Publication No. WO 92/07065; Usman et al, International PCT Publication No. WO 93/15187; Uhhnan & Peyman, supra all are hereby incorporated by reference herein). There are several examples of modified nucleic acid bases known in the art as summarized by Limbach et al., 1994, Nucleic Acids Res. 22, 2183. Some of the non-limiting examples of chemically modified and other natural nucleic acid bases that can be introduced into nucleic acids include, inosine, purine, pyridin-4-one, pyridin-2-one, phenyl, pseudouracil, 2, 4, 6-trimethoxy benzene, 3- methyl uracil, dihydrouridine, naphthyl, aminophenyl, 5-alkylcytidines (e.g., 5-methylcytidine), 5-alkyluridines (e.g., ribothymidine), 5-halouridine (e.g., 5-bromouridine) or 6-azapyrimidines or 6-alkylpyrimidines (e.g. 6-methyluridine), propyne, quesosine, 2-thiouridine, 4-thiouridine, wybutosine, wybutoxosine, 4-acetylcytidine, 5-(carboxyhydroxymethyl)uridine, 5'- carboxymethylaminomethyl-2-thiouridine, 5 -carboxymethylaminomethyluridine, -D- galactosylqueosine, 1-methyladenosine, 1-methylinosine, 2,2-dimethylguanosine, 3- methylcytidine, 2-methyladenosine, 2-methylguanosine, N6-methyladenosine, 7- methylguanosine, 5-methoxyaminomethyl-2-thiouridine, 5-methylaminomethyluridine, 5- methylcarbonylmethyluridine, 5-methyloxyuridine, 5-methyl-2-thiouridine, 2-methylthio-N6- isopentenyladenosine, beta-D-mannosylqueosine, uridine-5-oxyacetic acid, 2-thiocytidine, threonine derivatives and others (Burgin et al., 1996, Biochemistry, 35, 14090; Uhhnan & Peyman, supra). By "modified bases" in this aspect is meant nucleoside bases other than adenine, guanine, cytosine and uracil at 1' position or their equivalents; such bases can be used at any position, for example, within the catalytic core of an enzymatic nucleic acid molecule and/or in the substrate-binding regions of the nucleic acid molecule. In a preferred embodiment, the invention features modified enzymatic nucleic acids with phosphate backbone modifications comprising one or more phosphorothioate, phosphorodithioate, methylphosphonate, morpholino, amidate carbamate, carboxymethyl, acetamidate, polyamide, sulfonate, sulfonamide, sulfamate, formacetal, thioformacetal, and/or alkylsilyl, substitutions. For a review of oligonucleotide backbone modifications, see Hunziker and Leumann, 1995, Nucleic Acid Analogues: Synthesis and Properties, in Modern Synthetic Methods, VCH, 331-417, and Mesmaeker et al, 1994, Novel Backbone Replacements for Oligonucleotides, in Carbohydrate Modifications in Antisense Research, ACS, 24-39. These references are hereby incorporated by reference herein. By "abasic" is meant sugar moieties lacking a base or having other chemical groups in place of a base at the 1' position, (for more details, see Wincott et al, International PCT publication No. WO 97/26270). By "unmodified nucleoside" is meant one of the bases adenine, cytosine, guanine, thymine, uracil joined to the 1' carbon of beta-D-ribo-furanose. By "modified nucleoside" is meant any nucleotide base which contains a modification in the chemical structure of an unmodified nucleotide base, sugar and/or phosphate. In connection with 2 '-modified nucleotides as described for the present invention, by "amino" is meant 2'-NH 2 or 2'-O- NH 2 , which can be modified or unmodified. Such modified groups are described, for example, in Eckstein et al, U.S. Patent 5,672,695 and Matulic-Adamic et al, WO 98/28317, respectively, which are both incorporated by reference herein in their entireties. Various modifications to nucleic acid (e.g., antisense and enzymatic nucleic acid) structure can be made to enhance the utility of these molecules. For example, such modifications enhance shelf-life, half-life in vitro, stability, and ease of introduction of such oligonucleotides to the target site, e.g., to enhance penetration of cellular membranes, and confer the ability to recognize and bind to targeted cells. Use of these molecules can lead to better treatment of the disease progression by affording the possibility of combination therapies (e.g., multiple enzymatic nucleic acids targeted to different genes, enzymatic nucleic acids coupled with known small molecule inhibitors, or intermittent treatment with combinations of enzymatic nucleic acids (including different enzymatic nucleic acid motifs and/or other chemical or biological molecules). The treatment of patients with nucleic acid molecules can also include combinations of different types of nucleic acid molecules. Therapies can be devised which include a mixture of enzymatic nucleic acids (including different enzymatic nucleic acid motifs), antisense and/or 2-5A chimera molecules to one or more targets to alleviate symptoms of a disease. Administration of Nucleic Acid Molecules Methods for the delivery of nucleic acid molecules are described in Akhtar et al, 1992, Trends Cell Bio., 2, 139; and _9e/tverv Strategies for Antisense Oligonucleotide Therapeutics, ed. Akhtar, 1995 which are both incorporated herein by reference. Sullivan et al, PCT WO 94/02595, further describes the general methods for delivery of enzymatic RNA molecules. These protocols can be utilized for the delivery of virtually any nucleic acid molecule. Nucleic acid molecules can be administered to cells by a variety of methods known to those familiar to the art, including, but not restricted to, encapsulation in liposomes, by iontophoresis, or by incorporation into other vehicles, such as hydrogels, cyclodextrins, biodegradable nanocapsules, and bioadhesive microspheres. Alternatively, the nucleic acid/vehicle combination is locally delivered by direct injection or by use of an infusion pump. Other routes of delivery include, but are not limited to oral (tablet or pill form) and/or intrathecal delivery (Gold, 1997, Neuroscience, 76, 1153-1158). More detailed descriptions of nucleic acid delivery and administration are provided in Sullivan et al, supra, Draper et al, PCT WO93/23569, Beigelman et al, PCT WO99/05094, and Klimuk et al, PCT WO99/04819 all of which have been incorporated by reference herein. The molecules of the instant invention can be used as pharmaceutical agents. Pharmaceutical agents prevent, inhibit the occurrence, or treat (alleviate a symptom to some extent, preferably all of the symptoms) of a disease state in a patient. The negatively charged polynucleotides of the invention can be administered (e.g., RNA, DNA or protein) and introduced into a patient by any standard means, with or without stabilizers, buffers, and the like, to form a pharmaceutical composition. When it is desired to use a liposome delivery mechanism, standard protocols for formation of liposomes can be followed. The compositions of the present invention can also be formulated and used as tablets, capsules or elixirs for oral administration, suppositories for rectal administration, sterile solutions; suspensions for injectable administration, and other compositions known in the art. The present invention also includes pharmaceutically acceptable formulations of the compounds described. These formulations include salts of the above compounds, e.g., acid addition salts, including salts of hydrochloric, hydrobromic, acetic acid, and benzene sulfonic acid. A pharmacological composition or formulation refers to a composition or formulation in a form suitable for administration, e.g., systemic administration, into a cell or patient, preferably a human. Suitable forms, in part, depend upon the use or the route of entry, for example, oral, transdermal, or by injection. Such forms should not prevent the composition or formulation from reaching a target cell (i.e., a cell to which the negatively charged polymer is desired to be delivered to). For example, pharmacological compositions injected into the blood stream should be soluble. Other factors are known in the art, and include considerations such as toxicity and forms which prevent the composition or formulation from exerting its effect. By "systemic administration" is meant in vivo systemic absorption or accumulation of drugs in the blood stream followed by distribution throughout the entire body. Administration routes that lead to systemic absorption include, without limitations: intravenous, subcutaneous, intraperitoneal, inhalation, oral, intrapulmonary and intramuscular. Each of these administration routes exposes the desired negatively charged polymers, e.g., nucleic acids, to an accessible diseased tissue. The rate of entry of a drug into the circulation has been shown to be a function of molecular weight or size. The use of a liposome or other drug carrier comprising the compounds of the instant invention can potentially localize the drug, for example, in certain tissue types, such as the tissues of the reticular endothelial system (RES). A liposome formulation that can facilitate the association of drug with the surface of cells, such as, lymphocytes and macrophages is also useful. This approach can provide enhanced delivery of the drug to target cells by taking advantage of the specificity of macrophage and lymphocyte immune recognition of abnormal cells, such as cancer cells. By "pharmaceutically acceptable formulation" is meant, a composition or formulation that allows for the effective distribution of the nucleic acid molecules of the instant invention in the physical location most suitable for their desired activity. The invention also features the use of the composition comprising surface- modified liposomes containing poly (ethylene glycol) lipids (PEG-modified, or long-circulating liposomes or stealth liposomes). These formulations offer a method for increasing the accumulation of drugs in target tissues. This class of drug carriers resists opsonization and elimination by the mononuclear phagocytic system (MPS or RES), thereby enabling longer blood circulation times and enhanced tissue exposure for the encapsulated drug (Lasic et al. Chem. Rev. 1995, 95, 2601-2627; Ishiwata et al, Chem. Pharm. Bull 1995, 43, 1005-1011). All incorporated by reference herein. Such liposomes have been shown to accumulate selectively in tumors, presumably by extravasation and capture in the neovascularized target tissues (Lasic et al, Science 1995, 267, 1275-1276; Oku et αZ., 1995, Biochim. Biophys. Ada, 1238, 86-90). All incorporated by reference herein. The long-circulating liposomes enhance the pharmacokinetics and pharmacodynamics of DNA and RNA, particularly compared to conventional cationic liposomes which are known to accumulate in tissues of the MPS (Liu et al, J. Biol. Chem. 1995, 42, 24864-24870; Choi et al, International PCT Publication No. WO 96/10391; Ansell et al, International PCT Publication No. WO 96/10390; Holland et al, International PCT Publication No. WO 96/10392; all of which are incorporated by reference herein). Long-circulating liposomes are also likely to protect drugs from nuclease degradation to a greater extent compared to cationic liposomes, based on their ability to avoid accumulation in metabolically aggressive MPS tissues such as the liver and spleen. With specific reference to nucleic acid molecules of the invention directed against NOGO, many examples in the art describe CNS delivery methods of oligonucleotides. Direct administration to the CNS has been described via osmotic pump, (see Chun et al, 1998, Neuroscience Letters, 257, 135-138, D'Aldin et al, 1998, Mol. Brain Research, 55, 151-164, Dryden et al, 1998, J Endocrinol, 157, 169-175, Ghirnikar et al, 1998, Neuroscience Letters, 247, 21-24) or direct infusion (Broaddus et al, 1997, Neurosurg. Focus, 3, article 4). For a comprehensive review on drug delivery strategies including broad coverage of CNS delivery, see Ho et al, 1999, Curr. Opin. Mol ' Ther., 1, 336-343 and Jain, Drug Delivery Systems: Technologies and Commercial Opportunities, Decision Resources, 1998 and Groothuis et al, 1997, J. NeuroVirol, 3, 387-400. Non-limiting examples of agents suitable for formulation with the nucleic acid molecules of the instant invention include: P-glycoprotein inhibitors (such as Pluronic P85) which can enhance entry of drugs into the CNS (Jolliet-Riant and Tillement, 1999, Fundam. Clin. Pharmacol, 13, 16-26); biodegradable polymers, such as poly (DL-lactide- coglycolide) microspheres for sustained release delivery after intracerebral implantation (Emerich, DF et al, 1999, Cell Transplant, 8, 47-58) Alkermes, Inc. Cambridge, MA; and loaded nanoparticles, such as those made of polybutylcyanoacrylate, which- can deliver drugs across the blood brain barrier and can alter neuronal uptake mechanisms (Prog Neuropsychopharmacol Biol Psychiatry, 23, 941-949, 1999). Other non-limiting examples of delivery strategies, including CNS delivery of the nucleic acid molecules of the instant invention include material described in Boado et al, 1998, J. Pharm. Sci., 87, 1308-1315; Tyler et al, 1999, FEBS Lett, 421, 280-284; Pardridge et al, 1995, PNAS USA., 92, 5592-5596; Boado, 1995, Adv. Drug Delivery Rev., 15, 73-107; Aldrian-Herrada et al, 1998, Nucleic Acids Res., 26, 4910-4916; and Tyler et al, 1999, PNAS USA., 96, 7053-7058. All these references are hereby incorporated herein by reference. The present invention also includes compositions prepared for storage or administration which include a pharmaceutically effective amount of the desired compounds in a pharmaceutically acceptable carrier or diluent. Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical art, and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co. (A.R. Gennaro edit. 1985) hereby incorporated by reference herein. For example, preservatives, stabilizers, dyes and flavoring agents can be provided. These include sodium benzoate, sorbic acid and esters of 7-hydroxybenzoic acid. In addition, antioxidants and suspending agents can be used. A pharmaceutically effective dose is that dose required to prevent, inhibit the occurrence, or treat (alleviate a symptom to some extent, preferably all of the symptoms) of a disease state. The pharmaceutically effective dose depends on the type of disease, the composition used, the route of administration, the type of mammal being treated, the physical characteristics of the specific mammal under consideration, concurrent medication, and other factors which those skilled in the medical arts will recognize. Generally, an amount between 0.1 mg/kg and 100 mg/kg body weight/day of active ingredients is administered dependent upon potency of the negatively charged polymer. The nucleic acid molecules of the present invention can also be administered to a patient in combination with other therapeutic compounds to increase the overall therapeutic effect. The use of multiple compounds to treat an indication can increase the beneficial effects while reducing the presence of side effects. Alternatively, certain of the nucleic acid molecules of the instant invention can be expressed within cells from eukaryotic promoters (e.g., Izant and Weintraub, 1985, Science, 229, 345; McGarry and Lindquist, 1986, Proc. Natl. Acad. Sci., USA 83, 399; Scanlon et al, 1991, Proc. Natl Acad. Sci. USA, 88, 10591-5; Kashani-Sabet et al, 1992, Antisense Res. Dev., 2, 3- 15; Dropulic et al, 1992, J. Virol, 66, 1432-41; Weerasinghe et al, 1991, J. Virol, 65, 5531-4; Ojwang et α/., 1992, Proc Natl. Acad. Sci. USA, 89, 10802-6; Chen et al, 1992, Nucleic Acids Res., 20, 4581-9; Sarver et al, 1990 Science, 247, 1222-1225; Thompson et al, 1995, Nucleic Acids Res., 23, 2259; Good et al, 1997, Gene Therapy, 4, 45; all of these references are hereby incorporated in their totalities by reference herein). Those skilled in the art realize that any nucleic acid can be expressed in eukaryotic cells from the appropriate DNA/RNA vector. The activity of such nucleic acids can be augmented by their release from the primary transcript by a enzymatic nucleic acid (Draper et al, PCT WO 93/23569, and Sullivan et al, PCT WO 94/02595; Ohkawa et al, 1992, Nucleic Acids Symp. Ser., 27, 15-6; Taira et al, 1991, Nucleic Acids Res., 19, 5125-30; Ventura et al, 1993, Nucleic Acids Res., 21, 3249-55; Chowrira et al, 1994, J. Biol. Chem., 269, 25856; all of these references are hereby incorporated in their totalities by reference herein). With specific reference to nucleic acid molecules of the invention directed against NOGO, gene therapy approaches specific to the CNS are described by Blesch et al, 2000, Drug News Perspect, 13, 269-280; Peterson et al, 2000, Cent. Nerv. Syst. Dis., 485-508; Peel and Klein, 2000, J. Neurosci. Methods, 98, 95-104; Hagihara et al, 2000, Gene Ther., 7, 759-763; and Herrlinger et al, 2000, Methods Mol. Med., 35, 287-312. AAV-mediated delivery of nucleic acid to cells of the nervous system is further described by Kaplitt et al, US 6,180,613. In another aspect of the invention, RNA molecules of the present invention are preferably expressed from transcription units (see, for example, Couture et al, 1996, TIG., 12, 510) inserted into DNA or RNA vectors. The recombinant vectors are preferably DNA plasmids or viral vectors. Enzymatic nucleic acid expressing viral vectors could be constructed based on, but not limited to, adeno-associated virus, retrovirus, adenovirus, or alphavirus. Preferably, the recombinant vectors capable of expressing the nucleic acid molecules are delivered as described above, and persist in target cells. Alternatively, viral vectors can be used that provide for transient expression of nucleic acid molecules. Such vectors can be repeatedly administered as necessary. Once expressed, the nucleic acid molecule binds to the target mRNA. Delivery of nucleic acid molecule expressing vectors can be systemic, such as by intravenous or intramuscular administration, by administration to target cells ex-planted from the patient followed by reintroduction into the patient, or by any other means that would allow for introduction into the desired target cell (for a review, see Couture et al, 1996, TIG, 12, 510). In one aspect, the invention features an expression vector comprising a nucleic acid sequence encoding at least one of the nucleic acid molecules disclosed in the instant invention. The nucleic acid sequence encoding the nucleic acid molecule of the instant invention is operable linked in a manner which allows expression of that nucleic acid molecule. In another aspect, the invention features an expression vector comprising: a) a transcription initiation region (e.g., eukaryotic pol I, II or III initiation region); b) a transcription termination region (e.g., eukaryotic pol I, II or III termination region); c) a nucleic acid sequence encoding at least one of the nucleic acid catalyst of the instant invention; and wherein said sequence is operably linked to said initiation region and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule. The vector can optionally include an open reading frame (ORF) for a protein operably linked on the 5' side or the 3'-side of the sequence encoding the nucleic acid catalyst of the invention; and/or an intron (intervening sequences). Transcription of the nucleic acid molecule sequences are driven from a promoter for eukaryotic RNA polymerase I (pol I), RNA polymerase II (pol II), or RNA polymerase III (pol III). Transcripts from pol II or pol III promoters will be expressed at high levels in all cells; the levels of a given pol II promoter in a given cell type will depend on the nature of the gene regulatory sequences (enhancers, silencers, etc.) present nearby. Prokaryotic RNA polymerase promoters are also used, provided that the prokaryotic RNA polymerase enzyme is expressed in the appropriate cells (Elroy-Stein and Moss, 1990, Proc. Natl Acad. Sci. U S A, 87, 6743-7; Gao and Huang 1993, Nucleic Acids Res., 21, 2867-72; Lieber et al, 1993, Methods Enzymol, 217, 47-66; Zhou et al, 1990, Mol Cell. Biol, 10, 4529-37). All of these references are incorporated by reference herein. Several investigators have demonstrated that nucleic acid molecules, such as enzymatic nucleic acids expressed from such promoters can function in mammalian cells (e.g. Kashani- Sabet et al, 1992, Antisense Res. Dev., 2, 3-15; Ojwang et al, 1992, Proc. Natl. Acad. Sci. U S A, 89, 10802-6; Chen et al, 1992, Nucleic Acids Res., 20, 4581-9; Yu et al, 1993, Proc. Natl. Acad. Sci. USA, 90, 6340-4; L'Huillier et al, 1992, EMBO J, 11, 4411-8; Lisziewicz et al, 1993, Proc. Natl. Acad. Sci. U S. A, 90, 8000-4; Thompson et al, 1995, Nucleic Acids Res., 23, 2259; and Sullenger & Cech, 1993, Science, 262, 1566). More specifically, transcription units such as the ones derived from genes encoding U6 small nuclear (snRNA), transfer RNA (tRNA) and adenovirus VA RNA are useful in generating high concentrations of desired RNA molecules such as ribozymes in cells (Thompson et al, supra; Couture and Stinchcomb, 1996, supra; Noonberg et al, 1994, Nucleic Acid Res., 22, 2830; Noonberg et al, US Patent No. 5,624,803; Good et al, 1997, Gene Ther., 4, 45; and Beigelman et al, International PCT Publication No. WO 96/18736; all of these publications are incorporated by reference herein. The above ribozyme transcription units can be incorporated into a variety of vectors for introduction into mammalian cells, including but not restricted to, plasmid DNA vectors, viral DNA vectors (such as adenovirus or adeno-associated virus vectors), or viral RNA vectors (such as retroviral or alphavirus vectors) (for a review, see Couture and Stinchcomb, 1996, supra). In yet another aspect, the invention features an expression vector comprising a nucleic acid sequence encoding at least one of the nucleic acid molecules of the invention, in a manner which allows expression of that nucleic acid molecule. The expression vector comprises in one embodiment; a) a transcription initiation region; b) a transcription termination region; c) a nucleic acid sequence encoding at least one said nucleic acid molecule; and wherein said sequence is operably linked to said initiation region and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule. In another preferred embodiment, the expression vector comprises: a) a transcription initiation region; b) a transcription termination region; c) an open reading frame; d) a nucleic acid sequence encoding at least one said nucleic acid molecule, wherein said sequence is operably linked to the 3 '-end of said open reading frame; and wherein said sequence is operably linked to said initiation region, said open reading frame and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule. In yet another embodiment the expression vector comprises: a) a transcription initiation region; b) a transcription termination region; c) an intron; d) a nucleic acid sequence encoding at least one said nucleic acid molecule; and wherein said sequence is operably linked to said initiation region, said intron and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule. In another embodiment, the expression vector comprises: a) a transcription initiation region; b) a transcription termination region; c) an intron; d) an open reading frame; e) a nucleic acid sequence encoding at least one said nucleic acid molecule, wherein said sequence is operably linked to the 3'-end of said open reading frame; and wherein said sequence is operably linked to said initiation region, said intron, said open reading frame and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule. Examples. The following are non-limiting examples showing the selection, isolation, synthesis and activity of nucleic acids of the instant invention. The following examples demonstrate the selection and design of Antisense, hammerhead, DNAzyme, Inozyme, Amberzyme, Zinzyme, or G-Cleaver enzymatic nucleic acid molecules and binding/cleavage sites within CD20 and NOGO RNA. Nucleic acid inhibition of NOGO target RNA The lack of axon regeneration capacity in the adult CNS manifests as a limiting factor in the treatment of CNS injury and cerebrovascular accident (CVA, stroke), chemotherapy-induced neuropathy, and possibly in neurodegenerative diseases such as Alzheimer's disease, dementia, multiple sclerosis (MS), chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS), Parldnson's disease, ataxia, Huntington's disease, Creutzfeldt- Jakob disease, and/or muscular dystrophy. Neuron growth inhibition results from physical barriers imposed by glial scars, a lack of neurotrophic factors, and growth-inhibitory molecules associated with myelin. The abrogation of neurite growth inhibition creates the potential to treat conditions for which there is currently no definitive medical intervention. In these studies, the inhibition of NOGO (GeneBank Accession No AB020693) is investigated. Example 1 : Identification of Potential Target Sites in Human CD20 and NOGO RNA The sequence of human CD20 and NOGO is screened for accessible sites using a computer-folding algorithm. Regions of the RNA are identified that do not form secondary folding structures. These regions contain potential enzymatic nucleic acid and/or antisense binding/cleavage sites. The sequences of these binding/cleavage sites are shown in Tables III- XIV. Example 2: Selection of Enzymatic Nucleic Acid Cleavage Sites in Human CD20 and NOGO RNA Enzymatic nucleic acid target sites are chosen by analyzing sequences of Human CD20 (GenBank accession number: X07203) and Human NOGO (Genbank accession No: AB020693) and prioritizing the sites on the basis of folding. Enzymatic nucleic acids are designed that could bind each target and are individually analyzed by computer folding (Christoffersen et al, 1994 J. Mol. Struc Theochem, 311, 273; jaeger et al, 1989, Proc. Natl. Acad. Sci. USA, 86, 7706) to assess whether the enzymatic nucleic acid sequences fold into the appropriate secondary structure. Those enzymatic nucleic acids with unfavorable intramolecular interactions between the binding arms and the catalytic core are eliminated from consideration. As noted below, varying binding arm lengths can be chosen to optimize activity. Generally, at least 5 bases on each arm are able to bind to, or otherwise interact with, the target RNA. Example 3 : Chemical Synthesis and Purification of Enzymatic nucleic acids and Antisense for Efficient Cleavage and/or blocking of CD20 and NOGO RNA Enzymatic nucleic acids and antisense constructs are designed to anneal to various sites in the RNA message. The binding arms of the enzymatic nucleic acids are complementary to the target site sequences described above, while the antisense constructs are fully complimentary to the target site sequences described above. The enzymatic nucleic acids and antisense constructs were chemically synthesized. The method of synthesis used followed the procedure for normal RNA synthesis as described above and in Usman et al, (1987 J. Am. Chem. Soc, 109, 7845), Scaringe et al, (1990 Nucleic Acids Res., 18, 5433) and Wincott et al, supra, and made use of common nucleic acid protecting and coupling groups, such as dimethoxytrityl at the 5 '-end, and phosphoramidites at the 3'-end. The average stepwise coupling yields were typically >98%. Enzymatic nucleic acids and antisense constructs are also synthesized from DNA templates using bacteriophage T7 RNA polymerase (Milligan and Uhlenbeck, 1989, Methods Enzymol. 180, 51). Enzymatic nucleic acids and antisense constructs are purified by gel electrophoresis using general methods or are purified by high pressure liquid chromatography (HPLC; see Wincott et al, supra; the totality of which is hereby incorporated herein by reference) and are resuspended in water. Example 4: Enzymatic nucleic acid Cleavage of CD20 and NOGO RNA Target in vitro Enzymatic nucleic acids targeted to the human CD20 and NOGO RNA are designed and synthesized as described above. These enzymatic nucleic acids can be tested for cleavage activity in vitro, for example, using the following procedure. The target sequences and the nucleotide location within the CD20 RNA are given in Tables IX-XIV. The target sequences and the nucleotide location within the NOGO RNA are given in Tables III- VIII. Cleavage Reactions: Full-length or partially full-length, internally-labeled target RNA for enzymatic nucleic acid cleavage assay is prepared by in vitro transcription in the presence of [a- 32 ] CTP, passed over a G 50 Sephadex® column by spin chromatography and used as substrate RNA without further purification. Alternately, substrates are 5'-32p-end labeled using T4 polynucleotide kinase enzyme. Assays are performed by pre-warming a 2X concentration of purified enzymatic nucleic acid in enzymatic nucleic acid cleavage buffer (50 mM Tris-HCl, pH 7.5 at 37°C, 10 mM MgC_2) and the cleavage reaction was initiated by adding the 2X enzymatic nucleic acid mix to an equal volume of substrate RNA (maximum of 1-5 nM) that was also pre- o warmed in cleavage buffer. As an initial screen, assays are carried out for 1 hour at 37 C using a final concentration of either 40 nM or 1 mM enzymatic nucleic acid, i.e., enzymatic nucleic acid excess. The reaction is quenched by the addition of an equal volume of 95%) formamide, 20 mM EDTA, 0.05% bromophenol blue and 0.05% xylene cyanol after which the sample is heated to 95 C for 2 minutes, quick chilled and loaded onto a denaturing polyacrylamide gel. Substrate RNA and the specific RNA cleavage products generated by enzymatic nucleic acid cleavage are visualized on an autoradiograph of the gel. The percentage of cleavage is determined by Phosphor Imager® quantitation of bands representing the intact substrate and the cleavage products. Example 5: Nucleic acid inhibition of CD20 target RNA in vivo Nucleic acid molecules targeted to the human CD20 RNA are designed and synthesized as described above. These nucleic acid molecules can be tested for cleavage activity in vivo, for example using the procedures described below. The target sequences and the nucleotide location within the CD20 RNA are given in Tables IX-XIV. Cell Culture Stacchini et al, 1999, Leuk. Res., 23(2), 127-126, describe the establishment of MEC1 and MEC2 cell lines derived from B-chronic lymphocytic leukemia in prolymphocytoid transformation. Matsuo et al, 1999, Leuk. Res., 23(6), 559-568, describe the establishment and characterization of a novel ALL-L3 cell line (BALM- 18) in the study of apoptotic induction by anti-IgM and the inhibtion of apoptosis by bone marrow stroma cells. Schmetzer et al, 1998, Haematologia, 29(3), 195-205, describes the cloning and characterization of bone marrow cells from patients with acute lymphoid leukemia (ALL) in agar cultures. These cell lines express mature B cell markers including CD20, and can be used to study the modulation of CD20 expression using nucleic acid molecules of the instant invention. Brandl et al, 1999, Exp. Hematol (N.Y.), 27(8), 1264-1270, describe the use of bispecific antibody fragments with CD20 x CD28 specificity to allow effective autologous and allogeneic T-cell activation against malignant cells in peripheral blood and bone marrow cultures from patients with B-cell lineage leukemia and lymphoma. A similar study using the nucleic acid molecules of the instant invention in place of antibody fragments can be used to evaluate the efficacy of nucleic acid molecules targeting CD20. Animal Models In order to evaluate the therapeutic potential of anti-CD20 enzymatic nucleic acids, several oncology models in rodent, rabbits and non-human primates can be utilized. Human Xenograft models in Immunocompromised Mice and/or Rats: The primary goal of these studies is to evaluate the effectiveness of anti-CD20 enzymatic nucleic acid therapy at reducing tumor burden and/or improving survival in ammals with B-cell derived lymphoma. A variety of human lymphoma cell lines grow well as a subcutaneous solid tumor in unmanipulated immunocompromised mice or in nude mice subjected to sublethal irradiation. This allows for ease in measurement of tumor volumes. Cell lines that can be utilized include, but are not limited to: JeKo-1 (mantle cell lymphoma), Hs455 (Hodgkin's lymphoma), Hs 602 (cervical lymphoma) or CD 20 + cells obtained from human patients. Human B lymphoid cells (BL2) can also be used to induce primary central nervous system lymphoma in nude rats (Jeon et al, 1998, Br. J. Haematol, 102(5), 1323-1326; Saini et al, 1999, J. Neurooncol, 43(2), 143-160). Viral Induction of Lymphoma: These studies evaluate the effectiveness of anti-CD20 enzymatic nucleic acid therapy at reducing tumor burden and/or improving survival in animals malignant lymphoma. Two animal models are available for inducing Epstein-Barr virus (EBV) related lymphomas. Rabbits can be inoculated orally with cell free pellets from cultured Si-IIA cells. These cells are a HTLV-II-transformed leukocyte cell line producing EBV. Malignant lymphomas developed after many weeks: Balb/c mice receiving subcutaneous transplants of human fetal nasopharyngeal mucosa infected with EBV can develop solid tumors provided that tumor promoters are administered concurrently. Subpopulations of tumor cells derived from such animals are CD20+. Tumor growth can be followed for up to 15 weeks post-inoculation (Koirala et al, 1997, Pathol Int., 47(7), 442-448; Liu et al, 1998, J Cancer. Res. Clin. Oncol, 124(10), 541-548). Syngeneic Lymphoma Models in Mice: A variety of syngeneic murine lymphoma cell lines are available and can be grown in immunocompetent mice. Cell lines that can be utilized include, but are not limited to: V 38C13( B cell lymphoma), WEHI-279 or 231 (Non-secreting B-cell lymphomas) or P388D1 (lymphoma). Tumor burden and survival will be endpoints. A genetically engineered mouse that spontaneously develops lymphoblastic lymphoma can also be utilized to verify activity of the anti-CD20 enzymatic nucleic acid. N:NTH(S)- bg-nu- xid mice develop a diffuse lymphoproliferative disorder by the age of 8 months. Lymph nodes are engorged with neoplastic lymphoblasts of B-cell origin (Weiner, 1992, Int. J. Cancer Suppl, 7, 63-66; Waggie et al, 1992, LabAnim. Sci., 42(2), 375-377). Indications Particular conditions and disease states that can be associated with CD20 expression modulation include but are not limited to lymphoma, leukemia, and arthropathy. In particular, the nucleic acid molecules of the instant invention can be used to treat lymphoma, leukemia, and arthropathy including but not limited to B-cell lymphoma, low-grade or follicular non-Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lypmphocytic leukemia, HIV associated NHL, mantle-cell lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma, immune thrombocytopenia, and inflammatory arthropathy. The present body of knowledge in CD20 research indicates the need for methods to assay CD20 activity and for compounds that can regulate CD20 expression for research, diagnostic, and therapeutic use. Monoclonal antibodies and conjugates such as Bexxar, Rituxan, and Zevalin, chemotherapeutic agents such as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), immunomodulators, and radiation treatments are non-limiting examples of compounds and/or methods that can be combined with or used in conjunction with the nucleic acid molecules (e.g. enzymatic nucleic acids and antisense molecules) of the instant invention. Those skilled in the art will recognize that other drug compounds and therapies can be similarly and readily combined with the nucleic acid molecules of the instant invention (e.g. enzymatic nucleic acids and antisense molecules) and are, therefore, within the scope of the instant invention. Example 6: Nucleic acid inhibition of NOGO target RNA in vivo Nucleic acid molecules targeted to the human NOGO RNA are designed and synthesized as described above. These nucleic acid molecules can be tested for cleavage activity in vivo, for example using the procedures described below. The target sequences and the nucleotide location within the NOGO RNA are given in Tables III-VIII. Cell Culture Spillmami et al, 1998, J Biol. Chem., 273, 19283-19293, describe the purification and biochemical characterization of a high molecular mass protein of bovine spinal cord myelin (bNI-220) which exerts potent inhibition of neurite outgrowth of NGF-primed PC 12 cells and chick DRG cells. This protein can be used to inhibit spreading of 3T3 fibroblasts and to induce collapse of chick DRG growth cones. The monoclonal antibody, mAb IN-1, can be used to fully neutralize the inhibitory activity of bNI-220, which is a presumed NOGO gene product. As such, nucleic acid molecules of the instant invention directed at the inhibition of NOGO expression can be used in place of mAb IN-1 in studying the inhibition of bNI-220 in cell culture experiments described in detail by Spillmann et al, supra. Criteria used in these experiments include the evaluation of spreading behavior of 3T3 fibroblasts, the nuerite outgrowth response of PC 12 cells, and the growth cone motility of chick DRG growth cones Animal models Bregman et al, 1995, Nature, 378, 498-501, describe a rat based system for evaluating the role of myelin-associated neurite growth inhibitory proteins in vivo. Young adult Lewis rats receive a mid-thoracic microsurgical spinal cord lesion. These animals are then treated with mAb IN-1 secreting hybridoma cell explants. A control population receive hybridoma explants which secrete horsreradish peroxidase (HRP) antibodies. Cyclosporin is used during the treatment period to allow hybridoma survival. Additional control rats receive either the spinal cord lesion without any further treatment or no lesion. After a 4-6 week recovery period, behavioral training is followed by the quantitative analysis of reflex and locomotor function. IN- 1 treated animals demonstrate growth of corticlspinal axons around the lesion site and into the spinal cord which persist past the longest time point of analysis (12 weeks). Furthermore, both reflex and locomotor function is restored in IN-1 treated animals. As such, a robust animal model as described by Bregman et al supra, can be used to evaluate nucleic acid molecules of the instant invention when used in place of or in conjunction with mAb IN-1 toward use as modulators of neurite growth inhibitor function (eg. NOGO) in vivo. Indications Particular degenerative and disease states that can be associated with NOGO expression modulation include but are not limited to CNS injury and cerebrovascular accident (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS), chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS), Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt- Jakob disease, muscular dystrophy, and/or other neurodegenerative disease states which respond to the modulation of NOGO expression. The present body of knowledge in NOGO research indicates the need for methods to assay NOGO activity and for compounds that can regulate NOGO expression for research, diagnostic, and therapeutic use. The use of monoclonal antibody (eg; mAb IN-1) treatment is a non-limiting example of a method that can be combined with or used in conjunction with the nucleic acid molecules (e.g. enzymatic nucleic acids and antisense molecules) of the instant invention. Those skilled in the art will recognize that other drug compounds and therapies can be similarly be readily combined with the nucleic acid molecules of the instant invention (e.g. enzymatic nucleic acids and antisense molecules) are hence within the scope of the instant invention. Example 7: Detection of Nucleic Acid Molecules In a preferred embodiment, the present invention relates to a novel method for the detection of nucleic acid molecules using enzymatic nucleic acid constructs. The invention further relates to the use of said process as a diagnostic application to identify the presence of genes and/or gene products which are indicative of a particular genotype and/or phenotype, for example a disease state, infection, or related condition within patients. The detection of nucleic acid can be highly beneficial in the diagnosis of diseases or medical disorders. By determining the presence of a specific nucleic acid sequence, investigators can confirm the presence of a virus, bacterium, genetic mutation, and other conditions which my relate to a disease. Assays for nucleic acid sequences can range from simple methods for detection, such as northern blot hybridization using a radiolabeled or fluorescent probe to detect the presence of a nucleic acid molecule, to the use of polymerase chain reaction (PCR) to amplify a small quantity of a specific nucleic acid to the point at which it can be used for detection of the sequence by hybridization techniques polymerase chain reaction, uses DNA polymerases to logarithmically amplify the desired sequence (U.S. Pat. 4,683,195; U.S. Pat.4,683,202) using prefabricated primers to locate specific sequences. Nucleotide probes can be labeled using dyes, fluorescent, chemiluminescent, radioactive, or enzymatic labels which are commercially available. These probes can be used to detect by hybridization, the expression of a gene or related sequences in cells or tissue samples in which the gene is a normal component, as well as to screen sera or tissue samples from humans suspected of having a disorder arising from infection with an organism, or to detect novel or altered genes as might be found in tumorigenic cells. Nucleic acid primers can also be prepared which, with reverse transcriptase or DNA polymerase and PCR, can be used for detection of nucleic acid molecules which are present in very small amounts in tissues or fluids. PCR utilizes protein enzymes (DNA polymerase) to detect specific nucleotide sequences. PCR has several disadvantages such as requiring a high degree of technical competence for reliability and also extremely sensitive to contamination resulting in false positives. Another class of enzymes which have been utilized for diagnostic purposes are nucleic acid catalysts (enzymatic nucleic acids). Since nucleic acid molecules have also been shown to have catalytic activity they may also be used for diagnostic applications. The enzymatic nature of a enzymatic nucleic acid is advantageous over other technologies, since the concentration of enzymatic nucleic acid necessary to affect a therapeutic treatment is lower. This advantage reflects the ability of the enzymatic nucleic acid to act enzymatically. Thus, a single enzymatic nucleic acid molecule is able to cleave many molecules of target RNA. In addition, the enzymatic nucleic acid is a highly specific inhibitor, with the specificity of inhibition depending not only on the base-pairing mechanism of binding to the target RNA, but also on the mechanism of target RNA cleavage. Single mismatches, or base-substitutions, near the site of cleavage can be chosen to completely eliminate catalytic activity of a enzymatic nucleic acid. Nucleic acid molecules having an endonuclease enzymatic activity are able to repeatedly cleave other separate RNA molecules in a nucleotide base sequence-specific manner. Such enzymatic nucleic acid molecules can be targeted to virtually any RNA transcript, and efficient cleavage achieved in vitro (Zaug et al., 324, Nature 429 1986 ; Uhlenbeck, 1987 Nature 328, 596; Kim et al., 84 Proc. Natl. Acad. Sci. USA 8788, 1987; Dreyfus, 1988, Einstein Quart. J. Bio. Med., 6, 92; Haseloff and Gerlach, 334 Nature 585, 1988; Cech, 260 JAMA 3030, 1988; and Jefferies et al., 17 Nucleic Acids Research 1371, 1989; Santoro et al, 1997 supra). Because of their sequence-specificity, trans-cleaving enzymatic nucleic acids show promise as therapeutic agents for human disease (Usman & McSwiggen, 1995 Ann. Rep. Med. Chem. 30, 285-294; Christoffersen and Marr, 1995 J. Med. Chem. 38, 2023-2037). Enzymatic nucleic acids can be designed to cleave specific RNA targets within the background of cellular RNA. Such a cleavage event renders the RNA non-functional and abrogates protein expression from that RNA. In this manner, synthesis of a protein associated with a disease state can be selectively inhibited. George et al., US Patent Nos. 5,834,186 and 5,741,679, describe regulatable RNA molecules which contain a ligand-binding RNA sequence and a enzymatic nucleic acid sequence capable of cleaving a separate targeted RNA sequence, wherein upon binding of the ligand to the ligand- binding RNA sequence, the activity of the enzymatic nucleic acid sequence against the targeted RNA sequence is altered. Shih et al., US Patent No. 5,589,332, describe a method for the use of enzymatic nucleic acids to detect macromolecules such as proteins and nucleic acid. Nathan et al., US Patent No 5,871,914, describe a method for detecting the presence of an assayed nucleic acid based on a two component enzymatic nucleic acid system containing a detection ensemble and an RNA amplification ensemble. This invention relates to a method for the detection of specific target molecules such as nucleic acid molecules, proteins, polysaccharides, sugars, metals, and organic and inorganic molecules. The method of nucleic acid detection of this invention is distinct from other methods known in the art. The invention further relates to the use of said method as a diagnostic application to identify the presence of a target molecule such as a gene and/or gene products which are indicative of a particular genotype and/or phenotype, for example a disease state, infection, or related condition within patients. The invention also relates to a method for example, the diagnosis of disease states or physiological abnormalities related to the expression of viral, bacterial or cellular RNA and DNA. In a preferred embodiment, the invention features a method for the detection and/or amplification of specific target molecules in a system using enzymatic nucleic acid molecules. Specifically, the invention features the use of at least one reporter molecule, at least one target molecule, and a diagnostic effector molecule which is comprised of an enzymatic nucleic acid component joined by a linker to one or more inhibitor components, where a inhibitor component for example is complimentary to one or more sequences within the enzymatic nucleic acid component. The enzymatic nucleic acid component's ability, in the diagnostic effector molecule, to catalyze a reaction is inhibited by the interaction of one or more inhibitor components. However, in the presence of one or more distinct target molecules, the inhibitor component interacts with its respective target molecule preferentially, allowing the enzymatic nucleic acid molecule to interact with a reporter molecule to catalyze a reaction. A catalytic reaction then take places on the reporter molecule, for example cleavage or ligation of the reporter molecule, the rate of which can then be measured by standard assays well known in the art. In another preferred embodiment, the invention features a method for the detection and/or amplification of specific target molecules in a system using at least one reporter molecule, at least one target molecule, and a diagnostic effector molecule which comprises an enzymatic nucleic acid component and at least one separate inhibitor component, where the inhibitor component or components interacts with one or more sequences within the nucleic acid catalyst. The enzymatic nucleic acid component's ability, in the diagnostic effector molecule, to catalyze a reaction is inhibited by the interaction of at least one inhibitor component. However, in the presence of a target molecule, the inhibitor component preferentially interacts with the target molecule, which allows the enzymatic nucleic acid molecule to interact with a reporter molecule and become functional. A catalytic reaction then takes place on the reporter molecule, for example cleavage or ligation of the reporter molecule, the rate of which can then be measured by standard assays well known in the art. In a preferred embodiment, the invention features a method for the detection and/or amplification of a specific target molecule in a system using at least one reporter molecule, at least one target molecule, and a diagnostic effector molecule which comprises an enzymatic nucleic acid component. The effector molecule is selected for having catalytic activity only through interaction with the target molecule. In the absence of the target molecule, the diagnostic effector molecule is inactive. In the presence of a target molecule the diagnostic effector molecule can adopt an active conformation and become functional. A catalytic reaction then take places on the reporter molecule, for example cleavage or ligation of the reporter molecule, the rate of which can then be measured by standard assays well known in the art. Alternatively, the diagnostic effector molecule can be selected to be inhibited through interaction with the target molecule, such that interaction with the target causes the diagnostic effector molecule to adopt an inactive conformation and become non-active. hi preferred embodiments, the reaction catalyzed by the enzymatic nucleic acid component of the diagnostic effector molecule with the reporter molecule of the invention features catalytic activity, for example cleavage activity, ligation activity, amplification activity, and/or polymerase activity. In yet another preferred embodiment, the enzymatic nucleic acid component of the diagnostic effector molecule features preferably the hammerhead, NCH (Inozyme), G-cleaver, amberzyme, zinzyme and/or DNAzyme motif. By "target molecule" is meant, a molecule, in a purified or unpurified form, that is capable of preferentially interacting with the inhibitor component of the diagnostic effector molecule. The target molecule may be a nucleic acid (RNA, DNA or analogs thereof), small molecules, peptides, proteins, antibodies, carbohydrates, organic or inorganic compounds, metals, or any other molecules capable of interacting with an inhibitor component of the diagnostic effector molecule. By "inhibitor component" of the diagnostic effector molecule is meant, a molecule such as a nucleic acid sequence (e.g., RNA or DNA or analogs thereof), peptide, or other chemical moiety which can interact with one or more regions of the enzymatic nucleic acid component of the diagnostic effector molecule to inhibit the catalytic activity of the enzymatic nucleic acid. The inhibitor component may be covalently linked to the diagnostic effector molecule or may be non-covalently associated. A person skilled in the act will recognize that all that is required is that the inhibitory component is able to selectively inhibit the activity of the enzymatic nucleic acid component of the diagnostic effector molecule. By "system" is meant, material, in a purified or unpurified form, from biological or non- biological sources, including but not limited to human, animal, plant, bacteria, virus, fungi, soil, water, or others that comprises the target molecule to be detected or amplified. The "biological system" as used herein may be a eukaryotic system or a prokaryotic system, may be a bacterial cell, plant cell or a mammalian cell, or may be of plant origin, mammalian origin, yeast origin, Drosophila origin, or archebacterial origin. By "reporter molecule" is meant a molecule, such as a nucleic acid sequence (e.g., RNA or DNA or analogs thereof) or peptides and/or other chemical moieties, able to stably interact with the enzymatic nucleic acid component of the diagnostic effector molecule and function as a substrate for the enzymatic nucleic acid molecule. The reporter molecule may also contain chemical moieties including but not limited to fluorescent, chromogenic, radioactive, enzymatic and/or chemiluminescent or other detectable labels which may then be detected using standard assays known in the art. In another preferred embodiment, the reporter molecule of the invention is an oligonucleotide primer, template, or probe, which can be used to modulate the amplification of additional nucleic acid sequences, for example, sequences comprising reporter molecules, target molecules, effector molecules, inhibitor molecules, and/or additional enzymatic nucleic acid molecules of the instant invention. By "unmodified nucleotide" is meant a nucleotide with one of the bases adenine, cytosine, guanine, thymine, uracil joined to the 1' carbon of beta-D-ribo-furanose. By "modified nucleotide" is meant a nucleotide which contains a modification in the chemical structure of an unmodified nucleotide base, sugar and/or phosphate. In a preferred embodiment the linker region, when present in the diagnostic effector molecule is further comprised of nucleotide, non-nucleotide chemical moieties or combinations thereof. In another embodiment, the non-nucleotide linker (L) is as defined herein. The term "non- nucleotide" as used herein include either abasic nucleotide, polyether, polyamine, polyamide, peptide, carbohydrate, lipid, or polyhydrocarbon compounds. Specific examples include those described by Seela and Kaiser, Nucleic Acids Res. 1990, 75:6353 and Nucleic Acids Res. 1987, 75:3113; Cload and Schepartz, J Am. Chem. Soc. 1991, 775:6324; Richardson and Schepartz, J. Am. Chem. Soc. 1991, 775:5109; Ma et al., Nucleic Acids Res. 1993, 27:2585 and Biochemistry 1993, 52:1751; Durand et al., Nucleic Acids Res. 1990, 75:6353; McCurdy et al, Nucleosides & Nucleotides 1991, 10:287; Jschke et al., Tetrahedron Lett. 1993, 54:301; Ono et al, Biochemistry 1991, 30:9914; Arnold et al, International Publication No. WO 89/02439; Usman et al, International Publication No. WO 95/06731; Dudycz et al, International Publication No. WO 95/11910 and Ferentz and Verdine, J. Am. Chem. Soc. 1991, 775:4000, all hereby incorporated by reference herein. Thus, in a preferred embodiment, the invention features an enzymatic nucleic acid molecule having one or more non-nucleotide moieties, and having enzymatic activity to cleave an RNA or DNA molecule. By the term "non-nucleotide" is meant any group or compound which can be incorporated into a nucleic acid chain in the place of one or more nucleotide units, including either sugar and/or phosphate substitutions, and allows the remaining bases to exhibit their enzymatic activity. The group or compound is abasic in that it does not contain a commonly recognized nucleotide base, such as adenine, guanine, cytosine, uracil or thymine. The terms "abasic" or "abasic nucleotide" as used herein encompass sugar moieties lacking a base or having other chemical groups in place of a base at the 1' position. In a preferred embodiment, the invention provides a method for producing a class of nucleic acid-based diagnostic agents which exhibit a high degree of specificity for the target molecule. In additional embodiments, the invention features a method of detecting target RNA and/or DNA in both in vitro and in vivo applications. In vitro diagnostic applications may comprise both solid support based and solution based chip, multichip-array, micro-well plate, and microbead derived applications as are commonly used in the art. In vivo diagnostic applications may include but are not limited to cell culture and animal model based applications, comprising differential gene expression arrays, FACS based assays, diagnostic imaging, and others. In a preferred embodiment, the invention features a method of detecting and/or amplifying target molecules, wherein said target molecule is a nucleic acid sequence such as RNA and/or DNA, in a system, preferably a mammalian system, comprising the steps of (1) contacting the system with the diagnostic effector molecule and the reporter molecule under conditions suitable for the target molecule, if present in the sample, to interact with the inhibitor molecule component of the effector molecule, such that the enzymatic nucleic acid component of the effector molecule can interact with the reporter molecule to catalyze a reaction; and (2) measuring of the extent of the reaction catalyzed by the enzymatic nucleic acid component of the effector molecule, indicating the presence of the target molecule. If the target molecule is not present in the sample, then no reaction above the background will be detected. The reporter molecule may be contacted with the system after the system is allowed to interact with the diagnostic effector molecule. In another preferred embodiment, the invention features a method of detecting and/or amplifying a target molecule, wherein the target molecule is RNA sequence derived from a virus, bacteria, fungi, mycoplasma or other infectious disease agent, in a system, where the system is a biological sample from a patient, animal, blood, food material, water, and/or other potential sources for infectious disease agents. The method comprises the steps of (1) contacting the system with the diagnostic effector molecule, where the effector molecule comprises an inhibitor component and an enzymatic nucleic acid component, under conditions suitable for preferential interaction of the inhibitor component with the target molecule that may be present in the system; (2) contacting the system with a reporter molecule under conditions suitable for the enzymatic nucleic acid component of the diagnostic effector molecule to catalyze a reaction with the reporter molecule; and (3) detecting the target molecule by measuring any reaction catalyzed in step (2). In another preferred embodiment, the invention features a method of the detecting and/or amplifying a target molecule , wherein the target molecule is RNA sequence derived from a virus, bacteria, fungi, mycoplasma or other infectious disease agent, in a system, where the system is a biological sample from a patient, animal, blood, food material, water, and/or other potential sources for infectious disease agents. The method comprises the steps of (1) contacting the reporter molecule with a mixture, comprising the system and the diagnostic effector molecule, under conditions suitable for the active configuration of the enzymatic nucleic acid component of the diagnostic effector molecule to interact with the reporter molecule to catalyze a reaction; and (2) detecting the target molecule by measuring the reaction catalyzed in step (1). If the target molecule is not present in the system, then the enzymatic nucleic acid component will not be able to catalyze a reaction with the reporter molecule and there will not be a signal to measure. Detection of Nucleic Acid Sequences In one embodiment, the present invention utilizes at least three oligonucleotide sequences for proper function: diagnostic effector molecule, reporter molecule, and target molecule. The diagnostic effector molecule is comprised of a inhibitor component, enzymatic nucleic acid component, and a linker between them which may be present or absent. The diagnostic effector molecule (Figure 7), is in its inactive state when the inhibitor component binds to the nucleic acid catalyst in the enzymatic nucleic acid component. The inhibitor component can bind to the substrate binding regions or nucleotides that contribute to the secondary or tertiary structure of the enzymatic nucleic acid component. For example, the inhibitor component can bind to nucleotides located within the enzymatic nucleic acid core, which can disrupt catalytic activity. The reporter molecule is able to bind to the diagnostic effector molecule, but a catalytic activity is inhibited since the molecule is structurally inactive. Alternatively, the inhibitor component can bind to the substrate binding region(s) of the enzymatic nucleic acid component, which can prevent the reporter molecule from binding to the diagnostic effector molecule. The inhibitor component is not be cleaved because the cleavage site contains either a chemical modification which prevents cleavage or an inappropriate sequence. For example, hammerhead ribozymes need to have a NUH motif in the molecule to be cleaved (H is adenosine, cytidine, or uridine) for proper cleavage. By adding a guanosine at the H position in the RNA to be cleaved, cleavage is inhibited. In the presence of the target molecule, the inhibitor can disassociate from the enzymatic nucleic acid component and bind to the target molecule preferentially. The inhibitor region can preferentially bind to the target molecule which results in the formation of a more stable complex. For example, the inhibitor region can bind to more nucleotides on the target molecule than on the diagnostic effector molecule. Binding to a larger number of nucleotides can have increased chemical stability and therefore is preferred over binding to a smaller number of nucleotides. When the inhibitor region is bound to the target molecule and the reporter molecule binds to the diagnostic effector molecule, a reaction may be catalyzed on the reporter molecule by the enzymatic nucleic acid component. For example, the reporter molecule can be cleaved. The cleavage event can then be detected by using a number of assays. For example, electrophoresis on a polyacrylamide gel detects not only the full length reporter oligonucleotide but also any cleavage products that are created by the functional diagnostic effector molecule. The detection of these cleavage products indicates the presence of the target molecule. In addition, the reporter molecule can contain a fluorescent molecule at one end, which fluorescence signal is quenched by another molecule attached at the other end of the reporter molecule. Cleavage of the reporter molecule in this case results in the disassociation of the florescent molecule and the quench molecule, resulting in a signal. This signal can be detected and/or quantified by methods known in the art (for example see Nathan et al, US Patent No. 5,871,914, Birkenmeyer, US Patent No. 5,427,930, and Lizardi et al, US Patent No. 5,652,107, George et al, US Patent Nos. 5,834,186 and 5,741,679, and Shih et al, US Patent No. 5,589,332). Alternatively, the inhibitory region of the effector molecule can comprise a separate oligonucleotide sequence, as shown for example in Figure 12, system M. Diagnostic screen A series of enzymatic nucleic acids with trans-acting inhibitory sequences were designed. Table XV shows the sequences that were used in this test. Sequences with names beginning with S- were the substrate sequences used in this experiment, and those beginning with Rz- were enzymatic nucleic acids. Sequences beginning with I- were inhibitory sequences that were designed to bind to portions of the enzymatic nucleic acid sequences (to varying degrees) and to prevent the enzymatic nucleic acid from binding and cleaving substrate; these sequences are shown in lower case because they were synthesized using 2'-O-methyl nucleotides in order to increase binding affinity. The one sequence labeled T-2a represents the target sequence which was designed to bind to the inhibitory sequences so as to prevent them from inhibiting the enzymatic nucleic acid activity. The system construct is shown in Figure 16. Figure 17 shows the results of testing some of these enzymatic nucleic acid/inhibitor combinations in a cleavage assay. The substrate molecules were 5'-end labeled with 32P- phosphate and incubated for 12 or 60 minutes in either: (1) buffer alone (50 mM Tris, pH 7.5, 10 mM MgC12), or in the presence of (2) 10 nM enzymatic nucleic acid, (3) 10 nM enzymatic nucleic acid plus 20 nM inhibitor, (4) 10 nM enzymatic nucleic acid plus 200 nM inhibitor, or (5) 10 nM enzymatic nucleic acid plus 20 nM inhibitor and 500 nM target. At the end of the incubation the reactions were loaded onto a PAGE gel to separate cleaved product from uncleaved substrate. The gel was imaged on a Molecular Dynamics phosphorimager and quantitated to determine the percent of substrate cleaved under each set of conditions. Control reactions were carried out to ensure that addition of inhibitor or target sequence, without enzymatic nucleic acid, did not result in substrate cleavage; only 0.2-0.4% of substrate was cleaved under these conditions. Figure 17 shows that enzymatic nucleic acid alone results in 40-60%> cleavage of substrate after 1 minute, and 85% cleavage after 60 minutes for these three enzymatic nucleic acids. When 20 nM inhibitor is added to the reaction, the cleavage activity is reduced by 30- 70%. When 200 nM inhibitor is added, the cleavage activity is reduced by 50-99%. Finally, addition of 500 nM target to a reaction containing 10 nM enzymatic nucleic acid and 20 nM target results in almost complete recovery of the cleavage activity up to the level observed with enzymatic nucleic acid alone. Diagnostic uses The nucleic acid molecules of this invention (e.g., ribozymes) can be used as diagnostic tools to examine genetic drift and mutations within diseased cells or to detect the presence of CD20 and or NOGO RNA in a cell. The close relationship between enzymatic nucleic acid activity and the structure of the target RNA allows the detection of mutations in any region of the molecule which alters the base-pairing and three-dimensional structure of the target RNA. By using multiple enzymatic nucleic acids described in this invention, one can map nucleotide changes that are important to RNA structure and function in vitro, as well as in cells and tissues. Cleavage of target RNAs with enzymatic nucleic acids can be used to inhibit gene expression and define the role (essentially) of specified gene products in the progression of disease. In this manner, other genetic targets can be defined as important mediators of the disease. These experiments can lead to better treatment of the disease progression by affording the possibility of combinational therapies (e.g., multiple enzymatic nucleic acids targeted to different genes, enzymatic nucleic acids coupled with known small molecule inhibitors, or intermittent treatment with combinations of enzymatic nucleic acids and/or other chemical or biological molecules). Other in vitro uses of enzymatic nucleic acids of this invention are well known in the art, and include detection of the presence of mRNAs associated with CD20-related condition. Such RNA is detected by determining the presence of a cleavage product after treatment with a enzymatic nucleic acid using standard methodology. In a specific example, enzymatic nucleic acids which cleave only wild-type or mutant forms of the target RNA are used for the assay. The first enzymatic nucleic acid is used to identify wild-type RNA present in the sample and the second enzymatic nucleic acid is used to identify mutant RNA in the sample. As reaction controls, synthetic substrates of both wild-type and mutant RNA are cleaved by both enzymatic nucleic acids to demonstrate the relative enzymatic nucleic acid efficiencies in the reactions and the absence of cleavage of the "non- targeted" RNA species. The cleavage products from the synthetic substrates also serve to generate size markers for the analysis of wild-type and mutant RNAs in the sample population. Thus, each analysis requires two enzymatic nucleic acids, two substrates and one unknown sample, which are combined into six reactions. The presence of cleavage products can be determined using an RNAse protection assay so that full-length and cleavage fragments of each RNA can be analyzed in one lane of a polyacrylamide gel. It is not absolutely required to quantify the results to gain insight into the expression of mutant RNAs and putative risk of the desired phenotypic changes in target cells. The expression of mRNA whose protein product is implicated in the development of the phenotype (i.e., CD20) is adequate to establish risk. If probes of comparable specific activity are used for both transcripts, then a qualitative comparison of RNA levels is adequate and decreases the cost of the initial diagnosis. Higher mutant form to wild-type ratios are correlated with higher risk whether RNA levels are compared qualitatively or quantitatively. Additional Uses Potential uses of sequence-specific enzymatic nucleic acid molecules of the instant invention have many of the same applications for the study of RNA that DNA restriction endonucleases have for the study of DNA (Nathans et al, 1975 Ann. Rev. Biochem. 44:273). For example, the pattern of restriction fragments can be used to establish sequence relationships between two related RNAs, and large RNAs could be specifically cleaved to fragments of a size more useful for study. The ability to engineer sequence specificity of the enzymatic nucleic acid molecule is ideal for cleavage of RNAs of unknown sequence. Applicant describes the use of nucleic acid molecules to down-regulate gene expression of target genes in bacterial, microbial, fungal, viral, and eukaryotic systems including plant, or mammalian cells. All patents and publications mentioned in the specification are indicative of the levels of skill of those skilled in the art to which the invention pertains. All references cited in this disclosure are incorporated by reference to the same extent as if each reference had been incorporated by reference in its entirety individually. One skilled in the art would readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The methods and compositions described herein as presently representative of preferred embodiments are exemplary and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art, which are encompassed within the spirit of the invention, are defined by the scope of the claims. It will be readily apparent to one skilled in the art that varying substitutions and modifications can be made to the invention disclosed herein without departing from the scope and spirit of the invention. Thus, such additional embodiments are within the scope of the present invention and the following claims. The invention illustratively described herein suitably can be practiced in the absence of any element or elements, limitation or limitations which is not specifically disclosed herein. Thus, for example, in each instance herein any of the terms "comprising," "consisting essentially of," and "consisting of may be replaced with either of the other two terms. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments, optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the description and the appended claims. In addition, where features or aspects of the invention are described in terms of Markush groups or other grouping of alternatives, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group or other group. Other embodiments are within the claims that follow. TABLE I Characteristics of naturally occurring ribozymes Group I Introns Size: -150 to >1000 nucleotides. • Requires a U in the target sequence immediately 5' of the cleavage site. • Binds 4-6 nucleotides at the 5'-side of the cleavage site. • Reaction mechanism: attack by the 3'-OH of guanosine to generate cleavage products with 3' -OH and 5'-guanosine. • Additional protein cofactors required in some cases to help folding and maintainance of the active structure. • Over 300 known members of this class. Found as an intervening sequence in Tetrahymena thermophila rRNA, fungal mitochondria, chloroplasts, phage T4, blue- green algae, and others. • Major structural features largely established through phylogenetic comparisons, mutagenesis, and biochemical studies [ ]. • Complete kinetic framework established for one ribozyme p / 1 ]- • Studies of ribozyme folding and substrate docking underway [ vii / viii / i ]. • Chemical modification investigation of important residues well established [ x , xi ]. • The small (4-6 nt) binding site may make this ribozyme too non-specific for targeted RNA cleavage, however, the Tetrahymena group I intron has been used to repair a "defective" -galactosidase message by the ligation of new - galactosidase sequences onto the defective message [ xii ]. RNAse P RNA (Ml RNA) Size: -290 to 400 nucleotides. • RNA portion of a ubiquitous ribonucleoprotein enzyme. • Cleaves tRNA precursors to form mature tRNA [ xiii ]. • Reaction mechanism: possible attack by M 2+ -OH to generate cleavage products with 3'-OH and 5'-phosphate. • RNAse P is found throughout the prokaryotes and eukaryotes. The RNA subunit has been sequenced from bacteria, yeast, rodents, and primates. • Recruitment of endogenous RNAse P for therapeutic applications is possible through hybridization of an External Guide Sequence (EGS) to the target RNA Txiv xvl • Important phosphate and 2' OH contacts recently identified [ x ^ xvu j Group II Introns • Size: >1000 nucleotides. • Trans cleavage of target RNAs recently demonstrated [ xvϋ yi x ] • Sequence requirements not fully determined. • Reaction mechanism: 2' -OH of an internal adenosine generates. cleavage products with 3'-OH and a "lariat" RNA containing a 3'-5' and a 2' -5' branch point. • Only natural ribozyme with demonstrated participation in DNA cleavage [ χχ , xxi ] in addition to RNA cleavage and ligation. • Major structural features largely established through phylogenetic comparisons [ " xxϋl • Important 2' OH contacts beginning to be identified [ xx ] • Kinetic framework under development [ xxiv ] Neurospora VS RNA • Size: -144 nucleotides. • Trans cleavage of hairpin target RNAs recently demonstrated [ xxv ]. • Sequence requirements not fully determined. • Reaction mechanism: attack by 2'-OH 5' to the scissile bond to generate cleavage products with 2',3' -cyclic phosphate and 5' -OH ends. • Binding sites and structural requirements not fully determined. • Only 1 known member of this class. Found in Neurospora VS RNA. Hammerhead Ribozyme (see text for references) Size: -13 to 40 nucleotides. Requires the target sequence UH immediately 5' of the cleavage site. Binds a variable number nucleotides on both sides of the cleavage site. Reaction mechanism: attack by 2'-OH 5' to the scissile bond to generate cleavage products with 2',3'-cyclic phosphate and 5' -OH ends. 14 known members of this class. Found in a number of plant pathogens (virusoids) that use RNA as the infectious agent. Essential structural features largely defined, including 2 crystal structures [ xx ^ xxvϋ ] Minimal ligation activity demonstrated (for engineering through in vitro selection) rxxvϋi] Complete kinetic framework established for two or more ribozymes [ xxix ]. Chemical modification investigation of important residues well established [ xxx ]. Hairpin Ribozyme • Size: -50 nucleotides. • Requires the target sequence GUC immediately 3' of the cleavage site. • Binds 4-6 nucleotides at the 5'-side of the cleavage site and a variable number to the 3 '-side of the cleavage site. • Reaction mechanism: attack by 2' -OH 5' to the scissile bond to generate cleavage products with 2',3'-cyclic phosphate and 5'-OH ends. • 3 known members of this class. Found in three plant pathogen (satellite RNAs of the tobacco ringspot virus, arabis mosaic virus and chicory yellow mottle virus) which uses RNA as the infectious agent. • Essential structural features largely defined [ χ χ . χχ i. χχ ii χχ i ] • Ligation activity (in addition to cleavage activity) makes ribozyme amenable to engineering through in vitro selection [ xxxv ] • Complete kinetic framework established for one ribozyme [ χχχ i ]. • Chemical modification investigation of important residues begun [ χχχ vϋ. χχχ vϋι] _ Hepatitis Delta Virus (HDV) Ribozyme • Size: -60 nucleotides. • Trans cleavage of target RNAs demonstrated [ χχχiχ ]. • Binding sites and structural requirements not fully determined, although no sequences 5' of cleavage site are required. Folded ribozyme contains a pseudoknot structure [ x1 ]. • Reaction mechanism: attack by 2'-OH 5' to the scissile bond to generate cleavage products with 2',3'-cyclic phosphate and 5' -OH ends. • Only 2 known members of this class. Found in human HDV. Circular form of HDV is active and shows increased nuclease stability [ xh ] Michel, Francois; Westhof, Eric. Slippery substrates. Nat. Struct. Biol. (1994), 1(1), 5-7. II . Lisacek, Frederique; Diaz, Yolande; Michel, Francois. Automatic identification of group I intron cores in genomic DNA sequences. J. Mol. Biol. (1994), 235(4), 1206-17. III . Herschlag, Daniel; Cech, Thomas R.. Catalysis of RNA cleavage by the Tetrahymena thermophila ribozyme. 1. Kinetic description of the reaction of an RNA substrate complementary to the active site. Biochemistry (1990), 29(44), 10159-71. IV . Herschlag, Daniel; Cech, Thomas R Catalysis of RNA cleavage by the Tetrahymena thermophila ribozyme. 2. Kinetic description of the reaction of an RNA substrate that forms a mismatch at the active site. Biochemistry (1990), 29(44), 10172-80. v . Knitt, Deborah S.; Herschlag, Daniel. pH Dependencies of the Tetrahymena Ribozyme Reveal an Unconventional Origin of an Apparent pKa. Biochemistry (1996), 35(5), 1560-70. VI . Bevilacqua, Philip C; Sugimoto, Naoki; Turner, Douglas H.. A mechanistic framework for the second step of splicing catalyzed by the Tetrahymena ribozyme. Biochemistry (1996), 35(2), 648-58. vn . Li, Yi, Bevilacqua, Philip C; Mathews, David; Turner, Douglas H.. Thermodynamic and activation parameters for binding of a pyrene-labeled substrate by the Tetrahymena ribozyme: docking is not diffusion-controlled and is driven by a favorable entropy change. Biochemistry (1995), 34(44), 14394-9. vιπ . Banerjee, Aloke Raj; Turner, Douglas H.. The time dependence of chemical modification reveals slow steps in the folding of a group I ribozyme. Biochemistry (1995), 34(19), 6504-12. ,x . Zarrinkar, Patrick P.; Williamson, James R.. The P9.1-P9.2 peripheral extension helps guide folding of the Tetrahymena ribozyme. Nucleic Acids Res. (1996), 24(5), 854-8. x . Strobel, Scott A.; Cech, Thomas R.. Minor groove recognition of the conserved G.cntdotU pair at the Tetrahymena ribozyme reaction site. Science (Washington, D. C.) (1995), 267(5198), 675-9. X1 . Strobel, Scott A.; Cech, Thomas R.. Exocyclic Amine of the Conserved G.cntdot.U Pair at the Cleavage Site of the Tetrahymena Ribozyme Contributes to 5'-Splice Site Selection and Transition State Stabilization. Biochemistry (1996), 35(4), 1201-11. xu . Sullenger, Bruce A.; Cech, Thomas R.. Ribozyme-mediated repair of defective mRNA by targeted trans-splicing. Nature (London) (1994), 371(6498), 619-22. Robertson, H.D.; Altman, S.; Smith, J D. J. Biol. Chem., 247, 5243-5251 (1972). X1V . Forster, Anthony C; Altman, Sidney. External guide sequences for an RNA enzyme. Science (Washington, D. C, 1883-) (1990), 249(4970), 783-6. xv . Yuan, Y.; Hwang, E. S.; Altman, S. Targeted cleavage of mRNA by human RNase P. Proc. Natl. Acad. Sci. USA (1992) 89, 8006-10. XVI . Harris, Michael E.; Pace, Norman R . Identification of phosphates involved in catalysis by the ribozyme RNase P RNA. RNA (1995), 1(2), 210-18. XVII . Pan, Tao; Loria, Andrew; Zhong, Kun. Probing of tertiary interactions in RNA: 2'-hydroxyl-base contacts between the RNase P RNA and pre-tRNA. Proc. Natl. Acad. Sci. U. S. A. (1995), 92(26), 12510-14. x iπ Pyle, Anna Marie; Green, Justin B.. Building a Kinetic Framework for Group II Intron Ribozyme Activity: Quantitation of Interdomain Binding and Reaction Rate. Biochemistry (1994), 33(9), 2716-25. X1X . Michels, William J. Jr.; Pyle, Anna Marie. Conversion of a Group II Intron into a New Multiple- Turnover Ribozyme that Selectively Cleaves Oligonucleotides: Elucidation of Reaction Mechanism and Structure/ Function Relationships. Biochemistry (1995), 34(9), 2965-77. xx . Zimmerly, Steven; Guo, Huatao; Eskes, Robert; Yang, Jian; Perlman, Philip S.; Lambowitz, Alan M.. A group II intron RNA is a catalytic component of a DNA endonuclease involved in intron mobility. Cell (Cambridge, Mass.) (1995), 83(4), 529-38. XX1 . Griffin, Edmund A., Jr.; Qin, Zhifeng; Michels, Williams J., Jr.; Pyle, Anna Marie. Group II intron ribozymes that cleave DNA and RNA linkages with similar efficiency, and lack contacts with substrate 2'- hydroxyl groups. Chem. Biol. (1995), 2(11), 761-70. π . Michel, Francois; Ferat, Jean Luc. Structure and activities of group II introns. Annu. Rev. Biochem. (1995), 64, 435-61. xxm . Abramovitz, Dana L.; Friedman, Richard A.; Pyle, Anna Marie. Catalytic role of 2'-hydroxyl groups within a group II intron active site. Science (Washington, D. C.) (1996), 271(5254), 1410-13. XX1 . Daniels, Danette L.; Michels, William J., Jr.; Pyle, Anna Marie. Two competing pathways for self- splicing by group II introns: a quantitative analysis of in vitro reaction rates and products. J. Mol. Biol. (1996), 256(1), 31-49. xxv . Guo, Hans C. T.; Collins, Richard A.. Efficient trans-cleavage of a stem-loop RNA substrate by a ribozyme derived from Neurospora VS RNA. EMBO J. (1995), 14(2), 368-76. XXV1 . Scott, W.G., Finch, J.T., Aaron,K. The crystal structure of an all RNA hammerhead πbozyme:Aproposed mechanism for RNA catalytic cleavage. Cell, (1995), 81, 991-1002. xxvπ . McKay, Structure and function of the hammerhead ribozyme: an unfinished story. RNA, (1996), 2, 395-403. xxvm . Long, D., Uhlenbeck, O., Hertel, K. Ligation with hammerhead ribozymes. US Patent No. 5,633,133. XIX . Hertel, K.J., Herschlag, D., Uhlenbeck, O. A kinetic and thermodynamic framework for the hammerhead ribozyme reaction. Biochemistry, (1994) 33, 3374-3385.Beigelman, L., et al., Chemical modifications of hammerhead ribozymes. J. Biol. Chem., (1995) 270, 25702-25708. xxx . Beigelman, L., et al., Chemical modifications of hammerhead ribozymes. J. Biol. Chem., (1995) 270, 25702-25708. XXXI . Hampel, Arnold; Tritz, Richard; Hicks, Margaret; Cruz, Phillip. 'Hairpin' catalytic RNA model: evidence for helixes and sequence requirement for substrate RNA. Nucleic Acids Res. (1990), 18(2), 299- 304. xxx " . Chowrira, Bharat M.; Berzal-Herranz, Alfredo; Burke, John M.. Novel guanosine requirement for catalysis by the hairpin ribozyme. Nature (London) (1991), 354(6351), 320-2. xxxm Berzal-Herranz, Alfredo; Joseph, Simpson; Chowrira, Bharat M.; Butcher, Samuel E.; Burke, John M.. Essential nucleotide sequences and secondary structure elements of the hairpin ribozyme. EMBO J. (1993), 12(6), 2567-73. xxxιv . Joseph, Simpson; Berzal-Herranz, Alfredo; Chowrira, Bharat M.; Butcher, Samuel E.. Substrate selection rules for the hairpin ribozyme determined by in vitro selection, mutation, and analysis of mismatched substrates. Genes Dev. (1993), 7(1), 130-8. xxxv Berzal-Herranz, Alfredo; Joseph, Simpson; Burke, John M.. In vitro selection of active hairpin ribozymes by sequential RNA-catalyzed cleavage and ligation reactions. Genes Dev. (1992), 6(1), 129-34. xvi Hegg, Lisa A.; Fedor, Martha J.. Kinetics and Thermodynamics of Intermolecular Catalysis by Hairpin Ribozymes. Biochemistry (1995), 34(48), 15813-28. xvu Grasby, Jane A.; Mersmann, Karin; Singh, Mohinder; Gait, Michael J.. Purine Functional Groups in Essential Residues of the Hairpin Ribozyme Required for Catalytic Cleavage of RNA. Biochemistry (1995), 34(12), 4068-76. xv Schmidt, Sabine; Beigelman, Leonid; Karpeisky, Alexander; Usman, Nassim; Sorensen, Ulrik S.; Gait, Michael J.. Base and sugar requirements for RNA cleavage of essential nucleoside residues in internal loop B of the hairpin ribozyme: implications for secondary structure. Nucleic Acids Res. (1996), 24(4), 573-81. x xxix Perrotta, Anne T.; Been, Michael D.. Cleavage of oligoribonucleotides by a ribozyme derived from the hepatitis .delta, virus RNA sequence. Biochemistry (1992), 31(1), 16-21. l . Perrotta, Anne T.; Been, Michael D.. A pseudoknot-like structure required for efficient self- cleavage of hepatitis delta virus RNA. Nature (London) (1991), 350(6317), 434-6. h . Puttaraju, M.; Perrotta, Anne T.; Been, Michael D.. A circular trans-acting hepatitis delta virus ribozyme. Nucleic Acids Res. (1993), 21(18), 4253-8. Table II: • Wait time does not include contact time during delivery. Table III: Human NOGO Hammerhead Ribozyme and Substrate Sequence Pos Substrate Seq ID Ribozyme Seq ID 10 ACCACAGU A GGUCCCUC 1 GAGGGACC CUGAUGAG GCCGUUAGGC CGAA ACUGUGGU 3794 14 CAGUAGGU C CCUCGGCU 2 AGCCGAGG CUGAUGAG GCCGUUAGGC CGAA ACCUACUG 3795 18 AGGUCCCU C GGCUCAGU 3 ACUGAGCC CUGAUGAG GCCGUUAGGC CGAA AGGGACCU 3796 23 CCUCGGCU C AGUCGGCC 4 GGCCGACU CUGAUGAG GCCGUUAGGC CGAA AGCCGAGG 3797 27 GGCUCAGU C GGCCCAGC 5 GCUGGGCC CUGAUGAG GCCGUUAGGC CGAA ACUGAGCC 3798 40 CAGCCCCU C UCAGUCCU 6 AGGACUGA CUGAUGAG GCCGUUAGGC CGAA AGGGGCUG 3799 42 GCCCCUCU C AGUCCUCC 7 GGAGGACU CUGAUGAG GCCGUUAGGC CGAA AGAGGGGC 3800 46 CUCUCAGU C CUCCCCAA 8 UUGGGGAG CUGAUGAG GCCGUUAGGC CGAA ACUGAGAG 3801 49 UCAGUCCU C CCCAACCC 9 GGGUUGGG CUGAUGAG GCCGUUAGGC CGAA AGGACUGA 3802 76 CCGCGGCU C UGAGACGC 10 GCGUCUCA CUGAUGAG GCCGUUAGGC CGAA AGCCGCGG 3803 117 UGCAGCAU C AUCUCCAC 11 GUGGAGAU CUGAUGAG GCCGUUAGGC CGAA AUGCUGCA 3804 120 AGCAUCAU C UCCACCCU 12 AGGGUGGA CUGAUGAG GCCGUUAGGC CGAA AUGAUGCU 3805 122 CAUCAUCU C CACCCUCC 13 GGAGGGUG CUGAUGAG GCCGUUAGGC CGAA AGAUGAUG 3806 129 UCCACCCU C CAGCCAUG 14 CAUGGCUG CUGAUGAG GCCGUUAGGC CGAA AGGGUGGA 3807 154 GGACCAGU C UCCUCUGG 15 CCAGAGGA CUGAUGAG GCCGUUAGGC CGAA ACUGGUCC 3808 156 ACCAGUCU c CUCUGGUC 16 GACCAGAG CUGAUGAG GCCGUUAGGC CGAA AGACUGGU 3809 159 AGUCUCCU c UGGUCUCG 17 CGAGACCA CUGAUGAG GCCGUUAGGC CGAA AGGAGACU 3810 164 CCUCUGGU c UCGUCCUC 18 GAGGACGA CUGAUGAG GCCGUUAGGC CGAA ACCAGAGG 3811 166 UCUGGUCU c GUCCUCGG 19 CCGAGGAC CUGAUGAG GCCGUUAGGC CGAA AGACCAGA 3812 169 GGUCUCGU c CUCGGACA 20 UGUCCGAG CUGAUGAG GCCGUUAGGC CGAA ACGAGACC 3813 172 CUCGUCCU c GGACAGCC 21 GGCUGUCC CUGAUGAG GCCGUUAGGC CGAA AGGACGAG 3814 202 GCCCGCGU U CAAGUACC 22 GGUACUUG CUGAUGAG GCCGUUAGGC CGAA ACGCGGGC 3815 203 CCCGCGUU c AAGUACCA 23 UGGUACUU CUGAUGAG GCCGUUAGGC CGAA AACGCGGG 3816 208 GUUCAAGU A CCAGUUCG 24 CGAACUGG CUGAUGAG GCCGUUAGGC CGAA ACUUGAAC 3817 214 GUACCAGU U CGUGAGGG 25 CCCUCACG CUGAUGAG GCCGUUAGGC CGAA ACUGGUAC 3818 215 UACCAGUU c GUGAGGGA 26 UCCCUCAC CUGAUGAG GCCGUUAGGC CGAA AACUGGUA 3819 325 CGGGCUGU c CGCGGCCC 27 GGGCCGCG CUGAUGAG GCCGUUAGGC CGAA ACAGCCCG 3820 376 GAUGGACU U CGGAAAUG 28 CAUUUCCG CUGAUGAG GCCGUUAGGC CGAA AGUCCAUC 3821 377 AUGGACUU c GGAAAUGA 29 UCAUUUCC CUGAUGAG GCCGUUAGGC CGAA AAGUCCAU 3822 388 AAAUGACU U CGUGCCGC 30 GCGGCACG CUGAUGAG GCCGUUAGGC CGAA AGUCAUUU 3823 389 AAUGACUU c GUGCCGCC 31 GGCGGCAC CUGAUGAG GCCGUUAGGC CGAA AAGUCAUU 3824 426 CGGCCGCU c CCCCCGUC 32 GACGGGGG CUGAUGAG GCCGUUAGGC CGAA AGCGGCCG 3825 434 CCCCCCGU c GCCCCGGA 33 UCCGGGGC CUGAUGAG GCCGUUAGGC CGAA ACGGGGGG 3826 454 GCAGCCGU c UUGGGACC 34 GGUCCCAA CUGAUGAG GCCGUUAGGC CGAA ACGGCUGC 3827 456 AGCCGUCU u GGGACCCG 35 CGGGUCCC CUGAUGAG GCCGUUAGGC CGAA AGACGGCU 3828 475 CCCGGUGU c GUCGACCG 36 CGGUCGAC CUGAUGAG GCCGUUAGGC CGAA ACACCGGG 3829 478 GGUGUCGU c GACCGUGC 37 GCACGGUC CUGAUGAG GCCGUUAGGC CGAA ACGACACC 3830 496 CGCGCCAU c CCCGCUGU 38 ACAGCGGG CUGAUGAG GCCGUUAGGC CGAA AUGGCGCG 3831 505 CCCGCUGU c UGCUGCCG 39 CGGCAGCA CUGAUGAG GCCGUUAGGC CGAA ACAGCGGG 3832 518 GCCGCAGU c UCGCCCUC 40 GAGGGCGA CUGAUGAG GCCGUUAGGC CGAA ACUGCGGC 3833 520 CGCAGUCU c GCCCUCCA 41 UGGAGGGC CUGAUGAG GCCGUUAGGC CGAA AGACUGCG 3834 526 CUCGCCCU c CAAGCUCC 42 GGAGCUUG CUGAUGAG GCCGUUAGGC CGAA AGGGCGAG 3835 533 UCCAAGCU c CCUGAGGA 43 UCCUCAGG CUGAUGAG GCCGUUAGGC CGAA AGCUUGGA 3836 552 ACGAGCCU c CGGCCCGG 44 CCGGGCCG CUGAUGAG GCCGUUAGGC CGAA AGGCUCGU 3837 564 CCCGGCCU c CCCCUCCU 45 AGGAGGGG CUGAUGAG GCCGUUAGGC CGAA AGGCCGGG 3838 570 CUCCCCCU c CUCCCCCG 46 CGGGGGAG CUGAUGAG GCCGUUAGGC CGAA AGGGGGAG 3839 573 CCCCUCCU c CCCCGGCC 47 GGCCGGGG CUGAUGAG GCCGUUAGGC CGAA AGGAGGGG 3840 630 CCCCGGCU c CCGCCGCG 48 CGCGGCGG CUGAUGAG GCCGUUAGGC CGAA AGCCGGGG 3841 646 GCCCCCCU c CACCCCGG 49 CCGGGGUG CUGAUGAG GCCGUUAGGC CGAA AGGGGGGC 3842 676 CAGGGGCU c CUCGGGCU 50 AGCCCGAG CUGAUGAG GCCGUUAGGC CGAA AGCCCCUG 3843 679 GGGCUCCU c GGGCUCAG 51 CUGAGCCC CUGAUGAG GCCGUUAGGC CGAA AGGAGCCC 3844 685 CUCGGGCU c AGUGGAUG 52 CAUCCACU CUGAUGAG GCCGUUAGGC CGAA AGCCCGAG 3845 701 GAGACCCU u UUUGCUCU 53 AGAGCAAA CUGAUGAG GCCGUUAGGC CGAA AGGGUCUC 3846 702 AGACCCUU U UUGCUCUU 54 AAGAGCAA CUGAUGAG GCCGUUAGGC CGAA AAGGGUCU 3847 703 GACCCUUU u UGCUCUUC 55 GAAGAGCA CUGAUGAG GCCGUUAGGC CGAA AAAGGGUC 3848 704 ACCCUUUU u GCUCUUCC 56 GGAAGAGC CUGAUGAG GCCGUUAGGC CGAA AAAAGGGU 3849 708 UUUUUGCU c UUCCUGCU 57 AGCAGGAA CUGAUGAG GCCGUUAGGC CGAA AGCAAAAA 3850 710 UUUGCUCU u CCUGCUGC 58 GCAGCAGG CUGAUGAG GCCGUUAGGC CGAA AGAGCAAA 3851 711 UUGCUCUU c CUGCUGCA 59 UGCAGCAG CUGAUGAG GCCGUUAGGC CGAA AAGAGCAA 3852 721 UGCUGCAU c UGAGCCUG 60 CAGGCUCA CUGAUGAG GCCGUUAGGC CGAA AUGCAGCA 3853 734 CCUGUGAU A CGCUCCUC 61 GAGGAGCG CUGAUGAG GCCGUUAGGC CGAA AUCACAGG 3854 739 GAUACGCU C CUCUGCAG 62 CUGCAGAG CUGAUGAG GCCGUUAGGC CGAA AGCGUAUC 3855 742 ACGCUCCU C UGCAGAAA 63 UUUCUGCA CUGAUGAG GCCGUUAGGC CGAA AGGAGCGU 3856 753 CAGAAAAU A UGGACUUG 64 CAAGUCCA CUGAUGAG GCCGUUAGGC CGAA AUUUUCUG 3857 760 UAUGGACU U GAAGGAGC 65 GCUCCUUC CUGAUGAG GCCGUUAGGC CGAA AGUCCAUA 3858 111 AGCCAGGU A ACACUAUU 66 AAUAGUGU CUGAUGAG GCCGUUAGGC CGAA ACCUGGCU 3859 783 GUAACACU A UUUCGGCU 67 AGCCGAAA CUGAUGAG GCCGUUAGGC CGAA AGUGUUAC 3860 785 AACACUAU U UCGGCUGG 68 CCAGCCGA CUGAUGAG GCCGUUAGGC CGAA AUAGUGUU 3861 786 ACACUAUU U CGGCUGGU 69 ACCAGCCG CUGAUGAG GCCGUUAGGC CGAA AAUAGUGU 3862 787 CACUAUUU C GGCUGGUC 70 GACCAGCC CUGAUGAG GCCGUUAGGC CGAA AAAUAGUG 3863 795 CGGCUGGU C AAGAGGAU 71 AUCCUCUU CUGAUGAG GCCGUUAGGC CGAA ACCAGCCG 3864 804 AAGAGGAU U UCCCAUCU 72 AGAUGGGA CUGAUGAG GCCGUUAGGC CGAA AUCCUCUU 3865 805 AGAGGAUU u CCCAUCUG 73 CAGAUGGG CUGAUGAG GCCGUUAGGC CGAA AAUCCUCU 3866 806 GAGGAUUU C CCAUCUGU 74 ACAGAUGG CUGAUGAG GCCGUUAGGC CGAA AAAUCCUC 3867 811 UUUCCCAU C UGUCCUGC 75 GCAGGACA CUGAUGAG GCCGUUAGGC CGAA AUGGGAAA 3868 815 CCAUCUGU C CUGCUUGA 76 UCAAGCAG CUGAUGAG GCCGUUAGGC CGAA ACAGAUGG 3869 821 GUCCUGCU u GAAACUGC 77 GCAGUUUC CUGAUGAG GCCGUUAGGC CGAA AGCAGGAC 3870 834 CUGCUGCU u CUCUUCCU 78 AGGAAGAG CUGAUGAG GCCGUUAGGC CGAA AGCAGCAG 3871 835 UGCUGCUU C UCUUCCUU 79 AAGGAAGA CUGAUGAG GCCGUUAGGC CGAA AAGCAGCA 3872 837 CUGCUUCU C UUCCUUCU 80 AGAAGGAA CUGAUGAG GCCGUUAGGC CGAA AGAAGCAG 3873 839 GCUUCUCU u CCUUCUCU 81 AGAGAAGG CUGAUGAG GCCGUUAGGC CGAA AGAGAAGC 3874 840 CUUCUCUU C CUUCUCUG 82 CAGAGAAG CUGAUGAG GCCGUUAGGC CGAA AAGAGAAG 3875 843 CUCUUCCU u CUCUGUCU 83 AGACAGAG CUGAUGAG GCCGUUAGGC CGAA AGGAAGAG 3876 844 UCUUCCUU C UCUGUCUC 84 GAGACAGA CUGAUGAG GCCGUUAGGC CGAA AAGGAAGA 3877 846 UUCCUUCU c UGUCUCCU 85 AGGAGACA CUGAUGAG GCCGUUAGGC CGAA AGAAGGAA 3878 850 UUCUCUGU C UCCUCUCU 86 AGAGAGGA CUGAUGAG GCCGUUAGGC CGAA ACAGAGAA 3879 852 CUCUGUCU c CUCUCUCA 87 UGAGAGAG CUGAUGAG GCCGUUAGGC CGAA AGACAGAG 3880 855 UGUCUCCU c UCUCAGCC 88 GGCUGAGA CUGAUGAG GCCGUUAGGC CGAA AGGAGACA 3881 857 UCUCCUCU c UCAGCCGC 89 GCGGCUGA CUGAUGAG GCCGUUAGGC CGAA AGAGGAGA 3882 859 UCCUCUCU c AGCCGCUU 90 AAGCGGCU CUGAUGAG GCCGUUAGGC CGAA AGAGAGGA 3883 867 CAGCCGCU u CUUUCAAA 91 UUUGAAAG CUGAUGAG GCCGUUAGGC CGAA AGCGGCUG 3884 868 AGCCGCUU c UUUCAAAG 92 CUUUGAAA CUGAUGAG GCCGUUAGGC CGAA AAGCGGCU 3885 870 CCGCUUCU u UCAAAGAA 93 UUCUUUGA CUGAUGAG GCCGUUAGGC CGAA AGAAGCGG 3886 871 CGCUUCUU u CAAAGAAC 94 GUUCUUUG CUGAUGAG GCCGUUAGGC CGAA AAGAAGCG 3887 872 GCUUCUUU c AAAGAACA 95 UGUUCUUU CUGAUGAG GCCGUUAGGC CGAA AAAGAAGC 3888 886 ACAUGAAU A CCUUGGUA 96 UACCAAGG CUGAUGAG GCCGUUAGGC CGAA AUUCAUGU 3889 890 GAAUACCU u GGUAAUUU 97 AAAUUACC CUGAUGAG GCCGUUAGGC CGAA AGGUAUUC 3890 894 ACCUUGGU A AUUUGUCA 98 UGACAAAU CUGAUGAG GCCGUUAGGC CGAA ACCAAGGU 3891 897 UUGGUAAU u UGUCAACA 99 UGUUGACA CUGAUGAG GCCGUUAGGC CGAA AUUACCAA 3892 898 UGGUAAUU u GUCAACAG 100 CUGUUGAC CUGAUGAG GCCGUUAGGC CGAA AAUUACCA 3893 901 UAAUUUGU c AACAGUAU 101 AUACUGUU CUGAUGAG GCCGUUAGGC CGAA ACAAAUUA 3894 908 UCAACAGU A UUACCCAC 102 GUGGGUAA CUGAUGAG GCCGUUAGGC CGAA ACUGUUGA 3895 910 AACAGUAU U ACCCACUG 103 CAGUGGGU CUGAUGAG GCCGUUAGGC CGAA AUACUGUU 3896 911 ACAGUAUU A CCCACUGA 104 UCAGUGGG CUGAUGAG GCCGUUAGGC CGAA AAUACUGU 3897 929 GGAACACU U CAAGAAAA 105 UUUUCUUG CUGAUGAG GCCGUUAGGC CGAA AGUGUUCC 3898 930 GAACACUU c AAGAAAAU 106 AUUUUCUU CUGAUGAG GCCGUUAGGC CGAA AAGUGUUC 3899 941 GAAAAUGU c AGUGAAGC 107 GCUUCACU CUGAUGAG GCCGUUAGGC CGAA ACAUUUUC 3900 951 GUGAAGCU U CUAAAGAG 108 CUCUUUAG CUGAUGAG GCCGUUAGGC CGAA AGCUUCAC 3901 952 UGAAGCUU c UAAAGAGG 109 CCUCUUUA CUGAUGAG GCCGUUAGGC CGAA AAGCUUCA 3902 954 AAGCUUCU A AAGAGGUC 110 GACCUCUU CUGAUGAG GCCGUUAGGC CGAA AGAAGCUU 3903 962 AAAGAGGU C UCAGAGAA 111 UUCUCUGA CUGAUGAG GCCGUUAGGC CGAA ACCUCUUU 3904 964 AGAGGUCU C AGAGAAGG 112 CCUUCUCU CUGAUGAG GCCGUUAGGC CGAA AGACCUCU 3905 981 CAAAAACU C UACUCAUA 113 UAUGAGUA CUGAUGAG GCCGUUAGGC CGAA AGUUUUUG 3906 983 AAAACUCU A CUCAUAGA 114 UCUAUGAG CUGAUGAG GCCGUUAGGC CGAA AGAGUUUU 3907 986 ACUCUACU C AUAGAUAG 115 CUAUCUAU CUGAUGAG GCCGUUAGGC CGAA AGUAGAGU 3908 989 CUACUCAU A GAUAGAGA 116 UCUCUAUC CUGAUGAG GCCGUUAGGC CGAA AUGAGUAG 3909 993 UCAUAGAU A GAGAUUUA 117 UAAAUCUC CUGAUGAG GCCGUUAGGC CGAA AUCUAUGA 3910 999 AUAGAGAU U UAACAGAG 118 CUCUGUUA CUGAUGAG GCCGUUAGGC CGAA AUCUCUAU 3911 1000 UAGAGAUU U AACAGAGU 119 ACUCUGUU CUGAUGAG GCCGUUAGGC CGAA AAUCUCUA 3912 1001 AGAGAUUU A ACAGAGUU 120 AACUCUGU CUGAUGAG GCCGUUAGGC CGAA AAAUCUCU 3913 1009 AACAGAGU U UUCAGAAU 121 AUUCUGAA CUGAUGAG GCCGUUAGGC CGAA ACUCUGUU 3914 1010 ACAGAGUU U UCAGAAUU 122 AAUUCUGA CUGAUGAG GCCGUUAGGC CGAA AACUCUGU 3915 1011 CAGAGUUU U CAGAAUUA 123 UAAUUCUG CUGAUGAG GCCGUUAGGC CGAA AAACUCUG 3916 1012 AGAGUUUU C AGAAUUAG 124 CUAAUUCU CUGAUGAG GCCGUUAGGC CGAA AAAACUCU 3917 1018 UUCAGAAU U AGAAUACU 125 AGUAUUCU CUGAUGAG GCCGUUAGGC CGAA AUUCUGAA 3918 1019 UCAGAAUU A GAAUACUC 126 GAGUAUUC CUGAUGAG GCCGUUAGGC CGAA AAUUCUGA 3919 1024 AUUAGAAU A CUCAGAAA 127 UUUCUGAG CUGAUGAG GCCGUUAGGC CGAA AUUCUAAU 3920 1027 AGAAUACU C AGAAAUGG 128 CCAUUUCU CUGAUGAG GCCGUUAGGC CGAA AGUAUUCU 3921 1039 AAUGGGAU C AUCGUUCA 129 UGAACGAU CUGAUGAG GCCGUUAGGC CGAA AUCCCAUU 3922 1042 GGGAUCAU C GUUCAGUG 130 CACUGAAC CUGAUGAG GCCGUUAGGC CGAA AUGAUCCC 3923 1045 AUCAUCGU U CAGUGUCU 131 AGACACUG CUGAUGAG GCCGUUAGGC CGAA ACGAUGAU 3924 1046 UCAUCGUU C AGUGUCUC 132 GAGACACU CUGAUGAG GCCGUUAGGC CGAA AACGAUGA 3925 1052 UUCAGUGU C UCUCCAAA 133 UUUGGAGA CUGAUGAG GCCGUUAGGC CGAA ACACUGAA 3926 1054 CAGUGUCU C UCCAAAAG 134 CUUUUGGA CUGAUGAG GCCGUUAGGC CGAA AGACACUG 3927 1056 GUGUCUCU C CAAAAGCA 135 UGCUUUUG CUGAUGAG GCCGUUAGGC CGAA AGAGACAC 3928 1069 AGCAGAAU C UGCCGUAA 136 UUACGGCA CUGAUGAG GCCGUUAGGC CGAA AUUCUGCU 3929 1076 UCUGCCGU A AUAGUAGC 137 GCUACUAU CUGAUGAG GCCGUUAGGC CGAA ACGGCAGA 3930 1079 GCCGUAAU A GUAGCAAA 138 UUUGCUAC CUGAUGAG GCCGUUAGGC CGAA AUUACGGC 3931 1082 GUAAUAGU A GCAAAUCC 139 GGAUUUGC CUGAUGAG GCCGUUAGGC CGAA ACUAUUAC 3932 1089 UAGCAAAU C CUAGGGAA 140 UUCCCUAG CUGAUGAG GCCGUUAGGC CGAA AUUUGCUA 3933 1092 CAAAUCCU A GGGAAGAA 141 UUCUUCCC CUGAUGAG GCCGUUAGGC CGAA AGGAUUUG 3934 1103 GAAGAAAU A AUCGUGAA 142 UUCACGAU CUGAUGAG GCCGUUAGGC CGAA AUUUCUUC 3935 1106 GAAAUAAU C GUGAAAAA 143 UUUUUCAC CUGAUGAG GCCGUUAGGC CGAA AUUAUUUC 3936 1116 UGAAAAAU A AAGAUGAA 144 UUCAUCUU CUGAUGAG GCCGUUAGGC CGAA AUUUUUCA 3937 1135 AGAGAAGU U AGUUAGUA 145 UACUAACU CUGAUGAG GCCGUUAGGC CGAA ACUUCUCU 3938 1136 GAGAAGUU A GUUAGUAA 146 UUACUAAC CUGAUGAG GCCGUUAGGC CGAA AACUUCUC 3939 1139 AAGUUAGU U AGUAAUAA 147 UUAUUACU CUGAUGAG GCCGUUAGGC CGAA ACUAACUU 3940 1140 AGUUAGUU A GUAAUAAC 148 GUUAUUAC CUGAUGAG GCCGUUAGGC CGAA AACUAACU 3941 1143 UAGUUAGU A AUAACAUC 149 GAUGUUAU CUGAUGAG GCCGUUAGGC CGAA ACUAACUA 3942 1146 UUAGUAAU A ACAUCCUU 150 AAGGAUGU CUGAUGAG GCCGUUAGGC CGAA AUUACUAA 3943 1151 AAUAACAU C CUUCAUAA 151 UUAUGAAG CUGAUGAG GCCGUUAGGC CGAA AUGUUAUU 3944 1154 AACAUCCU U CAUAAUCA 152 UGAUUAUG CUGAUGAG GCCGUUAGGC CGAA AGGAUGUU 3945 1155 ACAUCCUU C AUAAUCAA 153 UUGAUUAU CUGAUGAG GCCGUUAGGC CGAA AAGGAUGU 3946 1158 UCCUUCAU A AUCAACAA 154 UUGUUGAU CUGAUGAG GCCGUUAGGC CGAA AUGAAGGA 3947 1161 UUCAUAAU C AACAAGAG 155 CUCUUGUU CUGAUGAG GCCGUUAGGC CGAA AUUAUGAA 3948 1171 ACAAGAGU U ACCUACAG 156 CUGUAGGU CUGAUGAG GCCGUUAGGC CGAA ACUCUUGU 3949 1172 CAAGAGUU A CCUACAGC 157 GCUGUAGG CUGAUGAG GCCGUUAGGC CGAA AACUCUUG 3950 1176 AGUUACCU A CAGCUCUU 158 AAGAGCUG CUGAUGAG GCCGUUAGGC CGAA AGGUAACU 3951 1182 CUACAGCU C UUACUAAA 159 UUUAGUAA CUGAUGAG GCCGUUAGGC CGAA AGCUGUAG 3952 1184 ACAGCUCU U ACUAAAUU 160 AAUUUAGU CUGAUGAG GCCGUUAGGC CGAA AGAGCUGU 3953 1185 CAGCUCUU A CUAAAUUG 161 CAAUUUAG CUGAUGAG GCCGUUAGGC CGAA AAGAGCUG 3954 1188 CUCUUACU A AAUUGGUU 162 AACCAAUU CUGAUGAG GCCGUUAGGC CGAA AGUAAGAG 3955 1192 UACUAAAU U GGUUAAAG 163 CUUUAACC CUGAUGAG GCCGUUAGGC CGAA AUUUAGUA 3956 1196 AAAUUGGU U AAAGAGGA 164 UCCUCUUU CUGAUGAG GCCGUUAGGC CGAA ACCAAUUU 3957 1197 AAUUGGUU A AAGAGGAU 165 AUCCUCUU CUGAUGAG GCCGUUAGGC CGAA AACCAAUU 3958 1211 GAUGAAGU U GUGUCUUC 166 GAAGACAC CUGAUGAG GCCGUUAGGC CGAA ACUUCAUC 3959 1216 AGUUGUGU C UUCAGAAA 167 UUUCUGAA CUGAUGAG GCCGUUAGGC CGAA ACACAACU 3960 1218 UUGUGUCU U CAGAAAAA 168 UUUUUCUG CUGAUGAG GCCGUUAGGC CGAA AGACACAA 3961 1219 UGUGUCUU C AGAAAAAG 169 CUUUUUCU CUGAUGAG GCCGUUAGGC CGAA AAGACACA 3962 1239 AAGACAGU U UUAAUGAA 170 UUCAUUAA CUGAUGAG GCCGUUAGGC CGAA ACUGUCUU 3963 1240 AGACAGUU U UAAUGAAA 171 UUUCAUUA CUGAUGAG GCCGUUAGGC CGAA AACUGUCU 3964 1241 GACAGUUU U AAUGAAAA 172 UUUUCAUU CUGAUGAG GCCGUUAGGC CGAA AAACUGUC 3965 1242 ACAGUUUU A AUGAAAAG 173 CUUUUCAU CUGAUGAG GCCGUUAGGC CGAA AAAACUGU 3966 1256 AAGAGAGU U GCAGUGGA 174 UCCACUGC CUGAUGAG GCCGUUAGGC CGAA ACUCUCUU 3967 1269 UGGAAGCU C CUAUGAGG 175 CCUCAUAG CUGAUGAG GCCGUUAGGC CGAA AGCUUCCA 3968 1272 AAGCUCCU A UGAGGGAG 176 CUCCCUCA CUGAUGAG GCCGUUAGGC CGAA AGGAGCUU 3969 1285 GGAGGAAU A UGCAGACU 177 AGUCUGCA CUGAUGAG GCCGUUAGGC CGAA AUUCCUCC 3970 1294 UGCAGACU U CAAACCAU 178 AUGGUUUG CUGAUGAG GCCGUUAGGC CGAA AGUCUGCA 3971 1295 GCAGACUU C AAACCAUU 179 AAUGGUUU CUGAUGAG GCCGUUAGGC CGAA AAGUCUGC 3972 1303 CAAACCAU U UGAGCGAG 180 CUCGCUCA CUGAUGAG GCCGUUAGGC CGAA AUGGUUUG 3973 1304 AAACCAUU U GAGCGAGU 181 ACUCGCUC CUGAUGAG GCCGUUAGGC CGAA AAUGGUUU 3974 1313 GAGCGAGU A UGGGAAGU 182 ACUUCCCA CUGAUGAG GCCGUUAGGC CGAA ACUCGCUC 3975 1329 UGAAAGAU A GUAAGGAA 183 UUCCUUAC CUGAUGAG GCCGUUAGGC CGAA AUCUUUCA 3976 1332 AAGAUAGU A AGGAAGAU 184 AUCUUCCU CUGAUGAG GCCGUUAGGC CGAA ACUAUCUU 3977 1341 AGGAAGAU A GUGAUAUG 185 CAUAUCAC CUGAUGAG GCCGUUAGGC CGAA AUCUUCCU 3978 1347 AUAGUGAU A UGUUGGCU 186 AGCCAACA CUGAUGAG GCCGUUAGGC CGAA AUCACUAU 3979 1351 UGAUAUGU U GGCUGCUG 187 CAGCAGCC CUGAUGAG GCCGUUAGGC CGAA ACAUAUCA 3980 1365 CUGGAGGU A AAAUCGAG 188 CUCGAUUU CUGAUGAG GCCGUUAGGC CGAA ACCUCCAG 3981 1370 GGUAAAAU C GAGAGCAA 189 UUGCUCUC CUGAUGAG GCCGUUAGGC CGAA AUUUUACC 3982 1381 GAGCAACU u GGAAAGUA 190 UACUUUCC CUGAUGAG GCCGUUAGGC CGAA AGUUGCUC 3983 1389 UGGAAAGU A AAGUGGAU 191 AUCCACUU CUGAUGAG GCCGUUAGGC CGAA ACUUUCCA 3984 1398 AAGUGGAU A AAAAAUGU 192 ACAUUUUU CUGAUGAG GCCGUUAGGC CGAA AUCCACUU 3985 1407 AAAAAUGU U UUGCAGAU 193 AUCUGCAA CUGAUGAG GCCGUUAGGC CGAA ACAUUUUU 3986 1408 AAAAUGUU U UGCAGAUA 194 UAUCUGCA CUGAUGAG GCCGUUAGGC CGAA AACAUUUU 3987 1409 AAAUGUUU U GCAGAUAG 195 CUAUCUGC CUGAUGAG GCCGUUAGGC CGAA AAACAUUU 3988 1416 UUGCAGAU A GCCUUGAG 196 CUCAAGGC CUGAUGAG GCCGUUAGGC CGAA AUCUGCAA 3989 1421 GAUAGCCU U GAGCAAAC 197 GUUUGCUC CUGAUGAG GCCGUUAGGC CGAA AGGCUAUC 3990 1431 AGCAAACU A AUCACGAA 198 UUCGUGAU CUGAUGAG GCCGUUAGGC CGAA AGUUUGCU 3991 1434 AAACUAAU C ACGAAAAA 199 UUUUUCGU CUGAUGAG GCCGUUAGGC CGAA AUUAGUUU 3992 1446 AAAAAGAU A GUGAGAGU 200 ACUCUCAC CUGAUGAG GCCGUUAGGC CGAA AUCUUUUU 3993 1455 GUGAGAGU A GUAAUGAU 201 AUCAUUAC CUGAUGAG GCCGUUAGGC CGAA ACUCUCAC 3994 1458 AGAGUAGU A AUGAUGAU 202 AUCAUCAU CUGAUGAG GCCGUUAGGC CGAA ACUACUCU 3995 1467 AUGAUGAU A CUUCUUUC 203 GAAAGAAG CUGAUGAG GCCGUUAGGC CGAA AUCAUCAU 3996 1470 AUGAUACU U CUUUCCCC 204 GGGGAAAG CUGAUGAG GCCGUUAGGC CGAA AGUAUCAU 3997 1471 UGAUACUU C UUUCCCCA 205 UGGGGAAA CUGAUGAG GCCGUUAGGC CGAA AAGUAUCA 3998 1473 AUACUUCU U UCCCCAGU 206 ACUGGGGA CUGAUGAG GCCGUUAGGC CGAA AGAAGUAU 3999 1474 UACUUCUU u CCCCAGUA 207 UACUGGGG CUGAUGAG GCCGUUAGGC CGAA AAGAAGUA 4000 1475 ACUUCUUU c CCCAGUAC 208 GUACUGGG CUGAUGAG GCCGUUAGGC CGAA AAAGAAGU 4001 1482 UCCCCAGU A CGCCAGAA 209 UUCUGGCG CUGAUGAG GCCGUUAGGC CGAA ACUGGGGA 4002 1494 CAGAAGGU A UAAAGGAU 210 AUCCUUUA CUGAUGAG GCCGUUAGGC CGAA ACCUUCUG 4003 1496 GAAGGUAU A AAGGAUCG 211 CGAUCCUU CUGAUGAG GCCGUUAGGC CGAA AUACCUUC 4004 1503 UAAAGGAU c GUUCAGGA 212 UCCUGAAC CUGAUGAG GCCGUUAGGC CGAA AUCCUUUA 4005 1506 AGGAUCGU U CAGGAGCA 213 UGCUCCUG CUGAUGAG GCCGUUAGGC CGAA ACGAUCCU 4006 1507 GGAUCGUU c AGGAGCAU 214 AUGCUCCU CUGAUGAG GCCGUUAGGC CGAA AACGAUCC 4007 1516 AGGAGCAU A UAUCACAU 215 AUGUGAUA CUGAUGAG GCCGUUAGGC CGAA AUGCUCCU 4008 1518 GAGCAUAU A UCACAUGU 216 ACAUGUGA CUGAUGAG GCCGUUAGGC CGAA AUAUGCUC 4009 1520 GCAUAUAU c ACAUGUGC 217 GCACAUGU CUGAUGAG GCCGUUAGGC CGAA AUAUAUGC 4010 1530 CAUGUGCU C CCUUUAAC 218 GUUAAAGG CUGAUGAG GCCGUUAGGC CGAA AGCACAUG 4011 1534 UGCUCCCU u UAACCCAG 219 CUGGGUUA CUGAUGAG GCCGUUAGGC CGAA AGGGAGCA 4012 1535 GCUCCCUU u AACCCAGC 220 GCUGGGUU CUGAUGAG GCCGUUAGGC CGAA AAGGGAGC 4013 1536 CUCCCUUU A ACCCAGCA 221 UGCUGGGU CUGAUGAG GCCGUUAGGC CGAA AAAGGGAG 4014 1559 GAGAGCAU U GCAACAAA 222 UUUGUUGC CUGAUGAG GCCGUUAGGC CGAA AUGCUCUC 4015 1571 ACAAACAU U UUUCCUUU 223 AAAGGAAA CUGAUGAG GCCGUUAGGC CGAA AUGUUUGU 4016 1572 CAAACAUU U UUCCUUUG 224 CAAAGGAA CUGAUGAG GCCGUUAGGC CGAA AAUGUUUG 4017 1573 AAACAUUU U UCCUUUGU 225 ACAAAGGA CUGAUGAG GCCGUUAGGC CGAA AAAUGUUU 4018 1574 AACAUUUU U CCUUUGUU 226 AACAAAGG CUGAUGAG GCCGUUAGGC CGAA AAAAUGUU 4019 1575 ACAUUUUU c CUUUGUUA 227 UAACAAAG CUGAUGAG GCCGUUAGGC CGAA AAAAAUGU 4020 1578 UUUUUCCU u UGUUAGGA 228 UCCUAACA CUGAUGAG GCCGUUAGGC CGAA AGGAAAAA 4021 1579 UUUUCCUU u GUUAGGAG 229 CUCCUAAC CUGAUGAG GCCGUUAGGC CGAA AAGGAAAA 4022 1582 UCCUUUGU u AGGAGAUC 230 GAUCUCCU CUGAUGAG GCCGUUAGGC CGAA ACAAAGGA 4023 1583 CCUUUGUU A GGAGAUCC 231 GGAUCUCC CUGAUGAG GCCGUUAGGC CGAA AACAAAGG 4024 1590 UAGGAGAU C CUACUUCA 232 UGAAGUAG CUGAUGAG GCCGUUAGGC CGAA AUCUCCUA 4025 1593 GAGAUCCU A CUUCAGAA 233 UUCUGAAG CUGAUGAG GCCGUUAGGC CGAA AGGAUCUC 4026 1596 AUCCUACU u CAGAAAAU 234 AUUUUCUG CUGAUGAG GCCGUUAGGC CGAA AGUAGGAU 4027 1597 UCCUACUU c AGAAAAUA 235 UAUUUUCU CUGAUGAG GCCGUUAGGC CGAA AAGUAGGA 4028 1605 CAGAAAAU A AGACCGAU 236 AUCGGUCU CUGAUGAG GCCGUUAGGC CGAA AUUUUCUG 4029 1625 AAAAAAAU A GAAGAAAA 237 UUUUCUUC CUGAUGAG GCCGUUAGGC CGAA AUUUUUUU 4030 1646 GCCCAAAU A GUAACAGA 238 UCUGUUAC CUGAUGAG GCCGUUAGGC CGAA AUUUGGGC 4031 1649 CAAAUAGU A ACAGAGAA 239 UUCUCUGU CUGAUGAG GCCGUUAGGC CGAA ACUAUUUG 4032 1662 AGAAGAAU A CUAGCACC 240 GGUGCUAG CUGAUGAG GCCGUUAGGC CGAA AUUCUUCU 4033 1665 AGAAUACU A GCACCAAA 241 UUUGGUGC CUGAUGAG GCCGUUAGGC CGAA AGUAUUCU 4034 1678 CAAAACAU C AAACCCUU 242 AAGGGUUU CUGAUGAG GCCGUUAGGC CGAA AUGUUUUG 4035 1686 CAAACCCU U UUCUUGUA 243 UACAAGAA CUGAUGAG GCCGUUAGGC CGAA AGGGUUUG 4036 1687 AAACCCUU U UCUUGUAG 244 CUACAAGA CUGAUGAG GCCGUUAGGC CGAA AAGGGUUU 4037 1688 AACCCUUU U CUUGUAGC 245 GCUACAAG CUGAUGAG GCCGUUAGGC CGAA AAAGGGUU 4038 1689 ACCCUUUU C UUGUAGCA 246 UGCUACAA CUGAUGAG GCCGUUAGGC CGAA AAAAGGGU 4039 1691 CCUUUUCU U GUAGCAGC 247 GCUGCUAC CUGAUGAG GCCGUUAGGC CGAA AGAAAAGG 4040 1694 UUUCUUGU A GCAGCACA 248 UGUGCUGC CUGAUGAG GCCGUUAGGC CGAA ACAAGAAA 4041 1707 CACAGGAU U CUGAGACA 249 UGUCUCAG CUGAUGAG GCCGUUAGGC CGAA AUCCUGUG 4042 1708 ACAGGAUU C UGAGACAG 250 CUGUCUCA CUGAUGAG GCCGUUAGGC CGAA AAUCCUGU 4043 1719 AGACAGAU U AUGUCACA 251 UGUGACAU CUGAUGAG GCCGUUAGGC CGAA AUCUGUCU 4044 1720 GACAGAUU A UGUCACAA 252 UUGUGACA CUGAUGAG GCCGUUAGGC CGAA AAUCUGUC 4045 1724 GAUUAUGU C ACAACAGA 253 UCUGUUGU CUGAUGAG GCCGUUAGGC CGAA ACAUAAUC 4046 1734 CAACAGAU A AUUUAACA 254 UGUUAAAU CUGAUGAG GCCGUUAGGC CGAA AUCUGUUG 4047 1737 CAGAUAAU U UAACAAAG 255 CUUUGUUA CUGAUGAG GCCGUUAGGC CGAA AUUAUCUG 4048 1738 AGAUAAUU U AACAAAGG 256 CCUUUGUU CUGAUGAG GCCGUUAGGC CGAA AAUUAUCU 4049 1739 GAUAAUUU A ACAAAGGU 257 ACCUUUGU CUGAUGAG GCCGUUAGGC CGAA AAAUUAUC 4050 1760 GAGGAAGU C GUGGCAAA 258 UUUGCCAC CUGAUGAG GCCGUUAGGC CGAA ACUUCCUC 4051 1788 GCCUGACU C CAGAUUUA 259 UAAAUCUG CUGAUGAG GCCGUUAGGC CGAA AGUCAGGC 4052 1794 CUCCAGAU U UAGUACAG 260 CUGUACUA CUGAUGAG GCCGUUAGGC CGAA AUCUGGAG 4053 1795 UCCAGAUU U AGUACAGG 261 CCUGUACU CUGAUGAG GCCGUUAGGC CGAA AAUCUGGA 4054 1796 CCAGAUUU A GUACAGGA 262 UCCUGUAC CUGAUGAG GCCGUUAGGC CGAA AAAUCUGG 4055 1799 GAUUUAGU A CAGGAAGC 263 GCUUCCUG CUGAUGAG GCCGUUAGGC CGAA ACUAAAUC 4056 1822 AAGUGAAU U GAAUGAAG 264 CUUCAUUC CUGAUGAG GCCGUUAGGC CGAA AUUCACUU 4057 1832 AAUGAAGU U ACUGGUAC 265 GUACCAGU CUGAUGAG GCCGUUAGGC CGAA ACUUCAUU 4058 1833 AUGAAGUU A CUGGUACA 266 UGUACCAG CUGAUGAG GCCGUUAGGC CGAA AACUUCAU 4059 1839 UUACUGGU A CAAAGAUU 267 AAUCUUUG CUGAUGAG GCCGUUAGGC CGAA ACCAGUAA 4060 1847 ACAAAGAU U GCUUAUGA 268 UCAUAAGC CUGAUGAG GCCGUUAGGC CGAA AUCUUUGU 4061 1851 AGAUUGCU U AUGAAACA 269 UGUUUCAU CUGAUGAG GCCGUUAGGC CGAA AGCAAUCU 4062 1852 GAUUGCUU A UGAAACAA 270 UUGUUUCA CUGAUGAG GCCGUUAGGC CGAA AAGCAAUC 4063 1870 AAUGGACU U GGUUCAAA 271 UUUGAACC CUGAUGAG GCCGUUAGGC CGAA AGUCCAUU 4064 1874 GACUUGGU U CAAACAUC 272 GAUGUUUG CUGAUGAG GCCGUUAGGC CGAA ACCAAGUC 4065 1875 ACUUGGUU C AAACAUCA 273 UGAUGUUU CUGAUGAG GCCGUUAGGC CGAA AACCAAGU 4066 1882 UCAAACAU C AGAAGUUA 274 UAACUUCU CUGAUGAG GCCGUUAGGC CGAA AUGUUUGA 4067 1889 UCAGAAGU U AUGCAAGA 275 UCUUGCAU CUGAUGAG GCCGUUAGGC CGAA ACUUCUGA 4068 1890 CAGAAGUU A UGCAAGAG 276 CUCUUGCA CUGAUGAG GCCGUUAGGC CGAA AACUUCUG 4069 1900 GCAAGAGU C ACUCUAUC 277 GAUAGAGU CUGAUGAG GCCGUUAGGC CGAA ACUCUUGC 4070 1904 GAGUCACU C UAUCCUGC 278 GCAGGAUA CUGAUGAG GCCGUUAGGC CGAA AGUGACUC 4071 1906 GUCACUCU A UCCUGCAG 279 CUGCAGGA CUGAUGAG GCCGUUAGGC CGAA AGAGUGAC 4072 1908 CACUCUAU C CUGCAGCA 280 UGCUGCAG CUGAUGAG GCCGUUAGGC CGAA AUAGAGUG 4073 1922 GCACAGCU U UGCCCAUC 281 GAUGGGCA CUGAUGAG GCCGUUAGGC CGAA AGCUGUGC 4074 1923 CACAGCUU U GCCCAUCA 282 UGAUGGGC CUGAUGAG GCCGUUAGGC CGAA AAGCUGUG 4075 1930 UUGCCCAU C AUUUGAAG 283 CUUCAAAU CUGAUGAG GCCGUUAGGC CGAA AUGGGCAA 4076 1933 CCCAUCAU U UGAAGAGU 284 ACUCUUCA CUGAUGAG GCCGUUAGGC CGAA AUGAUGGG 4077 1934 CCAUCAUU U GAAGAGUC 285 GACUCUUC CUGAUGAG GCCGUUAGGC CGAA AAUGAUGG 4078 1942 UGAAGAGU C AGAAGCUA 286 UAGCUUCU CUGAUGAG GCCGUUAGGC CGAA ACUCUUCA 4079 1950 CAGAAGCU A CUCCUUCA 287 UGAAGGAG CUGAUGAG GCCGUUAGGC CGAA AGCUUCUG 4080 1953 AAGCUACU C CUUCACCA 288 UGGUGAAG CUGAUGAG GCCGUUAGGC CGAA AGUAGCUU 4081 1956 CUACUCCU u CACCAGUU 289 AACUGGUG CUGAUGAG GCCGUUAGGC CGAA AGGAGUAG 4082 1957 UACUCCUU c ACCAGUUU 290 AAACUGGU CUGAUGAG GCCGUUAGGC CGAA AAGGAGUA 4083 1964 UCACCAGU u UUGCCUGA 291 UCAGGCAA CUGAUGAG GCCGUUAGGC CGAA ACUGGUGA 4084 1965 CACCAGUU u UGCCUGAC 292 GUCAGGCA CUGAUGAG GCCGUUAGGC CGAA AACUGGUG 4085 1966 ACCAGUUU u GCCUGACA 293 UGUCAGGC CUGAUGAG GCCGUUAGGC CGAA AAACUGGU 4086 1976 CCUGACAU u GUUAUGGA 294 UCCAUAAC CUGAUGAG GCCGUUAGGC CGAA AUGUCAGG 4087 1979 GACAUUGU u AUGGAAGC 295 GCUUCCAU CUGAUGAG GCCGUUAGGC CGAA ACAAUGUC 4088 1980 ACAUUGUU A UGGAAGCA 296 UGCUUCCA CUGAUGAG GCCGUUAGGC CGAA AACAAUGU 4089 1993 AGCACCAU u GAAUUCUG 297 CAGAAUUC CUGAUGAG GCCGUUAGGC CGAA AUGGUGCU 4090 1998 CAUUGAAU U CUGCAGUU 298 AACUGCAG CUGAUGAG GCCGUUAGGC CGAA AUUCAAUG 4091 1999 AUUGAAUU C UGCAGUUC 299 GAACUGCA CUGAUGAG GCCGUUAGGC CGAA AAUUCAAU 4092 2006 UCUGCAGU u CCUAGUGC 300 GCACUAGG CUGAUGAG GCCGUUAGGC CGAA ACUGCAGA 4093 2007 CUGCAGUU c CUAGUGCU 301 AGCACUAG CUGAUGAG GCCGUUAGGC CGAA AACUGCAG 4094 2010 CAGUUCCU A GUGCUGGU 302 ACCAGCAC CUGAUGAG GCCGUUAGGC CGAA AGGAACUG 4095 2022 CUGGUGCU U CCGUGAUA 303 UAUCACGG CUGAUGAG GCCGUUAGGC CGAA AGCACCAG 4096 2023 UGGUGCUU C CGUGAUAC 304 GUAUCACG CUGAUGAG GCCGUUAGGC CGAA AAGCACCA 4097 2030 UCCGUGAU A CAGCCCAG 305 CUGGGCUG CUGAUGAG GCCGUUAGGC CGAA AUCACGGA 4098 2041 GCCCAGCU C AUCACCAU 306 AUGGUGAU CUGAUGAG GCCGUUAGGC CGAA AGCUGGGC 4099 2044 CAGCUCAU C ACCAUUAG 307 CUAAUGGU CUGAUGAG GCCGUUAGGC CGAA AUGAGCUG 4100 2050 AUCACCAU U AGAAGCUU 308 AAGCUUCU CUGAUGAG GCCGUUAGGC CGAA AUGGUGAU 4101 2051 UCACCAUU A GAAGCUUC 309 GAAGCUUC CUGAUGAG GCCGUUAGGC CGAA AAUGGUGA 4102 2058 UAGAAGCU U CUUCAGUU 310 AACUGAAG CUGAUGAG GCCGUUAGGC CGAA AGCUUCUA 4103 2059 AGAAGCUU C UUCAGUUA 311 UAACUGAA CUGAUGAG GCCGUUAGGC CGAA AAGCUUCU 4104 2061 AAGCUUCU U CAGUUAAU 312 AUUAACUG CUGAUGAG GCCGUUAGGC CGAA AGAAGCUU 4105 2062 AGCUUCUU C AGUUAAUU 313 AAUUAACU CUGAUGAG GCCGUUAGGC CGAA AAGAAGCU 4106 2066 UCUUCAGU U AAUUAUGA 314 UCAUAAUU CUGAUGAG GCCGUUAGGC CGAA ACUGAAGA 4107 2067 CUUCAGUU A AUUAUGAA 315 UUCAUAAU CUGAUGAG GCCGUUAGGC CGAA AACUGAAG 4108 2070 CAGUUAAU U AUGAAAGC 316 GCUUUCAU CUGAUGAG GCCGUUAGGC CGAA AUUAACUG 4109 2071 AGUUAAUU A UGAAAGCA 317 UGCUUUCA CUGAUGAG GCCGUUAGGC CGAA AAUUAACU 4110 2081 GAAAGCAU A AAACAUGA 318 UCAUGUUU CUGAUGAG GCCGUUAGGC CGAA AUGCUUUC 4111 2110 CCCACCAU A UGAAGAGG 319 CCUCUUCA CUGAUGAG GCCGUUAGGC CGAA AUGGUGGG 4112 2129 AUGAGUGU A UCACUAAA 320 UUUAGUGA CUGAUGAG GCCGUUAGGC CGAA ACACUCAU 4113 2131 GAGUGUAU C ACUAAAAA 321 UUUUUAGU CUGAUGAG GCCGUUAGGC CGAA AUACACUC 4114 2135 GUAUCACU A AAAAAAGU 322 ACUUUUUU CUGAUGAG GCCGUUAGGC CGAA AGUGAUAC 4115 2144 AAAAAAGU A UCAGGAAU 323 AUUCCUGA CUGAUGAG GCCGUUAGGC CGAA ACUUUUUU 4116 2146 AAAAGUAU C AGGAAUAA 324 UUAUUCCU CUGAUGAG GCCGUUAGGC CGAA AUACUUUU 4117 2153 UCAGGAAU A AAGGAAGA 325 UCUUCCUU CUGAUGAG GCCGUUAGGC CGAA AUUCCUGA 4118 2165 GAAGAAAU U AAAGAGCC 326 GGCUCUUU CUGAUGAG GCCGUUAGGC CGAA AUUUCUUC 4119 2166 AAGAAAUU A AAGAGCCU 327 AGGCUCUU CUGAUGAG GCCGUUAGGC CGAA AAUUUCUU 4120 2181 CUGAAAAU A UUAAUGCA 328 UGCAUUAA CUGAUGAG GCCGUUAGGC CGAA AUUUUCAG 4121 2183 GAAAAUAU U AAUGCAGC 329 GCUGCAUU CUGAUGAG GCCGUUAGGC CGAA AUAUUUUC 4122 2184 AAAAUAUU A AUGCAGCU 330 AGCUGCAU CUGAUGAG GCCGUUAGGC CGAA AAUAUUUU 4123 2193 AUGCAGCU C UUCAAGAA 331 UUCUUGAA CUGAUGAG GCCGUUAGGC CGAA AGCUGCAU 4124 2195 GCAGCUCU U CAAGAAAC 332 GUUUCUUG CUGAUGAG GCCGUUAGGC CGAA AGAGCUGC 4125 2196 CAGCUCUU C AAGAAACA 333 UGUUUCUU CUGAUGAG GCCGUUAGGC CGAA AAGAGCUG 4126 2211 CAGAAGCU C CUUAUAUA 334 UAUAUAAG CUGAUGAG GCCGUUAGGC CGAA AGCUUCUG 4127 2214 AAGCUCCU U AUAUAUCU 335 AGAUAUAU CUGAUGAG GCCGUUAGGC CGAA AGGAGCUU 4128 2215 AGCUCCUU A UAUAUCUA 336 UAGAUAUA CUGAUGAG GCCGUUAGGC CGAA AAGGAGCU 4129 2217 CUCCUUAU A UAUCUAUU 337 AAUAGAUA CUGAUGAG GCCGUUAGGC CGAA AUAAGGAG 4130 2219 CCUUAUAU A UCUAUUGC 338 GCAAUAGA CUGAUGAG GCCGUUAGGC CGAA AUAUAAGG 4131 2221 UUAUAUAU C UAUUGCAU 339 AUGCAAUA CUGAUGAG GCCGUUAGGC CGAA AUAUAUAA 4132 2223 AUAUAUCU A UUGCAUGU 340 ACAUGCAA CUGAUGAG GCCGUUAGGC CGAA AGAUAUAU 4133 2225 AUAUCUAU U GCAUGUGA 341 UCACAUGC CUGAUGAG GCCGUUAGGC CGAA AUAGAUAU 4134 2235 CAUGUGAU U UAAUUAAA 342 UUUAAUUA CUGAUGAG GCCGUUAGGC CGAA AUCACAUG 4135 2236 AUGUGAUU U AAUUAAAG 343 CUUUAAUU CUGAUGAG GCCGUUAGGC CGAA AAUCACAU 4136 2237 UGUGAUUU A AUUAAAGA 344 UCUUUAAU CUGAUGAG GCCGUUAGGC CGAA AAAUCACA 4137 2240 GAUUUAAU U AAAGAAAC 345 GUUUCUUU CUGAUGAG GCCGUUAGGC CGAA AUUAAAUC 4138 2241 AUUUAAUU A AAGAAACA 346 UGUUUCUU CUGAUGAG GCCGUUAGGC CGAA AAUUAAAU 4139 2255 ACAAAGCU U UCUGCUGA 347 UCAGCAGA CUGAUGAG GCCGUUAGGC CGAA AGCUUUGU 4140 2256 CAAAGCUU U CUGCUGAA 348 UUCAGCAG CUGAUGAG GCCGUUAGGC CGAA AAGCUUUG 4141 2257 AAAGCUUU C UGCUGAAC 349 GUUCAGCA CUGAUGAG GCCGUUAGGC CGAA AAAGCUUU 4142 2271 AACCAGCU C CGGAUUUC 350 GAAAUCCG CUGAUGAG GCCGUUAGGC CGAA AGCUGGUU 4143 2277 CUCCGGAU U UCUCUGAU 351 AUCAGAGA CUGAUGAG GCCGUUAGGC CGAA AUCCGGAG 4144 2278 UCCGGAUU U CUCUGAUU 352 AAUCAGAG CUGAUGAG GCCGUUAGGC CGAA AAUCCGGA 4145 2279 CCGGAUUU C UCUGAUUA 353 UAAUCAGA CUGAUGAG GCCGUUAGGC CGAA AAAUCCGG 4146 2281 GGAUUUCU C UGAUUAUU 354 AAUAAUCA CUGAUGAG GCCGUUAGGC CGAA AGAAAUCC 4147 2286 UCUCUGAU U AUUCAGAA 355 UUCUGAAU CUGAUGAG GCCGUUAGGC CGAA AUCAGAGA 4148 2287 CUCUGAUU A UUCAGAAA 356 UUUCUGAA CUGAUGAG GCCGUUAGGC CGAA AAUCAGAG 4149 2289 CUGAUUAU U CAGAAAUG 357 CAUUUCUG CUGAUGAG GCCGUUAGGC CGAA AUAAUCAG 4150 2290 UGAUUAUU C AGAAAUGG 358 CCAUUUCU CUGAUGAG GCCGUUAGGC CGAA AAUAAUCA 4151 2306 GCAAAAGU U GAACAGCC 359 GGCUGUUC CUGAUGAG GCCGUUAGGC CGAA ACUUUUGC 4152 2325 UGCCUGAU C AUUCUGAG 360 CUCAGAAU CUGAUGAG GCCGUUAGGC CGAA AUCAGGCA 4153 2328 CUGAUCAU U CUGAGCUA 361 UAGCUCAG CUGAUGAG GCCGUUAGGC CGAA AUGAUCAG 4154 2329 UGAUCAUU C UGAGCUAG 362 CUAGCUCA CUGAUGAG GCCGUUAGGC CGAA AAUGAUCA 4155 2336 UCUGAGCU A GUUGAAGA 363 UCUUCAAC CUGAUGAG GCCGUUAGGC CGAA AGCUCAGA 4156 2339 GAGCUAGU U GAAGAUUC 364 GAAUCUUC CUGAUGAG GCCGUUAGGC CGAA ACUAGCUC 4157 2346 UUGAAGAU U CCUCACCU 365 AGGUGAGG CUGAUGAG GCCGUUAGGC CGAA AUCUUCAA 4158 2347 UGAAGAUU C CUCACCUG 366 CAGGUGAG CUGAUGAG GCCGUUAGGC CGAA AAUCUUCA 4159 2350 AGAUUCCU C ACCUGAUU 367 AAUCAGGU CUGAUGAG GCCGUUAGGC CGAA AGGAAUCU 4160 2358 CACCUGAU U CUGAACCA 368 UGGUUCAG CUGAUGAG GCCGUUAGGC CGAA AUCAGGUG 4161 2359 ACCUGAUU C UGAACCAG 369 CUGGUUCA CUGAUGAG GCCGUUAGGC CGAA AAUCAGGU 4162 2369 GAACCAGU U GACUUAUU 370 AAUAAGUC CUGAUGAG GCCGUUAGGC CGAA ACUGGUUC 4163 2374 AGUUGACU U AUUUAGUG 371 CACUAAAU CUGAUGAG GCCGUUAGGC CGAA AGUCAACU 4164 2375 GUUGACUU A UUUAGUGA 372 UCACUAAA CUGAUGAG GCCGUUAGGC CGAA AAGUCAAC 4165 2377 UGACUUAU U UAGUGAUG 373 CAUCACUA CUGAUGAG GCCGUUAGGC CGAA AUAAGUCA 4166 2378 GACUUAUU U AGUGAUGA 374 UCAUCACU CUGAUGAG GCCGUUAGGC CGAA AAUAAGUC 4167 2379 ACUUAUUU A GUGAUGAU 375 AUCAUCAC CUGAUGAG GCCGUUAGGC CGAA AAAUAAGU 4168 2388 GUGAUGAU U CAAUACCU 376 AGGUAUUG CUGAUGAG GCCGUUAGGC CGAA AUCAUCAC 4169 2389 UGAUGAUU C AAUACCUG 377 CAGGUAUU CUGAUGAG GCCGUUAGGC CGAA AAUCAUCA 4170 2393 GAUUCAAU A CCUGACGU 378 ACGUCAGG CUGAUGAG GCCGUUAGGC CGAA AUUGAAUC 4171 2402 CCUGACGU U CCACAAAA 379 UUUUGUGG CUGAUGAG GCCGUUAGGC CGAA ACGUCAGG 4172 2403 CUGACGUU C CACAAAAA 380 UUUUUGUG CUGAUGAG GCCGUUAGGC CGAA AACGUCAG 4173 2432 GUGAUGCU U GUGAAAGA 381 UCUUUCAC CUGAUGAG GCCGUUAGGC CGAA AGCAUCAC 4174 2445 AAGAAAGU C UCACUGAG 382 CUCAGUGA CUGAUGAG GCCGUUAGGC CGAA ACUUUCUU 4175 2447 GAAAGUCU C ACUGAGAC 383 GUCUCAGU CUGAUGAG GCCGUUAGGC CGAA AGACUUUC 4176 2457 CUGAGACU U CAUUUGAG 384 CUCAAAUG CUGAUGAG GCCGUUAGGC CGAA AGUCUCAG 4177 2458 UGAGACUU C AUUUGAGU 385 ACUCAAAU CUGAUGAG GCCGUUAGGC CGAA AAGUCUCA 4178 2461 GACUUCAU U UGAGUCAA 386 UUGACUCA CUGAUGAG GCCGUUAGGC CGAA AUGAAGUC 4179 2462 ACUUCAUU U GAGUCAAU 387 AUUGACUC CUGAUGAG GCCGUUAGGC CGAA AAUGAAGU 4180 2467 AUUUGAGU C AAUGAUAG 388 CUAUCAUU CUGAUGAG GCCGUUAGGC CGAA ACUCAAAU 4181 2474 UCAAUGAU A GAAUAUGA 389 UCAUAUUC CUGAUGAG GCCGUUAGGC CGAA AUCAUUGA 4182 2479 GAUAGAAU A UGAAAAUA 390 UAUUUUCA CUGAUGAG GCCGUUAGGC CGAA AUUCUAUC 4183 2487 AUGAAAAU A AGGAAAAA 391 UUUUUCCU CUGAUGAG GCCGUUAGGC CGAA AUUUUCAU 4184 2498 GAAAAACU C AGUGCUUU 392 AAAGCACU CUGAUGAG GCCGUUAGGC CGAA AGUUUUUC 4185 2505 UCAGUGCU U UGCCACCU 393 AGGUGGCA CUGAUGAG GCCGUUAGGC CGAA AGCACUGA 4186 2506 CAGUGCUU u GCCACCUG 394 CAGGUGGC CUGAUGAG GCCGUUAGGC CGAA AAGCACUG 4187 2530 AAAGCCAU A UUUGGAAU 395 AUUCCAAA CUGAUGAG GCCGUUAGGC CGAA AUGGCUUU 4188 2532 AGCCAUAU U UGGAAUCU 396 AGAUUCCA CUGAUGAG GCCGUUAGGC CGAA AUAUGGCU 4189 2533 GCCAUAUU U GGAAUCUU 397 AAGAUUCC CUGAUGAG GCCGUUAGGC CGAA AAUAUGGC 4190 2539 UUUGGAAU C UUUUAAGC 398 GCUUAAAA CUGAUGAG GCCGUUAGGC CGAA AUUCCAAA 4191 2541 UGGAAUCU U UUAAGCUC 399 GAGCUUAA CUGAUGAG GCCGUUAGGC CGAA AGAUUCCA 4192 2542 GGAAUCUU U UAAGCUCA 400 UGAGCUUA CUGAUGAG GCCGUUAGGC CGAA AAGAUUCC 4193 2543 GAAUCUUU u AAGCUCAG 401 CUGAGCUU CUGAUGAG GCCGUUAGGC CGAA AAAGAUUC 4194 2544 AAUCUUUU A AGCUCAGU 402 ACUGAGCU CUGAUGAG GCCGUUAGGC CGAA AAAAGAUU 4195 2549 UUUAAGCU C AGUUUAGA 403 UCUAAACU CUGAUGAG GCCGUUAGGC CGAA AGCUUAAA 4196 2553 AGCUCAGU U UAGAUAAC 404 GUUAUCUA CUGAUGAG GCCGUUAGGC CGAA ACUGAGCU 4197 2554 GCUCAGUU U AGAUAACA 405 UGUUAUCU CUGAUGAG GCCGUUAGGC CGAA AACUGAGC 4198 2555 CUCAGUUU A GAUAACAC 406 GUGUUAUC CUGAUGAG GCCGUUAGGC CGAA AAACUGAG 4199 2559 GUUUAGAU A ACACAAAA 407 UUUUGUGU CUGAUGAG GCCGUUAGGC CGAA AUCUAAAC 4200 2571 CAAAAGAU A CCCUGUUA 408 UAACAGGG CUGAUGAG GCCGUUAGGC CGAA AUCUUUUG 4201 2578 UACCCUGU U ACCUGAUG 409 CAUCAGGU CUGAUGAG GCCGUUAGGC CGAA ACAGGGUA 4202 2579 ACCCUGUU A CCUGAUGA 410 UCAUCAGG CUGAUGAG GCCGUUAGGC CGAA AACAGGGU 4203 2591 GAUGAAGU U UCAACAUU 411 AAUGUUGA CUGAUGAG GCCGUUAGGC CGAA ACUUCAUC 4204 2592 AUGAAGUU U CAACAUUG 412 CAAUGUUG CUGAUGAG GCCGUUAGGC CGAA AACUUCAU 4205 2593 UGAAGUUU C AACAUUGA 413 UCAAUGUU CUGAUGAG GCCGUUAGGC CGAA AAACUUCA 4206 2599 UUCAACAU U GAGCAAAA 414 UUUUGCUC CUGAUGAG GCCGUUAGGC CGAA AUGUUGAA 4207 2618 GAGAAAAU U CCUUUGCA 415 UGCAAAGG CUGAUGAG GCCGUUAGGC CGAA AUUUUCUG 4208 2619 AGAAAAUU C CUUUGCAG 416 CUGCAAAG CUGAUGAG GCCGUUAGGC CGAA AAUUUUCU 4209 2622 AAAUUCCU U UGCAGAUG 417 CAUCUGCA CUGAUGAG GCCGUUAGGC CGAA AGGAAUUU 4210 2623 AAUUCCUU U GCAGAUGG 418 CCAUCUGC CUGAUGAG GCCGUUAGGC CGAA AAGGAAUU 4211 2639 GAGGAGCU C AGUACUGC 419 GCAGUACU CUGAUGAG GCCGUUAGGC CGAA AGCUCCUC 4212 2643 AGCUCAGU A CUGCAGUU 420 AACUGCAG CUGAUGAG GCCGUUAGGC CGAA ACUGAGCU 4213 2651 ACUGCAGU U UAUUCAAA 421 UUUGAAUA CUGAUGAG GCCGUUAGGC CGAA ACUGCAGU 4214 2652 CUGCAGUU U AUUCAAAU 422 AUUUGAAU CUGAUGAG GCCGUUAGGC CGAA AACUGCAG 4215 2653 UGCAGUUU A UUCAAAUG 423 CAUUUGAA CUGAUGAG GCCGUUAGGC CGAA AAACUGCA 4216 2655 CAGUUUAU U CAAAUGAU 424 AUCAUUUG CUGAUGAG GCCGUUAGGC CGAA AUAAACUG 4217 2656 AGUUUAUU C AAAUGAUG 425 CAUCAUUU CUGAUGAG GCCGUUAGGC CGAA AAUAAACU 4218 2668 UGAUGACU U AUUUAUUU 426 AAAUAAAU CUGAUGAG GCCGUUAGGC CGAA AGUCAUCA 4219 2669 GAUGACUU A UUUAUUUC 427 GAAAUAAA CUGAUGAG GCCGUUAGGC CGAA AAGUCAUC 4220 2671 UGACUUAU U UAUUUCUA 428 UAGAAAUA CUGAUGAG GCCGUUAGGC CGAA AUAAGUCA 4221 2672 GACUUAUU U AUUUCUAA 429 UUAGAAAU CUGAUGAG GCCGUUAGGC CGAA AAUAAGUC 4222 2673 ACUUAUUU A UUUCUAAG 430 CUUAGAAA CUGAUGAG GCCGUUAGGC CGAA AAAUAAGU 4223 2675 UUAUUUAU U UCUAAGGA 431 UCCUUAGA CUGAUGAG GCCGUUAGGC CGAA AUAAAUAA 4224 2676 UAUUUAUU U CUAAGGAA 432 UUCCUUAG CUGAUGAG GCCGUUAGGC CGAA AAUAAAUA 4225 2677 AUUUAUUU C UAAGGAAG 433 CUUCCUUA CUGAUGAG GCCGUUAGGC CGAA AAAUAAAU 4226 2679 UUAUUUCU A AGGAAGCA 434 UGCUUCCU CUGAUGAG GCCGUUAGGC CGAA AGAAAUAA 4227 2693 GCACAGAU A AGAGAAAC 435 GUUUCUCU CUGAUGAG GCCGUUAGGC CGAA AUCUGUGC 4228 2710 UGAAACGU U UUCAGAUU 436 AAUCUGAA CUGAUGAG GCCGUUAGGC CGAA ACGUUUCA 4229 2711 GAAACGUU U UCAGAUUC 437 GAAUCUGA CUGAUGAG GCCGUUAGGC CGAA AACGUUUC 4230 2712 AAACGUUU U CAGAUUCA 438 UGAAUCUG CUGAUGAG GCCGUUAGGC CGAA AAACGUUU 4231 2713 AACGUUUU C AGAUUCAU 439 AUGAAUCU CUGAUGAG GCCGUUAGGC CGAA AAAACGUU 4232 2718 UUUCAGAU U CAUCUCCA 440 UGGAGAUG CUGAUGAG GCCGUUAGGC CGAA AUCUGAAA 4233 2719 UUCAGAUU C AUCUCCAA 441 UUGGAGAU CUGAUGAG GCCGUUAGGC CGAA AAUCUGAA 4234 2722 AGAUUCAU C UCCAAUUG 442 CAAUUGGA CUGAUGAG GCCGUUAGGC CGAA AUGAAUCU 4235 2724 AUUCAUCU C CAAUUGAA 443 UUCAAUUG CUGAUGAG GCCGUUAGGC CGAA AGAUGAAU 4236 2729 UCUCCAAU U GAAAUUAU 444 AUAAUUUC CUGAUGAG GCCGUUAGGC CGAA AUUGGAGA 4237 2735 AUUGAAAU U AUAGAUGA 445 UCAUCUAU CUGAUGAG GCCGUUAGGC CGAA AUUUCAAU 4238 2736 UUGAAAUU A UAGAUGAG 446 CUCAUCUA CUGAUGAG GCCGUUAGGC CGAA AAUUUCAA 4239 2738 GAAAUUAU A GAUGAGUU 447 AACUCAUC CUGAUGAG GCCGUUAGGC CGAA AUAAUUUC 4240 2746 AGAUGAGU U CCCUACAU 448 AUGUAGGG CUGAUGAG GCCGUUAGGC CGAA ACUCAUCU 4241 2747 GAUGAGUU C CCUACAUU 449 AAUGUAGG CUGAUGAG GCCGUUAGGC CGAA AACUCAUC 4242 2751 AGUUCCCU A CAUUGAUC 450 GAUCAAUG CUGAUGAG GCCGUUAGGC CGAA AGGGAACU 4243 2755 CCCUACAU U GAUCAGUU 451 AACUGAUC CUGAUGAG GCCGUUAGGC CGAA AUGUAGGG 4244 2759 ACAUUGAU C AGUUCUAA 452 UUAGAACU CUGAUGAG GCCGUUAGGC CGAA AUCAAUGU 4245 2763 UGAUCAGU U CUAAAACU 453 AGUUUUAG CUGAUGAG GCCGUUAGGC CGAA ACUGAUCA 4246 2764 GAUCAGUU C UAAAACUG 454 CAGUUUUA CUGAUGAG GCCGUUAGGC CGAA AACUGAUC 4247 2766 UCAGUUCU A AAACUGAU 455 AUCAGUUU CUGAUGAG GCCGUUAGGC CGAA AGAACUGA 4248 2775 AAACUGAU U CAUUUUCU 456 AGAAAAUG CUGAUGAG GCCGUUAGGC CGAA AUCAGUUU 4249 2776 AACUGAUU C AUUUUCUA 457 UAGAAAAU CUGAUGAG GCCGUUAGGC CGAA AAUCAGUU 4250 2779 UGAUUCAU U UUCUAAAU 458 AUUUAGAA CUGAUGAG GCCGUUAGGC CGAA AUGAAUCA 4251 2780 GAUUCAUU u UCUAAAUU 459 AAUUUAGA CUGAUGAG GCCGUUAGGC CGAA AAUGAAUC 4252 2781 AUUCAUUU u CUAAAUUA 460 UAAUUUAG CUGAUGAG GCCGUUAGGC CGAA AAAUGAAU 4253 2782 UUCAUUUU c UAAAUUAG 461 CUAAUUUA CUGAUGAG GCCGUUAGGC CGAA AAAAUGAA 4254 2784 CAUUUUCU A AAUUAGCC 462 GGCUAAUU CUGAUGAG GCCGUUAGGC CGAA AGAAAAUG 4255 2788 UUCUAAAU U AGCCAGGG 463 CCCUGGCU CUGAUGAG GCCGUUAGGC CGAA AUUUAGAA 4256 2789 UCUAAAUU A GCCAGGGA 464 UCCCUGGC CUGAUGAG GCCGUUAGGC CGAA AAUUUAGA 4257 2800 CAGGGAAU A UACUGACC 465 GGUCAGUA CUGAUGAG GCCGUUAGGC CGAA AUUCCCUG 4258 2802 GGGAAUAU A CUGACCUA 466 UAGGUCAG CUGAUGAG GCCGUUAGGC CGAA AUAUUCCC 4259 2810 ACUGACCU A GAAGUAUC 467 GAUACUUC CUGAUGAG GCCGUUAGGC CGAA AGGUCAGU 4260 2816 CUAGAAGU A UCCCACAA 468 UUGUGGGA CUGAUGAG GCCGUUAGGC CGAA ACUUCUAG 4261 2818 AGAAGUAU c CCACAAAA 469 UUUUGUGG CUGAUGAG GCCGUUAGGC CGAA AUACUUCU 4262 2834 AGUGAAAU U GCUAAUGC 470 GCAUUAGC CUGAUGAG GCCGUUAGGC CGAA AUUUCACU 4263 2838 AAAUUGCU A AUGCCCCG 471 CGGGGCAU CUGAUGAG GCCGUUAGGC CGAA AGCAAUUU 4264 2860 AGCUGGGU C AUUGCCUU 472 AAGGCAAU CUGAUGAG GCCGUUAGGC CGAA ACCCAGCU 4265 2863 UGGGUCAU U GCCUUGCA 473 UGCAAGGC CUGAUGAG GCCGUUAGGC CGAA AUGACCCA 4266 2868 CAUUGCCU U GCACAGAA 474 UUCUGUGC CUGAUGAG GCCGUUAGGC CGAA AGGCAAUG 4267 2878 CACAGAAU u GCCCCAUG 475 CAUGGGGC CUGAUGAG GCCGUUAGGC CGAA AUUCUGUG 4268 2891 CAUGACCU u UCUUUGAA 476 UUCAAAGA CUGAUGAG GCCGUUAGGC CGAA AGGUCAUG 4269 2892 AUGACCUU u CUUUGAAG 477 CUUCAAAG CUGAUGAG GCCGUUAGGC CGAA AAGGUCAU 4270 2893 UGACCUUU c UUUGAAGA 478 UCUUCAAA CUGAUGAG GCCGUUAGGC CGAA AAAGGUCA 4271 2895 ACCUUUCU u UGAAGAAC 479 GUUCUUCA CUGAUGAG GCCGUUAGGC CGAA AGAAAGGU 4272 2896 CCUUUCUU u GAAGAACA 480 UGUUCUUC CUGAUGAG GCCGUUAGGC CGAA AAGAAAGG 4273 2906 AAGAACAU A CAACCCAA 481 UUGGGUUG CUGAUGAG GCCGUUAGGC CGAA AUGUUCUU 4274 2918 CCCAAAGU U GAAGAGAA 482 UUCUCUUC CUGAUGAG GCCGUUAGGC CGAA ACUUUGGG 4275 2930 GAGAAAAU C AGUUUCUC 483 GAGAAACU CUGAUGAG GCCGUUAGGC CGAA AUUUUCUC 4276 2934 AAAUCAGU u UCUCAGAU 484 AUCUGAGA CUGAUGAG GCCGUUAGGC CGAA ACUGAUUU 4277 2935 AAUCAGUU u CUCAGAUG 485 CAUCUGAG CUGAUGAG GCCGUUAGGC CGAA AACUGAUU 4278 2936 AUCAGUUU c UCAGAUGA 486 UCAUCUGA CUGAUGAG GCCGUUAGGC CGAA AAACUGAU 4279 2938 CAGUUUCU c AGAUGACU 487 AGUCAUCU CUGAUGAG GCCGUUAGGC CGAA AGAAACUG 4280 2947 AGAUGACU u UUCUAAAA 488 UUUUAGAA CUGAUGAG GCCGUUAGGC CGAA AGUCAUCU 4281 2948 GAUGACUU u UCUAAAAA 489 UUUUUAGA CUGAUGAG GCCGUUAGGC CGAA AAGUCAUC 4282 2949 AUGACUUU u CUAAAAAU 490 AUUUUUAG CUGAUGAG GCCGUUAGGC CGAA AAAGUCAU 4283 2950 UGACUUUU c UAAAAAUG 491 CAUUUUUA CUGAUGAG GCCGUUAGGC CGAA AAAAGUCA 4284 2952 ACUUUUCU A AAAAUGGG 492 CCCAUUUU CUGAUGAG GCCGUUAGGC CGAA AGAAAAGU 4285 2962 AAAUGGGU c UGCUACAU 493 AUGUAGCA CUGAUGAG GCCGUUAGGC CGAA ACCCAUUU 4286 2967 GGUCUGCU A CAUCAAAG 494 CUUUGAUG CUGAUGAG GCCGUUAGGC CGAA AGCAGACC 4287 2971 UGCUACAU C AAAGGUGC 495 GCACCUUU CUGAUGAG GCCGUUAGGC CGAA AUGUAGCA 4288 2981 AAGGUGCU C UUAUUGCC 496 GGCAAUAA CUGAUGAG GCCGUUAGGC CGAA AGCACCUU 4289 2983 GGUGCUCU U AUUGCCUC 497 GAGGCAAU CUGAUGAG GCCGUUAGGC CGAA AGAGCACC 4290 2984 GUGCUCUU A UUGCCUCC 498 GGAGGCAA CUGAUGAG GCCGUUAGGC CGAA AAGAGCAC 4291 2986 GCUCUUAU U GCCUCCAG 499 CUGGAGGC CUGAUGAG GCCGUUAGGC CGAA AUAAGAGC 4292 2991 UAUUGCCU C CAGAUGUU 500 AACAUCUG CUGAUGAG GCCGUUAGGC CGAA AGGCAAUA 4293 2999 CCAGAUGU U UCUGCUUU 501 AAAGCAGA CUGAUGAG GCCGUUAGGC CGAA ACAUCUGG 4294 3000 CAGAUGUU U CUGCUUUG 502 CAAAGCAG CUGAUGAG GCCGUUAGGC CGAA AACAUCUG 4295 3001 AGAUGUUU C UGCUUUGG 503 CCAAAGCA CUGAUGAG GCCGUUAGGC CGAA AAACAUCU 4296 3006 UUUCUGCU u UGGCCACU 504 AGUGGCCA CUGAUGAG GCCGUUAGGC CGAA AGCAGAAA 4297 3007 UUCUGCUU u GGCCACUC 505 GAGUGGCC CUGAUGAG GCCGUUAGGC CGAA AAGCAGAA 4298 3015 UGGCCACU c AAGCAGAG 506 CUCUGCUU CUGAUGAG GCCGUUAGGC CGAA AGUGGCCA 4299 3026 GCAGAGAU A GAGAGCAU 507 AUGCUCUC CUGAUGAG GCCGUUAGGC CGAA AUCUCUGC 4300 3035 GAGAGCAU A GUUAAACC 508 GGUUUAAC CUGAUGAG GCCGUUAGGC CGAA AUGCUCUC 4301 3038 AGCAUAGU U AAACCCAA 509 UUGGGUUU CUGAUGAG GCCGUUAGGC CGAA ACUAUGCU 4302 3039 GCAUAGUU A AACCCAAA 510 UUUGGGUU CUGAUGAG GCCGUUAGGC CGAA AACUAUGC 4303 3050 CCCAAAGU U CUUGUGAA 511 UUCACAAG CUGAUGAG GCCGUUAGGC CGAA ACUUUGGG 4304 3051 CCAAAGUU C UUGUGAAA 512 UUUCACAA CUGAUGAG GCCGUUAGGC CGAA AACUUUGG 4305 3053 AAAGUUCU U GUGAAAGA 513 UCUUUCAC CUGAUGAG GCCGUUAGGC CGAA AGAACUUU 4306 3077 AAAAAACU u CCUUCCGA 514 UCGGAAGG CUGAUGAG GCCGUUAGGC CGAA AGUUUUUU 4307 3078 AAAAACUU c CUUCCGAU 515 AUCGGAAG CUGAUGAG GCCGUUAGGC CGAA AAGUUUUU 4308 3081 AACUUCCU u CCGAUACA 516 UGUAUCGG CUGAUGAG GCCGUUAGGC CGAA AGGAAGUU 4309 3082 ACUUCCUU c CGAUACAG 517 CUGUAUCG CUGAUGAG GCCGUUAGGC CGAA AAGGAAGU 4310 3087 CUUCCGAU A CAGAAAAA 518 UUUUUCUG CUGAUGAG GCCGUUAGGC CGAA AUCGGAAG 4311 3106 GGACAGAU C ACCAUCUG 519 CAGAUGGU CUGAUGAG GCCGUUAGGC CGAA AUCUGUCC 4312 3112 AUCACCAU C UGCUAUAU 520 AUAUAGCA CUGAUGAG GCCGUUAGGC CGAA AUGGUGAU 4313 3117 CAUCUGCU A UAUUUUCA 521 UGAAAAUA CUGAUGAG GCCGUUAGGC CGAA AGCAGAUG 4314 3119 UCUGCUAU A UUUUCAGC 522 GCUGAAAA CUGAUGAG GCCGUUAGGC CGAA AUAGCAGA 4315 3121 UGCUAUAU U UUCAGCAG 523 CUGCUGAA CUGAUGAG GCCGUUAGGC CGAA AUAUAGCA 4316 3122 GCUAUAUU U UCAGCAGA 524 UCUGCUGA CUGAUGAG GCCGUUAGGC CGAA AAUAUAGC 4317 3123 CUAUAUUU U CAGCAGAG 525 CUCUGCUG CUGAUGAG GCCGUUAGGC CGAA AAAUAUAG 4318 3124 UAUAUUUU C AGCAGAGC 526 GCUCUGCU CUGAUGAG GCCGUUAGGC CGAA AAAAUAUA 4319 3138 AGCUGAGU A AAACUUCA 527 UGAAGUUU CUGAUGAG GCCGUUAGGC CGAA ACUCAGCU 4320 3144 GUAAAACU U CAGUUGUU 528 AACAACUG CUGAUGAG GCCGUUAGGC CGAA AGUUUUAC 4321 3145 UAAAACUU c AGUUGUUG 529 CAACAACU CUGAUGAG GCCGUUAGGC CGAA AAGUUUUA 4322 3149 ACUUCAGU u GUUGACCU 530 AGGUCAAC CUGAUGAG GCCGUUAGGC CGAA ACUGAAGU 4323 3152 UCAGUUGU u GACCUCCU 531 AGGAGGUC CUGAUGAG GCCGUUAGGC CGAA ACAACUGA 4324 3158 GUUGACCU c CUGUACUG 532 CAGUACAG CUGAUGAG GCCGUUAGGC CGAA AGGUCAAC 4325 3163 CCUCCUGU A CUGGAGAG 533 CUCUCCAG CUGAUGAG GCCGUUAGGC CGAA ACAGGAGG 4326 3176 AGAGACAU U AAGAAGAC 534 GUCUUCUU CUGAUGAG GCCGUUAGGC CGAA AUGUCUCU 4327 3177 GAGACAUU A AGAAGACU 535 AGUCUUCU CUGAUGAG GCCGUUAGGC CGAA AAUGUCUC 4328 3196 AGUGGUGU U UGGUGCCA 536 UGGCACCA CUGAUGAG GCCGUUAGGC CGAA ACACCACU 4329 3197 GUGGUGUU U GGUGCCAG 537 CUGGCACC CUGAUGAG GCCGUUAGGC CGAA AACACCAC 4330 3209 GCCAGCCU A UUCCUGCU 538 AGCAGGAA CUGAUGAG GCCGUUAGGC CGAA AGGCUGGC 4331 3211 CAGCCUAU U CCUGCUGC 539 GCAGCAGG CUGAUGAG GCCGUUAGGC CGAA AUAGGCUG 4332 3212 AGCCUAUU C CUGCUGCU 540 AGCAGCAG CUGAUGAG GCCGUUAGGC CGAA AAUAGGCU 4333 3221 CUGCUGCU U UCAUUGAC 541 GUCAAUGA CUGAUGAG GCCGUUAGGC CGAA AGCAGCAG 4334 3222 UGCUGCUU U CAUUGACA 542 UGUCAAUG CUGAUGAG GCCGUUAGGC CGAA AAGCAGCA 4335 3223 GCUGCUUU C AUUGACAG 543 CUGUCAAU CUGAUGAG GCCGUUAGGC CGAA AAAGCAGC 4336 3226 GCUUUCAU U GACAGUAU 544 AUACUGUC CUGAUGAG GCCGUUAGGC CGAA AUGAAAGC 4337 3233 UUGACAGU A UUCAGCAU 545 AUGCUGAA CUGAUGAG GCCGUUAGGC CGAA ACUGUCAA 4338 3235 GACAGUAU U CAGCAUUG 546 CAAUGCUG CUGAUGAG GCCGUUAGGC CGAA AUACUGUC 4339 3236 ACAGUAUU C AGCAUUGU 547 ACAAUGCU CUGAUGAG GCCGUUAGGC CGAA AAUACUGU 4340 3242 UUCAGCAU U GUGAGCGU 548 ACGCUCAC CUGAUGAG GCCGUUAGGC CGAA AUGCUGAA 4341 3251 GUGAGCGU A ACAGCCUA 549 UAGGCUGU CUGAUGAG GCCGUUAGGC CGAA ACGCUCAC 4342 3259 AACAGCCU A CAUUGCCU 550 AGGCAAUG CUGAUGAG GCCGUUAGGC CGAA AGGCUGUU 4343 3263 GCCUACAU U GCCUUGGC 551 GCCAAGGC CUGAUGAG GCCGUUAGGC CGAA AUGUAGGC 4344 3268 CAUUGCCU U GGCCCUGC 552 GCAGGGCC CUGAUGAG GCCGUUAGGC CGAA AGGCAAUG 4345 3278 GCCCUGCU C UCUGUGAC 553 GUCACAGA CUGAUGAG GCCGUUAGGC CGAA AGCAGGGC 4346 3280 CCUGCUCU c UGUGACCA 554 UGGUCACA CUGAUGAG GCCGUUAGGC CGAA AGAGCAGG 4347 3290 GUGACCAU c AGCUUUAG 555 CUAAAGCU CUGAUGAG GCCGUUAGGC CGAA AUGGUCAC 4348 3295 CAUCAGCU u UAGGAUAU 556 AUAUCCUA CUGAUGAG GCCGUUAGGC CGAA AGCUGAUG 4349 3296 AUCAGCUU u AGGAUAUA 557 UAUAUCCU CUGAUGAG GCCGUUAGGC CGAA AAGCUGAU 4350 3297 UCAGCUUU A GGAUAUAC 558 GUAUAUCC CUGAUGAG GCCGUUAGGC CGAA AAAGCUGA 4351 3302 UUUAGGAU A UACAAGGG 559 CCCUUGUA CUGAUGAG GCCGUUAGGC CGAA AUCCUAAA 4352 3304 UAGGAUAU A CAAGGGUG 560 CACCCUUG CUGAUGAG GCCGUUAGGC CGAA AUAUCCUA 4353 3317 GGUGUGAU c CAAGCUAU 561 AUAGCUUG CUGAUGAG GCCGUUAGGC CGAA AUCACACC 4354 3324 UCCAAGCU A UCCAGAAA 562 UUUCUGGA CUGAUGAG GCCGUUAGGC CGAA AGCUUGGA 4355 3326 CAAGCUAU C CAGAAAUC 563 GAUUUCUG CUGAUGAG GCCGUUAGGC CGAA AUAGCUUG 4356 3334 CCAGAAAU C AGAUGAAG 564 CUUCAUCU CUGAUGAG GCCGUUAGGC CGAA AUUUCUGG 4357 3352 CCACCCAU U CAGGGCAU 565 AUGCCCUG CUGAUGAG GCCGUUAGGC CGAA AUGGGUGG 4358 3353 CACCCAUU C AGGGCAUA 566 UAUGCCCU CUGAUGAG GCCGUUAGGC CGAA AAUGGGUG 4359 3361 CAGGGCAU A UCUGGAAU 567 AUUCCAGA CUGAUGAG GCCGUUAGGC CGAA AUGCCCUG 4360 3363 GGGCAUAU C UGGAAUCU 568 AGAUUCCA CUGAUGAG GCCGUUAGGC CGAA AUAUGCCC 4361 3370 UCUGGAAU C UGAAGUUG 569 CAACUUCA CUGAUGAG GCCGUUAGGC CGAA AUUCCAGA 4362 3377 UCUGAAGU U GCUAUAUC 570 GAUAUAGC CUGAUGAG GCCGUUAGGC CGAA ACUUCAGA 4363 3381 AAGUUGCU A UAUCUGAG 571 CUCAGAUA CUGAUGAG GCCGUUAGGC CGAA AGCAACUU 4364 3383 GUUGCUAU A UCUGAGGA 572 UCCUCAGA CUGAUGAG GCCGUUAGGC CGAA AUAGCAAC 4365 3385 UGCUAUAU C UGAGGAGU 573 ACUCCUCA CUGAUGAG GCCGUUAGGC CGAA AUAUAGCA 4366 3394 UGAGGAGU U GGUUCAGA 574 UCUGAACC CUGAUGAG GCCGUUAGGC CGAA ACUCCUCA 4367 3398 GAGUUGGU U CAGAAGUA 575 UACUUCUG CUGAUGAG GCCGUUAGGC CGAA ACCAACUC 4368 3399 AGUUGGUU c AGAAGUAC 576 GUACUUCU CUGAUGAG GCCGUUAGGC CGAA AACCAACU 4369 3406 UCAGAAGU A CAGUAAUU 577 AAUUACUG CUGAUGAG GCCGUUAGGC CGAA ACUUCUGA 4370 3411 AGUACAGU A AUUCUGCU 578 AGCAGAAU CUGAUGAG GCCGUUAGGC CGAA ACUGUACU 4371 3414 ACAGUAAU U CUGCUCUU 579 AAGAGCAG CUGAUGAG GCCGUUAGGC CGAA AUUACUGU 4372 3415 CAGUAAUU C UGCUCUUG 580 CAAGAGCA CUGAUGAG GCCGUUAGGC CGAA AAUUACUG 4373 3420 AUUCUGCU C UUGGUCAU 581 AUGACCAA CUGAUGAG GCCGUUAGGC CGAA AGCAGAAU 4374 3422 UCUGCUCU U GGUCAUGU 582 ACAUGACC CUGAUGAG GCCGUUAGGC CGAA AGAGCAGA 4375 3426 CUCUUGGU C AUGUGAAC 583 GUUCACAU CUGAUGAG GCCGUUAGGC CGAA ACCAAGAG 4376 3443 UGCACGAU A AAGGAACU 584 AGUUCCUU CUGAUGAG GCCGUUAGGC CGAA AUCGUGCA 4377 3452 AAGGAACU C AGGCGCCU 585 AGGCGCCU CUGAUGAG GCCGUUAGGC CGAA AGUUCCUU 4378 3461 AGGCGCCU C UUCUUAGU 586 ACUAAGAA CUGAUGAG GCCGUUAGGC CGAA AGGCGCCU 4379 3463 GCGCCUCU U CUUAGUUG 587 CAACUAAG CUGAUGAG GCCGUUAGGC CGAA AGAGGCGC 4380 3464 CGCCUCUU C UUAGUUGA 588 UCAACUAA CUGAUGAG GCCGUUAGGC CGAA AAGAGGCG 4381 3466 CCUCUUCU U AGUUGAUG 589 CAUCAACU CUGAUGAG GCCGUUAGGC CGAA AGAAGAGG 4382 3467 CUCUUCUU A GUUGAUGA 590 UCAUCAAC CUGAUGAG GCCGUUAGGC CGAA AAGAAGAG 4383 3470 UUCUUAGU U GAUGAUUU 591 AAAUCAUC CUGAUGAG GCCGUUAGGC CGAA ACUAAGAA 4384 3477 UUGAUGAU U UAGUUGAU 592 AUCAACUA CUGAUGAG GCCGUUAGGC CGAA AUCAUCAA 4385 3478 UGAUGAUU U AGUUGAUU 593 AAUCAACU CUGAUGAG GCCGUUAGGC CGAA AAUCAUCA 4386 3479 GAUGAUUU A GUUGAUUC 594 GAAUCAAC CUGAUGAG GCCGUUAGGC CGAA AAAUCAUC 4387 3482 GAUUUAGU U GAUUCUCU 595 AGAGAAUC CUGAUGAG GCCGUUAGGC CGAA ACUAAAUC 4388 3486 UAGUUGAU U CUCUGAAG 596 CUUCAGAG CUGAUGAG GCCGUUAGGC CGAA AUCAACUA 4389 3487 AGUUGAUU C UCUGAAGU 597 ACUUCAGA CUGAUGAG GCCGUUAGGC CGAA AAUCAACU 4390 3489 UUGAUUCU C UGAAGUUU 598 AAACUUCA CUGAUGAG GCCGUUAGGC CGAA AGAAUCAA 4391 3496 UCUGAAGU U UGCAGUGU 599 ACACUGCA CUGAUGAG GCCGUUAGGC CGAA ACUUCAGA 4392 3497 CUGAAGUU U GCAGUGUU 600 AACACUGC CUGAUGAG GCCGUUAGGC CGAA AACUUCAG 4393 3505 UGCAGUGU U GAUGUGGG 601 CCCACAUC CUGAUGAG GCCGUUAGGC CGAA ACACUGCA 4394 3515 AUGUGGGU A UUUACCUA 602 UAGGUAAA CUGAUGAG GCCGUUAGGC CGAA ACCCACAU 4395 3517 GUGGGUAU U UACCUAUG 603 CAUAGGUA CUGAUGAG GCCGUUAGGC CGAA AUACCCAC 4396 3518 UGGGUAUU U ACCUAUGU 604 ACAUAGGU CUGAUGAG GCCGUUAGGC CGAA AAUACCCA 4397 3519 GGGUAUUU A CCUAUGUU 605 AACAUAGG CUGAUGAG GCCGUUAGGC CGAA AAAUACCC 4398 3523 AUUUACCU A UGUUGGUG 606 CACCAACA CUGAUGAG GCCGUUAGGC CGAA AGGUAAAU 4399 3527 ACCUAUGU U GGUGCCUU 607 AAGGCACC CUGAUGAG GCCGUUAGGC CGAA ACAUAGGU 4400 3535 UGGUGCCU U GUUUAAUG 608 CAUUAAAC CUGAUGAG GCCGUUAGGC CGAA AGGCACCA 4401 3538 UGCCUUGU U UAAUGGUC 609 GACCAUUA CUGAUGAG GCCGUUAGGC CGAA ACAAGGCA 4402 3539 GCCUUGUU U AAUGGUCU 610 AGACCAUU CUGAUGAG GCCGUUAGGC CGAA AACAAGGC 4403 3540 CCUUGUUU A AUGGUCUG 611 CAGACCAU CUGAUGAG GCCGUUAGGC CGAA AAACAAGG 4404 3546 UUAAUGGU C UGACACUA 612 UAGUGUCA CUGAUGAG GCCGUUAGGC CGAA ACCAUUAA 4405 3554 CUGACACU A CUGAUUUU 613 AAAAUCAG CUGAUGAG GCCGUUAGGC CGAA AGUGUCAG 4406 3560 CUACUGAU U UUGGCUCU 614 AGAGCCAA CUGAUGAG GCCGUUAGGC CGAA AUCAGUAG 4407 3561 UACUGAUU U UGGCUCUC 615 GAGAGCCA CUGAUGAG GCCGUUAGGC CGAA AAUCAGUA 4408 3562 ACUGAUUU U GGCUCUCA 616 UGAGAGCC CUGAUGAG GCCGUUAGGC CGAA AAAUCAGU 4409 3567 UUUUGGCU C UCAUUUCA 617 UGAAAUGA CUGAUGAG GCCGUUAGGC CGAA AGCCAAAA 4410 3569 UUGGCUCU C AUUUCACU 618 AGUGAAAU CUGAUGAG GCCGUUAGGC CGAA AGAGCCAA 4411 3572 GCUCUCAU U UCACUCUU 619 AAGAGUGA CUGAUGAG GCCGUUAGGC CGAA AUGAGAGC 4412 3573 CUCUCAUU U CACUCUUC 620 GAAGAGUG CUGAUGAG GCCGUUAGGC CGAA AAUGAGAG 4413 3574 UCUCAUUU C ACUCUUCA 621 UGAAGAGU CUGAUGAG GCCGUUAGGC CGAA AAAUGAGA 4414 3578 AUUUCACU C UUCAGUGU 622 ACACUGAA CUGAUGAG GCCGUUAGGC CGAA AGUGAAAU 4415 3580 UUCACUCU u CAGUGUUC 623 GAACACUG CUGAUGAG GCCGUUAGGC CGAA AGAGUGAA 4416 3581 UCACUCUU c AGUGUUCC 624 GGAACACU CUGAUGAG GCCGUUAGGC CGAA AAGAGUGA 4417 3587 UUCAGUGU u CCUGUUAU 625 AUAACAGG CUGAUGAG GCCGUUAGGC CGAA ACACUGAA 4418 3588 UCAGUGUU c CUGUUAUU 626 AAUAACAG CUGAUGAG GCCGUUAGGC CGAA AACACUGA 4419 3593 GUUCCUGU u AUUUAUGA 627 UCAUAAAU CUGAUGAG GCCGUUAGGC CGAA ACAGGAAC 4420 3594 UUCCUGUU A UUUAUGAA 628 UUCAUAAA CUGAUGAG GCCGUUAGGC CGAA AACAGGAA 4421 3596 CCUGUUAU U UAUGAACG 629 CGUUCAUA CUGAUGAG GCCGUUAGGC CGAA AUAACAGG 4422 3597 CUGUUAUU U AUGAACGG 630 CCGUUCAU CUGAUGAG GCCGUUAGGC CGAA AAUAACAG 4423 3598 UGUUAUUU A UGAACGGC 631 GCCGUUCA CUGAUGAG GCCGUUAGGC CGAA AAAUAACA 4424 3609 AACGGCAU C AGGCACAG 632 CUGUGCCU CUGAUGAG GCCGUUAGGC CGAA AUGCCGUU 4425 3620 GCACAGAU A GAUCAUUA 633 UAAUGAUC CUGAUGAG GCCGUUAGGC CGAA AUCUGUGC 4426 3624 AGAUAGAU C AUUAUCUA 634 UAGAUAAU CUGAUGAG GCCGUUAGGC CGAA AUCUAUCU 4427 3627 UAGAUCAU U AUCUAGGA 635 UCCUAGAU CUGAUGAG GCCGUUAGGC CGAA AUGAUCUA 4428 3628 AGAUCAUU A UCUAGGAC 636 GUCCUAGA CUGAUGAG GCCGUUAGGC CGAA AAUGAUCU 4429 3630 AUCAUUAU C UAGGACUU 637 AAGUCCUA CUGAUGAG GCCGUUAGGC CGAA AUAAUGAU 4430 3632 CAUUAUCU A GGACUUGC 638 GCAAGUCC CUGAUGAG GCCGUUAGGC CGAA AGAUAAUG 4431 3638 CUAGGACU U GCAAAUAA 639 UUAUUUGC CUGAUGAG GCCGUUAGGC CGAA AGUCCUAG 4432 3645 UUGCAAAU A AGAAUGUU 640 AACAUUCU CUGAUGAG GCCGUUAGGC CGAA AUUUGCAA 4433 3653 AAGAAUGU U AAAGAUGC 641 GCAUCUUU CUGAUGAG GCCGUUAGGC CGAA ACAUUCUU 4434 3654 AGAAUGUU A AAGAUGCU 642 AGCAUCUU CUGAUGAG GCCGUUAGGC CGAA AACAUUCU 4435 3663 AAGAUGCU A UGGCUAAA 643 UUUAGCCA CUGAUGAG GCCGUUAGGC CGAA AGCAUCUU 4436 3669 CUAUGGCU A AAAUCCAA 644 UUGGAUUU CUGAUGAG GCCGUUAGGC CGAA AGCCAUAG 4437 3674 GCUAAAAU C CAAGCAAA 645 UUUGCUUG CUGAUGAG GCCGUUAGGC CGAA AUUUUAGC 4438 3686 GCAAAAAU C CCUGGAUU 646 AAUCCAGG CUGAUGAG GCCGUUAGGC CGAA AUUUUUGC 4439 3694 CCCUGGAU U GAAGCGCA 647 UGCGCUUC CUGAUGAG GCCGUUAGGC CGAA AUCCAGGG 4440 3727 CCCAAAAU A AUUAGUAG 648 CUACUAAU CUGAUGAG GCCGUUAGGC CGAA AUUUUGGG 4441 3730 AAAAUAAU U AGUAGGAG 649 CUCCUACU CUGAUGAG GCCGUUAGGC CGAA AUUAUUUU 4442 3731 AAAUAAUU A GUAGGAGU 650 ACUCCUAC CUGAUGAG GCCGUUAGGC CGAA AAUUAUUU 4443 3734 UAAUUAGU A GGAGUUCA 651 UGAACUCC CUGAUGAG GCCGUUAGGC CGAA ACUAAUUA 4444 3740 GUAGGAGU U CAUCUUUA 652 UAAAGAUG CUGAUGAG GCCGUUAGGC CGAA ACUCCUAC 4445 3741 UAGGAGUU C AUCUUUAA 653 UUAAAGAU CUGAUGAG GCCGUUAGGC CGAA AACUCCUA 4446 3744 GAGUUCAU C UUUAAAGG 654 CCUUUAAA CUGAUGAG GCCGUUAGGC CGAA AUGAACUC 4447 3746 GUUCAUCU U UAAAGGGG 655 CCCCUUUA CUGAUGAG GCCGUUAGGC CGAA AGAUGAAC 4448 3747 UUCAUCUU U AAAGGGGA 656 UCCCCUUU CUGAUGAG GCCGUUAGGC CGAA AAGAUGAA 4449 3748 UCAUCUUU A AAGGGGAU 657 AUCCCCUU CUGAUGAG GCCGUUAGGC CGAA AAAGAUGA 4450 3757 AAGGGGAU A UUCAUUUG 658 CAAAUGAA CUGAUGAG GCCGUUAGGC CGAA AUCCCCUU 4451 3759 GGGGAUAU U CAUUUGAU 659 AUCAAAUG CUGAUGAG GCCGUUAGGC CGAA AUAUCCCC 4452 3760 GGGAUAUU C AUUUGAUU 660 AAUCAAAU CUGAUGAG GCCGUUAGGC CGAA AAUAUCCC 4453 3763 AUAUUCAU U UGAUUAUA 661 UAUAAUCA CUGAUGAG GCCGUUAGGC CGAA AUGAAUAU 4454 3764 UAUUCAUU U GAUUAUAC 662 GUAUAAUC CUGAUGAG GCCGUUAGGC CGAA AAUGAAUA 4455 3768 CAUUUGAU U AUACGGGG 663 CCCCGUAU CUGAUGAG GCCGUUAGGC CGAA AUCAAAUG 4456 3769 AUUUGAUU A UACGGGGG 664 CCCCCGUA CUGAUGAG GCCGUUAGGC CGAA AAUCAAAU 4457 3771 UUGAUUAU A CGGGGGAG 665 CUCCCCCG CUGAUGAG GCCGUUAGGC CGAA AUAAUCAA 4458 3783 GGGAGGGU C AGGGAAGA 666 UCUUCCCU CUGAUGAG GCCGUUAGGC CGAA ACCCUCCC 4459 3800 ACGAACCU U GACGUUGC 667 GCAACGUC CUGAUGAG GCCGUUAGGC CGAA AGGUUCGU 4460 3806 CUUGACGU u GCAGUGCA 668 UGCACUGC CUGAUGAG GCCGUUAGGC CGAA ACGUCAAG 4461 3817 AGUGCAGU u UCACAGAU 669 AUCUGUGA CUGAUGAG GCCGUUAGGC CGAA ACUGCACU 4462 3818 GUGCAGUU u CACAGAUC 670 GAUCUGUG CUGAUGAG GCCGUUAGGC CGAA AACUGCAC 4463 3819 UGCAGUUU C ACAGAUCG 671 CGAUCUGU CUGAUGAG GCCGUUAGGC CGAA AAACUGCA 4464 3826 UCACAGAU C GUUGUUAG 672 CUAACAAC CUGAUGAG GCCGUUAGGC CGAA AUCUGUGA 4465 3829 CAGAUCGU u GUUAGAUC 673 GAUCUAAC CUGAUGAG GCCGUUAGGC CGAA ACGAUCUG 4466 3832 AUCGUUGU u AGAUCUUU 674 AAAGAUCU CUGAUGAG GCCGUUAGGC CGAA ACAACGAU 4467 3833 UCGUUGUU A GAUCUUUA 675 UAAAGAUC CUGAUGAG GCCGUUAGGC CGAA AACAACGA 4468 3837 UGUUAGAU C UUUAUUUU 676 AAAAUAAA CUGAUGAG GCCGUUAGGC CGAA AUCUAACA 4469 3839 UUAGAUCU U UAUUUUUA 677 UAAAAAUA CUGAUGAG GCCGUUAGGC CGAA AGAUCUAA 4470 3840 UAGAUCUU u AUUUUUAG 678 CUAAAAAU CUGAUGAG GCCGUUAGGC CGAA AAGAUCUA 4471 3841 AGAUCUUU A UUUUUAGC 679 GCUAAAAA CUGAUGAG GCCGUUAGGC CGAA AAAGAUCU 4472 3843 AUCUUUAU U UUUAGCCA 680 UGGCUAAA CUGAUGAG GCCGUUAGGC CGAA AUAAAGAU 4473 3844 UCUUUAUU U UUAGCCAU 681 AUGGCUAA CUGAUGAG GCCGUUAGGC CGAA AAUAAAGA 4474 3845 CUUUAUUU U UAGCCAUG 682 CAUGGCUA CUGAUGAG GCCGUUAGGC CGAA AAAUAAAG 4475 3846 UUUAUUUU U AGCCAUGC 683 GCAUGGCU CUGAUGAG GCCGUUAGGC CGAA AAAAUAAA 4476 3847 UUAUUUUU A GCCAUGCA 684 UGCAUGGC CUGAUGAG GCCGUUAGGC CGAA AAAAAUAA 4477 3860 UGCAGUGU U GUGAGGAA 685 UUCCUCAC CUGAUGAG GCCGUUAGGC CGAA ACAGUGCA 4478 3873 GGAAAAAU U ACCUGUCU 686 AGACAGGU CUGAUGAG GCCGUUAGGC CGAA AUUUUUCC 4479 3874 GAAAAAUU A CCUGUCUU 687 AAGACAGG CUGAUGAG GCCGUUAGGC CGAA AAUUUUUC 4480 3880 UUACCUGU C UUGACUGC 688 GCAGUCAA CUGAUGAG GCCGUUAGGC CGAA ACAGGUAA 4481 3882 ACCUGUCU U GACUGCCA 689 UGGCAGUC CUGAUGAG GCCGUUAGGC CGAA AGACAGGU 4482 3896 CCAUGUGU U CAUCAUCU 690 AGAUGAUG CUGAUGAG GCCGUUAGGC CGAA ACACAUGG 4483 3897 CAUGUGUU C AUCAUCUU 691 AAGAUGAU CUGAUGAG GCCGUUAGGC CGAA AACACAUG 4484 3900 GUGUUCAU C AUCUUAAG 692 CUUAAGAU CUGAUGAG GCCGUUAGGC CGAA AUGAACAC 4485 3903 UUCAUCAU C UUAAGUAU 693 AUACUUAA CUGAUGAG GCCGUUAGGC CGAA AUGAUGAA 4486 3905 CAUCAUCU U AAGUAUUG 694 CAAUACUU CUGAUGAG GCCGUUAGGC CGAA AGAUGAUG 4487 3906 AUCAUCUU A AGUAUUGU 695 AGAAUACU CUGAUGAG GCCGUUAGGC CGAA AAGAUGAU 4488 3910 UCUUAAGU A UUGUAAGC 696 GCUUACAA CUGAUGAG GCCGUUAGGC CGAA ACUUAAGA 4489 3912 UUAAGUAU U GUAAGCUG 697 CAGCUUAC CUGAUGAG GCCGUUAGGC CGAA AUACUUAA 4490 3915 AGUAUUGU A AGCUGCUA 698 UAGCAGCU CUGAUGAG GCCGUUAGGC CGAA AGAAUACU 4491 3923 AAGCUGCU A UGUAUGGA 699 UCCAUACA CUGAUGAG GCCGUUAGGC CGAA AGCAGCUU 4492 3927 UGCUAUGU A UGGAUUUA 700 UAAAUCCA CUGAUGAG GCCGUUAGGC CGAA ACAUAGCA 4493 3933 GUAUGGAU U UAAACCGU 701 ACGGUUUA CUGAUGAG GCCGUUAGGC CGAA AUCCAUAC 4494 3934 UAUGGAUU U AAACCGUA 702 UACGGUUU CUGAUGAG GCCGUUAGGC CGAA AAUCCAUA 4495 3935 AUGGAUUU A AACCGUAA 703 UUACGGUU CUGAUGAG GCCGUUAGGC CGAA AAAUCCAU 4496 3942 UAAACCGU A AUCAUAUC 704 GAUAUGAU CUGAUGAG GCCGUUAGGC CGAA ACGGUUUA 4497 3945 ACCGUAAU C AUAUCUUU 705 AAAGAUAU CUGAUGAG GCCGUUAGGC CGAA AUUACGGU 4498 3948 GUAAUCAU A UCUUUUUC 706 GAAAAAGA CUGAUGAG GCCGUUAGGC CGAA AUGAUUAC 4499 3950 AAUCAUAU C UUUUUCCU 707 AGGAAAAA CUGAUGAG GCCGUUAGGC CGAA AUAUGAUU 4500 3952 UCAUAUCU U UUUCCUAU 708 AUAGGAAA CUGAUGAG GCCGUUAGGC CGAA AGAUAUGA 4501 3953 CAUAUCUU u UUCCUAUC 709 GAUAGGAA CUGAUGAG GCCGUUAGGC CGAA AAGAUAUG 4502 3954 AUAUCUUU u UCCUAUCU 710 AGAUAGGA CUGAUGAG GCCGUUAGGC CGAA AAAGAUAU 4503 3955 UAUCUUUU u CCUAUCUG 711 CAGAUAGG CUGAUGAG GCCGUUAGGC CGAA AAAAGAUA 4504 3956 AUCUUUUU c CUAUCUGA 712 UCAGAUAG CUGAUGAG GCCGUUAGGC CGAA AAAAAGAU 4505 3959 UUUUUCCU A UCUGAGGC 713 GCCUCAGA CUGAUGAG GCCGUUAGGC CGAA AGGAAAAA 4506 3961 UUUCCUAU C UGAGGCAC 714 GUGCCUCA CUGAUGAG GCCGUUAGGC CGAA AUAGGAAA 4507 3979 GGUGGAAU A AAAAACCU 715 AGGUUUUU CUGAUGAG GCCGUUAGGC CGAA AUUCCACC 4508 3990 AAACCUGU A UAUUUUAC 716 GUAAAAUA CUGAUGAG GCCGUUAGGC CGAA ACAGGUUU 4509 3992 ACCUGUAU A UUUUACUU 717 AAGUAAAA CUGAUGAG GCCGUUAGGC CGAA AUACAGGU 4510 3994 CUGUAUAU U UUACUUUG 718 CAAAGUAA CUGAUGAG GCCGUUAGGC CGAA AUAUACAG 4511 3995 UGUAUAUU U UACUUUGU 719 ACAAAGUA CUGAUGAG GCCGUUAGGC CGAA AAUAUACA 4512 3996 GUAUAUUU U ACUUUGUU 720 AACAAAGU CUGAUGAG GCCGUUAGGC CGAA AAAUAUAC 4513 3997 UAUAUUUU A CUUUGUUG 721 CAACAAAG CUGAUGAG GCCGUUAGGC CGAA AAAAUAUA 4514 4000 AUUUUACU U UGUUGCAG 722 CUGCAACA CUGAUGAG GCCGUUAGGC CGAA AGUAAAAU 4515 4001 UUUUACUU U GUUGCAGA 723 UCUGCAAC CUGAUGAG GCCGUUAGGC CGAA AAGUAAAA 4516 4004 UACUUUGU U GCAGAUAG 724 CUAUCUGC CUGAUGAG GCCGUUAGGC CGAA ACAAAGUA 4517 4011 UUGCAGAU A GUCUUGCC 725 GGCAAGAC CUGAUGAG GCCGUUAGGC CGAA AUCUGCAA 4518 4014 CAGAUAGU C UUGCCGCA 726 UGCGGCAA CUGAUGAG GCCGUUAGGC CGAA ACUAUCUG 4519 4016 GAUAGUCU U GCCGCAUC 727 GAUGCGGC CUGAUGAG GCCGUUAGGC CGAA AGACUAUC 4520 4024 UGCCGCAU C UUGGCAAG 728 CUUGCCAA CUGAUGAG GCCGUUAGGC CGAA AUGCGGCA 4521 4026 CCGCAUCU U GGCAAGUU 729 AACUUGCC CUGAUGAG GCCGUUAGGC CGAA AGAUGCGG 4522 4034 UGGCAAGU U GCAGAGAU 730 AUCUCUGC CUGAUGAG GCCGUUAGGC CGAA ACUUGCCA 4523 Input Sequence = AB020693. Cut Site = UH/ . Stem Length = 8 . Core Sequence = CUGAUGAG GCCGUUAGGC CGAA AB020693 (Homo sapiens mRNA for KIAA0886 protein (Nogo-A) ; 4053 bp) Underlined region can be any X sequence or linker, as previously described herein. Table IV: Human NOGO Inozyme and Substrate Sequence Pos Substrate Seq ID Inozyme Seq ID 15 AGUAGGUC C CUCGGCUC 731 GAGCCGAG CUGAUGAG GCCGUUAGGC CGAA IACCUACU 4524 16 GUAGGUCC C UCGGCUCA 732 UGAGCCGA CUGAUGAG GCCGUUAGGC CGAA IGACCUAC 4525 17 UAGGUCCC U CGGCUCAG 733 CUGAGCCG CUGAUGAG GCCGUUAGGC CGAA IGGACCUA 4526 22 CCCUCGGC U CAGUCGGC 734 GCCGACUG CUGAUGAG GCCGUUAGGC CGAA ICCGAGGG 4527 24 CUCGGCUC A GUCGGCCC 735 GGGCCGAC CUGAUGAG GCCGUUAGGC CGAA IAGCCGAG 4528 31 CAGUCGGC C CAGCCCCU 736 AGGGGCUG CUGAUGAG GCCGUUAGGC CGAA ICCGACUG 4529 32 AGUCGGCC C AGCCCCUC 737 GAGGGGCU CUGAUGAG GCCGUUAGGC CGAA IGCCGACU 4530 33 GUCGGCCC A GCCCCUCU 738 AGAGGGGC CUGAUGAG GCCGUUAGGC CGAA IGGCCGAC 4531 36 GGCCCAGC C CCUCUCAG 739 CUGAGAGG CUGAUGAG GCCGUUAGGC CGAA ICUGGGCC 4532 37 GCCCAGCC C CUCUCAGU 740 ACUGAGAG CUGAUGAG GCCGUUAGGC CGAA IGCUGGGC 4533 38 CCCAGCCC C UCUCAGUC 741 GACUGAGA CUGAUGAG GCCGUUAGGC CGAA IGGCUGGG 4534 39 CCAGCCCC u CUCAGUCC 742 GGACUGAG CUGAUGAG GCCGUUAGGC CGAA IGGGCUGG 4535 41 AGCCCCUC u CAGUCCUC 743 GAGGACUG CUGAUGAG GCCGUUAGGC CGAA IAGGGGCU 4536 43 CCCCUCUC A GUCCUCCC 744 GGGAGGAC CUGAUGAG GCCGUUAGGC CGAA IAGAGGGG 4537 47 UCUCAGUC C UCCCCAAC 745 GUUGGGGA CUGAUGAG GCCGUUAGGC CGAA IACUGAGA 4538 48 CUCAGUCC u CCCCAACC 746 GGUUGGGG CUGAUGAG GCCGUUAGGC CGAA IGACUGAG 4539 50 CAGUCCUC c CCAACCCC 747 GGGGUUGG CUGAUGAG GCCGUUAGGC CGAA IAGGACUG 4540 51 AGUCCUCC c CAACCCCC 748 GGGGGUUG CUGAUGAG GCCGUUAGGC CGAA IGAGGACU 4541 52 GUCCUCCC c AACCCCCA 749 UGGGGGUU CUGAUGAG GCCGUUAGGC CGAA IGGAGGAC 4542 53 UCCUCCCC A ACCCCCAC 750 GUGGGGGU CUGAUGAG GCCGUUAGGC CGAA IGGGAGGA 4543 56 UCCCCAAC C CCCACAAC 751 GUUGUGGG CUGAUGAG GCCGUUAGGC CGAA IUUGGGGA 4544 57 CCCCAACC C CCACAACC 752 GGUUGUGG CUGAUGAG GCCGUUAGGC CGAA IGUUGGGG 4545 58 CCCAACCC C CACAACCG 753 CGGUUGUG CUGAUGAG GCCGUUAGGC CGAA IGGUUGGG 4546 59 CCAACCCC c ACAACCGC 754 GCGGUUGU CUGAUGAG GCCGUUAGGC CGAA IGGGUUGG 4547 60 CAACCCCC A CAACCGCC 755 GGCGGUUG CUGAUGAG GCCGUUAGGC CGAA IGGGGUUG 4548 62 ACCCCCAC A ACCGCCCG 756 CGGGCGGU CUGAUGAG GCCGUUAGGC CGAA IUGGGGGU 4549 65 CCCACAAC C GCCCGCGG 757 CCGCGGGC CUGAUGAG GCCGUUAGGC CGAA IUUGUGGG 4550 68 ACAACCGC C CGCGGCUC 758 GAGCCGCG CUGAUGAG GCCGUUAGGC CGAA ICGGUUGU 4551 69 CAACCGCC C GCGGCUCU 759 AGAGGCGC CUGAUGAG GCCGUUAGGC CGAA IGCGGUUG 4552 75 CCCGCGGC U CUGAGACG 760 CGUCUCAG CUGAUGAG GCCGUUAGGC CGAA ICCGCGGG 4553 77 CGCGGCUC U GAGACGCG 761 CGCGUCUC CUGAUGAG GCCGUUAGGC CGAA IAGCCGCG 4554 88 GACGCGGC c CCGGCGGC 762 GCCGCCGG CUGAUGAG GCCGUUAGGC CGAA ICCGCGUC 4555 89 ACGCGGCC c CGGCGGCG 763 CGCCGCCG CUGAUGAG GCCGUUAGGC CGAA IGCCGCGU 4556 90 CGCGGCCC c GGCGGCGG 764 CCGCCGCC CUGAUGAG GCCGUUAGGC CGAA IGGCCGCG 4557 103 GCGGCGGC A GCAGCUGC 765 GCAGCUGC CUGAUGAG GCCGUUAGGC CGAA ICCGCCGC 4558 106 GCGGCAGC A GCUGCAGC 766 GCUGCAGC CUGAUGAG GCCGUUAGGC CGAA ICUGCCGC 4559 109 GCAGCAGC u GCAGCAUC 767 GAUGCUGC CUGAUGAG GCCGUUAGGC CGAA ICUGCUGC 4560 112 GCAGCUGC A GCAUCAUC 768 GAUGAUGC CUGAUGAG GCCGUUAGGC CGAA ICAGCUGC 4561 115 GCUGCAGC A UCAUCUCC 769 GGAGAUGA CUGAUGAG GCCGUUAGGC CGAA ICUGCAGC 4562 118 GCAGCAUC A UCUCCACC 770 GGUGGAGA CUGAUGAG GCCGUUAGGC CGAA IAUGCUGC 4563 121 GCAUCAUC U CCACCCUC 771 GAGGGUGG CUGAUGAG GCCGUUAGGC CGAA IAUGAUGC 4564 123 AUCAUCUC C ACCCUCCA 772 UGGAGGGU CUGAUGAG GCCGUUAGGC CGAA IAGAUGAU 4565 124 UCAUCUCC A CCCUCCAG 773 CUGGAGGG CUGAUGAG GCCGUUAGGC CGAA IGAGAUGA 4566 126 AUCUCCAC C CUCCAGCC 774 GGCUGGAG CUGAUGAG GCCGUUAGGC CGAA IUGGAGAU 4567 127 UCUCCACC C UCCAGCCA 775 UGGCUGGA CUGAUGAG GCCGUUAGGC CGAA IGUGGAGA 4568 128 CUCCACCC U CCAGCCAU 776 AUGGCUGG CUGAUGAG GCCGUUAGGC CGAA IGGUGGAG 4569 130 CCACCCUC C AGCCAUGG 777 CCAUGGCU CUGAUGAG GCCGUUAGGC CGAA IAGGGUGG 4570 131 CACCCUCC A GCCAUGGA 778 UCCAUGGC CUGAUGAG GCCGUUAGGC CGAA IGAGGGUG 4571 134 CCUCCAGC C AUGGAAGA 779 UCUUCCAU CUGAUGAG GCCGUUAGGC CGAA ICUGGAGG 4572 135 CUCCAGCC A UGGAAGAC 780 GUCUUCCA CUGAUGAG GCCGUUAGGC CGAA IGCUGGAG 4573 144 UGGAAGAC C UGGACCAG 781 CUGGUCCA CUGAUGAG GCCGUUAGGC CGAA IUCUUCCA 4574 145 GGAAGACC U GGACCAGU 782 ACUGGUCC CUGAUGAG GCCGUUAGGC CGAA IGUCUUCC 4575 150 ACCUGGAC C AGUCUCCU 783 AGGAGACU CUGAUGAG GCCGUUAGGC CGAA IUCCAGGU 4576 151 CCUGGACC A GUCUCCUC 784 GAGGAGAC CUGAUGAG GCCGUUAGGC CGAA IGUCCAGG 4577 155 GACCAGUC U CCUCUGGU 785 ACCAGAGG CUGAUGAG GCCGUUAGGC CGAA IACUGGUC 4578 157 CCAGUCUC C UCUGGUCU 786 AGACCAGA CUGAUGAG GCCGUUAGGC CGAA IAGACUGG 4579 158 CAGUCUCC U CUGGUCUC 787 GAGACCAG CUGAUGAG GCCGUUAGGC CGAA IGAGACUG 4580 160 GUCUCCUC U GGUCUCGU 788 ACGAGACC CUGAUGAG GCCGUUAGGC CGAA IAGGAGAC 4581 165 CUCUGGUC U CGUCCUCG 789 CGAGGACG CUGAUGAG GCCGUUAGGC CGAA IACCAGAG 4582 170 GUCUCGUC c UCGGACAG 790 CUGUCCGA CUGAUGAG GCCGUUAGGC CGAA IACGAGAC 4583 171 UCUCGUCC u CGGACAGC 791 GCUGUCCG CUGAUGAG GCCGUUAGGC CGAA IGACGAGA 4584 177 CCUCGGAC A GCCCACCC 792 GGGUGGGC CUGAUGAG GCCGUUAGGC CGAA IUCCGAGG 4585 180 CGGACAGC C CACCCCGG 793 CCGGGGUG CUGAUGAG GCCGUUAGGC CGAA ICUGUCCG 4586 181 GGACAGCC C ACCCCGGC 794 GCCGGGGU CUGAUGAG GCCGUUAGGC CGAA IGCUGUCC 4587 182 GACAGCCC A CCCCGGCC 795 GGCCGGGG CUGAUGAG GCCGUUAGGC CGAA IGGCUGUC 4588 184 CAGCCCAC C CCGGCCGC 796 GCGGCCGG CUGAUGAG GCCGUUAGGC CGAA IUGGGCUG 4589 185 AGCCCACC C CGGCCGCA 797 UGCGGCCG CUGAUGAG GCCGUUAGGC CGAA IGUGGGCU 4590 186 GCCCACCC C GGCCGCAG 798 CUGCGGCC CUGAUGAG GCCGUUAGGC CGAA IGGUGGGC 4591 190 ACCCCGGC c GCAGCCCG 799 CGGGCUGC CUGAUGAG GCCGUUAGGC CGAA ICCGGGGU 4592 193 CCGGCCGC A GCCCGCGU 800 ACGCGGGC CUGAUGAG GCCGUUAGGC CGAA ICGGCCGG 4593 196 GCCGCAGC C CGCGUUCA 801 UGAACGCG CUGAUGAG GCCGUUAGGC CGAA ICUGCGGC 4594 197 CCGCAGCC C GCGUUCAA 802 UUGAACGC CUGAUGAG GCCGUUAGGC CGAA IGCUGCGG 4595 204 CCGCGUUC A AGUACCAG 803 CUGGUACU CUGAUGAG GCCGUUAGGC CGAA IAACGCGG 4596 210 UCAAGUAC C AGUUCGUG 804 CACGAACU CUGAUGAG GCCGUUAGGC CGAA IUACUUGA 4597 211 CAAGUACC A GUUCGUGA 805 UCACGAAC CUGAUGAG GCCGUUAGGC CGAA IGUACUUG 4598 226 GAGGGAGC C CGAGGACG 806 CGUCCUCG CUGAUGAG GCCGUUAGGC CGAA ICUCCCUC 4599 227 AGGGAGCC C GAGGACGA 807 UCGUCCUC CUGAUGAG GCCGUUAGGC CGAA IGCUCCCU 4600 279 ACGAAGAC C UGGAGGAG 808 CUCCUCCA CUGAUGAG GCCGUUAGGC CGAA IUCUUCGU 4601 280 CGAAGACC U GGAGGAGC 809 GCUCCUCC CUGAUGAG GCCGUUAGGC CGAA IGUCUUCG 4602 289 GGAGGAGC U GGAGGUGC 810 GCACCUCC CUGAUGAG GCCGUUAGGC CGAA ICUCCUCC 4603 298 GGAGGUGC u GGAGAGGA 811 UCCUCUCC CUGAUGAG GCCGUUAGGC CGAA ICACCUCC 4604 310 GAGGAAGC c CGCCGCCG 812 CGGCGGCG CUGAUGAG GCCGUUAGGC CGAA ICUUCCUC 4605 311 AGGAAGCC c GCCGCCGG 813 CCGGCGGC CUGAUGAG GCCGUUAGGC CGAA IGCUUCCU 4606 314 AAGCCCGC c GCCGGGCU 814 AGCCCGGC CUGAUGAG GCCGUUAGGC CGAA ICGGGCUU 4607 317 CCCGCCGC c GGGCUGUC 815 GACAGCCC CUGAUGAG GCCGUUAGGC CGAA ICGGCGGG 4608 322 CGCCGGGC u GUCCGCGG 816 CCGCGGAC CUGAUGAG GCCGUUAGGC CGAA ICCCGGCG 4609 326 GGGCUGUC c GCGGCCCC 817 GGGGCCGC CUGAUGAG GCCGUUAGGC CGAA IACAGCCC 4610 332 UCCGCGGC c CCAGUGCC 818 GGCACUGG CUGAUGAG GCCGUUAGGC CGAA ICCGCGGA 4611 333 CCGCGGCC c CAGUGCCC 819 GGGCACUG CUGAUGAG GCCGUUAGGC CGAA IGCCGCGG 4612 334 CGCGGCCC c AGUGCCCA 820 UGGGCACU CUGAUGAG GCCGUUAGGC CGAA IGGCCGCG 4613 335 GCGGCCCC A GUGCCCAC 821 GUGGGCAC CUGAUGAG GCCGUUAGGC CGAA IGGGCCGC 4614 340 CCCAGUGC c CACCGCCC 822 GGGCGGUG CUGAUGAG GCCGUUAGGC CGAA ICACUGGG 4615 341 CCAGUGCC c ACCGCCCC 823 GGGGCGGU CUGAUGAG GCCGUUAGGC CGAA IGCACUGG 4616 342 CAGUGCCC A CCGCCCCU 824 AGGGGCGG CUGAUGAG GCCGUUAGGC CGAA IGGCACUG 4617 344 GUGCCCAC C GCCCCUGC 825 GCAGGGGC CUGAUGAG GCCGUUAGGC CGAA IUGGGCAC 4618 347 CCCACCGC C CCUGCCGC 826 GCGGCAGG CUGAUGAG GCCGUUAGGC CGAA ICGGUGGG 4619 348 CCACCGCC C CUGCCGCC 827 GGCGGCAG CUGAUGAG GCCGUUAGGC CGAA IGCGGUGG 4620 349 CACCGCCC C UGCCGCCG 828 CGGCGGCA CUGAUGAG GCCGUUAGGC CGAA IGGCGGUG 4621 350 ACCGCCCC u GCCGCCGG 829 CCGGCGGC CUGAUGAG GCCGUUAGGC CGAA IGGGCGGU 4622 353 GCCCCUGC c GCCGGCGC 830 GCGCCGGC CUGAUGAG GCCGUUAGGC CGAA ICAGGGGC 4623 356 CCUGCCGC c GGCGCGCC 831 GGCGCGCC CUGAUGAG GCCGUUAGGC CGAA ICGGCAGG 4624 364 CGGCGCGC c CCUGAUGG 832 CCAUCAGG CUGAUGAG GCCGUUAGGC CGAA ICGCGCCG 4625 365 GGCGCGCC c CUGAUGGA 833 UCCAUCAG CUGAUGAG GCCGUUAGGC CGAA IGCGCGCC 4626 366 GCGCGCCC c UGAUGGAC 834 GUCCAUCA CUGAUGAG GCCGUUAGGC CGAA IGGCGCGC 4627 367 CGCGCCCC u GAUGGACU 835 AGUCCAUC CUGAUGAG GCCGUUAGGC CGAA IGGGCGCG 4628 375 UGAUGGAC u UCGGAAAU 836 AUUUCCGA CUGAUGAG GCCGUUAGGC CGAA lUCCAUCA 4629 387 GAAAUGAC u UCGUGCCG 837 CGGCACGA CUGAUGAG GCCGUUAGGC CGAA IUCAUUUC 4630 394 CUUCGUGC c GCCGGCGC 838 GCGCCGGC CUGAUGAG GCCGUUAGGC CGAA ICACGAAG 4631 397 CGUGCCGC c GGCGCGCC 839 GGGGCGCC CUGAUGAG GCCGUUAGGC CGAA ICGGCACG 4632 403 GCCGGCGC c CCGGGGAC 840 GUCCCCGG CUGAUGAG GCCGUUAGGC CGAA ICGCCGGC 4633 404 CCGGCGCC c CGGGGACC 841 GGUCCCCG CUGAUGAG GCCGUUAGGC CGAA IGCGCCGG 4634 405 CGGCGCCC c GGGGACCC 842 GGGUCCCC CUGAUGAG GCCGUUAGGC CGAA IGGCGCCG 4635 412 CCGGGGAC c CCUGCCGG 843 CCGGCAGG CUGAUGAG GCCGUUAGGC CGAA IUCCCCGG 4636 413 CGGGGACC c CUGCCGGC 844 GCCGGCAG CUGAUGAG GCCGUUAGGC CGAA IGUCCCCG 4637 414 GGGGACCC c UGCCGGCC 845 GGCCGGCA CUGAUGAG GCCGUUAGGC CGAA IGGUCCCC 4638 ' 415 GGGACCCC u GCCGGCCG 846 CGGCCGGC CUGAUGAG GCCGUUAGGC CGAA IGGGUCCC 4639 418 ACCCCUGC c GGCCGCUC 847 GAGCGGCC CUGAUGAG GCCGUUAGGC CGAA ICAGGGGU 4640 422 CUGCCGGC c GCUCCCCC 848 GGGGGAGC CUGAUGAG GCCGUUAGGC CGAA ICCGGCAG 4641 425 CCGGCCGC u CCCCCCGU 849 ACGGGGGG CUGAUGAG GCCGUUAGGC CGAA ICGGCCGG 4642 427 GGCCGCUC c CCCCGUCG 850 CGACGGGG CUGAUGAG GCCGUUAGGC CGAA IAGCGGCC 4643 428 GCCGCUCC c CCCGUCGC 851 GCGACGGG CUGAUGAG GCCGUUAGGC CGAA IGAGCGGC 4644 429 CCGCUCCC c CCGUCGCC 852 GGCGACGG CUGAUGAG GCCGUUAGGC CGAA IGGAGCGG 4645 430 CGCUCCCC c CGUCGCCC 853 GGGCGACG CUGAUGAG GCCGUUAGGC CGAA IGGGAGCG 4646 431 GCUCCCCC C GUCGCCCC 854 GGGGCGAC CUGAUGAG GCCGUUAGGC CGAA IGGGGAGC 4647 437 CCCGUCGC C CCGGAGCG 855 CGCUCCGG CUGAUGAG GCCGUUAGGC CGAA ICGACGGG 4648 438 CCGUCGCC C CGGAGCGG 856 CCGCUCCG CUGAUGAG GCCGUUAGGC CGAA IGCGACGG 4649 439 CGUCGCCC C GGAGCGGC 857 GCCGCUCC CUGAUGAG GCCGUUAGGC CGAA IGGCGACG 4650 448 GGAGCGGC A GCCGUCUU 858 AAGACGGC CUGAUGAG GCCGUUAGGC CGAA ICCGCUCC 4651 451 GCGGCAGC C GUCUUGGG 859 CCCAAGAC CUGAUGAG GCCGUUAGGC CGAA ICUGCCGC 4652 455 CAGCCGUC U UGGGACCC 860 GGGUCCCA CUGAUGAG GCCGUUAGGC CGAA IACGGCUG 4653 462 CUUGGGAC C CGAGCCCG 861 CGGGCUCG CUGAUGAG GCCGUUAGGC CGAA IUCCCAAG 4654 463 UUGGGACC C GAGCCCGG 862 CCGGGCUC CUGAUGAG GCCGUUAGGC CGAA IGUCCCAA 4655 468 ACCCGAGC C CGGUGUCG 863 CGACACCG CUGAUGAG GCCGUUAGGC CGAA ICUCGGGU 4656 469 CCCGAGCC C GGUGUCGU 864 ACGACACC CUGAUGAG GCCGUUAGGC CGAA IGCUCGGG 4657 482 UCGUCGAC C GUGCCCGC 865 GCGGGCAC CUGAUGAG GCCGUUAGGC CGAA IUCGACGA 4658 487 GACCGUGC C CGCGCCAU 866 AUGGCGCG CUGAUGAG GCCGUUAGGC CGAA ICACGGUC 4659 488 ACCGUGCC C GCGCCAUC 867 GAUGGCGC CUGAUGAG GCCGUUAGGC CGAA IGCACGGU 4660 493 GCCCGCGC c AUCCCCGC 868 GCGGGGAU CUGAUGAG GCCGUUAGGC CGAA ICGCGGGC 4661 494 CCCGCGCC A UCCCCGCU 869 AGCGGGGA CUGAUGAG GCCGUUAGGC CGAA IGCGCGGG 4662 497 GCGCCAUC C CCGCUGUC 870 GACAGCGG CUGAUGAG GCCGUUAGGC CGAA IAUGGCGC 4663 498 CGCCAUCC C CGCUGUCU 871 AGACAGCG CUGAUGAG GCCGUUAGGC CGAA IGAUGGCG 4664 499 GCCAUCCC C GCUGUCUG 872 CAGACAGC CUGAUGAG GCCGUUAGGC CGAA IGGAUGGC 4665 502 AUCCCCGC U GUCUGCUG 873 CAGCAGAC CUGAUGAG GCCGUUAGGC CGAA ICGGGGAU 4666 506 CCGCUGUC U GCUGCCGC 874 GCGGCAGC CUGAUGAG GCCGUUAGGC CGAA IACAGCGG 4667 509 CUGUCUGC U GCCGCAGU 875 ACUGCGGC CUGAUGAG GCCGUUAGGC CGAA ICAGACAG 4668 512 UCUGCUGC C GCAGUCUC 876 GAGACUGC CUGAUGAG GCCGUUAGGC CGAA ICAGCAGA 4669 515 GCUGCCGC A GUCUCGCC 877 GGCGAGAC CUGAUGAG GCCGUUAGGC CGAA ICGGCAGC 4670 519 CCGCAGUC U CGCCCUCC 878 GGAGGGCG CUGAUGAG GCCGUUAGGC CGAA IACUGCGG 4671 523 AGUCUCGC C CUCCAAGC 879 GCUUGGAG CUGAUGAG GCCGUUAGGC CGAA ICGAGACU 4672 524 GUCUCGCC C UCCAAGCU 880 AGCUUGGA CUGAUGAG GCCGUUAGGC CGAA IGCGAGAC 4673 525 UCUCGCCC U CCAAGCUC 881 GAGCUUGG CUGAUGAG GCCGUUAGGC CGAA IGGCGAGA 4674 527 UCGCCCUC c AAGCUCCC 882 GGGAGCUU CUGAUGAG GCCGUUAGGC CGAA IAGGGCGA 4675 528 CGCCCUCC A AGCUCCCU 883 AGGGAGCU CUGAUGAG GCCGUUAGGC CGAA IGAGGGCG 4676 532 CUCCAAGC U CCCUGAGG 884 CCUCAGGG CUGAUGAG GCCGUUAGGC CGAA ICUUGGAG 4677 534 CCAAGCUC C CUGAGGAC 885 GUCCUCAG CUGAUGAG GCCGUUAGGC CGAA IAGCUUGG 4678 535 CAAGCUCC C UGAGGACG 886 CGUCCUCA CUGAUGAG GCCGUUAGGC CGAA IGAGCUUG 4679 536 AAGCUCCC U GAGGACGA 887 UCGUCCUC CUGAUGAG GCCGUUAGGC CGAA IGGAGCUU 4680 550 CGACGAGC C UCCGGCCC 888 GGGCCGGA CUGAUGAG GCCGUUAGGC CGAA ICUCGUCG 4681 551 GACGAGCC U CCGGCCCG 889 CGGGCCGG CUGAUGAG GCCGUUAGGC CGAA IGCUCGUC 4682 553 CGAGCCUC c GGCCCGGC 890 GCCGGGCC CUGAUGAG GCCGUUAGGC CGAA IAGGCUCG 4683 557 CCUCCGGC c CGGCCUCC 891 GGAGGCCG CUGAUGAG GCCGUUAGGC CGAA ICCGGAGG 4684 558 CUCCGGCC c GGCCUCCC 892 GGGAGGCC CUGAUGAG GCCGUUAGGC CGAA IGCCGGAG 4685 562 GGCCCGGC c UCCCCCUC 893 GAGGGGGA CUGAUGAG GCCGUUAGGC CGAA ICCGGGCC 4686 563 GCCCGGCC u CCCCCUCC 894 GGAGGGGG CUGAUGAG GCCGUUAGGC CGAA IGCCGGGC 4687 565 CCGGCCUC c CCCUCCUC 895 GAGGAGGG CUGAUGAG GCCGUUAGGC CGAA IAGGCCGG 4688 566 CGGCCUCC c CCUCCUCC 896 GGAGGAGG CUGAUGAG GCCGUUAGGC CGAA IGAGGCCG 4689 567 GGCCUCCC c CUCCUCCC 897 GGGAGGAG CUGAUGAG GCCGUUAGGC CGAA IGGAGGCC 4690 568 GCCUCCCC c UCCUCCCC 898 GGGGAGGA CUGAUGAG GCCGUUAGGC CGAA IGGGAGGC 4691 569 CCUCCCCC u CCUCCCCC 899 GGGGGAGG CUGAUGAG GCCGUUAGGC CGAA IGGGGAGG 4692 571 ucccccuc c UCCCCCGG 900 CCGGGGGA CUGAUGAG GCCGUUAGGC CGAA IAGGGGGA 4693 572 cccccucc u CCCCCGGC 901 GCCGGGGG CUGAUGAG GCCGUUAGGC CGAA IGAGGGGG 4694 574 cccuccuc c CCCGGCCA 902 UGGCCGGG CUGAUGAG GCCGUUAGGC CGAA IAGGAGGG 4695 575 ccuccucc c CCGGCCAG 903 CUGGCCGG CUGAUGAG GCCGUUAGGC CGAA IGAGGAGG 4696 576 GUCCUCCC c CGGCCAGC 904 GCUGGCCG CUGAUGAG GCCGUUAGGC CGAA IGGAGGAG 4697 577 UCCUCCCC c GGCCAGCG 905 CGCUGGCC CUGAUGAG GCCGUUAGGC CGAA IGGGAGGA 4698 581 CCCCCGGC c AGCGUGAG 906 CUCACGCU CUGAUGAG GCCGUUAGGC CGAA ICCGGGGG 4699 582 CCCCGGCC A GCGUGAGC 907 GCUCACGC CUGAUGAG GCCGUUAGGC CGAA IGCCGGGG 4700 591 GCGUGAGC c CCCAGGCA 908 UGCCUGGG CUGAUGAG GCCGUUAGGC CGAA ICUCACGC 4701 592 CGUGAGCC c CCAGGCAG 909 CUGCCUGG CUGAUGAG GCCGUUAGGC CGAA IGCUCACG 4702 593 GUGAGCCC c CAGGCAGA 910 UCUGCCUG CUGAUGAG GCCGUUAGGC CGAA IGGCUCAC 4703 594 UGAGCCCC c AGGCAGAG 911 CUCUGCCU CUGAUGAG GCCGUUAGGC CGAA IGGGCUCA 4704 595 GAGCCCCC A GGCAGAGC 912 GCUCUGCC CUGAUGAG GCCGUUAGGC CGAA IGGGGCUC 4705 599 CCCCAGGC A GAGCCCGU 913 ACGGGCUC CUGAUGAG GCCGUUAGGC CGAA ICCUGGGG 4706 604 GGCAGAGC C CGUGUGGA 914 UCCACACG CUGAUGAG GCCGUUAGGC CGAA ICUCUGCC 4707 605 GCAGAGCC C GUGUGGAC 915 GUCCACAC CUGAUGAG GCCGUUAGGC CGAA IGCUCUGC 4708 614 GUGUGGAC C CCGCCAGC 916 GCUGGCGG CUGAUGAG GCCGUUAGGC CGAA IUCCACAC 4709 615 UGUGGACC C CGCCAGCC 917 GGCUGGCG CUGAUGAG GCCGUUAGGC CGAA IGUCCACA 4710 616 GUGGACCC C GCCAGCCC 918 GGGCUGGC CUGAUGAG GCCGUUAGGC CGAA IGGUCCAC 4711 619 GACCCCGC C AGCCCCGG 919 CCGGGGCU CUGAUGAG GCCGUUAGGC CGAA ICGGGGUC 4712 620 ACCCCGGC A GCGCCGGC 920 GCCGGGGC CUGAUGAG GCCGUUAGGC CGAA IGCGGGGU 4713 623 CCGCCAGC C CCGGCUCC 921 GGAGCCGG CUGAUGAG GCCGUUAGGC CGAA ICUGGCGG 4714 624 CGCCAGCC C CGGCUCCC 922 GGGAGCCG CUGAUGAG GCCGUUAGGC CGAA IGCUGGCG 4715 625 GCCAGCCC C GGCUCCCG 923 CGGGAGCC CUGAUGAG GCCGUUAGGC CGAA IGGCUGGC 4716 629 GGCCCGGC U CCCGCCGC 924 GCGGCGGG CUGAUGAG GCCGUUAGGC CGAA ICCGGGGC 4717 631 CCCGGCUC C CGCCGCGC 925 GCGCGGCG CUGAUGAG GCCGUUAGGC CGAA IAGCCGGG 4718 632 CCGGCUCC C GCCGCGCC 926 GGCGCGGC CUGAUGAG GCCGUUAGGC CGAA IGAGCCGG 4719 635 GCUGCCGC C GCGCCCCC 927 GGGGGCGC CUGAUGAG GCCGUUAGGC CGAA ICGGGAGC 4720 640 CGCCGCGC C CCCCUCCA 928 UGGAGGGG CUGAUGAG GCCGUUAGGC CGAA ICGCGGCG 4721 641 GCCGCGCC C CCCUCCAC 929 GUGGAGGG CUGAUGAG GCCGUUAGGC CGAA IGCGCGGC 4722 642 CCGCGCCC C CCUCCACC 930 GGUGGAGG CUGAUGAG GCCGUUAGGC CGAA IGGCGCGG 4723 643 CGCGCCCC C CUCCACCC 931 GGGUGGAG CUGAUGAG GCCGUUAGGC CGAA IGGGCGCG 4724 644 GCGCCCCC C UCCACCCC 932 GGGGUGGA CUGAUGAG GCCGUUAGGC CGAA IGGGGCGC 4725 645 CGCCCCCC u CCACCCCG 933 CGGGGUGG CUGAUGAG GCCGUUAGGC CGAA IGGGGGCG 4726 647 CCCCCCUC C ACCCCGGC 934 GCCGGGGU CUGAUGAG GCCGUUAGGC CGAA IAGGGGGG 4727 648 CCCCCUCC A CCCCGGCC 935 GGCCGGGG CUGAUGAG GCCGUUAGGC CGAA IGAGGGGG 4728 650 CCCUCCAC C CCGGCCGC 936 GCGGCCGG CUGAUGAG GCCGUUAGGC CGAA IUGGAGGG 4729 651 CCUCCACC C CGGCCGCG 937 CGCGGCCG CUGAUGAG GCCGUUAGGC CGAA IGUGGAGG 4730 652 CUCCACCC C GGCCGCGC 938 GCGCGGCC CUGAUGAG GCCGUUAGGC CGAA IGGUGGAG 4731 656 ACCCCGGC c GCGCCCAA 939 UUGGGCGC CUGAUGAG GCCGUUAGGC CGAA ICCGGGGU 4732 661 GGCCGCGC c CAAGCGCA 940 UGCGCUUG CUGAUGAG GCCGUUAGGC CGAA ICGCGGCC 4733 662 GCCGCGCC c AAGCGCAG 941 CUGCGCUU CUGAUGAG GCCGUUAGGC CGAA IGCGCGGC 4734 663 CCGCGCCC A AGCGCAGG 942 CCUGCGCU CUGAUGAG GCCGUUAGGC CGAA IGGCGCGG 4735 669 CCAAGCGC A GGGGCUCC 943 GGAGCCCC CUGAUGAG GCCGUUAGGC CGAA ICGCUUGG 4736 675 GCAGGGGC u CCUCGGGC 944 GCCCGAGG CUGAUGAG GCCGUUAGGC CGAA ICCCCUGC 4737 677 AGGGGCUG c UCGGGCUC 945 GAGCCCGA CUGAUGAG GCCGUUAGGC CGAA IAGCCCCU 4738 678 GGGGCUCC U CGGGCUCA 946 UGAGCCCG CUGAUGAG GCCGUUAGGC CGAA IGAGCCCC 4739 684 CCUCGGGC u CAGUGGAU 947 AUCCACUG CUGAUGAG GCCGUUAGGC CGAA ICCCGAGG 4740 686 UCGGGCUC A GUGGAUGA 948 UCAUCCAC CUGAUGAG GCCGUUAGGC CGAA IAGCCCGA 4741 698 GAUGAGAC C CUUUUUGC 949 GCAAAAAG CUGAUGAG GCCGUUAGGC CGAA IUCUCAUC 4742 699 AUGAGACC C UUUUUGCU 950 AGCAAAAA CUGAUGAG GCCGUUAGGC CGAA IGUCUCAU 4743 700 UGAGAGCC U UUUUGCUC 951 GAGCAAAA CUGAUGAG GCCGUUAGGC CGAA IGGUCUCA 4744 707 CUUUUUGC U CUUCCUGC 952 GCAGGAAG CUGAUGAG GCCGUUAGGC CGAA ICAAAAAG 4745 709 UUUUGCUC U UCCUGCUG 953 CAGCAGGA CUGAUGAG GCCGUUAGGC CGAA IAGCAAAA 4746 712 UGCUCUUC c UGCUGCAU 954 AUGCAGCA CUGAUGAG GCCGUUAGGC CGAA IAAGAGCA 4747 713 GCUCUUCC u GCUGCAUC 955 GAUGCAGC CUGAUGAG GCCGUUAGGC CGAA IGAAGAGC 4748 716 CUUCCUGC u GCAUCUGA 956 UCAGAUGC CUGAUGAG GCCGUUAGGC CGAA ICAGGAAG 4749 719 CCUGCUGC A UCUGAGCC 957 GGCUCAGA CUGAUGAG GCCGUUAGGC CGAA ICAGCAGG 4750 722 GCUGCAUC U GAGCCUGU 958 ACAGGCUC CUGAUGAG GCCGUUAGGC CGAA IAUGCAGC 4751 727 AUCUGAGC c UGUGAUAC 959 GUAUCACA CUGAUGAG GCCGUUAGGC CGAA ICUCAGAU 4752 728 UCUGAGCC U GUGAUACG 960 CGUAUCAC CUGAUGAG GCCGUUAGGC CGAA IGCUCAGA 4753 738 UGAUACGC u CCUCUGCA 961 UGCAGAGG CUGAUGAG GCCGUUAGGC CGAA ICGUAUCA 4754 740 AUACGCUC c UCUGCAGA 962 UCUGCAGA CUGAUGAG GCCGUUAGGC CGAA IAGCGUAU 4755 741 UACGCUCC u CUGCAGAA 963 UUCUGCAG CUGAUGAG GCCGUUAGGC CGAA IGAGCGUA 4756 743 CGCUCCUC u GCAGAAAA 964 UUUUCUGC CUGAUGAG GCCGUUAGGC CGAA IAGGAGCG 4757 746 UCCUCUGC A GAAAAUAU 965 AUAUUUUC CUGAUGAG GCCGUUAGGC CGAA ICAGAGGA 4758 759 AUAUGGAC U UGAAGGAG 966 CUCCUUCA CUGAUGAG GCCGUUAGGC CGAA IUCCAUAU 4759 769 GAAGGAGC A GCCAGGUA 967 UACCUGGC CUGAUGAG GCCGUUAGGC CGAA ICUCCUUC 4760 772 GGAGCAGC C AGGUAACA 968 UGUUACCU CUGAUGAG GCCGUUAGGC CGAA ICUGCUCC 4761 773 GAGCAGCC A GGUAACAC 969 GUGUUACC CUGAUGAG GCCGUUAGGC CGAA IGCUGCUC 4762 780 CAGGUAAC A CUAUUUCG 970 CGAAAUAG CUGAUGAG GCCGUUAGGC CGAA IUUACCUG 4763 782 GGUAACAC U AUUUCGGC 971 GCCGAAAU CUGAUGAG GCCGUUAGGC CGAA IUGUUACC 4764 791 AUUUCGGC U GGUCAAGA 972 UCUUGACC CUGAUGAG GCCGUUAGGC CGAA ICCGAAAU 4765 796 GGCUGGUC A AGAGGAUU 973 AAUCCUCU CUGAUGAG GCCGUUAGGC CGAA IACCAGCC 4766 807 AGGAUUUC c CAUCUGUC 974 GACAGAUG CUGAUGAG GCCGUUAGGC CGAA IAAAUCCU 4767 808 GGAUUUCC c AUCUGUCC 975 GGACAGAU CUGAUGAG GCCGUUAGGC CGAA IGAAAUCC 4768 809 GAUUUCCC A UCUGUCCU 976 AGGACAGA CUGAUGAG GCCGUUAGGC CGAA IGGAAAUC 4769 812 UUCCCAUC U GUCCUGCU 977 AGCAGGAC CUGAUGAG GCCGUUAGGC CGAA lAUGGGAA 4770 816 CAUCUGUC c UGCUUGAA 978 UUCAAGCA CUGAUGAG GCCGUUAGGC CGAA IACAGAUG 4771 817 AUCUGUCC U GCUUGAAA 979 UUUCAAGC CUGAUGAG GCCGUUAGGC CGAA IGACAGAU 4772 820 UGUCCUGC U UGAAACUG 980 CAGUUUCA CUGAUGAG GCCGUUAGGC CGAA ICAGGACA 4773 827 CUUGAAAC U GCUGCUUC 981 GAAGCAGC CUGAUGAG GCCGUUAGGC CGAA IUUUCAAG 4774 830 GAAACUGC U GCUUCUCU 982 AGAGAAGC CUGAUGAG GCCGUUAGGC CGAA ICAGUUUC 4775 833 ACUGCUGC U UCUCUUCC 983 GGAAGAGA CUGAUGAG GCCGUUAGGC CGAA ICAGCAGU 4776 836 GCUGCUUC U CUUCCUUC 984 GAAGGAAG CUGAUGAG GCCGUUAGGC CGAA IAAGCAGC 4777 838 UGCUUCUC U UCCUUCUC 985 GAGAAGGA CUGAUGAG GCCGUUAGGC CGAA IAGAAGCA 4778 841 UUCUCUUC C UUCUCUGU 986 ACAGAGAA CUGAUGAG GCCGUUAGGC CGAA IAAGAGAA 4779 842 ucucuucc U UCUCUGUC 987 GACAGAGA CUGAUGAG GCCGUUAGGC CGAA IGAAGAGA 4780 845 cuuccuuc u CUGUCUCC 988 GGAGACAG CUGAUGAG GCCGUUAGGC CGAA IAAGGAAG 4781 847 uccuucuc u GUCUCCUC 989 GAGGAGAC CUGAUGAG GCCGUUAGGC CGAA IAGAAGGA 4782 851 UCUCUGUC u CCUCUCUC 990 GAGAGAGG CUGAUGAG GCCGUUAGGC CGAA IACAGAGA 4783 853 UCUGUCUC c UCUCUCAG 991 CUGAGAGA CUGAUGAG GCCGUUAGGC CGAA IAGACAGA 4784 854 CUGUCUCC u CUCUCAGC 992 GCUGAGAG CUGAUGAG GCCGUUAGGC CGAA IGAGACAG 4785 856 GUCUCCUC u CUCAGCCG 993 CGGCUGAG CUGAUGAG GCCGUUAGGC CGAA IAGGAGAC 4786 858 CUCCUCUC u CAGCCGCU 994 AGCGGCUG CUGAUGAG GCCGUUAGGC CGAA IAGAGGAG 4787 860 ccucucuc A GCCGCUUC 995 GAAGCGGC CUGAUGAG GCCGUUAGGC CGAA IAGAGAGG 4788 863 CUCUCAGC C GCUUCUUU 996 AAAGAAGC CUGAUGAG GCCGUUAGGC CGAA ICUGAGAG 4789 866 UCAGCCGC u UCUUUCAA 997 UUGAAAGA CUGAUGAG GCCGUUAGGC CGAA ICGGCUGA 4790 869 GCCGCUUC u UUCAAAGA 998 UCUUUGAA CUGAUGAG GCCGUUAGGC CGAA IAAGCGGC 4791 873 CUUCUUUC A AAGAACAU 999 AUGUUCUU CUGAUGAG GCCGUUAGGC CGAA IAAAGAAG 4792 880 CAAAGAAC A UGAAUACC 1000 GGUAUUCA CUGAUGAG GCCGUUAGGC CGAA IUUCUUUG 4793 888 AUGAAUAC C UUGGUAAU 1001 AUUACCAA CUGAUGAG GCCGUUAGGC CGAA lUAUUCAU 4794 889 UGAAUACC U UGGUAAUU 1002 AAUUACCA CUGAUGAG GCCGUUAGGC CGAA IGUAUUCA 4795 902 AAUUUGUC A ACAGUAUU 1003 AAUACUGU CUGAUGAG GCCGUUAGGC CGAA IACAAAUU 4796 905 UUGUCAAC A GUAUUACC 1004 GGUAAUAC CUGAUGAG GCCGUUAGGC CGAA lUUGACAA 4797 913 AGUAUUAC C CACUGAAG 1005 CUUCAGUG CUGAUGAG GCCGUUAGGC CGAA IUAAUACU 4798 914 GUAUUACC C ACUGAAGG 1006 CCUUCAGU CUGAUGAG GCCGUUAGGC CGAA IGUAAUAC 4799 915 UAUUACCC A CUGAAGGA 1007 UCCUUCAG CUGAUGAG GCCGUUAGGC CGAA IGGUAAUA 4800 917 UUACCCAC U GAAGGAAC 1008 GUUCCUUC CUGAUGAG GCCGUUAGGC CGAA IUGGGUAA 4801 926 GAAGGAAC A CUUCAAGA 1009 UCUUGAAG CUGAUGAG GCCGUUAGGC CGAA IUUCCUUC 4802 928 AGGAACAC U UCAAGAAA 1010 UUUCUUGA CUGAUGAG GCCGUUAGGC CGAA IUGUUCCU 4803 931 AACACUUC A AGAAAAUG 1011 CAUUUUCU CUGAUGAG GCCGUUAGGC CGAA IAAGUGUU 4804 942 AAAAUGUC A GUGAAGCU 1012 AGCUUCAC CUGAUGAG GCCGUUAGGC CGAA IACAUUUU 4805 950 AGUGAAGC U UCUAAAGA 1013 UCUUUAGA CUGAUGAG GCCGUUAGGC CGAA ICUUCACU 4806 953 GAAGCUUC U AAAGAGGU 1014 ACCUCUUU CUGAUGAG GCCGUUAGGC CGAA IAAGCUUC 4807 963 AAGAGGUC U CAGAGAAG 1015 CUUCUCUG CUGAUGAG GCCGUUAGGC CGAA IACCUCUU 4808 965 GAGGUCUC A GAGAAGGC 1016 GCCUUCUC CUGAUGAG GCCGUUAGGC CGAA IAGACCUC 4809 974 GAGAAGGC A AAAACUCU 1017 AGAGUUUU CUGAUGAG GCCGUUAGGC CGAA ICCUUCUC 4810 980 GCAAAAAC U CUACUCAU 1018 AUGAGUAG CUGAUGAG GCCGUUAGGC CGAA IUUUUUGC 4811 982 AAAAACUC U ACUCAUAG 1019 CUAUGAGU CUGAUGAG GCCGUUAGGC CGAA IAGUUUUU 4812 985 AACUCUAC U CAUAGAUA 1020 UAUCUAUG CUGAUGAG GCCGUUAGGC CGAA IUAGAGUU 4813 987 CUCUACUC A UAGAUAGA 1021 UCUAUCUA CUGAUGAG GCCGUUAGGC CGAA IAGUAGAG 4814 1004 GAUUUAAC A GAGUUUUC 1022 GAAAACUC CUGAUGAG GCCGUUAGGC CGAA IUUAAAUC 4815 1013 GAGUUUUC A GAAUUAGA 1023 UCUAAUUC CUGAUGAG GCCGUUAGGC CGAA IAAAACUC 4816 1026 UAGAAUAC U CAGAAAUG 1024 CAUUUCUG CUGAUGAG GCCGUUAGGC CGAA IUAUUCUA 4817 1028 GAAUACUC A GAAAUGGG 1025 CCCAUUUC CUGAUGAG GCCGUUAGGC CGAA IAGUAUUC 4818 1040 AUGGGAUC A UCGUUCAG 1026 CUGAACGA CUGAUGAG GCCGUUAGGC CGAA IAUCCCAU 4819 1047 CAUCGUUC A GUGUCUCU 1027 AGAGACAC CUGAUGAG GCCGUUAGGC CGAA IAACGAUG 4820 1053 UCAGUGUC U CUCCAAAA 1028 UUUUGGAG CUGAUGAG GCCGUUAGGC CGAA IACACUGA 4821 1055 AGUGUCUC U CCAAAAGC 1029 GCUUUUGG CUGAUGAG GCCGUUAGGC CGAA IAGACACU 4822 1057 UGUCUCUC c AAAAGCAG 1030 CUGCUUUU CUGAUGAG GCCGUUAGGC CGAA IAGAGACA 4823 1058 GUCUCUCC A AAAGCAGA 1031 UCUGCUUU CUGAUGAG GCCGUUAGGC CGAA IGAGAGAC 4824 1064 CCAAAAGC A GAAUCUGC 1032 GCAGAUUC CUGAUGAG GCCGUUAGGC CGAA ICUUUUGG 4825 1070 GCAGAAUC U GCCGUAAU 1033 AUUACGGC CUGAUGAG GCCGUUAGGC CGAA IAUUCUGC 4826 1073 GAAUCUGC c GUAAUAGU 1034 ACUAUUAC CUGAUGAG GCCGUUAGGC CGAA ICAGAUUC 4827 1085 AUAGUAGC A AAUCCUAG 1035 CUAGGAUU CUGAUGAG GCCGUUAGGC CGAA ICUACUAU 4828 1090 AGCAAAUC C UAGGGAAG 1036 CUUCCCUA CUGAUGAG GCCGUUAGGC CGAA IAUUUGCU 4829 1091 GCAAAUCC U AGGGAAGA 1037 UCUUCCCU CUGAUGAG GCCGUUAGGC CGAA IGAUUUGC 4830 1149 GUAAUAAC A UCCUUCAU 1038 AUGAAGGA CUGAUGAG GCCGUUAGGC CGAA IUUAUUAC 4831 1152 AUAACAUC C UUCAUAAU 1039 AUUAUGAA CUGAUGAG GCCGUUAGGC CGAA lAUGUUAU 4832 1153 UAACAUCC U UCAUAAUC 1040 GAUUAUGA CUGAUGAG GCCGUUAGGC CGAA IGAUGUUA 4833 1156 CAUCCUUC A UAAUCAAC 1041 GUUGAUUA CUGAUGAG GCCGUUAGGC CGAA IAAGGAUG 4834 1162 UCAUAAUC A ACAAGAGU 1042 ACUCUUGU CUGAUGAG GCCGUUAGGC CGAA lAUUAUGA 4835 1165 UAAUCAAC A AGAGUUAC 1043 GUAACUCU CUGAUGAG GCCGUUAGGC CGAA IUUGAUUA 4836 1174 AGAGUUAC C UACAGCUC 1044 GAGCUGUA CUGAUGAG GCCGUUAGGC CGAA IUAACUCU 4837 1175 GAGUUACC U ACAGCUCU 1045 AGAGCUGU CUGAUGAG GCCGUUAGGC CGAA IGUAACUC 4838 1178 UUACCUAC A GCUCUUAC 1046 GUAAGAGC CUGAUGAG GCCGUUAGGC CGAA IUAGGUAA 4839 1181 CCUACAGC U CUUACUAA 1047 UUAGUAAG CUGAUGAG GCCGUUAGGC CGAA ICUGUAGG 4840 1183 UACAGCUC U UACUAAAU 1048 AUUUAGUA CUGAUGAG GCCGUUAGGC CGAA lAGCUGUA 4841 1187 GCUCUUAC U AAAUUGGU 1049 ACCAAUUU CUGAUGAG GCCGUUAGGC CGAA IUAAGAGC 4842 1217 GUUGUGUC U UCAGAAAA 1050 UUUUCUGA CUGAUGAG GCCGUUAGGC CGAA IACACAAC 4843 1220 GUGUCUUC A GAAAAAGC 1051 GCUUUUUC CUGAUGAG GCCGUUAGGC CGAA IAAGACAC 4844 1229 GAAAAAGC A AAAGACAG 1052 CUGUCUUU CUGAUGAG GCCGUUAGGC CGAA ICUUUUUC 4845 1236 CAAAAGAC A GUUUUAAU 1053 AUUAAAAC CUGAUGAG GCCGUUAGGC CGAA IUCUUUUG 4846 1259 AGAGUUGC A GUGGAAGC 1054 GCUUCCAC CUGAUGAG GCCGUUAGGC CGAA ICAACUCU 4847 1268 GUGGAAGC U CCUAUGAG 1055 CUCAUAGG CUGAUGAG GCCGUUAGGC CGAA ICUUCCAC 4848 1270 GGAAGCUC C UAUGAGGG 1056 CCCUCAUA CUGAUGAG GCCGUUAGGC CGAA IAGCUUCC 4849 1271 GAAGCUCC U AUGAGGGA 1057 UCCCUCAU CUGAUGAG GCCGUUAGGC CGAA IGAGCUUC 4850 1289 GAAUAUGC A GACUUCAA 1058 UUGAAGUC CUGAUGAG GCCGUUAGGC CGAA ICAUAUUC 4851 1293 AUGCAGAC U UCAAACCA 1059 UGGUUUGA CUGAUGAG GCCGUUAGGC CGAA IUCUGCAU 4852 1296 CAGACUUC A AACCAUUU 1060 AAAUGGUU CUGAUGAG GCCGUUAGGC CGAA IAAGUCUG 4853 1300 CUUCAAAC C AUUUGAGC 1061 GCUCAAAU CUGAUGAG GCCGUUAGGC CGAA IUUUGAAG 4854 1301 UUCAAACC A UUUGAGCG 1062 CGCUCAAA CUGAUGAG GCCGUUAGGC CGAA IGUUUGAA 4855 1355 AUGUUGGC U GCUGGAGG 1063 CCUCCAGC CUGAUGAG GCCGUUAGGC CGAA ICCAACAU 4856 1358 UUGGCUGC U GGAGGUAA 1064 UUACCUCC CUGAUGAG GCCGUUAGGC CGAA ICAGCCAA 4857 1377 UCGAGAGC A ACUUGGAA 1065 UUCCAAGU CUGAUGAG GCCGUUAGGC CGAA ICUCUCGA 4858 1380 AGAGCAAC U UGGAAAGU 1066 ACUUUCCA CUGAUGAG GCCGUUAGGC CGAA IUUGCUCU 4859 1412 UGUUUUGC A GAUAGCCU 1067 AGGCUAUC CUGAUGAG GCCGUUAGGC CGAA ICAAAACA 4860 1419 CAGAUAGC C UUGAGCAA 1068 UUGCUCAA CUGAUGAG GCCGUUAGGC CGAA ICUAUCUG 4861 1420 AGAUAGCC U UGAGCAAA 1069 UUUGCUCA CUGAUGAG GCCGUUAGGC CGAA IGCUAUCU 4862 1426 CCUUGAGC A AACUAAUC 1070 GAUUAGUU CUGAUGAG GCCGUUAGGC CGAA ICUCAAGG 4863 1430 GAGCAAAC U AAUCACGA 1071 UCGUGAUU CUGAUGAG GCCGUUAGGC CGAA IUUUGCUC 4864 1435 AACUAAUC A CGAAAAAG 1072 CUUUUUCG CUGAUGAG GCCGUUAGGC CGAA IAUUAGUU 4865 1469 GAUGAUAC U UCUUUCCC 1073 GGGAAAGA CUGAUGAG GCCGUUAGGC CGAA IUAUCAUC 4866 1472 GAUACUUC U UUCCCCAG 1074 CUGGGGAA CUGAUGAG GCCGUUAGGC CGAA IAAGUAUC 4867 1476 CUUCUUUC c CCAGUACG 1075 CGUACUGG CUGAUGAG GCCGUUAGGC CGAA IAAAGAAG 4868 1477 UUCUUUCC c CAGUACGC 1076 GCGUACUG CUGAUGAG GCCGUUAGGC CGAA IGAAAGAA 4869 1478 UCUUUCCC c AGUACGCC 1077 GGCGUACU CUGAUGAG GCCGUUAGGC CGAA IGGAAAGA 4870 1479 CUUUCCCC A GUACGCCA 1078 UGGCGUAC CUGAUGAG GCCGUUAGGC CGAA IGGGAAAG 4871 1486 CAGUACGC C AGAAGGUA 1079 UACCUUCU CUGAUGAG GCCGUUAGGC CGAA ICGUACUG 4872 1487 AGUACGCC A GAAGGUAU 1080 AUACCUUC CUGAUGAG GCCGUUAGGC CGAA IGCGUACU 4873 1508 GAUCGUUC A GGAGCAUA 1081 UAUGCUCC CUGAUGAG GCCGUUAGGC CGAA IAACGAUC 4874 1514 UCAGGAGC A UAUAUCAC 1082 GUGAUAUA CUGAUGAG GCCGUUAGGC CGAA ICUCCUGA 4875 1521 CAUAUAUC A CAUGUGCU 1083 AGCAGAUG CUGAUGAG GCCGUUAGGC CGAA IAUAUAUG 4876 1523 UAUAUCAC A UGUGCUCC 1084 GGAGCACA CUGAUGAG GCCGUUAGGC CGAA IUGAUAUA 4877 1529 ACAUGUGC U CCCUUUAA 1085 UUAAAGGG CUGAUGAG GCCGUUAGGC CGAA ICACAUGU 4878 1531 AUGUGCUC C CUUUAACC 1086 GGUUAAAG CUGAUGAG GCCGUUAGGC CGAA IAGCACAU 4879 1532 UGUGCUCC C UUUAACCC 1087 GGGUUAAA CUGAUGAG GCCGUUAGGC CGAA IGAGCACA 4880 1533 GUGCUCCC U UUAACCCA 1088 UGGGUUAA CUGAUGAG GCCGUUAGGC CGAA IGGAGCAC 4881 1539 CCUUUAAC C CAGCAGCA 1089 UGCUGCUG CUGAUGAG GCCGUUAGGC CGAA IUUAAAGG 4882 1540 CUUUAACC C AGCAGCAA 1090 UUGCUGCU CUGAUGAG GCCGUUAGGC CGAA IGUUAAAG 4883 1541 UUUAACCC A GCAGCAAC 1091 GUUGCUGC CUGAUGAG GCCGUUAGGC CGAA IGGUUAAA 4884 1544 AACCCAGC A GCAACUGA 1092 UCAGUUGC CUGAUGAG GCCGUUAGGC CGAA ICUGGGUU 4885 1547 CCAGCAGC A ACUGAGAG 1093 CUCUCAGU CUGAUGAG GCCGUUAGGC CGAA ICUGCUGG 4886 1550 GCAGCAAC U GAGAGCAU 1094 AUGCUCUC CUGAUGAG GCCGUUAGGC CGAA IUUGCUGC 4887 1557 CUGAGAGC A UUGCAACA 1095 UGUUGCAA CUGAUGAG GCCGUUAGGC CGAA ICUCUCAG 4888 1562 AGCAUUGC A ACAAACAU 1096 AUGUUUGU CUGAUGAG GCCGUUAGGC CGAA ICAAUGCU 4889 1565 AUUGCAAC A AACAUUUU 1097 AAAAUGUU CUGAUGAG GCCGUUAGGC CGAA IUUGCAAU 4890 1569 CAACAAAC A UUUUUCCU 1098 AGGAAAAA CUGAUGAG GCCGUUAGGC CGAA IUUUGUUG 4891 1576 CAUUUUUC C UUUGUUAG 1099 CUAACAAA CUGAUGAG GCCGUUAGGC CGAA IAAAAAUG 4892 1577 AUUUUUCC U UUGUUAGG 1100 CCUAACAA CUGAUGAG GCCGUUAGGC CGAA IGAAAAAU 4893 1591 AGGAGAUC C UACUUCAG 1101 CUGAAGUA CUGAUGAG GCCGUUAGGC CGAA IAUCUCCU 4894 1592 GGAGAUCC U ACUUCAGA 1102 UCUGAAGU CUGAUGAG GCCGUUAGGC CGAA IGAUCUCC 4895 1595 GAUCCUAC U UCAGAAAA 1103 UUUUCUGA CUGAUGAG GCCGUUAGGC CGAA IUAGGAUC 4896 1598 CCUACUUC A GAAAAUAA 1104 UUAUUUUC CUGAUGAG GCCGUUAGGC CGAA IAAGUAGG 4897 1610 AAUAAGAC C GAUGAAAA 1105 UUUUCAUC CUGAUGAG GCCGUUAGGC CGAA IUCUUAUU 4898 1640 AAGAAGGC C CAAAUAGU 1106 ACUAUUUG CUGAUGAG GCCGUUAGGC CGAA ICCUUCUU 4899 1641 AGAAGGCC C AAAUAGUA 1107 UACUAUUU CUGAUGAG GCCGUUAGGC CGAA IGCCUUCU 4900 1642 GAAGGCCC A AAUAGUAA 1108 UUACUAUU CUGAUGAG GCCGUUAGGC CGAA IGGCCUUC 4901 1652 AUAGUAAC A GAGAAGAA 1109 UUCUUCUC CUGAUGAG GCCGUUAGGC CGAA IUUACUAU 4902 1664 AAGAAUAC U AGCACCAA 1110 UUGGUGCU CUGAUGAG GCCGUUAGGC CGAA IUAUUCUU 4903 1668 AUACUAGC A CCAAAACA 1111 UGUUUUGG CUGAUGAG GCCGUUAGGC CGAA ICUAGUAU 4904 1670 ACUAGCAC C AAAACAUC 1112 GAUGUUUU CUGAUGAG GCCGUUAGGC CGAA IUGCUAGU 4905 1671 CUAGCACC A AAACAUCA 1113 UGAUGUUU CUGAUGAG GCCGUUAGGC CGAA IGUGCUAG 4906 1676 ACCAAAAC A UCAAACCC 1114 GGGUUUGA CUGAUGAG GCCGUUAGGC CGAA IUUUUGGU 4907 1679 AAAACAUC A AACCCUUU 1115 AAAGGGUU CUGAUGAG GCCGUUAGGC CGAA lAUGUUUU 4908 1683 CAUCAAAC C CUUUUCUU 1116 AAGAAAAG CUGAUGAG GCCGUUAGGC CGAA IUUUGAUG 4909 1684 AUCAAACC C UUUUCUUG 1117 CAAGAAAA CUGAUGAG GCCGUUAGGC CGAA IGUUUGAU 4910 1685 UCAAACCC U UUUCUUGU 1118 ACAAGAAA CUGAUGAG GCCGUUAGGC CGAA IGGUUUGA 4911 1690 CCCUUUUC u UGUAGCAG 1119 CUGCUACA CUGAUGAG GCCGUUAGGC CGAA IAAAAGGG 4912 1697 CUUGUAGC A GCACAGGA 1120 UCCUGUGC CUGAUGAG GCCGUUAGGC CGAA ICUACAAG 4913 1700 GUAGCAGC A CAGGAUUC 1121 GAAUCCUG CUGAUGAG GCCGUUAGGC CGAA ICUGCUAC 4914 1702 AGCAGGAC A GGAUUCUG 1122 CAGAAUCC CUGAUGAG GCCGUUAGGC CGAA IUGCUGCU 4915 1709 CAGGAUUC U GAGACAGA 1123 UCUGUCUC CUGAUGAG GCCGUUAGGC CGAA IAAUCCUG 4916 1715 UCUGAGAC A GAUUAUGU 1124 ACAUAAUC CUGAUGAG GCCGUUAGGC CGAA IUCUCAGA 4917 1725 AUUAUGUC A CAACAGAU 1125 AUCUGUUG CUGAUGAG GCCGUUAGGC CGAA IACAUAAU 4918 1727 UAUGUCAC A ACAGAUAA 1126 UUAUCUGU CUGAUGAG GCCGUUAGGC CGAA IUGACAUA 4919 1730 GUCACAAC A GAUAAUUU 1127 AAAUUAUC CUGAUGAG GCCGUUAGGC CGAA IUUGUGAC 4920 1742 AAUUUAAC A AAGGUGAC 1128 GUCACCUU CUGAUGAG GCCGUUAGGC CGAA IUUAAAUU 4921 1751 AAGGUGAC U GAGGAAGU 1129 ACUUCCUC CUGAUGAG GCCGUUAGGC CGAA IUCACCUU 4922 1766 GUCGUGGC A AACAUGCC 1130 GGCAUGUU CUGAUGAG GCCGUUAGGC CGAA ICCACGAC 4923 1770 UGGCAAAC A UGCCUGAA 1131 UUCAGGCA CUGAUGAG GCCGUUAGGC CGAA IUUUGCCA 4924 1774 AAACAUGC C UGAAGGCC 1132 GGCCUUCA CUGAUGAG GCCGUUAGGC CGAA ICAUGUUU 4925 1775 AACAUGCC U GAAGGCCU 1133 AGGCCUUC CUGAUGAG GCCGUUAGGC CGAA IGCAUGUU 4926 1782 CUGAAGGC C UGACUCCA 1134 UGGAGUCA CUGAUGAG GCCGUUAGGC CGAA ICCUUCAG 4927 1783 UGAAGGCC U GACUCCAG 1135 CUGGAGUC CUGAUGAG GCCGUUAGGC CGAA IGCCUUCA 4928 1787 GGCCUGAC U CCAGAUUU 1136 AAAUCUGG CUGAUGAG GCCGUUAGGC CGAA IUCAGGCC 4929 1789 CCUGACUC c AGAUUUAG 1137 CUAAAUCU CUGAUGAG GCCGUUAGGC CGAA IAGUCAGG 4930 1790 CUGACUCC A GAUUUAGU 1138 ACUAAAUC CUGAUGAG GCCGUUAGGC CGAA IGAGUCAG 4931 1801 UUUAGUAC A GGAAGCAU 1139 AUGCUUCC CUGAUGAG GCCGUUAGGC CGAA lUACUAAA 4932 1808 CAGGAAGC A UGUGAAAG 1140 CUUUCACA CUGAUGAG GCCGUUAGGC CGAA ICUUCCUG 4933 1835 GAAGUUAC U GGUACAAA 1141 UUUGUACC CUGAUGAG GCCGUUAGGC CGAA IUAACUUC 4934 1841 ACUGGUAC A AAGAUUGC 1142 GCAAUCUU CUGAUGAG GCCGUUAGGC CGAA IUACCAGU 4935 1850 AAGAUUGC U UAUGAAAC 1143 GUUUCAUA CUGAUGAG GCCGUUAGGC CGAA ICAAUCUU 4936 1859 UAUGAAAC A AAAAUGGA 1144 UCCAUUUU CUGAUGAG GCCGUUAGGC CGAA IUUUCAUA 4937 1869 AAAUGGAC U UGGUUCAA 1145 UUGAACCA CUGAUGAG GCCGUUAGGC CGAA IUCCAUUU 4938 1876 CUUGGUUC A AACAUCAG 1146 CUGAUGUU CUGAUGAG GCCGUUAGGC CGAA IAACCAAG 4939 1880 GUUCAAAC A UCAGAAGU 1147 ACUUCUGA CUGAUGAG GCCGUUAGGC CGAA IUUUGAAC 4940 1883 CAAACAUC A GAAGUUAU 1148 AUAACUUC CUGAUGAG GCCGUUAGGC CGAA IAUGUUUG 4941 1894 AGUUAUGC A AGAGUCAC 1149 GUGACUCU CUGAUGAG GCCGUUAGGC CGAA ICAUAACU 4942 1901 CAAGAGUC A CUCUAUCC 1150 GGAUAGAG CUGAUGAG GCCGUUAGGC CGAA IACUCUUG 4943 1903 AGAGUCAC U CUAUCCUG 1151 CAGGAUAG CUGAUGAG GCCGUUAGGC CGAA IUGACUCU 4944 1905 AGUCACUC U AUCCUGCA 1152 UGCAGGAU CUGAUGAG GCCGUUAGGC CGAA IAGUGACU 4945 1909 ACUCUAUC C UGCAGCAC 1153 GUGCUGCA CUGAUGAG GCCGUUAGGC CGAA IAUAGAGU 4946 1910 CUCUAUCC U GCAGCACA 1154 UGUGCUGC CUGAUGAG GCCGUUAGGC CGAA IGAUAGAG 4947 1913 UAUCCUGC A GCACAGCU 1155 AGCUGUGC CUGAUGAG GCCGUUAGGC CGAA ICAGGAUA 4948 1916 CCUGCAGC A CAGCUUUG 1156 CAAAGCUG CUGAUGAG GCCGUUAGGC CGAA ICUGCAGG 4949 1918 UGCAGCAC A GCUUUGCC 1157 GGCAAAGC CUGAUGAG GCCGUUAGGC CGAA IUGCUGCA 4950 1921 AGCACAGC U UUGCCCAU 1158 AUGGGCAA CUGAUGAG GCCGUUAGGC CGAA ICUGUGCU 4951 1926 AGCUUUGC C CAUCAUUU 1159 AAAUGAUG CUGAUGAG GCCGUUAGGC CGAA ICAAAGCU 4952 1927 GCUUUGCC C AUCAUUUG 1160 CAAAUGAU CUGAUGAG GCCGUUAGGC CGAA IGCAAAGC 4953 1928 CUUUGCCC A UCAUUUGA 1161 UCAAAUGA CUGAUGAG GCCGUUAGGC CGAA IGGCAAAG 4954 1931 UGCCCAUC A UUUGAAGA 1162 UCUUCAAA CUGAUGAG GCCGUUAGGC CGAA IAUGGGCA 4955 1943 GAAGAGUC A GAAGCUAC 1163 GUAGCUUC CUGAUGAG GCCGUUAGGC CGAA IACUCUUC 4956 1949 UCAGAAGC U ACUCCUUC 1164 GAAGGAGU CUGAUGAG GCCGUUAGGC CGAA ICUUCUGA 4957 1952 GAAGCUAC U CCUUCACC 1165 GGUGAAGG CUGAUGAG GCCGUUAGGC CGAA IUAGCUUC 4958 1954 AGCUACUC C UUCACCAG 1166 CUGGUGAA CUGAUGAG GCCGUUAGGC CGAA IAGUAGCU 4959 1955 GCUACUCC U UCACCAGU 1167 ACUGGUGA CUGAUGAG GCCGUUAGGC CGAA IGAGUAGC 4960 1958 ACUCCUUC A CCAGUUUU 1168 AAAACUGG CUGAUGAG GCCGUUAGGC CGAA IAAGGAGU 4961 I960 UCCUUCAC C AGUUUUGC 1169 GCAAAACU CUGAUGAG GCCGUUAGGC CGAA IUGAAGGA 4962 1961 CCUUCACC A GUUUUGCC 1170 GGCAAAAC CUGAUGAG GCCGUUAGGC CGAA IGUGAAGG 4963 1969 AGUUUUGC C UGACAUUG 1171 CAAUGUCA CUGAUGAG GCCGUUAGGC CGAA ICAAAACU 4964 1970 GUUUUGCC U GACAUUGU 1172 ACAAUGUC CUGAUGAG GCCGUUAGGC CGAA IGCAAAAC 4965 1974 UGCCUGAC A UUGUUAUG 1173 CAUAACAA CUGAUGAG GCCGUUAGGC CGAA IUCAGGCA 4966 1988 AUGGAAGC A CCAUUGAA 1174 UUCAAUGG CUGAUGAG GCCGUUAGGC CGAA ICUUCCAU 4967 1990 GGAAGCAC C AUUGAAUU 1175 AAUUCAAU CUGAUGAG GCCGUUAGGC CGAA IUGCUUCC 4968 1991 GAAGCACC A UUGAAUUC 1176 GAAUUCAA CUGAUGAG GCCGUUAGGC CGAA IGUGCUUC 4969 2000 UUGAAUUC U GCAGUUCC 1177 GGAACUGC CUGAUGAG GCCGUUAGGC CGAA IAAUUCAA 4970 2003 AAUUCUGC A GUUCCUAG 1178 CUAGGAAC CUGAUGAG GCCGUUAGGC CGAA ICAGAAUU 4971 2008 UGCAGUUC C UAGUGCUG 1179 CAGCACUA CUGAUGAG GCCGUUAGGC CGAA IAACUGCA 4972 2009 GCAGUUCC U AGUGCUGG 1180 CCAGCACU CUGAUGAG GCCGUUAGGC CGAA IGAACUGC 4973 2015 CCUAGUGC u GGUGCUUC 1181 GAAGCACC CUGAUGAG GCCGUUAGGC CGAA ICACUAGG 4974 2021 GCUGGUGC u UCCGUGAU 1182 AUCACGGA CUGAUGAG GCCGUUAGGC CGAA ICACCAGC 4975 2024 GGUGCUUC c GUGAUACA 1183 UGUAUCAC CUGAUGAG GCCGUUAGGC CGAA IAAGCACC 4976 2032 CGUGAUAC A GCCCAGCU 1184 AGCUGGGC CUGAUGAG GCCGUUAGGC CGAA IUAUCACG 4977 2035 GAUACAGC C CAGCUCAU 1185 AUGAGCUG CUGAUGAG GCCGUUAGGC CGAA ICUGUAUC 4978 2036 AUACAGCC C AGCUCAUC 1186 GAUGAGCU CUGAUGAG GCCGUUAGGC CGAA IGCUGUAU 4979 2037 UACAGCCC A GCUCAUCA 1187 UGAUGAGC CUGAUGAG GCCGUUAGGC CGAA IGGCUGUA 4980 2040 AGCCCAGC U CAUCACCA 1188 UGGUGAUG CUGAUGAG GCCGUUAGGC CGAA ICUGGGCU 4981 2042 CCCAGCUC A UCACCAUU 1189 AAUGGUGA CUGAUGAG GCCGUUAGGC CGAA IAGCUGGG 4982 2045 AGCUCAUC A CCAUUAGA 1190 UCUAAUGG CUGAUGAG GCCGUUAGGC CGAA lAUGAGCU 4983 2047 CUCAUCAC C AUUAGAAG 1191 CUUCUAAU CUGAUGAG GCCGUUAGGC CGAA IUGAUGAG 4984 2048 UCAUCACC A UUAGAAGC 1192 GCUUCUAA CUGAUGAG GCCGUUAGGC CGAA IGUGAUGA 4985 2057 UUAGAAGC U UCUUCAGU 1193 ACUGAAGA CUGAUGAG GCCGUUAGGC CGAA ICUUCUAA 4986 2060 GAAGCUUC U UCAGUUAA 1194 UUAACUGA CUGAUGAG GCCGUUAGGC CGAA IAAGCUUC 4987 2063 GCUUCUUC A GUUAAUUA 1195 UAAUUAAC CUGAUGAG GCCGUUAGGC CGAA IAAGAAGC 4988 2079 AUGAAAGC A UAAAACAU 1196 AUGUUUUA CUGAUGAG GCCGUUAGGC CGAA ICUUUCAU 4989 2086 CAUAAAAC A UGAGCCUG 1197 CAGGCUCA CUGAUGAG GCCGUUAGGC CGAA IUUUUAUG 4990 2092 ACAUGAGC C UGAAAACC 1198 GGUUUUCA CUGAUGAG GCCGUUAGGC CGAA ICUCAUGU 4991 2093 CAUGAGCC U GAAAACCC 1199 GGGUUUUC CUGAUGAG GCCGUUAGGC CGAA IGCUCAUG 4992 2100 CUGAAAAC C CCCCACCA 1200 UGGUGGGG CUGAUGAG GCCGUUAGGC CGAA IUUUUCAG 4993 2101 UGAAAACC c CCCACCAU 1201 AUGGUGGG CUGAUGAG GCCGUUAGGC CGAA IGUUUUCA 4994 2102 GAAAACCC c CCACCAUA 1202 UAUGGUGG CUGAUGAG GCCGUUAGGC CGAA IGGUUUUC 4995 2103 AAAACCCC c CACCAUAU 1203 AUAUGGUG CUGAUGAG GCCGUUAGGC CGAA IGGGUUUU 4996 2104 AAACCCCC c ACCAUAUG 1204 CAUAUGGU CUGAUGAG GCCGUUAGGC CGAA IGGGGUUU 4997 2105 AACCCCCC A CCAUAUGA 1205 UCAUAUGG CUGAUGAG GCCGUUAGGC CGAA IGGGGGUU 4998 2107 CCCCCCAC C AUAUGAAG 1206 CUUCAUAU CUGAUGAG GCCGUUAGGC CGAA IUGGGGGG 4999 2108 CCCCCACC A UAUGAAGA 1207 UCUUCAUA CUGAUGAG GCCGUUAGGC CGAA IGUGGGGG 5000 2120 GAAGAGGC C AUGAGUGU 1208 ACACUCAU CUGAUGAG GCCGUUAGGC CGAA ICCUCUUC 5001 2121 AAGAGGCC A UGAGUGUA 1209 UACACUCA CUGAUGAG GCCGUUAGGC CGAA IGCCUCUU 5002 2132 AGUGUAUC A CUAAAAAA 1210 UUUUUUAG CUGAUGAG GCCGUUAGGC CGAA IAUACACU 5003 2134 UGUAUCAC U AAAAAAAG 1211 CUUUUUUU CUGAUGAG GCCGUUAGGC CGAA IUGAUACA 5004 2147 AAAGUAUC A GGAAUAAA 1212 UUUAUUCC CUGAUGAG GCCGUUAGGC CGAA IAUACUUU 5005 2173 UAAAGAGC C UGAAAAUA 1213 UAUUUUCA CUGAUGAG GCCGUUAGGC CGAA ICUCUUUA 5006 2174 AAAGAGCC U GAAAAUAU 1214 AUAUUUUC CUGAUGAG GCCGUUAGGC CGAA IGCUCUUU 5007 2189 AUUAAUGC A GCUCUUCA 1215 UGAAGAGC CUGAUGAG GCCGUUAGGC CGAA ICAUUAAU 5008 2192 AAUGCAGC U CUUCAAGA 1216 UCUUGAAG CUGAUGAG GCCGUUAGGC CGAA ICUGCAUU 5009 2194 UGCAGCUC u UCAAGAAA 1217 UUUCUUGA CUGAUGAG GCCGUUAGGC CGAA IAGCUGCA 5010 2197 AGCUCUUC A AGAAACAG 1218 CUGUUUCU CUGAUGAG GCCGUUAGGC CGAA IAAGAGCU 5011 2204 CAAGAAAC A GAAGCUCC 1219 GGAGCUUC CUGAUGAG GCCGUUAGGC CGAA IUUUCUUG 5012 2210 ACAGAAGC U CCUUAUAU 1220 AUAUAAGG CUGAUGAG GCCGUUAGGC CGAA ICUUCUGU 5013 2212 AGAAGCUC c UUAUAUAU 1221 AUAUAUAA CUGAUGAG GCCGUUAGGC CGAA IAGCUUCU 5014 2213 GAAGCUCC u UAUAUAUC 1222 GAUAUAUA CUGAUGAG GCCGUUAGGC CGAA IGAGCUUC 5015 2222 UAUAUAUC u AUUGCAUG 1223 CAUGCAAU CUGAUGAG GCCGUUAGGC CGAA IAUAUAUA 5016 2228 UCUAUUGC A UGUGAUUU 1224 AAAUCACA CUGAUGAG GCCGUUAGGC CGAA ICAAUAGA 5017 2249 AAAGAAAC A AAGCUUUC 1225 GAAAGCUU CUGAUGAG GCCGUUAGGC CGAA IUUUCUUU 5018 2254 AACAAAGC U UUCUGCUG 1226 CAGCAGAA CUGAUGAG GCCGUUAGGC CGAA ICUUUGUU 5019 2258 AAGCUUUC U GCUGAACC 1227 GGUUCAGC CUGAUGAG GCCGUUAGGC CGAA IAAAGCUU 5020 2261 CUUUCUGC U GAACCAGC 1228 GCUGGUUC CUGAUGAG GCCGUUAGGC CGAA ICAGAAAG 5021 2266 UGCUGAAC C AGCUCCGG 1229 CCGGAGCU CUGAUGAG GCCGUUAGGC CGAA IUUCAGCA 5022 2267 GCUGAACC A GCUCCGGA 1230 UCCGGAGC CUGAUGAG GCCGUUAGGC CGAA IGUUCAGC 5023 2270 GAACCAGC U CCGGAUUU 1231 AAAUCCGG CUGAUGAG GCCGUUAGGC CGAA ICUGGUUC 5024 2272 ACCAGCUC C GGAUUUCU 1232 AGAAAUCC CUGAUGAG GCCGUUAGGC CGAA IAGCUGGU 5025 2280 CGGAUUUC U CUGAUUAU 1233 AUAAUCAG CUGAUGAG GCCGUUAGGC CGAA IAAAUCCG 5026 2282 GAUUUCUC U GAUUAUUC 1234 GAAUAAUC CUGAUGAG GCCGUUAGGC CGAA IAGAAAUC 5027 2291 GAUUAUUC A GAAAUGGC 1235 GCCAUUUC CUGAUGAG GCCGUUAGGC CGAA IAAUAAUC 5028 2300 GAAAUGGC A AAAGUUGA 1236 UCAACUUU CUGAUGAG GCCGUUAGGC CGAA ICCAUUUC 5029 2311 AGUUGAAC A GCCAGUGC 1237 GCACUGGC CUGAUGAG GCCGUUAGGC CGAA IUUCAACU 5030 2314 UGAACAGC C AGUGCCUG 1238 CAGGCACU CUGAUGAG GCCGUUAGGC CGAA ICUGUUCA 5031 2315 GAACAGCC A GUGCCUGA 1239 UCAGGCAC CUGAUGAG GCCGUUAGGC CGAA IGCUGUUC 5032 2320 GCCAGUGC C UGAUGAUU 1240 AAUGAUCA CUGAUGAG GCCGUUAGGC CGAA ICACUGGC 5033 2321 CCAGUGCC U GAUCAUUC 1241 GAAUGAUC CUGAUGAG GCCGUUAGGC CGAA IGCACUGG 5034 2326 GCCUGAUC A UUCUGAGC 1242 GCUCAGAA CUGAUGAG GCCGUUAGGC CGAA IAUCAGGC 5035 2330 GAUCAUUC U GAGCUAGU 1243 ACUAGCUC CUGAUGAG GCCGUUAGGC CGAA IAAUGAUC 5036 2335 UUCUGAGC u AGUUGAAG 1244 CUUCAACU CUGAUGAG GCCGUUAGGC CGAA ICUCAGAA 5037 2348 GAAGAUUC c UCACCUGA 1245 UCAGGUGA CUGAUGAG GCCGUUAGGC CGAA IAAUCUUC 5038 2349 AAGAUUCC u CACCUGAU 1246 AUCAGGUG CUGAUGAG GCCGUUAGGC CGAA IGAAUCUU 5039 2351 GAUUCCUC A CCUGAUUC 1247 GAAUCAGG CUGAUGAG GCCGUUAGGC CGAA IAGGAAUC 5040 2353 UUCCUCAC C UGAUUCUG 1248 CAGAAUCA CUGAUGAG GCCGUUAGGC CGAA IUGAGGAA 5041 2354 UCCUCACC U GAUUCUGA 1249 UCAGAAUC CUGAUGAG GCCGUUAGGC CGAA IGUGAGGA 5042 2360 CCUGAUUC U GAACCAGU 1250 ACUGGUUC CUGAUGAG GCCGUUAGGC CGAA IAAUCAGG 5043 2365 UUCUGAAC C AGUUGACU 1251 AGUCAACU CUGAUGAG GCCGUUAGGC CGAA lUUCAGAA 5044 2366 UCUGAACC A GUUGACUU 1252 AAGUCAAC CUGAUGAG GCCGUUAGGC CGAA IGUUCAGA 5045 2373 CAGUUGAC U UAUUUAGU 1253 ACUAAAUA CUGAUGAG GCCGUUAGGC CGAA IUCAACUG 5046 2390 GAUGAUUC A AUACCUGA 1254 UCAGGUAU CUGAUGAG GCCGUUAGGC CGAA IAAUCAUC 5047 2395 UUCAAUAC C UGACGUUC 1255 GAACGUCA CUGAUGAG GCCGUUAGGC CGAA IUAUUGAA 5048 2396 UCAAUACC U GACGUUCC 1256 GGAACGUC CUGAUGAG GCCGUUAGGC CGAA IGUAUUGA 5049 2404 UGACGUUC C ACAAAAAC 1257 GUUUUUGU CUGAUGAG GCCGUUAGGC CGAA IAACGUCA 5050 2405 GACGUUCC A CAAAAACA 1258 UGUUUUUG CUGAUGAG GCCGUUAGGC CGAA IGAACGUC 5051 2407 CGUUCCAC A AAAACAAG 1259 CUUGUUUU CUGAUGAG GCCGUUAGGC CGAA IUGGAACG 5052 2413 ACAAAAAC A AGAUGAAA 1260 UUUCAUCU CUGAUGAG GCCGUUAGGC CGAA IUUUUUGU 5053 2423 GAUGAAAC U GUGAUGCU 1261 AGCAUCAC CUGAUGAG GCCGUUAGGC CGAA IUUUCAUC 5054 2431 UGUGAUGC U UGUGAAAG 1262 CUUUCACA CUGAUGAG GCCGUUAGGC CGAA ICAUCACA 5055 2446 AGAAAGUC U CACUGAGA 1263 UCUCAGUG CUGAUGAG GCCGUUAGGC CGAA lACUUUCU 5056 2448 AAAGUCUC A CUGAGACU 1264 AGUCUCAG CUGAUGAG GCCGUUAGGC CGAA lAGACUUU 5057 2450 AGUCUCAC U GAGACUUC 1265 GAAGUCUC CUGAUGAG GCCGUUAGGC CGAA IUGAGACU 5058 2456 ACUGAGAC U UCAUUUGA 1266 UCAAAUGA CUGAUGAG GCCGUUAGGC CGAA IUCUCAGU 5059 2459 GAGACUUC A UUUGAGUC 1267 GACUCAAA CUGAUGAG GCCGUUAGGC CGAA IAAGUCUC 5060 2468 UUUGAGUC A AUGAUAGA 1268 UCUAUCAU CUGAUGAG GCCGUUAGGC CGAA IACUCAAA 5061 2497 GGAAAAAC U CAGUGCUU 1269 AAGCACUG CUGAUGAG GCCGUUAGGC CGAA IUUUUUCC 5062 2499 AAAAACUC A GUGCUUUG 1270 CAAAGCAC CUGAUGAG GCCGUUAGGC CGAA IAGUUUUU 5063 2504 CUCAGUGC U UUGCCACC 1271 GGUGGCAA CUGAUGAG GCCGUUAGGC CGAA ICACUGAG 5064 2509 UGCUUUGC C ACCUGAGG 1272 CCUCAGGU CUGAUGAG GCCGUUAGGC CGAA ICAAAGCA 5065 2510 GCUUUGCC A CCUGAGGG 1273 CCCUCAGG CUGAUGAG GCCGUUAGGC CGAA IGCAAAGC 5066 2512 UUUGCCAC C UGAGGGAG 1274 CUCCCUCA CUGAUGAG GCCGUUAGGC CGAA IUGGCAAA 5067 2513 UUGCCACC U GAGGGAGG 1275 CCUCCCUC CUGAUGAG GCCGUUAGGC CGAA IGUGGCAA 5068 2527 AGGAAAGC C AUAUUUGG 1276 CCAAAUAU CUGAUGAG GCCGUUAGGC CGAA ICUUUCCU 5069 2528 GGAAAGCC A UAUUUGGA 1277 UCCAAAUA CUGAUGAG GCCGUUAGGC CGAA IGCUUUCC 5070 2540 UUGGAAUC U UUUAAGCU 1278 AGCUUAAA CUGAUGAG GCCGUUAGGC CGAA lAUUCCAA 5071 2548 UUUUAAGC U CAGUUUAG 1279 CUAAACUG CUGAUGAG GCCGUUAGGC CGAA ICUUAAAA 5072 2550 UUAAGCUC A GUUUAGAU 1280 AUCUAAAC CUGAUGAG GCCGUUAGGC CGAA lAGCUUAA 5073 2562 UAGAUAAC A CAAAAGAU 1281 AUCUUUUG CUGAUGAG GCCGUUAGGC CGAA lUUAUCUA 5074 2564 GAUAACAC A AAAGAUAC 1282 GUAUCUUU CUGAUGAG GCCGUUAGGC CGAA IUGUUAUC 5075 2573 AAAGAUAC C CUGUUACC 1283 GGUAACAG CUGAUGAG GCCGUUAGGC CGAA IUAUCUUU 5076 2574 AAGAUACC C UGUUACCU 1284 AGGUAACA CUGAUGAG GCCGUUAGGC CGAA IGUAUCUU 5077 2575 AGAUACCC U GUUACCUG 1285 CAGGUAAC CUGAUGAG GCCGUUAGGC CGAA IGGUAUCU 5078 2581 CCUGUUAC C UGAUGAAG 1286 CUUCAUCA CUGAUGAG GCCGUUAGGC CGAA IUAACAGG 5079 2582 CUGUUACC U GAUGAAGU 1287 ACUUCAUC CUGAUGAG GCCGUUAGGC CGAA IGUAACAG 5080 2594 GAAGUUUC A ACAUUGAG 1288 CUCAAUGU CUGAUGAG GCCGUUAGGC CGAA IAAACUUC 5081 2597 GUUUCAAC A UUGAGCAA 1289 UUGCUCAA CUGAUGAG GCCGUUAGGC CGAA IUUGAAAC 5082 2604 CAUUGAGC A AAAAGGAG 1290 CUCCUUUU CUGAUGAG GCCGUUAGGC CGAA ICUCAAUG 5083 2620 GAAAAUUC C UUUGCAGA 1291 UCUGCAAA CUGAUGAG GCCGUUAGGC CGAA IAAUUUUC 5084 2621 AAAAUUCC U UUGCAGAU 1292 AUCUGCAA CUGAUGAG GCCGUUAGGC CGAA IGAAUUUU 5085 2626 UCCUUUGC A GAUGGAGG 1293 CCUCCAUC CUGAUGAG GCCGUUAGGC CGAA ICAAAGGA 5086 2638 GGAGGAGC U CAGUACUG 1294 CAGUACUG CUGAUGAG GCCGUUAGGC CGAA ICUCCUCC 5087 2640 AGGAGCUC A GUACUGCA 1295 UGCAGUAC CUGAUGAG GCCGUUAGGC CGAA IAGCUCCU 5088 2645 CUCAGUAC U GCAGUUUA 1296 UAAACUGC CUGAUGAG GCCGUUAGGC CGAA IUACUGAG 5089 2648 AGUACUGC A GUUUAUUC 1297 GAAUAAAC CUGAUGAG GCCGUUAGGC CGAA ICAGUACU 5090 2657 GUUUAUUC A AAUGAUGA 1298 UCAUCAUU CUGAUGAG GCCGUUAGGC CGAA IAAUAAAC 5091 2667 AUGAUGAC U UAUUUAUU 1299 AAUAAAUA CUGAUGAG GCCGUUAGGC CGAA lUCAUCAU 5092 2678 UUUAUUUC U AAGGAAGC 1300 GCUUCCUU CUGAUGAG GCCGUUAGGC CGAA IAAAUAAA 5093 2687 AAGGAAGC A CAGAUAAG 1301 CUUAUCUG CUGAUGAG GCCGUUAGGC CGAA ICUUCCUU 5094 2689 GGAAGCAC A GAUAAGAG 1302 CUCUUAUC CUGAUGAG GCCGUUAGGC CGAA IUGCUUCC 5095 2702 AGAGAAAC U GAAACGUU 1303 AACGUUUC CUGAUGAG GCCGUUAGGC CGAA IUUUCUCU 5096 2714 ACGUUUUC A GAUUCAUC 1304 GAUGAAUC CUGAUGAG GCCGUUAGGC CGAA IAAAACGU 5097 2720 UCAGAUUC A UCUCCAAU 1305 AUUGGAGA CUGAUGAG GCCGUUAGGC CGAA lAAUCUGA 5098 2723 GAUUCAUC U CCAAUUGA 1306 UCAAUUGG CUGAUGAG GCCGUUAGGC CGAA IAUGAAUC 5099 2725 UUCAUCUC c AAUUGAAA 1307 UUUCAAUU CUGAUGAG GCCGUUAGGC CGAA IAGAUGAA 5100 2726 UCAUCUCC A AUUGAAAU 1308 AUUUCAAU CUGAUGAG GCCGUUAGGC CGAA IGAGAUGA 5101 2748 AUGAGUUC C CUACAUUG 1309 CAAUGUAG CUGAUGAG GCCGUUAGGC CGAA IAACUCAU 5102 2749 UGAGUUCC C UACAUUGA 1310 UCAAUGUA CUGAUGAG GCCGUUAGGC CGAA IGAACUCA 5103 2750 GAGUUCCC U ACAUUGAU 1311 AUCAAUGU CUGAUGAG GCCGUUAGGC CGAA IGGAACUC 5104 2753 UUCCCUAC A UUGAUCAG 1312 CUGAUCAA CUGAUGAG GCCGUUAGGC CGAA IUAGGGAA 5105 2760 CAUUGAUC A GUUCUAAA 1313 UUUAGAAC CUGAUGAG GCCGUUAGGC CGAA IAUCAAUG 5106 2765 AUCAGUUC U AAAACUGA 1314 UCAGUUUU CUGAUGAG GCCGUUAGGC CGAA IAACUGAU 5107 2771 UCUAAAAC U GAUUCAUU 1315 AAUGAAUC CUGAUGAG GCCGUUAGGC CGAA lUUUUAGA 5108 2777 ACUGAUUC A UUUUCUAA 1316 UUAGAAAA CUGAUGAG GCCGUUAGGC CGAA IAAUCAGU 5109 2783 UCAUUUUC U AAAUUAGC 1317 GCUAAUUU CUGAUGAG GCCGUUAGGC CGAA IAAAAUGA 5110 2792 AAAUUAGC C AGGGAAUA 1318 UAUUCCCU CUGAUGAG GCCGUUAGGC CGAA ICUAAUUU 5111 2793 AAUUAGCC A GGGAAUAU 1319 AUAUUCCC CUGAUGAG GCCGUUAGGC CGAA IGCUAAUU 5112 2804 GAAUAUAC U GACCUAGA 1320 UCUAGGUC CUGAUGAG GCCGUUAGGC CGAA IUAUAUUC 5113 2808 AUACUGAC C UAGAAGUA 1321 UACUUCUA CUGAUGAG GCCGUUAGGC CGAA IUCAGUAU 5114 2809 UACUGACC U AGAAGUAU 1322 AUACUUCU CUGAUGAG GCCGUUAGGC CGAA IGUCAGUA 5115 2819 GAAGUAUC C CACAAAAG 1323 CUUUUGUG CUGAUGAG GCCGUUAGGC CGAA IAUACUUC 5116 2820 AAGUAUCC C ACAAAAGU 1324 ACUUUUGU CUGAUGAG GCCGUUAGGC CGAA IGAUACUU 5117 2821 AGUAUCCC A CAAAAGUG 1325 CACUUUUG CUGAUGAG GCCGUUAGGC CGAA IGGAUACU 5118 2823 UAUCCCAC A AAAGUGAA 1326 UUCACUUU CUGAUGAG GCCGUUAGGC CGAA IUGGGAUA 5119 2837 GAAAUUGC U AAUGCCCC 1327 GGGGCAUU CUGAUGAG GCCGUUAGGC CGAA ICAAUUUC 5120 2843 GCUAAUGC C CCGGAUGG 1328 CCAUCCGG CUGAUGAG GCCGUUAGGC CGAA ICAUUAGC 5121 2844 CUAAUGCC C CGGAUGGA 1329 UCCAUCCG CUGAUGAG GCCGUUAGGC CGAA IGCAUUAG 5122 2845 UAAUGCCC C GGAUGGAG 1330 CUCCAUCC CUGAUGAG GCCGUUAGGC CGAA IGGCAUUA 5123 2855 GAUGGAGC U GGGUCAUU 1331 AAUGACCC CUGAUGAG GCCGUUAGGC CGAA ICUCCAUC 5124 2861 GCUGGGUC A UUGCCUUG 1332 CAAGGCAA CUGAUGAG GCCGUUAGGC CGAA IACCCAGC 5125 2866 GUCAUUGC C UUGCACAG 1333 CUGUGCAA CUGAUGAG GCCGUUAGGC CGAA ICAAUGAC 5126 2867 UCAUUGCC U UGCACAGA 1334 UCUGUGCA CUGAUGAG GCCGUUAGGC CGAA IGCAAUGA 5127 2871 UGCCUUGC A CAGAAUUG 1335 CAAUUCUG CUGAUGAG GCCGUUAGGC CGAA ICAAGGCA 5128 2873 CCUUGCAC A GAAUUGCC 1336 GGCAAUUC CUGAUGAG GCCGUUAGGC CGAA IUGCAAGG 5129 2881 AGAAUUGC C CCAUGACC 1337 GGUCAUGG CUGAUGAG GCCGUUAGGC CGAA ICAAUUCU 5130 2882 GAAUUGCC C CAUGACCU 1338 AGGUCAUG CUGAUGAG GCCGUUAGGC CGAA IGCAAUUC 5131 2883 AAUUGCCC C AUGACCUU 1339 AAGGUCAU CUGAUGAG GCCGUUAGGC CGAA IGGCAAUU 5132 2884 AUUGCCCC A UGACCUUU 1340 AAAGGUCA CUGAUGAG GCCGUUAGGC CGAA IGGGCAAU 5133 2889 CCCAUGAC C UUUCUUUG 1341 CAAAGAAA CUGAUGAG GCCGUUAGGC CGAA IUCAUGGG 5134 2890 CCAUGACC U UUCUUUGA 1342 UCAAAGAA CUGAUGAG GCCGUUAGGC CGAA IGUCAUGG 5135 2894 GACCUUUC U UUGAAGAA 1343 UUCUUCAA CUGAUGAG GCCGUUAGGC CGAA IAAAGGUC 5136 2904 UGAAGAAC A UACAACCC 1344 GGGUUGUA CUGAUGAG GCCGUUAGGC CGAA IUUCUUCA 5137 2908 GAACAUAC A ACCCAAAG 1345 CUUUGGGU CUGAUGAG GCCGUUAGGC CGAA IUAUGUUC 5138 2911 CAUACAAC C CAAAGUUG 1346 CAACUUUG CUGAUGAG GCCGUUAGGC CGAA IUUGUAUG 5139 2912 AUACAACC C AAAGUUGA 1347 UCAACUUU CUGAUGAG GCCGUUAGGC CGAA IGUUGUAU 5140 2913 UACAACCC A AAGUUGAA 1348 UUCAACUU CUGAUGAG GCCGUUAGGC CGAA IGGUUGUA 5141 2931 AGAAAAUC A GUUUCUCA 1349 UGAGAAAC CUGAUGAG GCCGUUAGGC CGAA IAUUUUCU 5142 2937 UCAGUUUC U CAGAUGAC 1350 GUCAUCUG CUGAUGAG GCCGUUAGGC CGAA IAAACUGA 5143 2939 AGUUUCUC A GAUGACUU 1351 AAGUCAUC CUGAUGAG GCCGUUAGGC CGAA lAGAAACU 5144 2946 CAGAUGAC U UUUCUAAA 1352 UUUAGAAA CUGAUGAG GCCGUUAGGC CGAA IUCAUCUG 5145 2951 GACUUUUC U AAAAAUGG 1353 CCAUUUUU CUGAUGAG GCCGUUAGGC CGAA IAAAAGUC 5146 2963 AAUGGGUC U GCUACAUC 1354 GAUGUAGC CUGAUGAG GCCGUUAGGC CGAA IACCCAUU 5147 2966 GGGUCUGC U ACAUCAAA 1355 UUUGAUGU CUGAUGAG GCCGUUAGGC CGAA ICAGACCC 5148 2969 UCUGCUAC A UCAAAGGU 1356 ACCUUUGA CUGAUGAG GCCGUUAGGC CGAA IUAGCAGA 5149 2972 GCUACAUC A AAGGUGCU 1357 AGCACCUU CUGAUGAG GCCGUUAGGC CGAA IAUGUAGC 5150 2980 AAAGGUGC U CUUAUUGC 1358 GCAAUAAG CUGAUGAG GCCGUUAGGC CGAA ICACCUUU 5151 2982 AGGUGCUC U UAUUGCCU 1359 AGGCAAUA CUGAUGAG GCCGUUAGGC CGAA lAGCACCU 5152 2989 CUUAUUGC C UCCAGAUG 1360 CAUCUGGA CUGAUGAG GCCGUUAGGC CGAA ICAAUAAG 5153 2990 UUAUUGCC U CCAGAUGU 1361 ACAUCUGG CUGAUGAG GCCGUUAGGC CGAA IGCAAUAA 5154 2992 AUUGCCUC C AGAUGUUU 1362 AAACAUCU CUGAUGAG GCCGUUAGGC CGAA IAGGCAAU 5155 2993 UUGCCUCC A GAUGUUUC 1363 GAAACAUC CUGAUGAG GCCGUUAGGC CGAA IGAGGCAA 5156 3002 GAUGUUUC U GCUUUGGC 1364 GCCAAAGC CUGAUGAG GCCGUUAGGC CGAA IAAACAUC 5157 3005 GUUUCUGC U UUGGCCAC 1365 GUGGCCAA CUGAUGAG GCCGUUAGGC CGAA ICAGAAAC 5158 3011 GCUUUGGC C ACUCAAGC 1366 GCUUGAGU CUGAUGAG GCCGUUAGGC CGAA ICCAAAGC 5159 3012 CUUUGGCC A CUCAAGCA 1367 UGCUUGAG CUGAUGAG GCCGUUAGGC CGAA IGCCAAAG 5160 3014 UUGGCCAC U CAAGCAGA 1368 UCUGCUUG CUGAUGAG GCCGUUAGGC CGAA IUGGCCAA 5161 3016 GGCCACUC A AGCAGAGA 1369 UCUCUGCU CUGAUGAG GCCGUUAGGC CGAA IAGUGGCC 5162 3020 ACUCAAGC A GAGAUAGA 1370 UCUAUCUC CUGAUGAG GCCGUUAGGC CGAA ICUUGAGU 5163 3033 UAGAGAGC A UAGUUAAA 1371 UUUAACUA CUGAUGAG GCCGUUAGGC CGAA ICUCUCUA 5164 3043 AGUUAAAC C CAAAGUUC 1372 GAACUUUG CUGAUGAG GCCGUUAGGC CGAA IUUUAACU 5165 3044 GUUAAACC C AAAGUUCU 1373 AGAACUUU CUGAUGAG GCCGUUAGGC CGAA IGUUUAAC 5166 3045 UUAAACCC A AAGUUCUU 1374 AAGAACUU CUGAUGAG GCCGUUAGGC CGAA IGGUUUAA 5167 3052 CAAAGUUC U UGUGAAAG 1375 CUUUCACA CUGAUGAG GCCGUUAGGC CGAA IAACUUUG 5168 3065 AAAGAAGC U GAGAAAAA 1376 UUUUUCUC CUGAUGAG GCCGUUAGGC CGAA ICUUCUUU 5169 3076 GAAAAAAC U UCCUUCCG 1377 CGGAAGGA CUGAUGAG GCCGUUAGGC CGAA IUUUUUUC 5170 3079 AAAACUUC C UUCCGAUA 1378 UAUCGGAA CUGAUGAG GCCGUUAGGC CGAA IAAGUUUU 5171 3080 AAACUUCC U UCCGAUAC 1379 GUAUCGGA CUGAUGAG GCCGUUAGGC CGAA IGAAGUUU 5172 3083 CUUCCUUC C GAUACAGA 1380 UCUGUAUC CUGAUGAG GCCGUUAGGC CGAA IAAGGAAG 5173 3089 UCCGAUAC A GAAAAAGA 1381 UCUUUUUC CUGAUGAG GCCGUUAGGC CGAA IUAUCGGA 5174 3102 AAGAGGAC A GAUCACCA 1382 UGGUGAUC CUGAUGAG GCCGUUAGGC CGAA IUCCUCUU 5175 3107 GACAGAUC A CCAUCUGC 1383 GCAGAUGG CUGAUGAG GCCGUUAGGC CGAA IAUCUGUC 5176 3109 CAGAUCAC C AUCUGCUA 1384 UAGCAGAU CUGAUGAG GCCGUUAGGC CGAA IUGAUCUG 5177 3110 AGAUCACC A UCUGCUAU 1385 AUAGCAGA CUGAUGAG GCCGUUAGGC CGAA IGUGAUCU 5178 3113 UCACCAUC U GCUAUAUU 1386 AAUAUAGC CUGAUGAG GCCGUUAGGC CGAA lAUGGUGA 5179 3116 CCAUCUGC U AUAUUUUC 1387 GAAAAUAU CUGAUGAG GCCGUUAGGC CGAA ICAGAUGG 5180 3125 AUAUUUUC A GCAGAGCU 1388 AGCUCUGC CUGAUGAG GCCGUUAGGC CGAA IAAAAUAU 5181 3128 UUUUCAGC A GAGCUGAG 1389 CUCAGCUC CUGAUGAG GCCGUUAGGC CGAA ICUGAAAA 5182 3133 AGCAGAGC U GAGUAAAA 1390 UUUUACUC CUGAUGAG GCCGUUAGGC CGAA ICUCUGCU 5183 3143 AGUAAAAC U UCAGUUGU 1391 AGAACUGA CUGAUGAG GCCGUUAGGC CGAA IUUUUACU 5184 3146 AAAACUUC A GUUGUUGA 1392 UCAACAAC CUGAUGAG GCCGUUAGGC CGAA IAAGUUUU 5185 3156 UUGUUGAC C UCCUGUAC 1393 GUACAGGA CUGAUGAG GCCGUUAGGC CGAA IUCAACAA 5186 3157 UGUUGACC U CCUGUACU 1394 AGUACAGG CUGAUGAG GCCGUUAGGC CGAA IGUCAACA 5187 3159 UUGACCUC C UGUACUGG 1395 CCAGUACA CUGAUGAG GCCGUUAGGC CGAA IAGGUCAA 5188 3160 UGACCUCC U GUACUGGA 1396 UCCAGUAC CUGAUGAG GCCGUUAGGC CGAA IGAGGUCA 5189 3165 UCCUGUAC U GGAGAGAC 1397 GUCUCUCC CUGAUGAG GCCGUUAGGC CGAA IUACAGGA 5190 3174 GGAGAGAC A UUAAGAAG 1398 CUUCUUAA CUGAUGAG GCCGUUAGGC CGAA IUCUCUCC 5191 3185 AAGAAGAC U GGAGUGGU 1399 ACCACUCC CUGAUGAG GCCGUUAGGC CGAA IUCUUCUU 5192 3203 UUUGGUGC C AGCCUAUU 1400 AAUAGGCU CUGAUGAG GCCGUUAGGC CGAA ICACCAAA 5193 3204 UUGGUGCC A GCCUAUUC 1401 GAAUAGGC CUGAUGAG GCCGUUAGGC CGAA IGCACCAA 5194 3207 GUGCCAGC C UAUUCCUG 1402 CAGGAAUA CUGAUGAG GCCGUUAGGC CGAA ICUGGCAC 5195 3208 UGCCAGCC U AUUCCUGC 1403 GCAGGAAU CUGAUGAG GCCGUUAGGC CGAA IGCUGGCA 5196 3213 GCCUAUUC C UGCUGCUU 1404 AAGCAGCA CUGAUGAG GCCGUUAGGC CGAA IAAUAGGC 5197 3214 CCUAUUCC U GCUGCUUU 1405 AAAGCAGC CUGAUGAG GCCGUUAGGC CGAA IGAAUAGG 5198 3217 AUUCCUGC U GCUUUCAU 1406 AUGAAAGC CUGAUGAG GCCGUUAGGC CGAA ICAGGAAU 5199 3220 CCUGCUGC U UUCAUUGA 1407 UCAAUGAA CUGAUGAG GCCGUUAGGC CGAA ICAGCAGG 5200 3224 CUGCUUUC A UUGACAGU 1408 ACUGUCAA CUGAUGAG GCCGUUAGGC CGAA IAAAGCAG 5201 3230 UCAUUGAC A GUAUUCAG 1409 CUGAAUAC CUGAUGAG GCCGUUAGGC CGAA IUCAAUGA 5202 3237 CAGUAUUC A GCAUUGUG 1410 CACAAUGC CUGAUGAG GCCGUUAGGC CGAA IAAUACUG 5203 3240 UAUUCAGC A UUGUGAGC 1411 GCUCACAA CUGAUGAG GCCGUUAGGC CGAA ICUGAAUA 5204 3254 AGCGUAAC A GCCUACAU 1412 AUGUAGGC CUGAUGAG GCCGUUAGGC CGAA lUUACGCU 5205 3257 GUAACAGC C UACAUUGC 1413 GCAAUGUA CUGAUGAG GCCGUUAGGC CGAA ICUGUUAC 5206 3258 UAACAGCC U ACAUUGCC 1414 GGCAAUGU CUGAUGAG GCCGUUAGGC CGAA IGCUGUUA 5207 3261 CAGCCUAC A UUGCCUUG 1415 CAAGGCAA CUGAUGAG GCCGUUAGGC CGAA IUAGGCUG 5208 3266 UACAUUGC C UUGGCCCU 1416 AGGGCCAA CUGAUGAG GCCGUUAGGC CGAA ICAAUGUA 5209 3267 ACAUUGCC U UGGCCCUG 1417 CAGGGCCA CUGAUGAG GCCGUUAGGC CGAA IGCAAUGU 5210 3272 GCCUUGGC C CUGCUCUC 1418 GAGAGCAG CUGAUGAG GCCGUUAGGC CGAA ICCAAGGC 5211 3273 CCUUGGCC c UGCUCUCU 1419 AGAGAGGA CUGAUGAG GCCGUUAGGC CGAA IGCCAAGG 5212 3274 CUUGGCCC u GCUCUCUG 1420 CAGAGAGC CUGAUGAG GCCGUUAGGC CGAA IGGCCAAG 5213 3277 GGCCCUGC U CUCUGUGA 1421 UCACAGAG CUGAUGAG GCCGUUAGGC CGAA ICAGGGCC 5214 3279 CCCUGCUC U CUGUGACC 1422 GGUCACAG CUGAUGAG GCCGUUAGGC CGAA IAGCAGGG 5215 3281 CUGCUCUC U GUGACCAU 1423 AUGGUCAC CUGAUGAG GCCGUUAGGC CGAA IAGAGCAG 5216 3287 UCUGUGAC C AUCAGCUU 1424 AAGCUGAU CUGAUGAG GCCGUUAGGC CGAA lUCACAGA 5217 3288 CUGUGACC A UCAGCUUU 1425 AAAGCUGA CUGAUGAG GCCGUUAGGC CGAA IGUCACAG 5218 3291 UGACCAUC A GCUUUAGG 1426 CCUAAAGC CUGAUGAG GCCGUUAGGC CGAA IAUGGUCA 5219 3294 CCAUCAGC U UUAGGAUA 1427 UAUCCUAA CUGAUGAG GCCGUUAGGC CGAA ICUGAUGG 5220 3306 GGAUAUAC A AGGGUGUG 1428 CACACCCU CUGAUGAG GCCGUUAGGC CGAA IUAUAUCC 5221 3318 GUGUGAUC C AAGCUAUC 1429 GAUAGCUU CUGAUGAG GCCGUUAGGC CGAA IAUCACAC 5222 3319 UGUGAUCC A AGCUAUCC 1430 GGAUAGCU CUGAUGAG GCCGUUAGGC CGAA IGAUCACA 5223 3323 AUCCAAGC U AUCCAGAA 1431 UUCUGGAU CUGAUGAG GCCGUUAGGC CGAA ICUUGGAU 5224 3327 AAGCUAUC C AGAAAUCA 1432 UGAUUUCU CUGAUGAG GCCGUUAGGC CGAA IAUAGCUU 5225 3328 AGCUAUCC A GAAAUCAG 1433 CUGAUUUC CUGAUGAG GCCGUUAGGC CGAA IGAUAGCU 5226 3335 CAGAAAUC A GAUGAAGG 1434 CCUUCAUC CUGAUGAG GCCGUUAGGC CGAA IAUUUCUG 5227 3345 AUGAAGGC C ACCCAUUC 1435 GAAUGGGU CUGAUGAG GCCGUUAGGC CGAA ICCUUCAU 5228 3346 UGAAGGCC A CCCAUUCA 1436 UGAAUGGG CUGAUGAG GCCGUUAGGC CGAA IGCCUUCA 5229 3348 AAGGCCAC C CAUUCAGG 1437 CCUGAAUG CUGAUGAG GCCGUUAGGC CGAA IUGGCCUU 5230 3349 AGGCCACC C AUUCAGGG 1438 CCCUGAAU CUGAUGAG GCCGUUAGGC CGAA IGUGGCCU 5231 3350 GGCCACCC A UUCAGGGC 1439 GCCCUGAA CUGAUGAG GCCGUUAGGC CGAA IGGUGGCC 5232 3354 ACCCAUUC A GGGCAUAU 1440 AUAUGCCC CUGAUGAG GCCGUUAGGC CGAA IAAUGGGU 5233 3359 UUCAGGGC A UAUCUGGA 1441 UCCAGAUA CUGAUGAG GCCGUUAGGC CGAA ICCCUGAA 5234 3364 GGCAUAUC U GGAAUCUG 1442 CAGAUUCC CUGAUGAG GCCGUUAGGC CGAA IAUAUGCC 5235 3371 CUGGAAUC U GAAGUUGC 1443 GCAACUUC CUGAUGAG GCCGUUAGGC CGAA IAUUCCAG 5236 3380 GAAGUUGC U AUAUCUGA 1444 UCAGAUAU CUGAUGAG GCCGUUAGGC CGAA ICAACUUC 5237 3386 GCUAUAUC U GAGGAGUU 1445 AACUCCUC CUGAUGAG GCCGUUAGGC CGAA IAUAUAGC 5238 3400 GUUGGUUC A GAAGUACA 1446 UGUACUUC CUGAUGAG GCCGUUAGGC CGAA lAACCAAC 5239 3408 AGAAGUAC A GUAAUUCU 1447 AGAAUUAC CUGAUGAG GCCGUUAGGC CGAA IUACUUCU 5240 3416 AGUAAUUC U GCUCUUGG 1448 CCAAGAGC CUGAUGAG GCCGUUAGGC CGAA IAAUUACU 5241 3419 AAUUCUGC U CUUGGUCA 1449 UGACCAAG CUGAUGAG GCCGUUAGGC CGAA ICAGAAUU 5242 3421 UUCUGCUC U UGGUCAUG 1450 CAUGACCA CUGAUGAG GCCGUUAGGC CGAA IAGCAGAA 5243 3427 UCUUGGUC A UGUGAACU 1451 AGUUCACA CUGAUGAG GCCGUUAGGC CGAA lACCAAGA 5244 3435 AUGUGAAC U GCACGAUA 1452 UAUCGUGC CUGAUGAG GCCGUUAGGC CGAA IUUCACAU 5245 3438 UGAACUGC A CGAUAAAG 1453 CUUUAUCG CUGAUGAG GCCGUUAGGC CGAA ICAGUUCA 5246 3451 AAAGGAAC U CAGGCGCC 1454 GGCGCCUG CUGAUGAG GCCGUUAGGC CGAA IUUCCUUU 5247 3453 AGGAACUC A GGCGCCUC 1455 GAGGCGCC CUGAUGAG GCCGUUAGGC CGAA IAGUUCCU 5248 3459 UCAGGCGC C UCUUCUUA 1456 UAAGAAGA CUGAUGAG GCCGUUAGGC CGAA ICGCCUGA 5249 3460 CAGGCGCC U CUUCUUAG 1457 CUAAGAAG CUGAUGAG GCCGUUAGGC CGAA IGCGCCUG 5250 3462 GGCGCCUC U UCUUAGUU 1458 AACUAAGA CUGAUGAG GCCGUUAGGC CGAA IAGGCGCC 5251 3465 GCCUCUUC U UAGUUGAU 1459 AUCAACUA CUGAUGAG GCCGUUAGGC CGAA IAAGAGGC 5252 3488 GUUGAUUC U CUGAAGUU 1460 AACUUCAG CUGAUGAG GCCGUUAGGC CGAA IAAUCAAC 5253 3490 UGAUUCUC U GAAGUUUG 1461 CAAACUUC CUGAUGAG GCCGUUAGGC CGAA IAGAAUCA 5254 3500 AAGUUUGC A GUGUUGAU 1462 AUCAACAC CUGAUGAG GCCGUUAGGC CGAA ICAAACUU 5255 3521 GUAUUUAC C UAUGUUGG 1463 CCAACAUA CUGAUGAG GCCGUUAGGC CGAA IUAAAUAC 5256 3522 UAUUUACC U AUGUUGGU 1464 ACCAACAU CUGAUGAG GCCGUUAGGC CGAA IGUAAAUA 5257 3533 GUUGGUGC C UUGUUUAA 1465 UUAAACAA CUGAUGAG GCCGUUAGGC CGAA ICACCAAC 5258 3534 UUGGUGCC U UGUUUAAU 1466 AUUAAACA CUGAUGAG GCCGUUAGGC CGAA IGCACCAA 5259 3547 UAAUGGUC U GACACUAC 1467 GUAGUGUC CUGAUGAG GCCGUUAGGC CGAA IACCAUUA 5260 3551 GGUCUGAC A CUACUGAU 1468 AUCAGUAG CUGAUGAG GCCGUUAGGC CGAA IUCAGACC 5261 3553 UCUGACAC U ACUGAUUU 1469 AAAUCAGU CUGAUGAG GCCGUUAGGC CGAA IUGUCAGA 5262 3556 GACACUAC U GAUUUUGG 1470 CCAAAAUC CUGAUGAG GCCGUUAGGC CGAA IUAGUGUC 5263 3566 AUUUUGGC U CUCAUUUC 1471 GAAAUGAG CUGAUGAG GCCGUUAGGC CGAA ICCAAAAU 5264 3568 UUUGGCUC U CAUUUCAC 1472 GUGAAAUG CUGAUGAG GCCGUUAGGC CGAA IAGCCAAA 5265 3570 UGGCUCUC A UUUCACUC 1473 GAGUGAAA CUGAUGAG GCCGUUAGGC CGAA IAGAGCCA 5266 3575 CUCAUUUC A CUCUUCAG 1474 CUGAAGAG CUGAUGAG GCCGUUAGGC CGAA IAAAUGAG 5267 3577 CAUUUCAC U CUUCAGUG 1475 CACUGAAG CUGAUGAG GCCGUUAGGC CGAA IUGAAAUG 5268 3579 UUUCACUC U UCAGUGUU 1476 AACACUGA CUGAUGAG GCCGUUAGGC CGAA IAGUGAAA 5269 3582 CACUCUUC A GUGUUCCU 1477 AGGAACAC CUGAUGAG GCCGUUAGGC CGAA IAAGAGUG 5270 3589 CAGUGUUC C UGUUAUUU 1478 AAAUAACA CUGAUGAG GCCGUUAGGC CGAA IAACACUG 5271 3590 AGUGUUCC U GUUAUUUA 1479 UAAAUAAC CUGAUGAG GCCGUUAGGC CGAA IGAACACU 5272 3607 UGAACGGC A UCAGGCAC 1480 GUGCCUGA CUGAUGAG GCCGUUAGGC CGAA ICCGUUCA 5273 3610 ACGGCAUC A GGCACAGA 1481 UCUGUGCC CUGAUGAG GCCGUUAGGC CGAA IAUGCCGU 5274 3614 CAUCAGGC A CAGAUAGA 1482 UCUAUCUG CUGAUGAG GCCGUUAGGC CGAA ICCUGAUG 5275 3616 UCAGGCAC A GAUAGAUC 1483 GAUCUAUC CUGAUGAG GCCGUUAGGC CGAA IUGCCUGA 5276 3625 GAUAGAUC A UUAUCUAG 1484 CUAGAUAA CUGAUGAG GCCGUUAGGC CGAA IAUCUAUC 5277 3631 UCAUUAUC U AGGACUUG 1485 CAAGUCCU CUGAUGAG GCCGUUAGGC CGAA IAUAAUGA 5278 3637 UCUAGGAC U UGCAAAUA 1486 UAUUUGCA CUGAUGAG GCCGUUAGGC CGAA lUCCUAGA 5279 3641 GGACUUGC A AAUAAGAA 1487 UUCUUAUU CUGAUGAG GCCGUUAGGC CGAA ICAAGUCC 5280 3662 AAAGAUGC U AUGGCUAA 1488 UUAGCCAU CUGAUGAG GCCGUUAGGC CGAA ICAUCUUU 5281 3668 GCUAUGGC U AAAAUCCA 1489 UGGAUUUU CUGAUGAG GCCGUUAGGC CGAA ICCAUAGC 5282 3675 CUAAAAUC C AAGCAAAA 1490 UUUUGCUU CUGAUGAG GCCGUUAGGC CGAA IAUUUUAG 5283 3676 UAAAAUCC A AGGAAAAA 1491 UUUUUGCU CUGAUGAG GCCGUUAGGC CGAA IGAUUUUA 5284 3680 AUCCAAGC A AAAAUCCC 1492 GGGAUUUU CUGAUGAG GCCGUUAGGC CGAA ICUUGGAU 5285 3687 CAAAAAUC C CUGGAUUG 1493 CAAUCCAG CUGAUGAG GCCGUUAGGC CGAA IAUUUUUG 5286 3688 AAAAAUCC C UGGAUUGA 1494 UCAAUCCA CUGAUGAG GCCGUUAGGC CGAA IGAUUUUU 5287 3689 AAAAUCCC U GGAUUGAA 1495 UUCAAUCC CUGAUGAG GCCGUUAGGC CGAA IGGAUUUU 5288 3702 UGAAGCGC A AAGCUGAA 1496 UUCAGCUU CUGAUGAG GCCGUUAGGC CGAA ICGCUUCA 5289 3707 CGCAAAGC U GAAUGAAA 1497 UUUCAUUC CUGAUGAG GCCGUUAGGC CGAA ICUUUGCG 5290 3720 GAAAACGC C CAAAAUAA 1498 UUAUUUUG CUGAUGAG GCCGUUAGGC CGAA ICGUUUUC 5291 3721 AAAACGCC C AAAAUAAU 1499 AUUAUUUU CUGAUGAG GCCGUUAGGC CGAA IGCGUUUU 5292 3722 AAACGCCC A AAAUAAUU 1500 AAUUAUUU CUGAUGAG GCCGUUAGGC CGAA IGGCGUUU 5293 3742 AGGAGUUC A UCUUUAAA 1501 UUUAAAGA CUGAUGAG GCCGUUAGGC CGAA IAACUCCU 5294 3745 AGUUCAUC U UUAAAGGG 1502 CCCUUUAA CUGAUGAG GCCGUUAGGC CGAA IAUGAACU 5295 3761 GGAUAUUC A UUUGAUUA 1503 UAAUCAAA CUGAUGAG GCCGUUAGGC CGAA IAAUAUCC 5296 3784 GGAGGGUC A GGGAAGAA 1504 UUCUUCCC CUGAUGAG GCCGUUAGGC CGAA IACCCUCC 5297 3798 GAACGAAC C UUGACGUU 1505 AACGUCAA CUGAUGAG GCCGUUAGGC CGAA IUUCGUUC 5298 3799 AACGAACC U UGACGUUG 1506 CAACGUCA CUGAUGAG GCCGUUAGGC CGAA IGUUCGUU 5299 3809 GACGUUGC A GUGCAGUU 1507 AACUGCAC CUGAUGAG GCCGUUAGGC CGAA ICAACGUC 5300 3814 UGCAGUGC A GUUUCACA 1508 UGUGAAAC CUGAUGAG GCCGUUAGGC CGAA ICACUGCA 5301 3820 GCAGUUUC A CAGAUCGU 1509 ACGAUCUG CUGAUGAG GCCGUUAGGC CGAA IAAACUGC 5302 3822 AGUUUCAC A GAUCGUUG 1510 CAACGAUC CUGAUGAG GCCGUUAGGC CGAA IUGAAACU 5303 3838 GUUAGAUC U UUAUUUUU 1511 AAAAAUAA CUGAUGAG GCCGUUAGGC CGAA IAUCUAAC 5304 3850 UUUUUAGC C AUGCACUG 1512 CAGUGCAU CUGAUGAG GCCGUUAGGC CGAA ICUAAAAA 5305 3851 UUUUAGCC A UGCACUGU 1513 ACAGUGCA CUGAUGAG GCCGUUAGGC CGAA IGCUAAAA 5306 3855 AGCCAUGC A CUGUUGUG 1514 CACAACAG CUGAUGAG GCCGUUAGGC CGAA ICAUGGCU 5307 3857 CCAUGCAC U GUUGUGAG 1515 CUCACAAC CUGAUGAG GCCGUUAGGC CGAA IUGCAUGG 5308 3876 AAAAUUAC C UGUCUUGA 1516 UCAAGACA CUGAUGAG GCCGUUAGGC CGAA IUAAUUUU 5309 3877 AAAUUAGC U GUCUUGAC 1517 GUCAAGAC CUGAUGAG GCCGUUAGGC CGAA IGUAAUUU 5310 3881 UACCUGUC U UGACUGCC 1518 GGCAGUCA CUGAUGAG GCCGUUAGGC CGAA IACAGGUA 5311 3886 GUCUUGAC U GCCAUGUG 1519 CACAUGGC CUGAUGAG GCCGUUAGGC CGAA IUCAAGAC 5312 3889 UUGACUGC C AUGUGUUC 1520 GAACACAU CUGAUGAG GCCGUUAGGC CGAA ICAGUCAA 5313 3890 UGACUGCC A UGUGUUCA 1521 UGAACACA CUGAUGAG GCCGUUAGGC CGAA IGCAGUCA 5314 3898 AUGUGUUC A UCAUCUUA 1522 UAAGAUGA CUGAUGAG GCCGUUAGGC CGAA IAACACAU 5315 3901 UGUUCAUC A UCUUAAGU 1523 ACUUAAGA CUGAUGAG GCCGUUAGGC CGAA IAUGAACA 5316 3904 UCAUCAUC U UAAGUAUU 1524 AAUACUUA CUGAUGAG GCCGUUAGGC CGAA IAUGAUGA 5317 3919 UUGUAAGC U GCUAUGUA 1525 UACAUAGC CUGAUGAG GCCGUUAGGC CGAA ICUUACAA 5318 3922 UAAGCUGC U AUGUAUGG 1526 CCAUACAU CUGAUGAG GCCGUUAGGC CGAA ICAGCUUA 5319 3939 AUUUAAAC C GUAAUCAU 1527 AUGAUUAC CUGAUGAG GCCGUUAGGC CGAA IUUUAAAU 5320 3946 CCGUAAUC A ' UAUCUUUU 1528 AAAAGAUA CUGAUGAG GCCGUUAGGC CGAA IAUUACGG 5321 3951 AUCAUAUC U UUUUCCUA 1529 UAGGAAAA CUGAUGAG GCCGUUAGGC CGAA IAUAUGAU 5322 3957 UCUUUUUC C UAUCUGAG 1530 CUCAGAUA CUGAUGAG GCCGUUAGGC CGAA IAAAAAGA 5323 3958 CUUUUUGC U AUCUGAGG 1531 CCUCAGAU CUGAUGAG GCCGUUAGGC CGAA IGAAAAAG 5324 3962 UUCCUAUC u GAGGCACU 1532 AGUGCCUC CUGAUGAG GCCGUUAGGC CGAA IAUAGGAA 5325 3968 UCUGAGGC A CUGGUGGA 1533 UCCACCAG CUGAUGAG GCCGUUAGGC CGAA ICCUCAGA 5326 3970 UGAGGCAC U GGUGGAAU 1534 AUUCCACC CUGAUGAG GCCGUUAGGC CGAA IUGCCUCA 5327 3986 UAAAAAAC C UGUAUAUU 1535 AAUAUACA CUGAUGAG GCCGUUAGGC CGAA IUUUUUUA 5328 3987 AAAAAACC U GUAUAUUU 1536 AAAUAUAC CUGAUGAG GCCGUUAGGC CGAA IGUUUUUU 5329 3999 UAUUUUAC u UUGUUGCA 1537 UGCAACAA CUGAUGAG GCCGUUAGGC CGAA IUAAAAUA 5330 4007 UUUGUUGC A GAUAGUCU 1538 AGACUAUC CUGAUGAG GCCGUUAGGC CGAA ICAACAAA 5331 4015 AGAUAGUC U UGCCGCAU 1539 AUGCGGCA CUGAUGAG GCCGUUAGGC CGAA IACUAUCU 5332 4019 AGUCUUGC C GCAUCUUG 1540 CAAGAUGC CUGAUGAG GCCGUUAGGC CGAA ICAAGACU 5333 4022 CUUGCCGC A UCUUGGCA 1541 UGCCAAGA CUGAUGAG GCCGUUAGGC CGAA ICGGCAAG 5334 4025 GCCGCAUC U UGGCAAGU 1542 ACUUGCCA CUGAUGAG GCCGUUAGGC CGAA IAUGCGGC 5335 4030 AUCUUGGC A AGUUGCAG 1543 CUGCAACU CUGAUGAG GCCGUUAGGC CGAA ICCAAGAU 5336 4037 CAAGUUGC A GAGAUGGU 1544 ACCAUCUC CUGAUGAG GCCGUUAGGC CGAA ICAACUUG 5337 Input Sequence = AB020693. Cut Site = CH/ . Stem Length = 8 . Core Sequence = CUGAUGAG GCCGUUAGGC CGAA AB020693 (Homo sapiens mRNA for KIAA0886 protein (Nogo-A) ; 4053 bp) Underlined region may be any X sequence or linker, as previously described herein. I = Inosine Table V: Human NOGO G-Cleaver and Substrate Sequence Pos Substrate Seq ID G-Cleaver Seq ID 66 CCACAACC G CCCGCGGC 1545 GCCGCGGG UGAUG GCAUGCACUAUGC GCG GGUUGUGG 5338 70 AACCGCCC G CGGCUCUG 1546 CAGAGCCG UGAUG GCAUGCACUAUGC GCG GGGCGGUU 5339 78 GCGGCUCU G AGACGCGG 1547 CCGCGUCU UGAUG GCAUGCACUAUGC GCG AGAGCCGC 5340 83 UCUGAGAC G CGGCCCCG 1548 CGGGGCCG UGAUG GCAUGCACUAUGC GCG GUCUCAGA 5341 110 CAGCAGCU G CAGCAUCA 1549 UGAUGCUG UGAUG GCAUGCACUAUGC GCG AGCUGCUG 5342 191 CCCCGGCC G CAGCCCGC 1550 GCGGGCUG UGAUG GCAUGCACUAUGC GCG GGCCGGGG 5343 198 CGCAGCCC G CGUUCAAG 1551 CUUGAACG UGAUG GCAUGCACUAUGC GCG GGGCUGCG 5344 218 CAGUUCGU G AGGGAGCC 1552 GGCUCCCU UGAUG GCAUGCACUAUGC GCG ACGAACUG 5345 228 GGGAGCCC G AGGACGAG 1553 CUCGUCCU UGAUG GCAUGCACUAUGC GCG GGGCUCCC 5346 234 CCGAGGAC G AGGAGGAA 1554 UUCCUCCU UGAUG GCAUGCACUAUGC GCG GUCCUCGG 5347 267 AGGAGGAC G AGGACGAA 1555 UUCGUCCU UGAUG GCAUGCACUAUGC GCG GUCCUCCU 5348 273 ACGAGGAC G AAGACCUG 1556 CAGGUCUU UGAUG GCAUGCACUAUGC GCG GUCCUCGU 5349 296 CUGGAGGU G CUGGAGAG 1557 CUCUCCAG UGAUG GCAUGCACUAUGC GCG ACCUCCAG 5350 312 GGAAGCCC G CCGCCGGG 1558 CCCGGCGG UGAUG GCAUGCACUAUGC GCG GGGCUUCC 5351 315 AGCCCGCC G CCGGGCUG 1559 CAGCCCGG UGAUG GCAUGCACUAUGC GCG GGCGGGCU 5352 327 GGCUGUCC G CGGCCCCA 1560 UGGGGCCG UGAUG GCAUGCACUAUGC GCG GGACAGCC 5353 338 GCCCCAGU G CCCACCGC 1561 GCGGUGGG UGAUG GCAUGCACUAUGC GCG ACUGGGGC 5354 345 UGCCCACC G CCCCUGCC 1562 GGCAGGGG UGAUG GCAUGCACUAUGC GCG GGUGGGCA 5355 351 CCGCCCCU G CCGCCGGC 1563 GCCGGCGG UGAUG GCAUGCACUAUGC GCG AGGGGCGG 5356 354 CCCCUGCC G CCGGCGCG 1564 CGCGCCGG UGAUG GCAUGCACUAUGC GCG GGCAGGGG 5357 360 CCGCCGGC G CGCCCCUG 1565 CAGGGGCG UGAUG GCAUGCACUAUGC GCG GCCGGCGG 5358 362 GCCGGCGC G CCCCUGAU 1566 AUCAGGGG UGAUG GCAUGCACUAUGC GCG GCGCCGGC 5359 368 GCGCCCCU G AUGGACUU 1567 AAGUCCAU UGAUG GCAUGCACUAUGC GCG AGGGGCGC 5360 384 UCGGAAAU G ACUUCGUG 1568 CACGAAGU UGAUG GCAUGCACUAUGC GCG AUUUCCGA 5361 392 GACUUCGU G CCGCCGGC 1569 GCCGGCGG UGAUG GCAUGCACUAUGC GCG ACGAAGUC 5362 395 UUCGUGCC G CCGGCGCC 1570 GGCGCCGG UGAUG GCAUGCACUAUGC GCG GGCACGAA 5363 401 CCGCCGGC G CCCCGGGG 1571 CCCCGGGG UGAUG GCAUGCACUAUGC GCG GCCGGCGG 5364 416 GGACCCCU G CCGGCCGC 1572 GCGGCCGG UGAUG GCAUGCACUAUGC GCG AGGGGUCC 5365 423 UGCCGGCC G CUCCCGCC 1573 GGGGGGAG UGAUG GCAUGCACUAUGC GCG GGCCGGCA 5366 435 CCCCCGUC G CCCCGGAG 1574 CUCCGGGG UGAUG GCAUGCACUAUGC GCG GACGGGGG 5367 464 UGGGACCC G AGCCCGGU 1575 ACCGGGCU UGAUG GCAUGCACUAUGC GCG GGGUCCCA 5368 479 GUGUCGUC G ACCGUGCC 1576 GGCACGGU UGAUG GCAUGCACUAUGC GCG GACGACAC 5369 485 UCGACCGU G CCCGCGCC 1577 GGCGCGGG UGAUG GCAUGCACUAUGC GCG ACGGUCGA 5370 489 CCGUGCCC G CGCCAUCC 1578 GGAUGGCG UGAUG GCAUGCACUAUGC GCG GGGCACGG 5371 491 GUGCCCGC G CCAUCCCC 1579 GGGGAUGG UGAUG GCAUGCACUAUGC GCG GCGGGCAC 5372 500 CCAUCCCC G CUGUCUGC 1580 GCAGACAG UGAUG GCAUGCACUAUGC GCG GGGGAUGG 5373 507 CGCUGUCU G CUGCCGCA 1581 UGCGGCAG UGAUG GCAUGCACUAUGC GCG AGACAGCG 5374 510 UGUCUGCU G CCGCAGUC 1582 GACUGCGG UGAUG GCAUGCACUAUGC GCG AGCAGACA 5375 513 CUGCUGCC G CAGUCUCG 1583 CGAGACUG UGAUG GCAUGCACUAUGC GCG GGCAGCAG 5376 521 GCAGUCUC G CCCUCCAA 1584 UUGGAGGG UGAUG GCAUGCACUAUGC GCG GAGACUGC 5377 537 AGCUCCCU G AGGACGAC 1585 GUCGUCCU UGAUG GCAUGCACUAUGC GCG AGGGAGCU 5378 543 CUGAGGAC G ACGAGCCU 1586 AGGCUCGU UGAUG GCAUGCACUAUGC GCG GUCCUCAG 5379 546 AGGACGAC G AGCCUCCG 1587 CGGAGGCU UGAUG GCAUGCACUAUGC GCG GUCGUCCU 5380 587 GCCAGCGU G AGCCCCCA 1588 UGGGGGCU UGAUG GCAUGCACUAUGC GCG ACGCUGGC 5381 617 UGGACCCC G CCAGCCCC 1589 GGGGCUGG UGAUG GCAUGCACUAUGC GCG GGGGUCCA 5382 633 CGGCUCCC G CCGCGCCC 1590 GGGCGCGG UGAUG GCAUGCACUAUGC GCG GGGAGCCG 5383 636 CUCCCGCC G CGCGCCCC 1591 GGGGGGCG UGAUG GCAUGCACUAUGC GCG GGCGGGAG 5384 638 CCCGCCGC G CCCCCCUC 1592 GAGGGGGG UGAUG GCAUGCACUAUGC GCG GCGGCGGG 5385 657 CCCCGGCC G CGCCCAAG 1593 CUUGGGCG UGAUG GCAUGCACUAUGC GCG GGCCGGGG 5386 659 CCGGCCGC G CCCAAGCG 1594 CGCUUGGG UGAUG GCAUGCACUAUGC GCG GCGGCCGG 5387 667 GCCCAAGC G CAGGGGCU 1595 AGCCCCUG UGAUG GCAUGCACUAUGC GCG GCUUGGGC 5388 693 CAGUGGAU G AGACCCUU 1596 AAGGGUCU UGAUG GCAUGCACUAUGC GCG AUCCACUG 5389 705 CCCUUUUU G CUCUUCCU 1597 AGGAAGAG UGAUG GCAUGCACUAUGC GCG AAAAAGGG 5390 714 CUCUUCCU G CUGCAUCU 1598 AGAUGCAG UGAUG GCAUGCACUAUGC GCG AGGAAGAG 5391 717 UUCCUGCU G CAUCUGAG 1599 CUCAGAUG UGAUG GCAUGCACUAUGC GCG AGCAGGAA 5392 723 CUGCAUCU G AGCCUGUG 1600 CACAGGCU UGAUG GCAUGCACUAUGC GCG AGAUGCAG 5393 731 GAGCCUGU G AUACGCUC 1601 GAGCGUAU UGAUG GCAUGCACUAUGC GCG ACAGGCUC 5394 736 UGUGAUAC G CUCCUCUG 1602 CAGAGGAG UGAUG GCAUGCACUAUGC GCG GUAUCACA 5395 744 GCUCCUCU G CAGAAAAU 1603 AUUUUCUG UGAUG GCAUGCACUAUGC GCG AGAGGAGC 5396 761 AUGGACUU G AAGGAGCA 1604 UGCUCCUU UGAUG GCAUGCACUAUGC GCG AAGUCCAU 5397 818 UCUGUCCU G CUUGAAAC 1605 GUUUCAAG UGAUG GCAUGCACUAUGC GCG AGGACAGA 5398 822 UCCUGCUU G AAACUGCU 1606 AGCAGUUU UGAUG GCAUGCACUAUGC GCG AAGCAGGA 5399 828 UUGAAACU G CUGCUUCU 1607 AGAAGCAG UGAUG GCAUGCACUAUGC GCG AGUUUCAA 5400 831 AAACUGCU G CUUCUCUU 1608 AAGAGAAG UGAUG GCAUGCACUAUGC GCG AGCAGUUU 5401 864 UCUCAGCC G CUUCUUUC 1609 GAAAGAAG UGAUG GCAUGCACUAUGC GCG GGCUGAGA 5402 882 AAGAACAU G AAUACCUU 1610 AAGGUAUU UGAUG GCAUGCACUAUGC GCG AUGUUCUU 5403 918 UACCCACU G AAGGAACA 1611 UGUUCCUU UGAUG GCAUGCACUAUGC GCG AGUGGGUA 5404 945 AUGUCAGU G AAGCUUCU 1612 AGAAGCUU UGAUG GCAUGCACUAUGC GCG ACUGACAU 5405 1071 CAGAAUCU G CCGUAAUA 1613 UAUUACGG UGAUG GCAUGCACUAUGC GCG AGAUUCUG 5406 1109 AUAAUCGU G AAAAAUAA 1614 UUAUUUUU UGAUG GCAUGCACUAUGC GCG ACGAUUAU 5407 1122 AUAAAGAU G AAGAAGAG 1615 CUCUUCUU UGAUG GCAUGCACUAUGC GCG AUCUUUAU 5408 1206 AAGAGGAU G AAGUUGUG 1616 CACAACUU UGAUG GCAUGCACUAUGC GCG AUCCUCUU 5409 1245 GUUUUAAU G AAAAGAGA 1617 UCUCUUUU UGAUG GCAUGCACUAUGC GCG AUUAAAAC 5410 1257 AGAGAGUU G CAGUGGAA 1618 UUCCACUG UGAUG GCAUGCACUAUGC GCG AACUCUCU 5411 1274 GCUCCUAU G AGGGAGGA 1619 UCCUCCCU UGAUG GCAUGCACUAUGC GCG AUAGGAGC 5412 1287 AGGAAUAU G CAGACUUC 1620 GAAGUCUG UGAUG GCAUGCACUAUGC GCG AUAUUCCU 5413 1305 AACCAUUU G AGCGAGUA 1621 UACUCGCU UGAUG GCAUGCACUAUGC GCG AAAUGGUU 5414 1309 AUUUGAGC G AGUAUGGG 1622 CCCAUACU UGAUG GCAUGCACUAUGC GCG GCUCAAAU 5415 1322 UGGGAAGU G AAAGAUAG 1623 CUAUCUUU UGAUG GCAUGCACUAUGC GCG ACUUCCCA 5416 1344 AAGAUAGU G AUAUGUUG 1624 CAACAUAU UGAUG GCAUGCACUAUGC GCG ACUAUCUU 5417 1356 UGUUGGCU G CUGGAGGU 1625 ACCUCCAG UGAUG GCAUGCACUAUGC GCG AGCCAACA 5418 1371 GUAAAAUC G AGAGCAAC 1626 GUUGCUCU UGAUG GCAUGCACUAUGC GCG GAUUUUAC 5419 1410 AAUGUUUU G CAGAUAGC 1627 GCUAUCUG UGAUG GCAUGCACUAUGC GCG AAAACAUU 5420 1422 AUAGCCUU G AGCAAACU 1628 AGUUUGCU UGAUG GCAUGCACUAUGC GCG AAGGCUAU 5421 1437 CUAAUCAC G AAAAAGAU 1629 AUCUUUUU UGAUG GCAUGCACUAUGC GCG GUGAUUAG 5422 1449 AAGAUAGU G AGAGUAGU 1630 ACUACUCU UGAUG GCAUGCACUAUGC GCG ACUAUCUU 5423 1461 GUAGUAAU G AUGAUACU 1631 AGUAUCAU UGAUG GCAUGCACUAUGC GCG AUUACUAC 5424 1464 GUAAUGAU G AUACUUCU 1632 AGAAGUAU UGAUG GCAUGCACUAUGC GCG AUCAUUAC 5425 1484 CCCAGUAC G CCAGAAGG 1633 CCUUCUGG UGAUG GCAUGCACUAUGC GCG GUACUGGG 5426 1527 UCACAUGU G CUCCCUUU 1634 AAAGGGAG UGAUG GCAUGCACUAUGC GCG ACAUGUGA 5427 1551 CAGCAACU G AGAGCAUU 1635 AAUGCUCU UGAUG GCAUGCACUAUGC GCG AGUUGCUG 5428 1560 AGAGCAUU G CAACAAAC 1636 GUUUGUUG UGAUG GCAUGCACUAUGC GCG AAUGCUCU 5429 1611 AUAAGACC G AUGAAAAA 1637 UUUUUCAU UGAUG GCAUGCACUAUGC GCG GGUCUUAU 5430 1614 AGACCGAU G AAAAAAAA 1638 UUUUUUUU UGAUG GCAUGCACUAUGC GCG AUCGGUCU 5431 1710 AGGAUUCU G AGACAGAU 1639 AUCUGUCU UGAUG GCAUGCACUAUGC GCG AGAAUCCU 5432 1748 ACAAAGGU G ACUGAGGA 1640 UCCUCAGU UGAUG GCAUGCACUAUGC GCG ACCUUUGU 5433 1752 AGGUGACU G AGGAAGUC 1641 GACUUCCU UGAUG GCAUGCACUAUGC GCG AGUCACCU 5434 1772 GCAAACAU G CCUGAAGG 1642 CCUUCAGG UGAUG GCAUGCACUAUGC GCG AUGUUUGC 5435 1776 ACAUGCCU G AAGGCCUG 1643 CAGGCCUU UGAUG GCAUGCACUAUGC GCG AGGCAUGU 5436 1784 GAAGGCCU G ACUCCAGA 1644 UCUGGAGU UGAUG GCAUGCACUAUGC GCG AGGCCUUC 5437 1812 AAGCAUGU G AAAGUGAA 1645 UUCACUUU UGAUG GCAUGCACUAUGC GCG ACAUGCUU 5438 1818 GUGAAAGU G AAUUGAAU 1646 AUUCAAUU UGAUG GCAUGCACUAUGC GCG ACUUUCAC 5439 1823 AGUGAAUU G AAUGAAGU 1647 ACUUCAUU UGAUG GCAUGCACUAUGC GCG AAUUCACU 5440 1827 AAUUGAAU G AAGUUACU 1648 AGUAACUU UGAUG GCAUGCACUAUGC GCG AUUCAAUU 5441 1848 CAAAGAUU G CUUAUGAA 1649 UUCAUAAG UGAUG GCAUGCACUAUGC GCG AAUCUUUG 5442 1854 UUGCUUAU G AAACAAAA 1650 UUUUGUUU UGAUG GCAUGCACUAUGC GCG AUAAGCAA 5443 1892 GAAGUUAU G CAAGAGUC 1651 GACUCUUG UGAUG GCAUGCACUAUGC GCG AUAACUUC 5444 1911 UCUAUCCU G CAGCACAG 1652 CUGUGCUG UGAUG GCAUGCACUAUGC GCG AGGAUAGA 5445 1924 ACAGCUUU G CCCAUCAU 1653 AUGAUGGG UGAUG GCAUGCACUAUGC GCG AAAGCUGU 5446 1935 CAUCAUUU G AAGAGUCA 1654 UGACUCUU UGAUG GCAUGCACUAUGC GCG AAAUGAUG 5447 1967 CCAGUUUU G CCUGACAU 1655 AUGUCAGG UGAUG GCAUGCACUAUGC GCG AAAACUGG 5448 1971 UUUUGCCU G ACAUUGUU 1656 AACAAUGU UGAUG GCAUGCACUAUGC GCG AGGCAAAA 5449 1994 GCACCAUU G AAUUCUGC 1657 GCAGAAUU UGAUG GCAUGCACUAUGC GCG AAUGGUGC 5450 2001 UGAAUUCU G CAGUUCCU 1658 AGGAACUG UGAUG GCAUGCACUAUGC GCG AGAAUUCA 5451 2013 UUCCUAGU G CUGGUGCU 1659 AGCACCAG UGAUG GCAUGCACUAUGC GCG ACUAGGAA 5452 2019 GUGCUGGU G CUUCCGUG 1660 CACGGAAG UGAUG GCAUGCACUAUGC GCG ACCAGCAC 5453 2027 GCUUCCGU G AUACAGCC 1661 GGCUGUAU UGAUG GCAUGCACUAUGC GCG ACGGAAGC 5454 2073 UUAAUUAU G AAAGCAUA 1662 UAUGCUUU UGAUG GCAUGCACUAUGC GCG AUAAUUAA 5455 2088 UAAAACAU G AGCCUGAA 1663 UUCAGGCU UGAUG GCAUGCACUAUGC GCG AUGUUUUA 5456 2094 AUGAGCCU G AAAACCCC 1664 GGGGUUUU UGAUG GCAUGCACUAUGC GCG AGGCUCAU 5457 2112 CACCAUAU G AAGAGGCC 1665 GGCCUCUU UGAUG GCAUGCACUAUGC GCG AUAUGGUG 5458 2123 GAGGCCAU G AGUGUAUC 1666 GAUACACU UGAUG GCAUGCACUAUGC GCG AUGGCCUC 5459 2175 AAGAGCCU G AAAAUAUU 1667 AAUAUUUU UGAUG GCAUGCACUAUGC GCG AGGCUCUU 5460 2187 AUAUUAAU G CAGCUCUU 1668 AAGAGCUG UGAUG GCAUGCACUAUGC GCG AUUAAUAU 5461 2226 UAUCUAUU G CAUGUGAU 1669 AUCACAUG UGAUG GCAUGCACUAUGC GCG AAUAGAUA 5462 2232 UUGCAUGU G AUUUAAUU 1670 AAUUAAAU UGAUG GCAUGCACUAUGC GCG ACAUGCAA 5463 2259 AGCUUUCU G CUGAACCA 1671 UGGUUCAG UGAUG GCAUGCACUAUGC GCG AGAAAGCU 5464 2262 UUUCUGCU G AACCAGCU 1672 AGCUGGUU UGAUG GCAUGCACUAUGC GCG AGCAGAAA 5465 2283 AUUUCUCU G AUUAUUCA 1673 UGAAUAAU UGAUG GCAUGCACUAUGC GCG AGAGAAAU 5466 2307 CAAAAGUU G AACAGCCA 1674 UGGCUGUU UGAUG GCAUGCACUAUGC GCG AACUUUUG 5467 2318 CAGCCAGU G CCUGAUCA 1675 UGAUCAGG UGAUG GCAUGCACUAUGC GCG ACUGGCUG 5468 2322 CAGUGCCU G AUCAUUCU 1676 AGAAUGAU UGAUG GCAUGCACUAUGC GCG AGGCACUG 5469 2331 AUCAUUCU G AGCUAGUU 1677 AACUAGCU UGAUG GCAUGCACUAUGC GCG AGAAUGAU 5470 2340 AGCUAGUU G AAGAUUCC 1678 GGAAUCUU UGAUG GCAUGCACUAUGC GCG AACUAGCU 5471 2355 CCUCACCU G AUUCUGAA 1679 UUCAGAAU UGAUG GCAUGCACUAUGC GCG AGGUGAGG 5472 2361 CUGAUUCU G AACCAGUU 1680 AACUGGUU UGAUG GCAUGCACUAUGC GCG AGAAUCAG 5473 2370 AACCAGUU G ACUUAUUU 1681 AAAUAAGU UGAUG GCAUGCACUAUGC GCG AACUGGUU 5474 2382 UAUUUAGU G AUGAUUCA 1682 UGAAUCAU UGAUG GCAUGCACUAUGC GCG ACUAAAUA 5475 2385 UUAGUGAU G AUUCAAUA 1683 UAUUGAAU UGAUG GCAUGCACUAUGC GCG AUCACUAA 5476 2397 CAAUACCU G ACGUUCCA 1684 UGGAACGU UGAUG GCAUGCACUAUGC GCG AGGUAUUG 5477 2418 AACAAGAU G AAACUGUG 1685 CACAGUUU UGAUG GCAUGCACUAUGC GCG AUCUUGUU 5478 2426 GAAACUGU G AUGCUUGU 1686 ACAAGCAU UGAUG GCAUGCACUAUGC GCG ACAGUUUC 5479 2429 ACUGUGAU G CUUGUGAA 1687 UUCACAAG UGAUG GCAUGCACUAUGC GCG AUCACAGU 5480 2435 AUGCUUGU G AAAGAAAG 1688 CUUUCUUU UGAUG GCAUGCACUAUGC GCG ACAAGCAU 5481 2451 GUCUCACU G AGACUUCA 1689 UGAAGUCU UGAUG GCAUGCACUAUGC GCG AGUGAGAC 5482 2463 CUUCAUUU G AGUCAAUG 1690 CAUUGACU UGAUG GCAUGCACUAUGC GCG AAAUGAAG 5483 2471 GAGUCAAU G AUAGAAUA 1691 UAUUCUAU UGAUG GCAUGCACUAUGC GCG AUUGACUC 5484 2481 UAGAAUAU G AAAAUAAG 1692 CUUAUUUU UGAUG GCAUGCACUAUGC GCG AUAUUCUA 5485 2502 AACUCAGU G CUUUGCCA 1693 UGGCAAAG UGAUG GCAUGCACUAUGC GCG ACUGAGUU 5486 2507 AGUGCUUU G CCACCUGA 1694 UCAGGUGG UGAUG GCAUGCACUAUGC GCG AAAGCACU 5487 2514 UGCCACCU G AGGGAGGA 1695 UCCUCCCU UGAUG GCAUGCACUAUGC GCG AGGUGGCA 5488 2583 UGUUACCU G AUGAAGUU 1696 AACUUCAU UGAUG GCAUGCACUAUGC GCG AGGUAACA 5489 2586 UACCUGAU G AAGUUUCA 1697 UGAAACUU UGAUG GCAUGCACUAUGC GCG AUCAGGUA 5490 2600 UCAACAUU G AGCAAAAA 1698 UUUUUGCU UGAUG GCAUGCACUAUGC GCG AAUGUUGA 5491 2624 AUUCCUUU G CAGAUGGA 1699 UCCAUCUG UGAUG GCAUGCACUAUGC GCG AAAGGAAU 5492 2646 UCAGUACU G CAGUUUAU 1700 AUAAACUG UGAUG GCAUGCACUAUGC GCG AGUACUGA 5493 2661 AUUCAAAU G AUGACUUA 1701 UAAGUCAU UGAUG GCAUGCACUAUGC GCG AUUUGAAU 5494 2664 CAAAUGAU G ACUUAUUU 1702 AAAUAAGU UGAUG GCAUGCACUAUGC GCG AUCAUUUG 5495 2703 GAGAAACU G AAACGUUU 1703 AAACGUUU UGAUG GCAUGCACUAUGC GCG AGUUUCUC 5496 2730 CUCCAAUU G AAAUUAUA 1704 UAUAAUUU UGAUG GCAUGCACUAUGC GCG AAUUGGAG 5497 2742 UUAUAGAU G AGUUCCCU 1705 AGGGAACU UGAUG GCAUGCACUAUGC GCG AUCUAUAA 5498 2756 CCUACAUU G AUCAGUUC 1706 GAACUGAU UGAUG GCAUGCACUAUGC GCG AAUGUAGG 5499 2772 CUAAAACU G AUUCAUUU 1707 AAAUGAAU UGAUG GCAUGCACUAUGC GCG AGUUUUAG 5500 2805 AAUAUACU G ACCUAGAA 1708 UUCUAGGU UGAUG GCAUGCACUAUGC GCG AGUAUAUU 5501 2829 ACAAAAGU G AAAUUGCU 1709 AGCAAUUU UGAUG GCAUGCACUAUGC GCG ACUUUUGU 5502 2835 GUGAAAUU G CUAAUGCC 1710 GGCAUUAG UGAUG GCAUGCACUAUGC GCG AAUUUCAC 5503 2841 UUGCUAAU G CCCCGGAU 1711 AUCCGGGG UGAUG GCAUGCACUAUGC GCG AUUAGCAA 5504 2864 GGGUCAUU G CCUUGCAC 1712 GUGCAAGG UGAUG GCAUGCACUAUGC GCG AAUGACCC 5505 2869 AUUGCCUU G CACAGAAU 1713 AUUCUGUG UGAUG GCAUGCACUAUGC GCG AAGGCAAU 5506 2879 ACAGAAUU G CCCCAUGA 1714 UCAUGGGG UGAUG GCAUGCACUAUGC GCG AAUUCUGU 5507 2886 UGCCCCAU G ACCUUUCU 1715 AGAAAGGU UGAUG GCAUGCACUAUGC GCG AUGGGGCA 5508 2897 CUUUCUUU G AAGAACAU 1716 AUGUUCUU UGAUG GCAUGCACUAUGC GCG AAAGAAAG 5509 2919 CCAAAGUU G AAGAGAAA 1717 UUUCUCUU UGAUG GCAUGCACUAUGC GCG AACUUUGG 5510 2943 UCUCAGAU G ACUUUUCU 1718 AGAAAAGU UGAUG GCAUGCACUAUGC GCG AUCUGAGA 5511 2964 AUGGGUCU G CUACAUCA 1719 UGAUGUAG UGAUG GCAUGCACUAUGC GCG AGACCCAU 5512 2978 UCAAAGGU G CUCUUAUU 1720 AAUAAGAG UGAUG GCAUGCACUAUGC GCG ACCUUUGA 5513 2987 CUGUUAUU G CCUCCAGA 1721 UCUGGAGG UGAUG GCAUGCACUAUGC GCG AAUAAGAG 5514 3003 AUGUUUCU G CUUUGGCC 1722 GGCCAAAG UGAUG GCAUGCACUAUGC GCG AGAAACAU 5515 3056 GUUCUUGU G AAAGAAGC 1723 GCUUCUUU UGAUG GCAUGCACUAUGC GCG ACAAGAAC 5516 3066 AAGAAGCU G AGAAAAAA 1724 UUUUUUCU UGAUG GCAUGCACUAUGC GCG AGCUUCUU 5517 3084 UUCCUUCC G AUACAGAA 1725 UUCUGUAU UGAUG GCAUGCACUAUGC GCG GGAAGGAA 5518 3114 CACCAUCU G CUAUAUUU 1726 AAAUAUAG UGAUG GCAUGCACUAUGC GCG AGAUGGUG 5519 3134 GCAGAGCU G AGUAAAAC 1727 GUUUUACU UGAUG GCAUGCACUAUGC GCG AGCUCUGC 5520 3153 CAGUUGUU G ACCUCCUG 1728 CAGGAGGU UGAUG GCAUGCACUAUGC GCG AACAACUG 5521 3201 UGUUUGGU G CCAGCCUA 1729 UAGGCUGG UGAUG GCAUGCACUAUGC GCG ACCAAACA 5522 3215 CUAUUCCU G CUGCUUUC 1730 GAAAGCAG UGAUG GCAUGCACUAUGC GCG AGGAAUAG 5523 3218 UUCCUGCU G CUUUCAUU 1731 AAUGAAAG UGAUG GCAUGCACUAUGC GCG AGCAGGAA 5524 3227 CUUUCAUU G ACAGUAUU 1732 AAUACUGU UGAUG GCAUGCACUAUGC GCG AAUGAAAG 5525 3245 AGCAUUGU G AGCGUAAC 1733 GUUACGCU UGAUG GCAUGCACUAUGC GCG ACAAUGCU 5526 3264 CCUACAUU G CCUUGGCC 1734 GGCCAAGG UGAUG GCAUGCACUAUGC GCG AAUGUAGG 5527 3275 UUGGCCCU G CUCUCUGU 1735 ACAGAGAG UGAUG GCAUGCACUAUGC GCG AGGGCCAA 5528 3284 CUCUCUGU G ACCAUCAG 1736 CUGAUGGU UGAUG GCAUGCACUAUGC GCG ACAGAGAG 5529 3314 AAGGGUGU G AUCCAAGC 1737 GCUUGGAU UGAUG GCAUGCACUAUGC GCG ACACCCUU 5530 3339 AAUCAGAU G AAGGCCAC 1738 GUGGCCUU UGAUG GCAUGCACUAUGC GCG AUCUGAUU 5531 3372 UGGAAUCU G AAGUUGCU 1739 AGCAACUU UGAUG GCAUGCACUAUGC GCG AGAUUCCA 5532 3378 CUGAAGUU G CUAUAUCU 1740 AGAUAUAG UGAUG GCAUGCACUAUGC GCG AACUUCAG 5533 3387 CUAUAUCU G AGGAGUUG 1741 CAACUCCU UGAUG GCAUGCACUAUGC GCG AGAUAUAG 5534 3417 GUAAUUCU G CUCUUGGU 1742 ACCAAGAG UGAUG GCAUGCACUAUGC GCG AGAAUUAC 5535 3431 GGUCAUGU G AACUGCAC 1743 GUGCAGUU UGAUG GCAUGCACUAUGC GCG ACAUGACC 5536 3436 UGUGAACU G CACGAUAA 1744 UUAUCGUG UGAUG GCAUGCACUAUGC GCG AGUUCACA 5537 3440 AACUGCAC G AUAAAGGA 1745 UCCUUUAU UGAUG GCAUGCACUAUGC GCG GUGCAGUU 5538 3457 ACUCAGGC G CCUCUUCU 1746 AGAAGAGG UGAUG GCAUGCACUAUGC GCG GCCUGAGU 5539 3471 UCUUAGUU G AUGAUUUA 1747 UAAAUCAU UGAUG GCAUGCACUAUGC GCG AACUAAGA 5540 3474 UAGUUGAU G AUUUAGUU 1748 AACUAAAU UGAUG GCAUGCACUAUGC GCG AUCAACUA 5541 3483 AUUUAGUU G AUUCUCUG 1749 CAGAGAAU UGAUG GCAUGCACUAUGC GCG AACUAAAU 5542 3491 GAUUCUCU G AAGUUUGC 1750 GCAAACUU UGAUG GCAUGCACUAUGC GCG AGAGAAUC 5543 3498 UGAAGUUU G CAGUGUUG 1751 CAACACUG UGAUG GCAUGCACUAUGC GCG AAACUUCA 5544 3506 GCAGUGUU G AUGUGGGU 1752 ACCCACAU UGAUG GCAUGCACUAUGC GCG AACACUGC 5545 3531 AUGUUGGU G CCUUGUUU 1753 AAACAAGG UGAUG GCAUGCACUAUGC GCG ACCAACAU 5546 3548 AAUGGUCU G ACACUACU 1754 AGUAGUGU UGAUG GCAUGCACUAUGC GCG AGACCAUU 5547 3557 ACACUACU G AUUUUGGC 1755 GCCAAAAU UGAUG GCAUGCACUAUGC GCG AGUAGUGU 5548 3600 UUAUUUAU G AACGGCAU 1756 AUGCCGUU UGAUG GCAUGCACUAUGC GCG AUAAAUAA 5549 3639 UAGGACUU G CAAAUAAG 1757 CUUAUUUG UGAUG GCAUGCACUAUGC GCG AAGUCCUA 5550 3660 UUAAAGAU G CUAUGGCU 1758 AGCCAUAG UGAUG GCAUGCACUAUGC GCG AUCUUUAA 5551 3695 CCUGGAUU G AAGCGCAA 1759 UUGCGCUU UGAUG GCAUGCACUAUGC GCG AAUCCAGG 5552 3700 AUUGAAGC G CAAAGCUG 1760 CAGCUUUG UGAUG GCAUGCACUAUGC GCG GCUUCAAU 5553 3708 GCAAAGCU G AAUGAAAA 1761 UUUUCAUU UGAUG GCAUGCACUAUGC GCG AGCUUUGC 5554 3712 AGCUGAAU G AAAACGCC 1762 GGCGUUUU UGAUG GCAUGCACUAUGC GCG AUUCAGCU 5555 3718 AUGAAAAC G CCCAAAAU 1763 AUUUUGGG UGAUG GCAUGCACUAUGC GCG GUUUUCAU 5556 3765 AUUCAUUU G AUUAUACG 1764 CGUAUAAU UGAUG GCAUGCACUAUGC GCG AAAUGAAU 5557 3794 GGAAGAAC G AACCUUGA 1765 UCAAGGUU UGAUG GCAUGCACUAUGC GCG GUUCUUCC 5558 3801 CGAACCUU G ACGUUGCA 1766 UGCAACGU UGAUG GCAUGCACUAUGC GCG AAGGUUCG 5559 3807 UUGACGUU G CAGUGCAG 1767 CUGCACUG UGAUG GCAUGCACUAUGC GCG AACGUCAA 5560 3812 GUUGCAGU G CAGUUUCA 1768 UGAAACUG UGAUG GCAUGCACUAUGC GCG ACUGCAAC 5561 3853 UUAGCCAU G CACUGUUG 1769 CAACAGUG UGAUG GCAUGCACUAUGC GCG AUGGCUAA 5562 3863 ACUGUUGU G AGGAAAAA 1770 UUUUUCCU UGAUG GCAUGCACUAUGC GCG ACAACAGU 5563 3883 CCUGUCUU G ACUGCCAU 1771 AUGGCAGU UGAUG GCAUGCACUAUGC GCG AAGACAGG 5564 3887 UCUUGACU G CCAUGUGU 1772 ACACAUGG UGAUG GCAUGCACUAUGC GCG AGUCAAGA 5565 3920 UGUAAGCU G CUAUGUAU 1773 AUACAUAG UGAUG GCAUGCACUAUGC GCG AGCUUACA 5566 3963 UCCUAUCU G AGGCACUG 1774 CAGUGCCU UGAUG GCAUGCACUAUGC GCG AGAUAGGA 5567 4005 ACUUUGUU G CAGAUAGU 1775 ACUAUCUG UGAUG GCAUGCACUAUGC GCG AACAAAGU 5568 4017 AUAGUCUU G CCGCAUCU 1776 AGAUGCGG UGAUG GCAUGCACUAUGC GCG AAGACUAU 5569 4020 GUCUUGCC G CAUCUUGG 1777 CCAAGAUG UGAUG GCAUGCACUAUGC GCG GGCAAGAC 5570 4035 GGCAAGUU G CAGAGAUG 1778 CAUCUCUG UGAUG GCAUGCACUAUGC GCG AACUUGCC 5571 Input Sequence = AB020693. Cut Site = YG/M or UG/U. Stem Length = 8. Core Sequence = UGAUG GCAUGCACUAUGC GCG AB020693 (Homo sapiens mRHA for KIAA0886 protein (Nogo-A) ; 4053 bp) Table VI: Human NOGO Zinzyme and Substrate Sequence Pos Substrate Seq ID Zinzyme Seq ID 66 CCACAACC G CCCGCGGC 1545 GCCGCGGG GCCGAAAGGCGAGUCAAGGUCU GGUUGUGG 5572 70 AACCGCCC G CGGCUCUG 1546 CAGAGCCG GCCGAAAGGCGAGUCAAGGUCU GGGCGGUU 5573 83 UCUGAGAC G CGGCCCCG 1548 CGGGGCCG GCCGAAAGGCGAGUCAAGGUCU GUCUCAGA 5574 110 CAGCAGCU G CAGCAUCA 1549 UGAUGCUG GCCGAAAGGCGAGUCAAGGUCU AGCUGCUG 5575 191 CCCCGGCC G CAGCCCGC 1550 GCGGGCUG GCCGAAAGGCGAGUCAAGGUCU GGCCGGGG 5576 198 CGCAGCCC G CGUUCAAG 1551 CUUGAACG GCCGAAAGGCGAGUCAAGGUCU GGGCUGCG 5577 296 CUGGAGGU G CUGGAGAG 1557 CUCUCCAG GCCGAAAGGCGAGUCAAGGUCU ACCUCCAG 5578 312 GGAAGCCC G CCGCCGGG 1558 CCCGGCGG GCCGAAAGGCGAGUCAAGGUCU GGGCUUCC 5579 315 AGCCCGCC G CCGGGCUG 1559 CAGCCCGG GCCGAAAGGCGAGUCAAGGUCU GGCGGGCU 5580 327 GGCUGUCC G CGGCCCCA 1560 UGGGGCCG GCCGAAAGGCGAGUCAAGGUCU GGACAGCC 5581 338 GCCCCAGU G CCCACCGC 1561 GCGGUGGG GCCGAAAGGCGAGUCAAGGUCU ACUGGGGC 5582 345 UGCCCACC G CCCCUGCC 1562 GGCAGGGG GCCGAAAGGCGAGUCAAGGUCU GGUGGGCA 5583 351 CCGCCCCU G CCGCCGGC 1563 GCCGGCGG GCCGAAAGGCGAGUCAAGGUCU AGGGGCGG 5584 354 CCCCUGCC G CCGGCGCG 1564 CGCGCCGG GCCGAAAGGCGAGUCAAGGUCU GGCAGGGG 5585 360 CCGCCGGC G CGCCCCUG 1565 CAGGGGCG GCCGAAAGGCGAGUCAAGGUCU GCCGGCGG 5586 362 GCCGGCGC G CCCCUGAU 1566 AUCAGGGG GCCGAAAGGCGAGUCAAGGUCU GCGCCGGC 5587 392 GACUUCGU G CCGCCGGC 1569 GCCGGCGG GCCGAAAGGCGAGUCAAGGUCU ACGAAGUC 5588 395 UUCGUGCC G CCGGCGGC 1570 GGCGCCGG GCCGAAAGGCGAGUCAAGGUCU GGCACGAA 5589 401 CCGCCGGC G CCCCGGGG 1571 CCCCGGGG GCCGAAAGGCGAGUCAAGGUCU GCCGGCGG 5590 416 GGACCCCU G CCGGCCGC 1572 GCGGCCGG GCCGAAAGGCGAGUCAAGGUCU AGGGGUCC 5591 423 UGCCGGCC G CUCCCCCC 1573 GGGGGGAG GCCGAAAGGCGAGUCAAGGUCU GGCCGGCA 5592 435 CCCCCGUC G CCCCGGAG 1574 CUCCGGGG GCCGAAAGGCGAGUCAAGGUCU GACGGGGG 5593 485 UCGACCGU G CCCGCGGC 1577 GGCGCGGG GCCGAAAGGCGAGUCAAGGUCU ACGGUCGA 5594 489 CCGUGCCC G CGCCAUCC 1578 GGAUGGCG GCCGAAAGGCGAGUCAAGGUCU GGGCACGG 5595 491 GUGCCCGC G CCAUCCCC 1579 GGGGAUGG GCCGAAAGGCGAGUCAAGGUCU GCGGGCAC 5596 500 CCAUCCCC G CUGUCUGC 1580 GCAGACAG GCCGAAAGGCGAGUCAAGGUCU GGGGAUGG 5597 507 CGCUGUCU G CUGCCGCA 1581 UGCGGCAG GCCGAAAGGCGAGUCAAGGUCU AGACAGCG 5598 510 UGUCUGCU G CCGCAGUC 1582 GACUGCGG GCCGAAAGGCGAGUCAAGGUCU AGCAGACA 5599 513 CUGCUGCC G CAGUCUCG 1583 CGAGACUG GCCGAAAGGCGAGUCAAGGUCU GGCAGCAG 5600 521 GCAGUCUC G CCCUCCAA 1584 UUGGAGGG GCCGAAAGGCGAGUCAAGGUCU GAGACUGC 5601 617 UGGACCCC G CCAGCCCC 1589 GGGGCUGG GCCGAAAGGCGAGUCAAGGUCU GGGGUCCA 5602 633 CGGCUCCC G CCGCGCCC 1590 GGGCGCGG GCCGAAAGGCGAGUCAAGGUCU GGGAGCCG 5603 636 CUCCCGCC G CGCCCCCC 1591 GGGGGGCG GCCGAAAGGCGAGUCAAGGUCU GGCGGGAG 5604 638 CCCGCCGC G CCCCCCUC 1592 GAGGGGGG GCCGAAAGGCGAGUCAAGGUCU GCGGCGGG 5605 657 CCCCGGCC G CGCCCAAG 1593 CUUGGGCG GCCGAAAGGCGAGUCAAGGUCU GGCCGGGG 5606 659 CCGGCCGC G CCCAAGCG 1594 CGCUUGGG GCCGAAAGGCGAGUCAAGGUCU GCGGCCGG 5607 667 GCCCAAGC G CAGGGGCU 1595 AGCCCCUG GCCGAAAGGCGAGUCAAGGUCU GCUUGGGC 5608 705 CCCUUUUU G CUCUUCCU 1597 AGGAAGAG GCCGAAAGGCGAGUCAAGGUCU AAAAAGGG 5609 714 CUCUUCCU G CUGCAUCU 1598 AGAUGCAG GCCGAAAGGCGAGUCAAGGUCU AGGAAGAG 5610 717 UUCCUGCU G CAUCUGAG 1599 CUCAGAUG GCCGAAAGGCGAGUCAAGGUCU AGCAGGAA 5611 736 UGUGAUAC G CUCCUCUG 1602 CAGAGGAG GCCGAAAGGCGAGUCAAGGUCU GUAUCACA 5612 744 GCUCCUCU G CAGAAAAU 1603 AUUUUCUG GCCGAAAGGCGAGUCAAGGUCU AGAGGAGC 5613 818 UCUGUCCU G CUUGAAAC 1605 GUUUCAAG GCCGAAAGGCGAGUCAAGGUCU AGGACAGA 5614 828 UUGAAACU G CUGCUUCU 1607 AGAAGCAG GCCGAAAGGCGAGUCAAGGUCU AGUUUCAA 5615 831 AAACUGCU G CUUCUCUU 1608 AAGAGAAG GCCGAAAGGCGAGUCAAGGUCU AGCAGUUU 5616 864 UCUCAGCC G CUUCUUUC 1609 GAAAGAAG GCCGAAAGGCGAGUCAAGGUCU GGCUGAGA 5617 1071 CAGAAUCU G CCGUAAUA 1613 UAUUACGG GCCGAAAGGCGAGUCAAGGUCU AGAUUCUG 5618 1257 AGAGAGUU G CAGUGGAA 1618 UUCCACUG GCCGAAAGGCGAGUCAAGGUCU AACUCUCU 5619 1287 AGGAAUAU G CAGACUUC 1620 GAAGUCUG GCCGAAAGGCGAGUCAAGGUCU AUAUUCCU 5620 1356 UGUUGGCU G CUGGAGGU 1625 ACCUCCAG GCCGAAAGGCGAGUCAAGGUCU AGCCAACA 5621 1410 AAUGUUUU G CAGAUAGC 1627 GCUAUCUG GCCGAAAGGCGAGUCAAGGUCU AAAACAUU 5622 1484 CCCAGUAC G CCAGAAGG 1633 CCUUCUGG GCCGAAAGGCGAGUCAAGGUCU GUACUGGG 5623 1527 UCACAUGU G CUCCCUUU 1634 AAAGGGAG GCCGAAAGGCGAGUCAAGGUCU ACAUGUGA 5624 1560 AGAGCAUU G CAACAAAC 1636 GUUUGUUG GCCGAAAGGCGAGUCAAGGUCU AAUGCUCU 5625 1772 GCAAACAU G CCUGAAGG 1642 CCUUCAGG GCCGAAAGGCGAGUCAAGGUCU AUGUUUGC 5626 1848 CAAAGAUU G CUUAUGAA 1649 UUCAUAAG GCCGAAAGGCGAGUCAAGGUCU AAUCUUUG 5627 1892 GAAGUUAU G CAAGAGUC 1651 GACUCUUG GCCGAAAGGCGAGUCAAGGUCU AUAACUUC 5628 1911 UCUAUCCU G CAGCACAG 1652 CUGUGCUG GCCGAAAGGCGAGUCAAGGUCU AGGAUAGA 5629 1924 ACAGCUUU G CCCAUCAU 1653 AUGAUGGG GCCGAAAGGCGAGUCAAGGUCU AAAGCUGU 5630 1967 CCAGUUUU G CCUGACAU 1655 AUGUCAGG GCCGAAAGGCGAGUCAAGGUCU AAAACUGG 5631 2001 UGAAUUCU G CAGUUCCU 1658 AGGAACUG GCCGAAAGGCGAGUCAAGGUCU AGAAUUCA 5632 2013 UUCCUAGU G CUGGUGCU 1659 AGCACCAG GCCGAAAGGCGAGUCAAGGUCU ACUAGGAA 5633 2019 GUGCUGGU G CUUCCGUG 1660 CACGGAAG GCCGAAAGGCGAGUCAAGGUCU ACCAGCAC 5634 2187 AUAUUAAU G CAGCUCUU 1668 AAGAGCUG GCCGAAAGGCGAGUCAAGGUCU AUUAAUAU 5635 2226 UAUCUAUU G CAUGUGAU 1669 AUCACAUG GCCGAAAGGCGAGUCAAGGUCU AAUAGAUA 5636 2259 AGCUUUCU G CUGAACCA 1671 UGGUUCAG GCCGAAAGGCGAGUCAAGGUCU AGAAAGCU 5637 2318 CAGCCAGU G CCUGAUCA 1675 UGAUCAGG GCCGAAAGGCGAGUCAAGGUCU ACUGGCUG 5638 2429 ACUGUGAU G CUUGUGAA 1687 UUCACAAG GCCGAAAGGCGAGUCAAGGUCU AUCACAGU 5639 2502 AACUCAGU G CUUUGCCA 1693 UGGCAAAG GCCGAAAGGCGAGUCAAGGUCU ACUGAGUU 5640 2507 AGUGCUUU G CCACCUGA 1694 UCAGGUGG GCCGAAAGGCGAGUCAAGGUCU AAAGCACU 5641 2624 AUUCCUUU G CAGAUGGA 1699 UCCAUCUG GCCGAAAGGCGAGUCAAGGUCU AAAGGAAU 5642 2646 UCAGUACU G CAGUUUAU 1700 AUAAACUG GCCGAAAGGCGAGUCAAGGUCU AGUACUGA 5643 2835 GUGAAAUU G CUAAUGCC 1710 GGCAUUAG GCCGAAAGGCGAGUCAAGGUCU AAUUUCAC 5644 2841 UUGCUAAU G CCCCGGAU 1711 AUCCGGGG GCCGAAAGGCGAGUCAAGGUCU AUUAGCAA 5645 2864 GGGUCAUU G CCUUGCAC 1712 GUGCAAGG GCCGAAAGGCGAGUCAAGGUCU AAUGACCC 5646 2869 AUUGCCUU G CACAGAAU 1713 AUUCUGUG GCCGAAAGGCGAGUCAAGGUCU AAGGCAAU 5647 2879 ACAGAAUU G CCCCAUGA 1714 UCAUGGGG GCCGAAAGGCGAGUCAAGGUCU AAUUCUGU 5648 2964 AUGGGUCU G CUACAUCA 1719 UGAUGUAG GCCGAAAGGCGAGUCAAGGUCU AGACCCAU 5649 2978 UCAAAGGU G CUGUUAUU 1720 AAUAAGAG GCCGAAAGGCGAGUCAAGGUCU ACCUUUGA 5650 2987 CUGUUAUU G CCUCCAGA 1721 UCUGGAGG GCCGAAAGGCGAGUCAAGGUCU AAUAAGAG 5651 3003 AUGUUUCU G CUUUGGCC 1722 GGCCAAAG GCCGAAAGGCGAGUCAAGGUCU AGAAACAU 5652 3114 CACCAUCU G CUAUAUUU 1726 AAAUAUAG GCCGAAAGGCGAGUCAAGGUCU AGAUGGUG 5653 3201 UGUUUGGU G CCAGCCUA 1729 UAGGCUGG GCCGAAAGGCGAGUCAAGGUCU ACCAAACA 5654 3215 CUAUUCCU G CUGCUUUC 1730 GAAAGCAG GCCGAAAGGCGAGUCAAGGUCU AGGAAUAG 5655 3218 UUCCUGCU G CUUUCAUU 1731 AAUGAAAG GCCGAAAGGCGAGUCAAGGUCU AGCAGGAA 5656 3264 CCUACAUU G CCUUGGCC 1734 GGCCAAGG GCCGAAAGGCGAGUCAAGGUCU AAUGUAGG 5657 3275 UUGGCCCU G CUCUCUGU 1735 ACAGAGAG GCCGAAAGGCGAGUCAAGGUCU AGGGCCAA 5658 3378 CUGAAGUU G CUAUAUCU 1740 AGAUAUAG GCCGAAAGGCGAGUCAAGGUCU AACUUCAG 5659 3417 GUAAUUCU G CUCUUGGU 1742 ACCAAGAG GCCGAAAGGCGAGUCAAGGUCU AGAAUUAC 5660 3436 UGUGAACU G CACGAUAA 1744 UUAUCGUG GCCGAAAGGCGAGUCAAGGUCU AGUUCACA 5661 3457 ACUCAGGC G CCUCUUCU 1746 AGAAGAGG GCCGAAAGGCGAGUCAAGGUCU GCCUGAGU 5662 3498 UGAAGUUU G CAGUGUUG 1751 CAACACUG GCCGAAAGGCGAGUCAAGGUCU AAACUUCA 5663 3531 AUGUUGGU G CCUUGUUU 1753 AAACAAGG GCCGAAAGGCGAGUCAAGGUCU ACCAACAU 5664 3639 UAGGACUU G CAAAUAAG 1757 CUUAUUUG GCCGAAAGGCGAGUCAAGGUCU AAGUCCUA 5665 3660 UUAAAGAU G CUAUGGCU 1758 AGCCAUAG GCCGAAAGGCGAGUCAAGGUCU AUCUUUAA 5666 3700 AUUGAAGC G CAAAGCUG 1760 CAGCUUUG GCCGAAAGGCGAGUCAAGGUCU GCUUCAAU 5667 3718 AUGAAAAC G CCCAAAAU 1763 AUUUUGGG GCCGAAAGGCGAGUCAAGGUCU GUUUUCAU 5668 3807 UUGACGUU G CAGUGCAG 1767 CUGCACUG GCCGAAAGGCGAGUCAAGGUCU AACGUCAA 5669 3812 GUUGCAGU G CAGUUUCA 1768 UGAAACUG GCCGAAAGGCGAGUCAAGGUCU ACUGCAAC 5670 3853 UUAGCCAU G CACUGUUG 1769 CAACAGUG GCCGAAAGGCGAGUCAAGGUCU AUGGCUAA 5671 3887 UCUUGACU G CCAUGUGU 1772 ACACAUGG GCCGAAAGGCGAGUCAAGGUCU AGUCAAGA 5672 3920 UGUAAGCU G CUAUGUAU 1773 AUACAUAG GCCGAAAGGCGAGUCAAGGUCU AGCUUACA 5673 4005 ACUUUGUU G CAGAUAGU 1775 ACUAUCUG GCCGAAAGGCGAGUCAAGGUCU AACAAAGU 5674 4017 AUAGUCUU G CCGCAUCU 1776 AGAUGCGG GCCGAAAGGCGAGUCAAGGUCU AAGACUAU 5675 4020 GUCUUGCC G CAUCUUGG 1777 CCAAGAUG GCCGAAAGGCGAGUCAAGGUCU GGCAAGAC 5676 4035 GGCAAGUU G CAGAGAUG 1778 CAUCUCUG GCCGAAAGGCGAGUCAAGGUCU AACUUGCC 5677 12 CACAGUAG G UCCCUCGG 1779 CCGAGGGA GCCGAAAGGCGAGUCAAGGUCU CUACUGUG 5678 20 GUCCCUCG G CUCAGUCG 1780 CGACUGAG GCCGAAAGGCGAGUCAAGGUCU CGAGGGAC 5679 25 UCGGCUCA G UCGGCCCA 1781 UGGGCCGA GCCGAAAGGCGAGUCAAGGUCU UGAGCCGA 5680 29 CUCAGUCG G CCCAGCCC 1782 GGGCUGGG GCCGAAAGGCGAGUCAAGGUCU CGACUGAG 5681 34 UCGGCCCA G CCCCUCUC 1783 GAGAGGGG GCCGAAAGGCGAGUCAAGGUCU UGGGCCGA 5682 44 CCCUCUCA G UCCUCCCC 1784 GGGGAGGA GCCGAAAGGCGAGUCAAGGUCU UGAGAGGG 5683 73 CGCCCGCG G CUCUGAGA 1785 UCUCAGAG GCCGAAAGGCGAGUCAAGGUCU CGCGGGCG 5684 86 GAGACGCG G CCCCGGCG 1786 CGCCGGGG GCCGAAAGGCGAGUCAAGGUCU CGCGUCUC 5685 92 CGGCCCCG G CGGCGGCG 1787 CGCCGCCG GCCGAAAGGCGAGUCAAGGUCU CGGGGCCG 5686 95 CCCCGGCG G CGGCGGCA 1788 UGCCGCCG GCCGAAAGGCGAGUCAAGGUCU CGCCGGGG 5687 98 CGGCGGCG G CGGCAGCA 1789 UGCUGCCG GCCGAAAGGCGAGUCAAGGUCU CGCCGCCG 5688 101 CGGCGGCG G CAGCAGCU 1790 AGCUGCUG GCCGAAAGGCGAGUCAAGGUCU CGCCGCCG 5689 104 CGGCGGCA G CAGCUGCA 1791 UGCAGCUG GCCGAAAGGCGAGUCAAGGUCU UGCCGCCG 5690 107 CGGCAGCA G CUGCAGCA 1792 UGCUGCAG GCCGAAAGGCGAGUCAAGGUCU UGCUGCCG 5691 113 CAGCUGCA G CAUCAUCU 1793 AGAUGAUG GCCGAAAGGCGAGUCAAGGUCU UGCAGCUG 5692 132 ACCCUCCA G CCAUGGAA 1794 UUCCAUGG GCCGAAAGGCGAGUCAAGGUCU UGGAGGGU 5693 152 CUGGACCA G UCUCCUCU 1795 AGAGGAGA GCCGAAAGGCGAGUCAAGGUCU UGGUCCAG 5694 162 CUCCUCUG G UCUCGUCC 1796 GGACGAGA GCCGAAAGGCGAGUCAAGGUCU CAGAGGAG 5695 167 CUGGUCUC G UCCUCGGA 1797 UCCGAGGA GCCGAAAGGCGAGUCAAGGUCU GAGACCAG 5696 178 CUCGGACA G CCCACCCC 1798 GGGGUGGG GCCGAAAGGCGAGUCAAGGUCU UGUCCGAG 5697 188 CCACCCCG G CCGCAGCC 1799 GGCUGCGG GCCGAAAGGCGAGUCAAGGUCU CGGGGUGG 5698 194 CGGCCGCA G CCCGCGUU 1800 AACGCGGG GCCGAAAGGCGAGUCAAGGUCU UGGGGCCG 5699 200 CAGCCCGC G UUCAAGUA 1801 UACUUGAA GCCGAAAGGCGAGUCAAGGUCU GCGGGCUG 5700 206 GCGUUCAA G UACCAGUU 1802 AACUGGUA GCCGAAAGGCGAGUCAAGGUCU UUGAACGC 5701 212 AAGUACCA G UUCGUGAG 1803 CUCACGAA GCCGAAAGGCGAGUCAAGGUCU UGGUACUU 5702 216 ACCAGUUC G UGAGGGAG 1804 CUCCCUCA GCCGAAAGGCGAGUCAAGGUCU GAACUGGU 5703 224 GUGAGGGA G CCCGAGGA 1805 UCCUCGGG GCCGAAAGGCGAGUCAAGGUCU UCCCUCAC 5704 287 CUGGAGGA G CUGGAGGU 1806 ACCUCCAG GCCGAAAGGCGAGUCAAGGUCU UCCUCCAG 5705 294 AGCUGGAG G UGCUGGAG 1807 CUCCAGCA GCCGAAAGGCGAGUCAAGGUCU CUCCAGCU 5706 308 GAGAGGAA G CCCGCCGC 1808 GCGGCGGG GCCGAAAGGCGAGUCAAGGUCU UUCCUCUC 5707 320 GCCGCCGG G CUGUCCGC 1809 GCGGACAG GCCGAAAGGCGAGUCAAGGUCU CCGGCGGC 5708 323 GCCGGGCU G UCCGCGGC 1810 GCCGCGGA GCCGAAAGGCGAGUCAAGGUCU AGCCCGGC 5709 330 UGUCCGCG G CCCCAGUG 1811 CACUGGGG GCCGAAAGGCGAGUCAAGGUCU CGCGGACA 5710 336 CGGCCCCA G UGCCCACC 1812 GGUGGGCA GCCGAAAGGCGAGUCAAGGUCU UGGGGCCG 5711 358 UGCCGCCG G CGCGCCCC 1813 GGGGCGCG GCCGAAAGGCGAGUCAAGGUCU CGGCGGCA 5712 390 AUGACUUC G UGCCGCCG 1814 CGGCGGCA GCCGAAAGGCGAGUCAAGGUCU GAAGUCAU 5713 399 UGCCGCCG G CGCCCCGG 1815 CCGGGGCG GCCGAAAGGCGAGUCAAGGUCU CGGCGGCA 5714 420 CCCUGCCG G CCGCUCCC 1816 GGGAGCGG GCCGAAAGGCGAGUCAAGGUCU CGGCAGGG 5715 432 CUCCCCCC G UCGCCCCG 1817 CGGGGCGA GCCGAAAGGCGAGUCAAGGUCU GGGGGGAG 5716 443 GCCCCGGA G CGGCAGCC 1818 GGCUGCCG GCCGAAAGGCGAGUCAAGGUCU UCCGGGGC 5717 446 CCGGAGCG G CAGCCGUC 1819 GACGGCUG GCCGAAAGGCGAGUCAAGGUCU CGCUCCGG 5718 449 GAGCGGCA G CCGUCUUG 1820 CAAGACGG GCCGAAAGGCGAGUCAAGGUCU UGCCGCUC 5719 452 CGGCAGCC G UCUUGGGA 1821 UCCCAAGA GCCGAAAGGCGAGUCAAGGUCU GGCUGCCG 5720 466 GGACCCGA G CCCGGUGU 1822 ACACCGGG GCCGAAAGGCGAGUCAAGGUCU UCGGGUCC 5721 471 CGAGCCCG G UGUCGUCG 1823 CGACGACA GCCGAAAGGCGAGUCAAGGUCU CGGGCUCG 5722 473 AGCCCGGU G UCGUCGAC 1824 GUCGACGA GCCGAAAGGCGAGUCAAGGUCU ACCGGGCU 5723 476 CCGGUGUC G UCGACCGU 1825 ACGGUCGA GCCGAAAGGCGAGUCAAGGUCU GACACCGG 5724 483 CGUCGACC G UGCCCGCG 1826 CGCGGGCA GCCGAAAGGCGAGUCAAGGUCU GGUCGACG 5725 503 UCCCCGCU G UCUGCUGC 1827 GCAGCAGA GCCGAAAGGCGAGUCAAGGUCU AGCGGGGA 5726 516 CUGCCGCA G UCUCGCCC 1828 GGGCGAGA GCCGAAAGGCGAGUCAAGGUCU UGCGGCAG 5727 530 CCCUCCAA G CUCCCUGA 1829 UCAGGGAG GCCGAAAGGCGAGUCAAGGUCU UUGGAGGG 5728 548 GACGACGA G CCUCCGGC 1830 GCCGGAGG GCCGAAAGGCGAGUCAAGGUCU UCGUCGUC 5729 555 AGCCUCCG G CCCGGCCU 1831 AGGCCGGG GCCGAAAGGCGAGUCAAGGUCU CGGAGGCU 5730 560 CCGGCCCG G CCUCCCCC 1832 GGGGGAGG GCCGAAAGGCGAGUCAAGGUCU CGGGCCGG 5731 579 CUCCCCCG G CCAGCGUG 1833 CACGCUGG GCCGAAAGGCGAGUCAAGGUCU CGGGGGAG 5732 583 CCCGGCCA G CGUGAGCC 1834 GGCUCACG GCCGAAAGGCGAGUCAAGGUCU UGGCCGGG 5733 585 CGGCCAGC G UGAGCCCC 1835 GGGGCUCA GCCGAAAGGCGAGUCAAGGUCU GCUGGCCG 5734 589 CAGCGUGA G CCCCCAGG 1836 CCUGGGGG GCCGAAAGGCGAGUCAAGGUCU UCACGCUG 5735 597 GCCCCCAG G CAGAGCCC 1837 GGGCUCUG GCCGAAAGGCGAGUCAAGGUCU CUGGGGGC 5736 602 CAGGCAGA G CCCGUGUG 1838 CACACGGG GCCGAAAGGCGAGUCAAGGUCU UCUGCCUG 5737 606 CAGAGCCC G UGUGGACC 1839 GGUCCACA GCCGAAAGGCGAGUCAAGGUCU GGGCUCUG 5738 608 GAGCCCGU G UGGACCCC 1840 GGGGUCCA GCCGAAAGGCGAGUCAAGGUCU ACGGGCUC 5739 621 CCCCGCCA G CCCCGGCU 1841 AGCCGGGG GCCGAAAGGCGAGUCAAGGUCU UGGCGGGG 5740 627 CAGCCCCG G CUCCCGCC 1842 GGCGGGAG GCCGAAAGGCGAGUCAAGGUCU CGGGGCUG 5741 654 CCACCCCG G CCGCGCCC 1843 GGGCGCGG GCCGAAAGGCGAGUCAAGGUCU CGGGGUGG 5742 665 GCGCCCAA G CGCAGGGG 1844 CCCCUGCG GCCGAAAGGCGAGUCAAGGUCU UUGGGCGC 5743 673 GCGCAGGG G CUCCUCGG 1845 CCGAGGAG GCCGAAAGGCGAGUCAAGGUCU CCCUGCGC 5744 682 CUCCUCGG G CUCAGUGG 1846 CCACUGAG GCCGAAAGGCGAGUCAAGGUCU CCGAGGAG 5745 687 CGGGCUCA G UGGAUGAG 1847 CUCAUCCA GCCGAAAGGCGAGUCAAGGUCU UGAGCCCG 5746 725 GCAUCUGA G CCUGUGAU 1848 AUCACAGG GCCGAAAGGCGAGUCAAGGUCU UCAGAUGC 5747 729 CUGAGCCU G UGAUACGC 1849 GCGUAUCA GCCGAAAGGCGAGUCAAGGUCU AGGCUCAG 5748 767 UUGAAGGA G CAGCCAGG 1850 CCUGGCUG GCCGAAAGGCGAGUCAAGGUCU UCCUUCAA 5749 770 AAGGAGCA G CCAGGUAA 1851 UUACCUGG GCCGAAAGGCGAGUCAAGGUCU UGCUCCUU 5750 775 GCAGCCAG G UAACACUA 1852 UAGUGUUA GCCGAAAGGCGAGUCAAGGUCU CUGGCUGC 5751 789 CUAUUUCG G CUGGUCAA 1853 UUGACCAG GCCGAAAGGCGAGUCAAGGUCU CGAAAUAG 5752 793 UUCGGCUG G UCAAGAGG 1854 CCUCUUGA GCCGAAAGGCGAGUCAAGGUCU CAGCCGAA 5753 813 UCCCAUCU G UCCUGCUU 1855 AAGCAGGA GCCGAAAGGCGAGUCAAGGUCU AGAUGGGA 5754 848 CCUUCUCU G UCUCCUCU 1856 AGAGGAGA GCCGAAAGGCGAGUCAAGGUCU AGAGAAGG 5755 861 CUCUCUCA G CCGCUUCU 1857 AGAAGCGG GCCGAAAGGCGAGUCAAGGUCU UGAGAGAG 5756 892 AUACCUUG G UAAUUUGU 1858 ACAAAUUA GCCGAAAGGCGAGUCAAGGUCU CAAGGUAU 5757 899 GGUAAUUU G UCAACAGU 1859 ACUGUUGA GCCGAAAGGCGAGUCAAGGUCU AAAUUACC 5758 906 UGUCAACA G UAUUACCC 1860 GGGUAAUA GCCGAAAGGCGAGUCAAGGUCU UGUUGACA 5759 939 AAGAAAAU G UCAGUGAA 1861 UUCACUGA GCCGAAAGGCGAGUCAAGGUCU AUUUUCUU 5760 943 AAAUGUCA G UGAAGCUU 1862 AAGCUUCA GCCGAAAGGCGAGUCAAGGUCU UGACAUUU 5761 948 UCAGUGAA G CUUCUAAA 1863 UUUAGAAG GCCGAAAGGCGAGUCAAGGUCU UUCACUGA 5762 960 CUAAAGAG G UCUCAGAG 1864 CUCUGAGA GCCGAAAGGCGAGUCAAGGUCU CUCUUUAG 5763 972 CAGAGAAG G CAAAAACU 1865 AGUUUUUG GCCGAAAGGCGAGUCAAGGUCU CUUCUCUG 5764 1007 UUAACAGA G UUUUCAGA 1866 UCUGAAAA GCCGAAAGGCGAGUCAAGGUCU UCUGUUAA 5765 1043 GGAUCAUC G UUCAGUGU 1867 ACACUGAA GCCGAAAGGCGAGUCAAGGUCU GAUGAUCC 5766 1048 AUCGUUCA G UGUCUCUC 1868 GAGAGACA GCCGAAAGGCGAGUCAAGGUCU UGAACGAU 5767 1050 CGUUCAGU G UCUCUCCA 1869 UGGAGAGA GCCGAAAGGCGAGUCAAGGUCU ACUGAACG 5768 1062 CUCCAAAA G CAGAAUCU 1870 AGAUUCUG GCCGAAAGGCGAGUCAAGGUCU UUUUGGAG 5769 1074 AAUCUGCC G UAAUAGUA 1871 UACUAUUA GCCGAAAGGCGAGUCAAGGUCU GGCAGAUU 5770 1080 CCGUAAUA G UAGCAAAU 1872 AUUUGCUA GCCGAAAGGCGAGUCAAGGUCU UAUUACGG 5771 1083 UAAUAGUA G CAAAUCCU 1873 AGGAUUUG GCCGAAAGGCGAGUCAAGGUCU UACUAUUA 5772 1107 AAAUAAUC G UGAAAAAU 1874 AUUUUUCA GCCGAAAGGCGAGUCAAGGUCU GAUUAUUU 5773 1133 GAAGAGAA G UUAGUUAG 1875 CUAACUAA GCCGAAAGGCGAGUCAAGGUCU UUCUCUUC 5774 1137 AGAAGUUA G UUAGUAAU 1876 AUUACUAA GCCGAAAGGCGAGUCAAGGUCU UAACϋUCU 5775 1141 GUUAGUUA G UAAUAACA 1877 UGUUAUUA GCCGAAAGGCGAGUCAAGGUCU UAACUAAC 5776 1169 CAACAAGA G UUACCUAC 1878 GUAGGUAA GCCGAAAGGCGAGUCAAGGUCU UCUUGUUG 5777 1179 UACCUACA G CUCUUACU 1879 AGUAAGAG GCCGAAAGGCGAGUCAAGGUCU UGUAGGUA 5778 1194 CUAAAUUG G UUAAAGAG 1880 CUCUUUAA GCCGAAAGGCGAGUCAAGGUCU CAAUUUAG 5779 1209 AGGAUGAA G UUGUGUCU 1881 AGACACAA GCCGAAAGGCGAGUCAAGGUCU UUCAUCCU 5780 1212 AUGAAGUU G UGUCUUCA 1882 UGAAGACA GCCGAAAGGCGAGUCAAGGUCU AACUUCAU 5781 1214 GAAGUUGU G UCUUCAGA 1883 UCUGAAGA GCCGAAAGGCGAGUCAAGGUCU ACAACUUC 5782 1227 CAGAAAAA G CAAAAGAC 1884 GUCUUUUG GCCGAAAGGCGAGUCAAGGUCU UUUUUCUG 5783 1237 AAAAGACA G UUUUAAUG 1885 CAUUAAAA GCCGAAAGGCGAGUCAAGGUCU UGUCUUUU 5784 1254 AAAAGAGA G UUGCAGUG 1886 CACUGCAA GCCGAAAGGCGAGUCAAGGUCU UCUCUUUU 5785 1260 GAGUUGCA G UGGAAGCU 1887 AGCUUCCA GCCGAAAGGCGAGUCAAGGUCU UGCAACUC 5786 1266 CAGUGGAA G CUCCUAUG 1888 CAUAGGAG GCCGAAAGGCGAGUCAAGGUCU UUCCACUG 5787 1307 CCAUUUGA G CGAGUAUG 1889 CAUACUCG GCCGAAAGGCGAGUCAAGGUCU UCAAAUGG 5788 1311 UUGAGCGA G UAUGGGAA 1890 UUCCCAUA GCCGAAAGGCGAGUCAAGGUCU UCGCUCAA 5789 1320 UAUGGGAA G UGAAAGAU 1891 AUCUUUCA GCCGAAAGGCGAGUCAAGGUCU UUCCCAUA 5790 1330 GAAAGAUA G UAAGGAAG 1892 CUUCCUUA GCCGAAAGGCGAGUCAAGGUCU UAUCUUUC 5791 1342 GGAAGAUA G UGAUAUGU 1893 ACAUAUCA GCCGAAAGGCGAGUCAAGGUCU UAUCUUCC 5792 1349 AGUGAUAU G UUGGCUGC 1894 GCAGCCAA GCCGAAAGGCGAGUCAAGGUCU AUAUCACU 5793 1353 AUAUGUUG G CUGCUGGA 1895 UCCAGCAG GCCGAAAGGCGAGUCAAGGUCU CAACAUAU 5794 1363 UGCUGGAG G UAAAAUCG 1896 CGAUUUUA GCCGAAAGGCGAGUCAAGGUCU CUCCAGCA 5795 1375 AAUCGAGA G CAACUUGG 1897 CCAAGUUG GCCGAAAGGCGAGUCAAGGUCU UCUCGAUU 5796 1387 CUUGGAAA G UAAAGUGG 1898 CCACUUUA GCCGAAAGGCGAGUCAAGGUCU UUUCCAAG 5797 1392 AAAGUAAA G UGGAUAAA 1899 UUUAUCCA GCCGAAAGGCGAGUCAAGGUCU UUUACUUU 5798 1405 UAAAAAAU G UUUUGCAG 1900 CUGCAAAA GCCGAAAGGCGAGUCAAGGUCU AUUUUUUA 5799 1417 UGCAGAUA G CCUUGAGC 1901 GCUCAAGG GCCGAAAGGCGAGUCAAGGUCU UAUCUGCA 5800 1424 AGCCUUGA G CAAACUAA 1902 UUAGUUUG GCCGAAAGGCGAGUCAAGGUCU UCAAGGCU 5801 1447 AAAAGAUA G UGAGAGUA 1903 UACUCUCA GCCGAAAGGCGAGUCAAGGUCU UAUCUUUU 5802 1453 UAGUGAGA G UAGUAAUG 1904 CAUUACUA GCCGAAAGGCGAGUCAAGGUCU UCUCACUA 5803 1456 UGAGAGUA G UAAUGAUG 1905 CAUCAUUA GCCGAAAGGCGAGUCAAGGUCU UACUCUCA 5804 1480 UUUCCCCA G UACGCCAG 1906 CUGGCGUA GCCGAAAGGCGAGUCAAGGUCU UGGGGAAA 5805 1492 GCCAGAAG G UAUAAAGG 1907 CCUUUAUA GCCGAAAGGCGAGUCAAGGUCU CUUCUGGC 5806 1504 AAAGGAUC G UUCAGGAG 1908 CUCCUGAA GCCGAAAGGCGAGUCAAGGUCU GAUCCUUU 5807 1512 GUUCAGGA G CAUAUAUC 1909 GAUAUAUG GCCGAAAGGCGAGUCAAGGUCU UCCUGAAC 5808 1525 UAUCACAU G UGCUCCCU 1910 AGGGAGCA GCCGAAAGGCGAGUCAAGGUCU AUGUGAUA 5809 1542 UUAACCCA G CAGCAACU 1911 AGUUGCUG GCCGAAAGGCGAGUCAAGGUCU UGGGUUAA 5810 1545 ACCCAGCA G CAACUGAG 1912 CUCAGUUG GCCGAAAGGCGAGUCAAGGUCU UGCUGGGU 5811 1555 AACUGAGA G CAUUGCAA 1913 UUGCAAUG GCCGAAAGGCGAGUCAAGGUCU UCUCAGUU 5812 1580 UUUCCUUU G UUAGGAGA 1914 UCUCCUAA GCCGAAAGGCGAGUCAAGGUCU AAAGGAAA 5813 1638 AAAAGAAG G CCCAAAUA 1915 UAUUUGGG GCCGAAAGGCGAGUCAAGGUCU CUUCUUUU 5814 1647 CCCAAAUA G UAACAGAG 1916 CUCUGUUA GCCGAAAGGCGAGUCAAGGUCU UAUUUGGG 5815 1666 GAAUACUA G CACCAAAA 1917 UUUUGGUG GCCGAAAGGCGAGUCAAGGUCU UAGUAUUC 5816 1692 CUUUUCUU G UAGCAGCA 1918 UGCUGCUA GCCGAAAGGCGAGUCAAGGUCU AAGAAAAG 5817 1695 UUCUUGUA G CAGCACAG 1919 CUGUGCUG GCCGAAAGGCGAGUCAAGGUCU UACAAGAA 5818 1698 UUGUAGCA G CACAGGAU 1920 AUCCUGUG GCCGAAAGGCGAGUCAAGGUCU UGCUACAA 5819 1722 CAGAUUAU G UCACAACA 1921 UGUUGUGA GCCGAAAGGCGAGUCAAGGUCU AUAAUCUG 5820 1746 UAACAAAG G UGACUGAG 1922 CUCAGUCA GCCGAAAGGCGAGUCAAGGUCU CUUUGUUA 5821 1758 CUGAGGAA G UCGUGGCA 1923 UGCCACGA GCCGAAAGGCGAGUCAAGGUCU UUCCUCAG 5822 1761 AGGAAGUC G UGGCAAAC 1924 GUUUGCCA GCCGAAAGGCGAGUCAAGGUCU GACUUCCU 5823 1764 AAGUCGUG G CAAACAUG 1925 CAUGUUUG GCCGAAAGGCGAGUCAAGGUCU CACGACUU 5824 1780 GCCUGAAG G CCUGACUC 1926 GAGUCAGG GCCGAAAGGCGAGUCAAGGUCU CUUCAGGC 5825 1797 CAGAUUUA G UACAGGAA 1927 UUCCUGUA GCCGAAAGGCGAGUCAAGGUCU UAAAUCUG 5826 1806 UACAGGAA G CAUGUGAA 1928 UUCACAUG GCCGAAAGGCGAGUCAAGGUCU UUCCUGUA 5827 1810 GGAAGCAU G UGAAAGUG 1929 CAGUUUCA GCCGAAAGGCGAGUCAAGGUCU AUGCUUCC 5828 1816 AUGUGAAA G UGAAUUGA 1930 UCAAUUCA GCCGAAAGGCGAGUCAAGGUCU UUUCACAU 5829 1830 UGAAUGAA G UUACUGGU 1931 ACCAGUAA GCCGAAAGGCGAGUCAAGGUCU UUCAUUCA 5830 1837 AGUUACUG G UACAAAGA 1932 UCUUUGUA GCCGAAAGGCGAGUCAAGGUCU CAGUAACU 5831 1872 UGGACUUG G UUCAAAGA 1933 UGUUUGAA GCCGAAAGGCGAGUCAAGGUCU CAAGUCCA 5832 1887 CAUCAGAA G UUAUGCAA 1934 UUGCAUAA GCCGAAAGGCGAGUCAAGGUCU UUCUGAUG 5833 1898 AUGCAAGA G UCACUCUA 1935 UAGAGUGA GCCGAAAGGCGAGUCAAGGUCU UCUUGCAU 5834 1914 AUCCUGCA G CACAGCUU 1936 AAGCUGUG GCCGAAAGGCGAGUCAAGGUCU UGCAGGAU 5835 1919 GCAGCACA G CUUUGCCC 1937 GGGCAAAG GCCGAAAGGCGAGUCAAGGUCU UGUGCUGC 5836 1940 UUUGAAGA G UCAGAAGC 1938 GCUUCUGA GCCGAAAGGCGAGUCAAGGUCU UCUUCAAA 5837 1947 AGUCAGAA G CUACUCCU 1939 AGGAGUAG GCCGAAAGGCGAGUCAAGGUCU UUCUGACU 5838 1962 CUUCACCA G UUUUGCCU 1940 AGGCAAAA GCCGAAAGGCGAGUCAAGGUCU UGGUGAAG 5839 1977 CUGACAUU G UUAUGGAA 1941 UUCCAUAA GCCGAAAGGCGAGUCAAGGUCU AAUGUCAG 5840 1986 UUAUGGAA G CACCAUUG 1942 CAAUGGUG GCCGAAAGGCGAGUCAAGGUCU UUCCAUAA 5841 2004 AUUCUGCA G UUCCUAGU 1943 ACUAGGAA GCCGAAAGGCGAGUCAAGGUCU UGCAGAAU 5842 2011 AGUUCCUA G UGCUGGUG 1944 CACCAGCA GCCGAAAGGCGAGUCAAGGUCU UAGGAACU 5843 2017 UAGUGCUG G UGCUUCCG 1945 CGGAAGCA GCCGAAAGGCGAGUCAAGGUCU CAGCACUA 5844 2025 GUGCUUCC G UGAUACAG 1946 CUGUAUCA GCCGAAAGGCGAGUCAAGGUCU GGAAGCAC 5845 2033 GUGAUACA G CCCAGCUC 1947 GAGCUGGG GCCGAAAGGCGAGUCAAGGUCU UGUAUCAC 5846 2038 ACAGCCCA G CUCAUCAC 1948 GUGAUGAG GCCGAAAGGCGAGUCAAGGUCU UGGGCUGU 5847 2055 CAUUAGAA G CUUCUUCA 1949 UGAAGAAG GCCGAAAGGCGAGUCAAGGUCU UUCUAAUG 5848 2064 CUUCUUCA G UUAAUUAU 1950 AUAAUUAA GCCGAAAGGCGAGUCAAGGUCU UGAAGAAG 5849 2077 UUAUGAAA G CAUAAAAC 1951 GUUUUAUG GCCGAAAGGCGAGUCAAGGUCU UUUCAUAA 5850 2090 AAACAUGA G CCUGAAAA 1952 UUUUCAGG GCCGAAAGGCGAGUCAAGGUCU UCAUGUUU 5851 2118 AUGAAGAG G CCAUGAGU 1953 ACUCAUGG GCCGAAAGGCGAGUCAAGGUCU CUCUUCAU 5852 2125 GGCCAUGA G UGUAUCAC 1954 GUGAUACA GCCGAAAGGCGAGUCAAGGUCU UCAUGGCC 5853 2127 CCAUGAGU G UAUCACUA 1955 UAGUGAUA GCCGAAAGGCGAGUCAAGGUCU ACUCAUGG 5854 2142 UAAAAAAA G UAUCAGGA 1956 UCCUGAUA GCCGAAAGGCGAGUCAAGGUCU UUUUUUUA 5855 2171 AUUAAAGA G CCUGAAAA 1957 UUUUCAGG GCCGAAAGGCGAGUCAAGGUCU UCUUUAAU 5856 2190 UUAAUGCA G CUCUUCAA 1958 UUGAAGAG GCCGAAAGGCGAGUCAAGGUCU UGCAUUAA 5857 2208 AAACAGAA G CUCCUUAU 1959 AUAAGGAG GCCGAAAGGCGAGUCAAGGUCU UUCUGUUU 5858 2230 UAUUGCAU G UGAUUUAA 1960 UUAAAUCA GCCGAAAGGCGAGUCAAGGUCU AUGCAAUA 5859 2252 GAAACAAA G CUUUCUGC 1961 GCAGAAAG GCCGAAAGGCGAGUCAAGGUCU UUUGUUUC 5860 2268 CUGAACCA G CUCCGGAU 1962 AUCCGGAG GCCGAAAGGCGAGUCAAGGUCU UGGUUCAG 5861 2298 CAGAAAUG G CAAAAGUU 1963 AACUUUUG GCCGAAAGGCGAGUCAAGGUCU CAUUUCUG 5862 2304 UGGCAAAA G UUGAACAG 1964 CUGUUCAA GCCGAAAGGCGAGUCAAGGUCU UUUUGCCA 5863 2312 GUUGAACA G CCAGUGCC 1965 GGCACUGG GCCGAAAGGCGAGUCAAGGUCU UGUUCAAC 5864 2316 AACAGCCA G UGCCUGAU 1966 AUCAGGCA GCCGAAAGGCGAGUCAAGGUCU UGGCUGUU 5865 2333 CAUUCUGA G CUAGUUGA 1967 UCAACUAG GCCGAAAGGCGAGUCAAGGUCU UCAGAAUG 5866 2337 CUGAGCUA G UUGAAGAU 1968 AUCUUCAA GCCGAAAGGCGAGUCAAGGUCU UAGCUCAG 5867 2367 CUGAACCA G UUGACUUA 1969 UAAGUCAA GCCGAAAGGCGAGUCAAGGUCU UGGUUCAG 5868 2380 CUUAUUUA G UGAUGAUU 1970 AAUCAUCA GCCGAAAGGCGAGUCAAGGUCU UAAAUAAG 5869 2400 UACCUGAC G UUCCACAA 1971 UUGUGGAA GCCGAAAGGCGAGUCAAGGUCU GUCAGGUA 5870 2424 AUGAAACU G UGAUGCUU 1972 AAGCAUCA GCCGAAAGGCGAGUCAAGGUCU AGUUUCAU 5871 2433 UGAUGCUU G UGAAAGAA 1973 UUCUUUCA GCCGAAAGGCGAGUCAAGGUCU AAGCAUCA 5872 2443 GAAAGAAA G UCUCACUG 1974 CAGUGAGA GCCGAAAGGCGAGUCAAGGUCU UUUCUUUC 5873 2465 UCAUUUGA G UCAAUGAU 1975 AUCAUUGA GCCGAAAGGCGAGUCAAGGUCU UCAAAUGA 5874 2500 AAAACUCA G UGCUUUGC 1976 GCAAAGCA GCCGAAAGGCGAGUCAAGGUCU UGAGUUUU 5875 2525 GGAGGAAA G CCAUAUUU 1977 AAAUAUGG GCCGAAAGGCGAGUCAAGGUCU UUUCCUCC 5876 2546 UCUUUUAA G CUCAGUUU 1978 AAACUGAG GCCGAAAGGCGAGUCAAGGUCU UUAAAAGA 5877 2551 UAAGCUCA G UUUAGAUA 1979 UAUCUAAA GCCGAAAGGCGAGUCAAGGUCU UGAGCUUA 5878 2576 GAUACCCU G UUACCUGA 1980 UCAGGUAA GCCGAAAGGCGAGUCAAGGUCU AGGGUAUC 5879 2589 CUGAUGAA G UUUCAACA 1981 UGUUGAAA GCCGAAAGGCGAGUCAAGGUCU UUCAUCAG 5880 2602 AACAUUGA G CAAAAAGG 1982 CCUUUUUG GCCGAAAGGCGAGUCAAGGUCU UCAAUGUU 5881 2636 AUGGAGGA G CUCAGUAC 1983 GUACUGAG GCCGAAAGGCGAGUCAAGGUCU UCCUCCAU 5882 2641 GGAGCUCA G UACUGCAG 1984 CUGCAGUA GCCGAAAGGCGAGUCAAGGUCU UGAGCUCC 5883 2649 GUACUGCA G UUUAUUCA 1985 UGAAUAAA GCCGAAAGGCGAGUCAAGGUCU UGCAGUAC 5884 2685 CUAAGGAA G CACAGAUA 1986 UAUCUGUG GCCGAAAGGCGAGUCAAGGUCU UUCCUUAG 5885 2708 ACUGAAAC G UUUUCAGA 1987 UCUGAAAA GCCGAAAGGCGAGUCAAGGUCU GUUUCAGU 5886 2744 AUAGAUGA G UUCCCUAC 1988 GUAGGGAA GCCGAAAGGCGAGUCAAGGUCU UCAUCUAU 5887 2761 AUUGAUCA G UUCUAAAA 1989 UUUUAGAA GCCGAAAGGCGAGUCAAGGUCU UGAUCAAU 5888 2790 CUAAAUUA G CCAGGGAA 1990 UUCCCUGG GCCGAAAGGCGAGUCAAGGUCU UAAUUUAG 5889 2814 ACCUAGAA G UAUCCCAC 1991 GUGGGAUA GCCGAAAGGCGAGUCAAGGUCU UUCUAGGU 5890 2827 CCACAAAA G UGAAAUUG 1992 CAAUUUCA GCCGAAAGGCGAGUCAAGGUCU UUUUGUGG 5891 2853 CGGAUGGA G CUGGGUCA 1993 UGACCCAG GCCGAAAGGCGAGUCAAGGUCU UCCAUCCG 5892 2858 GGAGCUGG G UCAUUGCC 1994 GGCAAUGA GCCGAAAGGCGAGUCAAGGUCU CCAGCUCC 5893 2916 AACCCAAA G UUGAAGAG 1995 CUCUUCAA GCCGAAAGGCGAGUCAAGGUCU UUUGGGUU 5894 2932 GAAAAUCA G UUUCUCAG 1996 CUGAGAAA GCCGAAAGGCGAGUCAAGGUCU UGAUUUUC 5895 2960 AAAAAUGG G UCUGCUAC 1997 GUAGCAGA GCCGAAAGGCGAGUCAAGGUCU CCAUUUUU 5896 2976 CAUCAAAG G UGCUCUUA 1998 UAAGAGCA GCCGAAAGGCGAGUCAAGGUCU CUUUGAUG 5897 2997 CUCCAGAU G UUUCUGCU 1999 AGCAGAAA GCCGAAAGGCGAGUCAAGGUCU AUCUGGAG 5898 3009 CUGCUUUG G CCACUCAA 2000 UUGAGUGG GCCGAAAGGCGAGUCAAGGUCU CAAAGCAG 5899 3018 CCACUCAA G CAGAGAUA 2001 UAUCUCUG GCCGAAAGGCGAGUCAAGGUCU UUGAGUGG 5900 3031 GAUAGAGA G CAUAGUUA 2002 UAACUAUG GCCGAAAGGCGAGUCAAGGUCU UCUCUAUC 5901 3036 AGAGCAUA G UUAAACCC 2003 GGGUUUAA GCCGAAAGGCGAGUCAAGGUCU UAUGCUCU 5902 3048 AACCCAAA G UUCUUGUG 2004 CACAAGAA GCCGAAAGGCGAGUCAAGGUCU UUUGGGUU 5903 3054 AAGUUCUU G UGAAAGAA 2005 UUCUUUCA GCCGAAAGGCGAGUCAAGGUCU AAGAACUU 5904 3063 UGAAAGAA G CUGAGAAA 2006 UUUCUCAG GCCGAAAGGCGAGUCAAGGUCU UUCUUUCA 5905 3126 UAUUUUCA G CAGAGCUG 2007 CAGCUCUG GCCGAAAGGCGAGUCAAGGUCU UGAAAAUA 5906 3131 UCAGCAGA G CUGAGUAA 2008 UUACUCAG GCCGAAAGGCGAGUCAAGGUCU UCUGCUGA 5907 3136 AGAGCUGA G UAAAACUU 2009 AAGUUUUA GCCGAAAGGCGAGUCAAGGUCU UCAGCUCU 5908 3147 AAACUUCA G UUGUUGAC 2010 GUCAACAA GCCGAAAGGCGAGUCAAGGUCU UGAAGUUU 5909 3150 CUUCAGUU G UUGACCUC 2011 GAGGUCAA GCCGAAAGGCGAGUCAAGGUCU AACUGAAG 5910 3161 GACCUCCU G UACUGGAG 2012 CUCCAGUA GCCGAAAGGCGAGUCAAGGUCU AGGAGGUC 5911 3189 AGACUGGA G UGGUGUUU 2013 AAACACCA GCCGAAAGGCGAGUCAAGGUCU UCCAGUCU 5912 3192 CUGGAGUG G UGUUUGGU 2014 ACCAAACA GCCGAAAGGCGAGUCAAGGUCU CACUCCAG 5913 3194 GGAGUGGU G UUUGGUGC 2015 GCACCAAA GCCGAAAGGCGAGUCAAGGUCU ACCACUCC 5914 3199 GGUGUUUG G UGCCAGCC 2016 GGCUGGCA GCCGAAAGGCGAGUCAAGGUCU CAAACACC 5915 3205 UGGUGCCA G CCUAUUCC 2017 GGAAUAGG GCCGAAAGGCGAGUCAAGGUCU UGGCACCA 5916 3231 CAUUGACA G UAUUCAGC 2018 GCUGAAUA GCCGAAAGGCGAGUCAAGGUCU UGUCAAUG 5917 3238 AGUAUUCA G CAUUGUGA 2019 UCACAAUG GCCGAAAGGCGAGUCAAGGUCU UGAAUACU 5918 3243 UCAGCAUU G UGAGCGUA 2020 UACGCUCA GCCGAAAGGCGAGUCAAGGUCU AAUGCUGA 5919 3247 CAUUGUGA G CGUAACAG 2021 CUGUUACG GCCGAAAGGCGAGUCAAGGUCU UCACAAUG 5920 3249 UUGUGAGC G UAACAGCC 2022 GGCUGUUA GCCGAAAGGCGAGUCAAGGUCU GCUCACAA 5921 3255 GCGUAACA G CCUACAUU 2023 AAUGUAGG GCCGAAAGGCGAGUCAAGGUCU UGUUACGC 5922 3270 UUGCCUUG G CCCUGCUC 2024 GAGCAGGG GCCGAAAGGCGAGUCAAGGUCU CAAGGCAA 5923 3282 UGCUCUCU G UGACCAUC 2025 GAUGGUCA GCCGAAAGGCGAGUCAAGGUCU AGAGAGCA 5924 3292 GACCAUCA G CUUUAGGA 2026 UCCUAAAG GCCGAAAGGCGAGUCAAGGUCU UGAUGGUC 5925 3310 AUACAAGG G UGUGAUCC 2027 GGAUCACA GCCGAAAGGCGAGUCAAGGUCU CCUUGUAU 5926 3312 ACAAGGGU G UGAUCCAA 2028 UUGGAUCA GCCGAAAGGCGAGUCAAGGUCU ACCCUUGU 5927 3321 UGAUCCAA G CUAUCCAG 2029 CUGGAUAG GCCGAAAGGCGAGUCAAGGUCU UUGGAUCA 5928 3343 AGAUGAAG G CCACCCAU 2030 AUGGGUGG GCCGAAAGGCGAGUCAAGGUCU CUUCAUCU 5929 3357 CAUUCAGG G CAUAUCUG 2031 CAGAUAUG GCCGAAAGGCGAGUCAAGGUCU CCUGAAUG 5930 3375 AAUCUGAA G UUGCUAUA 2032 UAUAGCAA GCCGAAAGGCGAGUCAAGGUCU UUCAGAUU 5931 3392 UCUGAGGA G UUGGUUCA 2033 UGAACCAA GCCGAAAGGCGAGUCAAGGUCU UCCUCAGA 5932 3396 AGGAGUUG G UUCAGAAG 2034 CUUCUGAA GCCGAAAGGCGAGUCAAGGUCU CAACUCCU 5933 3404 GUUCAGAA G UACAGUAA 2035 UUACUGUA GCCGAAAGGCGAGUCAAGGUCU UUCUGAAC 5934 3409 GAAGUACA G UAAUUCUG 2036 CAGAAUUA GCCGAAAGGCGAGUCAAGGUCU UGUACUUC 5935 3424 UGCUCUUG G UCAUGUGA 2037 UCACAUGA GCCGAAAGGCGAGUCAAGGUCU CAAGAGCA 5936 3429 UUGGUCAU G UGAACUGC 2038 GCAGUUCA GCCGAAAGGCGAGUCAAGGUCU AUGACCAA 5937 3455 GAACUCAG G CGCCUCUU 2039 AAGAGGCG GCCGAAAGGCGAGUCAAGGUCU CUGAGUUC 5938 3468 UCUUCUUA G UUGAUGAU 2040 AUCAUCAA GCCGAAAGGCGAGUCAAGGUCU UAAGAAGA 5939 3480 AUGAUUUA G UUGAUUCU 2041 AGAAUCAA GCCGAAAGGCGAGUCAAGGUCU UAAAUCAU 5940 3494 UCUCUGAA G UUUGCAGU 2042 ACUGCAAA GCCGAAAGGCGAGUCAAGGUCU UUCAGAGA 5941 3501 AGUUUGCA G UGUUGAUG 2043 CAUCAACA GCCGAAAGGCGAGUCAAGGUCU UGCAAACU 5942 3503 UUUGCAGU G UUGAUGUG 2044 CACAUCAA GCCGAAAGGCGAGUCAAGGUCU ACUGCAAA 5943 3509 GUGUUGAU G UGGGUAUU 2045 AAUACCCA GCCGAAAGGCGAGUCAAGGUCU AUCAACAC 5944 3513 UGAUGUGG G UAUUUACC 2046 GGUAAAUA GCCGAAAGGCGAGUCAAGGUCU CCACAUCA 5945 3525 UUACCUAU G UUGGUGCC 2047 GGCACCAA GCCGAAAGGCGAGUCAAGGUCU AUAGGUAA 5946 3529 CUAUGUUG G UGCCUUGU 2048 ACAAGGCA GCCGAAAGGCGAGUCAAGGUCU CAACAUAG 5947 3536 GGUGCCUU G UUUAAUGG 2049 CCAUUAAA GCCGAAAGGCGAGUCAAGGUCU AAGGCACC 5948 3544 GUUUAAUG G UCUGACAC 2050 GUGUCAGA GCCGAAAGGCGAGUCAAGGUCU CAUUAAAC 5949 3564 UGAUUUUG G CUCUCAUU 2051 AAUGAGAG GCCGAAAGGCGAGUCAAGGUCU CAAAAUCA 5950 3583 ACUCUUCA G UGUUCCUG 2052 CAGGAACA GCCGAAAGGCGAGUCAAGGUCU UGAAGAGU 5951 3585 UCUUCAGU G UUCCUGUU 2053 AACAGGAA GCCGAAAGGCGAGUCAAGGUCU ACUGAAGA 5952 3591 GUGUUCCU G UUAUUUAU 2054 AUAAAUAA GCCGAAAGGCGAGUCAAGGUCU AGGAACAC 5953 3605 UAUGAACG G CAUCAGGC 2055 GCCUGAUG GCCGAAAGGCGAGUCAAGGUCU CGUUCAUA 5954 3612 GGCAUCAG G CACAGAUA 2056 UAUCUGUG GCCGAAAGGCGAGUCAAGGUCU CUGAUGCC 5955 3651 AUAAGAAU G UUAAAGAU 2057 AUCUUUAA GCCGAAAGGCGAGUCAAGGUCU AUUCUUAU 5956 3666 AUGCUAUG G CUAAAAUC 2058 GAUUUUAG GCCGAAAGGCGAGUCAAGGUCU CAUAGCAU 5957 3678 AAAUCCAA G CAAAAAUC 2059 GAUUUUUG GCCGAAAGGCGAGUCAAGGUCU UUGGAUUU 5958 3698 GGAUUGAA G CGCAAAGC 2060 GCUUUGCG GCCGAAAGGCGAGUCAAGGUCU UUCAAUCC 5959 3705 AGCGCAAA G CUGAAUGA 2061 UCAUUCAG GCCGAAAGGCGAGUCAAGGUCU UUUGCGCU 5960 3732 AAUAAUUA G UAGGAGUU 2062 AACUCCUA GCCGAAAGGCGAGUCAAGGUCU UAAUUAUU 5961 3738 UAGUAGGA G UUCAUCUU 2063 AAGAUGAA GCCGAAAGGCGAGUCAAGGUCU UCCUACUA 5962 3781 GGGGGAGG G UCAGGGAA 2064 UUCCCUGA GCCGAAAGGCGAGUCAAGGUCU CCUCCCCC 5963 3804 ACCUUGAC G UUGCAGUG 2065 CACUGCAA GCCGAAAGGCGAGUCAAGGUCU GUCAAGGU 5964 3810 ACGUUGCA G UGCAGUUU 2066 AAACUGCA GCCGAAAGGCGAGUCAAGGUCU UGCAACGU 5965 3815 GCAGUGCA G UUUCACAG 2067 CUGUGAAA GCCGAAAGGCGAGUCAAGGUCU UGCACUGC 5966 3827 CACAGAUC G UUGUUAGA 2068 UCUAACAA GCCGAAAGGCGAGUCAAGGUCU GAUCUGUG 5967 3830 AGAUCGUU G UUAGAUCU 2069 AGAUCUAA GCCGAAAGGCGAGUCAAGGUCU AACGAUCU 5968 3848 UAUUUUUA G CCAUGCAC 2070 GUGCAUGG GCCGAAAGGCGAGUCAAGGUCU UAAAAAUA 5969 3858 CAUGCACU G UUGUGAGG 2071 CCUCACAA GCCGAAAGGCGAGUCAAGGUCU AGUGCAUG 5970 3861 GCACUGUU G UGAGGAAA 2072 UUUCCUCA GCCGAAAGGCGAGUCAAGGUCU AACAGUGC 5971 3878 AAUUACCU G UCUUGACU 2073 AGUCAAGA GCCGAAAGGCGAGUCAAGGUCU AGGUAAUU 5972 3892 ACUGCCAU G UGUUCAUC 2074 GAUGAACA GCCGAAAGGCGAGUCAAGGUCU AUGGCAGU 5973 3894 UGCCAUGU G UUCAUCAU 2075 AUGAUGAA GCCGAAAGGCGAGUCAAGGUCU ACAUGGCA 5974 3908 CAUCUUAA G UAUUGUAA 2076 UUACAAUA GCCGAAAGGCGAGUCAAGGUCU UUAAGAUG 5975 3913 UAAGUAUU G UAAGCUGC 2077 GCAGCUUA GCCGAAAGGCGAGUCAAGGUCU AAUACUUA 5976 3917 UAUUGUAA G CUGCUAUG 2078 CAUAGCAG GCCGAAAGGCGAGUCAAGGUCU UUACAAUA 5977 3925 GCUGCUAU G UAUGGAUU 2079 AAUCCAUA GCCGAAAGGCGAGUCAAGGUCU AUAGCAGC 5978 3940 UUUAAACC G UAAUCAUA 2080 UAUGAUUA GCCGAAAGGCGAGUCAAGGUCU GGUUUAAA 5979 3966 UAUCUGAG G CACUGGUG 2081 CACCAGUG GCCGAAAGGCGAGUCAAGGUCU CUCAGAUA 5980 3972 AGGCACUG G UGGAAUAA 2082 UUAUUCCA GCCGAAAGGCGAGUCAAGGUCU CAGUGCCU 5981 3988 AAAAACCU G UAUAUUUU 2083 AAAAUAUA GCCGAAAGGCGAGUCAAGGUCU AGGUUUUU 5982 4002 UUUACUUU G UUGCAGAU 2084 AUCUGCAA GCCGAAAGGCGAGUCAAGGUCU AAAGUAAA 5983 4012 UGCAGAUA G UCUUGCCG 2085 CGGCAAGA GCCGAAAGGCGAGUCAAGGUCU UAUCUGCA 5984 4028 GCAUCUUG G CAAGUUGC 2086 GCAACUUG GCCGAAAGGCGAGUCAAGGUCU CAAGAUGC 5985 4032 CUUGGCAA G UUGCAGAG 2087 CUCUGCAA GCCGAAAGGCGAGUCAAGGUCU UUGCCAAG 5986 4044 CAGAGAUG G UGGAGCUA 2088 UAGCUCCA GCCGAAAGGCGAGUCAAGGUCU CAUCUCUG 5987 Input Sequence = AB020693. Cut Site = G/Y Stem Length = 8 . Core Sequence = GCcgaaagGCGaGuCaaGGuCu AB020693 (Homo sapiens mRNA for KIAA0886 protein (Nogo-A) ; 4053 bp) Table VII: Human NOGO DNAzyme and Substrate Sequence Pos Substrate Seq ID DNAzyme Seq ID 208 GUUCAAGU A CCAGUUCG 24 CGAACTGG GGCTAGCTACAACGA ACTTGAAC 5988 734 CCUGUGAU A CGCUCCUC 61 GAGGAGCG GGCTAGCTACAACGA ATCACAGG 5989 753 CAGAAAAU A UGGACUUG 64 CAAGTCCA GGCTAGCTACAACGA ATTTTCTG 5990 783 GUAACACU A UUUCGGCU 67 AGCCGAAA GGCTAGCTACAACGA AGTGTTAC 5991 886 ACAUGAAU A CCUUGGUA 96 TACCAAGG GGCTAGCTACAACGA ATTCATGT 5992 908 UCAACAGU A UUACCCAC 102 GTGGGTAA GGCTAGCTACAACGA ACTGTTGA 5993 911 ACAGUAUU A CCCACUGA 104 TCAGTGGG GGCTAGCTACAACGA AATACTGT 5994 983 AAAACUCU A CUCAUAGA 114 TCTATGAG GGCTAGCTACAACGA AGAGTTTT 5995 1024 AUUAGAAU A CUCAGAAA 127 TTTCTGAG GGCTAGCTACAACGA ATTCTAAT 5996 1172 CAAGAGUU A CCUACAGC 157 GCTGTAGG GGCTAGCTACAACGA AACTCTTG 5997 1176 AGUUACCU A CAGCUCUU 158 AAGAGCTG GGCTAGCTACAACGA AGGTAACT 5998 1185 CAGCUCUU A CUAAAUUG 161 CAATTTAG GGCTAGCTACAACGA AAGAGCTG 5999 1272 AAGCUCCU A UGAGGGAG 176 CTCCCTCA GGCTAGCTACAACGA AGGAGCTT 6000 1285 GGAGGAAU A UGCAGACU 177 AGTCTGCA GGCTAGCTACAACGA ATTCCTCC 6001 1313 GAGCGAGU A UGGGAAGU 182 ACTTCCCA GGCTAGCTACAACGA ACTCGCTC 6002 1347 AUAGUGAU A UGUUGGCU 186 AGCCAACA GGCTAGCTACAACGA ATCACTAT 6003 1467 AUGAUGAU A CUUCUUUC 203 GAAAGAAG GGCTAGCTACAACGA ATCATCAT 6004 1482 UCCCCAGU A CGCCAGAA 209 TTCTGGCG GGCTAGCTACAACGA ACTGGGGA 6005 1494 CAGAAGGU A UAAAGGAU 210 ATCCTTTA GGCTAGCTACAACGA ACCTTCTG 6006 1516 AGGAGCAU A UAUCACAU 215 ATGTGATA GGCTAGCTACAACGA ATGCTCCT 6007 1518 GAGCAUAU A UCACAUGU 216 ACATGTGA GGCTAGCTACAACGA ATATGCTC 6008 1593 GAGAUCCU A CUUCAGAA 233 TTCTGAAG GGCTAGCTACAACGA AGGATCTC 6009 1662 AGAAGAAU A CUAGCACC 240 GGTGCTAG GGCTAGCTACAACGA ATTCTTCT 6010 1720 GACAGAUU A UGUCACAA 252 TTGTGACA GGCTAGCTACAACGA AATCTGTC 6011 1799 GAUUUAGU A CAGGAAGC 263 GCTTCCTG GGCTAGCTACAACGA ACTAAATC 6012 1833 AUGAAGUU A CUGGUACA 266 TGTACCAG GGCTAGCTACAACGA AACTTCAT 6013 1839 UUACUGGU A CAAAGAUU 267 AATCTTTG GGCTAGCTACAACGA ACCAGTAA 6014 1852 GAUUGCUU A UGAAACAA 270 TTGTTTCA GGCTAGCTACAACGA AAGCAATC 6015 1890 CAGAAGUU A UGCAAGAG 276 CTCTTGCA GGCTAGCTACAACGA AACTTCTG 6016 1906 GUCACUCU A UCCUGCAG 279 CTGCAGGA GGCTAGCTACAACGA AGAGTGAC 6017 1950 CAGAAGCU A CUCCUUCA 287 TGAAGGAG GGCTAGCTACAACGA AGCTTCTG 6018 1980 ACAUUGUU A UGGAAGCA 296 TGCTTCCA GGCTAGCTACAACGA AACAATGT 6019 2030 UCCGUGAU A CAGCCCAG 305 CTGGGCTG GGCTAGCTACAACGA ATCACGGA 6020 2071 AGUUAAUU A UGAAAGCA 317 TGCTTTCA GGCTAGCTACAACGA AATTAACT 6021 2110 CCCACCAU A UGAAGAGG 319 CCTCTTCA GGCTAGCTACAACGA ATGGTGGG 6022 2129 AUGAGUGU A UCACUAAA 320 TTTAGTGA GGCTAGCTACAACGA ACACTCAT 6023 2144 AAAAAAGU A UCAGGAAU 323 ATTCCTGA GGCTAGCTACAACGA ACTTTTTT 6024 2181 CUGAAAAU A UUAAUGCA 328 TGCATTAA GGCTAGCTACAACGA ATTTTCAG 6025 2215 AGCUCCUU A UAUAUCUA 336 TAGATATA GGCTAGCTACAACGA AAGGAGCT 6026 2217 CUCCUUAU A UAUCUAUU 337 AATAGATA GGCTAGCTACAACGA ATAAGGAG 6027 2219 CCUUAUAU A UCUAUUGC 338 GCAATAGA GGCTAGCTACAACGA ATATAAGG 6028 2223 AUAUAUCU A UUGCAUGU 340 ACATGCAA GGCTAGCTACAACGA AGATATAT 6029 2287 CUCUGAUU A UUCAGAAA 356 TTTCTGAA GGCTAGCTACAACGA AATCAGAG 6030 2375 GUUGACUU A UUUAGUGA 372 TCACTAAA GGCTAGCTACAACGA AAGTCAAC 6031 2393 GAUUCAAU A CCUGACGU 378 ACGTCAGG GGCTAGCTACAACGA ATTGAATC 6032 2479 GAUAGAAU A UGAAAAUA 390 TATTTTCA GGCTAGCTACAACGA ATTCTATC 6033 2530 AAAGCCAU A UUUGGAAU 395 ATTCCAAA GGCTAGCTACAACGA ATGGCTTT 6034 2571 CAAAAGAU A CCCUGUUA 408 TAACAGGG GGCTAGCTACAACGA ATCTTTTG 6035 2579 ACCCUGUU A CCUGAUGA 410 TCATCAGG GGCTAGCTACAACGA AACAGGGT 6036 2643 AGCUCAGU A CUGCAGUU 420 AACTGCAG GGCTAGCTACAACGA ACTGAGCT 6037 2653 UGCAGUUU A UUCAAAUG 423 CATTTGAA GGCTAGCTACAACGA AAACTGCA 6038 2669 GAUGACUU A UUUAUUUC 427 GAAATAAA GGCTAGCTACAACGA AAGTCATC 6039 2673 ACUUAUUU A UUUCUAAG 430 CTTAGAAA GGCTAGCTACAACGA AAATAAGT 6040 2736 UUGAAAUU A UAGAUGAG 446 CTCATCTA GGCTAGCTACAACGA AATTTCAA 6041 2751 AGUUCCCU A CAUUGAUC 450 GATCAATG GGCTAGCTACAACGA AGGGAACT 6042 2800 CAGGGAAU A UACUGACC 465 GGTCAGTA GGCTAGCTACAACGA ATTCCCTG 6043 2802 GGGAAUAU A CUGACCUA 466 TAGGTCAG GGCTAGCTACAACGA ATATTCCC 6044 2816 CUAGAAGU A UCCCACAA 468 TTGTGGGA GGCTAGCTACAACGA ACTTCTAG 6045 2906 AAGAACAU A CAACCCAA 481 TTGGGTTG GGCTAGCTACAACGA ATGTTCTT 6046 2967 GGUCUGCU A CAUCAAAG 494 CTTTGATG GGCTAGCTACAACGA AGCAGACC 6047 2984 GUGCUCUU A UUGCCUCC 498 GGAGGCAA GGCTAGCTACAACGA AAGAGCAC 6048 3087 CUUCCGAU A CAGAAAAA 518 TTTTTCTG GGCTAGCTACAACGA ATCGGAAG 6049 3117 CAUCUGCU A UAUUUUCA 521 TGAAAATA GGCTAGCTACAACGA AGCAGATG 6050 3119 UCUGCUAU A UUUUCAGC 522 GCTGAAAA GGCTAGCTACAACGA ATAGCAGA 6051 3163 CCUCCUGU A CUGGAGAG 533 CTCTCCAG GGCTAGCTACAACGA ACAGGAGG 6052 3209 GCCAGCCU A UUCCUGCU 538 AGCAGGAA GGCTAGCTACAACGA AGGCTGGC 6053 3233 UUGACAGU A UUCAGCAU 545 ATGCTGAA GGCTAGCTACAACGA ACTGTCAA 6054 3259 AACAGCCU A CAUUGCCU 550 AGGCAATG GGCTAGCTACAACGA AGGCTGTT 6055 3302 UUUAGGAU A UACAAGGG 559 CCCTTGTA GGCTAGCTACAACGA ATCCTAAA 6056 3304 UAGGAUAU A CAAGGGUG 560 CACCCTTG GGCTAGCTACAACGA ATATCCTA 6057 3324 UCCAAGCU A UCCAGAAA 562 TTTCTGGA GGCTAGCTACAACGA AGCTTGGA 6058 3361 CAGGGCAU A UCUGGAAU 567 ATTCCAGA GGCTAGCTACAACGA ATGCCCTG 6059 3381 AAGUUGCU A UAUCUGAG 571 CTCAGATA GGCTAGCTACAACGA AGCAACTT 6060 3383 GUUGCUAU A UCUGAGGA 572 TCCTCAGA GGCTAGCTACAACGA ATAGCAAC 6061 3406 UCAGAAGU A CAGUAAUU 577 AATTACTG GGCTAGCTACAACGA ACTTCTGA 6062 3515 AUGUGGGU A UUUACCUA 602 TAGGTAAA GGCTAGCTACAACGA ACCCACAT 6063 3519 GGGUAUUU A CCUAUGUU 605 AACATAGG GGCTAGCTACAACGA AAATACCC 6064 3523 AUUUACCU A UGUUGGUG 606 CACCAACA GGCTAGCTACAACGA AGGTAAAT 6065 3554 CUGACACU A CUGAUUUU 613 AAAATCAG GGCTAGCTACAACGA AGTGTCAG 6066 3594 UUCCUGUU A UUUAUGAA 628 TTCATAAA GGCTAGCTACAACGA AACAGGAA 6067 3598 UGUUAUUU A UGAACGGC 631 GCCGTTCA GGCTAGCTACAACGA AAATAACA 6068 3628 AGAUCAUU A UCUAGGAC 636 GTCCTAGA GGCTAGCTACAACGA AATGATCT 6069 3663 AAGAUGCU A UGGCUAAA 643 TTTAGCCA GGCTAGCTACAACGA AGCATCTT 6070 3757 AAGGGGAU A UUCAUUUG 658 CAAATGAA GGCTAGCTACAACGA ATCCCCTT 6071 3769 AUUUGAUU A UACGGGGG 664 CCCCCGTA GGCTAGCTACAACGA AATCAAAT 6072 3771 UUGAUUAU A CGGGGGAG 665 CTCCCCCG GGCTAGCTACAACGA ATAATCAA 6073 3841 AGAUCUUU A UUUUUAGC 679 GCTAAAAA GGCTAGCTACAACGA AAAGATCT 6074 3874 GAAAAAUU A CCUGUCUU 687 AAGACAGG GGCTAGCTACAACGA AATTTTTC 6075 3910 UCUUAAGU A UUGUAAGC 696 GCTTACAA GGCTAGCTACAACGA ACTTAAGA 6076 3923 AAGCUGCU A UGUAUGGA 699 TCCATACA GGCTAGCTACAACGA AGCAGCTT 6077 3927 UGCUAUGU A UGGAUUUA 700 TAAATCCA GGCTAGCTACAACGA ACATAGCA 6078 3948 GUAAUCAU A UCUUUUUC 706 GAAAAAGA GGCTAGCTACAACGA ATGATTAC 6079 3959 UUUUUCCU A UCUGAGGC 713 GCCTCAGA GGCTAGCTACAACGA AGGAAAAA 6080 3990 AAACCUGU A UAUUUUAC 716 GTAAAATA GGCTAGCTACAACGA ACAGGTTT 6081 3992 ACCUGUAU A UUUUACUU 717 AAGTAAAA GGCTAGCTACAACGA ATACAGGT 6082 3997 UAUAUUUU A CUUUGUUG 721 CAACAAAG GGCTAGCTACAACGA AAAATATA 6083 60 CAACCCCC A CAACCGCC 755 GGCGGTTG GGCTAGCTACAACGA GGGGGTTG 6084 115 GCUGCAGC A UCAUCUCC 769 GGAGATGA GGCTAGCTACAACGA GCTGCAGC 6085 118 GCAGCAUC A UCUCCACC 770 GGTGGAGA GGCTAGCTACAACGA GATGCTGC 6086 124 UCAUCUCC A CCCUCCAG 773 CTGGAGGG GGCTAGCTACAACGA GGAGATGA 6087 135 CUCCAGCC A UGGAAGAC 780 GTCTTCCA GGCTAGCTACAACGA GGCTGGAG 6088 182 GACAGCCC A CCCCGGCC 795 GGCCGGGG GGCTAGCTACAACGA GGGCTGTC 6089 342 CAGUGCCC A CCGCCCCU 824 AGGGGCGG GGCTAGCTACAACGA GGGCACTG 6090 494 CCCGCGCC A UCCCCGCU 869 AGCGGGGA GGCTAGCTACAACGA GGCGCGGG 6091 648 CCCCCUCC A CCCCGGCC 935 GGCCGGGG GGCTAGCTACAACGA GGAGGGGG 6092 719 CCUGCUGC A UCUGAGCC 957 GGCTCAGA GGCTAGCTACAACGA GCAGCAGG 6093 780 CAGGUAAC A CUAUUUCG 970 CGAAATAG GGCTAGCTACAACGA GTTACCTG 6094 809 GAUUUCCC A UCUGUCCU 976 AGGACAGA GGCTAGCTACAACGA GGGAAATC 6095 880 CAAAGAAC A UGAAUACC 1000 GGTATTCA GGCTAGCTACAACGA GTTCTTTG 6096 915 UAUUACCC A CUGAAGGA 1007 TCCTTCAG GGCTAGCTACAACGA GGGTAATA 6097 926 GAAGGAAC A CUUCAAGA 1009 TCTTGAAG GGCTAGCTACAACGA GTTCCTTC 6098 987 CUCUACUC A UAGAUAGA 1021 TCTATCTA GGCTAGCTACAACGA GAGTAGAG 6099 1040 AUGGGAUC A UCGUUCAG 1026 CTGAACGA GGCTAGCTACAACGA GATCCCAT 6100 1149 GUAAUAAC A UCCUUCAU 1038 ATGAAGGA GGCTAGCTACAACGA GTTATTAC 6101 1156 CAUCCUUC A UAAUCAAC 1041 GTTGATTA GGCTAGCTACAACGA GAAGGATG 6102 1301 UUCAAACC A UUUGAGCG 1062 CGCTCAAA GGCTAGCTACAACGA GGTTTGAA 6103 1435 AACUAAUC A CGAAAAAG 1072 CTTTTTCG GGCTAGCTACAACGA GATTAGTT 6104 1514 UCAGGAGC A UAUAUCAC 1082 GTGATATA GGCTAGCTACAACGA GCTCCTGA 6105 1521 CAUAUAUC A CAUGUGCU 1083 AGCACATG GGCTAGCTACAACGA GATATATG 6106 1523 UAUAUCAC A UGUGCUCC 1084 GGAGCACA GGCTAGCTACAACGA GTGATATA 6107 1557 CUGAGAGC A UUGCAACA 1095 TGTTGCAA GGCTAGCTACAACGA GCTCTCAG 6108 1569 CAACAAAC A UUUUUCCU 1098 AGGAAAAA GGCTAGCTACAACGA GTTTGTTG 6109 1668 AUACUAGC A CCAAAACA 1111 TGTTTTGG GGCTAGCTACAACGA GCTAGTAT 6110 1676 ACCAAAAC A UCAAACCC 1114 GGGTTTGA GGCTAGCTACAACGA GTTTTGGT 6111 1700 GUAGCAGC A CAGGAUUC 1121 GAATCCTG GGCTAGCTACAACGA GCTGCTAC 6112 1725 AUUAUGUC A CAACAGAU 1125 ATCTGTTG GGCTAGCTACAACGA GACATAAT 6113 1770 UGGCAAAC A UGCCUGAA 1131 TTCAGGCA GGCTAGCTACAACGA GTTTGCCA 6114 1808 CAGGAAGC A UGUGAAAG 1140 CTTTCACA GGCTAGCTACAACGA GCTTCCTG 6115 1880 GUUCAAAC A UCAGAAGU 1147 ACTTCTGA GGCTAGCTACAACGA GTTTGAAC 6116 1901 CAAGAGUC A CUCUAUCC 1150 GGATAGAG GGCTAGCTACAACGA GACTCTTG 6117 1916 GCUGCAGC A CAGCUUUG 1156 CAAAGCTG GGCTAGCTACAACGA GCTGCAGG 6118 1928 CUUUGCCC A UCAUUUGA 1161 TCAAATGA GGCTAGCTACAACGA GGGCAAAG 6119 1931 UGCCCAUC A UUUGAAGA 1162 TCTTCAAA GGCTAGCTACAACGA GATGGGCA 6120 1958 ACUCCUUC A CCAGUUUU 1168 AAAACTGG GGCTAGCTACAACGA GAAGGAGT 6121 1974 UGCCUGAC A UUGUUAUG 1173 CATAACAA GGCTAGCTACAACGA GTCAGGCA 6122 1988 AUGGAAGC A CCAUUGAA 1174 TTCAATGG GGCTAGCTACAACGA GCTTCCAT 6123 1991 GAAGCACC A UUGAAUUC 1176 GAATTCAA GGCTAGCTACAACGA GGTGCTTC 6124 2042 CCCAGCUC A UCACCAUU 1189 AATGGTGA GGCTAGCTACAACGA GAGCTGGG 6125 2045 AGCUCAUC A CCAUUAGA 1190 TCTAATGG GGCTAGCTACAACGA GATGAGCT 6126 2048 UCAUCACC A UUAGAAGC 1192 GCTTCTAA GGCTAGCTACAACGA GGTGATGA 6127 2079 AUGAAAGC A UAAAACAU 1196 ATGTTTTA GGCTAGCTACAACGA GCTTTCAT 6128 2086 CAUAAAAC A UGAGCCUG 1197 CAGGCTCA GGCTAGCTACAACGA GTTTTATG 6129 2105 AACCCCCC A CCAUAUGA 1205 TCATATGG GGCTAGCTACAACGA GGGGGGTT 6130 2108 CCCCCACC A UAUGAAGA 1207 TCTTCATA GGCTAGCTACAACGA GGTGGGGG 6131 2121 AAGAGGCC A UGAGUGUA 1209 TACACTCA GGCTAGCTACAACGA GGCCTCTT 6132 2132 AGUGUAUC A CUAAAAAA 1210 TTTTTTAG GGCTAGCTACAACGA GATACACT 6133 2228 UCUAUUGC A UGUGAUUU 1224 AAATCACA GGCTAGCTACAACGA GCAATAGA 6134 2326 GCCUGAUC A UUCUGAGC 1242 GCTCAGAA GGCTAGCTACAACGA GATCAGGC 6135 2351 GAUUCCUC A CCUGAUUC 1247 GAATCAGG GGCTAGCTACAACGA GAGGAATC 6136 2405 GACGUUCC A CAAAAACA 1258 TGTTTTTG GGCTAGCTACAACGA GGAACGTC 6137 2448 AAAGUCUC A CUGAGACU 1264 AGTCTCAG GGCTAGCTACAACGA GAGACTTT 6138 2459 GAGACUUC A UUUGAGUC 1267 GACTCAAA GGCTAGCTACAACGA GAAGTCTC 6139 2510 GCUUUGCC A CCUGAGGG 1273 CCCTCAGG GGCTAGCTACAACGA GGCAAAGC 6140 2528 GGAAAGCC A UAUUUGGA 1277 TCCAAATA GGCTAGCTACAACGA GGCTTTCC 6141 2562 UAGAUAAC A CAAAAGAU 1281 ATCTTTTG GGCTAGCTACAACGA GTTATCTA 6142 2597 GUUUCAAC A UUGAGCAA 1289 TTGCTCAA GGCTAGCTACAACGA GTTGAAAC 6143 2687 AAGGAAGC A CAGAUAAG 1301 CTTATCTG GGCTAGCTACAACGA GCTTCCTT 6144 2720 UCAGAUUC A UCUCCAAU 1305 ATTGGAGA GGCTAGCTACAACGA GAATCTGA 6145 2753 UUCCCUAC A UUGAUCAG 1312 CTGATCAA GGCTAGCTACAACGA GTAGGGAA 6146 2777 ACUGAUUC A UUUUCUAA 1316 TTAGAAAA GGCTAGCTACAACGA GAATCAGT 6147 2821 AGUAUCCC A CAAAAGUG 1325 CACTTTTG GGCTAGCTACAACGA GGGATACT 6148 2861 GCUGGGUC A UUGCCUUG 1332 CAAGGCAA GGCTAGCTACAACGA GACCCAGC 6149 2871 UGCCUUGC A CAGAAUUG 1335 CAATTCTG GGCTAGCTACAACGA GCAAGGCA 6150 2884 AUUGCCCC A UGACCUUU 1340 AAAGGTCA GGCTAGCTACAACGA GGGGCAAT 6151 2904 UGAAGAAC A UACAACCC 1344 GGGTTGTA GGCTAGCTACAACGA GTTCTTCA 6152 2969 UCUGCUAC A UCAAAGGU 1356 ACCTTTGA GGCTAGCTACAACGA GTAGCAGA 6153 3012 CUUUGGCC A CUCAAGCA 1367 TGCTTGAG GGCTAGCTACAACGA GGCCAAAG 6154 3033 UAGAGAGC A UAGUUAAA 1371 TTTAACTA GGCTAGCTACAACGA GCTCTCTA 6155 3107 GACAGAUC A CCAUCUGC 1383 GCAGATGG GGCTAGCTACAACGA GATCTGTC 6156 3110 AGAUCACC A UCUGCUAU 1385 ATAGCAGA GGCTAGCTACAACGA GGTGATCT 6157 3174 GGAGAGAC A UUAAGAAG 1398 CTTCTTAA GGCTAGCTACAACGA GTCTCTCC 6158 3224 CUGCUUUC A UUGACAGU 1408 ACTGTCAA GGCTAGCTACAACGA GAAAGCAG 6159 3240 UAUUCAGC A UUGUGAGC 1411 GCTCACAA GGCTAGCTACAACGA GCTGAATA 6160 3261 CAGCCUAC A UUGCCUUG 1415 CAAGGCAA GGCTAGCTACAACGA GTAGGCTG 6161 3288 CUGUGACC A UCAGCUUU 1425 AAAGCTGA GGCTAGCTACAACGA GGTCACAG 6162 3346 UGAAGGCC A CCCAUUCA 1436 TGAATGGG GGCTAGCTACAACGA GGCCTTCA 6163 3350 GGCCACCC A UUCAGGGC 1439 GCCCTGAA GGCTAGCTACAACGA GGGTGGCC 6164 3359 UUCAGGGC A UAUCUGGA 1441 TCCAGATA GGCTAGCTACAACGA GCCCTGAA 6165 3427 UCUUGGUC A UGUGAACU 1451 AGTTCACA GGCTAGCTACAACGA GACCAAGA 6166 3438 UGAACUGC A CGAUAAAG 1453 CTTTATCG GGCTAGCTACAACGA GCAGTTCA 6167 3551 GGUCUGAC A CUACUGAU 1468 ATCAGTAG GGCTAGCTACAACGA GTCAGACC 6168 3570 UGGCUCUC A UUUCACUC 1473 GAGTGAAA GGCTAGCTACAACGA GAGAGCCA 6169 3575 CUCAUUUC A CUCUUCAG 1474 CTGAAGAG GGCTAGCTACAACGA GAAATGAG 6170 3607 UGAACGGC A UCAGGCAC 1480 GTGCCTGA GGCTAGCTACAACGA GCCGTTCA 6171 3614 CAUCAGGC A CAGAUAGA 1482 TCTATCTG GGCTAGCTACAACGA GCCTGATG 6172 3625 GAUAGAUC A UUAUCUAG 1484 CTAGATAA GGCTAGCTACAACGA GATCTATC 6173 3742 AGGAGUUC A UCUUUAAA 1501 TTTAAAGA GGCTAGCTACAACGA GAACTCCT 6174 3761 GGAUAUUC A UUUGAUUA 1503 TAATCAAA GGCTAGCTACAACGA GAATATCC 6175 3820 GCAGUUUC A CAGAUCGU 1509 ACGATCTG GGCTAGCTACAACGA GAAACTGC 6176 3851 UUUUAGCC A UGCACUGU 1513 ACAGTGCA GGCTAGCTACAACGA GGCTAAAA 6177 3855 AGCCAUGC A CUGUUGUG 1514 CACAACAG GGCTAGCTACAACGA GCATGGCT 6178 3890 UGACUGCC A UGUGUUCA 1521 TGAACACA GGCTAGCTACAACGA GGCAGTCA 6179 3898 AUGUGUUC A UCAUCUUA 1522 TAAGATGA GGCTAGCTACAACGA GAACACAT 6180 3901 UGUUCAUC A UCUUAAGU 1523 ACTTAAGA GGCTAGCTACAACGA GATGAACA 6181 3946 CCGUAAUC A UAUCUUUU 1528 AAAAGATA GGCTAGCTACAACGA GATTACGG 6182 3968 UCUGAGGC A CUGGUGGA 1533 TCCACCAG GGCTAGCTACAACGA GCCTCAGA 6183 4022 CUUGCCGC A UCUUGGCA 1541 TGCCAAGA GGCTAGCTACAACGA GCGGCAAG 6184 66 CCACAACC G CCCGCGGC 1545 GCGGCGGG GGCTAGCTACAACGA GGTTGTGG 6185 70 AACCGCCC G CGGCUCUG 1546 CAGAGCCG GGCTAGCTACAACGA GGGCGGTT 6186 83 UCUGAGAC G CGGCCCCG 1548 CGGGGCCG GGCTAGCTACAACGA GTCTCAGA 6187 110 CAGCAGCU G CAGCAUCA 1549 TGATGCTG GGCTAGCTACAACGA AGCTGCTG 6188 191 CCCCGGCC G CAGCCCGC 1550 GCGGGCTG GGCTAGCTACAACGA GGCCGGGG 6189 198 CGCAGCCC G CGUUCAAG 1551 CTTGAACG GGCTAGCTACAACGA GGGCTGCG 6190 296 CUGGAGGU G CUGGAGAG 1557 CTCTCCAG GGCTAGCTACAACGA ACCTCCAG 6191 312 GGAAGCCC G CCGCCGGG 1558 CCCGGCGG GGCTAGCTACAACGA GGGCTTCC 6192 315 AGCCCGCC G CCGGGCUG 1559 CAGCCCGG GGCTAGCTACAACGA GGCGGGCT 6193 327 GGCUGUCC G CGGCCCCA 1560 TGGGGCCG GGCTAGCTACAACGA GGACAGCC 6194 338 GCCCCAGU G CCCACCGC 1561 GCGGTGGG GGCTAGCTACAACGA ACTGGGGC 6195 345 UGCCCACC G CCCCUGCC 1562 GGCAGGGG GGCTAGCTACAACGA GGTGGGCA 6196 351 CCGCCCCU G CCGCCGGC 1563 GCCGGCGG GGCTAGCTACAACGA AGGGGCGG 6197 354 CCCCUGCC G CCGGCGCG 1564 CGCGCCGG GGCTAGCTACAACGA GGCAGGGG 6198 360 CCGCCGGC G CGCCCCUG 1565 CAGGGGCG GGCTAGCTACAACGA GCCGGCGG 6199 362 GCCGGCGC G CCCCUGAU 1566 ATCAGGGG GGCTAGCTACAACGA GCGCCGGC 6200 392 GACUUCGU G CCGCCGGC 1569 GCCGGCGG GGCTAGCTACAACGA ACGAAGTC 6201 395 UUCGUGCC G CCGGCGCC 1570 GGCGCCGG GGCTAGCTACAACGA GGCACGAA 6202 401 CCGCCGGC G CCCCGGGG 1571 CCCCGGGG GGCTAGCTACAACGA GCCGGCGG 6203 416 GGACCCCU G CCGGCCGC 1572 GCGGCCGG GGCTAGCTACAACGA AGGGGTCC 6204 423 UGCCGGCC G CUCCCCCC 1573 GGGGGGAG GGCTAGCTACAACGA GGCCGGCA 6205 435 CCCCCGUC G CCCCGGAG 1574 CTCCGGGG GGCTAGCTACAACGA GACGGGGG 6206 485 UCGACCGU G GCCGCGCC 1577 GGCGCGGG GGCTAGCTACAACGA ACGGTCGA 6207 489 CCGUGCCC G CGCCAUCC 1578 GGATGGCG GGCTAGCTACAACGA GGGCACGG 6208 491 GUGCCCGC G CCAUCCCC 1579 GGGGATGG GGCTAGCTACAACGA GCGGGCAC 6209 500 CCAUCCCC G CUGUCUGC 1580 GCAGACAG GGCTAGCTACAACGA GGGGATGG 6210 507 CGCUGUCU G CUGCCGCA 1581 TGCGGCAG GGCTAGCTACAACGA AGACAGCG 6211 510 UGUCUGCU G CCGCAGUC 1582 GACTGCGG GGCTAGCTACAACGA AGGAGACA 6212 513 CUGCUGCC G CAGUCUCG 1583 CGAGACTG GGCTAGCTACAACGA GGCAGCAG 6213 521 GCAGUCUC G CCCUCCAA 1584 TTGGAGGG GGCTAGCTACAACGA GAGACTGC 6214 617 UGGACCCC G CCAGCCCC 1589 GGGGCTGG GGCTAGCTACAACGA GGGGTCCA 6215 633 CGGCUCCC G CCGCGCCC 1590 GGGCGCGG GGCTAGCTACAACGA GGGAGCCG 6216 636 CUCCCGCC G CGCCCCCC 1591 GGGGGGCG GGCTAGCTACAACGA GGCGGGAG 6217 638 CCCGCCGC ' G CCCCCCUC 1592 GAGGGGGG GGCTAGCTACAACGA GCGGCGGG 6218 657 CCCCGGCC G CGCCCAAG 1593 CTTGGGCG GGCTAGCTACAACGA GGCCGGGG 6219 659 CCGGCCGC G CCCAAGCG 1594 CGCTTGGG GGCTAGCTACAACGA GCGGCCGG 6220 667 GCCCAAGC G CAGGGGCU 1595 AGCCCCTG GGCTAGCTACAACGA GCTTGGGC 6221 705 CCCUUUUU G CUCUUCCU 1597 AGGAAGAG GGCTAGCTACAACGA AAAAAGGG 6222 714 CUCUUCCU G CUGCAUCU 1598 AGATGCAG GGCTAGCTACAACGA AGGAAGAG 6223 717 UUCCUGCU G CAUCUGAG 1599 CTCAGATG GGCTAGCTACAACGA AGCAGGAA 6224 736 UGUGAUAC G CUCCUCUG 1602 CAGAGGAG GGCTAGCTACAACGA GTATCACA 6225 744 GCUCCUCU G CAGAAAAU 1603 ATTTTCTG GGCTAGCTACAACGA AGAGGAGC 6226 818 UCUGUCCU G CUUGAAAC 1605 GTTTCAAG GGCTAGCTACAACGA AGGACAGA 6227 828 UUGAAACU G CUGCUUCU 1607 AGAAGCAG GGCTAGCTACAACGA AGTTTCAA 6228 831 AAACUGCU G CUUCUCUU 1608 AAGAGAAG GGCTAGCTACAACGA AGCAGTTT 6229 864 UCUCAGCC G CUUCUUUC 1609 GAAAGAAG GGCTAGCTACAACGA GGCTGAGA 6230 1071 CAGAAUCU G CCGUAAUA 1613 TATTACGG GGCTAGCTACAACGA AGATTCTG 6231 1257 AGAGAGUU G CAGUGGAA 1618 TTCCACTG GGCTAGCTACAACGA AACTCTCT 6232 1287 AGGAAUAU G CAGACUUC 1620 GAAGTCTG GGCTAGCTACAACGA ATATTCCT 6233 1356 UGUUGGCU G CUGGAGGU 1625 ACCTCCAG GGCTAGCTACAACGA AGCCAACA 6234 1410 AAUGUUUU G CAGAUAGC 1627 GCTATCTG GGCTAGCTACAACGA AAAACATT 6235 1484 CCCAGUAC G CCAGAAGG 1633 CCTTCTGG GGCTAGCTACAACGA GTACTGGG 6236 1527 UCACAUGU G CUCCCUUU 1634 AAAGGGAG GGCTAGCTACAACGA ACATGTGA 6237 1560 AGAGCAUU G CAACAAAC 1636 GTTTGTTG GGCTAGCTACAACGA AATGCTCT 6238 1772 GCAAACAU G CCUGAAGG 1642 CCTTCAGG GGCTAGCTACAACGA ATGTTTGC 6239 1848 CAAAGAUU G CUUAUGAA 1649 TTCATAAG GGCTAGCTACAACGA AATCTTTG 6240 1892 GAAGUUAU G CAAGAGUC 1651 GACTCTTG GGCTAGCTACAACGA ATAACTTC 6241 1911 UCUAUCCU G CAGCACAG 1652 CTGTGCTG GGCTAGCTACAACGA AGGATAGA 6242 1924 ACAGCUUU G CCCAUCAU 1653 ATGATGGG GGCTAGCTACAACGA AAAGCTGT 6243 1967 CCAGUUUU G CCUGACAU 1655 ATGTCAGG GGCTAGCTACAACGA AAAACTGG 6244 2001 UGAAUUCU G CAGUUCCU 1658 AGGAACTG GGCTAGCTACAACGA AGAATTCA 6245 2013 UUCCUAGU G CUGGUGCU 1659 AGCACCAG GGCTAGCTACAACGA ACTAGGAA 6246 2019 GUGCUGGU G CUUCCGUG 1660 CACGGAAG GGCTAGCTACAACGA ACCAGCAC 6247 2187 AUAUUAAU G CAGCUCUU 1668 AAGAGCTG GGCTAGCTACAACGA ATTAATAT 6248 2226 UAUCUAUU G CAUGUGAU 1669 ATCACATG GGCTAGCTACAACGA AATAGATA 6249 2259 AGCUUUCU G CUGAACCA 1671 TGGTTCAG GGCTAGCTACAACGA AGAAAGCT 6250 2318 CAGCCAGU G CCUGAUCA 1675 TGATCAGG GGCTAGCTACAACGA ACTGGCTG 6251 2429 ACUGUGAU G CUUGUGAA 1687 TTCACAAG GGCTAGCTACAACGA ATCACAGT 6252 2502 AACUCAGU G CUUUGCCA 1693 TGGCAAAG GGCTAGCTACAACGA ACTGAGTT 6253 2507 AGUGCUUU G CCACCUGA 1694 TCAGGTGG GGCTAGCTACAACGA AAAGCACT 6254 2624 AUUCCUUU G CAGAUGGA 1699 TCCATCTG GGCTAGCTACAACGA AAAGGAAT 6255 2646 UCAGUACU G CAGUUUAU 1700 ATAAACTG GGCTAGCTACAACGA AGTACTGA 6256 2835 GUGAAAUU G CUAAUGCC 1710 GGCATTAG GGCTAGCTACAACGA AATTTCAC 6257 2841 UUGCUAAU G CCCCGGAU 1711 ATCCGGGG GGCTAGCTACAACGA ATTAGCAA 6258 2864 GGGUCAUU G CCUUGCAC 1712 GTGCAAGG GGCTAGCTACAACGA AATGACCC 6259 2869 AUUGCCUU G CACAGAAU 1713 ATTCTGTG GGCTAGCTACAACGA AAGGCAAT 6260 2879 ACAGAAUU G CCCCAUGA 1714 TCATGGGG GGCTAGCTACAACGA AATTCTGT 6261 2964 AUGGGUCU G CUACAUCA 1719 TGATGTAG GGCTAGCTACAACGA AGACCCAT 6262 2978 UCAAAGGU G CUCUUAUU 1720 AATAAGAG GGCTAGCTACAACGA ACCTTTGA 6263 2987 CUCUUAUU G CCUCCAGA 1721 TCTGGAGG GGCTAGCTACAACGA AATAAGAG 6264 3003 AUGUUUCU G CUUUGGCC 1722 GGCCAAAG GGCTAGCTACAACGA AGAAACAT 6265 3114 CACCAUCU G CUAUAUUU 1726 AAATATAG GGCTAGCTACAACGA AGATGGTG 6266 3201 UGUUUGGU G CCAGCCUA 1729 TAGGCTGG GGCTAGCTACAACGA ACCAAACA 6267 3215 CUAUUCCU G CUGCUUUC 1730 GAAAGCAG GGCTAGCTACAACGA AGGAATAG 6268 3218 UUCCUGCU G CUUUCAUU 1731 AATGAAAG GGCTAGCTACAACGA AGCAGGAA 6269 3264 CCUACAUU G CCUUGGCC 1734 GGCCAAGG GGCTAGCTACAACGA AATGTAGG 6270 3275 UUGGCCCU G CUCUCUGU 1735 ACAGAGAG GGCTAGCTACAACGA AGGGCCAA 6271 3378 CUGAAGUU G CUAUAUCU 1740 AGATATAG GGCTAGCTACAACGA AACTTCAG 6272 3417 GUAAUUCU G CUCUUGGU 1742 ACCAAGAG GGCTAGCTACAACGA AGAATTAC 6273 3436 UGUGAACU G CACGAUAA 1744 TTATCGTG GGCTAGCTACAACGA AGTTCACA 6274 3457 ACUCAGGC G CCUCUUCU 1746 AGAAGAGG GGCTAGCTACAACGA GCCTGAGT 6275 3498 UGAAGUUU G CAGUGUUG 1751 CAACACTG GGCTAGCTACAACGA AAACTTCA 6276 3531 AUGUUGGU G CCUUGUUU 1753 AAACAAGG GGCTAGCTACAACGA ACCAACAT 6277 3639 UAGGACUU G CAAAUAAG 1757 CTTATTTG GGCTAGCTACAACGA AAGTCCTA 6278 3660 UUAAAGAU G CUAUGGCU 1758 AGCCATAG GGCTAGCTACAACGA ATCTTTAA 6279 3700 AUUGAAGC G CAAAGCUG 1760 CAGCTTTG GGCTAGCTACAACGA GCTTCAAT 6280 3718 AUGAAAAC G CCCAAAAU 1763 ATTTTGGG GGCTAGCTACAACGA GTTTTCAT 6281 3807 UUGACGUU G CAGUGCAG 1767 CTGCACTG GGCTAGCTACAACGA AACGTCAA 6282 3812 GUUGCAGU G CAGUUUCA 1768 TGAAACTG GGCTAGCTACAACGA ACTGCAAC 6283 3853 UUAGCCAU G CACUGUUG 1769 CAACAGTG GGCTAGCTACAACGA ATGGCTAA 6284 3887 UCUUGACU G CCAUGUGU 1772 ACACATGG GGCTAGCTACAACGA AGTCAAGA 6285 3920 UGUAAGCU G CUAUGUAU 1773 ATACATAG GGCTAGCTACAACGA AGCTTACA 6286 4005 ACUUUGUU G CAGAUAGU 1775 ACTATCTG GGCTAGCTACAACGA AACAAAGT 6287 4017 AUAGUCUU G CCGCAUCU 1776 AGATGCGG GGCTAGCTACAACGA AAGACTAT 6288 4020 GUCUUGCC G CAUCUUGG 1777 CCAAGATG GGCTAGCTACAACGA GGCAAGAC 6289 4035 GGCAAGUU G CAGAGAUG 1778 CATCTCTG GGCTAGCTACAACGA AACTTGCC 6290 12 CACAGUAG G UCCCUCGG 1779 CCGAGGGA GGCTAGCTACAACGA CTACTGTG 6291 20 GUCCCUCG G CUCAGUCG 1780 CGACTGAG GGCTAGCTACAACGA CGAGGGAC 6292 25 UCGGCUCA G UCGGCCCA 1781 TGGGCCGA GGCTAGCTACAACGA TGAGCCGA 6293 29 CUCAGUCG G CCCAGCCC 1782 GGGCTGGG GGCTAGCTACAACGA CGACTGAG 6294 34 UCGGCCCA G CCCCUCUC 1783 GAGAGGGG GGCTAGCTACAACGA TGGGCCGA 6295 44 CCCUCUCA G UCCUCCCC 1784 GGGGAGGA GGCTAGCTACAACGA TGAGAGGG 6296 73 CGCCCGCG G CUCUGAGA 1785 TCTCAGAG GGCTAGCTACAACGA CGCGGGCG 6297 86 GAGACGCG G CCCCGGCG 1786 CGCCGGGG GGCTAGCTACAACGA CGCGTCTC 6298 92 CGGCCCCG G CGGCGGCG 1787 CGCCGCCG GGCTAGCTACAACGA CGGGGCCG 6299 95 CCCCGGCG G CGGCGGCA 1788 TGCCGCCG GGCTAGCTACAACGA CGCCGGGG 6300 98 CGGCGGCG G CGGCAGCA 1789 TGCTGCCG GGCTAGCTACAACGA CGCCGCCG 6301 101 CGGCGGCG G CAGCAGCU 1790 AGCTGCTG GGCTAGCTACAACGA CGCCGCCG 6302 104 CGGCGGCA G CAGCUGCA 1791 TGCAGCTG GGCTAGCTACAACGA TGCCGCCG 6303 107 CGGCAGCA G CUGCAGCA 1792 TGCTGCAG GGCTAGCTACAACGA TGCTGCCG 6304 113 CAGCUGCA G CAUCAUCU 1793 AGATGATG GGCTAGCTACAACGA TGCAGCTG 6305 132 ACCCUCCA G CCAUGGAA 1794 TTCCATGG GGCTAGCTACAACGA TGGAGGGT 6306 152 CUGGACCA G UCUCCUCU 1795 AGAGGAGA GGCTAGCTACAACGA TGGTCCAG 6307 162 CUCCUCUG G UCUCGUCC 1796 GGACGAGA GGCTAGCTACAACGA CAGAGGAG 6308 167 CUGGUCUC G UCCUCGGA 1797 TCCGAGGA GGCTAGCTACAACGA GAGACCAG 6309 178 CUCGGACA G CCCACCCC 1798 GGGGTGGG GGCTAGCTACAACGA TGTCCGAG 6310 188 CCACCCCG G CCGCAGCC 1799 GGCTGCGG GGCTAGCTACAACGA CGGGGTGG 6311 194 CGGCGGCA G CCCGCGUU 1800 AACGCGGG GGCTAGCTACAACGA TGCGGCCG 6312 200 CAGCCCGC G UUCAAGUA 1801 TACTTGAA GGCTAGCTACAACGA GCGGGCTG 6313 206 GCGUUCAA G UACCAGUU 1802 AACTGGTA GGCTAGCTACAACGA TTGAACGC 6314 212 AAGUACCA G UUCGUGAG 1803 CTCACGAA GGCTAGCTACAACGA TGGTACTT 6315 216 ACCAGUUC G UGAGGGAG 1804 CTCCCTCA GGCTAGCTACAACGA GAACTGGT 6316 224 GUGAGGGA G CCCGAGGA 1805 TCCTCGGG GGCTAGCTACAACGA TCCCTCAC 6317 287 CUGGAGGA G CUGGAGGU 1806 ACCTCCAG GGCTAGCTACAACGA TCCTCCAG 6318 294 AGCUGGAG G UGCUGGAG 1807 CTCCAGCA GGCTAGCTACAACGA CTCCAGCT 6319 308 GAGAGGAA G CCCGCCGC 1808 GCGGCGGG GGCTAGCTACAACGA TTCCTCTC 6320 320 GCCGCCGG G CUGUCCGC 1809 GCGGACAG GGCTAGCTACAACGA CCGGCGGC 6321 323 GCCGGGCU G UCCGCGGC 1810 GCCGCGGA GGCTAGCTACAACGA AGCCCGGC 6322 330 UGUCCGCG G CCCCAGUG 1811 CACTGGGG GGCTAGCTACAACGA CGCGGACA 6323 336 CGGCCCCA G UGCCCACC 1812 GGTGGGCA GGCTAGCTACAACGA TGGGGCCG 6324 358 UGCCGCCG G CGCGCCCC 1813 GGGGCGCG GGCTAGCTACAACGA CGGCGGCA 6325 390 AUGACUUC G UGCCGCCG 1814 CGGCGGCA GGCTAGCTACAACGA GAAGTCAT 6326 399 UGCCGCCG G CGCCCCGG 1815 CCGGGGCG GGCTAGCTACAACGA CGGCGGCA 6327 420 CCCUGCCG G CGGCUCCC 1816 GGGAGCGG GGCTAGCTACAACGA CGGCAGGG 6328 432 CUCCCCCC G UCGCCCCG 1817 CGGGGCGA GGCTAGCTACAACGA GGGGGGAG 6329 443 GCCCCGGA G CGGCAGCC 1818 GGCTGCCG GGCTAGCTACAACGA TCCGGGGC 6330 446 CCGGAGCG G CAGCCGUC 1819 GACGGCTG GGCTAGCTACAACGA CGCTCCGG 6331 449 GAGCGGCA G CCGUCUUG 1820 CAAGACGG GGCTAGCTACAACGA TGCCGCTC 6332 452 CGGCAGCC G UCUUGGGA 1821 TCCCAAGA GGCTAGCTACAACGA GGCTGCCG 6333 466 GGACCCGA G CCCGGUGU 1822 ACACCGGG GGCTAGCTACAACGA TCGGGTCC 6334 471 CGAGCCCG G UGUCGUCG 1823 CGACGACA GGCTAGCTACAACGA CGGGCTCG 6335 473 AGCCCGGU G UCGUCGAC 1824 GTCGACGA GGCTAGCTACAACGA ACCGGGCT 6336 476 CCGGUGUC G UCGACCGU 1825 ACGGTCGA GGCTAGCTACAACGA GACACCGG 6337 483 CGUCGACC G UGCCCGCG 1826 CGCGGGCA GGCTAGCTACAACGA GGTCGACG 6338 503 UCCCCGCU G UCUGCUGC 1827 GCAGCAGA GGCTAGCTACAACGA AGCGGGGA 6339 516 CUGCCGCA G UCUCGCCC 1828 GGGCGAGA GGCTAGCTACAACGA TGCGGCAG 6340 530 CCCUCCAA G CUCCCUGA 1829 TCAGGGAG GGCTAGCTACAACGA TTGGAGGG 6341 548 GACGACGA G CCUCCGGC 1830 GCCGGAGG GGCTAGCTACAACGA TCGTCGTC 6342 555 AGCCUCCG G CCCGGCCU 1831 AGGCCGGG GGCTAGCTACAACGA CGGAGGCT 6343 560 CCGGCCCG G CCUCCCCC 1832 GGGGGAGG GGCTAGCTACAACGA CGGGCCGG 6344 579 CUCCCCCG G CCAGCGUG 1833 CACGCTGG GGCTAGCTACAACGA CGGGGGAG 6345 583 CCCGGCCA G CGUGAGCC 1834 GGCTCACG GGCTAGCTACAACGA TGGCCGGG 6346 585 CGGCCAGC G UGAGCCCC 1835 GGGGCTCA GGCTAGCTACAACGA GCTGGCCG 6347 589 CAGCGUGA G CCCCCAGG 1836 CCTGGGGG GGCTAGCTACAACGA TCACGCTG 6348 597 GCCCCCAG G CAGAGCCC 1837 GGGCTCTG GGCTAGCTACAACGA CTGGGGGC 6349 602 CAGGCAGA G CCCGUGUG 1838 CACACGGG GGCTAGCTACAACGA TCTGCCTG 6350 606 CAGAGCCC G UGUGGACC 1839 GGTCCACA GGCTAGCTACAACGA GGGCTCTG 6351 608 GAGCCCGU G UGGACCCC 1840 GGGGTCCA GGCTAGCTACAACGA ACGGGCTC 6352 621 CCCCGCCA G CCCCGGCU 1841 AGCCGGGG GGCTAGCTACAACGA TGGCGGGG 6353 627 CAGCCCCG G CUCCCGCC 1842 GGCGGGAG GGCTAGCTACAACGA CGGGGCTG 6354 654 CCACCCCG G CCGCGCCC 1843 GGGCGCGG GGCTAGCTACAACGA CGGGGTGG 6355 665 GCGCCCAA G CGCAGGGG 1844 CCCCTGCG GGCTAGCTACAACGA TTGGGCGC 6356 673 GCGCAGGG G CUCCUCGG 1845 CCGAGGAG GGCTAGCTACAACGA CCCTGCGC 6357 682 CUCCUCGG G CUCAGUGG 1846 CGACTGAG GGCTAGCTACAACGA CCGAGGAG 6358 687 CGGGCUCA G UGGAUGAG 1847 CTCATCCA GGCTAGCTACAACGA TGAGCCCG 6359 725 GCAUCUGA G CCUGUGAU 1848 ATCACAGG GGCTAGCTACAACGA TCAGATGC 6360 729 CUGAGCCU G UGAUACGC 1849 GCGTATCA GGCTAGCTACAACGA AGGCTCAG 6361 767 UUGAAGGA G CAGCCAGG 1850 CCTGGCTG GGCTAGCTACAACGA TCCTTCAA 6362 770 AAGGAGCA G CCAGGUAA 1851 TTACCTGG GGCTAGCTACAACGA TGCTCCTT 6363 775 GCAGCCAG G UAACACUA 1852 TAGTGTTA GGCTAGCTACAACGA CTGGCTGC 6364 789 CUAUUUCG G CUGGUCAA 1853 TTGACCAG GGCTAGCTACAACGA CGAAATAG 6365 793 UUCGGCUG G UCAAGAGG 1854 CCTCTTGA GGCTAGCTACAACGA CAGCCGAA 6366 813 UCCCAUCU G UCCUGCUU 1855 AAGCAGGA GGCTAGCTACAACGA AGATGGGA 6367 848 CCUUCUCU G UCUCCUCU 1856 AGAGGAGA GGCTAGCTACAACGA AGAGAAGG 6368 861 CUCUCUCA G CCGCUUCU 1857 AGAAGCGG GGCTAGCTACAACGA TGAGAGAG 6369 892 AUACCUUG G UAAUUUGU 1858 ACAAATTA GGCTAGCTACAACGA CAAGGTAT 6370 899 GGUAAUUU G UCAACAGU 1859 ACTGTTGA GGCTAGCTACAACGA AAATTACC 6371 906 UGUCAACA G UAUUACCC 1860 GGGTAATA GGCTAGCTACAACGA TGTTGACA 6372 939 AAGAAAAU G UCAGUGAA 1861 TTCACTGA GGCTAGCTACAACGA ATTTTCTT 6373 943 AAAUGUCA G UGAAGCUU 1862 AAGCTTCA GGCTAGCTACAACGA TGACATTT 6374 948 UCAGUGAA G CUUCUAAA 1863 TTTAGAAG GGCTAGCTACAACGA TTCACTGA 6375 960 CUAAAGAG G UCUCAGAG 1864 CTCTGAGA GGCTAGCTACAACGA CTCTTTAG 6376 972 CAGAGAAG G CAAAAACU 1865 AGTTTTTG GGCTAGCTACAACGA CTTCTCTG 6377 1007 UUAACAGA G UUUUCAGA 1866 TCTGAAAA GGCTAGCTACAACGA TCTGTTAA 6378 1043 GGAUCAUC G UUCAGUGU 1867 ACACTGAA GGCTAGCTACAACGA GATGATCC 6379 1048 AUCGUUCA G UGUCUCUC 1868 GAGAGACA GGCTAGCTACAACGA TGAACGAT 6380 1050 CGUUCAGU G UCUCUCCA 1869 TGGAGAGA GGCTAGCTACAACGA ACTGAACG 6381 1062 CUCCAAAA G CAGAAUCU 1870 AGATTCTG GGCTAGCTACAACGA TTTTGGAG 6382 1074 AAUCUGCC G UAAUAGUA 1871 TACTATTA GGCTAGCTACAACGA GGCAGATT 6383 1080 CCGUAAUA G UAGCAAAU 1872 ATTTGCTA GGCTAGCTACAACGA TATTACGG 6384 1083 UAAUAGUA G CAAAUCCU 1873 AGGATTTG GGCTAGCTACAACGA TACTATTA 6385 1107 AAAUAAUC G UGAAAAAU 1874 ATTTTTCA GGCTAGCTACAACGA GATTATTT 6386 1133 GAAGAGAA G UUAGUUAG 1875 CTAACTAA GGCTAGCTACAACGA TTCTCTTC 6387 1137 AGAAGUUA G UUAGUAAU 1876 ATTACTAA GGCTAGCTACAACGA TAACTTCT 6388 1141 GUUAGUUA G UAAUAACA 1877 TGTTATTA GGCTAGCTACAACGA TAACTAAC 6389 1169 CAACAAGA G UUACCUAC 1878 GTAGGTAA GGCTAGCTACAACGA TCTTGTTG 6390 1179 UACCUACA G CUCUUACU 1879 AGTAAGAG GGCTAGCTACAACGA TGTAGGTA 6391 1194 CUAAAUUG G UUAAAGAG 1880 CTCTTTAA GGCTAGCTACAACGA CAATTTAG 6392 1209 AGGAUGAA G UUGUGUCU 1881 AGACACAA GGCTAGCTACAACGA TTCATCCT 6393 1212 AUGAAGUU G UGUCUUCA 1882 TGAAGACA GGCTAGCTACAACGA AACTTCAT 6394 1214 GAAGUUGU G UCUUCAGA 1883 TCTGAAGA GGCTAGCTACAACGA ACAACTTC 6395 1227 CAGAAAAA G CAAAAGAC 1884 GTCTTTTG GGCTAGCTACAACGA TTTTTCTG 6396 1237 AAAAGACA G UUUUAAUG 1885 CATTAAAA GGCTAGCTACAACGA TGTCTTTT 6397 1254 AAAAGAGA G UUGCAGUG 1886 CACTGCAA GGCTAGCTACAACGA TCTCTTTT 6398 1260 GAGUUGCA G UGGAAGCU 1887 AGCTTCCA GGCTAGCTACAACGA TGCAACTC 6399 1266 CAGUGGAA G CUCCUAUG 1888 CATAGGAG GGCTAGCTACAACGA TTCCACTG 6400 1307 CCAUUUGA G CGAGUAUG 1889 CATACTCG GGCTAGCTACAACGA TCAAATGG 6401 1311 UUGAGCGA G UAUGGGAA 1890 TTCCCATA GGCTAGCTACAACGA TCGCTCAA 6402 1320 UAUGGGAA G UGAAAGAU 1891 ATCTTTCA GGCTAGCTACAACGA TTCCCATA 6403 1330 GAAAGAUA G UAAGGAAG 1892 CTTCCTTA GGCTAGCTACAACGA TATCTTTC 6404 1342 GGAAGAUA G UGAUAUGU 1893 ACATATCA GGCTAGCTACAACGA TATCTTCC 6405 1349 AGUGAUAU G UUGGCUGC 1894 GCAGCCAA GGCTAGCTACAACGA ATATCACT 6406 1353 AUAUGUUG G CUGCUGGA 1895 TCCAGCAG GGCTAGCTACAACGA CAACATAT 6407 1363 UGCUGGAG G UAAAAUCG 1896 CGATTTTA GGCTAGCTACAACGA CTCCAGCA 6408 1375 AAUCGAGA G CAACUUGG 1897 CCAAGTTG GGCTAGCTACAACGA TCTCGATT 6409 1387 CUUGGAAA G UAAAGUGG 1898 CCACTTTA GGCTAGCTACAACGA TTTCCAAG 6410 1392 AAAGUAAA G UGGAUAAA 1899 TTTATCCA GGCTAGCTACAACGA TTTACTTT 6411 1405 UAAAAAAU G UUUUGCAG 1900 CTGCAAAA GGCTAGCTACAACGA ATTTTTTA 6412 1417 UGCAGAUA G CCUUGAGC 1901 GCTCAAGG GGCTAGCTACAACGA TATCTGCA 6413 1424 AGCCUUGA G CAAACUAA 1902 TTAGTTTG GGCTAGCTACAACGA TCAAGGCT 6414 1447 AAAAGAUA G UGAGAGUA 1903 TACTCTCA GGCTAGCTACAACGA TATCTTTT 6415 1453 UAGUGAGA G UAGUAAUG 1904 CATTACTA GGCTAGCTACAACGA TCTCACTA 6416 1456 UGAGAGUA G UAAUGAUG 1905 CATCATTA GGCTAGCTACAACGA TACTCTCA 6417 1480 UUUCCCCA G UACGCCAG 1906 CTGGCGTA GGCTAGCTACAACGA TGGGGAAA 6418 1492 GCCAGAAG G UAUAAAGG 1907 CCTTTATA GGCTAGCTACAACGA CTTCTGGC 6419 1504 AAAGGAUC G UUCAGGAG 1908 CTCCTGAA GGCTAGCTACAACGA GATCCTTT 6420 1512 GUUCAGGA G CAUAUAUC 1909 GATATATG GGCTAGCTACAACGA TCCTGAAC 6421 1525 UAUCACAU G UGCUCCCU 1910 AGGGAGCA GGCTAGCTACAACGA ATGTGATA 6422 1542 UUAACCCA G CAGCAACU 1911 AGTTGCTG GGCTAGCTACAACGA TGGGTTAA 6423 1545 ACCCAGCA G CAACUGAG 1912 CTCAGTTG GGCTAGCTACAACGA TGCTGGGT 6424 1555 AACUGAGA G CAUUGCAA 1913 TTGCAATG GGCTAGCTACAACGA TCTCAGTT 6425 1580 UUUCCUUU G UUAGGAGA 1914 TCTCCTAA GGCTAGCTACAACGA AAAGGAAA 6426 1638 AAAAGAAG G CCCAAAUA 1915 TATTTGGG GGCTAGCTACAACGA CTTCTTTT 6427 1647 CCCAAAUA G UAACAGAG 1916 CTCTGTTA GGCTAGCTACAACGA TATTTGGG 6428 1666 GAAUACUA G CACCAAAA 1917 TTTTGGTG GGCTAGCTACAACGA TAGTATTC 6429 1692 CUUUUCUU G UAGCAGCA 1918 TGCTGCTA GGCTAGCTACAACGA AAGAAAAG 6430 1695 UUCUUGUA G CAGCACAG 1919 CTGTGCTG GGCTAGCTACAACGA TACAAGAA 6431 1698 UUGUAGCA G CACAGGAU 1920 ATCCTGTG GGCTAGCTACAACGA TGCTACAA 6432 1722 CAGAUUAU G UCACAACA 1921 TGTTGTGA GGCTAGCTACAACGA ATAATCTG 6433 1746 UAACAAAG G UGACUGAG 1922 CTCAGTCA GGCTAGCTACAACGA CTTTGTTA 6434 1758 CUGAGGAA G UCGUGGCA 1923 TGCCACGA GGCTAGCTACAACGA TTCCTCAG 6435 1761 AGGAAGUC G UGGCAAAC 1924 GTTTGCCA GGCTAGCTACAACGA GACTTCCT 6436 1764 AAGUCGUG G CAAACAUG 1925 CATGTTTG GGCTAGCTACAACGA CACGACTT 6437 1780 GCCUGAAG G CCUGACUC 1926 GAGTCAGG GGCTAGCTACAACGA CTTCAGGC 6438 1797 CAGAUUUA G UACAGGAA 1927 TTCCTGTA GGCTAGCTACAACGA TAAATCTG 6439 1806 UACAGGAA G CAUGUGAA 1928 TTCACATG GGCTAGCTACAACGA TTCCTGTA 6440 1810 GGAAGCAU G UGAAAGUG 1929 CACTTTCA GGCTAGCTACAACGA ATGCTTCC 6441 1816 AUGUGAAA G UGAAUUGA 1930 TCAATTCA GGCTAGCTACAACGA TTTCACAT 6442 1830 UGAAUGAA G UUACUGGU 1931 ACCAGTAA GGCTAGCTACAACGA TTCATTCA 6443 1837 AGUUACUG G UACAAAGA 1932 TCTTTGTA GGCTAGCTACAACGA CAGTAACT 6444 1872 UGGACUUG G UUCAAACA 1933 TGTTTGAA GGCTAGCTACAACGA CAAGTCCA 6445 1887 CAUCAGAA G UUAUGCAA 1934 TTGCATAA GGCTAGCTACAACGA TTCTGATG 6446 1898 AUGCAAGA G UCACUCUA 1935 TAGAGTGA GGCTAGCTACAACGA TCTTGCAT 6447 1914 AUCCUGCA G CACAGCUU 1936 AAGCTGTG GGCTAGCTACAACGA TGCAGGAT 6448 1919 GCAGCACA G CUUUGCCC 1937 GGGCAAAG GGCTAGCTACAACGA TGTGCTGC 6449 1940 UUUGAAGA G UCAGAAGC 1938 GCTTCTGA GGCTAGCTACAACGA TCTTCAAA 6450 1947 AGUCAGAA G CUACUCCU 1939 AGGAGTAG GGCTAGCTACAACGA TTCTGACT 6451 1962 CUUCACCA G UUUUGCCU 1940 AGGCAAAA GGCTAGCTACAACGA TGGTGAAG 6452 1977 CUGACAUU G UUAUGGAA 1941 TTCCATAA GGCTAGCTACAACGA AATGTCAG 6453 1986 UUAUGGAA G CACCAUUG 1942 CAATGGTG GGCTAGCTACAACGA TTCCATAA 6454 2004 AUUCUGCA G UUCCUAGU 1943 ACTAGGAA GGCTAGCTACAACGA TGCAGAAT 6455 2011 AGUUCCUA G UGCUGGUG 1944 CACCAGCA GGCTAGCTACAACGA TAGGAACT 6456 2017 UAGUGCUG G UGCUUCCG 1945 CGGAAGCA GGCTAGCTACAACGA CAGCACTA 6457 2025 GUGCUUCC G UGAUACAG 1946 CTGTATCA GGCTAGCTACAACGA GGAAGCAC 6458 2033 GUGAUACA G CCCAGCUC 1947 GAGCTGGG GGCTAGCTACAACGA TGTATCAC 6459 2038 ACAGCCCA G CUCAUCAC 1948 GTGATGAG GGCTAGCTACAACGA TGGGCTGT 6460 2055 CAUUAGAA G CUUCUUCA 1949 TGAAGAAG GGCTAGCTACAACGA TTCTAATG 6461 2064 CUUCUUCA G UUAAUUAU 1950 ATAATTAA GGCTAGCTACAACGA TGAAGAAG 6462 2077 UUAUGAAA G CAUAAAAC 1951 GTTTTATG GGCTAGCTACAACGA TTTCATAA 6463 2090 AAACAUGA G CCUGAAAA 1952 TTTTCAGG GGCTAGCTACAACGA TCATGTTT 6464 2118 AUGAAGAG G CCAUGAGU 1953 ACTCATGG GGCTAGCTACAACGA CTCTTCAT 6465 2125 GGCCAUGA G UGUAUCAC 1954 GTGATACA GGCTAGCTACAACGA TCATGGCC 6466 2127 CCAUGAGU G UAUCACUA 1955 TAGTGATA GGCTAGCTACAACGA ACTCATGG 6467 2142 UAAAAAAA G UAUCAGGA 1956 TCCTGATA GGCTAGCTACAACGA TTTTTTTA 6468 2171 AUUAAAGA G CCUGAAAA 1957 TTTTCAGG GGCTAGCTACAACGA TCTTTAAT 6469 2190 UUAAUGCA G CUCUUCAA 1958 TTGAAGAG GGCTAGCTACAACGA TGCATTAA 6470 2208 AAACAGAA G CUCCUUAU 1959 ATAAGGAG GGCTAGCTACAACGA TTCTGTTT 6471 2230 UAUUGCAU G UGAUUUAA 1960 TTAAATCA GGCTAGCTACAACGA ATGCAATA 6472 2252 GAAACAAA G CUUUCUGC 1961 GCAGAAAG GGCTAGCTACAACGA TTTGTTTC 6473 2268 CUGAACCA G CUCCGGAU 1962 ATCCGGAG GGCTAGCTACAACGA TGGTTCAG 6474 2298 CAGAAAUG G CAAAAGUU 1963 AACTTTTG GGCTAGCTACAACGA CATTTCTG 6475 2304 UGGCAAAA G UUGAACAG 1964 CTGTTCAA GGCTAGCTACAACGA TTTTGCCA 6476 2312 GUUGAACA G CCAGUGCC 1965 GGCACTGG GGCTAGCTACAACGA TGTTCAAC 6477 2316 AACAGCCA G UGCCUGAU 1966 ATCAGGCA GGCTAGCTACAACGA TGGCTGTT 6478 2333 CAUUGUGA G CUAGUUGA 1967 TCAACTAG GGCTAGCTACAACGA TCAGAATG 6479 2337 CUGAGCUA G UUGAAGAU 1968 ATCTTCAA GGCTAGCTACAACGA TAGCTCAG 6480 2367 CUGAACCA G UUGACUUA 1969 TAAGTCAA GGCTAGCTACAACGA TGGTTCAG 6481 2380 CUUAUUUA G UGAUGAUU 1970 AATCATCA GGCTAGCTACAACGA TAAATAAG 6482 2400 UACCUGAC G UUCCACAA 1971 TTGTGGAA GGCTAGCTACAACGA GTCAGGTA 6483 2424 AUGAAACU G UGAUGCUU 1972 AAGCATCA GGCTAGCTACAACGA AGTTTCAT 6484 2433 UGAUGCUU G UGAAAGAA 1973 TTCTTTCA GGCTAGCTACAACGA AAGCATCA 6485 2443 GAAAGAAA G UCUCACUG 1974 CAGTGAGA GGCTAGCTACAACGA TTTCTTTC 6486 2465 UCAUUUGA G UCAAUGAU 1975 ATCATTGA GGCTAGCTACAACGA TCAAATGA 6487 2500 AAAACUCA G UGCUUUGC 1976 GCAAAGCA GGCTAGCTACAACGA TGAGTTTT 6488 2525 GGAGGAAA G CCAUAUUU 1977 AAATATGG GGCTAGCTACAACGA TTTCCTCC 6489 2546 UCUUUUAA G CUCAGUUU 1978 AAACTGAG GGCTAGCTACAACGA TTAAAAGA 6490 2551 UAAGCUCA G UUUAGAUA 1979 TATCTAAA GGCTAGCTACAACGA TGAGCTTA 6491 2576 GAUACCCU G UUACCUGA 1980 TCAGGTAA GGCTAGCTACAACGA AGGGTATC 6492 2589 CUGAUGAA G UUUCAACA 1981 TGTTGAAA GGCTAGCTACAACGA TTCATCAG 6493 2602 AACAUUGA G CAAAAAGG 1982 CCTTTTTG GGCTAGCTACAACGA TCAATGTT 6494 2636 AUGGAGGA G CUCAGUAC 1983 GTACTGAG GGCTAGCTACAACGA TCCTCCAT 6495 2641 GGAGCUCA G UACUGCAG 1984 CTGCAGTA GGCTAGCTACAACGA TGAGCTCC 6496 2649 GUACUGCA G UUUAUUCA 1985 TGAATAAA GGCTAGCTACAACGA TGCAGTAC 6497 2685 CUAAGGAA G CACAGAUA 1986 TATCTGTG GGCTAGCTACAACGA TTCCTTAG 6498 2708 ACUGAAAC G UUUUCAGA 1987 TCTGAAAA GGCTAGCTACAACGA GTTTCAGT 6499 2744 AUAGAUGA G UUCCCUAC 1988 GTAGGGAA GGCTAGCTACAACGA TCATCTAT 6500 2761 AUUGAUCA G UUCUAAAA 1989 TTTTAGAA GGCTAGCTACAACGA TGATCAAT 6501 2790 CUAAAUUA G CCAGGGAA 1990 TTCCCTGG GGCTAGCTACAACGA TAATTTAG 6502 2814 ACCUAGAA G UAUCCCAC 1991 GTGGGATA GGCTAGCTACAACGA TTCTAGGT 6503 2827 CCACAAAA G UGAAAUUG 1992 CAATTTCA GGCTAGCTACAACGA TTTTGTGG 6504 2853 CGGAUGGA G CUGGGUCA 1993 TGACCCAG GGCTAGCTACAACGA TCCATCCG 6505 2858 GGAGCUGG G UCAUUGCC 1994 GGCAATGA GGCTAGCTACAACGA CCAGCTCC 6506 2916 AACCCAAA G UUGAAGAG 1995 CTCTTCAA GGCTAGCTACAACGA TTTGGGTT 6507 2932 GAAAAUCA G UUUCUCAG 1996 CTGAGAAA GGCTAGCTACAACGA TGATTTTC 6508 2960 AAAAAUGG G UCUGCUAC 1997 GTAGCAGA GGCTAGCTACAACGA CCATTTTT 6509 2976 CAUCAAAG G UGCUCUUA 1998 TAAGAGCA GGCTAGCTACAACGA CTTTGATG 6510 2997 CUCCAGAU G UUUCUGCU 1999 AGCAGAAA GGCTAGCTACAACGA ATCTGGAG 6511 3009 CUGCUUUG G CCACUCAA 2000 TTGAGTGG GGCTAGCTACAACGA CAAAGCAG 6512 3018 CCACUCAA G CAGAGAUA 2001 TATCTCTG GGCTAGCTACAACGA TTGAGTGG 6513 3031 GAUAGAGA G CAUAGUUA 2002 TAACTATG GGCTAGCTACAACGA TCTCTATC 6514 3036 AGAGCAUA G UUAAACCC 2003 GGGTTTAA GGCTAGCTACAACGA TATGCTCT 6515 3048 AACCCAAA G UUCUUGUG 2004 CACAAGAA GGCTAGCTACAACGA TTTGGGTT 6516 3054 AAGUUCUU G UGAAAGAA 2005 TTCTTTCA GGCTAGCTACAACGA AAGAACTT 6517 3063 UGAAAGAA G CUGAGAAA 2006 TTTCTCAG GGCTAGCTACAACGA TTCTTTCA 6518 3126 UAUUUUCA G CAGAGCUG 2007 CAGCTCTG GGCTAGCTACAACGA TGAAAATA 6519 3131 UCAGCAGA G CUGAGUAA 2008 TTACTCAG GGCTAGCTACAACGA TCTGCTGA 6520 3136 AGAGCUGA G UAAAACUU 2009 AAGTTTTA GGCTAGCTACAACGA TCAGCTCT 6521 3147 AAACUUCA G UUGUUGAC 2010 GTCAACAA GGCTAGCTACAACGA TGAAGTTT 6522 3150 CUUCAGUU G UUGACCUC 2011 GAGGTCAA GGCTAGCTACAACGA AACTGAAG 6523 3161 GACCUCCU G UACUGGAG 2012 CTCCAGTA GGCTAGCTACAACGA AGGAGGTC 6524 3189 AGACUGGA G UGGUGUUU 2013 AAACACCA GGCTAGCTACAACGA TCCAGTCT 6525 3192 CUGGAGUG G UGUUUGGU 2014 ACCAAACA GGCTAGCTACAACGA CACTCCAG 6526 3194 GGAGUGGU G UUUGGUGC 2015 GCACCAAA GGCTAGCTACAACGA ACCACTCC 6527 3199 GGUGUUUG G UGCCAGCC 2016 GGCTGGCA GGCTAGCTACAACGA CAAACACC 6528 3205 UGGUGCCA G CCUAUUCC 2017 GGAATAGG GGCTAGCTACAACGA TGGCACCA 6529 3231 CAUUGACA G UAUUCAGC 2018 GCTGAATA GGCTAGCTACAACGA TGTCAATG 6530 3238 AGUAUUCA G CAUUGUGA 2019 TCACAATG GGCTAGCTACAACGA TGAATACT 6531 3243 UCAGCAUU G UGAGCGUA 2020 TACGCTCA GGCTAGCTACAACGA AATGCTGA 6532 3247 CAUUGUGA G CGUAACAG 2021 CTGTTACG GGCTAGCTACAACGA TCACAATG 6533 3249 UUGUGAGC G UAACAGCC 2022 GGCTGTTA GGCTAGCTACAACGA GCTCACAA 6534 3255 GCGUAACA G CCUACAUU 2023 AATGTAGG GGCTAGCTACAACGA TGTTACGC 6535 3270 UUGCCUUG G CCCUGCUC 2024 GAGCAGGG GGCTAGCTACAACGA CAAGGCAA 6536 3282 UGCUCUCU G UGACCAUC 2025 GATGGTCA GGCTAGCTACAACGA AGAGAGGA 6537 3292 GACCAUCA G CUUUAGGA 2026 TCCTAAAG GGCTAGCTACAACGA TGATGGTC 6538 3310 AUACAAGG G UGUGAUCC 2027 GGATCACA GGCTAGCTACAACGA CCTTGTAT 6539 3312 ACAAGGGU G UGAUCCAA 2028 TTGGATCA GGCTAGCTACAACGA ACCCTTGT 6540 3321 UGAUCCAA G CUAUCCAG 2029 CTGGATAG GGCTAGCTACAACGA TTGGATCA 6541 3343 AGAUGAAG G CCACCCAU 2030 ATGGGTGG GGCTAGCTACAACGA CTTCATCT 6542 3357 CAUUCAGG G CAUAUCUG 2031 CAGATATG GGCTAGCTACAACGA CCTGAATG 6543 3375 AAUCUGAA G UUGCUAUA 2032 TATAGCAA GGCTAGCTACAACGA TTCAGATT 6544 3392 UCUGAGGA G UUGGUUCA 2033 TGAACCAA GGCTAGCTACAACGA TCCTCAGA 6545 3396 AGGAGUUG G UUCAGAAG 2034 CTTCTGAA GGCTAGCTACAACGA CAACTCCT 6546 3404 GUUCAGAA G UACAGUAA 2035 TTACTGTA GGCTAGCTACAACGA TTCTGAAC 6547 3409 GAAGUACA G UAAUUCUG 2036 CAGAATTA GGCTAGCTACAACGA TGTACTTC 6548 3424 UGCUCUUG G UCAUGUGA 2037 TCACATGA GGCTAGCTACAACGA CAAGAGCA 6549 3429 UUGGUCAU G UGAACUGC 2038 GCAGTTCA GGCTAGCTACAACGA ATGACCAA 6550 3455 GAACUCAG G CGCCUCUU 2039 AAGAGGCG GGCTAGCTACAACGA CTGAGTTC 6551 3468 UCUUCUUA G UUGAUGAU 2040 ATCATCAA GGCTAGCTACAACGA TAAGAAGA 6552 3480 AUGAUUUA G UUGAUUCU 2041 AGAATCAA GGCTAGCTACAACGA TAAATCAT 6553 3494 UCUCUGAA G UUUGCAGU 2042 ACTGCAAA GGCTAGCTACAACGA TTCAGAGA 6554 3501 AGUUUGCA G UGUUGAUG 2043 CATCAACA GGCTAGCTACAACGA TGCAAACT 6555 3503 UUUGCAGU G UUGAUGUG 2044 CACATCAA GGCTAGCTACAACGA ACTGCAAA 6556 3509 GUGUUGAU G UGGGUAUU 2045 AATACCCA GGCTAGCTACAACGA ATCAACAC 6557 3513 UGAUGUGG G UAUUUACC 2046 GGTAAATA GGCTAGCTACAACGA CCACATCA 6558 3525 UUACCUAU G UUGGUGCC 2047 GGCACCAA GGCTAGCTACAACGA ATAGGTAA 6559 3529 CUAUGUUG G UGCCUUGU 2048 ACAAGGCA GGCTAGCTACAACGA CAACATAG 6560 3536 GGUGCCUU G UUUAAUGG 2049 CCATTAAA GGCTAGCTACAACGA AAGGCACC 6561 3544 GUUUAAUG G UCUGACAC 2050 GTGTCAGA GGCTAGCTACAACGA CATTAAAC 6562 3564 UGAUUUUG G CUCUCAUU 2051 AATGAGAG GGCTAGCTACAACGA CAAAATCA 6563 3583 ACUCUUCA G UGUUCCUG 2052 CAGGAACA GGCTAGCTACAACGA TGAAGAGT 6564 3585 UCUUCAGU G UUCCUGUU 2053 AACAGGAA GGCTAGCTACAACGA ACTGAAGA 6565 3591 GUGUUCCU G UUAUUUAU 2054 ATAAATAA GGCTAGCTACAACGA AGGAACAC 6566 3605 UAUGAACG G CAUCAGGC 2055 GCCTGATG GGCTAGCTACAACGA CGTTCATA 6567 3612 GGCAUCAG G CACAGAUA 2056 TATCTGTG GGCTAGCTACAACGA CTGATGCC 6568 3651 AUAAGAAU G UUAAAGAU 2057 ATCTTTAA GGCTAGCTACAACGA ATTCTTAT 6569 3666 AUGCUAUG G CUAAAAUC 2058 GATTTTAG GGCTAGCTACAACGA CATAGCAT 6570 3678 AAAUCCAA G CAAAAAUC 2059 GATTTTTG GGCTAGCTACAACGA TTGGATTT 6571 3698 GGAUUGAA G CGCAAAGC 2060 GCTTTGCG GGCTAGCTACAACGA TTCAATCC 6572 3705 AGCGCAAA G CUGAAUGA 2061 TCATTCAG GGCTAGCTACAACGA TTTGCGCT 6573 3732 AAUAAUUA G UAGGAGUU 2062 AACTCCTA GGCTAGCTACAACGA TAATTATT 6574 3738 UAGUAGGA G UUCAUCUU 2063 AAGATGAA GGCTAGCTACAACGA TCCTACTA 6575 3781 GGGGGAGG G UCAGGGAA 2064 TTCCCTGA GGCTAGCTACAACGA CCTCCCCC 6576 3804 ACCUUGAC G UUGCAGUG 2065 CACTGCAA GGCTAGCTACAACGA GTCAAGGT 6577 3810 ACGUUGCA G UGCAGUUU 2066 AAACTGCA GGCTAGCTACAACGA TGCAACGT 6578 3815 GCAGUGCA G UUUCACAG 2067 CTGTGAAA GGCTAGCTACAACGA TGCACTGC 6579 3827 CACAGAUC G UUGUUAGA 2068 TCTAACAA GGCTAGCTACAACGA GATCTGTG 6580 3830 AGAUCGUU G UUAGAUCU 2069 AGATCTAA GGCTAGCTACAACGA AACGATCT 6581 3848 UAUUUUUA G CCAUGCAC 2070 GTGCATGG GGCTAGCTACAACGA TAAAAATA 6582 3858 CAUGCACU G UUGUGAGG 2071 CCTCACAA GGCTAGCTACAACGA AGTGCATG 6583 3861 GCACUGUU G UGAGGAAA 2072 TTTCCTCA GGCTAGCTACAACGA AACAGTGC 6584 3878 AAUUACCU G UCUUGACU 2073 AGTCAAGA GGCTAGCTACAACGA AGGTAATT 6585 3892 ACUGCCAU G UGUUCAUC 2074 GATGAACA GGCTAGCTACAACGA ATGGCAGT 6586 3894 UGCCAUGU G UUCAUCAU 2075 ATGATGAA GGCTAGCTACAACGA ACATGGCA 6587 3908 CAUCUUAA G UAUUGUAA 2076 TTACAATA GGCTAGCTACAACGA TTAAGATG 6588 3913 UAAGUAUU G UAAGCUGC 2077 GCAGCTTA GGCTAGCTACAACGA AATACTTA 6589 3917 UAUUGUAA G CUGCUAUG 2078 CATAGCAG GGCTAGCTACAACGA TTACAATA 6590 3925 GCUGCUAU G UAUGGAUU 2079 AATCCATA GGCTAGCTACAACGA ATAGCAGC 6591 3940 UUUAAACC G UAAUCAUA 2080 TATGATTA GGCTAGCTACAACGA GGTTTAAA 6592 3966 UAUCUGAG G CACUGGUG 2081 CACCAGTG GGCTAGCTACAACGA CTCAGATA 6593 3972 AGGCACUG G UGGAAUAA 2082 TTATTCCA GGCTAGCTACAACGA CAGTGCCT 6594 3988 AAAAACCU G UAUAUUUU 2083 AAAATATA GGCTAGCTACAACGA AGGTTTTT 6595 4002 UUUACUUU G UUGCAGAU 2084 ATCTGCAA GGCTAGCTACAACGA AAAGTAAA 6596 4012 UGCAGAUA G UCUUGCCG 2085 CGGCAAGA GGCTAGCTACAACGA TATCTGCA 6597 4028 GCAUCUUG G CAAGUUGC 2086 GCAACTTG GGCTAGCTACAACGA CAAGATGC 6598 4032 CUUGGCAA G UUGCAGAG 2087 CTCTGCAA GGCTAGCTACAACGA TTGCCAAG 6599 4044 CAGAGAUG G UGGAGCUA 2088 TAGCTCCA GGCTAGCTACAACGA CATCTCTG 6600 54 CCUCCCCA A CCCCCACA 2089 TGTGGGGG GGCTAGCTACAACGA TGGGGAGG 6601 63 CCCCCACA A CCGCCGGC 2090 GCGGGCGG GGCTAGCTACAACGA TGTGGGGG 6602 81 GCUCUGAG A CGCGGCCC 2091 GGGCCGCG GGCTAGCTACAACGA CTCAGAGC 6603 142 CAUGGAAG A CCUGGACC 2092 GGTCCAGG GGCTAGCTACAACGA CTTCCATG 6604 148 AGACCUGG A CCAGUCUC 2093 GAGACTGG GGCTAGCTACAACGA CCAGGTCT 6605 175 GUCCUCGG A CAGCCCAC 2094 GTGGGCTG GGCTAGCTACAACGA CCGAGGAC 6606 232 GCCCGAGG A CGAGGAGG 2095 CCTCCTCG GGCTAGCTACAACGA CCTCGGGC 6607 265 AGAGGAGG A CGAGGACG 2096 CGTCCTCG GGCTAGCTACAACGA CCTCCTCT 6608 271 GGACGAGG A CGAAGACC 2097 GGTCTTCG GGCTAGCTACAACGA CCTCGTCC 6609 277 GGACGAAG A CCUGGAGG 2098 CCTCCAGG GGCTAGCTACAACGA CTTCGTCC 6610 369 CGCCCCUG A UGGACUUC 2099 GAAGTCCA GGCTAGCTACAACGA CAGGGGCG 6611 373 CCUGAUGG A CUUCGGAA 2100 TTCCGAAG GGCTAGCTACAACGA CCATCAGG 6612 382 CUUCGGAA A UGACUUCG 2101 CGAAGTCA GGCTAGCTACAACGA TTCCGAAG 6613 385 CGGAAAUG A CUUCGUGC 2102 GCACGAAG GGCTAGCTACAACGA CATTTCCG 6614 410 CCCCGGGG A CCCCUGCC 2103 GGCAGGGG GGCTAGCTACAACGA CCCCGGGG 6615 460 GUCUUGGG A CCCGAGCC 2104 GGCTCGGG GGCTAGCTACAACGA CCCAAGAC 6616 480 UGUCGUCG A CCGUGCCC 2105 GGGCACGG GGCTAGCTACAACGA CGACGACA 6617 541 CCCUGAGG A CGACGAGC 2106 GCTCGTCG GGCTAGCTACAACGA CCTCAGGG 6618 544 UGAGGACG A CGAGCCUC 2107 GAGGCTCG GGCTAGCTACAACGA CGTCCTCA 6619 612 CCGUGUGG A CCCCGCCA 2108 TGGCGGGG GGCTAGCTACAACGA CCACACGG 6620 691 CUCAGUGG A UGAGAGCC 2109 GGGTCTCA GGCTAGCTACAACGA CCACTGAG 6621 696 UGGAUGAG A CCCUUUUU 2110 AAAAAGGG GGCTAGCTACAACGA CTCATCCA 6622 732 AGCCUGUG A UACGCUCC 2111 GGAGCGTA GGCTAGCTACAACGA CACAGGCT 6623 751 UGCAGAAA A UAUGGACU 2112 AGTCCATA GGCTAGCTACAACGA TTTCTGCA 6624 757 AAAUAUGG A CUUGAAGG 2113 CCTTCAAG GGCTAGCTACAACGA CCATATTT 6625 778 GCCAGGUA A CACUAUUU 2114 AAATAGTG GGCTAGCTACAACGA TACCTGGC 6626 802 UCAAGAGG A UUUCCCAU 2115 ATGGGAAA GGCTAGCTACAACGA CCTCTTGA 6627 825 UGCUUGAA A CUGCUGCU 2116 AGCAGCAG GGCTAGCTACAACGA TTCAAGCA 6628 878 UUCAAAGA A CAUGAAUA 2117 TATTCATG GGCTAGCTACAACGA TCTTTGAA 6629 884 GAACAUGA A UACCUUGG 2118 CCAAGGTA GGCTAGCTACAACGA TCATGTTC 6630 895 CCUUGGUA A UUUGUCAA 2119 TTGACAAA GGCTAGCTACAACGA TACCAAGG 6631 903 AUUUGUCA A CAGUAUUA 2120 TAATACTG GGCTAGCTACAACGA TGACAAAT 6632 924 CUGAAGGA A CACUUCAA 2121 TTGAAGTG GGCTAGCTACAACGA TCCTTCAG 6633 937 UCAAGAAA A UGUCAGUG 2122 CACTGACA GGCTAGCTACAACGA TTTCTTGA 6634 978 AGGCAAAA A CUCUACUC 2123 GAGTAGAG GGCTAGCTACAACGA TTTTGCCT 6635 991 ACUCAUAG A UAGAGAUU 2124 AATCTCTA GGCTAGCTACAACGA CTATGAGT 6636 997 AGAUAGAG A UUUAACAG 2125 CTGTTAAA GGCTAGCTACAACGA CTCTATCT 6637 1002 GAGAUUUA A CAGAGUUU 2126 AAACTCTG GGCTAGCTACAACGA TAAATCTC 6638 1016 UUUUCAGA A UUAGAAUA 2127 TATTCTAA GGCTAGCTACAACGA TCTGAAAA 6639 1022 GAAUUAGA A UACUCAGA 2128 TCTGAGTA GGCTAGCTACAACGA TCTAATTC 6640 1032 ACUCAGAA A UGGGAUCA 2129 TGATCCCA GGCTAGCTACAACGA TTCTGAGT 6641 1037 GAAAUGGG A UCAUCGUU 2130 AACGATGA GGCTAGCTACAACGA CCCATTTC 6642 1067 AAAGCAGA A UCUGCCGU 2131 ACGGCAGA GGCTAGCTACAACGA TCTGCTTT 6643 1077 CUGCCGUA A UAGUAGGA 2132 TGCTACTA GGCTAGCTACAACGA TACGGCAG 6644 1087 AGUAGCAA A UCCUAGGG 2133 CCCTAGGA GGCTAGCTACAACGA TTGCTACT 6645 1101 GGGAAGAA A UAAUCGUG 2134 CACGATTA GGCTAGCTACAACGA TTCTTCCC 6646 1104 AAGAAAUA A UCGUGAAA 2135 TTTCACGA GGCTAGCTACAACGA TATTTCTT 6647 1114 CGUGAAAA A UAAAGAUG 2136 CATCTTTA GGCTAGCTACAACGA TTTTCACG 6648 1120 AAAUAAAG A UGAAGAAG 2137 CTTCTTCA GGCTAGCTACAACGA CTTTATTT 6649 1144 AGUUAGUA A UAACAUCC 2138 GGATGTTA GGCTAGCTACAACGA TACTAACT 6650 1147 UAGUAAUA A CAUCCUUC 2139 GAAGGATG GGCTAGCTACAACGA TATTACTA 6651 1159 CCUUCAUA A UCAACAAG 2140 CTTGTTGA GGCTAGCTACAACGA TATGAAGG 6652 1163 CAUAAUCA A CAAGAGUU 2141 AACTCTTG GGCTAGCTACAACGA TGATTATG 6653 1190 CUUACUAA A UUGGUUAA 2142 TTAACCAA GGCTAGCTACAACGA TTAGTAAG 6654 1204 UAAAGAGG A UGAAGUUG 2143 CAACTTCA GGCTAGCTACAACGA CCTCTTTA 6655 1234 AGCAAAAG A CAGUUUUA 2144 TAAAACTG GGCTAGCTACAACGA CTTTTGCT 6656 1243 CAGUUUUA A UGAAAAGA 2145 TCTTTTCA GGCTAGCTACAACGA TAAAACTG 6657 1283 AGGGAGGA A UAUGCAGA 2146 TCTGCATA GGCTAGCTACAACGA TCCTCCCT 6658 1291 AUAUGCAG A CUUCAAAC 2147 GTTTGAAG GGCTAGCTACAACGA CTGCATAT 6659 1298 GACUUCAA A CCAUUUGA 2148 TCAAATGG GGCTAGCTACAACGA TTGAAGTC 6660 1327 AGUGAAAG A UAGUAAGG 2149 CCTTACTA GGCTAGCTACAACGA CTTTCACT 6661 1339 UAAGGAAG A UAGUGAUA 2150 TATCACTA GGCTAGCTACAACGA CTTCCTTA 6662 1345 AGAUAGUG A UAUGUUGG 2151 CCAACATA GGCTAGCTACAACGA CACTATCT 6663 1368 GAGGUAAA A UCGAGAGC 2152 GCTCTCGA GGCTAGCTACAACGA TTTACCTC 6664 1378 CGAGAGCA A CUUGGAAA 2153 TTTCCAAG GGCTAGCTACAACGA TGCTCTCG 6665 1396 UAAAGUGG A UAAAAAAU 2154 ATTTTTTA GGCTAGCTACAACGA CCACTTTA 6666 1403 GAUAAAAA A UGUUUUGC 2155 GCAAAACA GGCTAGCTACAACGA TTTTTATC 6667 1414 UUUUGCAG A UAGCCUUG 2156 CAAGGCTA GGCTAGCTACAACGA CTGCAAAA 6668 1428 UUGAGCAA A CUAAUCAC 2157 GTGATTAG GGCTAGCTACAACGA TTGCTCAA 6669 1432 GCAAACUA A UCACGAAA 2158 TTTCGTGA GGCTAGCTACAACGA TAGTTTGC 6670 1444 CGAAAAAG A UAGUGAGA 2159 TCTCACTA GGCTAGCTACAACGA CTTTTTCG 6671 1459 GAGUAGUA A UGAUGAUA 2160 TATCATCA GGCTAGCTACAACGA TACTACTC 6672 1462 UAGUAAUG A UGAUACUU 2161 AAGTATCA GGCTAGCTACAACGA CATTACTA 6673 1465 UAAUGAUG A UACUUCUU 2162 AAGAAGTA GGCTAGCTACAACGA CATCATTA 6674 1501 UAUAAAGG A UCGUUCAG 2163 CTGAACGA GGCTAGCTACAACGA CCTTTATA 6675 1537 UCCCUUUA A CCCAGCAG 2164 CTGCTGGG GGCTAGCTACAACGA TAAAGGGA 6676 1548 CAGCAGCA A CUGAGAGC 2165 GCTCTCAG GGCTAGCTACAACGA TGCTGCTG 6677 1563 GCAUUGCA A CAAACAUU 2166 AATGTTTG GGCTAGCTACAACGA TGCAATGC 6678 1567 UGCAACAA A CAUUUUUC 2167 GAAAAATG GGCTAGCTACAACGA TTGTTGCA 6679 1588 GUUAGGAG A UCCUACUU 2168 AAGTAGGA GGCTAGCTACAACGA CTCCTAAC 6680 1603 UUCAGAAA A UAAGACCG 2169 CGGTCTTA GGCTAGCTACAACGA TTTCTGAA 6681 1608 AAAAUAAG A CCGAUGAA 2170 TTCATCGG GGCTAGCTACAACGA CTTATTTT 6682 1612 UAAGACCG A UGAAAAAA 2171 TTTTTTCA GGCTAGCTACAACGA CGGTCTTA 6683 1623 AAAAAAAA A UAGAAGAA 2172 TTCTTCTA GGCTAGCTACAACGA 6684 1644 AGGCCCAA A UAGUAACA 2173 TGTTACTA GGCTAGCTACAACGA TTGGGCCT 6685 1650 AAAUAGUA A CAGAGAAG 2174 CTTCTCTG GGCTAGCTACAACGA TACTATTT 6686 1660 AGAGAAGA A UACUAGCA 2175 TGCTAGTA GGCTAGCTACAACGA TCTTCTCT 6687 1674 GCACCAAA A CAUCAAAG 2176 GTTTGATG GGCTAGCTACAACGA TTTGGTGC 6688 1681 AACAUCAA A CCCUUUUC 2177 GAAAAGGG GGCTAGCTACAACGA TTGATGTT 6689 1705 AGCACAGG A UUCUGAGA 2178 TCTCAGAA GGCTAGCTACAACGA CCTGTGCT 6690 1713 AUUCUGAG A CAGAUUAU 2179 ATAATCTG GGCTAGCTACAACGA CTCAGAAT 6691 1717 UGAGACAG A UUAUGUCA 2180 TGACATAA GGCTAGCTACAACGA CTGTCTCA 6692 1728 AUGUCACA A CAGAUAAU 2181 ATTATCTG GGCTAGCTACAACGA TGTGACAT 6693 1732 CACAACAG A UAAUUUAA 2182 TTAAATTA GGCTAGCTACAACGA CTGTTGTG 6694 1735 AACAGAUA A UUUAACAA 2183 TTGTTAAA GGCTAGCTACAACGA TATCTGTT 6695 1740 AUAAUUUA A CAAAGGUG 2184 CACCTTTG GGCTAGCTACAACGA TAAATTAT 6696 1749 CAAAGGUG A CUGAGGAA 2185 TTCCTCAG GGCTAGCTACAACGA CACCTTTG 6697 1768 CGUGGCAA A CAUGCCUG 2186 CAGGCATG GGCTAGCTACAACGA TTGCCACG 6698 1785 AAGGCCUG A CUCCAGAU 2187 ATCTGGAG GGCTAGCTACAACGA CAGGCCTT 6699 1792 GACUCCAG A UUUAGUAC 2188 GTACTAAA GGCTAGCTACAACGA CTGGAGTC 6700 1820 GAAAGUGA A UUGAAUGA 2189 TCATTCAA GGCTAGCTACAACGA TCACTTTC 6701 1825 UGAAUUGA A UGAAGUUA 2190 TAACTTCA GGCTAGCTACAACGA TCAATTCA 6702 1845 GUACAAAG A UUGCUUAU 2191 ATAAGCAA GGCTAGCTACAACGA CTTTGTAC 6703 1857 CUUAUGAA A CAAAAAUG 2192 GATTTTTG GGCTAGCTACAACGA TTCATAAG 6704 1863 AAACAAAA A UGGACUUG 2193 CAAGTCCA GGCTAGCTACAACGA TTTTGTTT 6705 1867 AAAAAUGG A CUUGGUUC 2194 GAACCAAG GGCTAGCTACAACGA CCATTTTT 6706 1878 UGGUUCAA A CAUCAGAA 2195 TTCTGATG GGCTAGCTACAACGA TTGAACCA 6707 1972 UUUGCCUG A CAUUGUUA 2196 TAACAATG GGCTAGCTACAACGA CAGGCAAA 6708 1996 ACCAUUGA A UUCUGCAG 2197 CTGCAGAA GGCTAGCTACAACGA TCAATGGT 6709 2028 CUUCCGUG A UACAGCCC 2198 GGGCTGTA GGCTAGCTACAACGA CACGGAAG 6710 2068 UUCAGUUA A UUAUGAAA 2199 TTTCATAA GGCTAGCTACAACGA TAACTGAA 6711 2084 AGCAUAAA A CAUGAGCC 2200 GGCTCATG GGCTAGCTACAACGA TTTATGCT 6712 2098 GCCUGAAA A CCCCCCAC 2201 GTGGGGGG GGCTAGCTACAACGA TTTCAGGC 6713 2151 UAUCAGGA A UAAAGGAA 2202 TTCCTTTA GGCTAGCTACAACGA TCCTGATA 6714 2163 AGGAAGAA A UUAAAGAG 2203 CTCTTTAA GGCTAGCTACAACGA TTCTTCCT 6715 2179 GCCUGAAA A UAUUAAUG 2204 CATTAATA GGCTAGCTACAACGA TTTCAGGC 6716 2185 AAAUAUUA A UGCAGCUC 2205 GAGCTGCA GGCTAGCTACAACGA TAATATTT 6717 2202 UUCAAGAA A CAGAAGCU 2206 AGCTTCTG GGCTAGCTACAACGA TTCTTGAA 6718 2233 UGCAUGUG A UUUAAUUA 2207 TAATTAAA GGCTAGCTACAACGA CACATGCA 6719 2238 GUGAUUUA A UUAAAGAA 2208 TTCTTTAA GGCTAGCTACAACGA TAAATCAC 6720 2247 UUAAAGAA A CAAAGCUU 2209 AAGCTTTG GGCTAGCTACAACGA TTCTTTAA 6721 2264 UCUGCUGA A CCAGCUCC 2210 GGAGCTGG GGCTAGCTACAACGA TCAGCAGA 6722 2275 AGCUCCGG A UUUCUCUG 2211 CAGAGAAA GGCTAGCTACAACGA CCGGAGCT 6723 2284 UUUCUCUG A UUAUUCAG 2212 CTGAATAA GGCTAGCTACAACGA CAGAGAAA 6724 2295 AUUCAGAA A UGGCAAAA 2213 TTTTGCCA GGCTAGCTACAACGA TTCTGAAT 6725 2309 AAAGUUGA A CAGCCAGU 2214 ACTGGCTG GGCTAGCTACAACGA TCAACTTT 6726 2323 AGUGCCUG A UCAUUCUG 2215 CAGAATGA GGCTAGCTACAACGA CAGGCACT 6727 2344 AGUUGAAG A UUCCUCAC 2216 GTGAGGAA GGCTAGCTACAACGA CTTCAACT 6728 2356 CUCACCUG A UUCUGAAC 2217 GTTCAGAA GGCTAGCTACAACGA CAGGTGAG 6729 2363 GAUUCUGA A CCAGUUGA 2218 TCAACTGG GGCTAGCTACAACGA TCAGAATC 6730 2371 ACCAGUUG A CUUAUUUA 2219 TAAATAAG GGCTAGCTACAACGA CAACTGGT 6731 2383 AUUUAGUG A UGAUUCAA 2220 TTGAATCA GGCTAGCTACAACGA CACTAAAT 6732 2386 UAGUGAUG A UUCAAUAC 2221 GTATTGAA GGCTAGCTACAACGA CATCACTA 6733 2391 AUGAUUCA A UACCUGAC 2222 GTCAGGTA GGCTAGCTACAACGA TGAATCAT 6734 2398 AAUACCUG A CGUUCCAC 2223 GTGGAACG GGCTAGCTACAACGA CAGGTATT 6735 2411 CCACAAAA A CAAGAUGA 2224 TCATCTTG GGCTAGCTACAACGA TTTTGTGG 6736 2416 AAAACAAG A UGAAACUG 2225 CAGTTTCA GGCTAGCTACAACGA CTTGTTTT 6737 2421 AAGAUGAA A CUGUGAUG 2226 CATCACAG GGCTAGCTACAACGA TTCATCTT 6738 2427 AAACUGUG A UGCUUGUG 2227 CACAAGCA GGCTAGCTACAACGA CACAGTTT 6739 2454 UCACUGAG A CUUCAUUU 2228 AAATGAAG GGCTAGCTACAACGA CTCAGTGA 6740 2469 UUGAGUCA A UGAUAGAA 2229 TTCTATCA GGCTAGCTACAACGA TGACTCAA 6741 2472 AGUCAAUG A UAGAAUAU 2230 ATATTCTA GGCTAGCTACAACGA CATTGACT 6742 2477 AUGAUAGA A UAUGAAAA 2231 TTTTCATA GGCTAGCTACAACGA TCTATCAT 6743 2485 AUAUGAAA A UAAGGAAA 2232 TTTCCTTA GGCTAGCTACAACGA TTTCATAT 6744 2495 AAGGAAAA A CUCAGUGC 2233 GCACTGAG GGCTAGCTACAACGA TTTTCCTT 6745 2537 UAUUUGGA A UCUUUUAA 2234 TTAAAAGA GGCTAGCTACAACGA TCCAAATA 6746 2557 CAGUUUAG A UAACACAA 2235 TTGTGTTA GGCTAGCTACAACGA CTAAACTG 6747 2560 UUUAGAUA A CACAAAAG 2236 CTTTTGTG GGCTAGCTACAACGA TATCTAAA 6748 2569 CACAAAAG A UACCCUGU 2237 ACAGGGTA GGCTAGCTACAACGA CTTTTGTG 6749 2584 GUUACCUG A UGAAGUUU 2238 AAACTTCA GGCTAGCTACAACGA CAGGTAAC 6750 2595 AAGUUUCA A CAUUGAGC 2239 GCTCAATG GGCTAGCTACAACGA TGAAACTT 6751 2616 AGGAGAAA A UUCCUUUG 2240 CAAAGGAA GGCTAGCTACAACGA TTTCTCCT 6752 2628 CUUUGCAG A UGGAGGAG 2241 CTCCTCCA GGCTAGCTACAACGA CTGCAAAG 6753 2659 UUAUUCAA A UGAUGACU 2242 AGTCATCA GGCTAGCTACAACGA TTGAATAA 6754 2662 UUCAAAUG A UGACUUAU 2243 ATAAGTCA GGCTAGCTACAACGA CATTTGAA 6755 2665 AAAUGAUG A CUUAUUUA 2244 TAAATAAG GGCTAGCTACAACGA CATCATTT 6756 2691 AAGCACAG A UAAGAGAA 2245 TTCTCTTA GGCTAGCTACAACGA CTGTGCTT 6757 2700 UAAGAGAA A CUGAAACG 2246 CGTTTCAG GGCTAGCTACAACGA TTCTCTTA 6758 2706 AAACUGAA A CGUUUUCA 2247 TGAAAACG GGCTAGCTACAACGA TTCAGTTT 6759 2716 GUUUUCAG A UUCAUCUC 2248 GAGATGAA GGCTAGCTACAACGA CTGAAAAC 6760 2727 CAUCUCCA A UUGAAAUU 2249 AATTTCAA GGCTAGCTACAACGA TGGAGATG 6761 2733 CAAUUGAA A UUAUAGAU 2250 ATCTATAA GGCTAGCTACAACGA TTCAATTG 6762 2740 AAUUAUAG A UGAGUUCC 2251 GGAACTCA GGCTAGCTACAACGA CTATAATT 6763 2757 CUACAUUG A UCAGUUCU 2252 AGAACTGA GGCTAGCTACAACGA CAATGTAG 6764 2769 GUUCUAAA A CUGAUUCA 2253 TGAATCAG GGCTAGCTACAACGA TTTAGAAC 6765 2773 UAAAACUG A UUCAUUUU 2254 AAAATGAA GGCTAGCTACAACGA CAGTTTTA 6766 2786 UUUUCUAA A UUAGCCAG 2255 CTGGCTAA GGCTAGCTACAACGA TTAGAAAA 6767 2798 GCCAGGGA A UAUACUGA 2256 TCAGTATA GGCTAGCTACAACGA TCCCTGGC 6768 2806 AUAUACUG A CCUAGAAG 2257 CTTCTAGG GGCTAGCTACAACGA CAGTATAT 6769 2832 AAAGUGAA A UUGCUAAU 2258 ATTAGCAA GGCTAGCTACAACGA TTCACTTT 6770 2839 AAUUGCUA A UGCCCCGG 2259 CCGGGGCA GGCTAGCTACAACGA TAGCAATT 6771 2848 UGCCCCGG A UGGAGCUG 2260 CAGCTCCA GGCTAGCTACAACGA CCGGGGCA 6772 2876 UGCACAGA A UUGCCCCA 2261 TGGGGCAA GGCTAGCTACAACGA TCTGTGCA 6773 2887 GCCCCAUG A CCUUUCUU 2262 AAGAAAGG GGCTAGCTACAACGA CATGGGGC 6774 2902 UUUGAAGA A CAUACAAC 2263 GTTGTATG GGCTAGCTACAACGA TCTTCAAA 6775 2909 AACAUACA A CCCAAAGU 2264 ACTTTGGG GGCTAGCTACAACGA TGTATGTT 6776 2928 AAGAGAAA A UCAGUUUC 2265 GAAACTGA GGCTAGCTACAACGA TTTCTCTT 6777 2941 UUUCUCAG A UGACUUUU 2266 AAAAGTCA GGCTAGCTACAACGA CTGAGAAA 6778 2944 CUCAGAUG A CUUUUCUA 2267 TAGAAAAG GGCTAGCTACAACGA CATCTGAG 6779 2956 UUCUAAAA A UGGGUCUG 2268 CAGACCCA GGCTAGCTACAACGA TTTTAGAA 6780 2995 GCCUCCAG A UGUUUCUG 2269 CAGAAACA GGCTAGCTACAACGA CTGGAGGC 6781 3024 AAGCAGAG A UAGAGAGC 2270 GCTCTCTA GGCTAGCTACAACGA CTGTGCTT 6782 3041 AUAGUUAA A CCCAAAGU 2271 ACTTTGGG GGCTAGCTACAACGA TTAACTAT 6783 3074 GAGAAAAA A CUUCCUUC 2272 GAAGGAAG GGCTAGCTACAACGA TTTTTCTC 6784 3085 UCCUUCCG A UACAGAAA 2273 TTTCTGTA GGCTAGCTACAACGA CGGAAGGA 6785 3100 AAAAGAGG A CAGAUCAC 2274 GTGATCTG GGCTAGCTACAACGA CCTCTTTT 6786 3104 GAGGACAG A UCACCAUC 2275 GATGGTGA GGCTAGCTACAACGA CTGTCCTC 6787 3141 UGAGUAAA A CUUCAGUU 2276 AACTGAAG GGCTAGCTACAACGA TTTACTCA 6788 3154 AGUUGUUG A CCUCCUGU 2277 ACAGGAGG GGCTAGCTACAACGA CAACAACT 6789 3172 CUGGAGAG A CAUUAAGA 2278 TCTTAATG GGCTAGCTACAACGA CTCTCCAG 6790 3183 UUAAGAAG A CUGGAGUG 2279 CACTCCAG GGCTAGCTACAACGA CTTCTTAA 6791 3228 UUUCAUUG A CAGUAUUC 2280 GAATACTG GGCTAGCTACAACGA CAATGAAA 6792 3252 UGAGCGUA A CAGCCUAC 2281 GTAGGCTG GGCTAGCTACAACGA TACGCTCA 6793 3285 UCUCUGUG A CCAUCAGC 2282 GCTGATGG GGCTAGCTACAACGA CACAGAGA 6794 3300 GCUUUAGG A UAUACAAG 2283 CTTGTATA GGCTAGCTACAACGA CCTAAAGC 6795 3315 AGGGUGUG A UCCAAGCU 2284 AGCTTGGA GGCTAGCTACAACGA CACACCCT 6796 3332 AUCCAGAA A UCAGAUGA 2285 TCATCTGA GGCTAGCTACAACGA TTCTGGAT 6797 3337 GAAAUCAG A UGAAGGCC 2286 GGCCTTCA GGCTAGCTACAACGA CTGATTTC 6798 3368 UAUCUGGA A UCUGAAGU 2287 ACTTCAGA GGCTAGCTACAACGA TCCAGATA 6799 3412 GUACAGUA A UUCUGCUC 2288 GAGCAGAA GGCTAGCTACAACGA TACTGTAC 6800 3433 UCAUGUGA A CUGCACGA 2289 TCGTGCAG GGCTAGCTACAACGA TCACATGA 6801 3441 ACUGCACG A UAAAGGAA 2290 TTCCTTTA GGCTAGCTACAACGA CGTGCAGT 6802 3449 AUAAAGGA A CUCAGGCG 2291 CGCCTGAG GGCTAGCTACAACGA TCCTTTAT 6803 3472 CUUAGUUG A UGAUUUAG 2292 CTAAATCA GGCTAGCTACAACGA CAACTAAG 6804 3475 AGUUGAUG A UUUAGUUG 2293 CAACTAAA GGCTAGCTACAACGA CATCAACT 6805 3484 UUUAGUUG A UUCUCUGA 2294 TCAGAGAA GGCTAGCTACAACGA CAACTAAA 6806 3507 CAGUGUUG A UGUGGGUA 2295 TACCCACA GGCTAGCTACAACGA CAACACTG 6807 3541 CUUGUUUA A UGGUCUGA 2296 TCAGACCA GGCTAGCTACAACGA TAAACAAG 6808 3549 AUGGUCUG A CAGUACUG 2297 CAGTAGTG GGCTAGCTACAACGA CAGACCAT 6809 3558 CAGUACUG A UUUUGGCU 2298 AGCCAAAA GGCTAGCTACAACGA CAGTAGTG 6810 3602 AUUUAUGA A CGGCAUCA 2299 TGATGCCG GGCTAGCTACAACGA TCATAAAT 6811 3618 AGGCACAG A UAGAUCAU 2300 ATGATCTA GGCTAGCTACAACGA CTGTGCCT 6812 3622 ACAGAUAG A UCAUUAUC 2301 GATAATGA GGCTAGCTACAACGA CTATCTGT 6813 3635 UAUCUAGG A CUUGCAAA 2302 TTTGCAAG GGCTAGCTACAACGA CCTAGATA 6814 3643 ACUUGCAA A UAAGAAUG 2303 CATTCTTA GGCTAGCTACAACGA TTGCAAGT 6815 3649 AAAUAAGA A UGUUAAAG 2304 CTTTAACA GGCTAGCTACAACGA TCTTATTT 6816 3658 UGUUAAAG A UGCUAUGG 2305 CCATAGCA GGCTAGCTACAACGA CTTTAACA 6817 3672 UGGCUAAA A UCCAAGCA 2306 TGCTTGGA GGCTAGCTACAACGA TTTAGCCA 6818 3684 AAGGAAAA A UCCCUGGA 2307 TCCAGGGA GGCTAGCTACAACGA TTTTGCTT 6819 3692 AUCCCUGG A UUGAAGCG 2308 CGCTTCAA GGCTAGCTACAACGA CCAGGGAT 6820 3710 AAAGCUGA A UGAAAACG 2309 CGTTTTCA GGCTAGCTACAACGA TCAGCTTT 6821 3716 GAAUGAAA A CGCCCAAA 2310 TTTGGGCG GGCTAGCTACAACGA TTTCATTC 6822 3725 CGCCCAAA A UAAUUAGU 2311 ACTAATTA GGCTAGCTACAACGA TTTGGGCG 6823 3728 CCAAAAUA A UUAGUAGG 2312 CCTACTAA GGCTAGCTACAACGA TATTTTGG 6824 3755 UAAAGGGG A UAUUCAUU 2313 AATGAATA GGCTAGCTACAACGA CCCCTTTA 6825 3766 UUCAUUUG A UUAUACGG 2314 CCGTATAA GGCTAGCTACAACGA CAAATGAA 6826 3792 AGGGAAGA A CGAACCUU 2315 AAGGTTCG GGCTAGCTACAACGA TCTTCCCT 6827 3796 AAGAACGA A CCUUGACG 2316 CGTCAAGG GGCTAGCTACAACGA TCGTTCTT 6828 3802 GAACCUUG A CGUUGCAG 2317 CTGCAACG GGCTAGCTACAACGA CAAGGTTC 6829 3824 UUUCACAG A UCGUUGUU 2318 AACAACGA GGCTAGCTACAACGA CTGTGAAA 6830 3835 GUUGUUAG A UCUUUAUU 2319 AATAAAGA GGCTAGCTACAACGA CTAACAAC 6831 3871 GAGGAAAA A UUACCUGU 2320 ACAGGTAA GGCTAGCTACAACGA TTTTCCTC 6832 3884 CUGUCUUG A CUGCCAUG 2321 CATGGCAG GGCTAGCTACAACGA CAAGACAG 6833 3931 AUGUAUGG A UUUAAACC 2322 GGTTTAAA GGCTAGCTACAACGA CCATACAT 6834 3937 GGAUUUAA A CCGUAAUC 2323 GATTACGG GGCTAGCTACAACGA TTAAATCC 6835 3943 AAACCGUA A UCAUAUCU 2324 AGATATGA GGCTAGCTACAACGA TACGGTTT 6836 3977 CUGGUGGA A UAAAAAAC 2325 GTTTTTTA GGCTAGCTACAACGA TCCACCAG 6837 3984 AAUAAAAA A CCUGUAUA 2326 TATACAGG GGCTAGCTACAACGA TTTTTATT 6838 4009 UGUUGCAG A UAGUCUUG 2327 CAAGACTA GGCTAGCTACAACGA CTGCAACA 6839 4041 UUGCAGAG A UGGUGGAG 2328 CTCCACCA GGCTAGCTACAACGA CTCTGCAA 6840 Input Sequence = AB020693 . Cut Site = R/Y Stem Length = 8 . Core Sequence = GGCTAGCTACAACGA AB020693 (Homo sapiens mRNA for KIAA0886 protein (Nogo-A) ; 4053 bp) Table VIII: Human NOGO Amberzyme and Substrate Sequence Pos Substrate Seq ID Amberzyme Seq ID 66 CCACAACC G CCCGCGGC 1545 GCGGCGGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGUUGUGG 6841 70 AACCGCCC G CGGCUCUG 1546 CAGAGCCG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGGCGGUU 6842 78 GCGGCUCU G AGACGCGG 1547 CCGCGUCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGAGGCGC 6843 83 UCUGAGAC G CGGCCCCG 1548 CGGGGCCG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GUCUCAGA 6844 110 CAGCAGCU G CAGCAUCA 1549 UGAUGCUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGCUGCUG 6845 191 CCCCGGCC G CAGCCCGC 1550 GCGGGCUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGCCGGGG 6846 198 CGCAGCCC G CGUUCAAG 1551 CUUGAACG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGGCUGCG 6847 218 CAGUUCGU G AGGGAGCC 1552 GGCUCCCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACGAACUG 6848 228 GGGAGCCC G AGGACGAG 1553 CUCGUCCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGGCUCCC 6849 234 CCGAGGAC G AGGAGGAA 1554 UUCCUCCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GUCCUCGG 6850 267 AGGAGGAC G AGGACGAA 1555 UUCGUCCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GUCCUCCU 6851 273 ACGAGGAC G AAGAGCUG 1556 CAGGUCUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GUCCUCGU 6852 296 CUGGAGGU G CUGGAGAG 1557 CUCUCCAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACCUCCAG 6853 312 GGAAGCCC G CCGCCGGG 1558 CCCGGCGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGGCUUCC 6854 315 AGCCCGCC G CCGGGCUG 1559 CAGCCCGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGCGGGCU 6855 327 GGCUGUCC G CGGCCCCA 1560 UGGGGCCG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGACAGCC 6856 338 GCCCCAGU G CCCACCGC 1561 GCGGUGGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACUGGGGC 6857 345 UGCCCACC G CCCCUGCC 1562 GGCAGGGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGUGGGCA 6858 351 CCGCCCCU G CCGCCGGC 1563 GCCGGCGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGGGGCGG 6859 354 CCCCUGCC G CCGGCGCG 1564 CGCGCCGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGCAGGGG 6860 360 CCGCCGGC G CGCCCCUG 1565 CAGGGGCG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GCCGGCGG 6861 362 GCCGGCGC G CCCCUGAU 1566 AUCAGGGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GCGCCGGC 6862 368 GCGCCCCU G AUGGACUU 1567 AAGUCCAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGGGGCGC 6863 384 UCGGAAAU G ACUUCGUG 1568 CACGAAGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUUUCCGA 6864 392 GACUUCGU G CCGCCGGC 1569 GCCGGCGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACGAAGUC 6865 395 UUCGUGCC G CCGGCGGC 1570 GGCGCCGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGCACGAA 6866 401 CCGCCGGC G CCCCGGGG 1571 CCCCGGGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GCCGGCGG 6867 416 GGACCCCU G CCGGCCGC 1572 GCGGCCGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGGGGUCC 6868 423 UGCCGGCC G CUCCCCCC 1573 GGGGGGAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGCCGGCA 6869 435 CCCCCGUC G CCCCGGAG 1574 CUCCGGGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GACGGGGG 6870 464 UGGGACCC G AGCCCGGU 1575 ACCGGGCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGGUCCCA 6871 479 GUGUCGUC G ACCGUGCC 1576 GGCACGGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GACGACAC 6872 485 UCGACCGU G CCCGCGCC 1577 GGCGCGGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACGGUCGA 6873 489 CCGUGCCC G CGCCAUCC 1578 GGAUGGCG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGGCACGG 6874 491 GUGCCCGC G CCAUCCCC 1579 GGGGAUGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GCGGGCAC 6875 500 CCAUCCCC G CUGUCUGC 1580 GCAGACAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGGGAUGG 6876 507 CGCUGUCU G CUGCCGCA 1581 UGCGGCAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGACAGCG 6877 510 UGUCUGCU G CCGCAGUC 1582 GACUGCGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGCAGACA 6878 513 CUGCUGCC G CAGUCUCG 1583 CGAGACUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGCAGCAG 6879 521 GCAGUCUC G CCCUCCAA 1584 UUGGAGGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GAGACUGC 6880 537 AGCUCCCU G AGGACGAC 1585 GUCGUCCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGGGAGCU 6881 543 CUGAGGAC G ACGAGCCU 1586 AGGCUCGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GUCCUCAG 6882 546 AGGACGAC G AGCCUCCG 1587 CGGAGGCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GUCGUCCU 6883 587 GCCAGCGU G AGCCCCCA 1588 UGGGGGCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACGCUGGC 6884 617 UGGACCCC G CCAGCCCC 1589 GGGGCUGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGGGUCCA 6885 633 CGGCUCCC G CCGCGCCC 1590 GGGCGCGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGGAGCCG 6886 636 CUCCCGCC G CGCCCCCC 1591 GGGGGGCG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGCGGGAG 6887 638 CCCGCCGC G CCCCCCUC 1592 GAGGGGGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GCGGCGGG 6888 657 CCCCGGCC G CGCCCAAG 1593 CUUGGGCG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGCCGGGG 6889 659 CCGGCCGC G CCCAAGCG 1594 CGCUUGGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GCGGCCGG 6890 661 GCCCAAGC G CAGGGGCU 1595 AGCCCCUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GCUUGGGC 6891 693 CAGUGGAU G AGACCCUU 1596 AAGGGUCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUCCACUG 6892 705 CCCUUUUU G CUCUUCCU 1597 AGGAAGAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAAAAGGG 6893 714 CUCUUCCU G CUGCAUCU 1598 AGAUGCAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGGAAGAG 6894 717 UUCCUGCU G CAUCUGAG 1599 CUCAGAUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGCAGGAA 6895 723 CUGCAUCU G AGCCUGUG 1600 CACAGGCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGAUGCAG 6896 731 GAGCCUGU G AUACGCUC 1601 GAGCGUAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACAGGCUC 6897 736 UGUGAUAC G CUCCUCUG 1602 CAGAGGAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GUAUCACA 6898 744 GCUCCUCU G CAGAAAAU 1603 AUUUUCUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGAGGAGC 6899 761 AUGGACUU G AAGGAGCA 1604 UGCUCCUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAGUCCAU 6900 818 UCUGUCCU G CUUGAAAC 1605 GUUUCAAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGGACAGA 6901 822 UCCUGCUU G AAACUGCU 1606 AGCAGUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAGCAGGA 6902 828 UUGAAACU G CUGCUUCU 1607 AGAAGCAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGUUUCAA 6903 831 AAACUGCU G CUUCUCUU 1608 AAGAGAAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGCAGUUU 6904 864 UCUCAGCC G CUUCUUUC 1609 GAAAGAAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGCUGAGA 6905 882 AAGAACAU G AAUACCUU 1610 AAGGUAUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUGUUCUU 6906 918 UACCCACU G AAGGAAGA 1611 UGUUCCUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGUGGGUA 6907 945 AUGUCAGU G AAGCUUCU 1612 AGAAGCUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACUGACAU 6908 1071 CAGAAUCU G CCGUAAUA 1613 UAUUACGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGAUUCUG 6909 1109 AUAAUCGU G AAAAAUAA 1614 UUAUUUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACGAUUAU 6910 1122 AUAAAGAU G AAGAAGAG 1615 CUCUUCUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUCUUUAU 6911 1206 AAGAGGAU G AAGUUGUG 1616 CACAACUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUCCUCUU 6912 1245 GUUUUAAU G AAAAGAGA 1617 UCUCUUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUUAAAAC 6913 1257 AGAGAGUU G CAGUGGAA 1618 UUCCACUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AACUCUCU 6914 1274 GCUCCUAU G AGGGAGGA 1619 UCCUCCCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUAGGAGC 6915 1287 AGGAAUAU G CAGACUUC 1620 GAAGUCUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUAUUCCU 6916 1305 AACCAUUU G AGCGAGUA 1621 UACUCGCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAAUGGUU 6917 1309 AUUUGAGC G AGUAUGGG 1622 CCCAUACU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GCUCAAAU 6918 1322 UGGGAAGU G AAAGAUAG 1623 CUAUCUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACUUCCCA 6919 1344 AAGAUAGU G AUAUGUUG 1624 CAACAUAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACUAUCUU 6920 1356 UGUUGGCU G CUGGAGGU 1625 ACCUCCAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGCCAACA 6921 1371 GUAAAAUC G AGAGCAAC 1626 GUUGCUCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GAUUUUAC 6922 1410 AAUGUUUU G CAGAUAGC 1627 GCUAUCUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAAACAUU 6923 1422 AUAGCCUU G AGCAAACU 1628 AGUUUGCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAGGCUAU 6924 1437 CUAAUCAC G AAAAAGAU 1629 AUCUUUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GUGAUUAG 6925 1449 AAGAUAGU G AGAGUAGU 1630 ACUACUCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACUAUCUU 6926 1461 GUAGUAAU G AUGAUACU 1631 AGUAUCAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUUACUAC 6927 1464 GUAAUGAU G AUACUUCU 1632 AGAAGUAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUCAUUAC 6928 1484 CCCAGUAC G CCAGAAGG 1633 CCUUCUGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GUACUGGG 6929 1527 UCACAUGU G CUCCCUUU 1634 AAAGGGAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACAUGUGA 6930 1551 CAGCAACU G AGAGCAUU 1635 AAUGCUCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGUUGCUG 6931 1560 AGAGCAUU G CAACAAAC 1636 GUUUGUUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAUGCUCU 6932 1611 AUAAGACC G AUGAAAAA 1637 UUUUUCAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGUCUUAU 6933 1614 AGACCGAU G AAAAAAAA 1638 UUUUUUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUCGGUCU 6934 1710 AGGAUUCU G AGACAGAU 1639 AUCUGUCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGAAUCCU 6935 1748 ACAAAGGU G ACUGAGGA 1640 UCCUCAGU GGAGGAAACUCC Cϋ UCAAGGACAUCGUCCGGG ACCUUUGU 6936 1752 AGGUGACU G AGGAAGUC 1641 GACUUCCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGUCACCU 6937 1772 GCAAACAU G CCUGAAGG 1642 CCUUCAGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUGUUUGC 6938 1776 ACAUGCCU G AAGGCCUG 1643 CAGGCCUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGGCAUGU 6939 1784 GAAGGCCU G ACUCCAGA 1644 UCUGGAGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGGCCUUC 6940 1812 AAGCAUGU G AAAGUGAA 1645 UUCACUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACAUGCUU 6941 1818 GUGAAAGU G AAUUGAAU 1646 AUUCAAUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACUUUCAC 6942 1823 AGUGAAUU G AAUGAAGU 1647 ACUUCAUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAUUCACU 6943 1827 AAUUGAAU G AAGUUACU 1648 AGUAACUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUUCAAUU 6944 1848 CAAAGAUU G CUUAUGAA 1649 UUCAUAAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAUCUUUG 6945 1854 UUGCUUAU G AAACAAAA 1650 UUUUGUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUAAGCAA 6946 1892 GAAGUUAU G CAAGAGUC 1651 GACUCUUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUAACUUC 6947 1911 UCUAUCCU G CAGCACAG 1652 CUGUGCUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGGAUAGA 6948 1924 ACAGCUUU G CCCAUCAU 1653 AUGAUGGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAAGCUGU 6949 1935 CAUCAUUU G AAGAGUCA 1654 UGACUCUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAAUGAUG 6950 1967 CCAGUUUU G CCUGACAU 1655 AUGUCAGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAAACUGG 6951 1971 UUUUGCCU G ACAUUGUU 1656 AACAAUGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGGCAAAA 6952 1994 GCACCAUU G AAUUCUGC 1657 GCAGAAUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAUGGUGC 6953 2001 UGAAUUCU G CAGUUCCU 1658 AGGAACUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGAAUUCA 6954 2013 UUCCUAGU G CUGGUGCU 1659 AGCACCAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACUAGGAA 6955 2019 GUGCUGGU G CUUCCGUG 1660 CACGGAAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACCAGCAC 6956 2027 GCUUCCGU G AUACAGCC 1661 GGCUGUAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACGGAAGC 6957 2073 UUAAUUAU G AAAGCAUA 1662 UAUGCUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUAAUUAA 6958 2088 UAAAACAU G AGCCUGAA 1663 UUCAGGCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUGUUUUA 6959 2094 AUGAGCCU G AAAACCCC 1664 GGGGUUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGGCUCAU 6960 2112 CACCAUAU G AAGAGGCC 1665 GGCCUCUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUAUGGUG 6961 2123 GAGGCCAU G AGUGUAUC 1666 GAUACACU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUGGCCUC 6962 2175 AAGAGCCU G AAAAUAUU 1667 AAUAUUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGGCUCUU 6963 2187 AUAUUAAU G CAGCUCUU 1668 AAGAGCUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUUAAUAU 6964 2226 UAUCUAUU G CAUGUGAU 1669 AUCACAUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAUAGAUA 6965 2232 UUGCAUGU G AUUUAAUU 1670 AAUUAAAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACAUGCAA 6966 2259 AGCUUUCU G CUGAACCA 1671 UGGUUCAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGAAAGCU 6967 2262 UUUCUGCU G AACCAGCU 1672 AGCUGGUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGCAGAAA 6968 2283 AUUUCUCU G AUUAUUCA 1673 UGAAUAAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGAGAAAU 6969 2307 CAAAAGUU G AACAGCCA 1674 UGGCUGUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AACUUUUG 6970 2318 CAGCCAGU G CCUGAUCA 1675 UGAUCAGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACUGGCUG 6971 2322 CAGUGCCU G AUCAUUCU 1676 AGAAUGAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGGCACUG 6972 2331 AUCAUUCU G AGCUAGUU 1677 AACUAGCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGAAUGAU 6973 2340 AGCUAGUU G AAGAUUCC 1678 GGAAUCUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AACUAGCU 6974 2355 CCUCACCU G AUUCUGAA 1679 UUCAGAAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGGUGAGG 6975 2361 CUGAUUCU G AACCAGUU 1680 AACUGGUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGAAUCAG 6976 2370 AACCAGUU G ACUUAUUU 1681 AAAUAAGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AACUGGUU 6977 2382 UAUUUAGU G AUGAUUCA 1682 UGAAUCAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACUAAAUA 6978 2385 UUAGUGAU G AUUCAAUA 1683 UAUUGAAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUCACUAA 6979 2397 CAAUACCU G ACGUUCCA 1684 UGGAACGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGGUAUUG 6980 2418 AACAAGAU G AAACUGUG 1685 CACAGUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUCUUGUU 6981 2426 GAAACUGU G AUGCUUGU 1686 ACAAGCAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACAGUUUC 6982 2429 ACUGUGAU G CUUGUGAA 1687 UUCACAAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUCACAGU 6983 2435 AUGCUUGU G AAAGAAAG 1688 CUUUCUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACAAGCAU 6984 2451 GUCUCACU G AGACUUCA 1689 UGAAGUCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGUGAGAC 6985 2463 CUUCAUUU G AGUCAAUG 1690 CAUUGACU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAAUGAAG 6986 2471 GAGUCAAU G AUAGAAUA 1691 UAUUCUAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUUGACUC 6987 2481 UAGAAUAU G AAAAUAAG 1692 CUUAUUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUAUUCUA 6988 2502 AACUCAGU G CUUUGCCA 1693 UGGCAAAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACUGAGUU 6989 2507 AGUGCUUU G CCACCUGA 1694 UCAGGUGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAAGCACU 6990 2514 UGCCACCU G AGGGAGGA 1695 UCCUCCCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGGUGGCA 6991 2583 UGUUACCU G AUGAAGUU 1696 AACUUCAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGGUAACA 6992 2586 UACCUGAU G AAGUUUCA 1697 UGAAACUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUCAGGUA 6993 2600 UCAACAUU G AGCAAAAA 1698 UUUUUGCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAUGUUGA 6994 2624 AUUCCUUU G CAGAUGGA 1699 UCCAUCUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAAGGAAU 6995 2646 UCAGUACU G CAGUUUAU 1700 AUAAACUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGUACUGA 6996 2661 AUUCAAAU G AUGACUUA 1701 UAAGUCAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUUUGAAU 6997 2664 CAAAUGAU G ACUUAUUU 1702 AAAUAAGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUCAUUUG 6998 2703 GAGAAACU G AAACGUUU 1703 AAACGUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGUUUCUC 6999 2730 CUCCAAUU G AAAUUAUA 1704 UAUAAUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAUUGGAG 7000 2742 UUAUAGAU G AGUUCCCU 1705 AGGGAACU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUCUAUAA 7001 2756 CCUACAUU G AUCAGUUC 1706 GAACUGAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAUGUAGG 7002 2772 CUAAAACU G AUUCAUUU 1707 AAAUGAAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGUUUUAG 7003 2805 AAUAUACU G ACCUAGAA 1708 UUCUAGGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGUAUAUU 7004 2829 ACAAAAGU G AAAUUGCU 1709 AGCAAUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACUUUUGU 7005 2835 GUGAAAUU G CUAAUGCC 1710 GGCAUUAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAUUUCAC 7006 2841 UUGCUAAU G CCCCGGAU 1711 AUCCGGGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUUAGCAA 7007 2864 GGGUCAUU G CCUUGCAC 1712 GUGCAAGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAUGACCC 7008 2869 AUUGCCUU G CACAGAAU 1713 AUUCUGUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAGGCAAU 7009 2879 ACAGAAUU G CCCCAUGA 1714 UCAUGGGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAUUCUGU 7010 2886 UGCCCCAU G ACCUUUCU 1715 AGAAAGGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUGGGGCA 7011 2897 CUUUCUUU G AAGAACAU 1716 AUGUUCUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAAGAAAG 7012 2919 CCAAAGUU G AAGAGAAA 1717 UUUCUCUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AACUUUGG 7013 2943 UCUCAGAU G ACUUUUCU 1718 AGAAAAGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUCUGAGA 7014 2964 AUGGGUCU G CUACAUCA 1719 UGAUGUAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGACCCAU 7015 2978 UCAAAGGU G CUCUUAUU 1720 AAUAAGAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACCUUUGA 7016 2987 CUCUUAUU G CCUCCAGA 1721 UCUGGAGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAUAAGAG 7017 3003 AUGUUUCU G CUUUGGCC 1722 GGCCAAAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGAAACAU 7018 3056 GUUCUUGU G AAAGAAGC 1723 GCUUCUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACAAGAAC 7019 3066 AAGAAGCU G AGAAAAAA 1724 UUUUUUCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGCUUCUU 7020 3084 UUCCUUCC G AUACAGAA 1725 UUCUGUAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGAAGGAA 7021 3114 CACCAUCU G CUAUAUUU 1726 AAAUAUAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGAUGGUG 7022 3134 GCAGAGCU G AGUAAAAC 1727 GUUUUACU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGCUCUGC 7023 3153 CAGUUGUU G ACCUCCUG 1728 CAGGAGGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AACAACUG 7024 3201 UGUUUGGU G CCAGCCUA 1729 UAGGCUGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACCAAACA 7025 3215 CUAUUCCU G CUGCUUUC 1730 GAAAGCAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGGAAUAG 7026 3218 UUCCUGCU G CUUUCAUU 1731 AAUGAAAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGCAGGAA 7027 3227 CUUUCAUU G ACAGUAUU 1732 AAUACUGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAUGAAAG 7028 3245 AGCAUUGU G AGCGUAAC 1733 GUUACGCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACAAUGCU 7029 3264 CCUACAUU G CCUUGGCC 1734 GGCCAAGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAUGUAGG 7030 3275 UUGGCCCU G CUCUCUGU 1735 ACAGAGAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGGGCCAA 7031 3284 CUCUCUGU G ACCAUCAG 1736 CUGAUGGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACAGAGAG 7032 3314 AAGGGUGU G AUCCAAGC 1737 GCUUGGAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACACCCUU 7033 3339 AAUCAGAU G AAGGCCAC 1738 GUGGCCUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUCUGAUU 7034 3372 UGGAAUCU G AAGUUGCU 1739 AGCAACUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGAUUCCA 7035 3378 CUGAAGUU G CUAUAUCU 1740 AGAUAUAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AACUUCAG 7036 3387 CUAUAUCU G AGGAGUUG 1741 CAACUCCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGAUAUAG 7037 3417 GUAAUUCU G CUCUUGGU 1742 ACCAAGAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGAAUUAC 7038 3431 GGUCAUGU G AACUGCAC 1743 GUGCAGUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACAUGACC 7039 3436 UGUGAACU G CACGAUAA 1744 UUAUCGUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGUUCACA 7040 3440 AACUGCAC G AUAAAGGA 1745 UCCUUUAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GUGCAGUU 7041 3457 ACUCAGGC G CCUCUUCU 1746 AGAAGAGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GCCUGAGU 7042 3471 UCUUAGUU G AUGAUUUA 1747 UAAAUCAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AACUAAGA 7043 3474 UAGUUGAU G AUUUAGUU 1748 AACUAAAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUCAACUA 7044 3483 AUUUAGUU G AUUCUCUG 1749 CAGAGAAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AACUAAAU 7045 3491 GAUUCUCU G AAGUUUGC 1750 GCAAACUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGAGAAUC 7046 3498 UGAAGUUU G CAGUGUUG 1751 CAACACUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAACUUCA 7047 3506 GCAGUGUU G AUGUGGGU 1752 ACCCACAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AACACUGC 7048 3531 AUGUUGGU G CCUUGUUU 1753 AAACAAGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACCAACAU 7049 3548 AAUGGUCU G ACACUACU 1754 AGUAGUGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGACCAUU 7050 3557 ACACUACU G AUUUUGGC 1755 GCCAAAAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGUAGUGU 7051 3600 UUAUUUAU G AACGGCAU 1756 AUGCCGUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUAAAUAA 7052 3639 UAGGACUU G CAAAUAAG 1757 CUUAUUUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAGUCCUA 7053 3660 UUAAAGAU G CUAUGGCU 1758 AGCCAUAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUCUUUAA 7054 3695 CCUGGAUU G AAGCGCAA 1759 UUGCGCUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAUCCAGG 7055 3700 AUUGAAGC G CAAAGCUG 1760 CAGCUUUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GCUUCAAU 7056 3708 GCAAAGCU G AAUGAAAA 1761 UUUUCAUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGCUUUGC 7057 3712 AGCUGAAU G AAAACGCC 1762 GGCGUUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUUCAGCU 7058 3718 AUGAAAAC G CCCAAAAU 1763 AUUUUGGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GUUUUCAU 7059 3765 AUUCAUUU G AUUAUACG 1764 CGUAUAAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAAUGAAU 7060 3794 GGAAGAAC G AACCUUGA 1765 UCAAGGUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GUUCUUCC 7061 3801 CGAACCUU G ACGUUGCA 1766 UGCAACGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAGGUUCG 7062 3807 UUGACGUU G CAGUGCAG 1767 CUGCACUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AACGUCAA 7063 3812 GUUGCAGU G CAGUUUCA 1768 UGAAACUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACUGCAAC 7064 3853 UUAGCCAU G CACUGUUG 1769 CAACAGUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUGGCUAA 7065 3863 ACUGUUGU G AGGAAAAA 1770 UUUUUCCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACAACAGU 7066 3883 CCUGUCUU G ACUGCCAU 1771 AUGGCAGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAGACAGG 7067 3887 UCUUGACU G CCAUGUGU 1772 ACACAUGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGUCAAGA 7068 3920 UGUAAGCU G CUAUGUAU 1773 AUACAUAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGCUUACA 7069 3963 UCCUAUCU G AGGCACUG 1774 CAGUGCCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGAUAGGA 7070 4005 ACUUUGUU G CAGAUAGU 1775 ACUAUCUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AACAAAGU 7071 4017 AUAGUCUU G CCGCAUCU 1776 AGAUGCGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAGACUAU 7072 4020 GUCUUGCC G CAUCUUGG 1777 CCAAGAUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGCAAGAC 7073 4035 GGCAAGUU G CAGAGAUG 1778 CAUCUCUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AACUUGCC 7074 12 CACAGUAG G UCCCUCGG 1779 CCGAGGGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUACUGUG 7075 20 GUCCCUCG G CUCAGUCG 1780 CGACUGAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CGAGGGAC 7076 25 UCGGCUCA G UCGGCCCA 1781 UGGGCCGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGAGCCGA 7077 29 CUCAGUCG G CCCAGCCC 1782 GGGCUGGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CGACUGAG 7078 34 UCGGCCCA G CCCCUCUC 1783 GAGAGGGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGGGCCGA 7079 44 CCCUCUCA G UCCUCCCC 1784 GGGGAGGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGAGAGGG 7080 73 CGCCCGCG G CUCUGAGA 1785 UCUCAGAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CGCGGGCG 7081 86 GAGACGCG G CCCCGGCG 1786 CGCCGGGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CGCGUCUC 7082 92 CGGCCCCG G CGGCGGCG 1787 CGCCGCCG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CGGGGCCG 7083 95 CCCCGGCG G CGGCGGCA 1788 UGCCGCCG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CGCCGGGG 7084 98 CGGCGGCG G CGGCAGCA 1789 UGCUGCCG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CGCCGCCG 7085 101 CGGCGGCG G CAGCAGCU 1790 AGCUGCUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CGCCGCCG 7086 104 CGGCGGCA G CAGCUGCA 1791 UGCAGCUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGCCGCCG 7087 107 CGGCAGCA G CUGCAGCA 1792 UGCUGCAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGCUGCCG 7088 113 CAGCUGCA G CAUCAUCU 1793 AGAUGAUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGCAGCUG 7089 132 ACCCUCCA G CCAUGGAA 1794 UUCCAUGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGGAGGGU 7090 152 CUGGACCA G UCUCCUCU 1795 AGAGGAGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGGUCCAG 7091 162 CUCCUCUG G UCUCGUCC 1796 GGACGAGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAGAGGAG 7092 167 CUGGUCUC G UCCUCGGA 1797 UCCGAGGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GAGACCAG 7093 178 CUCGGACA G CCCACCCC 1798 GGGGUGGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGUCCGAG 7094 188 CCACCCCG G CCGCAGCC 1799 GGCUGCGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CGGGGUGG 7095 194 CGGCCGCA G CCCGCGUU 1800 AACGCGGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGGGGCCG 7096 200 CAGCCCGC G UUCAAGUA 1801 UACUUGAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GCGGGCUG 7097 206 GCGUUCAA G UACCAGUU 1802 AACUGGUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUGAACGC 7098 212 AAGUACCA G UUCGUGAG 1803 CUCACGAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGGUACUU 7099 216 ACCAGUUC G UGAGGGAG 1804 CUCCCUCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GAACUGGU 7100 224 GUGAGGGA G CCCGAGGA 1805 UCCUCGGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCCCUCAC 7101 287 CUGGAGGA G CUGGAGGU 1806 ACCUCCAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCCUCCAG 7102 294 AGCUGGAG G UGCUGGAG 1807 CUCCAGCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUCCAGCU 7103 308 GAGAGGAA G CCCGCCGC 1808 GCGGCGGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCCUCUC 7104 320 GCCGCCGG G CUGUCCGC 1809 GCGGACAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCGGCGGC 7105 323 GCCGGGGU G UCCGCGGC 1810 GCCGCGGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGCCCGGC 7106 330 UGUCCGCG G CCCCAGUG 1811 CACUGGGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CGCGGACA 7107 336 CGGCCCCA G UGCCCACC 1812 GGUGGGCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGGGGCCG 7108 358 UGCCGCCG G CGCGCCCC 1813 GGGGCGCG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CGGCGGCA 7109 390 AUGACUUC G UGCCGCCG 1814 CGGCGGCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GAAGUCAU 7110 399 UGCCGCCG G CGCCCCGG 1815 CCGGGGCG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CGGCGGCA 7111 420 CCCUGCCG G CCGCUCCC 1816 GGGAGCGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CGGCAGGG 7112 432 CUCCCCCC G UCGCCCCG 1817 CGGGGCGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGGGGGAG 7113 443 GCCCCGGA G CGGCAGCC 1818 GGCUGCCG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCCGGGGC 7114 446 CCGGAGCG G CAGCCGUC 1819 GACGGCUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CGCUCCGG 7115 449 GAGCGGCA G CCGUCUUG 1820 CAAGACGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGCCGCUC 7116 452 CGGCAGCC G UCUUGGGA 1821 UCCCAAGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGCUGCCG 7117 466 GGACCCGA G CCCGGUGU 1822 ACACCGGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCGGGUCC 7118 471 CGAGCCCG G UGUCGUCG 1823 CGACGACA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CGGGCUCG 7119 473 AGCCCGGU G UCGUCGAC 1824 GUCGACGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACCGGGCU 7120 476 CCGGUGUC G UCGACCGU 1825 ACGGUCGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GACACCGG 7121 483 CGUCGACC G UGCCCGCG 1826 CGCGGGCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGUCGACG 7122 503 UCCCCGCU G UCUGCUGC 1827 GCAGCAGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGCGGGGA 7123 516 CUGCCGCA G UCUCGCCC 1828 GGGCGAGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGCGGCAG 7124 530 CCCUCCAA G CUCCCUGA 1829 UCAGGGAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUGGAGGG 7125 548 GACGACGA G CCUCCGGC 1830 GCCGGAGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCGUCGUC 7126 555 AGCCUCCG G CCCGGCCU 1831 AGGCCGGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CGGAGGCU 7127 560 CCGGCCCG G CCUCCCCC 1832 GGGGGAGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CGGGCCGG 7128 579 CUCCCCCG G CCAGCGUG 1833 CACGCUGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGGGGGAG 7129 583 CCCGGCCA G CGUGAGCC 1834 GGCUCACG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGGCCGGG 7130 585 CGGCCAGC G UGAGCCCC 1835 GGGGCUCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GCUGGCCG 7131 589 CAGCGUGA G CCCCCAGG 1836 CCUGGGGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCACGCUG 7132 597 GCCCCCAG G CAGAGCCC 1837 GGGCUCUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUGGGGGC 7133 602 CAGGCAGA G CCCGUGUG 1838 CACACGGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCUGCCUG 7134 606 CAGAGCCC G UGUGGACC 1839 GGUCCACA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGGCUCUG 7135 608 GAGCCCGU G UGGACCCC 1840 GGGGUCCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACGGGCUC 7136 621 CCCCGCCA G CCCCGGCU 1841 AGCCGGGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGGCGGGG 7137 627 CAGCCCCG G CUCCCGCC 1842 GGCGGGAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CGGGGCUG 7138 654 CCACCCCG G CCGCGCCC 1843 GGGCGCGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CGGGGUGG 7139 665 GCGCCCAA G GGCAGGGG 1844 CCCCUGCG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUGGGCGC 7140 673 GCGCAGGG G CUCCUCGG 1845 CCGAGGAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCCUGCGC 7141 682 CUCCUCGG G CUCAGUGG 1846 CCACUGAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCGAGGAG 7142 687 CGGGCUCA G UGGAUGAG 1847 CUCAUCCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGAGCCCG 7143 725 GCAUCUGA G CCUGUGAU 1848 AUCACAGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCAGAUGC 7144 729 CUGAGCCU G UGAUACGC 1849 GCGUAUCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGGCUCAG 7145 767 UUGAAGGA G CAGCCAGG 1850 CCUGGCUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCCUUCAA 7146 770 AAGGAGCA G CCAGGUAA 1851 UUACCUGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGCUCCUU 7147 775 GCAGCCAG G UAACACUA 1852 UAGUGUUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUGGCUGC 7148 789 CUAUUUCG G CUGGUCAA 1853 UUGACCAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CGAAAUAG 7149 793 UUCGGCUG G UCAAGAGG 1854 CCUCUUGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAGCCGAA 7150 813 UCCCAUCU G UCCUGCUU 1855 AAGCAGGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGAUGGGA 7151 848 CCUUCUCU G UCUCCUCU 1856 AGAGGAGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGAGAAGG 7152 861 CUCUCUCA G CCGCUUCU 1857 AGAAGCGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGAGAGAG 7153 892 AUACCUUG G UAAUUUGU 1858 ACAAAUUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAAGGUAU 7154 899 GGUAAUUU G UCAACAGU 1859 ACUGUUGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAAUUACC 7155 906 UGUCAACA G UAUUACCC 1860 GGGUAAUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGUUGACA 7156 939 AAGAAAAU G UCAGUGAA 1861 UUCACUGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUUUUCUU 7157 943 AAAUGUCA G UGAAGCUU 1862 AAGCUUCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGACAUUU 7158 948 UCAGUGAA G CUUCUAAA 1863 UUUAGAAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCACUGA 7159 960 CUAAAGAG G UCUCAGAG 1864 CUCUGAGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUCUUUAG 7160 972 CAGAGAAG G CAAAAACU 1865 AGUUUUUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUUCUCUG 7161 1007 UUAACAGA G UUUUCAGA 1866 UCUGAAAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCUGUUAA 7162 1043 GGAUCAUC G UUCAGUGU 1867 ACACUGAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GAUGAUCC 7163 1048 AUCGUUCA G UGUCUCUC 1868 GAGAGACA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGAACGAU 7164 1050 CGUUCAGU G UCUCUCCA 1869 UGGAGAGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACUGAACG 7165 A G CAGAAUCU 1870 AGAUUCUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUUUGGAG 7166 :c G UAAUAGUA 1871 UACUAUUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGCAGAUU 7167 ΓA G UAGCAAAU 1872 AUUUGCUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAUUACGG 7168 ΓA G CAAAUCCU 1873 AGGAUUUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UACUAUUA 7169 re G UGAAAAAU 1874 AUUUUUCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GAUUAUUU 7170 A G UUAGUUAG 1875 CUAACUAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCUCUUC 7171 A G UUAGUAAU 1876 AUUACUAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAACUUCU 7172 ΓA G UAAUAACA 1877 UGUUAUUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAACUAAC 7173 !A G UUACCUAC 1878 GUAGGUAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCUUGUUG 7174 :A G CUCUUACU 1879 AGUAAGAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGUAGGUA 7175 ΓG G UUAAAGAG 1880 CUCUUUAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAAUUUAG 7176 A G UUGUGUCU 1881 AGACACAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCAUCCU 7177 U G UGUCUUCA 1882 UGAAGACA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AACUUCAU 7178 IU G UCUUCAGA 1883 UCUGAAGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACAACUUC 7179 A G CAAAAGAC 1884 GUCUUUUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUUUUCUG 7180 A G UUUUAAUG 1885 CAUUAAAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGUCUUUU 7181 !A G UUGCAGUG 1886 CACUGCAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCUCUUUU 7182 :A G UGGAAGCU 1887 AGCUUCCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGCAACUC 7183 A G CUCCUAUG 1888 CAUAGGAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCCACUG 7184 iA G CGAGUAUG 1889 CAUACUCG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCAAAUGG 7185 IA G UAUGGGAA 1890 UUCCCAUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCGCUCAA 7186 A G UGAAAGAU 1891 AUCUUUCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCCCAUA 7187 A G UAAGGAAG 1892 CUUCCUUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAUCUUUC 7188 A G UGAUAUGU 1893 ACAUAUCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAUCUUCC 7189 U G UUGGCUGC 1894 GCAGCCAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUAUCACU 7190 G G CUGCUGGA 1895 UCCAGCAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAACAUAU 7191 G G UAAAAUCG 1896 CGAUUUUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUCCAGCA 7192 A G CAACUUGG 1897 CCAAGUUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCUCGAUU 7193 A G UAAAGUGG 1898 CCACUUUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUUCCAAG 7194 A G UGGAUAAA 1899 UUUAUCCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUUACUUU 7195 U G UUUUGCAG 1900 CUGCAAAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUUUUUUA 7196 A G CCUUGAGC 1901 GCUCAAGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAUCUGCA 7197 A G CAAACUAA 1902 UUAGUUUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCAAGGCU 7198 A G UGAGAGUA 1903 UACUCUCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAUCUUUU , 7199 A G UAGUAAUG 1904 CAUUACUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCUCACUA '7200 A G UAAUGAUG 1905 CAUCAUUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UACUCUCA 7201 A G UACGCCAG 1906 CUGGCGUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGGGGAAA 7202 G G UAUAAAGG 1907 CCUUUAUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUUCUGGC 7203 C G UUCAGGAG 1908 CUCCUGAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GAUCCUUU 7204 A G CAUAUAUC 1909 GAUAUAUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCCUGAAC 7205 U G UGCUCCCU 1910 AGGGAGCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUGUGAUA 7206 1542 UUAACCCA G CAGCAACU 1911 AGUUGCUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGGGUUAA 7207 1545 ACCCAGCA G CAACUGAG 1912 CUCAGUUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGCUGGGU 7208 1555 AACUGAGA G CAUUGCAA 1913 UUGCAAUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCUCAGUU 7209 1580 UUUCCUUU G UUAGGAGA 1914 UCUCCUAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAAGGAAA 7210 1638 AAAAGAAG G CCCAAAUA 1915 UAUUUGGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUUCUUUU 7211 1647 CCCAAAUA G UAACAGAG 1916 CUCUGUUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAUUUGGG 7212 1666 GAAUACUA G CACCAAAA 1917 UUUUGGUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAGUAUUC 7213 1692 CUUUUCUU G UAGCAGCA 1918 UGCUGCUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAGAAAAG 7214 1695 UUCUUGUA G CAGCACAG 1919 CUGUGCUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UACAAGAA 7215 1698 UUGUAGCA G CACAGGAU 1920 AUCCUGUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGCUACAA 7216 1722 CAGAUUAU G UCACAACA 1921 UGUUGUGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUAAUCUG 7217 1746 UAACAAAG G UGACUGAG 1922 CUCAGUCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUUUGUUA 7218 1758 CUGAGGAA G UCGUGGCA 1923 UGCCACGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCCUCAG 7219 1761 AGGAAGUC G UGGCAAAC 1924 GUUUGCCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GACUUCCU 7220 1764 AAGUCGUG G CAAACAUG 1925 CAUGUUUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CACGACUU 7221 1780 GCCUGAAG G CCUGACUC 1926 GAGUCAGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUUCAGGC 7222 1797 CAGAUUUA G UACAGGAA 1927 UUCCUGUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAAAUCUG 7223 1806 UACAGGAA G CAUGUGAA 1928 UUCACAUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCCUGUA 7224 1810 GGAAGCAU G UGAAAGUG 1929 CACUUUCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUGCUUCC 7225 1816 AUGUGAAA G UGAAUUGA 1930 UCAAUUCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUUCACAU 7226 1830 UGAAUGAA G UUACUGGU 1931 ACCAGUAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCAUUCA 7227 1837 AGUUACUG G UACAAAGA 1932 UCUUUGUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAGUAACU 7228 1872 UGGACUUG G UUCAAACA 1933 UGUUUGAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAAGUCCA 7229 1887 CAUCAGAA G UUAUGCAA 1934 UUGCAUAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCUGAUG 7230 1898 AUGCAAGA G UCACUCUA 1935 UAGAGUGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCUUGCAU 7231 1914 AUCCUGCA G CACAGCUU 1936 AAGCUGUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGCAGGAU 7232 1919 GCAGCACA G CUUUGCCC 1937 GGGCAAAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGUGCUGC 7233 1940 UUUGAAGA G UCAGAAGC 1938 GCUUCUGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCUUCAAA 7234 1947 AGUCAGAA G CUACUCCU 1939 AGGAGUAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCUGACU 7235 1962 CUUCACCA G UUUUGCCU 1940 AGGCAAAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGGUGAAG 7236 1977 CUGACAUU G UUAUGGAA 1941 UUCCAUAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAUGUCAG 7237 1986 UUAUGGAA G CACCAUUG 1942 CAAUGGUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCCAUAA 7238 2004 AUUCUGCA G UUCCUAGU 1943 ACUAGGAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGCAGAAU 7239 2011 AGUUCCUA G UGCUGGUG 1944 CACCAGCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAGGAACU 7240 2017 UAGUGCUG G UGCUUCCG 1945 CGGAAGCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAGCACUA 7241 2025 GUGCUUCC G UGAUACAG 1946 CUGUAUCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGAAGCAC 7242 2033 GUGAUACA G CCCAGCUC 1947 GAGCUGGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGUAUCAC 7243 2038 ACAGCCCA G CUCAUCAC 1948 GUGAUGAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGGGCUGU 7244 2055 CAUUAGAA G CUUCUUCA 1949 UGAAGAAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCUAAUG 7245 2064 CUUCUUCA G UUAAUUAU 1950 AUAAUUAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGAAGAAG 7246 2077 UUAUGAAA G CAUAAAAC 1951 GUUUUAUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUUCAUAA 7247 2090 AAACAUGA G CCUGAAAA 1952 UUUUCAGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCAUGUUU 7248 2118 AUGAAGAG G CCAUGAGU 1953 ACUCAUGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUCUUCAU 7249 2125 GGCCAUGA G UGUAUCAC 1954 GUGAUACA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCAUGGCC 7250 2127 CCAUGAGU G UAUCACUA 1955 UAGUGAUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACUCAUGG 7251 2142 UAAAAAAA G UAUCAGGA 1956 UCCUGAUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUUUUUUA 7252 2171 AUUAAAGA G CCUGAAAA 1957 UUUUCAGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCUUUAAU 7253 2190 UUAAUGCA G CUCUUCAA 1958 UUGAAGAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGCAUUAA 7254 2208 AAACAGAA G CUCCUUAU 1959 AUAAGGAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCUGUUU 7255 2230 UAUUGCAU G UGAUUUAA 1960 UUAAAUCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUGCAAUA 7256 2252 GAAACAAA G CUUUCUGC 1961 GCAGAAAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUUGUUUC 7257 2268 CUGAACCA G CUCCGGAU 1962 AUCCGGAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGGUUCAG 7258 2298 CAGAAAUG G CAAAAGUU 1963 AACUUUUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAUUUCUG 7259 2304 UGGCAAAA G UUGAACAG 1964 CUGUUCAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUUUGCCA 7260 2312 GUUGAACA G CCAGUGCC 1965 GGCACUGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGUUCAAC 7261 2316 AACAGCCA G UGCCUGAU 1966 AUCAGGCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGGCUGUU 7262 2333 CAUUCUGA G CUAGUUGA 1967 UCAACUAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCAGAAUG 7263 2337 CUGAGCUA G UUGAAGAU 1968 AUCUUCAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAGCUCAG 7264 2367 CUGAACCA G UUGACUUA 1969 UAAGUCAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGGUUCAG 7265 2380 CUUAUUUA G UGAUGAUU 1970 AAUCAUCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAAAUAAG 7266 2400 UACCUGAC G UUCCACAA 1971 UUGUGGAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GUCAGGUA 7267 2424 AUGAAACU G UGAUGCUU 1972 AAGCAUCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGUUUCAU 7268 2433 UGAUGCUU G UGAAAGAA 1973 UUCUUUCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAGCAUCA 7269 2443 GAAAGAAA G UCUCACUG 1974 CAGUGAGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUUCUUUC 7270 2465 UCAUUUGA G UCAAUGAU 1975 AUCAUUGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCAAAUGA 7271 2500 AAAACUCA G UGCUUUGC 1976 GCAAAGCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGAGUUUU 7272 2525 GGAGGAAA G CCAUAUUU 1977 AAAUAUGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUUCCUCC 7273 2546 UCUUUUAA G CUCAGUUU 1978 AAACUGAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUAAAAGA 7274 2551 UAAGCUCA G UUUAGAUA 1979 UAUCUAAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGAGCUUA 7275 2576 GAUACCCU G UUACCUGA 1980 UCAGGUAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGGGUAUC 7276 2589 CUGAUGAA G UUUCAACA 1981 UGUUGAAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCAUCAG 7277 2602 AACAUUGA G CAAAAAGG 1982 CCUUUUUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCAAUGUU 7278 2636 AUGGAGGA G CUCAGUAC 1983 GUACUGAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCCUCCAU 7279 2641 GGAGCUCA G UACUGCAG 1984 CUGCAGUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGAGCUCC 7280 2649 GUACUGCA G UUUAUUCA 1985 UGAAUAAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGCAGUAC 7281 2685 CUAAGGAA G CACAGAUA 1986 UAUCUGUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCCUUAG 7282 2708 ACUGAAAC G UUUUCAGA 1987 UCUGAAAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GUUUCAGU 7283 2744 AUAGAUGA G UUCCCUAC 1988 GUAGGGAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCAUCUAU 7284 2761 AUUGAUCA G UUCUAAAA 1989 UUUUAGAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGAUCAAU 7285 2790 CUAAAUUA G CCAGGGAA 1990 UUCCCUGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAAUUUAG 7286 2814 ACCUAGAA G UAUCCCAC 1991 GUGGGAUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCUAGGU 7287 2827 CCACAAAA G UGAAAUUG 1992 CAAUUUCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUUUGUGG 7288 2853 CGGAUGGA G CUGGGUCA 1993 UGACCCAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCCAUCCG 7289 2858 GGAGCUGG G UCAUUGCC 1994 GGCAAUGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCAGCUCC 7290 2916 AACCCAAA G UUGAAGAG 1995 CUCUUCAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUUGGGUU 7291 2932 GAAAAUCA G UUUCUCAG 1996 CUGAGAAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGAUUUUC 7292 2960 AAAAAUGG G UCUGCUAC 1997 GUAGCAGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCAUUUUU 7293 2976 CAUCAAAG G UGCUCUUA 1998 UAAGAGCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUUUGAUG 7294 2997 CUCCAGAU G UUUCUGCU 1999 AGCAGAAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUCUGGAG 7295 3009 CUGCUUUG G CCACUCAA 2000 UUGAGUGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAAAGCAG 7296 3018 CCACUCAA G CAGAGAUA 2001 UAUCUCUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUGAGUGG 7297 3031 GAUAGAGA G CAUAGUUA 2002 UAACUAUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCUCUAUC 7298 3036 AGAGCAUA G UUAAACCC 2003 GGGUUUAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAUGCUCU 7299 3048 AACCCAAA G UUCUUGUG 2004 CACAAGAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUUGGGUU 7300 3054 AAGUUCUU G UGAAAGAA 2005 UUCUUUCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAGAACUU 7301 3063 UGAAAGAA G CUGAGAAA 2006 UUUCUCAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCUUUCA 7302 3126 UAUUUUCA G CAGAGCUG 2007 CAGCUCUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGAAAAUA 7303 3131 UCAGCAGA G CUGAGUAA 2008 UUACUCAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCUGCUGA 7304 3136 AGAGCUGA G UAAAACUU 2009 AAGUUUUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCAGCUCU 7305 3147 AAACUUCA G UUGUUGAC 2010 GUCAACAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGAAGUUU 7306 3150 CUUCAGUU G UUGACCUC 2011 GAGGUCAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AACUGAAG 7307 3161 GACCUCCU G UACUGGAG 2012 CUCCAGUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGGAGGUC 7308 3189 AGACUGGA G UGGUGUUU 2013 AAACACCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCCAGUCU 7309 3192 CUGGAGUG G UGUUUGGU 2014 ACCAAACA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CACUCCAG 7310 3194 GGAGUGGU G UUUGGUGC 2015 GCACCAAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACCACUCC 7311 3199 GGUGUUUG G UGCCAGCC 2016 GGCUGGCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAAACACC 7312 3205 UGGUGCCA G CCUAUUCC 2017 GGAAUAGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGGCACCA 7313 3231 CAUUGACA G UAUUCAGC 2018 GCUGAAUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGUCAAUG 7314 3238 AGUAUUCA G CAUUGUGA 2019 UCACAAUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGAAUACU 7315 3243 UCAGCAUU G UGAGCGUA 2020 UACGCUCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAUGCUGA 7316 3247 CAUUGUGA G CGUAACAG 2021 CUGUUACG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCACAAUG 7317 3249 UUGUGAGC G UAACAGCC 2022 GGCUGUUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GCUCACAA 7318 3255 GCGUAACA G CCUACAUU 2023 AAUGUAGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGUUACGC 7319 3270 UUGCCUUG G CCCUGCUC 2024 GAGCAGGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAAGGCAA 7320 3282 UGCUCUCU G UGACCAUC 2025 GAUGGUCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGAGAGCA 7321 3292 GACCAUCA G CUUUAGGA 2026 UCCUAAAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGAUGGUC 7322 3310 AUACAAGG G UGUGAUCC 2027 GGAUCACA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCUUGUAU 7323 3312 ACAAGGGU G UGAUCCAA 2028 UUGGAUCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACCCUUGU 7324 3321 UGAUCCAA G CUAUCCAG 2029 CUGGAUAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUGGAUCA 7325 3343 AGAUGAAG G CCACCCAU 2030 AUGGGUGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUUCAUCU 7326 3357 CAUUCAGG G CAUAUCUG 2031 CAGAUAUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCUGAAUG 7327 3375 AAUCUGAA G UUGCUAUA 2032 UAUAGCAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCAGAUU 7328 3392 UCUGAGGA G UUGGUUCA 2033 UGAACCAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCCUCAGA 7329 3396 AGGAGUUG G UUCAGAAG 2034 CUUCUGAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAACUCCU 7330 3404 GUUCAGAA G UACAGUAA 2035 UUACUGUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCUGAAC 7331 3409 GAAGUACA G UAAUUCUG 2036 CAGAAUUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGUACUUC 7332 3424 UGCUCUUG G UCAUGUGA 2037 UCACAUGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAAGAGCA 7333 3429 UUGGUCAU G UGAACUGC 2038 GCAGUUCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUGACCAA 7334 3455 GAACUCAG G CGCCUCUU 2039 AAGAGGCG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUGAGUUC 7335 3468 UCUUCUUA G UUGAUGAU 2040 AUCAUCAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAAGAAGA 7336 3480 AUGAUUUA G UUGAUUCU 2041 AGAAUCAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAAAUCAU 7337 3494 UCUCUGAA G UUUGCAGU 2042 ACUGCAAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCAGAGA 7338 3501 AGUUUGCA G UGUUGAUG 2043 CAUCAACA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGCAAACU 7339 3503 UUUGCAGU G UUGAUGUG 2044 CACAUCAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACUGCAAA 7340 3509 GUGUUGAU G UGGGUAUU 2045 AAUACCCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUCAACAC 7341 3513 UGAUGUGG G UAUUUACC 2046 GGUAAAUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCACAUCA 7342 3525 UUACCUAU G UUGGUGCC 2047 GGCACCAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUAGGUAA 7343 3529 CUAUGUUG G UGCCUUGU 2048 ACAAGGCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAACAUAG 7344 3536 GGUGCCUU G UUUAAUGG 2049 CCAUUAAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAGGCACC 7345 3544 GUUUAAUG G UCUGACAC 2050 GUGUCAGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAUUAAAC 7346 3564 UGAUUUUG G CUCUGAUU 2051 AAUGAGAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAAAAUCA 7347 3583 ACUCUUCA G UGUUCCUG 2052 CAGGAACA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGAAGAGU 7348 3585 UCUUCAGU G UUCCUGUU 2053 AACAGGAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACUGAAGA 7349 3591 GUGUUCCU G UUAUUUAU 2054 AUAAAUAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGGAACAC 7350 3605 UAUGAACG G CAUCAGGC 2055 GCCUGAUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CGUUCAUA 7351 3612 GGCAUCAG G CACAGAUA 2056 UAUCUGUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUGAUGCC 7352 3651 AUAAGAAU G UUAAAGAU 2057 AUCUUUAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUUCUUAU 7353 3666 AUGCUAUG G CUAAAAUC 2058 GAUUUUAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAUAGCAU 7354 3678 AAAUCCAA G CAAAAAUC 2059 GAUUUUUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUGGAUUU 7355 3698 GGAUUGAA G CGCAAAGC 2060 GCUUUGCG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCAAUCC 7356 3705 AGCGCAAA G CUGAAUGA 2061 UCAUUCAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUUGCGCU 7357 3732 AAUAAUUA G UAGGAGUU 2062 AACUCCUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAAUUAUU 7358 3738 UAGUAGGA G UUCAUCUU 2063 AAGAUGAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCCUACUA 7359 3781 GGGGGAGG G UCAGGGAA 2064 UUCCCUGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCUCCCCC 7360 3804 ACCUUGAC G UUGCAGUG 2065 CACUGCAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GUCAAGGU 7361 3810 ACGUUGCA G UGCAGUUU 2066 AAACUGCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGCAACGU 7362 3815 GCAGUGCA G UUUCACAG 2067 CUGUGAAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGCACUGC 7363 3827 CACAGAUC G UUGUUAGA 2068 UCUAACAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GAUCUGUG 7364 3830 AGAUCGUU G UUAGAUCU 2069 AGAUCUAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AACGAUCU 7365 3848 UAUUUUUA G CCAUGCAC 2070 GUGCAUGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAAAAAUA 7366 3858 CAUGCACU G UUGUGAGG 2071 CCUCACAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGUGCAUG 7367 3861 GCACUGUU G UGAGGAAA 2072 UUUCCUCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AACAGUGC 7368 3878 AAUUACCU G UCUUGACU 2073 AGUCAAGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGGUAAUU 7369 3892 ACUGCCAU G UGUUCAUC 2074 GAUGAACA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUGGCAGU 7370 3894 UGCCAUGU G UUCAUCAU 2075 AUGAUGAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACAUGGCA 7371 3908 CAUCUUAA G UAUUGUAA 2076 UUACAAUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUAAGAUG 7372 3913 UAAGUAUU G UAAGCUGC 2077 GCAGCUUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAUACUUA 7373 3917 UAUUGUAA G CUGCUAUG 2078 CAUAGCAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUACAAUA 7374 3925 GCUGCUAU G UAUGGAUU 2079 AAUCCAUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUAGCAGC 7375 3940 UUUAAACC G UAAUCAUA 2080 UAUGAUUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGUUUAAA 7376 3966 UAUCUGAG G CACUGGUG 2081 CACCAGUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUCAGAUA 7377 3972 AGGCACUG G UGGAAUAA 2082 UUAUUCCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAGUGCCU 7378 3988 AAAAACCU G UAUAUUUU 2083 AAAAUAUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGGUUUUU 7379 4002 UUUACUUU G UUGCAGAU 2084 AUCUGCAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAAGUAAA 7380 4012 UGCAGAUA G UCUUGCCG 2085 CGGCAAGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAUCUGCA 7381 4028 GCAUCUUG G CAAGUUGC 2086 GCAACUUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAAGAUGC 7382 4032 CUUGGCAA G UUGCAGAG 2087 CUCUGCAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUGCCAAG 7383 4044 CAGAGAUG G UGGAGCUA 2088 UAGCUCCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAUCUCUG 7384 11 CCACAGUA G GUCCCUCG 2329 CGAGGGAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UACUGUGG 7385 19 GGUCCCUC G GCUCAGUC 2330 GACUGAGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GAGGGACC 7386 28 GCUCAGUC G GCCCAGCC 2331 GGCUGGGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GACUGAGC 7387 72 CCGCCCGC G GCUCUGAG 2332 CUCAGAGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GCGGGCGG 7388 80 GGCUCUGA G ACGCGGCC 2333 GGCCGCGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCAGAGCC 7389 85 UGAGACGC G GCCCCGGC 2334 GCCGGGGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GCGUCUCA 7390 91 GCGGCCCC G GCGGCGGC 2335 GCCGCCGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGGGCCGC 7391 94 GCGCCGGC G GCGGCGGC 2336 GCCGCCGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GCCGGGGC 7392 97 CCGGCGGC G GCGGCAGC 2337 GCUGCCGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GCCGCCGG 7393 100 GCGGCGGC G GCAGCAGC 2338 GCUGCUGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GCCGCCGG 7394 137 CCAGCCAU G GAAGACCU 2339 AGGUCUUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUGGCUGG 7395 138 CAGCCAUG G AAGACCUG 2340 CAGGUCUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAUGGCUG 7396 141 CCAUGGAA G ACCUGGAC 2341 GUCCAGGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCCAUGG 7397 146 GAAGACCU G GACCAGUC 2342 GACUGGUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGGUCUUC 7398 147 AAGACCUG G ACCAGUCU 2343 AGACUGGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAGGUCUU 7399 161 UCUCCUCU G GUCUCGUC 2344 GACGAGAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGAGGAGA 7400 173 UCGUCCUC G GACAGCCC 2345 GGGCUGUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GAGGACGA 7401 174 CGUCCUCG G ACAGCCCA 2346 UGGGCUGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CGAGGACG 7402 187 CCCACCCC G GCCGCAGC 2347 GCUGCGGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGGGUGGG 7403 220 GUUCGUGA G GGAGCCCG 2348 CGGGCUCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCACGAAC 7404 221 UUCGUGAG G GAGCCCGA 2349 UCGGGCUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUCACGAA 7405 222 UCGUGAGG G AGCCCGAG 2350 CUCGGGCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCUCACGA 7406 230 GAGCCCGA G GACGAGGA 2351 UCCUCGUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCGGGCUC 7407 231 AGCCCGAG G ACGAGGAG 2352 CUCCUCGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUCGGGCU 7408 236 GAGGACGA G GAGGAAGA 2353 UCUUCCUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCGUCCUC 7409 237 AGGACGAG G AGGAAGAA 2354 uucuuccu GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GUCGUCCU 7410 239 GACGAGGA G GAAGAAGA 2355 ucuucuuc GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCCUCGUC 7411 240 ACGAGGAG G AAGAAGAG 2356 CUCUUCUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GUCCUCGU 7412 243 AGGAGGAA G AAGAGGAG 2357 CUCCUCUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCCUCCU 7413 246 AGGAAGAA G AGGAGGAG 2358 CUCCUCCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCUUCCU 7414 248 GAAGAAGA G GAGGAGGA 2359 uccuccuc GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ucuucuuc 7415 249 AAGAAGAG G AGGAGGAA 2360 uuccuccu GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUCUUCUU 7416 251 GAAGAGGA G GAGGAAGA 2361 ucuuccuc GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG uccucuuc 7417 252 AAGAGGAG G AGGAAGAG 2362 cucuuccu GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG cuccucuu 7418 254 GAGGAGGA G GAAGAGGA 2363 uccucuuc GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG uccuccuc 7419 255 AGGAGGAG G AAGAGGAG 2364 CUCCUCUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUCCUCCU 7420 258 AGGAGGAA G AGGAGGAC 2365 GUCCUCCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCCUCCU 7421 260 GAGGAAGA G GAGGACGA 2366 UCGUCCUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ucuuccuc 7422 261 AGGAAGAG G AGGACGAG 2367 CUCGUCCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUCUUCCU 7423 263 GAAGAGGA G GACGAGGA 2368 UCCUCGUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCUCUUC 7424 264 AAGAGGAG G ACGAGGAC 2369 GUCCUCGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUCCUCUU 7425 269 GAGGACGA G GACGAAGA 2370 UCUUCGUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCGUCCUC 7426 270 AGGACGAG G ACGAAGAC 2371 GUCUUCGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUCGUCCU 7427 276 AGGACGAA G ACCUGGAG 2372 CUCCAGGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCGUCCU 7428 281 GAAGACCU G GAGGAGCU 2373 AGCUCCUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGGUCUUC 7429 282 AAGACCUG G AGGAGCUG 2374 CAGCUCCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAGGUCUU 7430 284 GACCUGGA G GAGCUGGA 2375 UCCAGCUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCCAGGUC 7431 285 ACCUGGAG G AGCUGGAG 2376 CUCCAGCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUCCAGGU 7432 290 GAGGAGCU G GAGGUGCU 2377 AGCACCUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGCUCCUC 7433 291 AGGAGCUG G AGGUGCUG 2378 CAGCAGCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAGCUCCU 7434 293 GAGCUGGA G GUGCUGGA 2379 UCCAGCAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCCAGCUC 7435 299 GAGGUGCU G GAGAGGAA 2380 UUCCUCUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGCACCUC 7436 300 AGGUGCUG G AGAGGAAG 2381 CUUCCUCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAGCACCU 7437 302 GUGCUGGA G AGGAAGCC 2382 GGCUUCCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCCAGCAC 7438 304 GCUGGAGA G GAAGCCCG 2383 CGGGCUUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCUCCAGC 7439 305 CUGGAGAG G AAGCCCGC 2384 GCGGGCUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUCUCCAG 7440 318 CCGCCGCC G GGCUGUCC 2385 GGACAGCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGCGGCGG 7441 319 CGCCGCCG G GCUGUCCG 2386 CGGACAGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CGGCGGCG 7442 329 CUGUCCGC G GCCCCAGU 2387 ACUGGGGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GCGGACAG 7443 357 CUGCCGGC G GCGCGCCC 2388 GGGCGCGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGCGGCAG 7444 371 CCCCUGAU G GACUUCGG 2389 CCGAAGUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUCAGGGG 7445 372 CCCUGAUG G ACUUCGGA 2390 UCCGAAGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAUCAGGG 7446 378 UGGACUUC G GAAAUGAC 2391 GUCAUUUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GAAGUCCA 7447 379 GGACUUCG G AAAUGACU 2392 AGUCAUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CGAAGUCC 7448 398 GUGCCGCC G GCGCCCCG 2393 CGGGGCGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGCGGCAC 7449 406 GGCGCCCC G GGGACCCC 2394 GGGGUCCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGGGCGCG 7450 407 GCGCCCCG G GGACCCCU 2395 AGGGGUCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CGGGGCGC 7451 408 CGCCCCGG G GACCCCUG 2396 CAGGGGUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCGGGGCG 7452 409 GCCCCGGG G ACCCCUGC 2397 GCAGGGGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GCCGGGGC 7453 419 CCCCUGCC G GCCGCUCC 2398 GGAGCGGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGCAGGGG 7454 440 GUCGGCCC G GAGCGGCA 2399 UGCCGCUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGGGCGAC 7455 441 UCGCCCCG G AGCGGCAG 2400 CUGCCGCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CGGGGCGA 7456 445 CCCGGAGC G GCAGCCGU 2401 ACGGCUGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GCUCCGGG 7457 457 GCCGUCUU G GGACCCGA 2402 UCGGGUCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAGACGGC 7458 458 CCGUCUUG G GACCCGAG 2403 CUCGGGUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAAGACGG 7459 459 CGUCUUGG G ACCCGAGC 2404 GCUCGGGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCAAGACG 7460 470 CCGAGCCC G GUGUCGUC 2405 GACGACAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGGCUCGG 7461 539 CUCCCUGA G GACGAGGA 2406 UCGUCGUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCAGGGAG 7462 540 UCCCUGAG G AGGACGAG 2407 CUCGUCGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUCAGGGA 7463 554 GAGCCUCC G GCCCGGCC 2408 GGCCGGGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGAGGCUC 7464 559 UCCGGCCC G GCCUCCCC 2409 GGGGAGGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGGCCGGA 7465 578 CCUCCCCC G GCCAGCGU 2410 ACGCUGGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGGGGAGG 7466 596 AGCCCCCA G GCAGAGCC 2411 GGCUCUGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGGGGGCU 7467 600 CCCAGGCA G AGCCCGUG 2412 CACGGGCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGCCUGGG 7468 610 GCCCGUGU G GACCCCGC 2413 GCGGGGUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACACGGGC 7469 611 CCCGUGUG G ACCCCGCC 2414 GGCGGGGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CACACGGG 7470 626 CCAGCCCC G GCUCCCGC 2415 GCGGGAGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGGGCUGG 7471 653 UCCACCCC G GCCGCGCC 2416 GGCGCGGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGGGUGGA 7472 670 CAAGCGCA G GGGCUCCU 2417 AGGAGCCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGCGCUUG 7473 671 AAGCGCAG G GGCUCCUC 2418 GAGGAGCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUGCGCUU 7474 672 AGCGCAGG G GCUCCUCG 2419 CGAGGAGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCUGCGCU 7475 680 GGCUCCUC G GGCUCAGU 2420 ACUGAGCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GAGGAGCC 7476 681 GCUCCUCG G GCUCAGUG 2421 CACUGAGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CGAGGAGC 7477 689 GGCUCAGU G GAUGAGAC 2422 GUCUCAUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACUGAGCC 7478 690 GCUCAGUG G AUGAGACC 2423 GGUCUCAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CACUGAGC 7479 695 GUGGAUGA G ACCCUUUU 2424 AAAAGGGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCAUCCAC 7480 747 CCUCUGCA G AAAAUAUG 2425 CAUAUUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGCAGAGG 7481 755 GAAAAUAU G GACUUGAA 2426 UUCAAGUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUAUUUUC 7482 756 AAAAUAUG G ACUUGAAG 2427 CUUCAAGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAUAUUUU 7483 764 GACUUGAA G GAGCAGCC 2428 GGCUGCUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCAAGUC 7484 765 ACUUGAAG G AGCAGCCA 2429 UGGCUGCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUUCAAGU 7485 774 AGCAGCCA G GUAACACU 2430 AGUGUUAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGGCUGCU 7486 788 ACUAUUUC G GCUGGUCA 2431 UGACCAGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GAAAUAGU 7487 792 UUUCGGCU G GUCAAGAG 2432 CUCUUGAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGCCGAAA 7488 798 CUGGUCAA G AGGAUUUC 2433 GAAAUCCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUGACCAG 7489 800 GGUCAAGA G GAUUUCCC 2434 GGGAAAUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCUUGACC 7490 801 GUCAAGAG G AUUUCCCA 2435 UGGGAAAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUCUUGAC 7491 876 CUUUCAAA G AACAUGAA 2436 UUCAUGUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUUGAAAG 7492 891 AAUACCUU G GUAAUUUG 2437 CAAAUUAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAGGUAUU 7493 921 CCACUGAA G GAACACUU 2438 AAGUGUUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUGAGUGG 7494 922 CACUGAAG G AACACUUC 2439 GAAGUGUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUUCAGUG 7495 933 CACUUCAA G AAAAUGUC 2440 GACAUUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUGAAGUG 7496 957 CUUCUAAA G AGGUCUCA 2441 UGAGACCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUUAGAAG 7497 959 UCUAAAGA G GUCUCAGA 2442 UCUGAGAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCUUUAGA 7498 966 AGGUCUCA G AGAAGGCA 2443 UGCCUUCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGAGACCU 7499 968 GUCUCAGA G AAGGCAAA 2444 UUUGCCUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCUGAGAC 7500 971 UCAGAGAA G GCAAAAAC 2445 GUUUUUGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCUCUGA 7501 990 UACUCAUA G AUAGAGAU 2446 AUCUCUAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAUGAGUA 7502 994 CAUAGAUA G AGAUUUAA 2447 UUAAAUCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAUCUAUG 7503 996 UAGAUAGA G AUUUAACA 2448 UGUUAAAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCUAUCUA 7504 1005 AUUUAACA G AGUUUUCA 2449 UGAAAACU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGUUAAAU 7505 1014 AGUUUUCA G AAUUAGAA 2450 UUCUAAUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGAAAACU 7506 1020 CAGAAUUA G AAUACUCA 2451 UGAGUAUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAAUUCUG 7507 1029 AAUACUCA G AAAUGGGA 2452 UCCCAUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGAGUAUU 7508 1034 UCAGAAAU G GGAUCAUC 2453 GAUGAUCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUUUCUGA 7509 1035 CAGAAAUG G GAUCAUCG 2454 CGAUGAUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAUUUCUG 7510 1036 AGAAAUGG G AUCAUCGU 2455 ACGAUGAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCAUUUCU 7511 1065 CAAAAGCA G AAUCUGCC 2456 GGCAGAUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGCUUUUG 7512 1093 AAAUCCUA G GGAAGAAA 2457 UUUCUUCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAGGAUUU 7513 1094 AAUCCUAG G GAAGAAAU 2458 AUUUCUUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUAGGAUU 7514 1095 AUCCUAGG G AAGAAAUA 2459 UAUUUCUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCUAGGAU 7515 1098 CUAGGGAA G AAAUAAUC 2460 GAUUAUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCCCUAG 7516 1119 AAAAUAAA G AUGAAGAA 2461 UUCUUCAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUUAUUUU 7517 1125 AAGAUGAA G AAGAGAAG 2462 CUUCUCUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCAUCUU 7518 1128 AUGAAGAA G AGAAGUUA 2463 UAACUUCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCUUCAU 7519 1130 GAAGAAGA G AAGUUAGU 2464 ACUAACUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCUUCUUC 7520 1167 AUCAACAA G AGUUACCU 2465 AGGUAACU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUGUUGAU 7521 1193 ACUAAAUU G GUUAAAGA 2466 UCUUUAAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAUUUAGU 7522 1200 UGGUUAAA G AGGAUGAA 2467 UUCAUCCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUUAACCA 7523 1202 GUUAAAGA G GAUGAAGU 2468 ACUUCAUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCUUUAAC 7524 1203 UUAAAGAG G AUGAAGUU 2469 AACUUCAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUCUUUAA 7525 1221 UGUCUUCA G AAAAAGCA 2470 UGCUUUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGAAGACA 7526 1233 AAGCAAAA G ACAGUUUU 2471 AAAACUGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUUUGCUU 7527 1250 AAUGAAAA G AGAGUUGC 2472 GCAACUCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUUUCAUU 7528 1252 UGAAAAGA G AGUUGCAG 2473 CUGCAACU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCUUUUCA 7529 1262 GUUGCAGU G GAAGCUCC 2474 GGAGCUUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACUGCAAC 7530 1263 UUGCAGUG G AAGCUCCU 2475 AGGAGCUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CACUGCAA 7531 1276 UCCUAUGA G GGAGGAAU 2476 AUUCCUCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCAUAGGA 7532 1277 CCUAUGAG G GAGGAAUA 2477 UAUUCCUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUCAUAGG 7533 1278 CUAUGAGG G AGGAAUAU 2478 AUAUUCCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCUCAUAG 7534 1280 AUGAGGGA G GAAUAUGC 2479 GCAUAUUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCCCUCAU 7535 1281 UGAGGGAG G AAUAUGCA 2480 UGCAUAUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUCCCUCA 7536 1290 AAUAUGCA G ACUUCAAA 2481 UUUGAAGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGCAUAUU 7537 1315 GCGAGUAU G GGAAGUGA 2482 UCACUUCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUACUCGC 7538 1316 CGAGUAUG G GAAGUGAA 2483 UUCACUUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAUACUCG 7539 1317 GAGUAUGG G AAGUGAAA 2484 UUUCACUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCAUACUC 7540 1326 AAGUGAAA G AUAGUAAG 2485 CUUACUAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUUCACUU 7541 1334 GAUAGUAA G GAAGAUAG 2486 CUAUCUUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUACUAUC 7542 1335 AUAGUAAG G AAGAUAGU 2487 ACUAUCUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUUACUAU 7543 1338 GUAAGGAA G AUAGUGAU 2488 AUCACUAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCCUUAC 7544 1352 GAUAUGUU G GCUGCUGG 2489 CCAGCAGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AACAUAUC 7545 1359 UGGCUGCU G GAGGUAAA 2490 UUUACCUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGCAGCCA 7546 1360 GGCUGCUG G AGGUAAAA 2491 UUUUACCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAGCAGCC 7547 1362 CUGCUGGA G GUAAAAUC 2492 GAUUUUAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCCAGCAG 7548 1373 AAAAUCGA G AGCAACUU 2493 AAGUUGCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCGAUUUU 7549 1382 AGCAACUU G GAAAGUAA 2494 UUACUUUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAGUUGCU 7550 1383 GCAACUUG G AAAGUAAA 2495 UUUACUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GAAGUUGC 7551 1394 AGUAAAGU G GAUAAAAA 2496 UUUUUAUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACUUUACU 7552 1395 GUAAAGUG G AUAAAAAA 2497 UUUUUUAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CACUUUAC 7553 1413 GUUUUGCA G AUAGCCUU 2498 AAGGCUAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGCAAAAC 7554 1443 ACGAAAAA G AUAGUGAG 2499 CUCACUAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUUUUCGU 7555 1451 GAUAGUGA G AGUAGUAA 2500 UUACUACU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCACUAUC 7556 1488 GUACGCCA G AAGGUAUA 2501 UAUACCUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGGCGUAC 7557 1491 CGCCAGAA G GUAUAAAG 2502 CUUUAUAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCUGGCG 7558 1499 GGUAUAAA G GAUCGUUC 2503 GAACGAUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUUAUACC 7559 1500 GUAUAAAG G AUCGUUCA 2504 UGAACGAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUUUAUAC 7560 1509 AUCGUUCA G GAGCAUAU 2505 AUAUGCUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGAACGAU 7561 1510 UCGUUCAG G AGCAUAUA 2506 UAUAUGCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUGAACGA 7562 1553 GCAACUGA G AGCAUUGC 2507 GCAAUGCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCAGUUGC 7563 1584 CUUUGUUA G GAGAUCCU 2508 AGGAUCUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAACAAAG 7564 1585 UUUGUUAG G AGAUCCUA 2509 UAGGAUCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUAACAAA 7565 1587 UGUUAGGA G AUCCUACU 2510 AGUAGGAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCCUAACA 7566 1599 CUACUUCA G AAAAUAAG 2511 CUUAUUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGAAGUAG 7567 1607 GAAAAUAA G ACCGAUGA 2512 UCAUCGGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUAUUUUC 7568 1626 AAAAAAUA G AAGAAAAG 2513 CUUUUCUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAUUUUUU 7569 1629 AAAUAGAA G AAAAGAAG 2514 CUUCUUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCUAUUU 7570 1634 GAAGAAAA G AAGGCCCA 2515 UGGGCCUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUUUCUUC 7571 1637 GAAAAGAA G GCCCAAAU 2516 AUUUGGGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG uucuuuuc 7572 1653 UAGUAACA G AGAAGAAU 2517 AUUCUUCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGUUACUA 7573 1655 GUAACAGA G AAGAAUAC 2518 GUAUUCUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCUGUUAC 7574 1658 ACAGAGAA G AAUACUAG 2519 CUAGUAUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCUCUGU 7575 1703 GCAGCACA G GAUUCUGA 2520 UCAGAAUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGUGCUGC 7576 1704 CAGCACAG G AUUCUGAG 2521 CUCAGAAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUGUGCUG 7577 1712 GAUUCUGA G ACAGAUUA 2522 UAAUCUGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCAGAAUC 7578 1716 CUGAGACA G AUUAUGUC 2523 GACAUAAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGUCUCAG 7579 1731 UCACAACA G AUAAUUUA 2524 UAAAUUAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGUUGUGA 7580 1745 UUAACAAA G GUGACUGA 2525 UCAGUCAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUUGUUAA 7581 1754 GUGACUGA G GAAGUCGU 2526 ACGACUUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCAGUCAC 7582 1755 UGACUGAG G AAGUCGUG 2527 CACGACUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUCAGUCA 7583 1763 GAAGUCGU G GCAAACAU 2528 AUGUUUGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACGACUUC 7584 1779 UGCCUGAA G GCCUGACU 2529 AGUCAGGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCAGGCA 7585 1791 UGACUCCA G AUUUAGUA 2530 UACUAAAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGGAGUCA 7586 1802 UUAGUACA G GAAGCAUG 2531 CAUGCUUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGUACUAA 7587 1803 UAGUACAG G AAGCAUGU 2532 ACAUGCUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUGUACUA 7588 1836 AAGUUACU G GUACAAAG 2533 CUUUGUAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGUAACUU 7589 1844 GGUACAAA G AUUGCUUA 2534 UAAGCAAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUUGUACC 7590 1865 ACAAAAAU G GACUUGGU 2535 ACCAAGUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUUUUUGU 7591 1866 CAAAAAUG G ACUUGGUU 2536 AACCAAGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAUUUUUG 7592 1871 AUGGACUU G GUUCAAAC 2537 GUUUGAAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAGUCCAU 7593 1884 AAACAUCA G AAGUUAUG 2538 CAUAACUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGAUGUUU 7594 1896 UUAUGCAA G AGUCACUC 2539 GAGUGACU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUGCAUAA 7595 1938 CAUUUGAA G AGUCAGAA 2540 UUCUGACU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCAAAUG 7596 1944 AAGAGUCA G AAGCUACU 2541 AGUAGCUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGACUCUU 7597 1982 AUUGUUAU G GAAGCACC 2542 GGUGCUUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUAACAAU 7598 1983 UUGUUAUG G AAGCACCA 2543 UGGUGCUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAUAACAA 7599 2016 CUAGUGCU G GUGCUUCC 2544 GGAAGCAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGCACUAG 7600 2052 CACCAUUA G AAGCUUCU 2545 AGAAGCUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAAUGGUG 7601 2115 CAUAUGAA G AGGCCAUG 2546 CAUGGCCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCAUAUG 7602 2117 UAUGAAGA G GCCAUGAG 2547 CUCAUGGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCUUCAUA 7603 2148 AAGUAUCA G GAAUAAAG 2548 GUUUAUUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGAUACUU 7604 2149 AGUAUCAG G AAUAAAGG 2549 CCUUUAUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUGAUACU 7605 2156 GGAAUAAA G GAAGAAAU 2550 AUUUCUUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUUAUUCC 7606 2157 GAAUAAAG G AAGAAAUU 2551 AAUUUCUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GUUUAUUC 7607 2160 UAAAGGAA G AAAUUAAA 2552 UUUAAUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCCUUUA 7608 2169 AAAUUAAA G AGCCUGAA 2553 UUCAGGCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUUAAUUU 7609 2199 CUCUUCAA G AAACAGAA 2554 UUCUGUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUGAAGAG 7610 2205 AAGAAACA G AAGCUCCU 2555 AGGAGCUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGUUUCUU 7611 2244 UAAUUAAA G AAACAAAG 2556 CUUUGUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUUAAUUA 7612 2273 CCAGCUCC G GAUUUCUC 2557 GAGAAAUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGAGCUGG 7613 2274 CAGCUCCG G AUUUCUCU 2558 AGAGAAAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CGGAGCUG 7614 2292 AUUAUUCA G AAAUGGCA 2559 UGCCAUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGAAUAAU 7615 2297 UCAGAAAU G GCAAAAGU 2560 ACUUUUGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUUUCUGA 7616 2343 UAGUUGAA G AUUCCUCA 2561 UGAGGAAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCAACUA 7617 2415 AAAAACAA G AUGAAACU 2562 AGUUUCAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUGUUUUU 7618 2439 UUGUGAAA G AAAGUCUC 2563 GAGACUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUUCACAA 7619 2453 CUCACUGA G ACUUCAUU 2564 AAUGAAGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCAGUGAG 7620 2475 CAAUGAUA G AAUAUGAA 2565 UUCAUAUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAUCAUUG 7621 2489 GAAAAUAA G GAAAAACU 2566 AGUUUUUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUAUUUUC 7622 2490 AAAAUAAG G AAAAACUC 2567 GAGUUUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUUAUUUU 7623 2516 CCACCUGA G GGAGGAAA 2568 UUUCCUCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCAGGUGG 7624 2517 CACCUGAG G GAGGAAAG 2569 CUUUCCUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUCAGGUG 7625 2518 ACCUGAGG G AGGAAAGC 2570 GCUUUCCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCUCAGGU 7626 2520 CUGAGGGA G GAAAGCCA 2571 UGGCUUUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCCCUCAG 7627 2521 UGAGGGAG G AAAGCCAU 2572 AUGGCUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUCCCUCA 7628 2534 CCAUAUUU G GAAUCUUU 2573 AAAGAUUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAAUAUGG 7629 2535 CAUAUUUG G AAUCUUUU 2574 AAAAGAUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAAAUAUG 7630 2556 UCAGUUUA G AUAACACA 2575 UGUGUUAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAAACUGA 7631 2568 ACACAAAA G AUACCCUG 2576 CAGGGUAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUUUGUGU 7632 2609 AGGAAAAA G GAGAAAAU 2577 AUUUUCUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUUUUGCU 7633 2610 GCAAAAAG G AGAAAAUU 2578 AAUUUUCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUUUUUGC 7634 2612 AAAAAGGA G AAAAUUCC 2579 GGAAUUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCCUUUUU 7635 2627 CCUUUGCA G AUGGAGGA 2580 UCCUCCAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGCAAAGG 7636 2630 UUGCAGAU G GAGGAGCU 2581 AGCUCCUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUCUGCAA 7637 2631 UGCAGAUG G AGGAGCUC 2582 GAGCUCCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAUCUGCA 7638 2633 CAGAUGGA G GAGCUCAG 2583 CUGAGCUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCCAUCUG 7639 2634 AGAUGGAG G AGCUCAGU 2584 ACUGAGCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUCCAUCU 7640 2681 AUUUCUAA G GAAGCACA 2585 UGUGCUUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUAGAAAU 7641 2682 UUUCUAAG G AAGCACAG 2586 CUGUGCUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUUAGAAA 7642 2690 GAAGCACA G AUAAGAGA 2587 UCUCUUAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGUGCUUC 7643 2695 ACAGAUAA G AGAAACUG 2588 CAGUUUCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUAUCUGU 7644 2697 AGAUAAGA G AAACUGAA 2589 UUCAGUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCUUAUCU 7645 2715 CGUUUUCA G AUUCAUCU 2590 AGAUGAAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGAAAACG 7646 2739 AAAUUAUA G AUGAGUUC 2591 GAACUCAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAUAAUUU 7647 2794 AUUAGCCA G GGAAUAUA 2592 UAUAUUCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGGCUAAU 7648 2795 UUAGCCAG G GAAUAUAC 2593 GUAUAUUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUGGCUAA 7649 2796 UAGCCAGG G AAUAUACU 2594 AGUAUAUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCUGGCUA 7650 2811 CUGACCUA G AAGUAUCC 2595 GGAUACUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAGGUCAG 7651 2846 AAUGCCCC G GAUGGAGC 2596 GCUCCAUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGGGCAUU 7652 2847 AUGCCCCG G AUGGAGCU 2597 AGCUCCAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CGGGGCAU 7653 2850 CCCCGGAU G GAGCUGGG 2598 CCCAGCUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUCCGGGG 7654 2851 CCCGGAUG G AGCUGGGU 2599 ACCCAGCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAUCCGGG 7655 2856 AUGGAGCU G GGUCAUUG 2600 CAAUGACC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGCUCCAU 7656 2857 UGGAGCUG G GUCAUUGC 2601 GCAAUGAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAGCUCCA 7657 2874 CUUGCACA G AAUUGCCC 2602 GGGCAAUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGUGCAAG 7658 2900 UCUUUGAA G AACAUACA 2603 UGUAUGUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCAAAGA 7659 2922 AAGUUGAA G AGAAAAUC 2604 GAUUUUCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCAACUU 7660 2924 GUUGAAGA G AAAAUCAG 2605 CUGAUUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCUUCAAC 7661 2940 GUUUCUCA G AUGACUUU 2606 AAAGUCAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGAGAAAC 7662 2958 CUAAAAAU G GGUCUGCU 2607 AGCAGACC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUUUUUAG 7663 2959 UAAAAAUG G GUCUGCUA 2608 UAGCAGAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAUUUUUA 7664 2975 ACAUCAAA G GUGCUCUU 2609 AAGAGCAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUUGAUGU 7665 2994 UGCCUCCA G AUGUUUCU 2610 AGAAACAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGGAGGCA 7666 3008 UCUGCUUU G GCCACUCA 2611 UGAGUGGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAAGCAGA 7667 3021 CUCAAGCA G AGAUAGAG 2612 CUCUAUCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGCUUGAG 7668 3023 CAAGCAGA G AUAGAGAG 2613 CUCUCUAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCUGCUUG 7669 3027 CAGAGAUA G AGAGCAUA 2614 UAUGCUCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAUCUCUG 7670 3029 GAGAUAGA G AGCAUAGU 2615 ACUAUGCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCUAUCUC 7671 3060 UUGUGAAA G AAGCUGAG 2616 CUCAGCUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUUCACAA 7672 3068 GAAGCUGA G AAAAAACU 2617 AGUUUUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCAGCUUC 7673 3090 CCGAUACA G AAAAAGAG 2618 CUCUUUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGUAUCGG 7674 3096 CAGAAAAA G AGGACAGA 2619 UCUGUCCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUUUUCUG 7675 3098 GAAAAAGA G GACAGAUC 2620 GAUCUGUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCUUUUUC 7676 3099 AAAAAGAG G ACAGAUCA 2621 UGAUCUGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUCUUUUU 1611 3103 AGAGGAGA G AUCACCAU 2622 AUGGUGAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGUCCUCU 7678 3129 UUUCAGCA G AGCUGAGU 2623 ACUCAGCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGCUGAAA 7679 3166 CCUGUACU G GAGAGACA 2624 UGUCUCUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGUACAGG 7680 3167 CUGUACUG G AGAGACAU 2625 AUGUCUCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAGUACAG 7681 3169 GUACUGGA G AGACAUUA 2626 UAAUGUCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCCAGUAC 7682 3171 ACUGGAGA G ACAUUAAG 2627 CUUAAUGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCUCCAGU 7683 3179 GACAUUAA G AAGACUGG 2628 CCAGUCUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUAAUGUC 7684 3182 AUUAAGAA G ACUGGAGU 2629 ACUCCAGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCUUAAU 7685 3186 AGAAGACU G GAGUGGUG 2630 CACCACUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGUCUUCU 7686 3187 GAAGACUG G AGUGGUGU 2631 ACACCACU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAGUCUUC 7687 3191 ACUGGAGU G GUGUUUGG 2632 CCAAACAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACUCCAGU 7688 3198 UGGUGUUU G GUGCCAGC 2633 GCUGGCAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAACACCA 7689 3269 AUUGCCUU G GCCCUGCU 2634 AGCAGGGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAGGCAAU 7690 3298 CAGCUUUA G GAUAUACA 2635 UGUAUAUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAAAGCUG 7691 3299 AGCUUUAG G AUAUACAA 2636 UUGUAUAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUAAAGCU 7692 3308 AUAUACAA G GGUGUGAU 2637 AUCACACC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUGUAUAU 7693 3309 UAUACAAG G GUGUGAUC 2638 GAUCACAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUUGUAUA 7694 3329 GCUAUCCA G AAAUCAGA 2639 UCUGAUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGGAUAGC 7695 3336 AGAAAUCA G AUGAAGGC 2640 GCCUUCAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGAUUUCU 7696 3342 CAGAUGAA G GCCACCCA 2641 UGGGUGGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCAUCUG 7697 3355 CCCAUUCA G GGCAUAUC 2642 GAUAUGCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGAAUGGG 7698 3356 CCAUUCAG G GCAUAUCU 2643 AGAUAUGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUGAAUGG 7699 3365 GCAUAUCU G GAAUCUGA 2644 UCAGAUUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGAUAUGC 7700 3366 CAUAUCUG G AAUCUGAA 2645 UUCAGAUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAGAUAUG 7701 3389 AUAUCUGA G GAGUUGGU 2646 ACCAACUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCAGAUAU 7702 3390 UAUCUGAG G AGUUGGUU 2647 AACCAACU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUCAGAUA 7703 3395 GAGGAGUU G GUUCAGAA 2648 UUCUGAAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AACUCCUC 7704 3401 UUGGUUCA G AAGUACAG 2649 CUGUACUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGAACCAA 7705 3423 CUGCUCUU G GUCAUGUG 2650 CACAUGAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAGAGCAG 7706 3446 ACGAUAAA G GAACUCAG 2651 CUGAGUUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUUAUCGU 7707 3447 CGAUAAAG G AACUCAGG 2652 CCUGAGUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUUUAUCG 7708 3454 GGAACUCA G GCGCCUCU 2653 AGAGGCGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGAGUUCC 7709 3511 GUUGAUGU G GGUAUUUA 2654 UAAAUACC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACAUCAAC 7710 3512 UUGAUGUG G GUAUUUAC 2655 GUAAAUAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CACAUCAA 7711 3528 CCUAUGUU G GUGCCUUG 2656 CAAGGCAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AACAUAGG 7712 3543 UGUUUAAU G GUCUGACA 2657 UGUCAGAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUUAAACA 7713 3563 CUGAUUUU G GCUCUCAU 2658 AUGAGAGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAAAUCAG 7714 3604 UUAUGAAC G GCAUCAGG 2659 CCUGAUGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GUUCAUAA 7715 3611 CGGCAUCA G GCACAGAU 2660 AUCUGUGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGAUGCCG 7716 3617 CAGGCACA G AUAGAUCA 2661 UGAUCUAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGUGCCUG 7717 3621 CACAGAUA G AUCAUUAU 2662 AUAAUGAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAUCUGUG 7718 3633 AUUAUCUA G GACUUGCA 2663 UGCAAGUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAGAUAAU 7719 3634 UUAUCUAG G ACUUGCAA 2664 UUGCAAGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUAGAUAA 7720 3647 GCAAAUAA G AAUGUUAA 2665 UUAACAUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUAUUUGC 7721 3657 AUGUUAAA G AUGCUAUG 2666 CAUAGCAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUUAACAU 7722 3665 GAUGCUAU G GCUAAAAU 2667 AUUUUAGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUAGCAUC 7723 3690 AAAUCCCU G GAUUGAAG 2668 CUUCAAUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGGGAUUU 7724 3691 AAUCCCUG G AUUGAAGC 2669 GCUUCAAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAGGGAUU 7725 3735 AAUUAGUA G GAGUUCAU 2670 AUGAACUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UACUAAUU 7726 3736 AUUAGUAG G AGUUCAUC 2671 GAUGAACU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUACUAAU 7727 3751 UCUUUAAA G GGGAUAUU 2672 AAUAUCCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUUAAAGA 7728 3752 CUUUAAAG G GGAUAUUC 2673 GAAUAUCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUUUAAAG 7729 3753 UUUAAAGG G GAUAUUCA 2674 UGAAUAUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCUUUAAA 7730 3754 UUAAAGGG G AUAUUCAU 2675 AUGAAUAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCCUUUAA 7731 3773 GAUUAUAC G GGGGAGGG 2676 CCCUCCCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GUAUAAUC 7732 3774 AUUAUACG G GGGAGGGU 2677 ACCCUCCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CGUAUAAU 7733 3775 UUAUACGG G GGAGGGUC 2678 GACCCUCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCGUAUAA 7734 3776 UAUACGGG G GAGGGUCA 2679 UGACCCUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCCGUAUA 7735 3777 AUACGGGG G AGGGUCAG 2680 CUGACCCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCCCGUAU 7736 3779 ACGGGGGA G GGUCAGGG 2681 CCCUGACC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCCCCCGU 7737 3780 CGGGGGAG G GUCAGGGA 2682 UCCCUGAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUCCCCCG 7738 3785 GAGGGUCA G GGAAGAAC 2683 GUUCUUCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGACCCUC 7739 3786 AGGGUCAG G GAAGAACG 2684 CGUUCUUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUGACCCU 7740 3787 GGGUCAGG G AAGAACGA 2685 UCGUUCUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCUGACCC 7741 3790 UCAGGGAA G AACGAACC 2686 GGUUCGUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCCCUGA 7742 3823 GUUUCACA G AUCGUUGU 2687 ACAACGAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGUGAAAC 7743 3834 CGUUGUUA G AUCUUUAU 2688 AUAAAGAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAACAACG 7744 3865 UGUUGUGA G GAAAAAUU 2689 AAUUUUUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCACAACA 7745 3866 GUUGUGAG G AAAAAUUA 2690 UAAUUUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUCACAAC 7746 3929 CUAUGUAU G GAUUUAAA 2691 UUUAAAUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUACAUAG 7747 3930 UAUGUAUG G AUUUAAAC 2692 GUUUAAAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAUACAUA 7748 3965 CUAUCUGA G GCACUGGU 2693 ACCAGUGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCAGAUAG 7749 3971 GAGGCACU G GUGGAAUA 2694 UAUUCCAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGUGCCUC 7750 3974 GCACUGGU G GAAUAAAA 2695 UUUUAUUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACCAGUGC 7751 3975 CACUGGUG G AAUAAAAA 2696 UUUUUAUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CACCAGUG 7752 4008 UUGUUGCA G AUAGUCUU 2697 AAGACUAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGCAACAA 7753 4027 CGCAUCUU G GCAAGUUG 2698 CAACUUGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAGAUGCG 7754 4038 AAGUUGCA G AGAUGGUG 2699 CACCAUCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGCAACUU 7755 4040 GUUGCAGA G AUGGUGGA 2700 UCCACCAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCUGCAAC 7756 4043 GCAGAGAU G GUGGAGCU 2701 AGCUCCAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUCUCUGC 7757 Input Sequence = AB020693. Cut Site = G/ . Stem Length = 8. Core Sequence = GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AB020693 (Homo sapiens mRNA for KIAA0886 protein (Nogo-A) ; 4053 bp) Table IX: Human CD20 Hammerhead Ribozyme and Substrate Sequence Pos Substrate Seq ID Ribozyme Seq ID 23 ACUGAACU C CGCAGCUA 2702 UAGCUGCG CUGAUGAG GCCGUUAGGC CGAA AGUUCAGU 7758 31 CCGCAGCU A GCAUCCAA 2703 UUGGAUGC CUGAUGAG GCCGUUAGGC CGAA AGCUGCGG 7759 36 GCUAGCAU C CAAAUCAG 2704 CUGAUUUG CUGAUGAG GCCGUUAGGC CGAA AUGCUAGC 7760 42 AUCCAAAU C AGCCCUUG 2705 CAAGGGCU CUGAUGAG GCCGUUAGGC CGAA AUUUGGAU 7761 49 UCAGCCCU U GAGAUUUG 2706 CAAAUCUC CUGAUGAG GCCGUUAGGC CGAA AGGGCUGA 7762 55 CUUGAGAU U UGAGGCCU 2707 AGGCCUCA CUGAUGAG GCCGUUAGGC CGAA AUCUCAAG 7763 56 UUGAGAUU U GAGGCCUU 2708 AAGGCCUC CUGAUGAG GCCGUUAGGC CGAA AAUCUCAA 7764 64 UGAGGCCU U GGAGACUC 2709 GAGUCUCC CUGAUGAG GCCGUUAGGC CGAA AGGCCUCA 7765 72 UGGAGACU C AGGAGUUU 2710 AAACUCCU CUGAUGAG GCCGUUAGGC CGAA AGUCUCCA 7766 79 UGAGGAGU U UUGAGAGC 2711 GCUCUCAA CUGAUGAG GCCGUUAGGC CGAA ACUCCUGA 7767 80 CAGGAGUU u UGAGAGCA 2712 UGCUCUCA CUGAUGAG GCCGUUAGGC CGAA AACUCCUG 7768 81 AGGAGUUU u GAGAGCAA 2713 UUGCUCUC CUGAUGAG GCCGUUAGGC CGAA AAACUCCU 7769 109 CCAGAAAU u CAGUAAAU 2714 AUUUACUG CUGAUGAG GCCGUUAGGC CGAA AUUUCUGG 7770 110 CAGAAAUU c AGUAAAUG 2715 CAUUUACU CUGAUGAG GCCGUUAGGC CGAA AAUUUCUG 7771 114 AAUUCAGU A AAUGGGAC 2716 GUCCCAUU CUGAUGAG GCCGUUAGGC CGAA ACUGAAUU 7772 124 AUGGGACU U UCCUGGCA 2717 UGCCAGGA CUGAUGAG GCCGUUAGGC CGAA AGUCCCAU 7773 125 UGGGACUU U CCUGGCAG 2718 CUGCCAGG CUGAUGAG GCCGUUAGGC CGAA AAGUCCCA 7774 126 GGGACUUU c CUGGCAGA 2719 UCUGCCAG CUGAUGAG GCCGUUAGGC CGAA AAAGUCCC 7775 151 AAGGCCCU A UUGCUAUG 2720 CAUAGCAA CUGAUGAG GCCGUUAGGC CGAA AGGGCCUU 7776 153 GGCCCUAU U GCUAUGCA 2721 UGCAUAGC CUGAUGAG GCCGUUAGGC CGAA AUAGGGCC 7777 157 CUAUUGCU A UGCAAUCU 2722 AGAUUGCA CUGAUGAG GCCGUUAGGC CGAA AGCAAUAG 7778 164 UAUGCAAU c UGGUCCAA 2723 UUGGACCA CUGAUGAG GCCGUUAGGC CGAA AUUGCAUA 7779 169 AAUCUGGU C CAAAACCA 2724 UGGUUUUG CUGAUGAG GCCGUUAGGC CGAA ACCAGAUU 7780 180 AAACCACU C UUCAGGAG 2725 CUCCUGAA CUGAUGAG GCCGUUAGGC CGAA AGUGGUUU 7781 182 ACCACUCU U CAGGAGGA 2726 UCCUCCUG CUGAUGAG GCCGUUAGGC CGAA AGAGUGGU 7782 183 CCACUCUU c AGGAGGAU 2727 AUCCUCCU CUGAUGAG GCCGUUAGGC CGAA AAGAGUGG 7783 194 GAGGAUGU c UUCACUGG 2728 CCAGUGAA CUGAUGAG GCCGUUAGGC CGAA ACAUCCUC 7784 196 GGAUGUCU u CACUGGUG 2729 CACCAGUG CUGAUGAG GCCGUUAGGC CGAA AGACAUCC 7785 197 GAUGUCUU c ACUGGUGG 2730 CCACCAGU CUGAUGAG GCCGUUAGGC CGAA AAGACAUC 7786 221 GCAAAGCU u CUUCAUGA 2731 UCAUGAAG CUGAUGAG GCCGUUAGGC CGAA AGCUUUGC 7787 222 CAAAGCUU c UUCAUGAG 2732 CUCAUGAA CUGAUGAG GCCGUUAGGC CGAA AAGCUUUG 7788 224 AAGCUUCU u CAUGAGGG 2733 CCCUCAUG CUGAUGAG GCCGUUAGGC CGAA AGAAGCUU 7789 225 AGCUUCUU c AUGAGGGA 2734 UCCCUCAU CUGAUGAG GCCGUUAGGC CGAA AAGAAGCU 7790 236 GAGGGAAU c UAAGACUU 2735 AAGUCUUA CUGAUGAG GCCGUUAGGC CGAA AUUCCCUC 7791 238 GGGAAUCU A AGACUUUG 2736 CAAAGUCU CUGAUGAG GCCGUUAGGC CGAA AGAUUCCC 7792 244 CUAAGACU U UGGGGGCU 2737 AGCCCCCA CUGAUGAG GCCGUUAGGC CGAA AGUCUUAG 7793 245 UAAGACUU u GGGGGCUG 2738 CAGCCCGC CUGAUGAG GCCGUUAGGC CGAA AAGUCUUA 7794 255 GGGGCUGU c CAGAUUAU 2739 AUAAUCUG CUGAUGAG GCCGUUAGGC CGAA ACAGCCCC 7795 261 GUCCAGAU u AUGAAUGG 2740 CCAUUCAU CUGAUGAG GCCGUUAGGC CGAA AUCUGGAC 7796 262 UCCAGAUU A UGAAUGGG 2741 CCCAUUCA CUGAUGAG GCCGUUAGGC CGAA AAUCUGGA 7797 273 AAUGGGCU C UUCCACAU 2742 AUGUGGAA CUGAUGAG GCCGUUAGGC CGAA AGCCCAUU 7798 275 UGGGCUCU u CCACAUUG 2743 CAAUGUGG CUGAUGAG GCCGUUAGGC CGAA AGAGCCCA 7799 276 GGGCUCUU c CACAUUGC 2744 GCAAUGUG CUGAUGAG GCCGUUAGGC CGAA AAGAGCCC 7800 282 UUCCACAU u GCCCUGGG 2745 CCCAGGGC CUGAUGAG GCCGUUAGGC CGAA AUGUGGAA 7801 295 UGGGGGGU c UUCUGAUG 2746 CAUCAGAA CUGAUGAG GCCGUUAGGC CGAA ACCCCCCA 7802 297 GGGGGUCU u CUGAUGAU 2747 AUCAUCAG CUGAUGAG GCCGUUAGGC CGAA AGACCCCC 7803 298 GGGGUCUU c UGAUGAUC 2748 GAUCAUCA CUGAUGAG GCCGUUAGGC CGAA AAGACCCC 7804 306 CUGAUGAU c CCAGCAGG 2749 CCUGCUGG CUGAUGAG GCCGUUAGGC CGAA AUCAUCAG 7805 318 GCAGGGAU c UAUGCACC 2750 GGUGCAUA CUGAUGAG GCCGUUAGGC CGAA AUCCCUGC 7806 320 AGGGAUCU A UGCACCCA 2751 UGGGUGCA CUGAUGAG GCCGUUAGGC CGAA AGAUCCCU 7807 330 GCACCCAU C UGUGUGAC 2752 GUCACACA CUGAUGAG GCCGUUAGGC CGAA AUGGGUGG 7808 347 UGUGUGGU A CCCUCUCU 2753 AGAGAGGG CUGAUGAG GCCGUUAGGC CGAA ACCACACA 7809 352 GGUACCCU C UCUGGGGA 2754 UCCCCAGA CUGAUGAG GCCGUUAGGC CGAA AGGGUACC 7810 354 UACCCUCU C UGGGGAGG 2755 CCUCCCCA CUGAUGAG GCCGUUAGGC CGAA AGAGGGUA 7811 366 GGAGGCAU u AUGUAUAU 2756 AUAUACAU CUGAUGAG GCCGUUAGGC CGAA AUGCCUCC 7812 367 GAGGCAUU A UGUAUAUU 2757 AAUAUACA CUGAUGAG GCCGUUAGGC CGAA AAUGCCUC 7813 371 CAUUAUGU A UAUUAUUU 2758 AAAUAAUA CUGAUGAG GCCGUUAGGC CGAA ACAUAAUG 7814 373 UUAUGUAU A UUAUUUCC 2759 GGAAAUAA CUGAUGAG GCCGUUAGGC CGAA AUACAUAA 7815 375 AUGUAUAU U AUUUCCGG 2760 CCGGAAAU CUGAUGAG GCCGUUAGGC CGAA AUAUACAU 7816 376 UGUAUAUU A UUUCCGGA 2761 UCCGGAAA CUGAUGAG GCCGUUAGGC CGAA AAUAUACA 7817 378 UAUAUUAU U UCCGGAUC 2762 GAUCCGGA CUGAUGAG GCCGUUAGGC CGAA AUAAUAUA 7818 379 AUAUUAUU U CCGGAUCA 2763 UGAUCCGG CUGAUGAG GCCGUUAGGC CGAA AAUAAUAU 7819 380 UAUUAUUU C CGGAUCAC 2764 GUGAUCCG CUGAUGAG GCCGUUAGGC CGAA AAAUAAUA 7820 386 UUCCGGAU C ACUCCUGG 2765 CCAGGAGU CUGAUGAG GCCGUUAGGC CGAA AUCCGGAA 7821 390 GGAUCACU C CUGGCAGC 2766 GCUGCCAG CUGAUGAG GCCGUUAGGC CGAA AGUGAUCC 7822 413 GAAAAACU C CAGGAAGU 2767 ACUUCCUG CUGAUGAG GCCGUUAGGC CGAA AGUUUUUC 7823 424 GGAAGUGU U UGGUCAAA 2768 UUUGACCA CUGAUGAG GCCGUUAGGC CGAA ACACUUCC 7824 425 GAAGUGUU U GGUCAAAG 2769 CUUUGACC CUGAUGAG GCCGUUAGGC CGAA AACACUUC 7825 429 UGUUUGGU C AAAGGAAA 2770 UUUCCUUU CUGAUGAG GCCGUUAGGC CGAA ACCAAACA 7826 444 AAAAUGAU A AUGAAUUC 2771 GAAUUCAU CUGAUGAG GCCGUUAGGC CGAA AUCAUUUU 7827 451 UAAUGAAU U CAUUGAGC 2772 GCUCAAUG CUGAUGAG GCCGUUAGGC CGAA AUUCAUUA 7828 452 AAUGAAUU C AUUGAGCC 2773 GGCUCAAU CUGAUGAG GCCGUUAGGC CGAA AAUUCAUU 7829 455 GAAUUCAU U GAGCCUCU 2774 AGAGGCUC CUGAUGAG GCCGUUAGGC CGAA AUGAAUUC 7830 462 UUGAGCCU C UUUGCUGC 2775 GCAGCAAA CUGAUGAG GCCGUUAGGC CGAA AGGCUCAA 7831 464 GAGCCUCU U UGCUGCCA 2776 UGGCAGCA CUGAUGAG GCCGUUAGGC CGAA AGAGGCUC 7832 465 AGCCUCUU U GCUGCCAU 2777 AUGGCAGC CUGAUGAG GCCGUUAGGC CGAA AAGAGGCU 7833 474 GCUGCCAU U UCUGGAAU 2778 AUUCCAGA CUGAUGAG GCCGUUAGGC CGAA AUGGCAGC 7834 475 CUGCCAUU U CUGGAAUG 2779 CAUUCCAG CUGAUGAG GCCGUUAGGC CGAA AAUGGCAG 7835 476 UGCCAUUU C UGGAAUGA 2780 UCAUUCCA CUGAUGAG GCCGUUAGGC CGAA AAAUGGCA 7836 486 GGAAUGAU U CUUUCAAU 2781 AUUGAAAG CUGAUGAG GCCGUUAGGC CGAA AUCAUUCC 7837 487 GAAUGAUU C UUUCAAUC 2782 GAUUGAAA CUGAUGAG GCCGUUAGGC CGAA AAUCAUUC 7838 489 AUGAUUCU u UCAAUCAU 2783 AUGAUUGA CUGAUGAG GCCGUUAGGC CGAA AGAAUCAU 7839 490 UGAUUCUU u CAAUCAUG 2784 CAUGAUUG CUGAUGAG GCCGUUAGGC CGAA AAGAAUCA 7840 491 GAUUCUUU c AAUCAUGG 2785 CCAUGAUU CUGAUGAG GCCGUUAGGC CGAA AAAGAAUC 7841 495 CUUUCAAU c AUGGACAU 2786 AUGUCCAU CUGAUGAG GCCGUUAGGC CGAA AUUGAAAG 7842 504 AUGGACAU A CUUAAUAU 2787 AUAUUAAG CUGAUGAG GCCGUUAGGC CGAA AUGUCCAU 7843 507 GACAUACU U AAUAUUAA 2788 UUAAUAUU CUGAUGAG GCCGUUAGGC CGAA AGUAUGUC 7844 508 ACAUACUU A AUAUUAAA 2789 UUUAAUAU CUGAUGAG GCCGUUAGGC CGAA AAGUAUGU 7845 511 UACUUAAU A UUAAAAUU 2790 AAUUUUAA CUGAUGAG GCCGUUAGGC CGAA AUUAAGUA 7846 513 CUUAAUAU U AAAAUUUC 2791 GAAAUUUU CUGAUGAG GCCGUUAGGC CGAA AUAUUAAG 7847 514 UUAAUAUU A AAAUUUCC 2792 GGAAAUUU CUGAUGAG GCCGUUAGGC CGAA AAUAUUAA 7848 519 AUUAAAAU U UCCCAUUU 2793 AAAUGGGA CUGAUGAG GCCGUUAGGC CGAA AUUUUAAU 7849 520 UUAAAAUU U CCCAUUUU 2794 AAAAUGGG CUGAUGAG GCCGUUAGGC CGAA AAUUUUAA 7850 521 UAAAAUUU C CCAUUUUU 2795 AAAAAUGG CUGAUGAG GCCGUUAGGC CGAA AAAUUUUA 7851 526 UUUCCCAU U UUUUAAAA 2796 UUUUAAAA CUGAUGAG GCCGUUAGGC CGAA AUGGGAAA 7852 527 UUCCCAUU U UUUAAAAA 2797 UUUUUAAA CUGAUGAG GCCGUUAGGC CGAA AAUGGGAA 7853 528 UCCCAUUU U UUAAAAAU 2798 AUUUUUAA CUGAUGAG GCCGUUAGGC CGAA AAAUGGGA 7854 529 CCCAUUUU U UAAAAAUG 2799 CAUUUUUA CUGAUGAG GCCGUUAGGC CGAA AAAAUGGG 7855 530 CCAUUUUU U AAAAAUGG 2800 CCAUUUUU CUGAUGAG GCCGUUAGGC CGAA AAAAAUGG 7856 531 CAUUUUUU A AAAAUGGA 2801 UCCAUUUU CUGAUGAG GCCGUUAGGC CGAA AAAAAAUG 7857 544 UGGAGAGU C UGAAUUUU 2802 AAAAUUCA CUGAUGAG GCCGUUAGGC CGAA ACUCUCCA 7858 550 GUCUGAAU U UUAUUAGA 2803 UCUAAUAA CUGAUGAG GCCGUUAGGC CGAA AUUCAGAC 7859 551 UCUGAAUU u UAUUAGAG 2804 CUCUAAUA CUGAUGAG GCCGUUAGGC CGAA AAUUCAGA 7860 552 CUGAAUUU u AUUAGAGC 2805 GCUCUAAU CUGAUGAG GCCGUUAGGC CGAA AAAUUCAG 7861 553 UGAAUUUU A UUAGAGCU 2806 AGCUCUAA CUGAUGAG GCCGUUAGGC CGAA AAAAUUCA 7862 555 AAUUUUAU U AGAGCUCA 2807 UGAGCUCU CUGAUGAG GCCGUUAGGC CGAA AUAAAAUU 7863 556 AUUUUAUU A GAGCUCAC 2808 GUGAGCUC CUGAUGAG GCCGUUAGGC CGAA AAUAAAAU 7864 562 UUAGAGCU C ACACACCA 2809 UGGUGUGU CUGAUGAG GCCGUUAGGC CGAA AGCUCUAA 7865 572 CACACCAU A UAUUAACA 2810 UGUUAAUA CUGAUGAG GCCGUUAGGC CGAA AUGGUGUG 7866 574 CACCAUAU A UUAACAUA 2811 UAUGUUAA CUGAUGAG GCCGUUAGGC CGAA AUAUGGUG 7867 576 CCAUAUAU U AACAUAUA 2812 UAUAUGUU CUGAUGAG GCCGUUAGGC CGAA AUAUAUGG 7868 577 CAUAUAUU A ACAUAUAC 2813 GUAUAUGU CUGAUGAG GCCGUUAGGC CGAA AAUAUAUG 7869 582 AUUAACAU A UACAACUG 2814 CAGUUGUA CUGAUGAG GCCGUUAGGC CGAA AUGUUAAU 7870 584 UAACAUAU A CAACUGUG 2815 CACAGUUG CUGAUGAG GCCGUUAGGC CGAA AUAUGUUA 7871 601 AACCAGCU A AUCCCUCU 2816 AGAGGGAU CUGAUGAG GCCGUUAGGC CGAA AGCUGGUU 7872 604 CAGCUAAU C CCUCUGAG 2817 CUCAGAGG CUGAUGAG GCCGUUAGGC CGAA AUUAGCUG 7873 608 UAAUCCCU C UGAGAAAA 2818 UUUUCUCA CUGAUGAG GCCGUUAGGC CGAA AGGGAUUA 7874 620 GAAAAACU C CCCAUCUA 2819 UAGAUGGG CUGAUGAG GCCGUUAGGC CGAA AGUUUUUC 7875 626 CUCCCCAU C UACCCAAU 2820 AUUGGGUA CUGAUGAG GCCGUUAGGC CGAA AUGGGGAG 7876 628 CCCCAUCU A CCCAAUAC 2821 GUAUUGGG CUGAUGAG GCCGUUAGGC CGAA AGAUGGGG 7877 635 UACCCAAU A CUGUUACA 2822 UGUAACAG CUGAUGAG GCCGUUAGGC CGAA AUUGGGUA 7878 640 AAUACUGU U ACAGCAUA 2823 UAUGCUGU CUGAUGAG GCCGUUAGGC CGAA ACAGUAUU 7879 641 AUACUGUU A CAGCAUAC 2824 GUAUGCUG CUGAUGAG GCCGUUAGGC CGAA AACAGUAU 7880 648 UACAGCAU A CAAUCUCU 2825 AGAGAUUG CUGAUGAG GCCGUUAGGC CGAA AUGCUGUA 7881 653 CAUACAAU C UCUGUUCU 2826 AGAACAGA CUGAUGAG GCCGUUAGGC CGAA AUUGUAUG 7882 655 UACAAUCU C UGUUCUUG 2827 CAAGAACA CUGAUGAG GCCGUUAGGC CGAA AGAUUGUA 7883 659 AUCUCUGU U CUUGGGCA 2828 UGCCCAAG CUGAUGAG GCCGUUAGGC CGAA ACAGAGAU 7884 660 UCUCUGUU C UUGGGCAU 2829 AUGCCCAA CUGAUGAG GCCGUUAGGC CGAA AACAGAGA 7885 662 UCUGUUCU U GGGCAUUU 2830 AAAUGCCC CUGAUGAG GCCGUUAGGC CGAA AGAACAGA 7886 669 UUGGGCAU U UUGUCAGU 2831 ACUGACAA CUGAUGAG GCCGUUAGGC CGAA AUGCCCAA 7887 670 UGGGCAUU U UGUCAGUG 2832 CACUGACA CUGAUGAG GCCGUUAGGC CGAA AAUGCCCA 7888 671 GGGCAUUU U GUCAGUGA 2833 UCACUGAC CUGAUGAG GCCGUUAGGC CGAA AAAUGCCC 7889 674 CAUUUUGU C AGUGAUGC 2834 GCAUCACU CUGAUGAG GCCGUUAGGC CGAA AGAAAAUG 7890 687 AUGGUGAU c UUUGCCUU 2835 AAGGCAAA CUGAUGAG GCCGUUAGGC CGAA AUCAGCAU 7891 689 GCUGAUCU u UGCCUUCU 2836 AGAAGGCA CUGAUGAG GCCGUUAGGC CGAA AGAUCAGC 7892 690 CUGAUCUU u GCCUUCUU 2837 AAGAAGGC CUGAUGAG GCCGUUAGGC CGAA AAGAUCAG 7893 695 CUUUGCCU u CUUCCAGG 2838 CCUGGAAG CUGAUGAG GCCGUUAGGC CGAA AGGCAAAG 7894 696 UUUGCCUU c UUCCAGGA 2839 UCCUGGAA CUGAUGAG GCCGUUAGGC CGAA AAGGCAAA 7895 698 UGCCUUCU u CCAGGAAC 2840 GUUCCUGG CUGAUGAG GCCGUUAGGC CGAA AGAAGGCA 7896 699 GCCUUCUU c CAGGAACU 2841 AGUUCCUG CUGAUGAG GCCGUUAGGC CGAA AAGAAGGC 7897 708 CAGGAACU u GUAAUAGC 2842 GCUAUUAC CUGAUGAG GCCGUUAGGC CGAA AGUUCCUG 7898 711 GAACUUGU A AUAGCUGG 2843 CCAGCUAU CUGAUGAG GCCGUUAGGC CGAA ACAAGUUC 7899 714 CUUGUAAU A GCUGGCAU 2844 AUGCCAGC CUGAUGAG GCCGUUAGGC CGAA AUUACAAG 7900 723 GCUGGCAU C GUUGAGAA 2845 UUCUCAAC CUGAUGAG GCCGUUAGGC CGAA AUGCCAGC 7901 726 GGCAUCGU U GAGAAUGA 2846 UCAUUCUC CUGAUGAG GCCGUUAGGC CGAA ACGAUGCC 7902 752 AACGUGCU C CAGACCCA 2847 UGGGUCUG CUGAUGAG GCCGUUAGGC CGAA AGCACGUU 7903 764 ACCCAAAU C UAACAUAG 2848 CUAUGUUA CUGAUGAG GCCGUUAGGC CGAA AUUUGGGU 7904 766 CCAAAUCU A ACAUAGUU 2849 AACUAUGU CUGAUGAG GCCGUUAGGC CGAA AGAUUUGG 7905 771 UCUAACAU A GUUCUCCU 2850 AGGAGAAC CUGAUGAG GCCGUUAGGC CGAA AUGUUAGA 7906 774 AAGAUAGU U CUCCUGUC 2851 GACAGGAG CUGAUGAG GCCGUUAGGC CGAA ACUAUGUU 7907 775 ACAUAGUU c UCCUGUCA 2852 UGACAGGA CUGAUGAG GCCGUUAGGC CGAA AACUAUGU 7908 777 AUAGUUCU c CUGUCAGC 2853 GCUGACAG CUGAUGAG GCCGUUAGGC CGAA AGAACUAU 7909 782 UCUCCUGU c AGCAGAAG 2854 CUUCUGCU CUGAUGAG GCCGUUAGGC CGAA ACAGGAGA 7910 808 AACAGACU A UUGAAAUA 2855 UAUUUCAA CUGAUGAG GCCGUUAGGC CGAA AGUCUGUU 7911 810 CAGACUAU U GAAAUAAA 2856 UUUAUUUC CUGAUGAG GCCGUUAGGC CGAA AUAGUCUG 7912 816 AUUGAAAU A AAAGAAGA 2857 UCUUCUUU CUGAUGAG GCCGUUAGGC CGAA AUUUCAAU 7913 831 GAAGUGGU U GGGCUAAC 2858 GUUAGCCC CUGAUGAG GCCGUUAGGC CGAA ACCACUUC 7914 837 GUUGGGCU A ACUGAAAC 2859 GUUUCAGU CUGAUGAG GCCGUUAGGC CGAA AGCCCAAC 7915 848 UGAAACAU C UUCCCAAC 2860 GUUGGGAA CUGAUGAG GCCGUUAGGC CGAA AUGUUUCA 7916 850 AAAGAUCU U CCCAACCA 2861 UGGUUGGG CUGAUGAG GCCGUUAGGC CGAA AGAUGUUU 7917 851 AACAUCUU C CCAACCAA 2862 UUGGUUGG CUGAUGAG GCCGUUAGGC CGAA AAGAUGUU 7918 876 GAAGACAU U GAAAUUAU 2863 AUAAUUUC CUGAUGAG GCCGUUAGGC CGAA AUGUCUUC 7919 882 AUUGAAAU u AUUCCAAU 2864 AUUGGAAU CUGAUGAG GCCGUUAGGC CGAA AUUUCAAU 7920 883 UUGAAAUU A UUCCAAUC 2865 GAUUGGAA CUGAUGAG GCCGUUAGGC CGAA AAUUUCAA 7921 885 GAAAUUAU u CCAAUCCA 2866 UGGAUUGG CUGAUGAG GCCGUUAGGC CGAA AUAAUUUC 7922 886 AAAUUAUU c CAAUCCAA 2867 UUGGAUUG CUGAUGAG GCCGUUAGGC CGAA AAUAAUUU 7923 891 AUUCCAAU c CAAGAAGA 2868 UCUUCUUG CUGAUGAG GCCGUUAGGC CGAA AUUGGAAU 7924 926 GACGAACU u UCCAGAAC 2869 GUUCUGGA CUGAUGAG GCCGUUAGGC CGAA AGUUCGUC 7925 927 ACGAACUU u CCAGAACC 2870 GGUUCUGG CUGAUGAG GCCGUUAGGC CGAA AAGUUCGU 7926 928 CGAACUUU c CAGAACCU 2871 AGGUUCUG CUGAUGAG GCCGUUAGGC CGAA AAAGUUCG 7927 937 CAGAACCU c CCCAAGAU 2872 AUCUUGGG CUGAUGAG GCCGUUAGGC CGAA AGGUUCUG 7928 946 CCCAAGAU c AGGAAUCC 2873 GGAUUCCU CUGAUGAG GCCGUUAGGC CGAA AUCUUGGG 7929 953 UCAGGAAU c CUCACCAA 2874 UUGGUGAG CUGAUGAG GCCGUUAGGC CGAA AUUCCUGA 7930 956 GGAAUCCU c ACCAAUAG 2875 CUAUUGGU CUGAUGAG GCCGUUAGGC CGAA AGGAUUCC 7931 963 UCACCAAU A GAAAAUGA 2876 UCAUUUUC CUGAUGAG GCCGUUAGGC CGAA AUUGGUGA 7932 977 UGACAGCU c UCCUUAAG 2877 CUUAAGGA CUGAUGAG GCCGUUAGGC CGAA AGCUGUCA 7933 979 ACAGCUCU c CUUAAGUG 2878 CACUUAAG CUGAUGAG GCCGUUAGGC CGAA AGAGCUGU 7934 982 GCUCUCCU u AAGUGAUU 2879 AAUCAGUU CUGAUGAG GCCGUUAGGC CGAA AGGAGAGC 7935 983 CUCUCCUU A AGUGAUUU 2880 AAAUCAGU CUGAUGAG GCCGUUAGGC CGAA AAGGAGAG 7936 990 UAAGUGAU U UCUUCUGU 2881 ACAGAAGA CUGAUGAG GCCGUUAGGC CGAA AUCACUUA 7937 991 AAGUGAUU U CUUCUGUU 2882 AACAGAAG CUGAUGAG GCCGUUAGGC CGAA AAUCACUU 7938 992 AGUGAUUU C UUCUGUUU 2883 AAACAGAA CUGAUGAG GCCGUUAGGC CGAA AAAUCACU 7939 994 UGAUUUCU U CUGUUUUC 2884 GAAAACAG CUGAUGAG GCCGUUAGGC CGAA AGAAAUCA 7940 995 GAUUUCUU C UGUUUUCU 2885 AGAAAACA CUGAUGAG GCCGUUAGGC CGAA AAGAAAUC 7941 999 UCUUCUGU u UUCUGUUU 2886 AAACAGAA CUGAUGAG GCCGUUAGGC CGAA ACAGAAGA 7942 1000 CUUCUGUU u UCUGUUUC 2887 GAAACAGA CUGAUGAG GCCGUUAGGC CGAA AACAGAAG 7943 1001 UUCUGUUU U CUGUUUCC 2888 GGAAACAG CUGAUGAG GCCGUUAGGC CGAA AAACAGAA 7944 1002 UCUGUUUU C UGUUUCCU 2889 AGGAAACA CUGAUGAG GCCGUUAGGC CGAA AAAACAGA 7945 1006 UUUUCUGU U UCCUUUUU 2890 AAAAAGGA CUGAUGAG GCCGUUAGGC CGAA ACAGAAAA 7946 1007 UUUCUGUU U ccuuuuuu 2891 AAAAAAGG CUGAUGAG GCCGUUAGGC CGAA AACAGAAA 7947 1008 UUCUGUUU C CUUUUUUA 2892 UAAAAAAG CUGAUGAG GCCGUUAGGC CGAA AAACAGAA 7948 1011 UGUUUCCU U UUUUAAAC 2893 GUUUAAAA CUGAUGAG GCCGUUAGGC CGAA AGGAAACA 7949 1012 GUUUCCUU U UUUAAAGA 2894 UGUUUAAA CUGAUGAG GCCGUUAGGC CGAA AAGGAAAC 7950 1013 UUUCCUUU U UUAAAGAU 2895 AUGUUUAA CUGAUGAG GCCGUUAGGC CGAA AAAGGAAA 7951 1014 uuccuuuu U UAAACAUU 2896 AAUGUUUA CUGAUGAG GCCGUUAGGC CGAA AAAAGGAA 7952 1015 uccuuuuu U AAACAUUA 2897 UAAUGUUU CUGAUGAG GCCGUUAGGC CGAA AAAAAGGA 7953 1016 ccuuuuuu A AACAUUAG 2898 CUAAUGUU CUGAUGAG GCCGUUAGGC CGAA AAAAAAGG 7954 1022 UUAAAGAU u AGUGUUCA 2899 UGAACACU CUGAUGAG GCCGUUAGGC CGAA AUGUUUAA 7955 1023 UAAACAUU A GUGUUCAU 2900 AUGAACAC CUGAUGAG GCCGUUAGGC CGAA AAUGUUUA 7956 1028 AUUAGUGU U CAUAGCUU 2901 AAGCUAUG CUGAUGAG GCCGUUAGGC CGAA ACACUAAU 7957 1029 UUAGUGUU c AUAGCUUG 2902 GAAGCUAU CUGAUGAG GCCGUUAGGC CGAA AACACUAA 7958 1032 GUGUUCAU A GCUUCCAA 2903 UUGGAAGC CUGAUGAG GCCGUUAGGC CGAA AUGAACAC 7959 1036 UCAUAGCU U CCAAGAGA 2904 UCUCUUGG CUGAUGAG GCCGUUAGGC CGAA AGCUAUGA 7960 1037 CAUAGCUU C CAAGAGAC 2905 GUCUCUUG CUGAUGAG GCCGUUAGGC CGAA AAGCUAUG 7961 1055 UGCUGACU U UCAUUUCU 2906 AGAAAUGA CUGAUGAG GCCGUUAGGC CGAA AGUCAGCA 7962 1056 GCUGACUU U CAUUUCUU 2907 AAGAAAUG CUGAUGAG GCCGUUAGGC CGAA AAGUCAGC 7963 1057 CUGACUUU C AUUUCUUG 2908 GAAGAAAU CUGAUGAG GCCGUUAGGC CGAA AAAGUCAG 7964 1060 ACUUUCAU u UCUUGAGG 2909 CCUCAAGA CUGAUGAG GCCGUUAGGC CGAA AUGAAAGU 7965 1061 CUUUCAUU u CUUGAGGU 2910 ACCUCAAG CUGAUGAG GCCGUUAGGC CGAA AAUGAAAG 7966 1062 UUUCAUUU c UUGAGGUA 2911 UACCUCAA CUGAUGAG GCCGUUAGGC CGAA AAAUGAAA 7967 1064 UCAUUUCU u GAGGUACU 2912 AGUACCUC CUGAUGAG GCCGUUAGGC CGAA AGAAAUGA 7968 1070 CUUGAGGU A CUCUGCAC 2913 GUGCAGAG CUGAUGAG GCCGUUAGGC CGAA ACCUCAAG 7969 1073 GAGGUACU C UGCACAUA 2914 UAUGUGCA CUGAUGAG GCCGUUAGGC CGAA AGUACCUC 7970 1081 CUGCACAU A CGCACCAC 2915 GUGGUGCG CUGAUGAG GCCGUUAGGC CGAA AUGUGCAG 7971 1092 CACCACAU C UCUAUCUG 2916 CAGAUAGA CUGAUGAG GCCGUUAGGC CGAA AUGUGGUG 7972 1094 CCACAUCU C UAUCUGGC 2917 GCCAGAUA CUGAUGAG GCCGUUAGGC CGAA AGAUGUGG 7973 1096 ACAUCUCU A UCUGGCCU 2918 AGGCCAGA CUGAUGAG GCCGUUAGGC CGAA AGAGAUGU 7974 1098 AUCUCUAU C UGGCCUUU 2919 AAAGGCCA CUGAUGAG GCCGUUAGGC CGAA AUAGAGAU 7975 1105 UCUGGCCU U UGCAUGGA 2920 UCCAUGCA CUGAUGAG GCCGUUAGGC CGAA AGGCCAGA 7976 1106 CUGGCCUU U GCAUGGAG 2921 CUCCAUGC CUGAUGAG GCCGUUAGGC CGAA AAGGCCAG 7977 1122 GUGACCAU A GCUCCUUC 2922 GAAGGAGC CUGAUGAG GCCGUUAGGC CGAA AUGGUCAC 7978 1126 CCAUAGCU C CUUCUCUC 2923 GAGAGAAG CUGAUGAG GCCGUUAGGC CGAA AGCUAUGG 7979 1129 UAGCUCCU U CUCUCUUA 2924 UAAGAGAG CUGAUGAG GCCGUUAGGC CGAA AGGAGCUA 7980 1130 AGCUCCUU C UCUCUUAC 2925 GUAAGAGA CUGAUGAG GCCGUUAGGC CGAA AAGGAGCU 7981 1132 CUCCUUCU C UCUUACAU 2926 AUGUAAGA CUGAUGAG GCCGUUAGGC CGAA AGAAGGAG 7982 1134 CCUUCUCU C UUACAUUG 2927 CAAUGUAA CUGAUGAG GCCGUUAGGC CGAA AGAGAAGG 7983 1136 uucucucu U ACAUUGAA 2928 UUCAAUGU CUGAUGAG GCCGUUAGGC CGAA AGAGAGAA 7984 1137 ucucucuu A CAUUGAAU 2929 AUUCAAUG CUGAUGAG GCCGUUAGGC CGAA AAGAGAGA 7985 1141 UCUUACAU U GAAUGUAG 2930 CUACAUUC CUGAUGAG GCCGUUAGGC CGAA AUGUAAGA 7986 1148 UUGAAUGU A GAGAAUGU 2931 ACAUUCUC CUGAUGAG GCCGUUAGGC CGAA ACAUUCAA 7987 1157 GAGAAUGU A GCCAUUGU 2932 ACAAUGGC CUGAUGAG GCCGUUAGGC CGAA ACAUUCUC 7988 1163 GUAGCCAU U GUAGCAGC 2933 GCUGCUAC CUGAUGAG GCCGUUAGGC CGAA AUGGCUAC 7989 1166 GCCAUUGU A GCAGCUUG 2934 CAAGCUGC CUGAUGAG GCCGUUAGGC CGAA ACAAUGGC 7990 1173 UAGCAGCU U GUGUUGUC 2935 GACAACAC CUGAUGAG GCCGUUAGGC CGAA AGCUGCUA 7991 1178 GCUUGUGU U GUCACGCU 2936 AGCGUGAC CUGAUGAG GCCGUUAGGC CGAA ACACAAGC 7992 1181 UGUGUUGU C ACGCUUCU 2937 AGAAGCGU CUGAUGAG GCCGUUAGGC CGAA ACAACACA 7993 1187 GUCACGCU U CUUCUUUU 2938 AAAAGAAG CUGAUGAG GCCGUUAGGC CGAA AGCGUGAC 7994 1188 UCACGCUU C UUCUUUUG 2939 CAAAAGAA CUGAUGAG GCCGUUAGGC CGAA AAGCGUGA 7995 1190 ACGCUUCU U CUUUUGAG 2940 CUCAAAAG CUGAUGAG GCCGUUAGGC CGAA AGAAGCGU 7996 1191 CGCUUCUU c UUUUGAGC 2941 GCUCAAAA CUGAUGAG GCCGUUAGGC CGAA AAGAAGCG 7997 1193 CUUCUUCU u UUGAGCAA 2942 UUGCUCAA CUGAUGAG GCCGUUAGGC CGAA AGAAGAAG 7998 1194 uucuucuu u UGAGCAAC 2943 GUUGCUCA CUGAUGAG GCCGUUAGGC CGAA AAGAAGAA 7999 1195 ucuucuuu u GAGCAACU 2944 AGUUGCUC CUGAUGAG GCCGUUAGGC CGAA AAAGAAGA 8000 1204 GAGCAACU u UCUUACAC 2945 GUGUAAGA CUGAUGAG GCCGUUAGGC CGAA AGUUGCUC 8001 1205 AGCAACUU u CUUACACU 2946 AGUGUAAG CUGAUGAG GCCGUUAGGC CGAA AAGUUGCU 8002 1206 GCAACUUU c UUACACUG 2947 CAGUGUAA CUGAUGAG GCCGUUAGGC CGAA AAAGUUGC 8003 1208 AACUUUCU u ACACUGAA 2948 UUCAGUGU CUGAUGAG GCCGUUAGGC CGAA AGAAAGUU 8004 1209 ACUUUCUU A CACUGAAG 2949 CUUCAGUG CUGAUGAG GCCGUUAGGC CGAA AAGAAAGU 8005 1236 UGAGUGCU U CAGAAUGU 2950 AGAUUCUG CUGAUGAG GCCGUUAGGC CGAA AGCACUCA 8006 1237 GAGUGCUU C AGAAUGUG 2951 CACAUUCU CUGAUGAG GCCGUUAGGC CGAA AAGCACUC 8007 1248 AAUGUGAU U UCCUACUA 2952 UAGUAGGA CUGAUGAG GCCGUUAGGC CGAA AUCACAUU 8008 1249 AUGUGAUU U CCUACUAA 2953 UUAGUAGG CUGAUGAG GCCGUUAGGC CGAA AAUCACAU 8009 1250 UGUGAUUU C CUACUAAC 2954 GUUAGUAG CUGAUGAG GCCGUUAGGC CGAA AAAUCACA 8010 1253 GAUUUCCU A CUAACCUG 2955 CAGGUUAG CUGAUGAG GCCGUUAGGC CGAA AGGAAAUC 8011 1256 UUCCUACU A ACCUGUUC 2956 GAACAGGU CUGAUGAG GCCGUUAGGC CGAA AGUAGGAA 8012 1263 UAACCUGU U CCUUGGAU 2957 AUCCAAGG CUGAUGAG GCCGUUAGGC CGAA ACAGGUUA 8013 1264 AACCUGUU c CUUGGAUA 2958 UAUCCAAG CUGAUGAG GCCGUUAGGC CGAA AACAGGUU 8014 1267 CUGUUCCU u GGAUAGGC 2959 GCCUAUCC CUGAUGAG GCCGUUAGGC CGAA AGGAAGAG 8015 1272 CCUUGGAU A GGCUUUUU 2960 AAAAAGCC CUGAUGAG GCCGUUAGGC CGAA AUCCAAGG 8016 1277 GAUAGGCU u UUUAGUAU 2961 AUACUAAA CUGAUGAG GCCGUUAGGC CGAA AGCCUAUC 8017 1278 AUAGGCUU u UUAGUAUA 2962 UAUACUAA CUGAUGAG GCCGUUAGGC CGAA AAGCCUAU 8018 1279 UAGGCUUU u UAGUAUAG 2963 CUAUACUA CUGAUGAG GCCGUUAGGC CGAA AAAGCCUA 8019 1280 AGGCUUUU u AGUAUAGU 2964 ACUAUACU CUGAUGAG GCCGUUAGGC CGAA AAAAGCCU 8020 1281 GGCUUUUU A GUAUAGUA 2965 UACUAUAC CUGAUGAG GCCGUUAGGC CGAA AAAAAGCC 8021 1284 UUUUUAGU A UAGUAUUU 2966 AAAUACUA CUGAUGAG GCCGUUAGGC CGAA ACUAAAAA 8022 1286 UUUAGUAU A GUAUUUUU 2967 AAAAAUAC CUGAUGAG GCCGUUAGGC CGAA AUACUAAA 8023 1289 AGUAUAGU A UUUUUUUU 2968 AAAAAAAA CUGAUGAG GCCGUUAGGC CGAA ACUAUACU 8024 1291 UAUAGUAU U UUUUUUUG 2969 CAAAAAAA CUGAUGAG GCCGUUAGGC CGAA AUACUAUA 8025 1292 AUAGUAUU U UUUUUUGU 2970 ACAAAAAA CUGAUGAG GCCGUUAGGC CGAA AAUACUAU 8026 1293 UAGUAUUU U UUUUUGUC 2971 GACAAAAA CUGAUGAG GCCGUUAGGC CGAA AAAUACUA 8027 1294 AGUAUUUU U UUUUGUCA 2972 UGACAAAA CUGAUGAG GCCGUUAGGC CGAA AAAAUACU 8028 1295 GUAUUUUU U UUUGUCAU 2973 AUGACAAA CUGAUGAG GCCGUUAGGC CGAA AAAAAUAC 8029 1296 UAUUUUUU U UUGUCAUU 2974 AAUGACAA CUGAUGAG GCCGUUAGGC CGAA AAAAAAUA 8030 1297 AUUUUUUU U UGUCAUUU 2975 AAAUGACA CUGAUGAG GCCGUUAGGC CGAA AAAAAAAU 8031 1298 UUUUUUUU U GUCAUUUU 2976 AAAAUGAC CUGAUGAG GCCGUUAGGC CGAA AAAAAAAA 8032 1301 UUUUUUGU C AUUUUCUC 2977 GAGAAAAU CUGAUGAG GCCGUUAGGC CGAA ACAAAAAA 8033 1304 UUUGUCAU U UUCUCCAU 2978 AUGGAGAA CUGAUGAG GCCGUUAGGC CGAA AUGACAAA 8034 1305 UUGUCAUU u UCUCCAUC 2979 GAUGGAGA CUGAUGAG GCCGUUAGGC CGAA AAUGACAA 8035 1306 UGUCAUUU u CUCCAUCA 2980 UGAUGGAG CUGAUGAG GCCGUUAGGC CGAA AAAUGACA 8036 1307 GUCAUUUU c UCCAUCAG 2981 CUGAUGGA CUGAUGAG GCCGUUAGGC CGAA AAAAUGAC 8037 1309 CAUUUUCU c CAUCAGCA 2982 UGCUGAUG CUGAUGAG GCCGUUAGGC CGAA AGAAAAUG 8038 1313 UUCUCCAU c AGCAACCA 2983 UGGUUGCU CUGAUGAG GCCGUUAGGC CGAA AUGGAGAA 8039 1348 GAAAAGAU A UAUGACUG 2984 CAGUCAUA CUGAUGAG GCCGUUAGGC CGAA AUCUUUUG 8040 1350 AAAGAUAU A UGACUGCU 2985 AGCAGUCA CUGAUGAG GCCGUUAGGC CGAA AUAUCUUU 8041 1359 UGACUGCU U CAUGACAU 2986 AUGUCAUG CUGAUGAG GCCGUUAGGC CGAA AGCAGUCA 8042 1360 GACUGCUU C AUGACAUU 2987 AAUGUCAU CUGAUGAG GCCGUUAGGC CGAA AAGCAGUC 8043 1368 CAUGACAU U CCUAAACU 2988 AGUUUAGG CUGAUGAG GCCGUUAGGC CGAA AUGUCAUG 8044 1369 AUGACAUU C CUAAACUA 2989 UAGUUUAG CUGAUGAG GCCGUUAGGC CGAA AAUGUCAU 8045 1372 ACAUUCCU A AACUAUCU 2990 AGAUAGUU CUGAUGAG GCCGUUAGGC CGAA AGGAAUGU 8046 1377 CCUAAACU A UCUUUUUU 2991 AAAAAAGA CUGAUGAG GCCGUUAGGC CGAA AGUUUAGG 8047 1379 UAAACUAU C UUUUUUUU 2992 AAAAAAAA CUGAUGAG GCCGUUAGGC CGAA AUAGUUUA 8048 1381 AACUAUGU U UUUUUUAU 2993 AUAAAAAA CUGAUGAG GCCGUUAGGC CGAA AGAUAGUU 8049 1382 ACUAUCUU U UUUUUAUU 2994 AAUAAAAA CUGAUGAG GCCGUUAGGC CGAA AAGAUAGU 8050 1383 CUAUCUUU U UUUUAUUC 2995 GAAUAAAA CUGAUGAG GCCGUUAGGC CGAA AAAGAUAG 8051 1384 UAUCUUUU U UUUAUUCC 2996 GGAAUAAA CUGAUGAG GCCGUUAGGC CGAA AAAAGAUA 8052 1385 AUCUUUUU U UUAUUCCA 2997 UGGAAUAA CUGAUGAG GCCGUUAGGC CGAA AAAAAGAU 8053 1386 UCUUUUUU U UAUUCCAC 2998 GUGGAAUA CUGAUGAG GCCGUUAGGC CGAA AAAAAAGA 8054 1387 cuuuuuuu U AUUCCACA 2999 UGUGGAAU CUGAUGAG GCCGUUAGGC CGAA AAAAAAAG 8055 1388 UUUUUUUU A UUCCACAU 3000 AUGUGGAA CUGAUGAG GCCGUUAGGC CGAA AAAAAAAA 8056 1390 UUUUUUAU U CCACAUCU 3001 AGAUGUGG CUGAUGAG GCCGUUAGGC CGAA AUAAAAAA 8057 1391 UUUUUAUU C CACAUCUA 3002 UAGAUGUG CUGAUGAG GCCGUUAGGC CGAA AAUAAAAA 8058 1397 UUCCACAU C UACGUUUU 3003 AAAACGUA CUGAUGAG GCCGUUAGGC CGAA AUGUGGAA 8059 1399 CCACAUCU A CGUUUUUG 3004 CAAAAACG CUGAUGAG GCCGUUAGGC CGAA AGAUGUGG 8060 1403 AUCUACGU U UUUGGUGG 3005 CCACCAAA CUGAUGAG GCCGUUAGGC CGAA ACGUAGAU 8061 1404 UCUACGUU U UUGGUGGA 3006 UCCACCAA CUGAUGAG GCCGUUAGGC CGAA AACGUAGA 8062 1405 CUACGUUU u UGGUGGAG 3007 CUCCACCA CUGAUGAG GCCGUUAGGC CGAA AAACGUAG 8063 1406 UACGUUUU u GGUGGAGU 3008 ACUCCACC CUGAUGAG GCCGUUAGGC CGAA AAAACGUA 8064 1415 GGUGGAGU C CCUUUUGC 3009 GCAAAAGG CUGAUGAG GCCGUUAGGC CGAA ACUCCACC 8065 1419 GAGUCCCU u UUGCAUCA 3010 UGAUGCAA CUGAUGAG GCCGUUAGGC CGAA AGGGACUC 8066 1420 AGUCCCUU u UGCAUCAU 3011 AUGAUGCA CUGAUGAG GCCGUUAGGC CGAA AAGGGACU 8067 1421 GUCCCUUU u GCAUCAUU 3012 AAUGAUGC CUGAUGAG GCCGUUAGGC CGAA AAAGGGAG 8068 1426 UUUUGCAU c AUUGUUUU 3013 AAAACAAU CUGAUGAG GCCGUUAGGC CGAA AUGCAAAA 8069 1429 UGCAUCAU U GUUUUAAG 3014 CUUAAAAC CUGAUGAG GCCGUUAGGC CGAA AUGAUGCA 8070 1432 AUCAUUGU U UUAAGGAU 3015 AUCCUUAA CUGAUGAG GCCGUUAGGC CGAA ACAAUGAU 8071 1433 UCAUUGUU U UAAGGAUG 3016 CAUCCUUA CUGAUGAG GCCGUUAGGC CGAA AACAAUGA 8072 1434 CAUUGUUU U AAGGAUGA 3017 UCAUCCUU CUGAUGAG GCCGUUAGGC CGAA AAACAAUG 8073 1435 AUUGUUUU A AGGAUGAU 3018 AUCAUCCU CUGAUGAG GCCGUUAGGC CGAA AAAACAAU 8074 1444 AGGAUGAU A AAAAAAAA 3019 UUUUUUUU CUGAUGAG GCCGUUAGGC CGAA AUCAUCCU 8075 1455 AAAAAAAU A ACAACUAG 3020 CUAGUUGU CUGAUGAG GCCGUUAGGC CGAA AUUUUUUU 8076 1462 UAACAACU A GGGACAAU 3021 AUUGUCCC CUGAUGAG GCCGUUAGGC CGAA AGUUGUUA 8077 1471 GGGACAAU A CAGAACCC 3022 GGGUUCUG CUGAUGAG GCCGUUAGGC CGAA AUUGUCCC 8078 1482 GAACCCAU U CCAUUUAU 3023 AUAAAUGG CUGAUGAG GCCGUUAGGC CGAA AUGGGUUC 8079 1483 AACCCAUU C CAUUUAUC 3024 GAUAAAUG CUGAUGAG GCCGUUAGGC CGAA AAUGGGUU 8080 1487 CAUUCCAU U UAUCUUUC 3025 GAAAGAUA CUGAUGAG GCCGUUAGGC CGAA AUGGAAUG 8081 1488 AUUCCAUU U AUCUUUCU 3026 AGAAAGAU CUGAUGAG GCCGUUAGGC CGAA AAUGGAAU 8082 1489 UUCCAUUU A UCUUUCUA 3027 UAGAAAGA CUGAUGAG GCCGUUAGGC CGAA AAAUGGAA 8083 1491 CCAUUUAU C UUUCUACA 3028 UGUAGAAA CUGAUGAG GCCGUUAGGC CGAA AUAAAUGG 8084 1493 AUUUAUCU U UCUACAGG 3029 CCUGUAGA CUGAUGAG GCCGUUAGGC CGAA AGAUAAAU 8085 1494 UUUAUCUU U CUACAGGG 3030 CCCUGUAG CUGAUGAG GCCGUUAGGC CGAA AAGAUAAA 8086 1495 UUAUCUUU C UACAGGGC 3031 GCCCUGUA CUGAUGAG GCCGUUAGGC CGAA AAAGAUAA 8087 1497 AUCUUUCU A CAGGGCUG 3032 CAGCCCUG CUGAUGAG GCCGUUAGGC CGAA AGAAAGAU 8088 1510 GCUGACAU U GUGGCACA 3033 UGUGCCAC CUGAUGAG GCCGUUAGGC CGAA AUGUCAGC 8089 1520 UGGCACAU U CUUAGAGU 3034 ACUCUAAG CUGAUGAG GCCGUUAGGC CGAA AUGUGCCA 8090 1521 GGCACAUU C UUAGAGUU 3035 AACUCUAA CUGAUGAG GCCGUUAGGC CGAA AAUGUGCC 8091 1523 CACAUUCU U AGAGUUAC 3036 GUAACUCU CUGAUGAG GCCGUUAGGC CGAA AGAAUGUG 8092 1524 ACAUUCUU A GAGUUACC 3037 GGUAACUC CUGAUGAG GCCGUUAGGC CGAA AAGAAUGU 8093 1529 CUUAGAGU U ACCACACC 3038 GGUGUGGU CUGAUGAG GCCGUUAGGC CGAA ACUCUAAG 8094 1530 UUAGAGUU A CCACACCC 3039 GGGUGUGG CUGAUGAG GCCGUUAGGC CGAA AACUCUAA 8095 1552 GGGAAGCU C UAAAUAGC 3040 GCUAUUUA CUGAUGAG GCCGUUAGGC CGAA AGCUUCCC 8096 1554 GAAGCUCU A AAUAGCCA 3041 UGGCUAUU CUGAUGAG GCCGUUAGGC CGAA AGAGCUUC 8097 1558 CUCUAAAU A GCCAACAC 3042 GUGUUGGC CUGAUGAG GCCGUUAGGC CGAA AUUUAGAG 8098 1571 ACACCCAU C UGUUUUUU 3043 AAAAAACA CUGAUGAG GCCGUUAGGC CGAA AUGGGUGU 8099 1575 CCAUCUGU U UUUUGUAA 3044 UUACAAAA CUGAUGAG GCCGUUAGGC CGAA ACAGAUGG 8100 1576 CAUCUGUU U UUUGUAAA 3045 UUUACAAA CUGAUGAG GCCGUUAGGC CGAA AACAGAUG 8101 1577 AUCUGUUU U UUGUAAAA 3046 UUUUACAA CUGAUGAG GCCGUUAGGC CGAA AAACAGAU 8102 1578 UCUGUUUU u UGUAAAAA 3047 UUUUUACA CUGAUGAG GCCGUUAGGC CGAA AAAACAGA 8103 1579 CUGUUUUU U GUAAAAAC 3048 GUUUUUAC CUGAUGAG GCCGUUAGGC CGAA AAAAACAG 8104 1582 UUUUUUGU A AAAACAGC 3049 GCUGUUUU CUGAUGAG GCCGUUAGGC CGAA ACAAAAAA 8105 Input Sequence = HSCD20A. Cut Site = UH/ . Stem Length = 8 . Core Sequence = CUGAUGAG GCCGUUAGGC CGAA HSCD20A (Human mRNA for CD20 receptor (S7) ; 1597 bp) Underlined region can be any X sequence or linker, as previously described herein. Table X: Human CD20 Inozyme and Substrate Sequence Pos Substrate Seq ID Inozyme Seq ID 11 CAAACUGC A CCCACUGA 3050 UCAGUGGG CUGAUGAG GCCGUUAGGC CGAA ICAGUUUG 8106 13 AACUGCAC C CACUGAAC 3051 GUUCAGUG CUGAUGAG GCCGUUAGGC CGAA IUGCAGUU 8107 14 ACUGCACC C ACUGAACU 3052 AGUUCAGU CUGAUGAG GCCGUUAGGC CGAA IGUGCAGU 8108 15 CUGCACCC A CUGAACUC 3053 GAGUUCAG CUGAUGAG GCCGUUAGGC CGAA IGGUGGAG 8109 17 GCACCCAC U GAACUCCG 3054 CGGAGUUC CUGAUGAG GCCGUUAGGC CGAA IUGGGUGC 8110 22 CACUGAAC U CCGCAGCU 3055 AGCUGCGG CUGAUGAG GCCGUUAGGC CGAA IUUCAGUG 8111 24 CUGAACUC C GCAGCUAG 3056 CUAGCUGC CUGAUGAG GCCGUUAGGC CGAA IAGUUCAG 8112 27 AACUCCGC A GCUAGCAU 3057 AUGCUAGC CUGAUGAG GCCGUUAGGC CGAA ICGGAGUU 8113 30 UCCGCAGC U AGCAUCCA 3058 UGGAUGCU CUGAUGAG GCCGUUAGGC CGAA ICUGCGGA 8114 34 CAGCUAGC A UCCAAAUC 3059 GAUUUGGA CUGAUGAG GCCGUUAGGC CGAA ICUAGCUG 8115 37 CUAGCAUC C AAAUCAGC 3060 GCUGAUUU CUGAUGAG GCCGUUAGGC CGAA IAUGCUAG 8116 38 UAGCAUCC A AAUCAGCC 3061 GGCUGAUU CUGAUGAG GCCGUUAGGC CGAA IGAUGCUA 8117 43 UCCAAAUC A GCCCUUGA 3062 UCAAGGGC CUGAUGAG GCCGUUAGGC CGAA IAUUUGGA 8118 46 AAAUCAGC C CUUGAGAU 3063 AUCUCAAG CUGAUGAG GCCGUUAGGC CGAA ICUGAUUU 8119 47 AAUCAGCC C UUGAGAUU 3064 AAUCUCAA CUGAUGAG GCCGUUAGGC CGAA IGCUGAUU 8120 48 AUCAGCCC U UGAGAUUU 3065 AAAUCUCA CUGAUGAG GCCGUUAGGC CGAA IGGCUGAU 8121 62 UUUGAGGC C UUGGAGAC 3066 GUCUCCAA CUGAUGAG GCCGUUAGGC CGAA ICCUCAAA 8122 63 UUGAGGCC U UGGAGACU 3067 AGUCUCCA CUGAUGAG GCCGUUAGGC CGAA IGCCUCAA 8123 71 UUGGAGAC U CAGGAGUU 3068 AACUCCUG CUGAUGAG GCCGUUAGGC CGAA IUCUCCAA 8124 73 GGAGACUC A GGAGUUUU 3069 AAAACUCC CUGAUGAG GCCGUUAGGC CGAA IAGUCUCC 8125 88 UUGAGAGC A AAAUGACA 3070 UGUCAUUU CUGAUGAG GCCGUUAGGC CGAA ICUCUCAA 8126 96 AAAAUGAC A ACACCCAG 3071 CUGGGUGU CUGAUGAG GCCGUUAGGC CGAA IUCAUUUU 8127 99 AUGACAAC A CCCAGAAA 3072 UUUCUGGG CUGAUGAG GCCGUUAGGC CGAA IUUGUCAU 8128 101 GACAACAC C CAGAAAUU 3073 AAUUUCUG CUGAUGAG GCCGUUAGGC CGAA IUGUUGUC 8129 102 ACAACACC C AGAAAUUC 3074 GAAUUUCU CUGAUGAG GCCGUUAGGC CGAA IGUGUUGU 8130 103 CAACACCC A GAAAUUCA 3075 UGAAUUUC CUGAUGAG GCCGUUAGGC CGAA IGGUGUUG 8131 111 AGAAAUUC A GUAAAUGG 3076 CCAUUUAC CUGAUGAG GCCGUUAGGC CGAA IAAUUUCU 8132 123 AAUGGGAC U UUCCUGGC 3077 GCCAGGAA CUGAUGAG GCCGUUAGGC CGAA IUCCCAUU 8133 127 GGACUUUC C UGGCAGAG 3078 CUCUGCCA CUGAUGAG GCCGUUAGGC CGAA IAAAGUCC 8134 128 GACUUUCC U GGCAGAGC 3079 GCUCUGCC CUGAUGAG GCCGUUAGGC CGAA IGAAAGUC 8135 132 UUCCUGGC A GAGCCAAU 3080 AUUGGCUC CUGAUGAG GCCGUUAGGC CGAA ICCAGGAA 8136 137 GGCAGAGC C AAUGAAAG 3081 CUUUCAUU CUGAUGAG GCCGUUAGGC CGAA ICUCUGCC 8137 138 GCAGAGCC A AUGAAAGG 3082 CCUUUCAU CUGAUGAG GCCGUUAGGC CGAA IGCUCUGC 8138 148 UGAAAGGC C CUAUUGCU 3083 AGCAAUAG CUGAUGAG GCCGUUAGGC CGAA ICCUUUCA 8139 149 GAAAGGCC C UAUUGCUA 3084 UAGCAAUA CUGAUGAG GCCGUUAGGC CGAA IGCCUUUC 8140 150 AAAGGCCC U AUUGCUAU 3085 AUAGCAAU CUGAUGAG GCCGUUAGGC CGAA IGGCCUUU 8141 156 CCUAUUGC U AUGCAAUC 3086 GAUUGCAU CUGAUGAG GCCGUUAGGC CGAA ICAAUAGG 8142 161 UGCUAUGC A AUCUGGUC 3087 GACCAGAU CUGAUGAG GCCGUUAGGC CGAA ICAUAGCA 8143 165 AUGCAAUC U GGUCCAAA 3088 UUUGGACC CUGAUGAG GCCGUUAGGC CGAA IAUUGCAU 8144 170 AUCUGGUC C AAAACCAC 3089 GUGGUUUU CUGAUGAG GCCGUUAGGC CGAA IACCAGAU 8145 171 UCUGGUCC A AAACCACU 3090 AGUGGUUU CUGAUGAG GCCGUUAGGC CGAA IGACCAGA 8146 176 UCCAAAAC C ACUCUUCA 3091 UGAAGAGU CUGAUGAG GCCGUUAGGC CGAA IUUUUGGA 8147 177 CCAAAACC A CUCUUCAG 3092 CUGAAGAG CUGAUGAG GCCGUUAGGC CGAA IGUUUUGG 8148 179 AAAACCAC U CUUCAGGA 3093 UCCUGAAG CUGAUGAG GCCGUUAGGC CGAA IUGGUUUU 8149 181 AACCACUC U UCAGGAGG 3094 CCUCCUGA CUGAUGAG GCCGUUAGGC CGAA IAGUGGUU 8150 184 CACUCUUC A GGAGGAUG 3095 CAUCCUCC CUGAUGAG GCCGUUAGGC CGAA IAAGAGUG 8151 195 AGGAUGUC U UCACUGGU 3096 ACCAGUGA CUGAUGAG GCCGUUAGGC CGAA IACAUCCU 8152 198 AUGUCUUC A CUGGUGGG 3097 CCCACCAG CUGAUGAG GCCGUUAGGC CGAA IAAGACAU 8153 200 GUCUUCAC U GGUGGGCC 3098 GGCCCACC CUGAUGAG GCCGUUAGGC CGAA IUGAAGAC 8154 208 UGGUGGGC C CCACGCAA 3099 UUGCGUGG CUGAUGAG GCCGUUAGGC CGAA ICCCACCA 8155 209 GGUGGGCC C CACGCAAA 3100 UUUGCGUG CUGAUGAG GCCGUUAGGC CGAA IGCCCACC 8156 210 GUGGGCCC C ACGCAAAG 3101 CUUUGCGU CUGAUGAG GCCGUUAGGC CGAA IGGCCCAC 8157 211 UGGGCCCC A CGCAAAGC 3102 GCUUUGCG CUGAUGAG GCCGUUAGGC CGAA IGGGCCCA 8158 215 CCCCACGC A AAGCUUCU 3103 AGAAGCUU CUGAUGAG GCCGUUAGGC CGAA ICGUGGGG 8159 220 CGCAAAGC U UCUUCAUG 3104 CAUGAAGA CUGAUGAG GCCGUUAGGC CGAA ICUUUGCG 8160 223 AAAGCUUC U UCAUGAGG 3105 CCUCAUGA CUGAUGAG GCCGUUAGGC CGAA IAAGCUUU 8161 226 GCUUCUUC A UGAGGGAA 3106 UUCCCUCA CUGAUGAG GCCGUUAGGC CGAA IAAGAAGC 8162 237 AGGGAAUC U AAGACUUU 3107 AAAGUCUU CUGAUGAG GCCGUUAGGC CGAA IAUUCCCU 8163 243 UCUAAGAC U UUGGGGGC 3108 GCCCCCAA CUGAUGAG GCCGUUAGGC CGAA IUCUUAGA 8164 252 UUGGGGGC U GUCCAGAU 3109 AUCUGGAC CUGAUGAG GCCGUUAGGC CGAA ICCCCCAA 8165 256 GGGCUGUC C AGAUUAUG 3110 CAUAAUCU CUGAUGAG GCCGUUAGGC CGAA IACAGCCC 8166 257 GGCUGUCC A GAUUAUGA 3111 UCAUAAUC CUGAUGAG GCCGUUAGGC CGAA IGACAGCC 8167 272 GAAUGGGC U CUUCCACA 3112 UGUGGAAG CUGAUGAG GCCGUUAGGC CGAA ICCCAUUC 8168 274 AUGGGCUC U UCCACAUU 3113 AAUGUGGA CUGAUGAG GCCGUUAGGC CGAA IAGCCCAU 8169 277 GGCUCUUC C ACAUUGCC 3114 GGCAAUGU CUGAUGAG GCCGUUAGGC CGAA IAAGAGCC 8170 278 GCUCUUCC A CAUUGCCC 3115 GGGCAAUG CUGAUGAG GCCGUUAGGC CGAA IGAAGAGC 8171 280 UCUUCCAC A UUGCCCUG 3116 CAGGGCAA CUGAUGAG GCCGUUAGGC CGAA IUGGAAGA 8172 285 CACAUUGC C CUGGGGGG 3117 CCCCCCAG CUGAUGAG GCCGUUAGGC CGAA ICAAUGUG 8173 286 ACAUUGCC C UGGGGGGU 3118 ACCCCCCA CUGAUGAG GCCGUUAGGC CGAA IGCAAUGU 8174 287 CAUUGCCC U GGGGGGUC 3119 GACCCCCC CUGAUGAG GCCGUUAGGC CGAA IGGCAAUG 8175 296 GGGGGGUC U UCUGAUGA 3120 UCAUCAGA CUGAUGAG GCCGUUAGGC CGAA IACCCCCC 8176 299 GGGUCUUC U GAUGAUCC 3121 GGAUCAUC CUGAUGAG GCCGUUAGGC CGAA IAAGACCC 8177 307 UGAUGAUC C CAGCAGGG 3122 CCCUGCUG CUGAUGAG GCCGUUAGGC CGAA IAUCAUCA 8178 308 GAUGAUCC C AGCAGGGA 3123 UCCCUGCU CUGAUGAG GCCGUUAGGC CGAA IGAUCAUC 8179 309 AUGAUCCC A GCAGGGAU 3124 AUCCCUGC CUGAUGAG GCCGUUAGGC CGAA IGGAUCAU 8180 312 AUCCCAGC A GGGAUCUA 3125 UAGAUCCC CUGAUGAG GCCGUUAGGC CGAA ICUGGGAU 8181 319 CAGGGAUC U AUGCACCC 3126 GGGUGCAU CUGAUGAG GCCGUUAGGC CGAA IAUCCCUG 8182 324 AUCUAUGC A CCCAUCUG 3127 CAGAUGGG CUGAUGAG GCCGUUAGGC CGAA ICAUAGAU 8183 326 CUAUGCAC C CAUCUGUG 3128 CACAGAUG CUGAUGAG GCCGUUAGGC CGAA IUGCAUAG 8184 327 UAUGCACC C AUCUGUGU 3129 ACACAGAU CUGAUGAG GCCGUUAGGC CGAA IGUGCAUA 8185 328 AUGCACCC A UCUGUGUG 3130 CACACAGA CUGAUGAG GCCGUUAGGC CGAA IGGUGCAU 8186 331 CACCCAUC U GUGUGACU 3131 AGUCACAC CUGAUGAG GCCGUUAGGC CGAA IAUGGGUG 8187 339 UGUGUGAC U GUGUGGUA 3132 UACCACAC CUGAUGAG GCCGUUAGGC CGAA IUCACACA 8188 349 UGUGGUAC C CUCUCUGG 3133 CCAGAGAG CUGAUGAG GCCGUUAGGC CGAA IUACCACA 8189 350 GUGGUACC C UCUCUGGG 3134 CCCAGAGA CUGAUGAG GCCGUUAGGC CGAA IGUACCAC 8190 351 UGGUACCC U CUCUGGGG 3135 CCCCAGAG CUGAUGAG GCCGUUAGGC CGAA IGGUACCA 8191 353 GUACCCUC U CUGGGGAG 3136 CUCCCCAG CUGAUGAG GCCGUUAGGC CGAA IAGGGUAC 8192 355 ACCCUCUC u GGGGAGGC 3137 GCCUCCCC CUGAUGAG GCCGUUAGGC CGAA IAGAGGGU 8193 364 GGGGAGGC A UUAUGUAU 3138 AUACAUAA CUGAUGAG GCCGUUAGGC CGAA ICCUCCCC 8194 381 AUUAUUUC C GGAUCACU 3139 AGUGAUCC CUGAUGAG GCCGUUAGGC CGAA IAAAUAAU 8195 387 UCCGGAUC A CUCCUGGC 3140 GCCAGGAG CUGAUGAG GCCGUUAGGC CGAA IAUCCGGA 8196 389 CGGAUCAC U CCUGGCAG 3141 CUGCCAGG CUGAUGAG GCCGUUAGGC CGAA IUGAUCCG 8197 391 GAUCACUC C UGGCAGCA 3142 UGCUGCCA CUGAUGAG GCCGUUAGGC CGAA IAGUGAUC 8198 392 AUCACUCC U GGCAGCAA 3143 UUGCUGCC CUGAUGAG GCCGUUAGGC CGAA IGAGUGAU 8199 396 CUCCUGGC A GCAACGGA 3144 UCCGUUGC CUGAUGAG GCCGUUAGGC CGAA ICCAGGAG 8200 399 CUGGCAGC A ACGGAGAA 3145 UUCUCCGU CUGAUGAG GCCGUUAGGC CGAA ICUGCCAG 8201 412 AGAAAAAC U CCAGGAAG 3146 CUUCCUGG CUGAUGAG GCCGUUAGGC CGAA IUUUUUCU 8202 414 AAAAACUC C AGGAAGUG 3147 CACUUCCU CUGAUGAG GCCGUUAGGC CGAA IAGUUUUU 8203 415 AAAACUCC A GGAAGUGU 3148 ACACUUCC CUGAUGAG GCCGUUAGGC CGAA IGAGUUUU 8204 430 GUUUGGUC A AAGGAAAA 3149 UUUUCCUU CUGAUGAG GCCGUUAGGC CGAA IACCAAAC 8205 453 AUGAAUUC A UUGAGCCU 3150 AGGCUCAA CUGAUGAG GCCGUUAGGC CGAA IAAUUCAU 8206 460 CAUUGAGC C UCUUUGCU 3151 AGCAAAGA CUGAUGAG GCCGUUAGGC CGAA ICUCAAUG 8207 461 AUUGAGCC U CUUUGCUG 3152 CAGCAAAG CUGAUGAG GCCGUUAGGC CGAA IGCUCAAU 8208 463 UGAGCCUC U UUGGUGCC 3153 GGCAGCAA CUGAUGAG GCCGUUAGGC CGAA IAGGCUCA 8209 468 CUCUUUGC U GCCAUUUC 3154 GAAAUGGC CUGAUGAG GCCGUUAGGC CGAA ICAAAGAG 8210 471 UUUGCUGC C AUUUCUGG 3155 CCAGAAAU CUGAUGAG GCCGUUAGGC CGAA ICAGCAAA 8211 472 UUGGUGCC A UUUCUGGA 3156 UCCAGAAA CUGAUGAG GCCGUUAGGC CGAA IGCAGCAA 8212 477 GCCAUUUC U GGAAUGAU 3157 AUCAUUCC CUGAUGAG GCCGUUAGGC CGAA IAAAUGGC 8213 488 AAUGAUUC U UUCAAUCA 3158 UGAUUGAA CUGAUGAG GCCGUUAGGC CGAA IAAUCAUU 8214 492 AUUCUUUC A AUCAUGGA 3159 UCCAUGAU CUGAUGAG GCCGUUAGGC CGAA IAAAGAAU 8215 496 UUUCAAUC A UGGACAUA 3160 UAUGUCCA CUGAUGAG GCCGUUAGGC CGAA IAUUGAAA 8216 502 UCAUGGAC A UACUUAAU 3161 AUUAAGUA CUGAUGAG GCCGUUAGGC CGAA IUCCAUGA 8217 506 GGACAUAC U UAAUAUUA 3162 UAAUAUUA CUGAUGAG GCCGUUAGGC CGAA IUAUGUCC 8218 522 AAAAUUUC C CAUUUUUU 3163 AAAAAAUG CUGAUGAG GCCGUUAGGC CGAA IAAAUUUU 8219 523 AAAUUUCC C AUUUUUUA 3164 UAAAAAAU CUGAUGAG GCCGUUAGGC CGAA IGAAAUUU 8220 524 AAUUUCCC A UUUUUUAA 3165 UUAAAAAA CUGAUGAG GCCGUUAGGC CGAA IGGAAAUU 8221 545 GGAGAGUC U GAAUUUUA 3166 UAAAAUUC CUGAUGAG GCCGUUAGGC CGAA IACUCUCC 8222 561 AUUAGAGC U CACACACC 3167 GGUGUGUG CUGAUGAG GCCGUUAGGC CGAA ICUCUAAU 8223 563 UAGAGCUC A CACACCAU 3168 AUGGUGUG CUGAUGAG GCCGUUAGGC CGAA IAGCUCUA 8224 565 GAGCUCAC A CACCAUAU 3169 AUAUGGUG CUGAUGAG GCCGUUAGGC CGAA IUGAGCUC 8225 567 GCUCACAC A CCAUAUAU 3170 AUAUAUGG CUGAUGAG GCCGUUAGGC CGAA IUGUGAGC 8226 569 UCACACAC C AUAUAUUA 3171 UAAUAUAU CUGAUGAG GCCGUUAGGC CGAA IUGUGUGA 8227 . 570 CACACACC A UAUAUUAA 3172 UUAAUAUA CUGAUGAG GCCGUUAGGC CGAA IGUGUGUG 8228 580 AUAUUAAC A UAUACAAC 3173 GUUGUAUA CUGAUGAG GCCGUUAGGC CGAA IUUAAUAU 8229 586 ACAUAUAC A ACUGUGAA 3174 UUCACAGU CUGAUGAG GCCGUUAGGC CGAA lUAUAUGU 8230 589 UAUACAAC U GUGAACCA 3175 UGGUUCAC CUGAUGAG GCCGUUAGGC CGAA lUUGUAUA 8231 596 CUGUGAAC C AGCUAAUC 3176 GAUUAGCU CUGAUGAG GCCGUUAGGC CGAA IUUCACAG 8232 597 UGUGAACC A GCUAAUCC 3177 GGAUUAGC CUGAUGAG GCCGUUAGGC CGAA IGUUCACA 8233 600 GAACCAGC U AAUCCCUC 3178 GAGGGAUU CUGAUGAG GCCGUUAGGC CGAA ICUGGUUC 8234 605 AGCUAAUC C CUCUGAGA 3179 UCUCAGAG CUGAUGAG GCCGUUAGGC CGAA IAUUAGCU 8235 606 GCUAAUCC C UCUGAGAA 3180 UUCUCAGA CUGAUGAG GCCGUUAGGC CGAA IGAUUAGC 8236 607 CUAAUCCC U CUGAGAAA 3181 UUUCUCAG CUGAUGAG GCCGUUAGGC CGAA IGGAUUAG 8237 609 AAUCCCUC u GAGAAAAA 3182 UUUUUCUC CUGAUGAG GCCGUUAGGC CGAA IAGGGAUU 8238 619 AGAAAAAC u CCGCAUCU 3183 AGAUGGGG CUGAUGAG GCCGUUAGGC CGAA IUUUUUCU 8239 621 AAAAACUC c CCAUCUAC 3184 GUAGAUGG CUGAUGAG GCCGUUAGGC CGAA IAGUUUUU 8240 622 AAAACUCC c CAUCUACC 3185 GGUAGAUG CUGAUGAG GCCGUUAGGC CGAA IGAGUUUU 8241 623 AAACUCCC c AUCUACCC 3186 GGGUAGAU CUGAUGAG GCCGUUAGGC CGAA IGGAGUUU 8242 624 AACUCCCC A UCUACCCA 3187 UGGGUAGA CUGAUGAG GCCGUUAGGC CGAA IGGGAGUU 8243 627 UCCCCAUC U ACCCAAUA 3188 UAUUGGGU CUGAUGAG GCCGUUAGGC CGAA IAUGGGGA 8244 630 CCAUCUAC c CAAUACUG 3189 CAGUAUUG CUGAUGAG GCCGUUAGGC CGAA IUAGAUGG 8245 631 CAUCUACC c AAUACUGU 3190 ACAGUAUU CUGAUGAG GCCGUUAGGC CGAA IGUAGAUG 8246 632 AUCUACCC A AUACUGUU 3191 AACAGUAU CUGAUGAG GCCGUUAGGC CGAA IGGUAGAU 8247 637 CCCAAUAC U GUUACAGC 3192 GCUGUAAC CUGAUGAG GCCGUUAGGC CGAA IUAUUGGG 8248 643 ACUGUUAC A GCAUACAA 3193 UUGUAUGC CUGAUGAG GCCGUUAGGC CGAA IUAACAGU 8249 646 GUUACAGC A UACAAUCU 3194 AGAUUGUA CUGAUGAG GCCGUUAGGC CGAA ICUGUAAC 8250 650 CAGCAUAC A AUCUCUGU 3195 ACAGAGAU CUGAUGAG GCCGUUAGGC CGAA IUAUGCUG 8251 654 AUACAAUC U CUGUUCUU 3196 AAGAACAG CUGAUGAG GCCGUUAGGC CGAA IAUUGUAU 8252 656 ACAAUCUC U GUUCUUGG 3197 CCAAGAAC CUGAUGAG GCCGUUAGGC CGAA IAGAUUGU 8253 661 CUCUGUUC U UGGGCAUU 3198 AAUGCCCA CUGAUGAG GCCGUUAGGC CGAA IAACAGAG 8254 667 UCUUGGGC A UUUUGUCA 3199 UGACAAAA CUGAUGAG GCCGUUAGGC CGAA ICCCAAGA 8255 675 AUUUUGUC A GUGAUGCU 3200 AGCAUCAC CUGAUGAG GCCGUUAGGC CGAA IACAAAAU 8256 683 AGUGAUGC U GAUCUUUG 3201 CAAAGAUC CUGAUGAG GCCGUUAGGC CGAA ICAUCACU 8257 688 UGCUGAUC U UUGCCUUC 3202 GAAGGCAA CUGAUGAG GCCGUUAGGC CGAA IAUCAGCA 8258 693 AUCUUUGC C UUCUUCCA 3203 UGGAAGAA CUGAUGAG GCCGUUAGGC CGAA ICAAAGAU 8259 694 UCUUUGCC U UCUUCCAG 3204 CUGGAAGA CUGAUGAG GCCGUUAGGC CGAA IGCAAAGA 8260 697 UUGCCUUC U UCCAGGAA 3205 UUCCUGGA CUGAUGAG GCCGUUAGGC CGAA IAAGGCAA 8261 700 CCUUCUUC C AGGAACUU 3206 AAGUUGCU CUGAUGAG GCCGUUAGGC CGAA IAAGAAGG 8262 701 cuucuucc A GGAACUUG 3207 CAAGUUCC CUGAUGAG GCCGUUAGGC CGAA IGAAGAAG 8263 707 CCAGGAAC U UGUAAUAG 3208 CUAUUACA CUGAUGAG GCCGUUAGGC CGAA IUUCCUGG 8264 717 GUAAUAGC U GGCAUCGU 3209 ACGAUGCC CUGAUGAG GCCGUUAGGC CGAA ICUAUUAC 8265 721 UAGCUGGC A UCGUUGAG 3210 CUCAACGA CUGAUGAG GCCGUUAGGC CGAA ICCAGCUA 8266 751 GAACGUGC U CCAGACCC 3211 GGGUCUGG CUGAUGAG GCCGUUAGGC CGAA ICACGUUC 8267 753 ACGUGCUC C AGACCCAA 3212 UUGGGUCU CUGAUGAG GCCGUUAGGC CGAA IAGCACGU 8268 754 CGUGCUCC A GACCCAAA 3213 UUUGGGUC CUGAUGAG GCCGUUAGGC CGAA IGAGCACG 8269 758 CUCCAGAC C CAAAUCUA 3214 UAGAUUUG CUGAUGAG GCCGUUAGGC CGAA IUCUGGAG 8270 759 UCCAGACC C AAAUCUAA 3215 UUAGAUUU CUGAUGAG GCCGUUAGGC CGAA IGUCUGGA 8271 760 CCAGACCC A AAUCUAAC 3216 GUUAGAUU CUGAUGAG GCCGUUAGGC CGAA IGGUCUGG 8272 765 CCCAAAUC U AAGAUAGU 3217 ACUAUGUU CUGAUGAG GCCGUUAGGC CGAA IAUUUGGG 8273 769 AAUCUAAC A UAGUUCUC 3218 GAGAACUA CUGAUGAG GCCGUUAGGC CGAA IUUAGAUU 8274 776 CAUAGUUC U CCUGUCAG 3219 CUGACAGG CUGAUGAG GCCGUUAGGC CGAA IAACUAUG 8275 778 UAGUUCUC C UGUCAGCA 3220 UGCUGACA CUGAUGAG GCCGUUAGGC CGAA IAGAACUA 8276 779 AGUUCUCC U GUCAGCAG 3221 CUGCUGAC CUGAUGAG GCCGUUAGGC CGAA IGAGAACU 8277 783 CUCCUGUC A GCAGAAGA 3222 UCUUCUGC CUGAUGAG GCCGUUAGGC CGAA IACAGGAG 8278 786 CUGUCAGC A GAAGAAAA 3223 UUUUCUUC CUGAUGAG GCCGUUAGGC CGAA ICUGACAG 8279 803 AAAAGAAC A GACUAUUG 3224 CAAUAGUC CUGAUGAG GCCGUUAGGC CGAA IUUCUUUU 8280 807 GAACAGAC U AUUGAAAU 3225 AUUUCAAU CUGAUGAG GCCGUUAGGC CGAA IUCUGUUC 8281 836 GGUUGGGC U AACUGAAA 3226 UUUCAGUU CUGAUGAG GCCGUUAGGC CGAA ICCCAACC 8282 840 GGGCUAAC U GAAACAUC 3227 GAUGUUUC CUGAUGAG GCCGUUAGGC CGAA IUUAGCCC 8283 846 ACUGAAAC A UCUUCCCA 3228 UGGGAAGA CUGAUGAG GCCGUUAGGC CGAA IUUUCAGU 8284 849 GAAACAUC U UCCCAACC 3229 GGUUGGGA CUGAUGAG GCCGUUAGGC CGAA IAUGUUUC 8285 852 ACAUCUUC C CAACCAAA 3230 UUUGGUUG CUGAUGAG GCCGUUAGGC CGAA IAAGAUGU 8286 853 CAUCUUCC C AACCAAAG 3231 CUUUGGUU CUGAUGAG GCCGUUAGGC CGAA IGAAGAUG 8287 854 AUCUUCCC A ACCAAAGA 3232 UGUUUGGU CUGAUGAG GCCGUUAGGC CGAA IGGAAGAU 8288 857 UUCCCAAC C AAAGAAUG 3233 CAUUCUUU CUGAUGAG GCCGUUAGGC CGAA IUUGGGAA 8289 858 UCCCAACC A AAGAAUGA 3234 UCAUUCUU CUGAUGAG GCCGUUAGGC CGAA IGUUGGGA 8290 874 AAGAAGAC A UUGAAAUU 3235 AAUUUCAA CUGAUGAG GCCGUUAGGC CGAA IUCUUCUU 8291 887 AAUUAUUC C AAUCCAAG 3236 CUUGGAUU CUGAUGAG GCCGUUAGGC CGAA IAAUAAUU 8292 888 AUUAUUCC A AUCCAAGA 3237 UCUUGGAU CUGAUGAG GCCGUUAGGC CGAA IGAAUAAU 8293 892 UUCCAAUC C AAGAAGAG 3238 CUCUUCUU CUGAUGAG GCCGUUAGGC CGAA IAUUGGAA 8294 893 UCCAAUCC A AGAAGAGG 3239 CCUCUUCU CUGAUGAG GCCGUUAGGC CGAA IGAUUGGA 8295 915 GAAGAAAC A GAGACGAA 3240 UUCGUCUC CUGAUGAG GCCGUUAGGC CGAA IUUUCUUC 8296 925 AGACGAAC U UUCCAGAA 3241 UUCUGGAA CUGAUGAG GCCGUUAGGC CGAA lUUCGUCU 8297 929 GAACUUUC C AGAACCUC 3242 GAGGUUCU CUGAUGAG GCCGUUAGGC CGAA IAAAGUUC 8298 930 AACUUUCC A GAACCUCC 3243 GGAGGUUC CUGAUGAG GCCGUUAGGC CGAA IGAAAGUU 8299 935 UCCAGAAC C UCCCCAAG 3244 CUUGGGGA CUGAUGAG GCCGUUAGGC CGAA IUUCUGGA 8300 936 CCAGAACC U CCCCAAGA 3245 UCUUGGGG CUGAUGAG GCCGUUAGGC CGAA IGUUCUGG 8301 938 AGAACCUC c CCAAGAUC 3246 GAUCUUGG CUGAUGAG GCCGUUAGGC CGAA IAGGUUCU 8302 939 GAACCUCC c CAAGAUCA 3247 UGAUCUUG CUGAUGAG GCCGUUAGGC CGAA IGAGGUUC 8303 940 AACCUCCC c AAGAUCAG 3248 CUGAUCUU CUGAUGAG GCCGUUAGGC CGAA IGGAGGUU 8304 941 ACCUCCCC A AGAUCAGG 3249 CCUGAUCU CUGAUGAG GCCGUUAGGC CGAA IGGGAGGU 8305 947 CCAAGAUC A GGAAUCCU 3250 AGGAUUCC CUGAUGAG GCCGUUAGGC CGAA IAUCUUGG 8306 954 CAGGAAUC C UCACCAAU 3251 AUUGGUGA CUGAUGAG GCCGUUAGGC CGAA IAUUCCUG 8307 955 AGGAAUCC U CACCAAUA 3252 UAUUGGUG CUGAUGAG GCCGUUAGGC CGAA IGAUUCCU 8308 957 GAAUCCUC A CCAAUAGA 3253 UCUAUUGG CUGAUGAG GCCGUUAGGC CGAA IAGGAUUC 8309 959 AUCCUCAC C AAUAGAAA 3254 UUUCUAUU CUGAUGAG GCCGUUAGGC CGAA IUGAGGAU 8310 960 UCCUCACC A AUAGAAAA 3255 UUUUCUAU CUGAUGAG GCCGUUAGGC CGAA IGUGAGGA 8311 973 AAAAUGAC A GCUCUCCU 3256 AGGAGAGC CUGAUGAG GCCGUUAGGC CGAA IUCAUUUU 8312 976 AUGACAGC U CUCCUUAA 3257 UUAAGGAG CUGAUGAG GCCGUUAGGC CGAA ICUGUCAU 8313 978 GACAGCUC U CCUUAAGU 3258 ACUUAAGG CUGAUGAG GCCGUUAGGC CGAA IAGCUGUC 8314 980 CAGCUCUC C UUAAGUGA 3259 UCACUUAA CUGAUGAG GCCGUUAGGC CGAA IAGAGCUG 8315 981 AGCUCUCC U UAAGUGAU 3260 AUCACUUA CUGAUGAG GCCGUUAGGC CGAA IGAGAGCU 8316 993 GUGAUUUC U UCUGUUUU 3261 AAAACAGA CUGAUGAG GCCGUUAGGC CGAA IAAAUCAC 8317 996 AUUUCUUC U GUUUUCUG 3262 CAGAAAAC CUGAUGAG GCCGUUAGGC CGAA IAAGAAAU 8318 1003 CUGUUUUC U GUUUCCUU 3263 AAGGAAAC CUGAUGAG GCCGUUAGGC CGAA IAAAACAG 8319 1009 UCUGUUUC c UUUUUUAA 3264 UUAAAAAA CUGAUGAG GCCGUUAGGC CGAA IAAACAGA 8320 1010 CUGUUUCC u UUUUUAAA 3265 UUUAAAAA CUGAUGAG GCCGUUAGGC CGAA IGAAACAG 8321 1020 UUUUAAAC A UUAGUGUU 3266 AACACUAA CUGAUGAG GCCGUUAGGC CGAA lUUUAAAA 8322 1030 UAGUGUUC A UAGCUUCC 3267 GGAAGCUA CUGAUGAG GCCGUUAGGC CGAA IAACACUA 8323 1035 UUCAUAGC U UCCAAGAG 3268 CUCUUGGA CUGAUGAG GCCGUUAGGC CGAA ICUAUGAA 8324 1038 AUAGCUUC c AAGAGACA 3269 UGUCUCUU CUGAUGAG GCCGUUAGGC CGAA IAAGCUAU 8325 1039 UAGCUUCC A AGAGACAU 3270 AUGUCUCU CUGAUGAG GCCGUUAGGC CGAA IGAAGCUA 8326 1046 CAAGAGAC A UGCUGACU 3271 AGUCAGCA CUGAUGAG GCCGUUAGGC CGAA IUCUCUUG 8327 1050 AGACAUGC U GACUUUCA 3272 UGAAAGUC CUGAUGAG GCCGUUAGGC CGAA ICAUGUCU 8328 1054 AUGCUGAC U UUCAUUUC 3273 GAAAUGAA CUGAUGAG GCCGUUAGGC CGAA IUCAGCAU 8329 1058 UGACUUUC A UUUCUUGA 3274 UCAAGAAA CUGAUGAG GCCGUUAGGC CGAA lAAAGUCA 8330 1063 UUCAUUUC U UGAGGUAC 3275 GUACCUCA CUGAUGAG GCCGUUAGGC CGAA IAAAUGAA 8331 1072 UGAGGUAC U CUGCACAU 3276 AUGUGCAG CUGAUGAG GCCGUUAGGC CGAA IUACCUCA 8332 1074 AGGUACUC U GCACAUAC 3277 GUAUGUGC CUGAUGAG GCCGUUAGGC CGAA IAGUACCU 8333 1077 UACUCUGC A CAUACGCA 3278 UGCGUAUG CUGAUGAG GCCGUUAGGC CGAA ICAGAGUA 8334 1079 CUCUGCAC A UACGCACC 3279 GGUGCGUA CUGAUGAG GCCGUUAGGC CGAA IUGCAGAG 8335 1085 ACAUACGC A CCACAUCU 3280 AGAUGUGG CUGAUGAG GCCGUUAGGC CGAA ICGUAUGU 8336 1087 AUACGCAC C ACAUCUCU 3281 AGAGAUGU CUGAUGAG GCCGUUAGGC CGAA IUGCGUAU 8337 1088 UACGCACC A CAUCUCUA 3282 UAGAGAUG CUGAUGAG GCCGUUAGGC CGAA IGUGCGUA 8338 1090 CGCACCAC A UCUCUAUC 3283 GAUAGAGA CUGAUGAG GCCGUUAGGC CGAA IUGGUGCG 8339 1093 ACCACAUC U CUAUCUGG 3284 CCAGAUAG CUGAUGAG GCCGUUAGGC CGAA IAUGUGGU 8340 1095 CACAUCUC U AUCUGGCC 3285 GGCCAGAU CUGAUGAG GCCGUUAGGC CGAA IAGAUGUG 8341 1099 UCUCUAUC U GGCCUUUG 3286 CAAAGGCC CUGAUGAG GCCGUUAGGC CGAA IAUAGAGA 8342 1103 UAUCUGGC C UUUGCAUG 3287 CAUGCAAA CUGAUGAG GCCGUUAGGC CGAA ICCAGAUA 8343 1104 AUCUGGCC U UUGCAUGG 3288 CCAUGCAA CUGAUGAG GCCGUUAGGC CGAA IGCCAGAU 8344 1109 GCCUUUGC A UGGAGUGA 3289 UCACUCCA CUGAUGAG GCCGUUAGGC CGAA ICAAAGGC 8345 1119 GGAGUGAC C AUAGCUCC 3290 GGAGCUAU CUGAUGAG GCCGUUAGGC CGAA IUCACUCC 8346 1120 GAGUGACC A UAGCUCCU 3291 AGGAGCUA CUGAUGAG GCCGUUAGGC CGAA IGUCACUC 8347 1125 ACCAUAGC U CCUUCUCU 3292 AGAGAAGG CUGAUGAG GCCGUUAGGC CGAA ICUAUGGU 8348 1127 CAUAGCUC C UUCUCUCU 3293 AGAGAGAA CUGAUGAG GCCGUUAGGC CGAA IAGCUAUG 8349 1128 AUAGCUCC U UCUCUCUU 3294 AAGAGAGA CUGAUGAG GCCGUUAGGC CGAA IGAGCUAU 8350 1131 GCUCCUUC U CUCUUACA 3295 UGUAAGAG CUGAUGAG GCCGUUAGGC CGAA IAAGGAGC 8351 1133 UCCUUCUC U CUUACAUU 3296 AAUGUAAG CUGAUGAG GCCGUUAGGC CGAA IAGAAGGA 8352 1135 CUUCUCUC U UACAUUGA 3297 UCAAUGUA CUGAUGAG GCCGUUAGGC CGAA IAGAGAAG 8353 1139 UCUCUUAC A UUGAAUGU 3298 ACAUUCAA CUGAUGAG GCCGUUAGGC CGAA lUAAGAGA 8354 1160 AAUGUAGC C AUUGUAGC 3299 GCUACAAU CUGAUGAG GCCGUUAGGC CGAA ICUACAUU 8355 1161 AUGUAGCC A UUGUAGCA 3300 UGCUACAA CUGAUGAG GCCGUUAGGC CGAA IGCUACAU 8356 1169 AUUGUAGC A GCUUGUGU 3301 ACACAAGC CUGAUGAG GCCGUUAGGC CGAA ICUACAAU 8357 1172 GUAGCAGC U UGUGUUGU 3302 ACAACACA CUGAUGAG GCCGUUAGGC CGAA ICUGCUAC 8358 1182 GUGUUGUC A CGCUUCUU 3303 AAGAAGCG CUGAUGAG GCCGUUAGGC CGAA IACAACAC 8359 1186 UGUCACGC U UCUUCUUU 3304 AAAGAAGA CUGAUGAG GCCGUUAGGC CGAA ICGUGACA 8360 1189 CACGCUUC U UCUUUUGA 3305 UCAAAAGA CUGAUGAG GCCGUUAGGC CGAA IAAGCGUG 8361 1192 GCUUCUUC U UUUGAGCA 3306 UGCUCAAA CUGAUGAG GCCGUUAGGC CGAA IAAGAAGC 8362 1200 UUUUGAGC A ACUUUCUU 3307 AAGAAAGU CUGAUGAG GCCGUUAGGC CGAA ICUCAAAA 8363 1203 UGAGCAAC U UUCUUACA 3308 UGUAAGAA CUGAUGAG GCCGUUAGGC CGAA IUUGCUCA 8364 1207 CAACUUUC U UACACUGA 3309 UCAGUGUA CUGAUGAG GCCGUUAGGC CGAA IAAAGUUG 8365 1211 UUUCUUAC A CUGAAGAA 3310 UUCUUCAG CUGAUGAG GCCGUUAGGC CGAA lUAAGAAA 8366 1213 UCUUACAC U GAAGAAAG 3311 CUUUCUUC CUGAUGAG GCCGUUAGGC CGAA IUGUAAGA 8367 1224 AGAAAGGC A GAAUGAGU 3312 ACUCAUUC CUGAUGAG GCCGUUAGGC CGAA ICCUUUCU 8368 1235 AUGAGUGC U UCAGAAUG 3313 CAUUGUGA CUGAUGAG GCCGUUAGGC CGAA ICACUCAU 8369 1238 AGUGCUUC A GAAUGUGA 3314 UCACAUUC CUGAUGAG GCCGUUAGGC CGAA lAAGCACU 8370 1251 GUGAUUUC C UACUAACC 3315 GGUUAGUA CUGAUGAG GCCGUUAGGC CGAA IAAAUCAC 8371 1252 UGAUUUCC U ACUAACCU 3316 AGGUUAGU CUGAUGAG GCCGUUAGGC CGAA IGAAAUCA 8372 1255 UUUCCUAC u AACCUGUU 3317 AACAGGUU CUGAUGAG GCCGUUAGGC CGAA lUAGGAAA 8373 1259 CUACUAAC c UGUUCCUU 3318 AAGGAACA CUGAUGAG GCCGUUAGGC CGAA IUUAGUAG 8374 1260 UACUAACC u GUUCCUUG 3319 CAAGGAAC CUGAUGAG GCCGUUAGGC CGAA IGUUAGUA 8375 1265 ACCUGUUC c UUGGAUAG 3320 CUAUCCAA CUGAUGAG GCCGUUAGGC CGAA IAACAGGU 8376 1266 CCUGUUCC u UGGAUAGG 3321 CCUAUCCA CUGAUGAG GCCGUUAGGC CGAA IGAACAGG 8377 1276 GGAUAGGC u UUUUAGUA 3322 UACUAAAA CUGAUGAG GCCGUUAGGC CGAA ICCUAUCC 8378 1302 UUUUUGUC A UUUUCUCC 3323 GGAGAAAA CUGAUGAG GCCGUUAGGC CGAA IACAAAAA 8379 1308 UCAUUUUC U CCAUCAGC 3324 GCUGAUGG CUGAUGAG GCCGUUAGGC CGAA IAAAAUGA 8380 1310 AUUUUCUC c AUCAGCAA 3325 UUGCUGAU CUGAUGAG GCCGUUAGGC CGAA IAGAAAAU 8381 1311 UUUUCUCC A UCAGCAAC 3326 GUUGCUGA CUGAUGAG GCCGUUAGGC CGAA IGAGAAAA 8382 1314 UCUCCAUC A GCAACCAG 3327 CUGGUUGC CUGAUGAG GCCGUUAGGC CGAA IAUGGAGA 8383 1317 CCAUCAGC A ACCAGGGA 3328 UCCCUGGU CUGAUGAG GCCGUUAGGC CGAA ICUGAUGG 8384 1320 UCAGCAAC C AGGGAGAC 3329 GUCUCCCU CUGAUGAG GCCGUUAGGC CGAA IUUGCUGA 8385 1321 CAGCAACC A GGGAGACU 3330 AGUCUCCC CUGAUGAG GCCGUUAGGC CGAA IGUUGCUG 8386 1329 AGGGAGAC U GCACCUGA 3331 UCAGGUGC CUGAUGAG GCCGUUAGGC CGAA IUCUCCCU 8387 1332 GAGACUGC A CCUGAUGG 3332 CCAUCAGG CUGAUGAG GCCGUUAGGC CGAA ICAGUCUC 8388 1334 GACUGCAC C UGAUGGAA 3333 UUCCAUCA CUGAUGAG GCCGUUAGGC CGAA IUGCAGUC 8389 1335 ACUGCACC U GAUGGAAA 3334 UUUCCAUC CUGAUGAG GCCGUUAGGC CGAA IGUGCAGU 8390 1355 UAUAUGAC U GCUUCAUG 3335 CAUGAAGC CUGAUGAG GCCGUUAGGC CGAA IUCAUAUA 8391 1358 AUGAGUGC U UCAUGACA 3336 UGUCAUGA CUGAUGAG GCCGUUAGGC CGAA ICAGUCAU 8392 1361 ACUGCUUC A UGACAUUC 3337 GAAUGUCA CUGAUGAG GCCGUUAGGC CGAA IAAGCAGU 8393 1366 UUCAUGAC A UUCCUAAA 3338 UUUAGGAA CUGAUGAG GCCGUUAGGC CGAA IUCAUGAA 8394 1370 UGACAUUC C UAAACUAU 3339 AUAGUUUA CUGAUGAG GCCGUUAGGC CGAA IAAUGUCA 8395 1371 GACAUUCC U AAACUAUC 3340 GAUAGUUU CUGAUGAG GCCGUUAGGC CGAA IGAAUGUC 8396 1376 UCCUAAAC U AUCUUUUU 3341 AAAAAGAU CUGAUGAG GCCGUUAGGC CGAA IUUUAGGA 8397 1380 AAACUAUC U UUUUUUUA 3342 UAAAAAAA CUGAUGAG GCCGUUAGGC CGAA IAUAGUUU 8398 1392 UUUUAUUC c ACAUCUAC 3343 GUAGAUGU CUGAUGAG GCCGUUAGGC CGAA IAAUAAAA 8399 1393 UUUAUUCC A CAUCUACG 3344 CGUAGAUG CUGAUGAG GCCGUUAGGC CGAA IGAAUAAA 8400 1395 UAUUCCAC A UCUACGUU 3345 AACGUAGA CUGAUGAG GCCGUUAGGC CGAA IUGGAAUA 8401 1398 UCCACAUC U ACGUUUUU 3346 AAAAACGU CUGAUGAG GCCGUUAGGC CGAA lAUGUGGA 8402 1416 GUGGAGUC C CUUUUGCA 3347 UGCAAAAG CUGAUGAG GCCGUUAGGC CGAA IACUCCAC 8403 1417 UGGAGUCC C UUUUGCAU 3348 AUGCAAAA CUGAUGAG GCCGUUAGGC CGAA IGACUCCA 8404 1418 GGAGUCCC u UUUGCAUC 3349 GAUGCAAA CUGAUGAG GCCGUUAGGC CGAA IGGACUCC 8405 1424 CCUUUUGC A UCAUUGUU 3350 AACAAUGA CUGAUGAG GCCGUUAGGC CGAA ICAAAAGG 8406 1427 UUUGCAUC A UUGUUUUA 3351 UAAAACAA CUGAUGAG GCCGUUAGGC CGAA IAUGCAAA 8407 1458 AAAAUAAC A ACUAGGGA 3352 UCCCUAGU CUGAUGAG GCCGUUAGGC CGAA IUUAUUUU 8408 1461 AUAACAAC U AGGGACAA 3353 UUGUCCCU CUGAUGAG GCCGUUAGGC CGAA IUUGUUAU 8409 1468 CUAGGGAC A AUACAGAA 3354 UUCUGUAU CUGAUGAG GCCGUUAGGC CGAA IUCCCUAG 8410 1473 GACAAUAC A GAACCCAU 3355 AUGGGUUC CUGAUGAG GCCGUUAGGC CGAA IUAUUGUC 8411 1478 UACAGAAC C CAUUCCAU 3356 AUGGAAUG CUGAUGAG GCCGUUAGGC CGAA IUUCUGUA 8412 1479 ACAGAACC C AUUCCAUU 3357 AAUGGAAU CUGAUGAG GCCGUUAGGC CGAA IGUUCUGU 8413 1480 CAGAACCC A UUCCAUUU 3358 AAAUGGAA CUGAUGAG GCCGUUAGGC CGAA IGGUUCUG 8414 1484 ACCCAUUC C AUUUAUCU 3359 AGAUAAAU CUGAUGAG GCCGUUAGGC CGAA IAAUGGGU 8415 1485 CCCAUUCC A UUUAUCUU 3360 AAGAUAAA CUGAUGAG GCCGUUAGGC CGAA IGAAUGGG 8416 1492 CAUUUAUC U UUCUACAG 3361 CUGUAGAA CUGAUGAG GCCGUUAGGC CGAA IAUAAAUG 8417 1496 UAUCUUUC U ACAGGGCU 3362 AGCCCUGU CUGAUGAG GCCGUUAGGC CGAA lAAAGAUA 8418 1499 CUUUCUAC A GGGCUGAC 3363 GUCAGCCC CUGAUGAG GCCGUUAGGC CGAA IUAGAAAG 8419 1504 UACAGGGC U GACAUUGU 3364 ACAAUGUC CUGAUGAG GCCGUUAGGC CGAA ICCCUGUA 8420 1508 GGGCUGAC A UUGUGGCA 3365 UGCCACAA CUGAUGAG GCCGUUAGGC CGAA IUCAGCCC 8421 1516 AUUGUGGC A CAUUCUUA 3366 UAAGAAUG CUGAUGAG GCCGUUAGGC CGAA ICCACAAU 8422 1518 UGUGGCAC A UUCUUAGA 3367 UCUAAGAA CUGAUGAG GCCGUUAGGC CGAA lUGCCACA 8423 1522 GCACAUUC U UAGAGUUA 3368 UAACUCUA CUGAUGAG GCCGUUAGGC CGAA IAAUGUGC 8424 1532 AGAGUUAC C ACACCCCA 3369 UGGGGUGU CUGAUGAG GCCGUUAGGC CGAA IUAACUCU 8425 1533 GAGUUACC A CACCCCAU 3370 AUGGGGUG CUGAUGAG GCCGUUAGGC CGAA IGUAACUC 8426 1535 GUUACCAC A CCCCAUGA 3371 UCAUGGGG CUGAUGAG GCCGUUAGGC CGAA IUGGUAAC 8427 1537 UACCACAC C CCAUGAGG 3372 CCUCAUGG CUGAUGAG GCCGUUAGGC CGAA IUGUGGUA 8428 1538 ACCACACC C CAUGAGGG 3373 CCCUCAUG CUGAUGAG GCCGUUAGGC CGAA IGUGUGGU 8429 1539 CCACACCC C AUGAGGGA 3374 UCCCUCAU CUGAUGAG GCCGUUAGGC CGAA IGGUGUGG 8430 1540 CACACCCC A UGAGGGAA 3375 UUCCCUCA CUGAUGAG GCCGUUAGGC CGAA IGGGUGUG 8431 1551 AGGGAAGC U CUAAAUAG 3376 CUAUUUAG CUGAUGAG GCCGUUAGGC CGAA ICUUCCCU 8432 1553 GGAAGCUC U AAAUAGCC 3377 GGCUAUUU CUGAUGAG GCCGUUAGGC CGAA IAGCUUCC 8433 1561 UAAAUAGC C AACACCCA 3378 UGGGUGUU CUGAUGAG GCCGUUAGGC CGAA ICUAUUUA 8434 1562 AAAUAGCC A ACACCCAU 3379 AUGGGUGU CUGAUGAG GCCGUUAGGC CGAA IGCUAUUU 8435 1565 UAGCCAAC A CCCAUCUG 3380 CAGAUGGG CUGAUGAG GCCGUUAGGC CGAA IUUGGCUA 8436 1567 GCCAACAC C CAUCUGUU 3381 AACAGAUG CUGAUGAG GCCGUUAGGC CGAA IUGUUGGC 8437 1568 CCAACACC C AUCUGUUU 3382 AAACAGAU CUGAUGAG GCCGUUAGGC CGAA IGUGUUGG 8438 1569 CAACACCC A UCUGUUUU 3383 AAAACAGA CUGAUGAG GCCGUUAGGC CGAA IGGUGUUG 8439 1572 CACCCAUC U GUUUUUUG 3384 CAAAAAAC CUGAUGAG GCCGUUAGGC CGAA IAUGGGUG 8440 1588 GUAAAAAC A GCAUAGCU 3385 AGCUAUGC CUGAUGAG GCCGUUAGGC CGAA IUUUUUAC 8441 Input Sequence = HSCD20A. Cut Site = CH/ . Stem Length = 8 . Core Sequence = CUGAUGAG GCCGUUAGGC CGAA HSCD20A (Human mRNA for CD20 receptor (S7) ; 1597 bp) Underlined region may be any X sequence or linker, as previously described herein. I = Inosine Table XI: Human CD20 G-Cleaver and Substrate Sequence Pos Substrate Seq ID G-Cleaver Seq ID 9 AACAAACU G CACCCACU 3386 AGUGGGUG UGAUG GCAUGCACUAUGC GCG AGUUUGUU 8442 18 CACCCACU G AACUCCGC 3387 GCGGAGUU UGAUG GCAUGCACUAUGC GCG AGUGGGUG 8443 25 UGAACUCC G CAGCUAGC 3388 GCUAGCUG UGAUG GCAUGCACUAUGC GCG GGAGUUCA 8444 50 CAGCCCUU G AGAUUUGA 3389 UCAAAUCU UGAUG GCAUGCACUAUGC GCG AAGGGCUG 8445 57 UGAGAUUU G AGGCCUUG 3390 CAAGGCCU UGAUG GCAUGCACUAUGC GCG AAAUCUCA 8446 82 GGAGUUUU G AGAGCAAA 3391 UUUGCUCU UGAUG GCAUGCACUAUGC GCG AAAACUCC 8447 93 AGCAAAAU G ACAACACC 3392 GGUGUUGU UGAUG GCAUGCACUAUGC GCG AUUUUGCU 8448 141 GAGCCAAU G AAAGGCCC 3393 GGGCCUUU UGAUG GCAUGCACUAUGC GCG AUUGGCUC 8449 154 GCCCUAUU G CUAUGCAA 3394 UUGCAUAG UGAUG GCAUGCACUAUGC GCG AAUAGGGC 8450 159 AUUGCUAU G CAAUCUGG 3395 CCAGAUUG UGAUG GCAUGCACUAUGC GCG AUAGCAAU 8451 213 GGCCCCAC G CAAAGCUU 3396 AAGCUUUG UGAUG GCAUGCACUAUGC GCG GUGGGGCC 8452 228 UUCUUCAU G AGGGAAUC 3397 GAUUCCCU UGAUG GCAUGCACUAUGC GCG AUGAAGAA 8453 264 CAGAUUAU G AAUGGGCU 3398 AGCCCAUU UGAUG GCAUGCACUAUGC GCG AUAAUCUG 8454 283 UCCACAUU G CCCUGGGG 3399 CCCCAGGG UGAUG GCAUGCACUAUGC GCG AAUGUGGA 8455 300 GGUCUUCU G AUGAUCCC 3400 GGGAUCAU UGAUG GCAUGCACUAUGC GCG AGAAGACC 8456 303 CUUCUGAU G AUCCCAGC 3401 GCUGGGAU UGAUG GCAUGCACUAUGC GCG AUCAGAAG 8457 322 GGAUCUAU G CACCCAUC 3402 GAUGGGUG UGAUG GCAUGCACUAUGC GCG AUAGAUCC 8458 336 AUCUGUGU G ACUGUGUG 3403 CACACAGU UGAUG GCAUGCACUAUGC GCG ACACAGAU 8459 441 GGAAAAAU G AUAAUGAA 3404 UUCAUUAU UGAUG GCAUGCACUAUGC GCG AUUUUUCC 8460 447 AUGAUAAU G AAUUCAUU 3405 AAUGAAUU UGAUG GCAUGCACUAUGC GCG AUUAUCAU 8461 456 AAUUCAUU G AGCCUCUU 3406 AAGAGGCU UGAUG GCAUGCACUAUGC GCG AAUGAAUU 8462 466 GCCUCUUU G CUGCCAUU 3407 AAUGGCAG UGAUG GCAUGCACUAUGC GCG AAAGAGGC 8463 469 UCUUUGCU G CCAUUUCU 3408 AGAAAUGG UGAUG GCAUGCACUAUGC GCG AGCAAAGA 8464 483 UCUGGAAU G AUUCUUUC 3409 GAAAGAAU UGAUG GCAUGCACUAUGC GCG AUUCCAGA 8465 546 GAGAGUCU G AAUUUUAU 3410 AUAAAAUU UGAUG GCAUGCACUAUGC GCG AGACUCUC 8466 592 ACAACUGU G AACCAGCU 3411 AGCUGGUU UGAUG GCAUGCACUAUGC GCG ACAGUUGU 8467 610 AUCCCUCU G AGAAAAAC 3412 GUUUUUCU UGAUG GCAUGCACUAUGC GCG AGAGGGAU 8468 678 UUGUCAGU G AUGGUGAU 3413 AUCAGCAU UGAUG GCAUGCACUAUGC GCG ACUGACAA 8469 681 UCAGUGAU G CUGAUCUU 3414 AAGAUCAG UGAUG GCAUGCACUAUGC GCG AUCACUGA 8470 684 GUGAUGCU G AUCUUUGC 3415 GCAAAGAU UGAUG GCAUGCACUAUGC GCG AGCAUCAC 8471 691 UGAUCUUU G CCUUCUUC 3416 GAAGAAGG UGAUG GCAUGCACUAUGC GCG AAAGAUCA 8472 727 GCAUCGUU G AGAAUGAA 3417 UUCAUUCU UGAUG GCAUGCACUAUGC GCG AACGAUGC 8473 733 UUGAGAAU G AAUGGAAA 3418 UUUCCAUU UGAUG GCAUGCACUAUGC GCG AUUCUCAA 8474 749 AAGAACGU G CUCCAGAC 3419 GUCUGGAG UGAUG GCAUGCACUAUGC GCG ACGUUCUU 8475 811 AGACUAUU G AAAUAAAA 3420 UUUUAUUU UGAUG GCAUGCACUAUGC GCG AAUAGUCU 8476 841 GGCUAACU G AAACAUCU 3421 AGAUGUUU UGAUG GCAUGCACUAUGC GCG AGUUAGCC 8477 865 CAAAGAAU G AAGAAGAC 3422 GUCUUCUU UGAUG GCAUGCACUAUGC GCG AUUCUUUG 8478 877 AAGACAUU G AAAUUAUU 3423 AAUAAUUU UGAUG GCAUGCACUAUGC GCG AAUGUCUU 8479 921 ACAGAGAC G AACUUUCC 3424 GGAAAGUU UGAUG GCAUGCACUAUGC GCG GUCUCUGU 8480 970 UAGAAAAU G ACAGCUCU 3425 AGAGCUGU UGAUG GCAUGCACUAUGC GCG AUUUUCUA 8481 987 CCUUAAGU G AUUUCUUC 3426 GAAGAAAU UGAUG GCAUGCACUAUGC GCG ACUUAAGG 8482 1048 AGAGACAU G CUGACUUU 3427 AAAGUCAG UGAUG GCAUGCACUAUGC GCG AUGUCUCU 8483 1051 GACAUGCU G ACUUUCAU 3428 AUGAAAGU UGAUG GCAUGCACUAUGC GCG AGCAUGUC 8484 1065 CAUUUCUU G AGGUACUC 3429 GAGUACCU UGAUG GCAUGCACUAUGC GCG AAGAAAUG 8485 1075 GGUACUCU G CACAUACG 3430 CGUAUGUG UGAUG GCAUGCACUAUGC GCG AGAGUACC 8486 1083 GCACAUAC G CACCACAU 3431 AUGUGGUG UGAUG GCAUGCACUAUGC GCG GUAUGUGC 8487 1107 UGGCCUUU G CAUGGAGU 3432 ACUCCAUG UGAUG GCAUGCACUAUGC GCG AAAGGCCA 8488 1116 CAUGGAGU G ACCAUAGC 3433 GCUAUGGU UGAUG GCAUGCACUAUGC GCG ACUCCAUG 8489 1142 CUUACAUU G AAUGUAGA 3434 UCUACAUU UGAUG GCAUGCACUAUGC GCG AAUGUAAG 8490 1184 GUUGUCAC G CUUCUUCU 3435 AGAAGAAG UGAUG GCAUGCACUAUGC GCG GUGACAAC 8491 1196 CUUCUUUU G AGCAACUU 3436 AAGUUGCU UGAUG GCAUGCACUAUGC GCG AAAAGAAG 8492 1214 CUUACACU G AAGAAAGG 3437 CCUUUCUU UGAUG GCAUGCACUAUGC GCG AGUGUAAG 8493 1229 GGCAGAAU G AGUGCUUC 3438 GAAGCACU UGAUG GCAUGCACUAUGC GCG AUUCUGCC 8494 1233 GAAUGAGU G CUUCAGAA 3439 UUCUGAAG UGAUG GCAUGCACUAUGC GCG ACUCAUUC 8495 1245 CAGAAUGU G AUUUCCUA 3440 UAGGAAAU UGAUG GCAUGCACUAUGC GCG ACAUUCUG 8496 1330 GGGAGACU G CACCUGAU 3441 AUCAGGUG UGAUG GCAUGCACUAUGC GCG AGUCUCCC 8497 1336 CUGCACCU G AUGGAAAA 3442 UUUUCCAU UGAUG GCAUGCACUAUGC GCG AGGUGCAG 8498 1352 AGAUAUAU G ACUGCUUC 3443 GAAGCAGU UGAUG GCAUGCACUAUGC GCG AUAUAUCU 8499 1356 AUAUGACU G CUUCAUGA 3444 UCAUGAAG UGAUG GCAUGCACUAUGC GCG AGUCAUAU 8500 1363 UGCUUCAU G ACAUUCCU 3445 AGGAAUGU UGAUG GCAUGCACUAUGC GCG AUGAAGCA 8501 Input Sequence = HSCD20A. Cut Site = YG/M or UG/U. Stem Length = 8. Core Sequence = UGAUG GCAUGCACUAUGC GCG HSCD20A (Human mRNA for CD20 receptor (S7) ; 1597 bp) Table XII: Human CD20 Zinzyme and Substrate Sequence Pos Substrate Seq ID Zinzyme Seq ID 9 AACAAACU G CACCCACU 3386 AGUGGGUG GCCGAAAGGCGAGUCAAGGUCU AGUUUGUU 8506 25 UGAACUCC G CAGCUAGC 3388 GCUAGCUG GCCGAAAGGCGAGUCAAGGUCU GGAGUUCA 8507 28 ACUCCGCA G CUAGCAUC 3450 GAUGCUAG GCCGAAAGGCGAGUCAAGGUCU UGCGGAGU 8508 32 CGCAGCUA G CAUCCAAA 3451 UUUGGAUG GCCGAAAGGCGAGUCAAGGUCU UAGCUGCG 8509 44 CCAAAUCA G CCCUUGAG 3452 CUCAAGGG GCCGAAAGGCGAGUCAAGGUCU UGAUUUGG 8510 60 GAUUUGAG G CCUUGGAG 3453 CUCCAAGG GCCGAAAGGCGAGUCAAGGUCU CUCAAAUC 8511 77 ACUCAGGA G UUUUGAGA 3454 UCUCAAAA GCCGAAAGGCGAGUCAAGGUCU UCCUGAGU 8512 86 UUUUGAGA G CAAAAUGA 3455 UCAUUUUG GCCGAAAGGCGAGUCAAGGUCU UCUCAAAA 8513 112 GAAAUUCA G UAAAUGGG 3456 CCCAUUUA GCCGAAAGGCGAGUCAAGGUCU UGAAUUUC 8514 130 CUUUCCUG G CAGAGCCA 3457 UGGCUCUG GCCGAAAGGCGAGUCAAGGUCU CAGGAAAG 8515 135 CUGGCAGA G CCAAUGAA 3458 UUCAUUGG GCCGAAAGGCGAGUCAAGGUCU UCUGCCAG 8516 146 AAUGAAAG G CCCUAUUG 3459 CAAUAGGG GCCGAAAGGCGAGUCAAGGUCU CUUUCAUU 8517 154 GCCCUAUU G CUAUGCAA 3394 UUGCAUAG GCCGAAAGGCGAGUCAAGGUCU AAUAGGGC 8518 159 AUUGCUAU G CAAUCUGG 3395 CCAGAUUG GCCGAAAGGCGAGUCAAGGUCU AUAGCAAU 8519 167 GCAAUCUG G UCCAAAAC 3460 GUUUUGGA GCCGAAAGGCGAGUCAAGGUCU CAGAUUGC 8520 192 AGGAGGAU G UCUUCACU 3461 AGUGAAGA GCCGAAAGGCGAGUCAAGGUCU AUCCUCCU 8521 202 CUUCACUG G UGGGCCCC 3462 GGGGCCCA GCCGAAAGGCGAGUCAAGGUCU CAGUGAAG 8522 206 ACUGGUGG G CCCCACGC 3463 GCGUGGGG GCCGAAAGGCGAGUCAAGGUCU CCACCAGU 8523 213 GGCCCCAC G CAAAGCUU 3396 AAGCUUUG GCCGAAAGGCGAGUCAAGGUCU GUGGGGCC 8524 218 CACGCAAA G CUUCUUCA 3464 UGAAGAAG GCCGAAAGGCGAGUCAAGGUCU UUUGCGUG 8525 250 CUUUGGGG G CUGUCCAG 3465 CUGGACAG GCCGAAAGGCGAGUCAAGGUCU CCCCAAAG 8526 253 UGGGGGCU G UCCAGAUU 3466 AAUCUGGA GCCGAAAGGCGAGUCAAGGUCU AGCCCCCA 8527 270 AUGAAUGG G CUCUUCCA 3467 UGGAAGAG GCCGAAAGGCGAGUCAAGGUCU CCAUUCAU 8528 283 UCCACAUU G CCCUGGGG 3399 CCCCAGGG GCCGAAAGGCGAGUCAAGGUCU AAUGUGGA 8529 293 CCUGGGGG G UCUUCUGA 3468 UCAGAAGA GCCGAAAGGCGAGUCAAGGUCU CCCCCAGG 8530 310 UGAUCCCA G CAGGGAUC 3469 GAUCCCUG GCCGAAAGGCGAGUCAAGGUCU UGGGAUCA 8531 322 GGAUCUAU G CACCCAUC 3402 GAUGGGUG GCCGAAAGGCGAGUCAAGGUCU AUAGAUCC 8532 332 ACCCAUCU G UGUGACUG 3470 CAGUCACA GCCGAAAGGCGAGUCAAGGUCU AGAUGGGU 8533 334 CCAUCUGU G UGACUGUG 3471 CACAGUCA GCCGAAAGGCGAGUCAAGGUCU ACAGAUGG 8534 340 GUGUGACU G UGUGGUAC 3472 GUACCACA GCCGAAAGGCGAGUCAAGGUCU AGUCACAC 8535 342 GUGACUGU G UGGUACCC 3473 GGGUACCA GCCGAAAGGCGAGUCAAGGUCU ACAGUCAC 8536 345 ACUGUGUG G UACCCUCU 3474 AGAGGGUA GCCGAAAGGCGAGUCAAGGUCU CACACAGU 8537 362 CUGGGGAG G CAUUAUGU 3475 ACAUAAUG GCCGAAAGGCGAGUCAAGGUCU CUCCCCAG 8538 369 GGCAUUAU G UAUAUUAU 3476 AUAAUAUA GCCGAAAGGCGAGUCAAGGUCU AUAAUGCC 8539 394 CACUCCUG G CAGCAACG 3477 CGUUGCUG GCCGAAAGGCGAGUCAAGGUCU CAGGAGUG 8540 397 UCCUGGCA G CAACGGAG 3478 CUCCGUUG GCCGAAAGGCGAGUCAAGGUCU UGCCAGGA 8541 420 UCCAGGAA G UGUUUGGU 3479 ACCAAACA GCCGAAAGGCGAGUCAAGGUCU UUCCUGGA 8542 422 CAGGAAGU G UUUGGUCA 3480 UGACCAAA GCCGAAAGGCGAGUCAAGGUCU ACUUCCUG 8543 427 AGUGUUUG G UCAAAGGA 3481 UCCUUUGA GCCGAAAGGCGAGUCAAGGUCU CAAACACU 8544 458 UUCAUUGA G CCUCUUUG 3482 CAAAGAGG GCCGAAAGGCGAGUCAAGGUCU UCAAUGAA 8545 466 GCCUCUUU G CUGCCAUU 3407 AAUGGCAG GCCGAAAGGCGAGUCAAGGUCU AAAGAGGC 8546 469 UCUUUGCU G CCAUUUCU 3408 AGAAAUGG GCCGAAAGGCGAGUCAAGGUCU AGCAAAGA 8547 542 AAUGGAGA G UCUGAAUU 3483 AAUUCAGA GCCGAAAGGCGAGUCAAGGUCU UCUCCAUU 8548 559 UUAUUAGA G CUCACACA 3484 UGUGUGAG GCCGAAAGGCGAGUCAAGGUCU UCUAAUAA 8549 590 AUACAACU G UGAACCAG 3485 CUGGUUCA GCCGAAAGGCGAGUCAAGGUCU AGUUGUAU 8550 598 GUGAACCA G CUAAUCCC 3486 GGGAUUAG GCCGAAAGGCGAGUCAAGGUCU UGGUUCAC 8551 638 CCAAUACU G UUACAGCA 3487 UGCUGUAA GCCGAAAGGCGAGUCAAGGUCU AGUAUUGG 8552 644 CUGUUACA G CAUACAAU 3488 AUUGUAUG GCCGAAAGGCGAGUCAAGGUCU UGUAACAG 8553 657 CAAUCUCU G UUCUUGGG 3489 CCCAAGAA GCCGAAAGGCGAGUCAAGGUCU AGAGAUUG 8554 665 GUUCUUGG G CAUUUUGU 3490 ACAAAAUG GCCGAAAGGCGAGUCAAGGUCU CCAAGAAC 8555 672 GGCAUUUU G UCAGUGAU 3491 AUCACUGA GCCGAAAGGCGAGUCAAGGUCU AAAAUGCC 8556 676 UUUUGUCA G UGAUGCUG 3492 CAGCAUCA GCCGAAAGGCGAGUCAAGGUCU UGACAAAA 8557 681 UCAGUGAU G CUGAUCUU 3414 AAGAUCAG GCCGAAAGGCGAGUCAAGGUCU AUCACUGA 8558 691 UGAUCUUU G CCUUCUUC 3416 GAAGAAGG GCCGAAAGGCGAGUCAAGGUCU AAAGAUCA 8559 709 AGGAACUU G UAAUAGCU 3493 AGCUAUUA GCCGAAAGGCGAGUCAAGGUCU AAGUUGCU 8560 715 UUGUAAUA G CUGGCAUC 3494 GAUGCCAG GCCGAAAGGCGAGUCAAGGUCU UAUUACAA 8561 719 AAUAGCUG G CAUCGUUG 3495 CAACGAUG GCCGAAAGGCGAGUCAAGGUCU CAGCUAUU 8562 724 CUGGCAUC G UUGAGAAU 3496 AUUCUCAA GCCGAAAGGCGAGUCAAGGUCU GAUGCCAG 8563 747 AAAAGAAC G UGCUCCAG 3497 CUGGAGCA GCCGAAAGGCGAGUCAAGGUCU GUUCUUUU 8564 749 AAGAACGU G CUCCAGAC 3419 GUCUGGAG GCCGAAAGGCGAGUCAAGGUCU ACGUUCUU 8565 772 CUAACAUA G UUCUCCUG 3498 CAGGAGAA GCCGAAAGGCGAGUCAAGGUCU UAUGUUAG 8566 780 GUUCUCCU G UCAGCAGA 3499 UCUGCUGA GCCGAAAGGCGAGUCAAGGUCU AGGAGAAC 8567 784 UCCUGUCA G CAGAAGAA 3500 UUCUUCUG GCCGAAAGGCGAGUCAAGGUCU UGACAGGA 8568 826 AAGAAGAA G UGGUUGGG 3501 CCCAACCA GCCGAAAGGCGAGUCAAGGUCU UUCUUCUU 8569 829 AAGAAGUG G UUGGGCUA 3502 UAGCCCAA GCCGAAAGGCGAGUCAAGGUCU CACUUCUU 8570 834 GUGGUUGG G CUAACUGA 3503 UCAGUUAG GCCGAAAGGCGAGUCAAGGUCU CCAACCAC 8571 974 AAAUGACA G CUCUCCUU 3504 AAGGAGAG GCCGAAAGGCGAGUCAAGGUCU UGUCAUUU 8572 985 CUCCUUAA G UGAUUUCU 3505 AGAAAUCA GCCGAAAGGCGAGUCAAGGUCU UUAAGGAG 8573 997 UUUCUUCU G UUUUCUGU 3506 ACAGAAAA GCCGAAAGGCGAGUCAAGGUCU AGAAGAAA 8574 1004 UGUUUUCU G UUUCCUUU 3507 AAAGGAAA GCCGAAAGGCGAGUCAAGGUCU AGAAAACA 8575 1024 AAACAUUA G UGUUCAUA 3508 UAUGAACA GCCGAAAGGCGAGUCAAGGUCU UAAUGUUU 8576 1026 ACAUUAGU G UUCAUAGC 3509 GCUAUGAA GCCGAAAGGCGAGUCAAGGUCU ACUAAUGU 8577 1033 UGUUCAUA G CUUCCAAG 3510 CUUGGAAG GCCGAAAGGCGAGUCAAGGUCU UAUGAACA 8578 1048 AGAGACAU G CUGACUUU 3427 AAAGUCAG GCCGAAAGGCGAGUCAAGGUCU AUGUCUCU 8579 1068 UUCUUGAG G UACUCUGC 3511 GCAGAGUA GCCGAAAGGCGAGUCAAGGUCU CUCAAGAA 8580 1075 GGUACUCU G CACAUACG 3430 CGUAUGUG GCCGAAAGGCGAGUCAAGGUCU AGAGUACC 8581 1083 GCACAUAC G CACCACAU 3431 AUGUGGUG GCCGAAAGGCGAGUCAAGGUCU GUAUGUGC 8582 1101 UCUAUCUG G CCUUUGCA 3512 UGCAAAGG GCCGAAAGGCGAGUCAAGGUCU CAGAUAGA 8583 1107 UGGCCUUU G CAUGGAGU 3432 ACUCCAUG GCCGAAAGGCGAGUCAAGGUCU AAAGGCCA 8584 1114 UGCAUGGA G UGACCAUA 3513 UAUGGUCA GCCGAAAGGCGAGUCAAGGUCU UCCAUGCA 8585 1123 UGACCAUA G CUCCUUCU 3514 AGAAGGAG GCCGAAAGGCGAGUCAAGGUCU UAUGGUCA 8586 1146 CAUUGAAU G UAGAGAAU 3515 AUUCUCUA GCCGAAAGGCGAGUCAAGGUCU AUUCAAUG 8587 1155 UAGAGAAU G UAGCCAUU 3516 AAUGGCUA GCCGAAAGGCGAGUCAAGGUCU AUUCUCUA 8588 1158 AGAAUGUA G CCAUUGUA 3517 UACAAUGG GCCGAAAGGCGAGUCAAGGUCU UACAUUCU 8589 1164 UAGCCAUU G UAGCAGCU 3518 AGCUGCUA GCCGAAAGGCGAGUCAAGGUCU AAUGGCUA 8590 1167 CCAUUGUA G CAGCUUGU 3519 ACAAGCUG GCCGAAAGGCGAGUCAAGGUCU UACAAUGG 8591 1170 UUGUAGCA G CUUGUGUU 3520 AACACAAG GCCGAAAGGCGAGUCAAGGUCU UGCUACAA 8592 1174 AGCAGCUU G UGUUGUCA 3521 UGACAACA GCCGAAAGGCGAGUCAAGGUCU AAGCUGCU 8593 1176 CAGCUUGU G UUGUCACG 3522 CGUGACAA GCCGAAAGGCGAGUCAAGGUCU ACAAGCUG 8594 1179 CUUGUGUU G UCACGCUU 3523 AAGCGUGA GCCGAAAGGCGAGUCAAGGUCU AACACAAG 8595 1184 GUUGUCAC G CUUCUUCU 3435 AGAAGAAG GCCGAAAGGCGAGUCAAGGUCU GUGACAAC 8596 1198 UCUUUUGA G CAACUUUC 3524 GAAAGUUG GCCGAAAGGCGAGUCAAGGUCU UCAAAAGA 8597 1222 GAAGAAAG G CAGAAUGA 3525 UCAUUCUG GCCGAAAGGCGAGUCAAGGUCU CUUUCUUC 8598 1231 CAGAAUGA G UGGUUCAG 3526 CUGAAGCA GCCGAAAGGCGAGUCAAGGUCU UCAUUCUG 8599 1233 GAAUGAGU G CUUCAGAA 3439 UUCUGAAG GCCGAAAGGCGAGUCAAGGUCU ACUCAUUC 8600 1243 UUGAGAAU G UGAUUUCC 3527 GGAAAUCA GCCGAAAGGCGAGUCAAGGUCU AUUCUGAA 8601 1261 ACUAACCU G UUCCUUGG 3528 CCAAGGAA GCCGAAAGGCGAGUCAAGGUCU AGGUUAGU 8602 1274 UUGGAUAG G CUUUUUAG 3529 CUAAAAAG GCCGAAAGGCGAGUCAAGGUCU CUAUCCAA 8603 1282 GCUUUUUA G UAUAGUAU 3530 AUACUAUA GCCGAAAGGCGAGUCAAGGUCU UAAAAAGC 8604 1287 UUAGUAUA G UAUUUUUU 3531 AAAAAAUA GCCGAAAGGCGAGUCAAGGUCU UAUACUAA 8605 1299 UUUUUUUU G UCAUUUUC 3532 GAAAAUGA GCCGAAAGGCGAGUCAAGGUCU AAAAAAAA 8606 1315 CUCCAUCA G CAACCAGG 3533 CCUGGUUG GCCGAAAGGCGAGUCAAGGUCU UGAUGGAG 8607 1330 GGGAGACU G CACCUGAU 3441 AUCAGGUG GCCGAAAGGCGAGUCAAGGUCU AGUCUCCC 8608 1356 AUAUGACU G CUUCAUGA 3444 UCAUGAAG GCCGAAAGGCGAGUCAAGGUCU AGUCAUAU 8609 1401 ACAUCUAC G UUUUUGGU 3534 ACCAAAAA GCCGAAAGGCGAGUCAAGGUCU GUAGAUGU 8610 1408 CGUUUUUG G UGGAGUCC 3535 GGACUCCA GCCGAAAGGCGAGUCAAGGUCU CAAAAACG 8611 1413 UUGGUGGA G UCCCUUUU 3536 AAAAGGGA GCCGAAAGGCGAGUCAAGGUCU UCCACCAA 8612 1422 UCCCUUUU G CAUCAUUG 3446 CAAUGAUG GCCGAAAGGCGAGUCAAGGUCU AAAAGGGA 8613 1430 GCAUCAUU G UUUUAAGG 3537 CCUUAAAA GCCGAAAGGCGAGUCAAGGUCU AAUGAUGC 8614 1502 UCUACAGG G CUGACAUU 3538 AAUGUCAG GCCGAAAGGCGAGUCAAGGUCU CCUGUAGA 8615 1511 CUGACAUU G UGGCACAU 3539 AUGUGCCA GCCGAAAGGCGAGUCAAGGUCU AAUGUCAG 8616 1514 ACAUUGUG G CACAUUCU 3540 AGAAUGUG GCCGAAAGGCGAGUCAAGGUCU CACAAUGU 8617 1527 UUCUUAGA G UUACCACA 3541 UGUGGUAA GCCGAAAGGCGAGUCAAGGUCU UCUAAGAA 8618 1549 UGAGGGAA G CUCUAAAU 3542 AUUUAGAG GCCGAAAGGCGAGUCAAGGUCU UUCCCUCA 8619 1559 UCUAAAUA G CCAACACC 3543 GGUGUUGG GCCGAAAGGCGAGUCAAGGUCU UAUUUAGA 8620 1573 ACCCAUCU G UUUUUUGU 3544 ACAAAAAA GCCGAAAGGCGAGUCAAGGUCU AGAUGGGU 8621 1580 UGUUUUUU G UAAAAACA 3545 UGUUUUUA GCCGAAAGGCGAGUCAAGGUCU AAAAAACA 8622 1589 UAAAAACA G CAUAGCUU 3546 AAGCUAUG GCCGAAAGGCGAGUCAAGGUCU UGUUUUUA 8623 Input Sequence = HSCD20A. Cut Site = G/Y Stem Length = 8 . Core Sequence = GCcgaaagGCGaGuCaaGGuCu HSCD20A (Human mRNA for CD20 receptor (S7) ; 1597 bp) Table XIII: Human CD20 DNAzyme and Substrate Sequence Pos Substrate Seq ID DNAzyme Seq ID 151 AAGGCCCU A UUGCUAUG 2720 CATAGCAA GGCTAGCTACAACGA AGGGCCTT 8624 157 CUAUUGCU A UGCAAUCU 2722 AGATTGCA GGCTAGCTACAACGA AGCAATAG 8625 262 UCCAGAUU A UGAAUGGG 2741 CCCATTCA GGCTAGCTACAACGA AATCTGGA 8626 320 AGGGAUCU A UGCACCCA 2751 TGGGTGCA GGCTAGCTACAACGA AGATCCCT 8627 347 UGUGUGGU A CCCUCUCU 2753 AGAGAGGG GGCTAGCTACAACGA ACCACACA 8628 367 GAGGGAUU A UGUAUAUU 2757 AATATACA GGCTAGCTACAACGA AATGCCTC 8629 371 CAUUAUGU A UAUUAUUU 2758 AAATAATA GGCTAGCTACAACGA ACATAATG 8630 373 UUAUGUAU A UUAUUUCC 2759 GGAAATAA GGCTAGCTACAACGA ATACATAA 8631 376 UGUAUAUU A UUUCCGGA 2761 TCCGGAAA GGCTAGCTACAACGA AATATACA 8632 504 AUGGACAU A CUUAAUAU 2787 ATATTAAG GGCTAGCTACAACGA ATGTCCAT 8633 511 UACUUAAU A UUAAAAUU 2790 AATTTTAA GGCTAGCTACAACGA ATTAAGTA 8634 553 UGAAUUUU A UUAGAGCU 2806 AGCTCTAA GGCTAGCTACAACGA AAAATTCA 8635 572 CACACCAU A UAUUAACA 2810 TGTTAATA GGCTAGCTACAACGA ATGGTGTG 8636 574 CACCAUAU A UUAACAUA 2811 TATGTTAA GGCTAGCTACAACGA ATATGGTG 8637 582 AUUAACAU A UACAACUG 2814 CAGTTGTA GGCTAGCTACAACGA ATGTTAAT 8638 584 UAACAUAU A CAACUGUG 2815 CACAGTTG GGCTAGCTACAACGA ATATGTTA 8639 628 CCCCAUCU A CCCAAUAC 2821 GTATTGGG GGCTAGCTACAACGA AGATGGGG 8640 635 UACCCAAU A CUGUUACA 2822 TGTAACAG GGCTAGCTACAACGA ATTGGGTA 8641 641 AUACUGUU A CAGCAUAC 2824 GTATGCTG GGCTAGCTACAACGA AACAGTAT 8642 648 UACAGCAU A CAAUCUCU 2825 AGAGATTG GGCTAGCTACAACGA ATGCTGTA 8643 808 AACAGAGU A UUGAAAUA 2855 TATTTCAA GGCTAGCTACAACGA AGTCTGTT 8644 883 UUGAAAUU A UUCCAAUC 2865 GATTGGAA GGCTAGCTACAACGA AATTTCAA 8645 1070 CUUGAGGU A CUCUGCAC 2913 GTGCAGAG GGCTAGCTACAACGA ACCTCAAG 8646 1081 CUGCACAU A CGCACCAC 2915 GTGGTGCG GGCTAGCTACAACGA ATGTGCAG 8647 1096 ACAUCUCU A UCUGGCCU 2918 AGGCCAGA GGCTAGCTACAACGA AGAGATGT 8648 1137 UCUCUCUU A CAUUGAAU 2929 ATTCAATG GGCTAGCTACAACGA AAGAGAGA 8649 1209 ACUUUCUU A CACUGAAG 2949 CTTCAGTG GGCTAGCTACAACGA AAGAAAGT 8650 1253 GAUUUCCU A CUAACCUG 2955 CAGGTTAG GGCTAGCTACAACGA AGGAAATC 8651 1284 UUUUUAGU A UAGUAUUU 2966 AAATACTA GGCTAGCTACAACGA ACTAAAAA 8652 1289 AGUAUAGU A UUUUUUUU 2968 AAAAAAAA GGCTAGCTACAACGA ACTATACT 8653 1348 GAAAAGAU A UAUGACUG 2984 CAGTCATA GGCTAGCTACAACGA ATCTTTTG 8654 1350 AAAGAUAU A UGACUGCU 2985 AGCAGTCA GGCTAGCTACAACGA ATATCTTT 8655 1377 CCUAAACU A UCUUUUUU 2991 AAAAAAGA GGCTAGCTACAACGA AGTTTAGG 8656 1388 UUUUUUUU A UUCCACAU 3000 ATGTGGAA GGCTAGCTACAACGA AAAAAAAA 8657 1399 CCACAUCU A CGUUUUUG 3004 CAAAAACG GGCTAGCTACAACGA AGATGTGG 8658 1471 GGGACAAU A CAGAACCC 3022 GGGTTCTG GGCTAGCTACAACGA ATTGTCCC 8659 1489 UUCCAUUU A UCUUUCUA 3027 TAGAAAGA GGCTAGCTACAACGA AAATGGAA 8660 1497 AUCUUUCU A CAGGGCUG 3032 CAGCCCTG GGCTAGCTACAACGA AGAAAGAT 8661 1530 UUAGAGUU A CCACACCC 3039 GGGTGTGG GGCTAGCTACAACGA AACTCTAA 8662 11 CAAACUGC A CCCACUGA 3050 TCAGTGGG GGCTAGCTACAACGA GCAGTTTG 8663 15 CUGCACCC A CUGAACUC 3053 GAGTTCAG GGCTAGCTACAACGA GGGTGCAG 8664 34 CAGCUAGC A UCCAAAUC 3059 GATTTGGA GGCTAGCTACAACGA GCTAGCTG 8665 99 AUGACAAC A CCCAGAAA 3072 TTTCTGGG GGCTAGCTACAACGA GTTGTCAT 8666 177 CCAAAACC A CUCUUCAG 3092 CTGAAGAG GGCTAGCTACAACGA GGTTTTGG 8667 198 AUGUCUUC A CUGGUGGG 3097 CCCACCAG GGCTAGCTACAACGA GAAGACAT 8668 211 UGGGCCCC A CGCAAAGC 3102 GCTTTGCG GGCTAGCTACAACGA GGGGCCCA 8669 226 GCUUCUUC A UGAGGGAA 3106 TTCCCTCA GGCTAGCTACAACGA GAAGAAGC 8670 278 GCUCUUCC A CAUUGCCC 3115 GGGCAATG GGCTAGCTACAACGA GGAAGAGC 8671 280 UCUUCCAC A UUGCCCUG 3116 CAGGGCAA GGCTAGCTACAACGA GTGGAAGA 8672 324 AUCUAUGC A CCCAUCUG 3127 CAGATGGG GGCTAGCTACAACGA GCATAGAT 8673 328 AUGCACCC A UCUGUGUG 3130 CACACAGA GGCTAGCTACAACGA GGGTGCAT 8674 364 GGGGAGGC A UUAUGUAU 3138 ATACATAA GGCTAGCTACAACGA GCCTCCCC 8675 387 UCCGGAUC A CUCCUGGC 3140 GCCAGGAG GGCTAGCTACAACGA GATCCGGA 8676 453 AUGAAUUC A UUGAGCCU 3150 AGGCTCAA GGCTAGCTACAACGA GAATTCAT 8677 472 UUGCUGCC A UUUCUGGA 3156 TCCAGAAA GGCTAGCTACAACGA GGCAGCAA 8678 496 UUUCAAUC A UGGACAUA 3160 TATGTCCA GGCTAGCTACAACGA GATTGAAA 8679 502 UCAUGGAC A UACUUAAU 3161 ATTAAGTA GGCTAGCTACAACGA GTCCATGA 8680 524 AAUUUCCC A UUUUUUAA 3165 TTAAAAAA GGCTAGCTACAACGA GGGAAATT 8681 563 UAGAGCUC A CACACCAU 3168 ATGGTGTG GGCTAGCTACAACGA GAGCTCTA 8682 565 GAGCUCAC A CACCAUAU 3169 ATATGGTG GGCTAGCTACAACGA GTGAGCTC 8683 567 GCUCACAC A CCAUAUAU 3170 ATATATGG GGCTAGCTACAACGA GTGTGAGC 8684 570 CACACACC A UAUAUUAA 3172 TTAATATA GGCTAGCTACAACGA GGTGTGTG 8685 580 AUAUUAAC A UAUACAAC 3173 GTTGTATA GGCTAGCTACAACGA GTTAATAT 8686 624 AACUCCCC A UCUACCCA 3187 TGGGTAGA GGCTAGCTACAACGA GGGGAGTT 8687 646 GUUACAGC A UACAAUCU 3194 AGATTGTA GGCTAGCTACAACGA GCTGTAAC 8688 667 UCUUGGGC A UUUUGUCA 3199 TGACAAAA GGCTAGCTACAACGA GCCCAAGA 8689 721 UAGCUGGC A UCGUUGAG 3210 CTCAACGA GGCTAGCTACAACGA GCCAGCTA 8690 769 AAUCUAAC A UAGUUCUC 3218 GAGAACTA GGCTAGCTACAACGA GTTAGATT 8691 846 ACUGAAAC A UCUUCCCA 3228 TGGGAAGA GGCTAGCTACAACGA GTTTCAGT 8692 874 AAGAAGAC A UUGAAAUU 3235 AATTTCAA GGCTAGCTACAACGA GTCTTCTT 8693 957 GAAUCCUC A CCAAUAGA 3253 TCTATTGG GGCTAGCTACAACGA GAGGATTC 8694 1020 UUUUAAAC A UUAGUGUU 3266 AACACTAA GGCTAGCTACAACGA GTTTAAAA 8695 1030 UAGUGUUC A UAGCUUCC 3267 GGAAGCTA GGCTAGCTACAACGA GAACACTA 8696 1046 CAAGAGAC A UGCUGACU 3271 AGTCAGCA GGCTAGCTACAACGA GTCTCTTG 8697 1058 UGACUUUC A UUUCUUGA 3274 TCAAGAAA GGCTAGCTACAACGA GAAAGTCA 8698 1077 UACUCUGC A CAUACGCA 3278 TGCGTATG GGCTAGCTACAACGA GCAGAGTA 8699 1079 CUCUGCAC A UACGCACC 3279 GGTGCGTA GGCTAGCTACAACGA GTGCAGAG 8700 1085 ACAUACGC A CCACAUCU 3280 AGATGTGG GGCTAGCTACAACGA GCGTATGT 8701 1088 UACGCACC A CAUCUCUA 3282 TAGAGATG GGCTAGCTACAACGA GGTGCGTA 8702 1090 CGCACCAC A UCUCUAUC 3283 GATAGAGA GGCTAGCTACAACGA GTGGTGCG 8703 1109 GCCUUUGC A UGGAGUGA 3289 TCACTCCA GGCTAGCTACAACGA GCAAAGGC 8704 1120 GAGUGACC A UAGCUCCU 3291 AGGAGCTA GGCTAGCTACAACGA GGTCACTC 8705 1139 UCUCUUAC A UUGAAUGU 3298 ACATTCAA GGCTAGCTACAACGA GTAAGAGA 8706 1161 AUGUAGCC A UUGUAGCA 3300 TGCTACAA GGCTAGCTACAACGA GGCTACAT 8707 1182 GUGUUGUC A CGCUUCUU 3303 AAGAAGCG GGCTAGCTACAACGA GACAACAC 8708 1211 UUUCUUAC A CUGAAGAA 3310 TTCTTCAG GGCTAGCTACAACGA GTAAGAAA 8709 1302 UUUUUGUC A UUUUCUCC 3323 GGAGAAAA GGCTAGCTACAACGA GACAAAAA 8710 1311 UUUUCUCC A UCAGCAAC 3326 GTTGCTGA GGCTAGCTACAACGA GGAGAAAA 8711 1332 GAGACUGC A CCUGAUGG 3332 CCATCAGG GGCTAGCTACAACGA GCAGTCTC 8712 1361 ACUGCUUC A UGACAUUC 3337 GAATGTCA GGCTAGCTACAACGA GAAGCAGT 8713 1366 UUCAUGAC A UUCCUAAA 3338 TTTAGGAA GGCTAGCTACAACGA GTCATGAA 8714 1393 UUUAUUCC A CAUCUACG 3344 CGTAGATG GGCTAGCTACAACGA GGAATAAA 8715 1395 UAUUCCAC A UCUACGUU 3345 AACGTAGA GGCTAGCTACAACGA GTGGAATA 8716 1424 CCUUUUGC A UCAUUGUU 3350 AACAATGA GGCTAGCTACAACGA GCAAAAGG 8717 1427 UUUGCAUC A UUGUUUUA 3351 TAAAACAA GGCTAGCTACAACGA GATGCAAA 8718 1480 CAGAACCC A UUCCAUUU 3358 AAATGGAA GGCTAGCTACAACGA GGGTTCTG 8719 1485 CCCAUUCC A UUUAUCUU 3360 AAGATAAA GGCTAGCTACAACGA GGAATGGG 8720 1508 GGGCUGAC A UUGUGGCA 3365 TGCCACAA GGCTAGCTACAACGA GTCAGCCC 8721 1516 AUUGUGGC A CAUUCUUA 3366 TAAGAATG GGCTAGCTACAACGA GCCACAAT 8722 1518 UGUGGCAC A UUCUUAGA 3367 TCTAAGAA GGCTAGCTACAACGA GTGCCACA 8723 1533 GAGUUACC A CACCCCAU 3370 ATGGGGTG GGCTAGCTACAACGA GGTAACTC 8724 1535 GUUACCAC A CCCCAUGA 3371 TCATGGGG GGCTAGCTACAACGA GTGGTAAC 8725 1540 CACACCCC A UGAGGGAA 3375 TTCCCTCA GGCTAGCTACAACGA GGGGTGTG 8726 1565 UAGCCAAC A CCCAUCUG 3380 CAGATGGG GGCTAGCTACAACGA GTTGGCTA 8727 1569 CAACACCC A UCUGUUUU 3383 AAAACAGA GGCTAGCTACAACGA GGGTGTTG 8728 9 AACAAACU G CACCCACU 3386 AGTGGGTG GGCTAGCTACAACGA AGTTTGTT 8729 25 UGAACUCC G CAGCUAGC 3388 GCTAGCTG GGCTAGCTACAACGA GGAGTTCA 8730 154 GCCCUAUU G CUAUGCAA 3394 TTGCATAG GGCTAGCTACAACGA AATAGGGC 8731 159 AUUGCUAU G CAAUCUGG 3395 CCAGATTG GGCTAGCTACAACGA ATAGCAAT 8732 213 GGCCCCAC G CAAAGCUU 3396 AAGCTTTG GGCTAGCTACAACGA GTGGGGCC 8733 283 UCCACAUU G CCCUGGGG 3399 CCCCAGGG GGCTAGCTACAACGA AATGTGGA 8734 322 GGAUCUAU G CACCCAUC 3402 GATGGGTG GGCTAGCTACAACGA ATAGATCC 8735 466 GCCUCUUU G CUGCCAUU 3407 AATGGCAG GGCTAGCTACAACGA AAAGAGGC 8736 469 UCUUUGCU G CCAUUUCU 3408 AGAAATGG GGCTAGCTACAACGA AGCAAAGA 8737 681 UCAGUGAU G CUGAUCUU 3414 AAGATCAG GGCTAGCTACAACGA ATCACTGA 8738 691 UGAUCUUU G CCUUCUUC 3416 GAAGAAGG GGCTAGCTACAACGA AAAGATCA 8739 749 AAGAACGU G CUCCAGAC 3419 GTCTGGAG GGCTAGCTACAACGA ACGTTCTT 8740 1048 AGAGACAU G CUGACUUU 3427 AAAGTCAG GGCTAGCTACAACGA ATGTCTCT 8741 1075 GGUACUCU G CACAUACG 3430 CGTATGTG GGCTAGCTACAACGA AGAGTACC 8742 1083 GCACAUAC G CACCACAU 3431 ATGTGGTG GGCTAGCTACAACGA GTATGTGC 8743 1107 UGGCCUUU G CAUGGAGU 3432 ACTCCATG GGCTAGCTACAACGA AAAGGCCA 8744 1184 GUUGUCAC G CUUCUUCU 3435 AGAAGAAG GGCTAGCTACAACGA GTGACAAC 8745 1233 GAAUGAGU G CUUCAGAA 3439 TTCTGAAG GGCTAGCTACAACGA ACTCATTC 8746 1330 GGGAGACU G CACCUGAU 3441 ATCAGGTG GGCTAGCTACAACGA AGTCTCCC 8747 1356 AUAUGACU G CUUCAUGA 3444 TCATGAAG GGCTAGCTACAACGA AGTCATAT 8748 1422 UCCCUUUU G CAUCAUUG 3446 CAATGATG GGCTAGCTACAACGA AAAAGGGA 8749 28 ACUCCGCA G CUAGCAUC 3450 GATGCTAG GGCTAGCTACAACGA TGCGGAGT 8750 32 CGCAGCUA G CAUCCAAA 3451 TTTGGATG GGCTAGCTACAACGA TAGCTGCG 8751 44 CCAAAUCA G CCCUUGAG 3452 CTCAAGGG GGCTAGCTACAACGA TGATTTGG 8752 60 GAUUUGAG G CCUUGGAG 3453 CTCCAAGG GGCTAGCTACAACGA CTCAAATC 8753 77 ACUCAGGA G UUUUGAGA 3454 TCTCAAAA GGCTAGCTACAACGA TCCTGAGT 8754 86 UUUUGAGA G CAAAAUGA 3455 TCATTTTG GGCTAGCTACAACGA TCTCAAAA 8755 112 GAAAUUCA G UAAAUGGG 3456 CCCATTTA GGCTAGCTACAACGA TGAATTTC 8756 130 CUUUCCUG G CAGAGCCA 3457 TGGCTCTG GGCTAGCTACAACGA CAGGAAAG 8757 135 CUGGCAGA G CCAAUGAA 3458 TTCATTGG GGCTAGCTACAACGA TCTGCCAG 8758 146 AAUGAAAG G CCCUAUUG 3459 CAATAGGG GGCTAGCTACAACGA CTTTCATT 8759 167 GCAAUCUG G UCCAAAAC 3460 GTTTTGGA GGCTAGCTACAACGA CAGATTGC 8760 192 AGGAGGAU G UCUUCACU 3461 AGTGAAGA GGCTAGCTACAACGA ATCCTCCT 8761 202 CUUCACUG G UGGGCCCC 3462 GGGGCCCA GGCTAGCTACAACGA CAGTGAAG 8762 206 ACUGGUGG G CCCCACGC 3463 GCGTGGGG GGCTAGCTACAACGA CCACCAGT 8763 218 CACGCAAA G CUUCUUCA 3464 TGAAGAAG GGCTAGCTACAACGA TTTGCGTG 8764 250 CUUUGGGG G CUGUCCAG 3465 CTGGACAG GGCTAGCTACAACGA CCCCAAAG 8765 253 UGGGGGCU G UCCAGAUU 3466 AATCTGGA GGCTAGCTACAACGA AGCCCCCA 8766 270 AUGAAUGG G CUCUUCCA 3467 TGGAAGAG GGCTAGCTACAACGA CCATTCAT 8767 293 CCUGGGGG G UCUUCUGA 3468 TCAGAAGA GGCTAGCTACAACGA CCCCCAGG 8768 310 UGAUCCCA G CAGGGAUC 3469 GATCCCTG GGCTAGCTACAACGA TGGGATCA 8769 332 ACCCAUCU G UGUGACUG 3470 CAGTCACA GGCTAGCTACAACGA AGATGGGT 8770 334 CCAUCUGU G UGACUGUG 3471 CACAGTCA GGCTAGCTACAACGA ACAGATGG 8771 340 GUGUGACU G UGUGGUAC 3472 GTACCACA GGCTAGCTACAACGA AGTCACAC 8772 342 GUGACUGU G UGGUACCC 3473 GGGTACCA GGCTAGCTACAACGA ACAGTCAC 8773 345 ACUGUGUG G UACCCUCU 3474 AGAGGGTA GGCTAGCTACAACGA CACACAGT 8774 362 CUGGGGAG G CAUUAUGU 3475 ACATAATG GGCTAGCTACAACGA CTCCCCAG 8775 369 GGCAUUAU G UAUAUUAU 3476 ATAATATA GGCTAGCTACAACGA ATAATGCC 8776 394 CACUCCUG G CAGCAACG 3477 CGTTGCTG GGCTAGCTACAACGA CAGGAGTG 8777 397 UCCUGGCA G CAACGGAG 3478 CTCCGTTG GGCTAGCTACAACGA TGCCAGGA 8778 420 UCCAGGAA G UGUUUGGU 3479 ACCAAACA GGCTAGCTACAACGA TTCCTGGA 8779 422 CAGGAAGU G UUUGGUCA 3480 TGACCAAA GGCTAGCTACAACGA ACTTCCTG 8780 427 AGUGUUUG G UCAAAGGA 3481 TCCTTTGA GGCTAGCTACAACGA CAAACACT 8781 458 UUCAUUGA G CCUCUUUG 3482 CAAAGAGG GGCTAGCTACAACGA TCAATGAA 8782 542 AAUGGAGA G UCUGAAUU 3483 AATTCAGA GGCTAGCTACAACGA TCTCCATT 8783 559 UUAUUAGA G CUCACACA 3484 TGTGTGAG GGCTAGCTACAACGA TCTAATAA 8784 590 AUACAACU G UGAACCAG 3485 CTGGTTCA GGCTAGCTACAACGA AGTTGTAT 8785 598 GUGAACCA G CUAAUCCC 3486 GGGATTAG GGCTAGCTACAACGA TGGTTCAG 8786 638 CCAAUACU G UUACAGCA 3487 TGCTGTAA GGCTAGCTACAACGA AGTATTGG 8787 644 CUGUUACA G CAUACAAU 3488 ATTGTATG GGCTAGCTACAACGA TGTAACAG 8788 657 CAAUCUCU G UUCUUGGG 3489 CCCAAGAA GGCTAGCTACAACGA AGAGATTG 8789 665 GUUCUUGG G CAUUUUGU 3490 ACAAAATG GGCTAGCTACAACGA CCAAGAAC 8790 672 GGCAUUUU G UCAGUGAU 3491 ATCACTGA GGCTAGCTACAACGA AAAATGCC 8791 676 UUUUGUCA G UGAUGCUG 3492 CAGCATCA GGCTAGCTACAACGA TGACAAAA 8792 709 AGGAACUU G UAAUAGCU 3493 AGCTATTA GGCTAGCTACAACGA AAGTTCCT 8793 715 UUGUAAUA G CUGGCAUC 3494 GATGCCAG GGCTAGCTACAACGA TATTACAA 8794 719 AAUAGCUG G CAUCGUUG 3495 CAACGATG GGCTAGCTACAACGA CAGCTATT 8795 724 CUGGCAUC G UUGAGAAU 3496 ATTCTCAA GGCTAGCTACAACGA GATGCCAG 8796 747 AAAAGAAC G UGCUCCAG 3497 CTGGAGCA GGCTAGCTACAACGA GTTCTTTT 8797 772 CUAACAUA G UUCUCCUG 3498 CAGGAGAA GGCTAGCTACAACGA TATGTTAG 8798 780 GUUCUCCU G UCAGCAGA 3499 TCTGCTGA GGCTAGCTACAACGA AGGAGAAC 8799 784 UCCUGUCA G CAGAAGAA 3500 TTCTTCTG GGCTAGCTACAACGA TGACAGGA 8800 826 AAGAAGAA G UGGUUGGG 3501 CCCAACCA GGCTAGCTACAACGA TTCTTCTT 8801 829 AAGAAGUG G UUGGGCUA 3502 TAGCCCAA GGCTAGCTACAACGA CACTTCTT 8802 834 GUGGUUGG G CUAACUGA 3503 TCAGTTAG GGCTAGCTACAACGA CCAACCAC 8803 974 AAAUGACA G CUCUCCUU 3504 AAGGAGAG GGCTAGCTACAACGA TGTCATTT 8804 985 CUCCUUAA G UGAUUUCU 3505 AGAAATCA GGCTAGCTACAACGA TTAAGGAG 8805 997 UUUCUUCU G UUUUCUGU 3506 ACAGAAAA GGCTAGCTACAACGA AGAAGAAA 8806 1004 UGUUUUCU G UUUCCUUU 3507 AAAGGAAA GGCTAGCTACAACGA AGAAAACA 8807 1024 AAACAUUA G UGUUCAUA 3508 TATGAACA GGCTAGCTACAACGA TAATGTTT 8808 1026 ACAUUAGU G UUCAUAGC 3509 GCTATGAA GGCTAGCTACAACGA ACTAATGT 8809 1033 UGUUCAUA G CUUCCAAG 3510 CTTGGAAG GGCTAGCTACAACGA TATGAACA 8810 1068 UUCUUGAG G UACUCUGC 3511 GCAGAGTA GGCTAGCTACAACGA CTCAAGAA 8811 1101 UCUAUCUG G CCUUUGCA 3512 TGCAAAGG GGCTAGCTACAACGA CAGATAGA 8812 1114 UGCAUGGA G UGACCAUA 3513 TATGGTCA GGCTAGCTACAACGA TCCATGCA 8813 1123 UGACCAUA G CUCCUUCU 3514 AGAAGGAG GGCTAGCTACAACGA TATGGTCA 8814 1146 CAUUGAAU G UAGAGAAU 3515 ATTCTCTA GGCTAGCTACAACGA ATTCAATG 8815 1155 UAGAGAAU G UAGCCAUU 3516 AATGGCTA GGCTAGCTACAACGA ATTCTCTA 8816 1158 AGAAUGUA G CCAUUGUA 3517 TACAATGG GGCTAGCTACAACGA TACATTCT 8817 1164 UAGCCAUU G UAGCAGCU 3518 AGCTGCTA GGCTAGCTACAACGA AATGGCTA 8818 1167 CCAUUGUA G CAGCUUGU 3519 ACAAGCTG GGCTAGCTACAACGA TACAATGG 8819 1170 UUGUAGCA G CUUGUGUU 3520 AACACAAG GGCTAGCTACAACGA TGCTACAA 8820 1174 AGCAGCUU G UGUUGUCA 3521 TGACAACA GGCTAGCTACAACGA AAGCTGCT 8821 1176 CAGCUUGU G UUGUCACG 3522 CGTGACAA GGCTAGCTACAACGA ACAAGCTG 8822 1179 CUUGUGUU G UCACGCUU 3523 AAGCGTGA GGCTAGCTACAACGA AACACAAG 8823 1198 UCUUUUGA G CAACUUUC 3524 GAAAGTTG GGCTAGCTACAACGA TCAAAAGA 8824 1222 GAAGAAAG G CAGAAUGA 3525 TCATTCTG GGCTAGCTACAACGA CTTTCTTC 8825 1231 CAGAAUGA G UGCUUCAG 3526 CTGAAGCA GGCTAGCTACAACGA TCATTCTG 8826 1243 UUCAGAAU G UGAUUUCC 3527 GGAAATCA GGCTAGCTACAACGA ATTCTGAA 8827 1261 ACUAACCU G UUCCUUGG 3528 CCAAGGAA GGCTAGCTACAACGA AGGTTAGT 8828 1274 UUGGAUAG G CUUUUUAG 3529 CTAAAAAG GGCTAGCTACAACGA CTATCCAA 8829 1282 GCUUUUUA G UAUAGUAU 3530 ATACTATA GGCTAGCTACAACGA TAAAAAGC 8830 1287 UUAGUAUA G UAUUUUUU 3531 AAAAAATA GGCTAGCTACAACGA TATACTAA 8831 1299 UUUUUUUU G UCAUUUUC 3532 GAAAATGA GGCTAGCTACAACGA AAAAAAAA 8832 1315 CUCCAUCA G CAACCAGG 3533 CCTGGTTG GGCTAGCTACAACGA TGATGGAG 8833 1401 ACAUCUAC G UUUUUGGU 3534 ACCAAAAA GGCTAGCTACAACGA GTAGATGT 8834 1408 CGUUUUUG G UGGAGUCC 3535 GGACTCCA GGCTAGCTACAACGA CAAAAACG 8835 1413 UUGGUGGA G UCCCUUUU 3536 AAAAGGGA GGCTAGCTACAACGA TCCACCAA 8836 1430 GCAUCAUU G UUUUAAGG 3537 CCTTAAAA GGCTAGCTACAACGA AATGATGC 8837 1502 UCUACAGG G CUGACAUU 3538 AATGTCAG GGCTAGCTACAACGA CCTGTAGA 8838 1511 CUGACAUU G UGGCACAU 3539 ATGTGCCA GGCTAGCTACAACGA AATGTCAG 8839 1514 ACAUUGUG G CACAUUCU 3540 AGAATGTG GGCTAGCTACAACGA CACAATGT 8840 1527 UUCUUAGA G UUACCACA 3541 TGTGGTAA GGCTAGCTACAACGA TCTAAGAA 8841 1549 UGAGGGAA G CUCUAAAU 3542 ATTTAGAG GGCTAGCTACAACGA TTCCCTCA 8842 1559 UCUAAAUA G CCAACACC 3543 GGTGTTGG GGCTAGCTACAACGA TATTTAGA 8843 1573 ACCCAUCU G UUUUUUGU 3544 ACAAAAAA GGCTAGCTACAACGA AGATGGGT 8844 1580 UGUUUUUU G UAAAAACA 3545 TGTTTTTA GGCTAGCTACAACGA AAAAAACA 8845 1589 UAAAAACA G CAUAGCUU 3546 AAGCTATG GGCTAGCTACAACGA TGTTTTTA 8846 20 CCCACUGA A CUCCGCAG 3547 CTGCGGAG GGCTAGCTACAACGA TCAGTGGG 8847 40 GCAUCCAA A UCAGCCCU 3548 AGGGCTGA GGCTAGCTACAACGA TTGGATGC 8848 53 CCCUUGAG A UUUGAGGC 3549 GCCTCAAA GGCTAGCTACAACGA CTCAAGGG 8849 69 CCUUGGAG A CUCAGGAG 3550 CTCCTGAG GGCTAGCTACAACGA CTCCAAGG 8850 91 AGAGCAAA A UGACAACA 3551 TGTTGTCA GGCTAGCTACAACGA TTTGCTCT 8851 94 GCAAAAUG A CAACACCC 3552 GGGTGTTG GGCTAGCTACAACGA CATTTTGC 8852 97 AAAUGACA A CACCCAGA 3553 TCTGGGTG GGCTAGCTACAACGA TGTCATTT 8853 107 ACCCAGAA A UUCAGUAA 3554 TTACTGAA GGCTAGCTACAACGA TTCTGGGT 8854 116 UUCAGUAA A UGGGACUU 3555 AAGTCCCA GGCTAGCTACAACGA TTACTGAA 8855 121 UAAAUGGG A CUUUCCUG 3556 CAGGAAAG GGCTAGCTACAACGA CCCATTTA 8856 139 CAGAGCCA A UGAAAGGC 3557 GCCTTTCA GGCTAGCTACAACGA TGGCTCTG 8857 162 GCUAUGCA A UCUGGUCC 3558 GGACCAGA GGCTAGCTACAACGA TGCATAGC 8858 174 GGUCCAAA A CCACUCUU 3559 AAGAGTGG GGCTAGCTACAACGA TTTGGACC 8859 190 UCAGGAGG A UGUCUUCA 3560 TGAAGACA GGCTAGCTACAACGA CCTCCTGA 8860 234 AUGAGGGA A UCUAAGAC 3561 GTCTTAGA GGCTAGCTACAACGA TCCCTCAT 8861 241 AAUGUAAG A CUUUGGGG 3562 CCCCAAAG GGCTAGCTACAACGA CTTAGATT 8862 259 CUGUCCAG A UUAUGAAU 3563 ATTCATAA GGCTAGCTACAACGA CTGGACAG 8863 266 GAUUAUGA A UGGGCUCU 3564 AGAGCCCA GGCTAGCTACAACGA TCATAATC 8864 301 GUCUUCUG A UGAUCCCA 3565 TGGGATCA GGCTAGCTACAACGA CAGAAGAC 8865 304 UUCUGAUG A UCCCAGCA 3566 TGCTGGGA GGCTAGCTACAACGA CATCAGAA 8866 316 CAGCAGGG A UCUAUGCA 3567 TGCATAGA GGCTAGCTACAACGA CCCTGCTG 8867 337 UCUGUGUG A CUGUGUGG 3568 CCACACAG GGCTAGCTACAACGA CACACAGA 8868 384 AUUUCCGG A UCACUCCU 3569 AGGAGTGA GGCTAGCTACAACGA CCGGAAAT 8869 400 UGGCAGCA A CGGAGAAA 3570 TTTCTCCG GGCTAGCTACAACGA TGCTGCCA 8870 410 GGAGAAAA A CUCCAGGA 3571 TCCTGGAG GGCTAGCTACAACGA TTTTCTCC 8871 439 AAGGAAAA A UGAUAAUG 3572 CATTATCA GGCTAGCTACAACGA TTTTCCTT 8872 442 GAAAAAUG A UAAUGAAU 3573 ATTCATTA GGCTAGCTACAACGA CATTTTTC 8873 445 AAAUGAUA A UGAAUUCA 3574 TGAATTCA GGCTAGCTACAACGA TATCATTT 8874 449 GAUAAUGA A UUCAUUGA 3575 TCAATGAA GGCTAGCTACAACGA TCATTATC 8875 481 UUUCUGGA A UGAUUCUU 3576 AAGAATCA GGCTAGCTACAACGA TCCAGAAA 8876 484 CUGGAAUG A UUCUUUCA 3577 TGAAAGAA GGCTAGCTACAACGA CATTCCAG 8877 493 UUCUUUCA A UCAUGGAC 3578 GTCCATGA GGCTAGCTACAACGA TGAAAGAA 8878 500 AAUCAUGG A CAUACUUA 3579 TAAGTATG GGCTAGCTACAACGA CCATGATT 8879 509 CAUACUUA A UAUUAAAA 3580 TTTTAATA GGCTAGCTACAACGA TAAGTATG 8880 517 AUAUUAAA A UUUCCCAU 3581 ATGGGAAA GGCTAGCTACAACGA TTTAATAT 8881 535 UUUUAAAA A UGGAGAGU 3582 ACTCTCCA GGCTAGCTACAACGA TTTTAAAA 8882 548 GAGUCUGA A UUUUAUUA 3583 TAATAAAA GGCTAGCTACAACGA TCAGACTC 8883 578 AUAUAUUA A CAUAUACA 3584 TGTATATG GGCTAGCTACAACGA TAATATAT 8884 587 CAUAUACA A CUGUGAAC 3585 GTTCACAG GGCTAGCTACAACGA TGTATATG 8885 594 AACUGUGA A CCAGCUAA 3586 TTAGCTGG GGCTAGCTACAACGA TCACAGTT 8886 602 ACCAGCUA A UCCCUCUG 3587 CAGAGGGA GGCTAGCTACAACGA TAGCTGGT 8887 617 UGAGAAAA A CUCCCCAU 3588 ATGGGGAG GGCTAGCTACAACGA TTTTCTCA 8888 633 UCUACCCA A UACUGUUA 3589 TAACAGTA GGCTAGCTACAACGA TGGGTAGA 8889 651 AGCAUACA A UCUCUGUU 3590 AAGAGAGA GGCTAGCTACAACGA TGTATGCT 8890 679 UGUCAGUG A UGCUGAUC 3591 GATCAGCA GGCTAGCTACAACGA CACTGACA 8891 685 UGAUGCUG A UCUUUGCC 3592 GGCAAAGA GGCTAGCTACAACGA CAGCATCA 8892 705 UUCCAGGA A CUUGUAAU 3593 ATTACAAG GGCTAGCTACAACGA TCCTGGAA 8893 712 AACUUGUA A UAGCUGGC 3594 GCCAGCTA GGCTAGCTACAACGA TACAAGTT 8894 731 CGUUGAGA A UGAAUGGA 3595 TCCATTCA GGCTAGCTACAACGA TCTCAACG 8895 735 GAGAAUGA A UGGAAAAG 3596 CTTTTCCA GGCTAGCTACAACGA TCATTCTG 8896 745 GGAAAAGA A CGUGCUCC 3597 GGAGCACG GGCTAGCTACAACGA TCTTTTCC 8897 756 UGCUCCAG A CCCAAAUC 3598 GATTTGGG GGCTAGCTACAACGA CTGGAGCA 8898 762 AGACCCAA A UCUAACAU 3599 ATGTTAGA GGCTAGCTACAACGA TTGGGTCT 8899 767 CAAAUCUA A CAUAGUUC 3600 GAACTATG GGCTAGCTACAACGA TAGATTTG 8900 801 AAAAAAGA A CAGACUAU 3601 ATAGTCTG GGCTAGCTACAACGA TCTTTTTT 8901 805 AAGAACAG A CUAUUGAA 3602 TTCAATAG GGCTAGCTACAACGA CTGTTCTT 8902 814 CUAUUGAA A UAAAAGAA 3603 TTCTTTTA GGCTAGCTACAACGA TTCAATAG 8903 838 UUGGGCUA A CUGAAACA 3604 TGTTTCAG GGCTAGCTACAACGA TAGCCCAA 8904 844 UAACUGAA A CAUCUUCC 3605 GGAAGATG GGCTAGCTACAACGA TTCAGTTA 8905 855 UCUUCCCA A CCAAAGAA 3606 TTCTTTGG GGCTAGCTACAACGA TGGGAAGA 8906 863 AGCAAAGA A UGAAGAAG 3607 CTTCTTCA GGCTAGCTACAACGA TCTTTGGT 8907 872 UGAAGAAG A CAUUGAAA 3608 TTTCAATG GGCTAGCTACAACGA CTTCTTCA 8908 880 ACAUUGAA A UUAUUCCA 3609 TGGAATAA GGCTAGCTACAACGA TTCAATGT 8909 889 UUAUUCCA A UCCAAGAA 3610 TTCTTGGA GGCTAGCTACAACGA TGGAATAA 8910 913 AAGAAGAA A CAGAGACG 3611 CGTCTCTG GGCTAGCTACAACGA TTCTTCTT 8911 919 AAACAGAG A CGAACUUU 3612 AAAGTTCG GGCTAGCTACAACGA CTCTGTTT 8912 923 AGAGACGA A CUUUCCAG 3613 CTGGAAAG GGCTAGCTACAACGA TCGTCTCT 8913 933 UUUCCAGA A CCUCCCCA 3614 TGGGGAGG GGCTAGCTACAACGA TCTGGAAA 8914 944 UCCCCAAG A UCAGGAAU 3615 ATTCCTGA GGCTAGCTACAACGA CTTGGGGA 8915 951 GAUCAGGA A UCCUCACC 3616 GGTGAGGA GGCTAGCTACAACGA TCCTGATC 8916 961 CCUCACCA A UAGAAAAU 3617 ATTTTCTA GGCTAGCTACAACGA TGGTGAGG 8917 968 AAUAGAAA A UGACAGCU 3618 AGCTGTCA GGCTAGCTACAACGA TTTCTATT 8918 971 AGAAAAUG A CAGCUCUC 3619 GAGAGCTG GGCTAGCTACAACGA CATTTTCT 8919 988 CUUAAGUG A UUUCUUCU 3620 AGAAGAAA GGCTAGCTACAACGA CACTTAAG 8920 1018 UUUUUUAA A CAUUAGUG 3621 CACTAATG GGCTAGCTACAACGA TTAAAAAA 8921 1044 UCCAAGAG A CAUGCUGA 3622 TCAGCATG GGCTAGCTACAACGA CTCTTGGA 8922 1052 ACAUGCUG A CUUUCAUU 3623 AATGAAAG GGCTAGCTACAACGA CAGCATGT 8923 1117 AUGGAGUG A CCAUAGCU 3624 AGCTATGG GGCTAGCTACAACGA CACTCCAT 8924 1144 UACAUUGA A UGUAGAGA 3625 TCTCTACA GGCTAGCTACAACGA TCAATGTA 8925 1153 UGUAGAGA A UGUAGCCA 3626 TGGCTACA GGCTAGCTACAACGA TCTCTACA 8926 1201 UUUGAGCA A CUUUCUUA 3627 TAAGAAAG GGCTAGCTACAACGA TGCTCAAA 8927 1227 AAGGCAGA A UGAGUGCU 3628 AGCACTCA GGCTAGCTACAACGA TCTGCCTT 8928 1241 GCUUCAGA A UGUGAUUU 3629 AAATCACA GGCTAGCTACAACGA TCTGAAGC 8929 1246 AGAAUGUG A UUUCCUAC 3630 GTAGGAAA GGCTAGCTACAACGA CACATTCT 8930 1257 UCCUACUA A CCUGUUCC 3631 GGAACAGG GGCTAGCTACAACGA TAGTAGGA 8931 1270 UUCCUUGG A UAGGCUUU 3632 AAAGCCTA GGCTAGCTACAACGA CCAAGGAA 8932 1318 CAUCAGCA A CCAGGGAG 3633 CTCCCTGG GGCTAGCTACAACGA TGCTGATG 8933 1327 CCAGGGAG A CUGCACCU 3634 AGGTGCAG GGCTAGCTACAACGA CTCCCTGG 8934 1337 UGCACCUG A UGGAAAAG 3635 CTTTTCCA GGCTAGCTACAACGA CAGGTGCA 8935 1346 UGGAAAAG A UAUAUGAC 3636 GTCATATA GGCTAGCTACAACGA CTTTTCCA 8936 1353 GAUAUAUG A CUGCUUCA 3637 TGAAGCAG GGCTAGCTACAACGA CATATATC 8937 1364 GCUUCAUG A CAUUCCUA 3638 TAGGAATG GGCTAGCTACAACGA CATGAAGC 8938 1374 AUUCCUAA A CUAUCUUU 3639 AAAGATAG GGCTAGCTACAACGA TTAGGAAT 8939 1439 UUUUAAGG A UGAUAAAA 3640 TTTTATCA GGCTAGCTACAACGA CCTTAAAA 8940 1442 UAAGGAUG A UAAAAAAA 3641 TTTTTTTA GGCTAGCTACAACGA CATCCTTA 8941 1453 AAAAAAAA A UAACAACU 3642 AGTTGTTA GGCTAGCTACAACGA 8942 1456 AAAAAAUA A CAACUAGG 3643 CCTAGTTG GGCTAGCTACAACGA TATTTTTT 8943 1459 AAAUAACA A CUAGGGAC 3644 GTCCCTAG GGCTAGCTACAACGA TGTTATTT 8944 1466 AACUAGGG A CAAUACAG 3645 CTGTATTG GGCTAGCTACAACGA CCCTAGTT 8945 1469 UAGGGACA A UACAGAAC 3646 GTTCTGTA GGCTAGCTACAACGA TGTCCCTA 8946 1476 AAUACAGA A CCCAUUCC 3647 GGAATGGG GGCTAGCTACAACGA TCTGTATT 8947 1506 CAGGGCUG A CAUUGUGG 3648 CCACAATG GGCTAGCTACAACGA CAGCCCTG 8948 1556 AGCUCUAA A UAGCCAAC 3649 GTTGGCTA GGCTAGCTACAACGA TTAGAGCT 8949 1563 AAUAGCCA A CACCCAUC 3650 GATGGGTG GGCTAGCTACAACGA TGGCTATT 8950 1586 UUGUAAAA A CAGCAUAG 3651 CTATGCTG GGCTAGCTACAACGA TTTTACAA 8951 Input Sequence = HSCD20A. Cut Site = R/Y Stem Length = 8 . Core Sequence = GGCTAGCTACAACGA HSCD20A (Human mRNA for CD20 receptor (S7) ; 1597 bp) Table XTV: Human CD20 Amberzyme and Substrate Sequence Pos Substrate Seq ID Amberzyme Seq ID 9 AACAAACU G CACCCACU 3386 AGUGGGUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGUUUGUU 8952 18 CACCCACU G AACUCCGC 3387 GCGGAGUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGUGGGUG 8953 25 UGAACUCC G CAGCUAGC 3388 GCUAGCUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGAGUUCA 8954 50 CAGCCCUU G AGAUUUGA 338\ UCAAAUCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAGGGCUG 8955 57 UGAGAUUU G AGGCCUUG 3390 CAAGGCCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAAUCUCA 8956 82 GGAGUUUU G AGAGCAAA 3391 UUUGCUCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAAACUCC 8957 93 AGCAAAAU G ACAACACC 3392 GGUGUUGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUUUUGCU 8958 141 GAGCCAAU G AAAGGCCC 3393 GGGCCUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUUGGCUC 8959 154 GCCCUAUU G CUAUGCAA 3394 UUGCAUAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAUAGGGC 8960 159 AUUGCUAU G CAAUCUGG 3395 CCAGAUUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUAGCAAU 8961 213 GGCCCCAC G CAAAGCUU 3396 AAGCUUUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GUGGGGCC 8962 228 UUCUUCAU G AGGGAAUC 3397 GAUUCCCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUGAAGAA 8963 264 CAGAUUAU G AAUGGGCU 3398 AGCCCAUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUAAUCUG 8964 283 UCCACAUU G CCCUGGGG 3399 CCCCAGGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAUGUGGA 8965 300 GGUCUUCU G AUGAUCCC 3400 GGGAUCAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGAAGACC 8966 303 CUUCUGAU G AUCCCAGC 3401 GCUGGGAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUCAGAAG 8967 322 GGAUCUAU G CACCCAUC 3402 GAUGGGUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUAGAUCC 8968 336 AUCUGUGU G ACUGUGUG 3403 CACACAGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACACAGAU 8969 441 GGAAAAAU G AUAAUGAA 3404 UUCAUUAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUUUUUCC 8970 447 AUGAUAAU G AAUUCAUU 3405 AAUGAAUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUUAUCAU 8971 456 AAUUCAUU G AGCCUCUU 3406 AAGAGGCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAUGAAUU 8972 466 GCCUCUUU G CUGCCAUU 3407 AAUGGCAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAAGAGGC 8973 469 UCUUUGCU G CCAUUUCU 3408 AGAAAUGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGCAAAGA 8974 483 UCUGGAAU G AUUCUUUC 3409 GAAAGAAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUUCCAGA 8975 546 GAGAGUCU G AAUUUUAU 3410 AUAAAAUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGACUCUC 8976 592 ACAACUGU G AACCAGCU 3411 AGCUGGUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACAGUUGU 8977 610 AUCCCUCU G AGAAAAAC 3412 GUUUUUCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGAGGGAU 8978 678 UUGUCAGU G AUGCUGAU 3413 AUCAGCAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACUGACAA 8979 681 UCAGUGAU G CUGAUCUU 3414 AAGAUCAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUCACUGA 8980 684 GUGAUGCU G AUCUUUGC 3415 GCAAAGAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGCAUCAC 8981 691 UGAUCUUU G CCUUCUUC 3416 GAAGAAGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAAGAUCA 8982 727 GCAUCGUU G AGAAUGAA 3417 UUCAUUCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AACGAUGC 8983 733 UUGAGAAU G AAUGGAAA 3418 UUUCCAUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUUCUCAA 8984 749 AAGAACGU G CUCCAGAC 3419 GUCUGGAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACGUUCUU 8985 811 AGACUAUU G AAAUAAAA 3420 UUUUAUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAUAGUCU 8986 841 GGCUAACU G AAACAUCU 3421 AGAUGUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGUUAGCC 8987 865 CAAAGAAU G AAGAAGAC 3422 GUCUUCUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUUCUUUG 8988 877 AAGACAUU G AAAUUAUU 3423 AAUAAUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAUGUCUU 8989 921 ACAGAGAC G AACUUUCC 3424 GGAAAGUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GUCUCUGU 8990 970 UAGAAAAU G ACAGCUCU 3425 AGAGCUGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUUUUCUA 8991 987 CCUUAAGU G AUUUCUUC 3426 GAAGAAAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACUUAAGG 8992 1048 AGAGACAU G CUGACUUU 3427 AAAGUCAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUGUCUCU 8993 1051 GACAUGCU G ACUUUCAU 3428 AUGAAAGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGCAUGUC 8994 1065 CAUUUCUU G AGGUACUC 3429 GAGUACCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAGAAAUG 8995 1075 GGUACUCU G CACAUACG 3430 CGUAUGUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGAGUACC 8996 1083 GCACAUAC G CACCACAU 3431 AUGUGGUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GUAUGUGC 8997 1107 UGGCCUUU G CAUGGAGU 3432 ACUCCAUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAAGGCCA 8998 1116 CAUGGAGU G ACCAUAGC 3433 GCUAUGGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACUCCAUG 8999 1142 CUUACAUU G AAUGUAGA 3434 UCUACAUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAUGUAAG 9000 1184 GUUGUCAC G CUUCUUCU 3435 AGAAGAAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GUGACAAC 9001 1196 CUUCUUUU G AGCAACUU 3436 AAGUUGCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAAAGAAG 9002 1214 CUUACACU G AAGAAAGG 3437 CCUUUGUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGUGUAAG 9003 1229 GGCAGAAU G AGUGCUUC 3438 GAAGCACU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUUCUGCC 9004 1233 GAAUGAGU G CUUCAGAA 3439 UUCUGAAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACUCAUUC 9005 1245 CAGAAUGU G AUUUCCUA 3440 UAGGAAAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACAUUCUG 9006 1330 GGGAGACU G CACCUGAU 3441 AUCAGGUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGUCUCCC 9007 1336 CUGCACCU G AUGGAAAA 3442 UUUUCCAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGGUGCAG 9008 1352 AGAUAUAU G ACUGCUUC 3443 GAAGCAGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUAUAUCU 9009 1356 AUAUGACU G CUUCAUGA 3444 UCAUGAAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGUCAUAU 9010 1363 UGCUUCAU G ACAUUCCU 3445 AGGAAUGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUGAAGCA 9011 1422 UCCCUUUU G CAUCAUUG 3446 CAAUGAUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAAAGGGA 9012 1441 UUAAGGAU G AUAAAAAA 3447 UUUUUUAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUCCUUAA 9013 1505 ACAGGGCU G ACAUUGUG 3448 CACAAUGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGCCCUGU 9014 1542 CACCCCAU G AGGGAAGC 3449 GCUUCCCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUGGGGUG 9015 28 ACUCCGCA G CUAGCAUC 3450 GAUGCUAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGCGGAGU 9016 32 CGCAGCUA G CAUCCAAA 3451 UUUGGAUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAGCUGCG 9017 44 CCAAAUCA G CCCUUGAG 3452 CUCAAGGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGAUUUGG 9018 60 GAUUUGAG G CCUUGGAG 3453 CUCCAAGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUCAAAUC 9019 77 ACUCAGGA G UUUUGAGA 3454 UCUCAAAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCCUGAGU 9020 86 UUUUGAGA G CAAAAUGA 3455 UCAUUUUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCUCAAAA 9021 112 GAAAUUCA G UAAAUGGG 3456 CCCAUUUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGAAUUUC 9022 130 CUUUCCUG G CAGAGCCA 3457 UGGCUCUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAGGAAAG 9023 135 CUGGCAGA G CCAAUGAA 3458 UUCAUUGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCUGCCAG 9024 146 AAUGAAAG G CCCUAUUG 3459 CAAUAGGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUUUCAUU 9025 167 GCAAUCUG G UCCAAAAC 3460 GUUUUGGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAGAUUGC 9026 192 AGGAGGAU G UCUUGACU 3461 AGUGAAGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUGCUCCU 9027 202 CUUCACUG G UGGGCCCC 3462 GGGGCCCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAGUGAAG 9028 206 ACUGGUGG G CCCCACGC 3463 GCGUGGGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCACCAGU 9029 218 CACGCAAA G CUUCUUCA 3464 UGAAGAAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUUGCGUG 9030 250 CUUUGGGG G CUGUCCAG 3465 CUGGACAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCCCAAAG 9031 253 UGGGGGCU G UCCAGAUU 3466 AAUCUGGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGCCCCCA 9032 270 AUGAAUGG G CUCUUCCA 3467 UGGAAGAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCAUUCAU 9033 293 CCUGGGGG G UCUUCUGA 3468 UCAGAAGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCCCCAGG 9034 310 UGAUCCCA G CAGGGAUC 3469 GAUCCCUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGGGAUCA 9035 332 ACCCAUCU G UGUGACUG 3470 CAGUCACA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGAUGGGU 9036 334 CCAUCUGU G UGACUGUG 3471 CACAGUCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACAGAUGG 9037 340 GUGUGACU G UGUGGUAC 3472 GUACCACA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGUCACAC 9038 342 GUGACUGU G UGGUACCC 3473 GGGUACCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACAGUCAC 9039 345 ACUGUGUG G UACCCUCU 3474 AGAGGGUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CACACAGU 9040 362 CUGGGGAG G CAUUAUGU 3475 ACAUAAUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUCCCCAG 9041 369 GGCAUUAU G UAUAUUAU 3476 AUAAUAUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUAAUGCC 9042 394 CACUCCUG G CAGCAACG 3477 CGUUGCUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAGGAGUG 9043 397 UCCUGGCA G CAACGGAG 3478 CUCCGUUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGCCAGGA 9044 420 UCCAGGAA G UGUUUGGU 3479 ACCAAACA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCCUGGA 9045 422 CAGGAAGU G UUUGGUCA 3480 UGACCAAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACUUCCUG 9046 427 AGUGUUUG G UCAAAGGA 3481 UCCUUUGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAAACACU 9047 458 UUCAUUGA G CCUCUUUG 3482 CAAAGAGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCAAUGAA 9048 542 AAUGGAGA G UCUGAAUU 3483 AAUUCAGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCUCCAUU 9049 559 UUAUUAGA G CUCACACA 3484 UGUGUGAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCUAAUAA 9050 590 AUACAACU G UGAACCAG 3485 CUGGUUCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGUUGUAU 9051 598 GUGAACCA G CUAAUCCC 3486 GGGAUUAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGGUUCAC 9052 638 CCAAUACU G UUACAGCA 3487 UGCUGUAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGUAUUGG 9053 644 CUGUUACA G CAUACAAU 3488 AUUGUAUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGUAACAG 9054 657 CAAUCUCU G UUCUUGGG 3489 CCCAAGAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGAGAUUG 9055 665 GUUCUUGG G CAUUUUGU 3490 ACAAAAUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCAAGAAC 9056 672 GGCAUUUU G UCAGUGAU 3491 AUCACUGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAAAUGCC 9057 676 UUUUGUCA G UGAUGCUG 3492 CAGCAUCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGACAAAA 9058 709 AGGAACUU G UAAUAGCU 3493 AGCUAUUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAGUUCCU 9059 715 UUGUAAUA G CUGGCAUC 3494 GAUGCCAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAUUACAA 9060 719 AAUAGCUG G CAUCGUUG 3495 CAACGAUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAGCUAUU 9061 724 CUGGCAUC G UUGAGAAU 3496 AUUCUCAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GAUGCCAG 9062 747 AAAAGAAC G UGCUCCAG 3497 CUGGAGCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GUUCUUUU 9063 772 CUAACAUA G UUCUCCUG 3498 CAGGAGAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAUGUUAG 9064 780 GUUCUCCU G UCAGCAGA 3499 UCUGCUGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGGAGAAC 9065 784 UCCUGUCA G CAGAAGAA 3500 UUCUUCUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGACAGGA 9066 826 AAGAAGAA G UGGUUGGG 3501 CCCAACCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCUUCUU 9067 829 AAGAAGUG G UUGGGCUA 3502 UAGCCCAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CACUUCUU 9068 834 GUGGUUGG G CUAACUGA 3503 UCAGUUAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCAACCAC 9069 974 AAAUGACA G CUCUCCUU 3504 AAGGAGAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGUCAUUU 9070 985 CUCCUUAA G UGAUUUCU 3505 AGAAAUCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUAAGGAG 9071 997 UUUCUUCU G UUUUCUGU 3506 ACAGAAAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGAAGAAA 9072 1004 UGUUUUCU G UUUCCUUU 3507 AAAGGAAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGAAAACA 9073 1024 AAACAUUA G UGUUCAUA 3508 UAUGAACA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAAUGUUU 9074 1026 ACAUUAGU G UUCAUAGC 3509 GCUAUGAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACUAAUGU 9075 1033 UGUUCAUA G CUUCCAAG 3510 CUUGGAAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAUGAACA 9076 1068 UUCUUGAG G UACUCUGC 3511 GCAGAGUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUCAAGAA 9077 1101 UCUAUCUG G CCUUUGCA 3512 UGCAAAGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAGAUAGA 9078 1114 UGCAUGGA G UGACCAUA 3513 UAUGGUCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCCAUGCA 9079 1123 UGACCAUA G CUCCUUCU 3514 AGAAGGAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAUGGUCA 9080 1146 CAUUGAAU G UAGAGAAU 3515 AUUCUCUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUUCAAUG 9081 1155 UAGAGAAU G UAGCCAUU 3516 AAUGGCUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUUCUCUA 9082 1158 AGAAUGUA G CCAUUGUA 3517 UACAAUGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UACAUUCU 9083 1164 UAGCCAUU G UAGCAGCU 3518 AGCUGCUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAUGGCUA 9084 1167 CCAUUGUA G CAGCUUGU 3519 ACAAGCUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UACAAUGG 9085 1170 UUGUAGCA G CUUGUGUU 3520 AACACAAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGCUACAA 9086 1174 AGGAGCUU G UGUUGUCA 3521 UGACAACA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAGCUGCU 9087 1176 CAGCUUGU G UUGUCACG 3522 CGUGACAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACAAGCUG 9088 1179 CUUGUGUU G UCACGCUU 3523 AAGCGUGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AACACAAG 9089 1198 UCUUUUGA G CAACUUUC 3524 GAAAGUUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCAAAAGA 9090 1222 GAAGAAAG G CAGAAUGA 3525 UCAUUCUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUUUCUUC 9091 1231 CAGAAUGA G UGGUUCAG 3526 CUGAAGCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCAUUCUG 9092 1243 UUCAGAAU G UGAUUUCC 3527 GGAAAUCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUUCUGAA 9093 1261 ACUAACCU G UUCCUUGG 3528 CCAAGGAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGGUUAGU 9094 1274 UUGGAUAG G CUUUUUAG 3529 CUAAAAAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUAUCCAA 9095 1282 GCUUUUUA G UAUAGUAU 3530 AUACUAUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAAAAAGC 9096 1287 UUAGUAUA G UAUUUUUU 3531 AAAAAAUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAUACUAA 9097 1299 UUUUUUUU G UCAUUUUC 3532 GAAAAUGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAAAAAAA 9098 1315 CUCCAUCA G CAACCAGG 3533 CCUGGUUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGAUGGAG 9099 1401 ACAUCUAC G UUUUUGGU 3534 ACCAAAAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GUAGAUGU 9100 1408 CGUUUUUG G UGGAGUCC 3535 GGACUCCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAAAAACG 9101 1413 UUGGUGGA G UCCCUUUU 3536 AAAAGGGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCCACCAA 9102 1430 GCAUCAUU G UUUUAAGG 3537 CCUUAAAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAUGAUGC 9103 1502 UCUACAGG G CUGACAUU 3538 AAUGUCAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCUGUAGA 9104 1511 CUGACAUU G UGGCACAU 3539 AUGUGCCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAUGUCAG 9105 1514 ACAUUGUG G CACAUUCU 3540 AGAAUGUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CACAAUGU 9106 1527 UUCUUAGA G UUACCACA 3541 UGUGGUAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCUAAGAA 9107 1549 UGAGGGAA G CUCUAAAU 3542 AUUUAGAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCCCUCA 9108 1559 UCUAAAUA G CCAACACC 3543 GGUGUUGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAUUUAGA 9109 1573 ACCCAUCU G UUUUUUGU 3544 ACAAAAAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGAUGGGU 9110 1580 UGUUUUUU G UAAAAACA 3545 UGUUUUUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAAAAACA 9111 1589 UAAAAACA G CAUAGCUU 3546 AAGCUAUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGUUUUUA 9112 52 GCCCUUGA G AUUUGAGG 3652 CCUCAAAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCAAGGGC 9113 59 AGAUUUGA G GCCUUGGA 3653 UCCAAGGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCAAAUCU 9114 65 GAGGCCUU G GAGACUCA 3654 UGAGUCUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAGGCCUC 9115 66 AGGCCUUG G AGACUCAG 3655 CUGAGUCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAAGGCCU 9116 68 GCCUUGGA G ACUCAGGA 3656 UCCUGAGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCCAAGGC 9117 74 GAGACUCA G GAGUUUUG 3657 CAAAACUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGAGUCUC 9118 75 AGACUCAG G AGUUUUGA 3658 UCAAAACU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUGAGUCU 9119 84 AGUUUUGA G AGCAAAAU 3659 AUUUUGCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCAAAACU 9120 104 AACACCCA G AAAUUCAG 3660 CUGAAUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGGGUGUU 9121 118 CAGUAAAU G GGACUUUC 3661 GAAAGUCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUUUACUG 9122 119 AGUAAAUG G GACUUUCC 3662 GGAAAGUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAUUUACU 9123 120 GUAAAUGG G ACUUUCCU 3663 AGGAAAGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCAUUUAC 9124 129 ACUUUCCU G GCAGAGCC 3664 GGCUCUGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGGAAAGU 9125 133 UCCUGGCA G AGCCAAUG 3665 CAUUGGCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGCCAGGA 9126 145 CAAUGAAA G GCCCUAUU 3666 AAUAGGGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUUCAUUG 9127 166 UGCAAUCU G GUCCAAAA 3667 UUUUGGAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGAUUGCA 9128 185 ACUCUUCA G GAGGAUGU 3668 ACAUCCUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGAAGAGU 9129 186 CUCUUCAG G AGGAUGUC 3669 GACAUCCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUGAAGAG 9130 188 CUUCAGGA G GAUGUCUU 3670 AAGACAUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCCUGAAG 9131 189 UUCAGGAG G AUGUCUUC 3671 GAAGACAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUCCUGAA 9132 201 UCUUCACU G GUGGGCCC 3672 GGGCCCAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGUGAAGA 9133 204 UCACUGGU G GGCCCCAC 3673 GUGGGGCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACCAGUGA 9134 205 CACUGGUG G GCCCCACG 3674 CGUGGGGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CACCAGUG 9135 230 CUUCAUGA G GGAAUCUA 3675 UAGAUUCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCAUGAAG 9136 231 UUCAUGAG G GAAUCUAA 3676 UUAGAUUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUCAUGAA 9137 232 UCAUGAGG G AAUGUAAG 3677 CUUAGAUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCUCAUGA 9138 240 GAAUCUAA G ACUUUGGG 3678 CCCAAAGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUAGAUUC 9139 246 AAGACUUU G GGGGCUGU 3679 ACAGCCCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAAGUCUU 9140 247 AGACUUUG G GGGCUGUC 3680 GACAGCCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAAAGUCU 9141 248 GACUUUGG G GGCUGUCC 3681 GGACAGCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCAAAGUC 9142 249 ACUUUGGG G GCUGUCCA 3682 UGGACAGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCCAAAGU 9143 258 GCUGUCCA G AUUAUGAA 3683 UUCAUAAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGGACAGC 9144 268 UUAUGAAU G GGCUCUUC 3684 GAAGAGCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUUCAUAA 9145 269 UAUGAAUG G GCUCUUCC 3685 GGAAGAGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAUUCAUA 9146 288 AUUGCCCU G GGGGGUCU 3686 AGACCCCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGGGCAAU 9147 289 UUGCCCUG G GGGGUCUU 3687 AAGACCCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAGGGCAA 9148 290 UGCCCUGG G GGGUCUUC 3688 GAAGACCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCAGGGCA 9149 291 GCCCUGGG G GGUCUUCU 3689 AGAAGACC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCCAGGGC 9150 292 CCCUGGGG G GUCUUCUG 3690 CAGAAGAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCCCAGGG 9151 313 UCCCAGCA G GGAUCUAU 3691 AUAGAUCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGCUGGGA 9152 314 CCCAGCAG G GAUCUAUG 3692 CAUAGAUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUGCUGGG 9153 315 CCAGCAGG G AUCUAUGC 3693 GCAUAGAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCUGCUGG 9154 344 GACUGUGU G GUACCCUC 3694 GAGGGUAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACACAGUC 9155 356 CCCUCUCU G GGGAGGCA 3695 UGCCUCCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGAGAGGG 9156 357 CCUCUCUG G GGAGGCAU 3696 AUGCCUCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAGAGAGG 9157 358 CUCUCUGG G GAGGCAUU 3697 AAUGCCUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCAGAGAG 9158 359 UCUCUGGG G AGGCAUUA 3698 UAAUGCCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCCAGAGA 9159 361 UCUGGGGA G GCAUUAUG 3699 CAUAAUGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCCCCAGA 9160 382 UUAUUUCC G GAUCACUC 3700 GAGUGAUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGAAAUAA 9161 383 UAUUUCCG G AUCACUCC 3701 GGAGUGAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CGGAAAUA 9162 393 UCACUCCU G GCAGCAAC 3702 GUUGCUGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGGAGUGA 9163 402 GCAGCAAC G GAGAAAAA 3703 UUUUUCUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GUUGCUGC 9164 403 CAGCAACG G AGAAAAAC 3704 GUUUUUCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CGUUGCUG 9165 405 GCAACGGA G AAAAACUC 3705 GAGUUUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCCGUUGC 9166 416 AAACUCCA G GAAGUGUU 3706 AACACUUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGGAGUUU 9167 417 AACUCCAG G AAGUGUUU 3707 AAACACUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUGGAGUU 9168 426 AAGUGUUU G GUCAAAGG 3708 CCUUUGAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAACACUU 9169 433 UGGUCAAA G GAAAAAUG 3709 CAUUUUUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUUGACCA 9170 434 GGUCAAAG G AAAAAUGA 3710 UCAUUUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUUUGACC 9171 478 CCAUUUCU G GAAUGAUU 3711 AAUCAUUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGAAAUGG 9172 479 CAUUUCUG G AAUGAUUC 3712 GAAUCAUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAGAAAUG 9173 498 UCAAUCAU G GACAUACU 3713 AGUAUGUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUGAUUGA 9174 499 CAAUCAUG G ACAUACUU 3714 AAGUAUGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAUGAUUG 9175 537 UUAAAAAU G GAGAGUCU 3715 AGACUCUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUUUUUAA 9176 538 UAAAAAUG G AGAGUCUG 3716 CAGACUCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAUUUUUA 9177 540 AAAAUGGA G AGUCUGAA 3717 UUCAGACU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCCAUUUU 9178 557 UUUUAUUA G AGCUCACA 3718 UGUGAGCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAAUAAAA 9179 612 CCCUCUGA G AAAAACUC 3719 GAGUUUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCAGAGGG 9180 663 CUGUUCUU G GGCAUUUU 3720 AAAAUGCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAGAACAG 9181 664 UGUUCUUG G GCAUUUUG 3721 CAAAAUGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAAGAACA 9182 702 UUCUUCCA G GAACUUGU 3722 ACAAGUUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGGAAGAA 9183 703 UCUUCCAG G AACUUGUA 3723 UACAAGUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUGGAAGA 9184 718 UAAUAGCU G GCAUCGUU 3724 AACGAUGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGCUAUUA 9185 729 AUCGUUGA G AAUGAAUG 3725 CAUUCAUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGAACGAU 9186 737 GAAUGAAU G GAAAAGAA 3726 UUCUUUUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUUCAUUC 9187 738 AAUGAAUG G AAAAGAAC 3727 GUUCUUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAUUCAUU 9188 743 AUGGAAAA G AACGUGCU 3728 AGCACGUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUUUCCAU 9189 755 GUGCUCCA G ACCCAAAU 3729 AUUUGGGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGGAGCAC 9190 787 UGUCAGCA G AAGAAAAA 3730 UUUUUCUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGCUGACA 9191 790 CAGCAGAA G AAAAAAAA 3731 UUUUUUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCUGCUG 9192 799 AAAAAAAA G AACAGAGU 3732 AGUCUGUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUUUUUUU 9193 804 AAAGAACA G ACUAUUGA 3733 UCAAUAGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGUUCUUU 9194 820 AAAUAAAA G AAGAAGUG 3734 CACUUCUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUUUAUUU 9195 823 UAAAAGAA G AAGUGGUU 3735 AACCACUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCUUUUA 9196 828 GAAGAAGU G GUUGGGCU 3736 AGCCCAAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACUUCUUC 9197 832 AAGUGGUU G GGCUAACU 3737 AGUUAGCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AACCACUU 9198 833 AGUGGUUG G GCUAACUG 3738 CAGUUAGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAACCACU 9199 861 CAACCAAA G AAUGAAGA 3739 UCUUCAUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUUGGUUG 9200 868 AGAAUGAA G AAGACAUU 3740 AAUGUCUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCAUUCU 9201 871 AUGAAGAA G ACAUUGAA 3741 UUCAAUGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCUUCAU 9202 895 CAAUCCAA G AAGAGGAA 3742 UUCCUCUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUGGAUUG 9203 898 UCCAAGAA G AGGAAGAA 3743 UUCUUCCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCUUGGA 9204 900 CAAGAAGA G GAAGAAGA 3744 ucuucuuc GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCUUCUUG 9205 901 AAGAAGAG G AAGAAGAA 3745 uucuucuu GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUCUUCUU 9206 904 AAGAGGAA G AAGAAGAA 3746 uucuucuu GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCCUCUU 9207 907 AGGAAGAA G AAGAAACA 3747 UGUUUCUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCUUCCU 9208 910 AAGAAGAA G AAACAGAG 3748 CUCUGUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG uucuucuu 9209 916 AAGAAACA G AGACGAAC 3749 GUUCGUCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGUUUCUU 9210 918 GAAACAGA G ACGAACUU 3750 AAGUUCGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCUGUUUC 9211 931 ACUUUCCA G AAGCUCCC 3751 GGGAGGUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGGAAAGU 9212 943 CUCCCCAA G AUCAGGAA 3752 UUCCUGAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUGGGGAG 9213 948 CAAGAUCA G GAAUCCUC 3753 GAGGAUUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGAUCUUG 9214 949 AAGAUCAG G AAUCCUCA 3754 UGAGGAUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUGAUCUU 9215 964 CACCAAUA G AAAAUGAC 3755 GUCAUUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAUUGGUG 9216 1041 GCUUCCAA G AGACAUGC 3756 GCAUGUCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUGGAAGC 9217 1043 UUCCAAGA G ACAUGCUG 3757 CAGCAUGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCUUGGAA 9218 1067 UUUCUUGA G GUACUCUG 3758 CAGAGUAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCAAGAAA 9219 1100 CUCUAUCU G GCCUUUGC 3759 GCAAAGGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGAUAGAG 9220 1111 CUUUGCAU G GAGUGACC 3760 GGUCACUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUGCAAAG 9221 1112 UUUGCAUG G AGUGACCA 3761 UGGUCACU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAUGCAAA 9222 1149 UGAAUGUA G AGAAUGUA 3762 UACAUUCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UACAUUCA 9223 1151 AAUGUAGA G AAUGUAGC 3763 GCUACAUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCUACAUU 9224 1217 ACACUGAA G AAAGGCAG 3764 CUGCCUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCAGUGU 9225 1221 UGAAGAAA G GCAGAAUG 3765 CAUUCUGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUUCUUCA 9226 1225 GAAAGGCA G AAUGAGUG 3766 CACUCAUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGCCUUUC 9227 1239 GUGCUUCA G AAUGUGAU 3767 AUCACAUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGAAGCAC 9228 1268 UGUUCCUU G GAUAGGCU 3768 AGCCUAUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAGGAACA 9229 1269 GUUCCUUG G AUAGGCUU 3769 AAGCCUAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GAAGGAAC 9230 1273 CUUGGAUA G GCUUUUUA 3770 UAAAAAGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAUCCAAG 9231 1322 AGCAACCA G GGAGACUG 3771 CAGUCUCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGGUUGCU 9232 1323 GCAACCAG G GAGACUGC 3772 GCAGUCUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUGGUUGC 9233 1324 CAACCAGG G AGACUGCA 3773 UGCAGUCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCUGGUUG 9234 1326 ACCAGGGA G ACUGCACC 3774 GGUGGAGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCCCUGGU 9235 1339 CACCUGAU G GAAAAGAU 3775 AUCUUUUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUCAGGUG 9236 1340 ACCUGAUG G AAAAGAUA 3776 UAUCUUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAUCAGGU 9237 1345 AUGGAAAA G AUAUAUGA 3777 UCAUAUAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUUUCCAU 9238 1407 ACGUUUUU G GUGGAGUC 3778 GACUCCAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAAAACGU 9239 1410 UUUUUGGU G GAGUCCCU 3779 AGGGACUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACCAAAAA 9240 1411 UUUUGGUG G AGUCCCUU 3780 AAGGGACU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CACCAAAA 9241 1437 UGUUUUAA G GAUGAUAA 3781 UUAUCAUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUAAAAGA 9242 1438 GUUUUAAG G AUGAUAAA 3782 UUUAUCAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUUAAAAC 9243 1463 AACAACUA G GGACAAUA 3783 UAUUGUCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAGUUGUU 9244 1464 ACAACUAG G GACAAUAC 3784 GUAUUGUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUAGUUGU 9245 1465 CAACUAGG G ACAAUACA 3785 UGUAUUGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCUAGUUG 9246 1474 ACAAUACA G AACCCAUU 3786 AAUGGGUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGUAUUGU 9247 1500 UUUCUACA G GGCUGACA 3787 UGUCAGCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGUAGAAA 9248 1501 UUCUACAG G GCUGACAU 3788 AUGUCAGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUGUAGAA 9249 1513 GACAUUGU G GCACAUUC 3789 GAAUGUGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACAAUGUC 9250 1525 CAUUCUUA G AGUUACCA 3790 UGGUAACU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAAGAAUG 9251 1544 CCCCAUGA G GGAAGCUC 3791 GAGCUUCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCAUGGGG 9252 1545 CCCAUGAG G GAAGCUCU 3792 AGAGCUUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUCAUGGG 9253 1546 CCAUGAGG G AAGCUCUA 3793 UAGAGCUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCUCAUGG 9254 Input Sequence = HSCD20A. Cut Site = G/ . Stem Length = 8. Core Sequence = GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG HSCD20A (Human mRNA for CD20 receptor (S7) ; 1597 bp) Table XV: Enzymatic nucleic acid effector molecule sequence UPPER CASE = RIBO lower case = 2'-O-methyl

Claims: CLAIMS What is claimed is: 1. A method of detecting a target molecule in a system, wherein said target molecule is a nucleic acid sequence, comprising the steps of: a. contacting the system with a diagnostic effector molecule, wherein the diagnostic effector molecule comprises: (i) an enzymatic nucleic acid component comprising a substrate binding region and a catalytic region; and (ii) a nucleic acid based inhibitor component which comprises sequence complementary to a sequence in the enzymatic nucleic acid component, wherein the inhibitor component interacts with its complementary sequence in the enzymatic nucleic acid component to inhibit the activity of the enzymatic nucleic acid component; and a nucleic acid based reporter molecule comprising, a sequence complementary to the substrate binding region of the enzymatic nucleic acid component of the diagnostic effector molecule where the interaction of the reporter molecule with its complementary sequence in the enzymatic nucleic acid component of the diagnostic effector molecule causes the cleavage of the reporter molecule, under conditions suitable for the target molecule, if present in the system, to interact with the inhibitor component of the diagnostic effector molecule, such that the enzymatic nucleic acid component of the diagnostic effector molecule can interact with the reporter molecule to catalyze the cleavage of the reporter molecule; and b. detecting the target molecule by measuring the extent of cleavage of the reporter molecule by the enzymatic nucleic acid component of the diagnostic effector molecule in the presence of the target molecule compared to the cleavage of the reporter molecule in the absence of the target molecule. 2. A method of detecting a target molecule in a system, wherein said target molecule is a nucleic acid sequence, comprising the steps of: a. contacting the system; a diagnostic effector molecule, wherein the diagnostic effector molecule comprises: (i) an enzymatic nucleic acid component comprising a substrate binding region and a catalytic region; and (ii) a nucleic acid based inhibitor component which comprises sequence complementary to a sequence in the enzymatic nucleic acid component, wherein the inhibitor component interacts with its complementary sequence in the enzymatic nucleic acid component to inhibit the activity of the enzymatic nucleic acid component; with a nucleic acid based reporter molecule comprising, a sequence complementary to the substrate binding region of the enzymatic nucleic acid component of the diagnostic effector molecule where the interaction of the reporter molecule with its complementary sequence in the enzymatic nucleic acid component of the diagnostic effector molecule causes the cleavage of the reporter molecule, under conditions suitable for the enzymatic nucleic acid component of the diagnostic effector molecule to interact with the reporter molecule to catalyze the cleavage of the reporter molecule; and b. detecting the target molecule by measuring the extent of cleavage of the reporter molecule by the enzymatic nucleic acid component of the diagnostic effector molecule in the presence of the target molecule compared to the cleavage of the reporter molecule in the absence of the target molecule. 3. The method of claims 1 or 2, wherein said system is an in vitro system. 4. The method of claim 3, wherein said in vitro system is a sample derived from the group consisting of a patient, plant, water, beverage, food preparation, and soil. 5. The method of claims 1 or 2, wherein said target molecule is an RNA, DNA, analog of RNA or analog of DNA. 6. The method of claims 1 or 2, wherein said targβt molecule is an RNA derived from a gene of bacteria, virus, fungi, plant or mammal. 7. The method of claims 1 or 2, wherein the enzymatic nucleic acid component of said diagnostic effector molecule is selected from the group of hammerhead, hairpin, inozyme, G-cleaver, Zinzyme, RNase P, EGS nucleic acid, and Amberzyme motif. 8. The method of claims 1 or 2, wherein the enzymatic nucleic acid component of said diagnostic effector molecule is a DNAzyme. 9. The method of claim 1 or claim 2, wherein said reporter molecule detectable labels are selected from the group consisting of chromogenic substrate, fluorescent labels, chemiluminescent labels, and radioactive labels. 10. The method of claim 1 or claim 2, wherein said reporter molecule is immobilized on a solid support. 11. The method of claim 1 or claim 2, wherein said inhibitor component of the diagnostic effector molecule is RNA, DNA, analog of RNA or analog of DNA. 12. The method of claim 1 or claim 2, wherein said inhibitor component of the diagnostic effector molecule is covalently linked to the diagnostic effector molecule by a linker. 13. The method of claim 12, wherein said linker is selected from the group comprising one or more, nucleotides, abasic moiety, polyether, polyamine, polyamide, peptide, carbohydrate, lipid, and polyhydrocarbon compounds. 14. The method of claim 1 or claim 2, wherein said inhibitor component of the diagnostic effector molecule is not covalently linked to the diagnostic effector molecule. 15. The method of claim 1 or claim 2, wherein said reporter molecule is RNA, DNA, RNA analog, or DNA analog. 16. A kit for detecting a target molecule in a system, wherein said target molecule is a nucleic acid sequence, comprising: a. a diagnostic effector molecule, wherein the diagnostic effector molecule comprises: (i) an enzymatic nucleic acid component comprising a substrate binding region and a catalytic region; and (ii) a nucleic acid based inhibitor component which comprises sequence complementary to a sequence in the enzymatic nucleic acid component, wherein the inhibitor component interacts with its complementary sequence in the enzymatic nucleic acid component to inhibit the activity of the enzymatic nucleic acid component; and b. a nucleic acid based reporter molecule comprising, a sequence complementary to the substrate binding region of the enzymatic nucleic acid component of the diagnostic effector molecule where the interaction of the reporter molecule with its complementary sequence in the enzymatic nucleic acid component of the diagnostic effector molecule causes the cleavage of the reporter molecule in the presence of the target molecule, wherein the reporter molecule is labeled with chemical moiety capable of emitting a detectable signal. 17. The kit of claim 16, wherein said said target molecule is an RNA derived from a gene of bacteria, virus, fungi, plant or mammal. 18. The kit of claim 16, wherein the enzymatic nucleic acid component of said diagnostic effector molecule is selected from the group of hammerhead, hairpin, inozyme, G- cleaver, Zinzyme, RNase P EGS nucleic acid and Amberzyme motif. 19. The kit of claim 16, wherein the enzymatic nucleic acid component of said diagnostic effector molecule is a DNAzyme. 20. The kit of claim 16, wherein said detectable label in the reporter molecule is selected from the group consisting of chromogenic substrate, fluorescent labels, chemiluminescent labels, and radioactive labels. 21. The kit of claim 16, wherein said reporter molecule is immobilized on a solid support. 22. The kit of claim 16, wherein said inhibitor component of the diagnostic effector molecule is RNA, DNA, analog of RNA or analog of DNA. 23. The kit of claim 16, wherein said inhibitor component of the diagnostic effector molecule is covalently linked to the diagnostic effector molecule by a linker. 24. The kit of claim 23, wherein said linker is selected from the group comprising one or more, nucleotides, abasic moiety, polyether, polyamine, polyamide, peptide, carbohydrate, lipid, and polyhydrocarbon compounds. 25. The kit of claim 16, wherein said inhibitor component of the diagnostic effector molecule is not covalently linked to the diagnostic effector molecule. 26. The kit of claim 16, wherein said reporter molecule is RNA, DNA, RNA analog, or DNA analog. 27. A nucleic acid molecule which down regulates expression of a CD20 gene. 28. The nucleic acid of claim 27, wherein said nucleic acid molecule is used to treat conditions selected from the group consisting of lymphoma, leukemia, arthropathy, B- cell lymphoma, low-grade or follicular non-Hodgkin's lymphoma (NHL), bulky low- grade or follicular NHL, lypmphocytic leukemia, HIN associated ΝHL, mantle-cell lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma, immune thrombocytopenia, and inflammatory arthropathy. 29. The nucleic acid molecule of claim 27, wherein said nucleic acid molecule is an enzymatic nucleic acid molecule having one or more binding arms. 30. The nucleic acid of claim 29, wherein a binding arm of said enzymatic nucleic acid molecule comprises a sequence complementary to any of the sequences selected from the group consisting of SEQ ID ΝOs. 2702-3793. 31. The nucleic acid molecule of claim 29, wherein said enzymatic nucleic acid molecule comprises a sequence selected from the group consisting of SEQ ID NOs. 7758-9254. 32. The nucleic acid molecule of claim 27, wherein said nucleic acid molecule is an antisense nucleic acid molecule. 33. The nucleic acid molecule of claim 32, wherein said antisense nucleic acid molecule comprises a sequence complementary to a sequence selected from the group consisting of SEQ ID NOs. 2702-3793. 34. The nucleic acid molecule of claim 29, wherein said enzymatic nucleic acid molecule is in a hammerhead (HH) motif. 35. The nucleic acid molecule of claim 29, wherein said enzymatic nucleic acid molecule is in a hairpin, hepatitis Delta virus, group I intron, NS nucleic acid, amberzyme, zinzyme, or RΝAse P nucleic acid motif. 36. The nucleic acid molecule of claim 29, wherein said enzymatic nucleic acid molecule is in an Inozyme motif. 37. The nucleic acid molecule of claim 29, wherein said enzymatic nucleic acid molecule is in a G-cleaver motif. 38. The nucleic acid molecule of claim 29, wherein said enzymatic nucleic acid molecule is a DNAzyme. 39. The nucleic acid molecule of claim 29, wherein said enzymatic nucleic acid molecule comprises between 12 and 100 bases complementary to the RNA of CD20 gene. 40. The nucleic acid of claim 29, wherein said enzymatic nucleic acid molecule comprises between 14 and 24 bases complementary to the RNA of CD20 gene. 41. The nucleic acid molecule of claim 27, wherein said nucleic acid is chemically synthesized. 42. The nucleic acid molecule of claim 27, wherein said nucleic acid comprises at least one 2 '-sugar modification. 43. The nucleic acid molecule of claim 27, wherein said nucleic acid comprises at least one nucleic acid base modification. 44. The nucleic acid molecule of claim 27, wherein said nucleic acid comprises at least one phosphate backbone modification. 45. A mammalian cell including the nucleic acid molecule of claim 27. 46. The mammalian cell of claim 45, wherein said mammalian cell is a human cell. 47. A method of reducing CD20 activity in a cell, comprising the step of contacting said cell with the nucleic acid molecule of claim 27, under conditions suitable for said reduction of CD20 activity. 48. A method of treatment of a patient having a condition associated with the level of CD20, comprising contacting cells of said patient with the nucleic acid molecule of claim 27, under conditions suitable for said treatment. 49. The method of claim 48 further comprising the use of one or more therapies under conditions suitable for said treatment. 50. A method of cleaving RNA of CD20 gene, comprising, contacting the nucleic acid molecule of claim 29, with said RNA under conditions suitable for the cleavage of said RNA. 51. The method of claim 50, wherein said cleavage is carried out in the presence of a divalent cation. 52. The method of claim 51 , wherein said divalent cation is Mg^ + . 53. The nucleic acid molecule of claim 27, wherein said nucleic acid comprises a cap structure, wherein the cap structure is at the 5 '-end or 3 '-end or both the 5 '-end and the 3 '-end. 54. The enzymatic nucleic acid molecule of claim 34, wherein said hammerhead motif comprises a sequence complementary to a sequence selected from the group consisting of SEQ ID NOs. 2702-3049. 55. The enzymatic nucleic acid molecule of claim 36, wherein said NCH motif comprises a sequence complementary to a sequence selected from the group consisting of SEQ ID NOs. 3050-3385. 56. The enzymatic nucleic acid molecule of claim 37, wherein said G-cleaver motif comprises a sequence complementary to a sequence selected from the group consisting of SEQ ID NOs. 3386-3449. 57. The enzymatic nucleic acid molecule of claim 38, wherein said DNAzyme comprises a sequence complementary to any of the sequences shown as substrate sequences in Table XIII. 58. The enzymatic nucleic acid molecule of claim 35, wherein said zinzyme comprises a sequence complementary to any of the sequences shown as substrate sequences in Table XII. 59. The enzymatic nucleic acid molecule of claim 35, wherein said amberzyme comprises a sequence complementary to any of the sequences shown as substrate sequences in Table XIV. 60. An expression vector comprising a nucleic acid sequence encoding at least one nucleic acid molecule of claim 27, in a manner which allows expression of the nucleic acid molecule. 61. A mammalian cell including an expression vector of claim 60. 62. The mammalian cell of claim 61 , wherein said mammalian cell is a human cell. 63. The expression vector of claim 60, wherein said nucleic acid molecule is an enzymatic nucleic acid molecule. 64. The expression vector of claim 60, wherein said expression vector further comprises a sequence for an antisense nucleic acid molecule complementary to the RNA of CD20 gene. 65. The expression vector of claim 60, wherein said expression vector comprises a sequence encoding at least two nucleic acid molecules of claim 27, which may be the same or different. 66. The expression vector of claim 65, wherein said expression vector further comprises a sequence encoding an antisense nucleic acid molecule complementary to the RNA of CD20 gene. 67. The expression vector of claim 65, wherein said expression vector further comprises a sequence encoding an enzymatic nucleic acid molecule complementary to the RNA of CD20 gene. 68. A method for treatment of lymphoma, comprising the step of administering to a patient the nucleic acid molecule of claim 27 under conditions suitable for said treatment. 69. A method for the treatment of leukemia, comprising the step of administering to a patient the nucleic acid molecule of claim 27 under conditions suitable for said treatment. 70. An enzymatic nucleic acid molecule which cleaves RNA derived from CD20 gene. 71. The enzymatic nucleic acid molecule of claim 70, wherein said enzymatic nucleic acid molecule is selected from the group consisting of Hammerhead, Hairpin, Inozyme, G- cleaver, DNAzyme, Amberzyme and Zinzyme. 72. The method of claim 68 or claim 69, wherein said method further comprises administering to said patient the nucleic acid molecule of claim 1 in conjunction with one or more other therapies. 73. The method of claim 72, wherein the other therapies are selected from the group consisting of radiation, chemotherapy, and cyclosporin treatment. 74. The nucleic acid molecule of claim 32, wherein said nucleic acid molecule comprises at least five ribose residues; at least ten 2'-O-methyl modifications, and a 3'- end modification. 75. The nucleic acid molecule of claim 74, wherein said nucleic acid molecule further comprises a phosphorothioate core with both 3' and 5' -end modifications. 76. The nucleic acid molecule of claim 74 or claim 75, wherein said 3' and/or 5'- end modification is a 3 '-3' inverted abasic moiety. 77. The nucleic acid molecule of claim 29, wherein said nucleic acid molecule comprises at least five ribose residues; at least ten 2 , -O-methyl modifications, and a 3'- end modification. 78. The nucleic acid molecule of claim 77, wherein said nucleic acid molecule further comprises phosphorothioate linkages on at least three of the 5' terminal nucleotides. 79. The nucleic acid molecule of claim 77, wherein said 3'- end modification is a 3'-3' inverted abasic moiety. 80. The enzymatic nucleic acid molecule of claim 38, wherein said DNAzyme comprises at least ten 2'-O-methyl modifications and a 3 '-end modification. 81. The enzymatic nucleic acid molecule of claim 80, wherein said DNAzyme further comprises phosphorothioate linkages on at least three of the 5' terminal nucleotides. 82. The enzymatic nucleic acid molecule of claim 80, wherein said 3'- end modification is a 3 '-3' inverted abasic moiety. 83. A nucleic acid molecule which down regulates expression of a neurite growth inhibitor gene. 84. A nucleic acid molecule of claim 83, wherein said neurite growth inhibitor gene is a NOGO gene. 85. The nucleic acid of claim 83, wherein said nucleic acid molecule is adapted for use to treat conditions selected from the group consisting of CNS injury and cerebrovascular accident. 86. The nucleic acid molecule of claim 83 or claim 84, wherein said nucleic acid molecule is an enzymatic nucleic acid molecule having one or more binding arms. 87. The nucleic acid molecule of claim 86, wherein said enzymatic nucleic acid molecule has an endonuclease activity to cleave RNA encoded by said NOGO gene. 88. The nucleic acid of claim 83, wherein a binding arm of said enzymatic nucleic acid molecule comprises a sequence complementary to a sequence selected from the group consisting of SEQ ID NOs. 1-2701. 89. An enzymatic nucleic acid molecule comprising a sequence selected from the group consisting of SEQ ID NOs. 3794-7757. 90. The nucleic acid molecule of claim 83, wherein said nucleic acid molecule is an antisense nucleic acid molecule. 91. An antisense nucleic acid molecule comprising a sequence complementary to any of the sequences selected from the group consisting of SEQ ID NOs. 1-2701. 92. The enzymatic nucleic acid molecule of claim 86, wherein said enzymatic nucleic acid molecule is in a hammerhead (HH) motif. 93. The enzymatic nucleic acid molecule of claim 86, wherein said enzymatic nucleic acid molecule is in a hairpin, hepatitis Delta virus, group I intron, NS nucleic acid, amberzyme, zinzyme or RΝAse P nucleic acid motif. 94. The enzymatic nucleic acid molecule of claim 93, wherein said zinzyme motif comprises a sequence selected from the group consisting of SEQ ID ΝOs. 5572-5987. 95. The enzymatic nucleic acid molecule of claim 93, wherein said amberzyme motif comprises a sequence selected from the group consisting of SEQ ID NOs. 6841-7757. 96. The enzymatic nucleic acid molecule of claim 86, wherein said enzymatic nucleic acid molecule is in a NCH motif. 97. The enzymatic nucleic acid molecule of claim 86, wherein said enzymatic nucleic acid molecule is in a G-cleaver motif. 98. The enzymatic nucleic acid molecule of claim 86, wherein said enzymatic nucleic acid molecule is a DNAzyme. 99. The nucleic acid molecule of claim 84, wherein said nucleic acid molecule comprises between 12 and 100 bases complementary to the RNA of NOGO gene. 100. The nucleic acid of claim 84, wherein said nucleic acid molecule comprises between 14 and 24 bases complementary to the RNA of NOGO gene. 101. The nucleic acid molecule of claim 83, wherein said nucleic acid is chemically synthesized. 102. The nucleic acid molecule of claim 83, wherein said nucleic acid comprises at least one 2 '-sugar modification. 103. The nucleic acid molecule of claim 83, wherein said nucleic acid comprises at least one nucleic acid base modification. 104. The nucleic acid molecule of claim 83, wherein said nucleic acid comprises at least one phosphate backbone modification. 105. A mammalian cell comprising the nucleic acid molecule of claim 83, wherein said mammalian cell is not a living human. 106. The mammalian cell of claim 105, wherein said mammalian cell is a human cell. 107. A method of reducing NOGO activity in a cell, comprising the step of contacting said cell with the nucleic acid molecule of claim 84, under conditions suitable for said inhibition. 108. A method of treatment of a patient having a condition associated with the level of NOGO, comprising contacting cells of said patient with the nucleic acid molecule of claim 84, under conditions suitable for said treatment. 109. The method of claim 108 further comprising the use of one or more drug therapies under conditions suitable for said treatment. 110. A method of cleaving RNA of NOGO gene comprising contacting the nucleic acid molecule of claim 84 with said RNA under conditions suitable for the cleavage of said RNA. 111. The method of claim 110, wherein said cleavage is carried out in the presence of a divalent cation. 112. The method of claim 111, wherein said divalent cation is Mg2+. 113. The nucleic acid molecule of claim 83, wherein said nucleic acid comprises a cap structure, wherein the cap structure is at the 5'-end, or the 3'-end, or both the 5'-end and the 3 '-end. 114. The enzymatic nucleic acid molecule of claim 92, wherein said hammerhead motif comprises a sequence selected from the group consisting of SEQ ID NOs. 3974-4523. 115. The enzymatic nucleic acid molecule of claim 96, wherein said NCH motif comprises a sequence selected from the group consisting of SEQ ID NOs. 4524-5337. 116. The enzymatic nucleic acid molecule of claim 97, wherein said G-cleaver motif comprises a sequence selected from the group consisting of SEQ ID NOs. 5338-5571. 117. The enzymatic nucleic acid molecule of claim 98, wherein said DNAzyme comprises a sequence selected from the group consisting of SEQ ID NOs. 5988-6840. 118. The method of claim 107, wherein said nucleic acid molecule is in a hammerhead motif. 119. The method of claim 107, wherein said nucleic acid molecule is a DNAzyme. 120. An expression vector comprising a nucleic acid sequence encoding at least one nucleic acid molecule of claim 83, in a manner which allows expression of that nucleic acid molecule. 121. A mammalian cell including an expression vector of claim 120, wherein said mammalian cell is not a living human. 122. The mammalian cell of claim 121, wherein said mammalian cell is a human cell. 123. The expression vector of claim 120, wherein said nucleic acid molecule is in a hammerhead motif. 124. The expression vector of claim 120, wherein said expression vector further comprises a sequence for an antisense nucleic acid molecule complementary to the RNA of NOGO gene. 125. The expression vector of claim 120, wherein said expression vector comprises a sequence encoding at least two nucleic acid molecules of claim 83, which may be the same or different. 126. The expression vector of claim 125, wherein said expression vector further comprises a sequence encoding an antisense nucleic acid molecule complementary to the RNA of NOGO gene. 127. A method for treatment of conditions selected from the group consisting of CNS injury and cerebrovascular accident comprising the step of administering to a patient the nucleic acid molecule of claim 83 under conditions suitable for said treatment. 128. The method of claim 127, wherein said treatment of CNS injury is treatment of spinal cord injury. 129. A method for treatment of conditions selected from the group consisting of CNS injury and cerebrovascular accident (CNA, stroke) comprising the step of administering to a patient the antisense nucleic acid molecule of claim 91 under conditions suitable for said treatment. 130. The method of claim 127, wherein said nucleic acid molecule is in a hammerhead motif. 131. The method of claim 127, wherein said method further comprises administering to said patient the nucleic acid molecule in conjunction with one or more of other therapies. 132. The nucleic acid molecule of claim 83, wherein said nucleic acid molecule comprises at least five ribose residues; at least ten 2'-O-methyl modifications, and a 3'- end modification. 133. The nucleic acid molecule of claim 132, wherein said nucleic acid molecule further comprises phosphorothioate linkages on at least three of the 5' terminal nucleotides. 134. The nucleic acid molecule of claim 132, wherein said 3'- end modification is a 3'-3' inverted abasic moiety. 135. The enzymatic nucleic acid molecule of claim 98, wherein said DNAzyme comprises at least ten 2'-O-methyl modifications and a 3 '-end modification. 136. The enzymatic nucleic acid molecule of claim 135, wherein said DNAzyme further comprises phosphorothioate linkages on at least three of the 5' terminal nucleotides. 137. The enzymatic nucleic acid molecule of claim 135, wherein said 3'- end modification is a 3 '-3' inverted abasic moiety.

Inventors: BLATT LAWRENCE, CHOWRIRA BHARAT M, MCSWIGGEN JAMES, BLATT, LAWRENCE, CHOWRIRA, BHARAT, M., MCSWIGGEN, JAMES
Applicants: BLATT LAWRENCE, CHOWRIRA BHARAT M, MCSWIGGEN JAMES, RIBOZYME PHARM INC, BLATT, LAWRENCE, CHOWRIRA, BHARAT, M., MCSWIGGEN, JAMES, RIBOZYME PHARMACEUTICALS, INC.
Application year: 2001
Main classification: C12N15
IPC codes: A61K31, A61K38, A61K45, A61K48, A61P7, A61P9, A61P19, A61P21, A61P25, A61P31, A61P35, A61P43, C12N5, C12N9, C12N15, C12Q1, G01N33